CA3073543A1 - Benzosulfonyl compounds - Google Patents
Benzosulfonyl compounds Download PDFInfo
- Publication number
- CA3073543A1 CA3073543A1 CA3073543A CA3073543A CA3073543A1 CA 3073543 A1 CA3073543 A1 CA 3073543A1 CA 3073543 A CA3073543 A CA 3073543A CA 3073543 A CA3073543 A CA 3073543A CA 3073543 A1 CA3073543 A1 CA 3073543A1
- Authority
- CA
- Canada
- Prior art keywords
- substituted
- unsubstituted
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 478
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 59
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims description 129
- 125000001072 heteroaryl group Chemical group 0.000 claims description 84
- 125000003118 aryl group Chemical group 0.000 claims description 67
- 201000011510 cancer Diseases 0.000 claims description 50
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 49
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 42
- 125000000623 heterocyclic group Chemical group 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 28
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 26
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 16
- 125000002950 monocyclic group Chemical group 0.000 claims description 16
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 10
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 10
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 9
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 8
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 7
- 125000002883 imidazolyl group Chemical group 0.000 claims description 7
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 claims description 7
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 7
- 125000003965 isoxazolidinyl group Chemical group 0.000 claims description 7
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 7
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 7
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 7
- 125000002971 oxazolyl group Chemical group 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 7
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims description 7
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 7
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 7
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 7
- 125000001984 thiazolidinyl group Chemical group 0.000 claims description 7
- 125000000335 thiazolyl group Chemical group 0.000 claims description 7
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 6
- 125000005303 dithiazolyl group Chemical group S1SNC(=C1)* 0.000 claims description 6
- 101150009274 nhr-1 gene Proteins 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 125000006747 (C2-C10) heterocycloalkyl group Chemical group 0.000 claims 14
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 11
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 7
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 3
- 230000003993 interaction Effects 0.000 abstract description 10
- 230000001404 mediated effect Effects 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 description 217
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 215
- -1 -CN radical Chemical class 0.000 description 160
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 107
- 238000002360 preparation method Methods 0.000 description 91
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 88
- 230000002829 reductive effect Effects 0.000 description 83
- 238000002953 preparative HPLC Methods 0.000 description 82
- 239000011541 reaction mixture Substances 0.000 description 79
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 76
- 238000005160 1H NMR spectroscopy Methods 0.000 description 74
- 239000000243 solution Substances 0.000 description 74
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 73
- 239000003112 inhibitor Substances 0.000 description 69
- 108700038175 YAP-Signaling Proteins Proteins 0.000 description 66
- 235000002639 sodium chloride Nutrition 0.000 description 62
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 59
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 59
- 102100027548 WW domain-containing transcription regulator protein 1 Human genes 0.000 description 59
- 101150041968 CDC13 gene Proteins 0.000 description 56
- 229910000027 potassium carbonate Inorganic materials 0.000 description 54
- 235000015320 potassium carbonate Nutrition 0.000 description 54
- 239000007832 Na2SO4 Substances 0.000 description 53
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 53
- 229910052938 sodium sulfate Inorganic materials 0.000 description 53
- 235000011152 sodium sulphate Nutrition 0.000 description 53
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 52
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 52
- 238000006243 chemical reaction Methods 0.000 description 52
- 125000000217 alkyl group Chemical group 0.000 description 50
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 50
- 239000012044 organic layer Substances 0.000 description 50
- 125000002947 alkylene group Chemical group 0.000 description 49
- 239000000047 product Substances 0.000 description 49
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 44
- 230000004655 Hippo pathway Effects 0.000 description 43
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 39
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 37
- 125000004432 carbon atom Chemical group C* 0.000 description 37
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- 108090000623 proteins and genes Proteins 0.000 description 34
- 229910052757 nitrogen Inorganic materials 0.000 description 32
- 239000007858 starting material Substances 0.000 description 32
- 239000002904 solvent Substances 0.000 description 31
- 150000003254 radicals Chemical class 0.000 description 29
- 239000000651 prodrug Substances 0.000 description 26
- 229940002612 prodrug Drugs 0.000 description 26
- 239000012043 crude product Substances 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- 229910000029 sodium carbonate Inorganic materials 0.000 description 25
- 235000017550 sodium carbonate Nutrition 0.000 description 25
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 24
- 239000012267 brine Substances 0.000 description 23
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 23
- 229910000024 caesium carbonate Inorganic materials 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 238000004128 high performance liquid chromatography Methods 0.000 description 20
- 201000007270 liver cancer Diseases 0.000 description 20
- 239000011369 resultant mixture Substances 0.000 description 20
- 239000000126 substance Substances 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 125000004452 carbocyclyl group Chemical group 0.000 description 18
- 125000004093 cyano group Chemical group *C#N 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 125000003709 fluoroalkyl group Chemical group 0.000 description 17
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 17
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 16
- 208000014018 liver neoplasm Diseases 0.000 description 16
- YCMLQMDWSXFTIF-UHFFFAOYSA-N 2-methylbenzenesulfonimidic acid Chemical compound CC1=CC=CC=C1S(N)(=O)=O YCMLQMDWSXFTIF-UHFFFAOYSA-N 0.000 description 15
- 206010009944 Colon cancer Diseases 0.000 description 15
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 15
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 15
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 15
- 201000005969 Uveal melanoma Diseases 0.000 description 15
- 229910052799 carbon Inorganic materials 0.000 description 15
- 201000004101 esophageal cancer Diseases 0.000 description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 125000001424 substituent group Chemical group 0.000 description 15
- 238000004809 thin layer chromatography Methods 0.000 description 15
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 14
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 14
- 238000005481 NMR spectroscopy Methods 0.000 description 14
- 230000036210 malignancy Effects 0.000 description 14
- 206010039491 Sarcoma Diseases 0.000 description 13
- 125000005884 carbocyclylalkyl group Chemical group 0.000 description 13
- 125000000753 cycloalkyl group Chemical group 0.000 description 13
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 12
- 206010027406 Mesothelioma Diseases 0.000 description 12
- 230000008901 benefit Effects 0.000 description 12
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 12
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 11
- 208000027205 Congenital disease Diseases 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 206010070308 Refractory cancer Diseases 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 125000004450 alkenylene group Chemical group 0.000 description 11
- 125000004429 atom Chemical group 0.000 description 11
- 238000004440 column chromatography Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000001257 hydrogen Substances 0.000 description 11
- 208000037819 metastatic cancer Diseases 0.000 description 11
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 239000003039 volatile agent Substances 0.000 description 11
- 201000009030 Carcinoma Diseases 0.000 description 10
- 125000004122 cyclic group Chemical group 0.000 description 10
- 125000005843 halogen group Chemical group 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- 239000012299 nitrogen atmosphere Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 206010006187 Breast cancer Diseases 0.000 description 9
- 208000026310 Breast neoplasm Diseases 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 9
- 208000000172 Medulloblastoma Diseases 0.000 description 9
- 206010033128 Ovarian cancer Diseases 0.000 description 9
- 206010061535 Ovarian neoplasm Diseases 0.000 description 9
- 108091000080 Phosphotransferase Proteins 0.000 description 9
- 206010035226 Plasma cell myeloma Diseases 0.000 description 9
- 206010060862 Prostate cancer Diseases 0.000 description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 9
- 208000005718 Stomach Neoplasms Diseases 0.000 description 9
- 125000003342 alkenyl group Chemical group 0.000 description 9
- 125000000304 alkynyl group Chemical group 0.000 description 9
- 208000029742 colonic neoplasm Diseases 0.000 description 9
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 9
- 239000003937 drug carrier Substances 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 206010017758 gastric cancer Diseases 0.000 description 9
- 201000005787 hematologic cancer Diseases 0.000 description 9
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 9
- 102000020233 phosphotransferase Human genes 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- 239000012453 solvate Substances 0.000 description 9
- 201000011549 stomach cancer Diseases 0.000 description 9
- 108091006027 G proteins Proteins 0.000 description 8
- 102000034286 G proteins Human genes 0.000 description 8
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000026731 phosphorylation Effects 0.000 description 8
- 238000006366 phosphorylation reaction Methods 0.000 description 8
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 7
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 7
- 102000011068 Cdc42 Human genes 0.000 description 7
- 108050001278 Cdc42 Proteins 0.000 description 7
- 208000006168 Ewing Sarcoma Diseases 0.000 description 7
- 108091000058 GTP-Binding Proteins 0.000 description 7
- 206010025323 Lymphomas Diseases 0.000 description 7
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 7
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 108700040558 Transcriptional Coactivator with PDZ-Binding Motif Proteins Proteins 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 229940125900 compound 59 Drugs 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- SVDVKEBISAOWJT-UHFFFAOYSA-N n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1 SVDVKEBISAOWJT-UHFFFAOYSA-N 0.000 description 7
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 6
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 6
- PUSFGYWMWOMIOD-UHFFFAOYSA-N 4-(cyclohexylamino)-N-methyl-3-(3-methylpyridin-2-yl)benzenesulfonamide Chemical compound C1(CCCCC1)NC1=C(C=C(C=C1)S(=O)(=O)NC)C1=NC=CC=C1C PUSFGYWMWOMIOD-UHFFFAOYSA-N 0.000 description 6
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 6
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 6
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 6
- 244000201986 Cassia tora Species 0.000 description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 6
- 208000032612 Glial tumor Diseases 0.000 description 6
- 206010018338 Glioma Diseases 0.000 description 6
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 6
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 208000034578 Multiple myelomas Diseases 0.000 description 6
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 6
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 208000006990 cholangiocarcinoma Diseases 0.000 description 6
- 229940125904 compound 1 Drugs 0.000 description 6
- 229940125844 compound 46 Drugs 0.000 description 6
- 239000010949 copper Substances 0.000 description 6
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 201000003444 follicular lymphoma Diseases 0.000 description 6
- 201000010536 head and neck cancer Diseases 0.000 description 6
- 208000014829 head and neck neoplasm Diseases 0.000 description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 6
- 230000017945 hippo signaling cascade Effects 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 201000005249 lung adenocarcinoma Diseases 0.000 description 6
- 206010027191 meningioma Diseases 0.000 description 6
- NCAIGTHBQTXTLR-UHFFFAOYSA-N phentermine hydrochloride Chemical compound [Cl-].CC(C)([NH3+])CC1=CC=CC=C1 NCAIGTHBQTXTLR-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 description 6
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000012279 sodium borohydride Substances 0.000 description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 description 6
- 125000003107 substituted aryl group Chemical group 0.000 description 6
- 229910052717 sulfur Chemical group 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 5
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 5
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 5
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 5
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 5
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 5
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 5
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 5
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 5
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 5
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 5
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 5
- VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 5
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 5
- DJMOXMNDXFFONV-UHFFFAOYSA-N 1,3-dimethyl-7-[2-(n-methylanilino)ethyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCN(C)C1=CC=CC=C1 DJMOXMNDXFFONV-UHFFFAOYSA-N 0.000 description 5
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 5
- MMWCIQZXVOZEGG-UHFFFAOYSA-N 1,4,5-IP3 Natural products OC1C(O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(O)C1OP(O)(O)=O MMWCIQZXVOZEGG-UHFFFAOYSA-N 0.000 description 5
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 5
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 5
- 102000004899 14-3-3 Proteins Human genes 0.000 description 5
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 5
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 5
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 5
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 5
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 5
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 5
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 5
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 5
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 5
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 5
- APVXCRJBERWROX-UHFFFAOYSA-N 4-(cyclohexylamino)-N-methyl-3-pyrimidin-2-ylbenzenesulfonamide Chemical compound C1(CCCCC1)NC1=C(C=C(C=C1)S(=O)(=O)NC)C1=NC=CC=N1 APVXCRJBERWROX-UHFFFAOYSA-N 0.000 description 5
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 5
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 5
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 5
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 5
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 5
- 102100022455 Adrenocorticotropic hormone receptor Human genes 0.000 description 5
- 102000043902 Angiomotin Human genes 0.000 description 5
- 108700020509 Angiomotin Proteins 0.000 description 5
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 5
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 5
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 5
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 5
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 5
- 206010067193 Naevus flammeus Diseases 0.000 description 5
- 208000006787 Port-Wine Stain Diseases 0.000 description 5
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 5
- 206010042265 Sturge-Weber Syndrome Diseases 0.000 description 5
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 5
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 5
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 5
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 5
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 150000007942 carboxylates Chemical class 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 239000012230 colorless oil Substances 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 229940127271 compound 49 Drugs 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 5
- 208000002026 familial multiple nevi flammei Diseases 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 5
- 125000001841 imino group Chemical group [H]N=* 0.000 description 5
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 5
- 150000005172 methylbenzenes Chemical class 0.000 description 5
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 5
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 5
- 239000001301 oxygen Chemical group 0.000 description 5
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 5
- 108091006108 transcriptional coactivators Proteins 0.000 description 5
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 5
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 4
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 4
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 4
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 4
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 4
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 4
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 4
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 4
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 4
- 101150056293 AJUBA gene Proteins 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 4
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 4
- 229940126657 Compound 17 Drugs 0.000 description 4
- 229940126639 Compound 33 Drugs 0.000 description 4
- 229940127007 Compound 39 Drugs 0.000 description 4
- MMWCIQZXVOZEGG-XJTPDSDZSA-N D-myo-Inositol 1,4,5-trisphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O MMWCIQZXVOZEGG-XJTPDSDZSA-N 0.000 description 4
- 102100025334 Guanine nucleotide-binding protein G(q) subunit alpha Human genes 0.000 description 4
- 101000857888 Homo sapiens Guanine nucleotide-binding protein G(q) subunit alpha Proteins 0.000 description 4
- 101001087426 Homo sapiens Tyrosine-protein phosphatase non-receptor type 14 Proteins 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 4
- 102000001419 Melatonin receptor Human genes 0.000 description 4
- 108050009605 Melatonin receptor Proteins 0.000 description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 102100033015 Tyrosine-protein phosphatase non-receptor type 14 Human genes 0.000 description 4
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 229920002301 cellulose acetate Polymers 0.000 description 4
- 229940125773 compound 10 Drugs 0.000 description 4
- 229940126543 compound 14 Drugs 0.000 description 4
- 229940125758 compound 15 Drugs 0.000 description 4
- 229940126142 compound 16 Drugs 0.000 description 4
- 229940125810 compound 20 Drugs 0.000 description 4
- 229940126086 compound 21 Drugs 0.000 description 4
- 229940126208 compound 22 Drugs 0.000 description 4
- 229940125833 compound 23 Drugs 0.000 description 4
- 229940125961 compound 24 Drugs 0.000 description 4
- 229940125846 compound 25 Drugs 0.000 description 4
- 229940125851 compound 27 Drugs 0.000 description 4
- 229940127204 compound 29 Drugs 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 229940125877 compound 31 Drugs 0.000 description 4
- 229940125878 compound 36 Drugs 0.000 description 4
- 229940125807 compound 37 Drugs 0.000 description 4
- 229940127573 compound 38 Drugs 0.000 description 4
- 229940126540 compound 41 Drugs 0.000 description 4
- 229940125936 compound 42 Drugs 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- 229940126545 compound 53 Drugs 0.000 description 4
- 229940127113 compound 57 Drugs 0.000 description 4
- 229940126179 compound 72 Drugs 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 4
- 101150100121 gna1 gene Proteins 0.000 description 4
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 4
- 125000004404 heteroalkyl group Chemical group 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 4
- LBTPIFQNEKOAIM-UHFFFAOYSA-N n-phenylmethanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1 LBTPIFQNEKOAIM-UHFFFAOYSA-N 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 125000004043 oxo group Chemical group O=* 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 201000000441 refractory hematologic cancer Diseases 0.000 description 4
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 102000030938 small GTPase Human genes 0.000 description 4
- 108060007624 small GTPase Proteins 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000011593 sulfur Chemical group 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- SKOKKOPKFKENHX-UHFFFAOYSA-N tert-butyl 3-(4-methylphenyl)sulfonyloxypiperidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC1CN(C(=O)OC(C)(C)C)CCC1 SKOKKOPKFKENHX-UHFFFAOYSA-N 0.000 description 4
- 125000000464 thioxo group Chemical group S=* 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 3
- USQCUKQZXOWUDF-YWZLYKJASA-N 6-chloro-n-[(3s)-1-[(2s)-1-(4-methyl-5-oxo-1,4-diazepan-1-yl)-1-oxopropan-2-yl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide Chemical compound O=C([C@@H](N1C([C@@H](NS(=O)(=O)C=2C=C3C=CC(Cl)=CC3=CC=2)CC1)=O)C)N1CCN(C)C(=O)CC1 USQCUKQZXOWUDF-YWZLYKJASA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 102000009346 Adenosine receptors Human genes 0.000 description 3
- 108050000203 Adenosine receptors Proteins 0.000 description 3
- 206010061424 Anal cancer Diseases 0.000 description 3
- 206010002412 Angiocentric lymphomas Diseases 0.000 description 3
- 208000007860 Anus Neoplasms Diseases 0.000 description 3
- 206010073360 Appendix cancer Diseases 0.000 description 3
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 description 3
- 206010004593 Bile duct cancer Diseases 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 208000011691 Burkitt lymphomas Diseases 0.000 description 3
- 201000004085 CLL/SLL Diseases 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 3
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 3
- 201000001342 Fallopian tube cancer Diseases 0.000 description 3
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 101000723543 Homo sapiens 14-3-3 protein theta Proteins 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 201000003791 MALT lymphoma Diseases 0.000 description 3
- 208000032271 Malignant tumor of penis Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 208000003445 Mouth Neoplasms Diseases 0.000 description 3
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 3
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N NMP Substances CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 3
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 208000013612 Parathyroid disease Diseases 0.000 description 3
- 208000002471 Penile Neoplasms Diseases 0.000 description 3
- 206010034299 Penile cancer Diseases 0.000 description 3
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 3
- 208000007452 Plasmacytoma Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 description 3
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 description 3
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 description 3
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 102000006478 Protein Phosphatase 2 Human genes 0.000 description 3
- 108010058956 Protein Phosphatase 2 Proteins 0.000 description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 102000042463 Rho family Human genes 0.000 description 3
- 108091078243 Rho family Proteins 0.000 description 3
- 108091007047 SCF complex Proteins 0.000 description 3
- 102000036366 SCF complex Human genes 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 description 3
- 206010057644 Testis cancer Diseases 0.000 description 3
- 206010043515 Throat cancer Diseases 0.000 description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 102000014384 Type C Phospholipases Human genes 0.000 description 3
- 108010079194 Type C Phospholipases Proteins 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 description 3
- 206010047741 Vulval cancer Diseases 0.000 description 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
- 239000012346 acetyl chloride Substances 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 3
- 125000004419 alkynylene group Chemical group 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 201000011165 anus cancer Diseases 0.000 description 3
- 208000021780 appendiceal neoplasm Diseases 0.000 description 3
- 150000005840 aryl radicals Chemical class 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- 208000026900 bile duct neoplasm Diseases 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
- 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 230000003436 cytoskeletal effect Effects 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 208000024519 eye neoplasm Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 208000021173 high grade B-cell lymphoma Diseases 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 208000003849 large cell carcinoma Diseases 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 3
- 206010024627 liposarcoma Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 description 3
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 238000006241 metabolic reaction Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 230000005937 nuclear translocation Effects 0.000 description 3
- 201000008106 ocular cancer Diseases 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 208000022560 parathyroid gland disease Diseases 0.000 description 3
- 208000010916 pituitary tumor Diseases 0.000 description 3
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 206010038038 rectal cancer Diseases 0.000 description 3
- 201000001275 rectum cancer Diseases 0.000 description 3
- 201000006845 reticulosarcoma Diseases 0.000 description 3
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 208000000649 small cell carcinoma Diseases 0.000 description 3
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 201000003120 testicular cancer Diseases 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical group C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 201000002510 thyroid cancer Diseases 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 230000034512 ubiquitination Effects 0.000 description 3
- 238000010798 ubiquitination Methods 0.000 description 3
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- 206010046766 uterine cancer Diseases 0.000 description 3
- 206010046885 vaginal cancer Diseases 0.000 description 3
- 208000013139 vaginal neoplasm Diseases 0.000 description 3
- 229910052720 vanadium Inorganic materials 0.000 description 3
- 201000005102 vulva cancer Diseases 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- CNWINRVXAYPOMW-FCNJXWMTSA-N 1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-1D-myo-inositol 4,5-biphosphate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O CNWINRVXAYPOMW-FCNJXWMTSA-N 0.000 description 2
- 101710112812 14-3-3 protein Proteins 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- QUYIXADQOJQBEI-UHFFFAOYSA-N 2-(cyclohexylamino)-N'-hydroxy-5-(methylsulfamoyl)benzenecarboximidamide Chemical compound CNS(=O)(=O)c1ccc(NC2CCCCC2)c(c1)C(\N)=N\O QUYIXADQOJQBEI-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- LCMCUBUUKDUPEM-UHFFFAOYSA-N 3-bromo-4-(cyclohexylamino)-N-methylbenzenesulfonamide Chemical compound BrC=1C=C(C=CC=1NC1CCCCC1)S(=O)(=O)NC LCMCUBUUKDUPEM-UHFFFAOYSA-N 0.000 description 2
- XXZZDFAHUYQRKE-UHFFFAOYSA-N 3-bromo-4-fluoro-N-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)c1ccc(F)c(Br)c1 XXZZDFAHUYQRKE-UHFFFAOYSA-N 0.000 description 2
- NYPYPOZNGOXYSU-UHFFFAOYSA-N 3-bromopyridine Chemical compound BrC1=CC=CN=C1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 2
- KSVMBENAURXIBC-UHFFFAOYSA-N 3-cyano-4-[(3,3-difluorocyclohexyl)amino]-N-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)c1ccc(NC2CCCC(F)(F)C2)c(c1)C#N KSVMBENAURXIBC-UHFFFAOYSA-N 0.000 description 2
- JANVIMDTZKNPJV-UHFFFAOYSA-N 3-cyano-4-[(4,4-difluorocyclohexyl)amino]-N-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC(C#N)=C(NC2CCC(F)(F)CC2)C=C1 JANVIMDTZKNPJV-UHFFFAOYSA-N 0.000 description 2
- GWSMACIBLPUZRL-UHFFFAOYSA-N 4-(cyclohexylamino)-N-methyl-3-(triazol-2-yl)benzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC(N2N=CC=N2)=C(NC2CCCCC2)C=C1 GWSMACIBLPUZRL-UHFFFAOYSA-N 0.000 description 2
- OQGPKHVHXKSVJI-UHFFFAOYSA-N 4-[(4,4-difluorocyclohexyl)amino]-N-methyl-3-(2-methyltetrazol-5-yl)benzenesulfonamide Chemical compound FC1(CCC(CC1)NC1=C(C=C(C=C1)S(=O)(=O)NC)C=1N=NN(N=1)C)F OQGPKHVHXKSVJI-UHFFFAOYSA-N 0.000 description 2
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 2
- FDHORRRGTYUUKU-UHFFFAOYSA-N 4-iodo-2-(triazol-2-yl)aniline Chemical compound NC1=C(C=C(I)C=C1)N1N=CC=N1 FDHORRRGTYUUKU-UHFFFAOYSA-N 0.000 description 2
- 102100040385 5-hydroxytryptamine receptor 4 Human genes 0.000 description 2
- 101710150225 5-hydroxytryptamine receptor 4 Proteins 0.000 description 2
- MIOQBSPUPLFYHC-UHFFFAOYSA-N 6-bromo-n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC(Br)=N1 MIOQBSPUPLFYHC-UHFFFAOYSA-N 0.000 description 2
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 2
- 102000017910 Adrenergic receptor Human genes 0.000 description 2
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102400000345 Angiotensin-2 Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 2
- 102000000905 Cadherin Human genes 0.000 description 2
- 108050007957 Cadherin Proteins 0.000 description 2
- 108010001789 Calcitonin Receptors Proteins 0.000 description 2
- 102100038520 Calcitonin receptor Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 description 2
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 2
- 102000008122 Casein Kinase I Human genes 0.000 description 2
- 108010049812 Casein Kinase I Proteins 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 101800001982 Cholecystokinin Proteins 0.000 description 2
- 102100025841 Cholecystokinin Human genes 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 2
- 108010074311 Corticotropin Receptors Proteins 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 102000005927 Cysteine Proteases Human genes 0.000 description 2
- 108010005843 Cysteine Proteases Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- 102000015554 Dopamine receptor Human genes 0.000 description 2
- 108050004812 Dopamine receptor Proteins 0.000 description 2
- 108010066805 F-Box Proteins Proteins 0.000 description 2
- 102000018700 F-Box Proteins Human genes 0.000 description 2
- 108010060374 FSH Receptors Proteins 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 102100027627 Follicle-stimulating hormone receptor Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101150056133 GNPNAT1 gene Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 102100023951 Glucosamine 6-phosphate N-acetyltransferase Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 108091006065 Gs proteins Proteins 0.000 description 2
- 101000678419 Homo sapiens Adrenocorticotropic hormone receptor Proteins 0.000 description 2
- 101001066435 Homo sapiens Hepatocyte growth factor-like protein Proteins 0.000 description 2
- 101001081180 Homo sapiens Humanin-like 10 Proteins 0.000 description 2
- 101000880431 Homo sapiens Serine/threonine-protein kinase 4 Proteins 0.000 description 2
- 101000608584 Homo sapiens Ubiquitin-like modifier-activating enzyme 5 Proteins 0.000 description 2
- 101000807859 Homo sapiens Vasopressin V2 receptor Proteins 0.000 description 2
- 101000814304 Homo sapiens WW domain-binding protein 2 Proteins 0.000 description 2
- 102100027734 Humanin-like 10 Human genes 0.000 description 2
- 102100037978 InaD-like protein Human genes 0.000 description 2
- 101710088275 InaD-like protein Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 description 2
- 102100038352 Metabotropic glutamate receptor 3 Human genes 0.000 description 2
- 102100038354 Metabotropic glutamate receptor 4 Human genes 0.000 description 2
- 102100038300 Metabotropic glutamate receptor 6 Human genes 0.000 description 2
- 102100038294 Metabotropic glutamate receptor 7 Human genes 0.000 description 2
- 102100037636 Metabotropic glutamate receptor 8 Human genes 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 206010073137 Myxoid liposarcoma Diseases 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- UEWXWILGLZMBNJ-UHFFFAOYSA-N N-tert-butyl-4-(cyclohexylamino)-3-(2H-tetrazol-5-yl)benzenesulfonamide Chemical compound C(C)(C)(C)NS(=O)(=O)C1=CC(=C(C=C1)NC1CCCCC1)C=1N=NNN=1 UEWXWILGLZMBNJ-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical group C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010050183 Prostaglandin Receptors Proteins 0.000 description 2
- 102000015433 Prostaglandin Receptors Human genes 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 102000000341 S-Phase Kinase-Associated Proteins Human genes 0.000 description 2
- 108010055623 S-Phase Kinase-Associated Proteins Proteins 0.000 description 2
- 101710204410 Scaffold protein Proteins 0.000 description 2
- 102100037629 Serine/threonine-protein kinase 4 Human genes 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000027077 Stickler syndrome Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 102000003938 Thromboxane Receptors Human genes 0.000 description 2
- 108090000300 Thromboxane Receptors Proteins 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 102100040114 Trace amine-associated receptor 1 Human genes 0.000 description 2
- 108090000946 Trace amine-associated receptor 1 Proteins 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 102100031873 Transcriptional coactivator YAP1 Human genes 0.000 description 2
- 102400000757 Ubiquitin Human genes 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 108010091546 Ubiquitin-Activating Enzymes Proteins 0.000 description 2
- 102000018478 Ubiquitin-Activating Enzymes Human genes 0.000 description 2
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 2
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 2
- 102000018390 Ubiquitin-Specific Proteases Human genes 0.000 description 2
- 108010066496 Ubiquitin-Specific Proteases Proteins 0.000 description 2
- 101710132695 Ubiquitin-conjugating enzyme E2 Proteins 0.000 description 2
- 102100039197 Ubiquitin-like modifier-activating enzyme 5 Human genes 0.000 description 2
- 102100037108 Vasopressin V2 receptor Human genes 0.000 description 2
- 102000052912 WW domain-binding protein 2 Human genes 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 102100023895 Zyxin Human genes 0.000 description 2
- 108010023249 Zyxin Proteins 0.000 description 2
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 102000035181 adaptor proteins Human genes 0.000 description 2
- 108091005764 adaptor proteins Proteins 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 210000002867 adherens junction Anatomy 0.000 description 2
- 201000006966 adult T-cell leukemia Diseases 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 230000006909 anti-apoptosis Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229940107137 cholecystokinin Drugs 0.000 description 2
- 230000003081 coactivator Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 150000001982 diacylglycerols Chemical class 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical group C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 description 2
- 108010038445 metabotropic glutamate receptor 3 Proteins 0.000 description 2
- 108010038422 metabotropic glutamate receptor 4 Proteins 0.000 description 2
- 108010038450 metabotropic glutamate receptor 6 Proteins 0.000 description 2
- 108010038449 metabotropic glutamate receptor 7 Proteins 0.000 description 2
- 108010038448 metabotropic glutamate receptor 8 Proteins 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- NJCMKVQJMGRUTH-UHFFFAOYSA-N n-tert-butyl-3-cyano-4-fluorobenzenesulfonamide Chemical compound CC(C)(C)NS(=O)(=O)C1=CC=C(F)C(C#N)=C1 NJCMKVQJMGRUTH-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 230000030648 nucleus localization Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 230000007319 proteasomal degradation pathway Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000009919 sequestration Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- RIOKPEBUTRGTEA-UHFFFAOYSA-N tert-butyl 3-(4-methylphenyl)sulfonyloxyazetidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC1CN(C(=O)OC(C)(C)C)C1 RIOKPEBUTRGTEA-UHFFFAOYSA-N 0.000 description 2
- UIJXHKXIOCDSEB-UHFFFAOYSA-N tert-butyl 3-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(O)C1 UIJXHKXIOCDSEB-UHFFFAOYSA-N 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 2
- 210000001578 tight junction Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- NHPQGZOBHSVTAQ-IBGZPJMESA-N (2s)-n-(3,5-dimethylphenyl)-1-(4-methoxyphenyl)sulfonylpyrrolidine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1[C@H](C(=O)NC=2C=C(C)C=C(C)C=2)CCC1 NHPQGZOBHSVTAQ-IBGZPJMESA-N 0.000 description 1
- KZEDPVFJLQLDIZ-UHFFFAOYSA-N (5-diphenylphosphanyl-9,9-dimethylxanthen-4-yl)-diphenylphosphane Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1.C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZEDPVFJLQLDIZ-UHFFFAOYSA-N 0.000 description 1
- 125000006732 (C1-C15) alkyl group Chemical group 0.000 description 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 125000006313 (C5-C8) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
- 125000005987 1-oxo-thiomorpholinyl group Chemical group 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical class OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- NQIBQILAMKZKFE-UHFFFAOYSA-N 2-(5-bromo-2-fluorophenyl)-3-fluoropyridine Chemical compound FC1=CC=C(Br)C=C1C1=NC=CC=C1F NQIBQILAMKZKFE-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- LVXLCZPTUBQNHH-UHFFFAOYSA-N 2-amino-5-[[1-(carboxymethylamino)-3-(2-chloro-1,1,2-trifluoroethyl)sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)C(N)CCC(=O)NC(CSC(F)(F)C(F)Cl)C(=O)NCC(O)=O LVXLCZPTUBQNHH-UHFFFAOYSA-N 0.000 description 1
- LROBAEGWLAMYMU-UHFFFAOYSA-N 2-anilinobenzenesulfonamide Chemical compound C1(=CC=CC=C1)NC1=C(C=CC=C1)S(=O)(=O)N LROBAEGWLAMYMU-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical class OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- SXZGCYPEALSLFY-UHFFFAOYSA-N 2-pyridin-4-ylbenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=NC=C1 SXZGCYPEALSLFY-UHFFFAOYSA-N 0.000 description 1
- LECKKBMOOVJZMV-UHFFFAOYSA-N 2-pyrimidin-2-ylbenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=NC=CC=N1 LECKKBMOOVJZMV-UHFFFAOYSA-N 0.000 description 1
- QBPILKHFXOYCNH-UHFFFAOYSA-N 2-pyrimidin-4-ylbenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=NC=N1 QBPILKHFXOYCNH-UHFFFAOYSA-N 0.000 description 1
- FEZBQTYFEIKWAC-UHFFFAOYSA-N 2-pyrimidin-5-ylbenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CN=CN=C1 FEZBQTYFEIKWAC-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- VEJXFHGPVSWRRL-UHFFFAOYSA-N 4-(2,5-difluoroanilino)-N-methyl-3-(2-methyltetrazol-5-yl)benzenesulfonamide Chemical compound CNS(=O)(=O)c1ccc(Nc2cc(F)ccc2F)c(c1)-c1nnn(C)n1 VEJXFHGPVSWRRL-UHFFFAOYSA-N 0.000 description 1
- WBTKTCUKEYNYEE-UHFFFAOYSA-N 4-(cyclohexylamino)-N-methyl-3-(1-methylimidazol-4-yl)benzenesulfonamide Chemical compound C1(CCCCC1)NC1=C(C=C(C=C1)S(=O)(=O)NC)C=1N=CN(C=1)C WBTKTCUKEYNYEE-UHFFFAOYSA-N 0.000 description 1
- KDHJUDLJKVRQPR-UHFFFAOYSA-N 4-(cyclohexylamino)-N-methyl-3-(1-methylpyrazol-3-yl)benzenesulfonamide Chemical compound C1(CCCCC1)NC1=C(C=C(C=C1)S(=O)(=O)NC)C1=NN(C=C1)C KDHJUDLJKVRQPR-UHFFFAOYSA-N 0.000 description 1
- CGYINAXWHICQPJ-UHFFFAOYSA-N 4-(cyclohexylamino)-N-methyl-3-(1-methyltriazol-4-yl)benzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC(C2=CN(C)N=N2)=C(NC2CCCCC2)C=C1 CGYINAXWHICQPJ-UHFFFAOYSA-N 0.000 description 1
- WZDAATZSJGGEQI-UHFFFAOYSA-N 4-(cyclohexylamino)-N-methyl-3-(2-methyltetrazol-5-yl)benzenesulfonamide Chemical compound C1(CCCCC1)NC1=C(C=C(C=C1)S(=O)(=O)NC)C=1N=NN(N=1)C WZDAATZSJGGEQI-UHFFFAOYSA-N 0.000 description 1
- UBYQWAGDYIHVSB-UHFFFAOYSA-N 4-(cyclohexylamino)-N-methyl-3-(5-methyl-1,2,4-oxadiazol-3-yl)benzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC(C2=NOC(C)=N2)=C(NC2CCCCC2)C=C1 UBYQWAGDYIHVSB-UHFFFAOYSA-N 0.000 description 1
- XEGMKHJUPJNCNJ-UHFFFAOYSA-N 4-(cyclohexylamino)-N-methyl-3-(5-methyl-1H-1,2,4-triazol-3-yl)benzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC(C2=NNC(C)=N2)=C(NC2CCCCC2)C=C1 XEGMKHJUPJNCNJ-UHFFFAOYSA-N 0.000 description 1
- XGBVSMHWANMJNJ-UHFFFAOYSA-N 4-(cyclohexylamino)-N-methyl-3-[2-(2,2,2-trifluoroethyl)tetrazol-5-yl]benzenesulfonamide Chemical compound C1(CCCCC1)NC1=C(C=C(C=C1)S(=O)(=O)NC)C=1N=NN(N=1)CC(F)(F)F XGBVSMHWANMJNJ-UHFFFAOYSA-N 0.000 description 1
- QJHYGKFVUNIFCW-UHFFFAOYSA-N 4-(cyclohexylamino)-N-methyl-3-[2-(pyridin-3-ylmethyl)tetrazol-5-yl]benzenesulfonamide Chemical compound C1(CCCCC1)NC1=C(C=C(C=C1)S(=O)(=O)NC)C=1N=NN(N=1)CC=1C=NC=CC=1 QJHYGKFVUNIFCW-UHFFFAOYSA-N 0.000 description 1
- ULRCSQROGXHWKR-UHFFFAOYSA-N 4-(cyclohexylamino)-N-methyl-3-[6-(methylamino)pyridin-2-yl]benzenesulfonamide Chemical compound C1(CCCCC1)NC1=C(C=C(C=C1)S(=O)(=O)NC)C1=NC(=CC=C1)NC ULRCSQROGXHWKR-UHFFFAOYSA-N 0.000 description 1
- RQAJCYUOUIOACJ-UHFFFAOYSA-N 4-(cyclohexylamino)-N-methyl-3-pyridin-2-ylbenzenesulfonamide Chemical compound C1(CCCCC1)NC1=C(C=C(C=C1)S(=O)(=O)NC)C1=NC=CC=C1 RQAJCYUOUIOACJ-UHFFFAOYSA-N 0.000 description 1
- SLESVBROWDUQMC-UHFFFAOYSA-N 4-(cyclohexylamino)-N-methyl-3-pyridin-3-ylbenzenesulfonamide Chemical compound C1(CCCCC1)NC1=C(C=C(C=C1)S(=O)(=O)NC)C=1C=NC=CC=1 SLESVBROWDUQMC-UHFFFAOYSA-N 0.000 description 1
- YKFOPXCUFBVDGU-UHFFFAOYSA-N 4-(cyclohexylamino)-N-methyl-3-pyridin-4-ylbenzenesulfonamide Chemical compound C1(CCCCC1)NC1=C(C=C(C=C1)S(=O)(=O)NC)C1=CC=NC=C1 YKFOPXCUFBVDGU-UHFFFAOYSA-N 0.000 description 1
- RXYMBBCKNZFAPW-UHFFFAOYSA-N 4-(cyclohexylamino)-N-methyl-3-pyrimidin-5-ylbenzenesulfonamide Chemical compound C1(CCCCC1)NC1=C(C=C(C=C1)S(=O)(=O)NC)C=1C=NC=NC=1 RXYMBBCKNZFAPW-UHFFFAOYSA-N 0.000 description 1
- BICYQEVNYIKZTM-UHFFFAOYSA-N 4-[(3,3-difluorocyclohexyl)amino]-N-methyl-3-(2-methyltetrazol-5-yl)benzenesulfonamide Chemical compound FC1(CC(CCC1)NC1=C(C=C(C=C1)S(=O)(=O)NC)C=1N=NN(N=1)C)F BICYQEVNYIKZTM-UHFFFAOYSA-N 0.000 description 1
- GUDJFFQZIISQJB-UHFFFAOYSA-N 4-cyano-5-(3,5-dichloropyridin-4-yl)sulfanyl-n-(4-methylsulfonylphenyl)thiophene-2-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1NC(=O)C(S1)=CC(C#N)=C1SC1=C(Cl)C=NC=C1Cl GUDJFFQZIISQJB-UHFFFAOYSA-N 0.000 description 1
- XJEVFFNOMKXBLU-UHFFFAOYSA-N 4-methylsulfonylaniline Chemical compound CS(=O)(=O)C1=CC=C(N)C=C1 XJEVFFNOMKXBLU-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- 102100040368 5-hydroxytryptamine receptor 6 Human genes 0.000 description 1
- 101710150235 5-hydroxytryptamine receptor 6 Proteins 0.000 description 1
- 102100039126 5-hydroxytryptamine receptor 7 Human genes 0.000 description 1
- 101710150237 5-hydroxytryptamine receptor 7 Proteins 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 108091008803 APLNR Proteins 0.000 description 1
- 101150028385 ATG2 gene Proteins 0.000 description 1
- 208000021970 Abdominal wall defect Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000005676 Adrenogenital syndrome Diseases 0.000 description 1
- 208000005748 Aggressive Fibromatosis Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- UIERETOOQGIECD-UHFFFAOYSA-N Angelic acid Natural products CC=C(C)C(O)=O UIERETOOQGIECD-UHFFFAOYSA-N 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 108050009086 Angiotensin II receptor type 1 Proteins 0.000 description 1
- 102000001838 Angiotensin II receptor type 1 Human genes 0.000 description 1
- 102100036822 Ankyrin repeat and KH domain-containing protein 1 Human genes 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 102000016555 Apelin receptors Human genes 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010092778 Autophagy-Related Protein 7 Proteins 0.000 description 1
- 102100028519 B2 bradykinin receptor Human genes 0.000 description 1
- 101710085045 B2 bradykinin receptor Proteins 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 108010073466 Bombesin Receptors Proteins 0.000 description 1
- 101150042405 CCN1 gene Proteins 0.000 description 1
- 208000016778 CD4+/CD56+ hematodermic neoplasm Diseases 0.000 description 1
- 108010061299 CXCR4 Receptors Proteins 0.000 description 1
- 102000012000 CXCR4 Receptors Human genes 0.000 description 1
- 101100268665 Caenorhabditis elegans acc-1 gene Proteins 0.000 description 1
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 description 1
- 102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 description 1
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 description 1
- 101100164184 Candida albicans (strain SC5314 / ATCC MYA-2876) SPO72 gene Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 229920008347 Cellulose acetate propionate Polymers 0.000 description 1
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010073140 Clear cell sarcoma of soft tissue Diseases 0.000 description 1
- 206010009269 Cleft palate Diseases 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 description 1
- 206010065859 Congenital fibrosarcoma Diseases 0.000 description 1
- 206010010510 Congenital hypothyroidism Diseases 0.000 description 1
- 239000004859 Copal Substances 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010056643 Corticotropin-Releasing Hormone Receptors Proteins 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241000242741 Cubozoa Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010073135 Dedifferentiated liposarcoma Diseases 0.000 description 1
- 206010059352 Desmoid tumour Diseases 0.000 description 1
- 208000008743 Desmoplastic Small Round Cell Tumor Diseases 0.000 description 1
- 206010064581 Desmoplastic small round cell tumour Diseases 0.000 description 1
- 108010093668 Deubiquitinating Enzymes Proteins 0.000 description 1
- 102000001477 Deubiquitinating Enzymes Human genes 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 102100023877 E3 ubiquitin-protein ligase RBX1 Human genes 0.000 description 1
- 101710095156 E3 ubiquitin-protein ligase RBX1 Proteins 0.000 description 1
- 201000006360 Edwards syndrome Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 description 1
- 208000007207 Epithelioid hemangioendothelioma Diseases 0.000 description 1
- 201000005231 Epithelioid sarcoma Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 229920003143 Eudragit® FS 30 D Polymers 0.000 description 1
- 229920003139 Eudragit® L 100 Polymers 0.000 description 1
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 1
- 229920003141 Eudragit® S 100 Polymers 0.000 description 1
- 102100035650 Extracellular calcium-sensing receptor Human genes 0.000 description 1
- 208000016937 Extranodal nasal NK/T cell lymphoma Diseases 0.000 description 1
- 208000016803 Extraskeletal Ewing sarcoma Diseases 0.000 description 1
- 201000003364 Extraskeletal myxoid chondrosarcoma Diseases 0.000 description 1
- 206010015848 Extraskeletal osteosarcomas Diseases 0.000 description 1
- 102100038576 F-box/WD repeat-containing protein 1A Human genes 0.000 description 1
- 102000036353 FBXWs Human genes 0.000 description 1
- 108091007023 FBXWs Proteins 0.000 description 1
- 241000272186 Falco columbarius Species 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010076288 Formyl peptide receptors Proteins 0.000 description 1
- 102000011652 Formyl peptide receptors Human genes 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 101150037782 GAL2 gene Proteins 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 208000027472 Galactosemias Diseases 0.000 description 1
- 102000011392 Galanin receptor Human genes 0.000 description 1
- 108050001605 Galanin receptor Proteins 0.000 description 1
- 102100021735 Galectin-2 Human genes 0.000 description 1
- 102100039997 Gastric inhibitory polypeptide receptor Human genes 0.000 description 1
- 108091006101 Gi proteins Proteins 0.000 description 1
- 102000034354 Gi proteins Human genes 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
- 108010063919 Glucagon Receptors Proteins 0.000 description 1
- 102100040890 Glucagon receptor Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 1
- 108091006067 Goα proteins Proteins 0.000 description 1
- 108091006068 Gq proteins Proteins 0.000 description 1
- 102000052606 Gq-G11 GTP-Binding Protein alpha Subunits Human genes 0.000 description 1
- 102100034154 Guanine nucleotide-binding protein G(i) subunit alpha-2 Human genes 0.000 description 1
- 102100034264 Guanine nucleotide-binding protein G(i) subunit alpha-3 Human genes 0.000 description 1
- 102100032610 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Human genes 0.000 description 1
- 102100039214 Guanine nucleotide-binding protein G(t) subunit alpha-2 Human genes 0.000 description 1
- 102100039215 Guanine nucleotide-binding protein G(t) subunit alpha-3 Human genes 0.000 description 1
- 102100039874 Guanine nucleotide-binding protein G(z) subunit alpha Human genes 0.000 description 1
- 102100023952 Guanine nucleotide-binding protein subunit alpha-14 Human genes 0.000 description 1
- 102100023954 Guanine nucleotide-binding protein subunit alpha-15 Human genes 0.000 description 1
- 241000782205 Guibourtia conjugata Species 0.000 description 1
- 208000006050 Hemangiopericytoma Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
- 102000003710 Histamine H2 Receptors Human genes 0.000 description 1
- 108090000050 Histamine H2 Receptors Proteins 0.000 description 1
- 102000004384 Histamine H3 receptors Human genes 0.000 description 1
- 108090000981 Histamine H3 receptors Proteins 0.000 description 1
- 102000004187 Histamine H4 receptors Human genes 0.000 description 1
- 108090000796 Histamine H4 receptors Proteins 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 206010050469 Holt-Oram syndrome Diseases 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 102100032827 Homeodomain-interacting protein kinase 2 Human genes 0.000 description 1
- 101000928335 Homo sapiens Ankyrin repeat and KH domain-containing protein 1 Proteins 0.000 description 1
- 101001030691 Homo sapiens F-box/WD repeat-containing protein 1A Proteins 0.000 description 1
- 101001070508 Homo sapiens Guanine nucleotide-binding protein G(i) subunit alpha-2 Proteins 0.000 description 1
- 101000997034 Homo sapiens Guanine nucleotide-binding protein G(i) subunit alpha-3 Proteins 0.000 description 1
- 101001014590 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Proteins 0.000 description 1
- 101001014594 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms short Proteins 0.000 description 1
- 101000888142 Homo sapiens Guanine nucleotide-binding protein G(t) subunit alpha-2 Proteins 0.000 description 1
- 101000888145 Homo sapiens Guanine nucleotide-binding protein G(t) subunit alpha-3 Proteins 0.000 description 1
- 101000887490 Homo sapiens Guanine nucleotide-binding protein G(z) subunit alpha Proteins 0.000 description 1
- 101000904077 Homo sapiens Guanine nucleotide-binding protein subunit alpha-14 Proteins 0.000 description 1
- 101000904080 Homo sapiens Guanine nucleotide-binding protein subunit alpha-15 Proteins 0.000 description 1
- 101100177268 Homo sapiens HCAR3 gene Proteins 0.000 description 1
- 101001066401 Homo sapiens Homeodomain-interacting protein kinase 2 Proteins 0.000 description 1
- 101000843809 Homo sapiens Hydroxycarboxylic acid receptor 2 Proteins 0.000 description 1
- 101001039035 Homo sapiens Lutropin-choriogonadotropic hormone receptor Proteins 0.000 description 1
- 101001038001 Homo sapiens Lysophosphatidic acid receptor 2 Proteins 0.000 description 1
- 101001038006 Homo sapiens Lysophosphatidic acid receptor 3 Proteins 0.000 description 1
- 101000969581 Homo sapiens MOB kinase activator 1A Proteins 0.000 description 1
- 101001115744 Homo sapiens MOB kinase activator 1B Proteins 0.000 description 1
- 101000978431 Homo sapiens Melanocortin receptor 3 Proteins 0.000 description 1
- 101000978418 Homo sapiens Melanocortin receptor 4 Proteins 0.000 description 1
- 101001134060 Homo sapiens Melanocyte-stimulating hormone receptor Proteins 0.000 description 1
- 101000644718 Homo sapiens NEDD8-conjugating enzyme UBE2F Proteins 0.000 description 1
- 101000644669 Homo sapiens NEDD8-conjugating enzyme Ubc12 Proteins 0.000 description 1
- 101000978734 Homo sapiens Nephrocystin-3 Proteins 0.000 description 1
- 101001014610 Homo sapiens Neuroendocrine secretory protein 55 Proteins 0.000 description 1
- 101000579300 Homo sapiens Prostaglandin F2-alpha receptor Proteins 0.000 description 1
- 101000797903 Homo sapiens Protein ALEX Proteins 0.000 description 1
- 101001094146 Homo sapiens SUMO-activating enzyme subunit 2 Proteins 0.000 description 1
- 101000939246 Homo sapiens SUMO-conjugating enzyme UBC9 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000775102 Homo sapiens Transcriptional coactivator YAP1 Proteins 0.000 description 1
- 101000653735 Homo sapiens Transcriptional enhancer factor TEF-1 Proteins 0.000 description 1
- 101000597045 Homo sapiens Transcriptional enhancer factor TEF-3 Proteins 0.000 description 1
- 101000597035 Homo sapiens Transcriptional enhancer factor TEF-4 Proteins 0.000 description 1
- 101000597043 Homo sapiens Transcriptional enhancer factor TEF-5 Proteins 0.000 description 1
- 101000759994 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 47 Proteins 0.000 description 1
- 101000807344 Homo sapiens Ubiquitin-conjugating enzyme E2 A Proteins 0.000 description 1
- 101000807337 Homo sapiens Ubiquitin-conjugating enzyme E2 B Proteins 0.000 description 1
- 101000807354 Homo sapiens Ubiquitin-conjugating enzyme E2 C Proteins 0.000 description 1
- 101000772904 Homo sapiens Ubiquitin-conjugating enzyme E2 D1 Proteins 0.000 description 1
- 101000772901 Homo sapiens Ubiquitin-conjugating enzyme E2 D2 Proteins 0.000 description 1
- 101000772913 Homo sapiens Ubiquitin-conjugating enzyme E2 D3 Proteins 0.000 description 1
- 101000644655 Homo sapiens Ubiquitin-conjugating enzyme E2 E1 Proteins 0.000 description 1
- 101000644653 Homo sapiens Ubiquitin-conjugating enzyme E2 E2 Proteins 0.000 description 1
- 101000644661 Homo sapiens Ubiquitin-conjugating enzyme E2 E3 Proteins 0.000 description 1
- 101000644657 Homo sapiens Ubiquitin-conjugating enzyme E2 G1 Proteins 0.000 description 1
- 101000761646 Homo sapiens Ubiquitin-conjugating enzyme E2 G2 Proteins 0.000 description 1
- 101000644682 Homo sapiens Ubiquitin-conjugating enzyme E2 H Proteins 0.000 description 1
- 101000644689 Homo sapiens Ubiquitin-conjugating enzyme E2 K Proteins 0.000 description 1
- 101000761737 Homo sapiens Ubiquitin-conjugating enzyme E2 L3 Proteins 0.000 description 1
- 101000761741 Homo sapiens Ubiquitin-conjugating enzyme E2 Q1 Proteins 0.000 description 1
- 101000808785 Homo sapiens Ubiquitin-conjugating enzyme E2 Q2 Proteins 0.000 description 1
- 101000808784 Homo sapiens Ubiquitin-conjugating enzyme E2 R1 Proteins 0.000 description 1
- 101000808789 Homo sapiens Ubiquitin-conjugating enzyme E2 R2 Proteins 0.000 description 1
- 101000837565 Homo sapiens Ubiquitin-conjugating enzyme E2 S Proteins 0.000 description 1
- 101000837581 Homo sapiens Ubiquitin-conjugating enzyme E2 T Proteins 0.000 description 1
- 101000837580 Homo sapiens Ubiquitin-conjugating enzyme E2 U Proteins 0.000 description 1
- 101000772891 Homo sapiens Ubiquitin-conjugating enzyme E2 Z Proteins 0.000 description 1
- 101000808753 Homo sapiens Ubiquitin-conjugating enzyme E2 variant 1 Proteins 0.000 description 1
- 101000940063 Homo sapiens Ubiquitin-conjugating enzyme E2 variant 2 Proteins 0.000 description 1
- 101000809090 Homo sapiens Ubiquitin-fold modifier-conjugating enzyme 1 Proteins 0.000 description 1
- 101000807306 Homo sapiens Ubiquitin-like modifier-activating enzyme 1 Proteins 0.000 description 1
- 101000662026 Homo sapiens Ubiquitin-like modifier-activating enzyme 7 Proteins 0.000 description 1
- 101000761740 Homo sapiens Ubiquitin/ISG15-conjugating enzyme E2 L6 Proteins 0.000 description 1
- 101000650162 Homo sapiens WW domain-containing transcription regulator protein 1 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 102100030643 Hydroxycarboxylic acid receptor 2 Human genes 0.000 description 1
- 102100039356 Hydroxycarboxylic acid receptor 3 Human genes 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 201000003803 Inflammatory myofibroblastic tumor Diseases 0.000 description 1
- 206010067917 Inflammatory myofibroblastic tumour Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 201000008869 Juxtacortical Osteosarcoma Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000028226 Krabbe disease Diseases 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102100040788 Lutropin-choriogonadotropic hormone receptor Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100040387 Lysophosphatidic acid receptor 2 Human genes 0.000 description 1
- 102100040388 Lysophosphatidic acid receptor 3 Human genes 0.000 description 1
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 1
- 102100021437 MOB kinase activator 1A Human genes 0.000 description 1
- 102100024997 MOB kinase activator 1B Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108700000232 Medium chain acyl CoA dehydrogenase deficiency Proteins 0.000 description 1
- 102000030612 Melanocortin 5 receptor Human genes 0.000 description 1
- 108010088565 Melanocortin 5 receptor Proteins 0.000 description 1
- 108090000950 Melanocortin Receptors Proteins 0.000 description 1
- 102000004378 Melanocortin Receptors Human genes 0.000 description 1
- 102100023726 Melanocortin receptor 3 Human genes 0.000 description 1
- 102100023724 Melanocortin receptor 4 Human genes 0.000 description 1
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 1
- 201000009574 Mesenchymal Chondrosarcoma Diseases 0.000 description 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 206010066948 Myxofibrosarcoma Diseases 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical class CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- YKGVBPZHEYWNRV-UHFFFAOYSA-N N-tert-butyl-4-(cyclohexylamino)-3-[2-(2-hydroxyethyl)tetrazol-5-yl]benzenesulfonamide Chemical compound C(C)(C)(C)NS(=O)(=O)C1=CC(=C(C=C1)NC1CCCCC1)C=1N=NN(N=1)CCO YKGVBPZHEYWNRV-UHFFFAOYSA-N 0.000 description 1
- 108091007791 NAE1 Proteins 0.000 description 1
- 102100029781 NEDD8-activating enzyme E1 regulatory subunit Human genes 0.000 description 1
- 102100020694 NEDD8-conjugating enzyme UBE2F Human genes 0.000 description 1
- 102100020710 NEDD8-conjugating enzyme Ubc12 Human genes 0.000 description 1
- 102100023188 Nephrocystin-3 Human genes 0.000 description 1
- 208000033383 Neuroendocrine tumor of pancreas Diseases 0.000 description 1
- 101100380548 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) apg-2 gene Proteins 0.000 description 1
- 108700010041 Nicotinic acid receptor Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100028646 Nociceptin receptor Human genes 0.000 description 1
- 102100027069 Odontogenic ameloblast-associated protein Human genes 0.000 description 1
- 101710091533 Odontogenic ameloblast-associated protein Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 102100037600 P2Y purinoceptor 1 Human genes 0.000 description 1
- 108050008996 P2Y purinoceptor 1 Proteins 0.000 description 1
- 102100028045 P2Y purinoceptor 2 Human genes 0.000 description 1
- 101710096700 P2Y purinoceptor 2 Proteins 0.000 description 1
- 102100028070 P2Y purinoceptor 4 Human genes 0.000 description 1
- 108050009478 P2Y purinoceptor 4 Proteins 0.000 description 1
- 102100028074 P2Y purinoceptor 6 Human genes 0.000 description 1
- 101710096702 P2Y purinoceptor 6 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010058828 Parathyroid Hormone Receptors Proteins 0.000 description 1
- 102100032256 Parathyroid hormone/parathyroid hormone-related peptide receptor Human genes 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 102100030919 Phosphatidylcholine:ceramide cholinephosphotransferase 1 Human genes 0.000 description 1
- 201000010395 Pleomorphic liposarcoma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102100035842 Prostaglandin E2 receptor EP1 subtype Human genes 0.000 description 1
- 101710097690 Prostaglandin E2 receptor EP1 subtype Proteins 0.000 description 1
- 102100024447 Prostaglandin E2 receptor EP3 subtype Human genes 0.000 description 1
- 101710125002 Prostaglandin E2 receptor EP3 subtype Proteins 0.000 description 1
- 102100028248 Prostaglandin F2-alpha receptor Human genes 0.000 description 1
- 102000002020 Protease-activated receptors Human genes 0.000 description 1
- 108050009310 Protease-activated receptors Proteins 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 102100022309 Protein KIBRA Human genes 0.000 description 1
- 101710145046 Protein kibra Proteins 0.000 description 1
- 102100022095 Protocadherin Fat 1 Human genes 0.000 description 1
- 101710095128 Protocadherin Fat 1 Proteins 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 101710178916 RING-box protein 1 Proteins 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 206010073139 Round cell liposarcoma Diseases 0.000 description 1
- 108700008242 S-(2-chloro-1,1,2-trifluoroethyl)glutathione Proteins 0.000 description 1
- 102100035250 SUMO-activating enzyme subunit 2 Human genes 0.000 description 1
- 102100029807 SUMO-conjugating enzyme UBC9 Human genes 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 102100028927 Secretin receptor Human genes 0.000 description 1
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 1
- 101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 108050001286 Somatostatin Receptor Proteins 0.000 description 1
- 102000011096 Somatostatin receptor Human genes 0.000 description 1
- 102100025749 Sphingosine 1-phosphate receptor 2 Human genes 0.000 description 1
- 101710155462 Sphingosine 1-phosphate receptor 2 Proteins 0.000 description 1
- 102100025747 Sphingosine 1-phosphate receptor 3 Human genes 0.000 description 1
- 101710155457 Sphingosine 1-phosphate receptor 3 Proteins 0.000 description 1
- 102100029803 Sphingosine 1-phosphate receptor 4 Human genes 0.000 description 1
- 101710155458 Sphingosine 1-phosphate receptor 4 Proteins 0.000 description 1
- 102100029802 Sphingosine 1-phosphate receptor 5 Human genes 0.000 description 1
- 101710155451 Sphingosine 1-phosphate receptor 5 Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 108700040013 TEA Domain Transcription Factors Proteins 0.000 description 1
- 108010072901 Tachykinin Receptors Proteins 0.000 description 1
- 102000007124 Tachykinin Receptors Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102100028651 Tenascin-N Human genes 0.000 description 1
- 101710087911 Tenascin-N Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102100029337 Thyrotropin receptor Human genes 0.000 description 1
- 102100025173 Trace amine-associated receptor 8 Human genes 0.000 description 1
- 101710116434 Trace amine-associated receptor 8 Proteins 0.000 description 1
- 101710193680 Transcriptional coactivator YAP1 Proteins 0.000 description 1
- 102100029898 Transcriptional enhancer factor TEF-1 Human genes 0.000 description 1
- 102100035148 Transcriptional enhancer factor TEF-3 Human genes 0.000 description 1
- 102100035146 Transcriptional enhancer factor TEF-4 Human genes 0.000 description 1
- 102100035147 Transcriptional enhancer factor TEF-5 Human genes 0.000 description 1
- 208000007159 Trisomy 18 Syndrome Diseases 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 108010021430 Type 2 Melanocortin Receptor Proteins 0.000 description 1
- 102000003436 UBA3 Human genes 0.000 description 1
- 108060008744 UBA3 Proteins 0.000 description 1
- 102100025029 Ubiquitin carboxyl-terminal hydrolase 47 Human genes 0.000 description 1
- 102000003431 Ubiquitin-Conjugating Enzyme Human genes 0.000 description 1
- 108060008747 Ubiquitin-Conjugating Enzyme Proteins 0.000 description 1
- 102100037261 Ubiquitin-conjugating enzyme E2 A Human genes 0.000 description 1
- 102100037262 Ubiquitin-conjugating enzyme E2 B Human genes 0.000 description 1
- 102100037256 Ubiquitin-conjugating enzyme E2 C Human genes 0.000 description 1
- 102100030433 Ubiquitin-conjugating enzyme E2 D1 Human genes 0.000 description 1
- 102100030439 Ubiquitin-conjugating enzyme E2 D2 Human genes 0.000 description 1
- 102100030425 Ubiquitin-conjugating enzyme E2 D3 Human genes 0.000 description 1
- 102100020711 Ubiquitin-conjugating enzyme E2 E1 Human genes 0.000 description 1
- 102100020704 Ubiquitin-conjugating enzyme E2 E2 Human genes 0.000 description 1
- 102100020709 Ubiquitin-conjugating enzyme E2 E3 Human genes 0.000 description 1
- 102100020712 Ubiquitin-conjugating enzyme E2 G1 Human genes 0.000 description 1
- 102100024870 Ubiquitin-conjugating enzyme E2 G2 Human genes 0.000 description 1
- 102100020698 Ubiquitin-conjugating enzyme E2 H Human genes 0.000 description 1
- 102100020696 Ubiquitin-conjugating enzyme E2 K Human genes 0.000 description 1
- 102100024861 Ubiquitin-conjugating enzyme E2 L3 Human genes 0.000 description 1
- 102100024846 Ubiquitin-conjugating enzyme E2 Q1 Human genes 0.000 description 1
- 102100038500 Ubiquitin-conjugating enzyme E2 Q2 Human genes 0.000 description 1
- 102100038466 Ubiquitin-conjugating enzyme E2 R1 Human genes 0.000 description 1
- 102100038499 Ubiquitin-conjugating enzyme E2 R2 Human genes 0.000 description 1
- 102100028718 Ubiquitin-conjugating enzyme E2 S Human genes 0.000 description 1
- 102100028705 Ubiquitin-conjugating enzyme E2 T Human genes 0.000 description 1
- 102100028710 Ubiquitin-conjugating enzyme E2 U Human genes 0.000 description 1
- 102100030441 Ubiquitin-conjugating enzyme E2 Z Human genes 0.000 description 1
- 102100038467 Ubiquitin-conjugating enzyme E2 variant 1 Human genes 0.000 description 1
- 102100031122 Ubiquitin-conjugating enzyme E2 variant 2 Human genes 0.000 description 1
- 102100038483 Ubiquitin-fold modifier-conjugating enzyme 1 Human genes 0.000 description 1
- 102100037160 Ubiquitin-like modifier-activating enzyme 1 Human genes 0.000 description 1
- 102100037938 Ubiquitin-like modifier-activating enzyme 7 Human genes 0.000 description 1
- 102100022979 Ubiquitin-like modifier-activating enzyme ATG7 Human genes 0.000 description 1
- 102100024843 Ubiquitin/ISG15-conjugating enzyme E2 L6 Human genes 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000004136 Vasopressin Receptors Human genes 0.000 description 1
- 108090000643 Vasopressin Receptors Proteins 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 101710088302 WW domain-containing transcription regulator protein 1 Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- UTKBLLDLHPDWDU-ODZAUARKSA-N acetic acid;(z)-but-2-enedioic acid Chemical compound CC(O)=O.OC(=O)\C=C/C(O)=O UTKBLLDLHPDWDU-ODZAUARKSA-N 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 1
- AEMQUICCWRPKDB-UHFFFAOYSA-N acetic acid;cyclohexane-1,2-dicarboxylic acid Chemical compound CC(O)=O.OC(=O)C1CCCCC1C(O)=O AEMQUICCWRPKDB-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005205 alkoxycarbonyloxyalkyl group Chemical group 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 1
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 1
- 208000008524 alveolar soft part sarcoma Diseases 0.000 description 1
- 208000010029 ameloblastoma Diseases 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OWCDMRFUFMERMZ-UHFFFAOYSA-N benzenesulfonamide;hydrochloride Chemical compound Cl.NS(=O)(=O)C1=CC=CC=C1 OWCDMRFUFMERMZ-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005870 benzindolyl group Chemical group 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000005875 benzo[b][1,4]dioxepinyl group Chemical group 0.000 description 1
- 125000005876 benzo[b][1,4]oxazinyl group Chemical group 0.000 description 1
- 125000005873 benzo[d]thiazolyl group Chemical group 0.000 description 1
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000005878 benzonaphthofuranyl group Chemical group 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 206010071434 biotinidase deficiency Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000008791 bone leiomyosarcoma Diseases 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- ILAJWURWJKXJPW-UHFFFAOYSA-N butanedioic acid;octanedioic acid Chemical class OC(=O)CCC(O)=O.OC(=O)CCCCCCC(O)=O ILAJWURWJKXJPW-UHFFFAOYSA-N 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 201000010882 cellular myxoid liposarcoma Diseases 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229920006218 cellulose propionate Polymers 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 201000000292 clear cell sarcoma Diseases 0.000 description 1
- 206010009259 cleft lip Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 201000006815 congenital muscular dystrophy Diseases 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000009504 deubiquitination Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000005509 dibenzothiophenyl group Chemical group 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 210000003237 epithelioid cell Anatomy 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 208000032099 esthesioneuroblastoma Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 201000008815 extraosseous osteosarcoma Diseases 0.000 description 1
- 208000020812 extrarenal rhabdoid tumor Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 201000000844 fibrous synovial sarcoma Diseases 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical group C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 1
- 125000003844 furanonyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 201000004502 glycogen storage disease II Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000000232 haloalkynyl group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
- 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000037417 hyperactivation Effects 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000018337 inherited hemoglobinopathy Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical class CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 201000008834 liposarcoma of bone Diseases 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000031852 maintenance of location in cell Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 206010061526 malignant mesenchymoma Diseases 0.000 description 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 208000005548 medium chain acyl-CoA dehydrogenase deficiency Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical class COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 108091006026 monomeric small GTPases Proteins 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- NOUUUQMKVOUUNR-UHFFFAOYSA-N n,n'-diphenylethane-1,2-diamine Chemical compound C=1C=CC=CC=1NCCNC1=CC=CC=C1 NOUUUQMKVOUUNR-UHFFFAOYSA-N 0.000 description 1
- JTSLALYXYSRPGW-UHFFFAOYSA-N n-[5-(4-cyanophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C1=C2)=CNC1=NC=C2C1=CC=C(C#N)C=C1 JTSLALYXYSRPGW-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- JGNUEHAWRGWWMP-UHFFFAOYSA-N n-phenyl-1,2,4-triazol-1-amine Chemical compound C1=NC=NN1NC1=CC=CC=C1 JGNUEHAWRGWWMP-UHFFFAOYSA-N 0.000 description 1
- QOMITRCCGIXFIG-UHFFFAOYSA-N n-pyridin-2-ylbenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC1=CC=CC=N1 QOMITRCCGIXFIG-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000000025 natural resin Substances 0.000 description 1
- 208000028732 neoplasm with perivascular epithelioid cell differentiation Diseases 0.000 description 1
- 201000010193 neural tube defect Diseases 0.000 description 1
- 208000029974 neurofibrosarcoma Diseases 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- PSACHCMMPFMFAJ-UHFFFAOYSA-N nmm n-methylmorpholine Chemical compound CN1CCOCC1.CN1CCOCC1 PSACHCMMPFMFAJ-UHFFFAOYSA-N 0.000 description 1
- 108010020615 nociceptin receptor Proteins 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Chemical group C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical class CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 201000003434 periosteal osteogenic sarcoma Diseases 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 201000005207 perivascular epithelioid cell tumor Diseases 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 125000005541 phosphonamide group Chemical group 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 201000009463 pleomorphic rhabdomyosarcoma Diseases 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001184 polypeptide Chemical group 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Chemical group 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 102000017953 prostanoid receptors Human genes 0.000 description 1
- 108050007059 prostanoid receptors Proteins 0.000 description 1
- 230000004063 proteosomal degradation Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical class OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 108700027603 secretin receptor Proteins 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000008864 small cell osteogenic sarcoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 208000014653 solitary fibrous tumor Diseases 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 1
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000035581 susceptibility to neural tube defects Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 201000011080 telangiectatic osteogenic sarcoma Diseases 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000004523 tetrazol-1-yl group Chemical group N1(N=NN=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 108040006218 thyroid-stimulating hormone receptor activity proteins Proteins 0.000 description 1
- UIERETOOQGIECD-ONEGZZNKSA-N tiglic acid Chemical compound C\C=C(/C)C(O)=O UIERETOOQGIECD-ONEGZZNKSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 206010053884 trisomy 18 Diseases 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000028973 vesicle-mediated transport Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.
Description
BENZOSULFONYL COMPOUNDS
CROSS-REFERENCE
[0001] This application claims benefit of U.S. Provisional Patent Application No. 62/548,037 filed on August 21, 2017, which is incorporated herein by reference in its entirety.
BACKGROUND OF THE DISCLOSURE
CROSS-REFERENCE
[0001] This application claims benefit of U.S. Provisional Patent Application No. 62/548,037 filed on August 21, 2017, which is incorporated herein by reference in its entirety.
BACKGROUND OF THE DISCLOSURE
[0002] YAP and TAZ are transcriptional co-activators of the Hippo pathway network and regulate cell proliferation, migration, and apoptosis. Inhibition of the Hippo pathway promotes YAP/TAZ translocation to the nucleus, wherein YAP/TAZ interact with transcriptional enhancer associate domain (TEAD) transcription factors and coactivate the expression of target genes and promote cell proliferation. Hyperactivation of YAP and TAZ and/or mutations in one or more members of the Hippo pathway network have been implicated in numerous cancers.
Described herein are inhibitors associated with one or more members of the Hippo pathway network, such as inhibitors of YAP/TAZ or inhibitors that modulate the interaction between YAP/TAZ and TEAD.
SUMMARY OF THE DISCLOSURE
Described herein are inhibitors associated with one or more members of the Hippo pathway network, such as inhibitors of YAP/TAZ or inhibitors that modulate the interaction between YAP/TAZ and TEAD.
SUMMARY OF THE DISCLOSURE
[0003] Provided herein are benzosulfonyl compounds and pharmaceutical compositions comprising said compounds. In some embodiments, the subject compounds are useful for the treatment of cancer.
[0004] Provided in one aspect is a compound of Formula (I) or a pharmaceutically acceptable salt thereof:
0- "
(R -( HN 41:1 (R2), Formula (I) wherein, (Rz),,-.
is a substituted or unsubstituted monocyclic 5-membered heterocyclic ring containing at least one N atom or a substituted or unsubstituted monocyclic 6-membered heteroaryl ring containing at least one N atom;
each Rz is independently H, halogen, -CN, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -L1-Y1, or -L2-L3-Y2;
M iS 0, 1, 2, 3, 4, 0r5;
L1 is substituted or unsubstituted Ci-C6alkylene, substituted or unsubstituted C2-Ciocyclolkylene, or substituted or unsubstituted C2- Cioheterocycloalkylene;
Y1 is substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cio heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
L2 is absent, substituted or unsubstituted Ci-C6alkylene, substituted or unsubstituted C2-Ciocyclolkylene, or substituted or unsubstituted C2-Cioheterocycloalkylene;
L3 is -0-, -S-, -(S=0)-, -(SO2)-, -NR3-, -(C=0)-, -(C=0)0-, -0(C=0)-, -(C=0)NR3-, -(C=0)NR3-0-, -0-NR3(C=0)-, -NR3(C=0)-, -NR3(C=0)NR3-, -0(C=0)NR3-, -NR3(C=0)0-, -NR3(S02)NR3-, -NR3(S02)-,-(S02)NR3-, -(S02)NR3-(C=0)-, -(C=0)-NR3(S02)-, -(S02)NR3-(C=0)0-, -0(C=0)-NR3(S02)-, -NR3(S02)NR3-(C=0)-, -(C=0)-NR3(S02)NR3-, -0(C=0)-NR3(S02)-NR3-, or -NR3(S02)NR3-(C=0)0-;
each R3 is independently H or substituted or unsubstituted Ci-C6alkyl;
Y2 is H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-C10cyc1oa1ky1, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
or R3 and Y2 on the same N atom are taken together with the N atom to which they are attached to form a substituted or unsubstituted N-containing heterocycle;
R is NHR1 or R1;
R1 is substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
ssc A (R2)n is substituted or unsubstituted phenyl or substituted or unsubstituted cyclohexyl;
each R2 is independently H, halogen, -N3, -CN, -SR4, -(S02)R4, -N(R4)2, -0O2R4, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, substituted or unsubstituted N=N
y( heteroaryl, or OF3 .
n is 0, 1, 2, 3, 4, or 5; and each R4 is independently H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
0- "
(R -( HN 41:1 (R2), Formula (I) wherein, (Rz),,-.
is a substituted or unsubstituted monocyclic 5-membered heterocyclic ring containing at least one N atom or a substituted or unsubstituted monocyclic 6-membered heteroaryl ring containing at least one N atom;
each Rz is independently H, halogen, -CN, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -L1-Y1, or -L2-L3-Y2;
M iS 0, 1, 2, 3, 4, 0r5;
L1 is substituted or unsubstituted Ci-C6alkylene, substituted or unsubstituted C2-Ciocyclolkylene, or substituted or unsubstituted C2- Cioheterocycloalkylene;
Y1 is substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cio heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
L2 is absent, substituted or unsubstituted Ci-C6alkylene, substituted or unsubstituted C2-Ciocyclolkylene, or substituted or unsubstituted C2-Cioheterocycloalkylene;
L3 is -0-, -S-, -(S=0)-, -(SO2)-, -NR3-, -(C=0)-, -(C=0)0-, -0(C=0)-, -(C=0)NR3-, -(C=0)NR3-0-, -0-NR3(C=0)-, -NR3(C=0)-, -NR3(C=0)NR3-, -0(C=0)NR3-, -NR3(C=0)0-, -NR3(S02)NR3-, -NR3(S02)-,-(S02)NR3-, -(S02)NR3-(C=0)-, -(C=0)-NR3(S02)-, -(S02)NR3-(C=0)0-, -0(C=0)-NR3(S02)-, -NR3(S02)NR3-(C=0)-, -(C=0)-NR3(S02)NR3-, -0(C=0)-NR3(S02)-NR3-, or -NR3(S02)NR3-(C=0)0-;
each R3 is independently H or substituted or unsubstituted Ci-C6alkyl;
Y2 is H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-C10cyc1oa1ky1, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
or R3 and Y2 on the same N atom are taken together with the N atom to which they are attached to form a substituted or unsubstituted N-containing heterocycle;
R is NHR1 or R1;
R1 is substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
ssc A (R2)n is substituted or unsubstituted phenyl or substituted or unsubstituted cyclohexyl;
each R2 is independently H, halogen, -N3, -CN, -SR4, -(S02)R4, -N(R4)2, -0O2R4, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, substituted or unsubstituted N=N
y( heteroaryl, or OF3 .
n is 0, 1, 2, 3, 4, or 5; and each R4 is independently H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
[0005] In some embodiments, is a substituted or unsubstituted monocyclic 5-membered heterocyclic ring containing at least one N atom.
(Rz),õ-0
(Rz),õ-0
[0006] In some embodiments, is a substituted or unsubstituted monocyclic 5-membered heterocyclic ring containing 1-4 N atoms, 0-2 0 atoms, and 0-2 S
atoms.
z2, -zi z ,
atoms.
z2, -zi z ,
[0007] In some embodiments, is Z2 Z1 is ¨N-, ¨CH-, or -C-;
each Z2 is independently -CRz, -CHRz-, -C(Rz)2-, -NRz-, -N-, -0-, or ¨S-, each - - is independently a single or double bond; and with the provision that the 5-membered heterocyclic ring contains at least one N atom.
each Z2 is independently -CRz, -CHRz-, -C(Rz)2-, -NRz-, -N-, -0-, or ¨S-, each - - is independently a single or double bond; and with the provision that the 5-membered heterocyclic ring contains at least one N atom.
[0008] In some embodiments, is substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted imidazolidinyl, substituted or unsubstituted pyrazolidinyl, substituted or unsubstituted oxazolidinyl, substituted or unsubstituted isoxazolidinyl, substituted or unsubstituted thiazolidinyl, or substituted or unsubstituted isothiazolidinyl.
Rz Rz Rz Rz-.......1\11N>1' Rz-S Rz-N
(Rz),¨. Rz__ Rz
Rz Rz Rz Rz-.......1\11N>1' Rz-S Rz-N
(Rz),¨. Rz__ Rz
[0009] In some embodiments, is Rz Rz Rz , , Rz\
N-N>11 Rz \
Rz).......,),õ Rz\ x Rz \N,V\ Rz \
N
Rz- L Rz-N Rz-N Rz-N\ I Rz- Rz-,Y, Rz )---Rz s,N---NRz r Rz ,N---NRz Rz Rz Rz Rz Rz Rz Rz , , , , , Rz Rz Rz Rz 0 >17 \NIJ'7 Rz)........)17 Rz)--r\ ).-NX Rz ,\N-.)17 Rz-NY?
Rz-c112Li 0' Rz Rz-N 0\ kr ,Rz R
Rz ---"` N-C) i z¨
NO'Rz O'Rz Rz Rz , Rz Rz , Rz Rz Rz Rz Rz Rz \
s-NX \NIV\ Rz ___(\ )NX
N
N
Rz--clo ? Rz-- S' -S S\
Rz )---iRz Rz-N Rz N SRz 1 r¨Rz Rz , ---Rz , Rz , Rz Rz , Rz S NRz ' ' , , Rz Rzy, \
N
Rz....Y17 Rz-N)s Rz ,or Rz =
(Rz),õ-0
N-N>11 Rz \
Rz).......,),õ Rz\ x Rz \N,V\ Rz \
N
Rz- L Rz-N Rz-N Rz-N\ I Rz- Rz-,Y, Rz )---Rz s,N---NRz r Rz ,N---NRz Rz Rz Rz Rz Rz Rz Rz , , , , , Rz Rz Rz Rz 0 >17 \NIJ'7 Rz)........)17 Rz)--r\ ).-NX Rz ,\N-.)17 Rz-NY?
Rz-c112Li 0' Rz Rz-N 0\ kr ,Rz R
Rz ---"` N-C) i z¨
NO'Rz O'Rz Rz Rz , Rz Rz , Rz Rz Rz Rz Rz Rz \
s-NX \NIV\ Rz ___(\ )NX
N
N
Rz--clo ? Rz-- S' -S S\
Rz )---iRz Rz-N Rz N SRz 1 r¨Rz Rz , ---Rz , Rz , Rz Rz , Rz S NRz ' ' , , Rz Rzy, \
N
Rz....Y17 Rz-N)s Rz ,or Rz =
(Rz),õ-0
[0010] In some embodiments, is substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted pyrazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted isothiazolyl, substituted or unsubstituted triazoyl, substituted or unsubstituted tetrazoyl, substituted or unsubstituted oxadiazolyl, substituted or unsubstituted thiadiazolyl, or substituted or unsubstituted dithiazolyl.
Rz Rz R),.., ______L>17 \NI,V\
Rz / N Rz-yi\ Rz-N
rRz (Rz),-41) Rz Rz
Rz Rz R),.., ______L>17 \NI,V\
Rz / N Rz-yi\ Rz-N
rRz (Rz),-41) Rz Rz
[0011] In some embodiments, is Rz Rz Rz , , Rz Rz ). X \
, N -.. / -..... _IN Rz-N, N'N-._,\ N N
\ I >zz.....-->"
Rz )----Rz \T¨Rz Rz-N y. --IN 1 Rz Rz-4 I
Rz Rz , Rz seNRz Rz N---NRz Rz , , , Rz N-.. N,..-,....)27 Rz Rz ,N--.21, Rz Nz:1)17 Y7 Rz).õ..õ., 0')..::::...N.
" z z N I -$0 N)\ 0 R R µ,.,_.,...N Rz¨ h):7-- Rz- I
O' Rz Rz l-1 Rz N' , Rz , Rz Rz , Rz N...)17 Rz N---/\ NY? Nz:1)'? Rzl._ i N,m)a, N. A, ', N
S' m)i-1)11 )----Rz II= I Rz- I ....-S Rz-$____s _ N N\ j Rz S"--NRz S"-NRz RI , Rz , Rz Rz `Rz , , , Rz Nf, \Ne2, RzRzy, N z =NY2' Rz Rz\
R -N y2, N
's I
:-N ):---N R
N z- - 's I f µN¨ µN
Rz Rz 1\1N Rz , µ1\1:"N , 1\1-"N , i\F--N , Rz ,µ
N, A, ,Nf Pf O'NY4 N ,O.õ)2, Rz-- Y Nµ I No I ).--:"--N Rz-- ''''''1)2' Ns-jrg Rz--- li N--:N Rz Rz Rz N-0 b-N NN , 0, A, , Rz 0, 22, N, A, N....f2, ,sf, s/NY?' Rz-N' N Rz--y 0' N
).____L \ is .,..A N: I No I
Rz Rz r-1Z RZ Rz Rz S Rz N
Rz Rz , rµ , , SNf, ,s- A Rz\
N, A, Rz¨N. IN NA Rz_..c...,,,.., S's IN , N S,}2, : ) z--µ...T ----=-J\Rz R \ IV, =)------ -- Rz-- -- II
Rz Rz N-S , Rz Rz , Rz Rz , or N-N .
, N -.. / -..... _IN Rz-N, N'N-._,\ N N
\ I >zz.....-->"
Rz )----Rz \T¨Rz Rz-N y. --IN 1 Rz Rz-4 I
Rz Rz , Rz seNRz Rz N---NRz Rz , , , Rz N-.. N,..-,....)27 Rz Rz ,N--.21, Rz Nz:1)17 Y7 Rz).õ..õ., 0')..::::...N.
" z z N I -$0 N)\ 0 R R µ,.,_.,...N Rz¨ h):7-- Rz- I
O' Rz Rz l-1 Rz N' , Rz , Rz Rz , Rz N...)17 Rz N---/\ NY? Nz:1)'? Rzl._ i N,m)a, N. A, ', N
S' m)i-1)11 )----Rz II= I Rz- I ....-S Rz-$____s _ N N\ j Rz S"--NRz S"-NRz RI , Rz , Rz Rz `Rz , , , Rz Nf, \Ne2, RzRzy, N z =NY2' Rz Rz\
R -N y2, N
's I
:-N ):---N R
N z- - 's I f µN¨ µN
Rz Rz 1\1N Rz , µ1\1:"N , 1\1-"N , i\F--N , Rz ,µ
N, A, ,Nf Pf O'NY4 N ,O.õ)2, Rz-- Y Nµ I No I ).--:"--N Rz-- ''''''1)2' Ns-jrg Rz--- li N--:N Rz Rz Rz N-0 b-N NN , 0, A, , Rz 0, 22, N, A, N....f2, ,sf, s/NY?' Rz-N' N Rz--y 0' N
).____L \ is .,..A N: I No I
Rz Rz r-1Z RZ Rz Rz S Rz N
Rz Rz , rµ , , SNf, ,s- A Rz\
N, A, Rz¨N. IN NA Rz_..c...,,,.., S's IN , N S,}2, : ) z--µ...T ----=-J\Rz R \ IV, =)------ -- Rz-- -- II
Rz Rz N-S , Rz Rz , Rz Rz , or N-N .
[0012] In some embodiments, is a substituted or unsubstituted monocyclic 6-membered heteroaryl ring containing at least one N atom.
(Rz)m-41)
(Rz)m-41)
[0013] In some embodiments, is a substituted or unsubstituted monocyclic 6-membered heteroaryl ring containing 1 or 2 N atoms.
Z2y\
II
(Rz),õ-41) Z2,z2-, Z2 =
Z2y\
II
(Rz),õ-41) Z2,z2-, Z2 =
[0014] In some embodiments, is =
, each Z2 is independently CRz or N; and at least one Z2 is N.
(Rz),¨.
, each Z2 is independently CRz or N; and at least one Z2 is N.
(Rz),¨.
[0015] In some embodiments, is substituted or unsubstituted pyridinyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted pyridazinyl.
Rz Rz Rz Rz N
(Rz),¨. Rz Rz RzRz N Rz
Rz Rz Rz Rz N
(Rz),¨. Rz Rz RzRz N Rz
[0016] In some embodiments, is Rz , Rz , Rz , Rz Rz Rz 1\1"-NA RzN)µ' Rzfr\jel' N NY22"
I
N Rz RzmN N z Rz,rN
RzjRz R
Rz Rz Rz Rz Rz N Rz, or Rz
I
N Rz RzmN N z Rz,rN
RzjRz R
Rz Rz Rz Rz Rz N Rz, or Rz
[0017] In some embodiments, the compound has the structure of Formula (Ia), or a pharmaceutically acceptable salt thereof:
0.-(Rz)m-1 HN
- A (R2)n Formula (Ia) wherein Z1 is -N-, -CH-, or -C-.
A
(Rz)m¨
ZI
In some embodiments, is a substituted or unsubstituted monocyclic membered heterocyclic ring containing at least one N atom, and the at least one N atom is adjacent to Z1.
Rz\
N, A = -zi 'NA
(Rz)m¨ Zo Z2 Z2
0.-(Rz)m-1 HN
- A (R2)n Formula (Ia) wherein Z1 is -N-, -CH-, or -C-.
A
(Rz)m¨
ZI
In some embodiments, is a substituted or unsubstituted monocyclic membered heterocyclic ring containing at least one N atom, and the at least one N atom is adjacent to Z1.
Rz\
N, A = -zi 'NA
(Rz)m¨ Zo Z2 Z2
[0018] In some embodiments, is µz2 --Z-or `z2--Z2 .
Z1 is -N-, -CH-, or -C-;
each Z2 is independently CRz, NRz, N, 0, or S;
each - - is independently a single or double bond; and with the provision that the 5-membered heterocyclic ring contains at least one N atom.
A
(Rz),õ¨
ZI
Z1 is -N-, -CH-, or -C-;
each Z2 is independently CRz, NRz, N, 0, or S;
each - - is independently a single or double bond; and with the provision that the 5-membered heterocyclic ring contains at least one N atom.
A
(Rz),õ¨
ZI
[0019] In some embodiments, is substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted imidazolidinyl, substituted or unsubstituted pyrazolidinyl, substituted or unsubstituted oxazolidinyl, substituted or unsubstituted isoxazolidinyl, substituted or unsubstituted thiazolidinyl, or substituted or unsubstituted isothiazolidinyl.
Rz Rz Rz\
\NIV\ \N-NX N-...V\
A =
01, Rz¨____., Rz¨s____L Rz-N
(Rz),¨ Z Rz Rz )----Rz
Rz Rz Rz\
\NIV\ \N-NX N-...V\
A =
01, Rz¨____., Rz¨s____L Rz-N
(Rz),¨ Z Rz Rz )----Rz
[0020] In some embodiments, is Rz Rz Rz , , Rz Rz z \N Rz Rz Rz N
Rz- Rz-_ 0' N---V\ Rz- s' Rz-___e7 N''-'=Rz =Rz )------==Rz Rz-< )----Rz Rzi , Rz , Rz 0"-xRz Rz Rz Rz , or , , Rz \N,7\
Rz-<
S"-NRz.
A' (Rz),¨
ZI
Rz- Rz-_ 0' N---V\ Rz- s' Rz-___e7 N''-'=Rz =Rz )------==Rz Rz-< )----Rz Rzi , Rz , Rz 0"-xRz Rz Rz Rz , or , , Rz \N,7\
Rz-<
S"-NRz.
A' (Rz),¨
ZI
[0021] In some embodiments, is substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted pyrazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted isothiazolyl, substituted or unsubstituted triazoyl, substituted or unsubstituted tetrazoyl, substituted or unsubstituted oxadiazolyl, substituted or unsubstituted thiadiazolyl, or substituted or unsubstituted dithiazolyl.
1,\I-NX N__-...õ.,)11 ziA Rz-s J., Rz¨ Rz¨N
(Rz),õ¨
1,\I-NX N__-...õ.,)11 ziA Rz-s J., Rz¨ Rz¨N
(Rz),õ¨
[0022] In some embodiments, is Rz Rz Rz , , R\ Rz).,.....1)1, Rz \
, NI I \N17\ RN N N
),--:---N Rz-$f 0/ of N---)z, Rz -$0 )NRz Rz-- I yRz Rz- I
Rz N"-iRz Rz , Rz , Rz 0--N-Rz Rz , , N-.}17 N-..(\ N,,,A, Rz Nf, \I\lf, S' -.../XN zR -cs Rzi_ 'I' N
)N1Rz Rz- I -N N\ i N, I
Rzr- `Rz Rz-N:N: 'NI
RZ
Rz N Rz\ Rz\
Nz, N õõrµ, )---.., m A, N,NA, ,Nfl Rz-NY Rz-N):---' f I N" '," Rz--sl\FNi\J-N 'N-:---N
Rz ,Ny2, 0 Rz N , \NI )z, 2, 0/1\if =-c_N)4 0, l' 'NI
02, 'Nf \ 1 µ ` N, )..----- Rz---µ II
-N N: I
N S
, Rz Rz Rz Rz Rz N Rz , S..,,, )--:-"N N Rz--µ ''' . = \ i ` N, )---- Rz--µ li Rz or N-1\1 .
A
(Rz)m¨
ZI
, NI I \N17\ RN N N
),--:---N Rz-$f 0/ of N---)z, Rz -$0 )NRz Rz-- I yRz Rz- I
Rz N"-iRz Rz , Rz , Rz 0--N-Rz Rz , , N-.}17 N-..(\ N,,,A, Rz Nf, \I\lf, S' -.../XN zR -cs Rzi_ 'I' N
)N1Rz Rz- I -N N\ i N, I
Rzr- `Rz Rz-N:N: 'NI
RZ
Rz N Rz\ Rz\
Nz, N õõrµ, )---.., m A, N,NA, ,Nfl Rz-NY Rz-N):---' f I N" '," Rz--sl\FNi\J-N 'N-:---N
Rz ,Ny2, 0 Rz N , \NI )z, 2, 0/1\if =-c_N)4 0, l' 'NI
02, 'Nf \ 1 µ ` N, )..----- Rz---µ II
-N N: I
N S
, Rz Rz Rz Rz Rz N Rz , S..,,, )--:-"N N Rz--µ ''' . = \ i ` N, )---- Rz--µ li Rz or N-1\1 .
A
(Rz)m¨
ZI
[0023] In some embodiments, is a substituted or unsubstituted monocyclic 6-membered heteroaryl ring containing at least one N atom, and wherein the at least one N atom is adjacent to Z1.
II
Z01A is 0z -.z2 ; and
II
Z01A is 0z -.z2 ; and
[0024] In some embodiments, each Z2 is independently CRz or N.
A' (Rz),õ ZI
¨
A' (Rz),õ ZI
¨
[0025] In some embodiments, is substituted or unsubstituted pyridinyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted pyridazinyl.
RN\ N , N \ Rz N ''22, A, 'C -RzrI ,Rz Rz I Rz NRz (Rz),¨ Z
0 [0026] In some embodiments, is Rz , Rz , Rz , Rz Rz N, A
Nrµ' &r TqN N
Rz Rz Rz , or Rz .
[0027] In some embodiments, each Rz is independently H, halogen, -CN, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In some embodiments, each Rz is independently H, halogen, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
In some embodiments, each Rz is independently H, -F, -Cl, -Br, -I, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or phenyl.
[0028] In some embodiments, each Rz is -L'-Y'. In some embodiments, LI is substituted or unsubstituted Ci-C4alkylene; and Y1 is substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cio heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
In some embodiments, each Rz is -L2-L3-Y2. In some embodiments, L2 is substituted or unsubstituted Ci-C6alkylene; L3 is -0-, -S-, -(S=0)-, -(SO2)-, -NR3-, -(C=0)-, -(C=0)0-, -0(C=0)-, -(C=0)NR3-, -(C=0)NR3-0-, -NR3(C=0)-, -NR3(C=0)NR3-, -0(C=0)NR3-, -NR3(C=0)0-, -NR3(S02)NR3-, -NR3(S02)-, -(S02)NR3-, -(S02)NR3-(C=0)-, -(S02)NR3-(C=0)0-, -NR3(S02)NR3-(C=0)-, or -NR3(S02)NR3-(C=0)0-; each R3 is independently H or substituted or unsubstituted Ci-C6alkyl; and Y2 is H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
[0029] In some embodiments, L2 is absent; L3 is -0-, -S-, -(S=0)-, -(SO2)-, -NR3-, -(C=0)-, -(C=0)0-, -0(C=0)-, -(C=0)NR3-, -(C=0)NR3-0-, -NR3(C=0)-, -NR3(C=0)NR3-, -0(C=0)NR3-, -NR3(C=0)0-, -NR3(502)NR3-, -NR3(S02)-, -(502)NR3-, -(S02)NR3-(C=0)-, -(502)NR3-(C=0)0-, -NR3(502)NR3-(C=0)-, or -NR3(502)NR3-(C=0)0-; each R3 is independently H or substituted or unsubstituted Ci-C6alkyl; and Y2 is H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
o,R
0- 0 0 0õ0 R
"S¨R ,s*
\SR HN,4 HN HN HN
[0030] In some embodiments, fr is .ss , or HN, R
o µI ,R
HN, [0031] In some embodiments, fr is [0032] In some embodiments, R is NHR1; and R1 is substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-C ioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
In some embodiments, RI is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or phenyl.
In some embodiments, R is RI; and RI is substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
In some embodiments, RI is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or phenyl.
7 7' HN 41:o HN
(R2), le (R2)r, [0033] In some embodiments, is [0034] In some embodiments, the compound has the structure of Formula (Ib), or a pharmaceutically acceptable salt thereof:
0- I, -S-R
HN
-(R2)r, Formula (Ib).
HN = (R2) HN i n [0035] In some embodiments, is IW .
'7 7' R2 -1- M
HN = (R2) is r or R2 HN i R2 HN 0 n 1W IW .
[0036] In some embodiments, is R2 7- R2 HN s HN HN
. (R2) r R2 HN 40 n R2 , R2 IW , [0037] In some embodiments, is , 7' 7' R HN
HN r R2 HN r HN R2 R2 IW R-, or R2 .
, 7 (R2) -1-In HN0 (R2)n [0038] In some embodiments, HN4, is [0039] In some embodiments, the compound has the structure of Formula (Ic), or a pharmaceutically acceptable salt thereof:
-S¨R
HN10(R2)n Formula (Ic).
¨1¨ ¨1¨
HN HNo (R2)n [0040] In some embodiments, is .
HNo HNt HN R2 FINO
________________________________ 2)n [0041] In some embodiments, (R is , or R2 HN HN
tR2 HN.(R2)n [0042] In some embodiments, is R2, R2 , M R HN HN R2 ,T, R2 R2 avr HNo_ HNb HN c(R2 HN HNI0 Z2 R2 or R2 , In some embodiments, each R2 is independently H, halogen, -N3, -CN, -SR4, -(S02)R4, -N(R4)2, -0O2R4, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Cr C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-C iocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
In some embodiments, the compound has the structure of Formula (Id), or a pharmaceutically acceptable salt thereof:
R
(Rz)õ,-HN =(R2)n Formula (Id).
[0043] In some embodiments, the compound has the structure of Formula (le), or a pharmaceutically acceptable salt thereof:
R
im HN
Formula (le).
[0044] In some embodiments, the compound has the structure of Formula (If), or a pharmaceutically acceptable salt thereof:
R
HN
______________________________________________ (R2), Formula (If).
[0045] In some embodiments, the compound has the structure of Formula (Ig), or a pharmaceutically acceptable salt thereof:
,R
(Rz)õ,-HN
Formula (Ig).
[0046] In some embodiments, the compound exhibits an IC50 of no more than about 3.000 .M.
[0047] Provided in another aspect is a compound, or pharmaceutically acceptable salt thereof, wherein the compound is a compound from Table 1, or a pharmaceutically acceptable salt thereof [0048] Provided in another aspect is a pharmaceutical composition comprising a pharmaceutically acceptable excipient and any one of the compounds disclosed herein or a pharmaceutically acceptable salt thereof [0049] Provided herein is a method for treating a cancer in a subject in need thereof comprising administering a therapeutically effective amount of a compound of any one of the compounds disclosed herein or a pharmaceutically acceptable salt thereof INCORPORATION BY REFERENCE
[0050] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
BRIEF DESCRIPTION OF THE DRAWINGS
[0051] Various aspects of the disclosure are set forth with particularity in the appended claims.
A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the disclosure are utilized, and the accompanying drawings of which:
[0052] FIG. 1 illustrates a schematic representation of the Hippo signaling network. Hippo pathway components shaded in dark gray indicate components that inhibit YAP/TAZ activity.
Hippo pathway components shaded in light gray indicate components that promote YAP/TAZ
activity. Pointed and blunt arrowheads indicate activating and inhibitory interactions, respectively. Abbreviations: a-CAT (a-Catenin), AJUB (Ajuba), AMOT
(Angiomotin), (3-TRCP
(0-transducing repeat containing protein), CK1 (Casein Kinase 1), CRB
(Crumbs), E-CAD (E-cadherin), EX (Expanded), GPCR (G-protein coupled receptor), HIPK (Homeodomain interacting protein kinase), KIBRA (Kidney brain), LATS (Large tumor suppressor), LGL
(Lethal giant larvae), MASK (Multiple ankyrin single KH), MER (Merlin), MOB
(Mps one binder), MST (Mammalian sterile 20 like), PALS (Protein Associated with Lin-7), PATJ (Pals 1-associated tight junction protein), PP2A (Protein phosphatase 2A), PTPN14 (Protein tyrosine phosphatase non-receptor type 14), RASSF (Ras associated factor), SAV
(Salvador), SCRIB
(Scribble), SIK (Salt inducible kinase), TAO (Thousand and one amino acid protein), TAZ
(transcriptional coactivator with PDZ-binding motif), TEAD (TEA domain protein), VGL4 (Vestigial-like 4), WBP2 (WW domain binding protein 2), YAP (Yes associated protein), ZO
(Zonula occludens), ZYX (Zyxin).
[0053] FIG. 2 illustrates a schematic representation of the Hippo signaling pathway regulated by G alpha proteins.
DETAILED DESCRIPTION OF THE DISCLOSURE
Certain Terminology [0054] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the claimed subject matter belongs. It is to be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of any subject matter claimed. In this application, the use of the singular includes the plural unless specifically stated otherwise. It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. In this application, the use of "or" means "and/or" unless stated otherwise.
Furthermore, use of the term "including" as well as other forms, such as "include", "includes,"
and "included," is not limiting.
[0055] As used herein, in some embodiments, ranges and amounts are expressed as "about" a particular value or range. About also includes the exact amount. Hence "about 5 uL" means "about 5 uL" and also "5 4." Generally, the term "about" includes an amount that is expected to be within experimental error.
[0056] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0057] As used herein, the terms "individual(s)", "subject(s)" and "patient(s)" mean any mammal. In some embodiments, the mammal is a human. In some embodiments, the mammal is anon-human. None of the terms require or are limited to situations characterized by the supervision (e.g. constant or intermittent) of a health care worker (e.g. a doctor, a registered nurse, a nurse practitioner, a physician's assistant, an orderly, or a hospice worker).
[0058] As used in the specification and appended claims, unless specified to the contrary, the following terms have the meaning indicated below.
[0059] "Amino" refers to the ¨NH2 radical.
[0060] "Cyano" refers to the -CN radical.
[0061] "Nitro" refers to the -NO2 radical.
[0062] "Oxa" refers to the -0- radical.
[0063] "Oxo" refers to the =0 radical.
[0064] "Thioxo" refers to the =S radical.
[0065] "Imino" refers to the =N-H radical.
[0066] "Oximo" refers to the =N-OH radical.
[0067] "Alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to fifteen carbon atoms (e.g., C1-C15 alkyl). In certain embodiments, an alkyl comprises one to thirteen carbon atoms (e.g., C1-C13 alkyl). In certain embodiments, an alkyl comprises one to eight carbon atoms (e.g., CI-Cs alkyl). In other embodiments, an alkyl comprises one to five carbon atoms (e.g., Ci-05 alkyl). In other embodiments, an alkyl comprises one to four carbon atoms (e.g., Ci-C4 alkyl). In other embodiments, an alkyl comprises one to three carbon atoms (e.g., Ci-C3 alkyl). In other embodiments, an alkyl comprises one to two carbon atoms (e.g., Ci-C2 alkyl).
In other embodiments, an alkyl comprises one carbon atom (e.g., C1 alkyl). In other embodiments, an alkyl comprises five to fifteen carbon atoms (e.g., C5-C15 alkyl). In other embodiments, an alkyl comprises five to eight carbon atoms (e.g., C5-C8 alkyl). In other embodiments, an alkyl comprises two to five carbon atoms (e.g., C2-05 alkyl). In other embodiments, an alkyl comprises three to five carbon atoms (e.g., C3-05 alkyl). In other embodiments, the alkyl group is selected from methyl, ethyl, 1-propyl (n-propyl), 1-methylethyl (iso-propyl), 1-butyl (n-butyl), 1-methylpropyl (sec-butyl), 2-methylpropyl (iso-butyl), 1,1-dimethylethyl (tert-butyl), 1-pentyl (n-penty1). The alkyl is attached to the rest of the molecule by a single bond.
Unless stated otherwise specifically in the specification, an alkyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -0Ra, -SRa, -0C(0)-Ra, -N(Ra)2, -C(0)Ra, -C(0)0Ra, -C(0)N(Ra)2, -N(Ra)C(0)0Rf, -0C(0)- NRaRf, -N(Ra)C(0)R, -N(Ra)S(0)tRf (where t is 1 or 2), -S(0)tORa (where t is 1 or 2), -S(0)tRf (where t is 1 or 2), and -S(0)N(Ra)2 (where t is 1 or 2), where each Ra is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, and each Rf is independently alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl.
[0068] "Alkoxy" refers to a radical bonded through an oxygen atom of the formula ¨0-alkyl, where alkyl is an alkyl chain as defined above.
[0069] "Alkenyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon double bond, and having from two to twelve carbon atoms. In certain embodiments, an alkenyl comprises two to eight carbon atoms. In other embodiments, an alkenyl comprises two to four carbon atoms. The alkenyl is attached to the rest of the molecule by a single bond, for example, ethenyl (i.e., vinyl), prop-l-enyl (i.e., allyl), but-l-enyl, pent-l-enyl, penta-1,4-dienyl, and the like. Unless stated otherwise specifically in the specification, an alkenyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -0Ra, -SRa, -0C(0)-Ra, -N(Ra)2, -C(0)Ra, -C(0)0Ra, -C(0)N(Ra)2, -N(Ra)C(0)0Rf, -0C(0)- NRaRf, -N(Ra)C(0)Rf, -N(Ra)S(0)tRf (where t is 1 or 2), -S(0)tORa (where t is 1 or 2), -S(0)tRf (where t is 1 or 2), and -S(0)N(Ra)2 (where t is 1 or 2), where each Ra is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, and each Rf is independently alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl.
[0070] "Alkynyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon triple bond, having from two to twelve carbon atoms. In certain embodiments, an alkynyl comprises two to eight carbon atoms. In other embodiments, an alkynyl has two to four carbon atoms.
The alkynyl is attached to the rest of the molecule by a single bond, for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like. Unless stated otherwise specifically in the specification, an alkynyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, oRa, -SR', -0C(0)-IV, -N(102, -C(0)1e, -C(0)01e, -C(0)N(102, -N(V)C(0)0Rf, -0C(0)- MeRf, -N(le)C(0)Rf, -N(10S(0)af (where t is 1 or 2), -S(0)tORa (where t is 1 or 2), -S(0)a (where t is 1 or 2), and -S(0)N(102 (where t is 1 or 2), where each IV is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, and each Rf is independently alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl.
[0071] "Alkylene" or "alkylene chain" refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing no unsaturation and having from one to twelve carbon atoms, for example, methylene, ethylene, propylene, n-butylene, and the like. The alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. In some embodiments, the points of attachment of the alkylene chain to the rest of the molecule and to the radical group are through one carbon in the alkylene chain or through any two carbons within the chain. In certain embodiments, an alkylene comprises one to eight carbon atoms (e.g., C i-C8 alkylene). In other embodiments, an alkylene comprises one to five carbon atoms (e.g., CI-05 alkylene). In other embodiments, an alkylene comprises one to four carbon atoms (e.g., C1-C4 alkylene). In other embodiments, an alkylene comprises one to three carbon atoms (e.g., C1-C3 alkylene). In other embodiments, an alkylene comprises one to two carbon atoms (e.g., C1-C2 alkylene). In other embodiments, an alkylene comprises one carbon atom (e.g., C1 alkylene). In other embodiments, an alkylene comprises five to eight carbon atoms (e.g., C5-C8 alkylene). In other embodiments, an alkylene comprises two to five carbon atoms (e.g., C2-05 alkylene). In other embodiments, an alkylene comprises three to five carbon atoms (e.g., C3-05 alkylene).
Unless stated otherwise specifically in the specification, an alkylene chain is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -01V, sRa,-0C(0)-Ra, -N(102, -C(0)Ra, -C(0)0IV, -C(0)N(102, -N(10C(0)0Rf, -0C(0)- NIZaRf, -N(V)C(0)Rf, -N(10S(0)af (where t is 1 or 2), -S(0)OW
(where t is 1 or 2), -S(0)tRf (where t is 1 or 2), and -S(0)N(102 (where t is 1 or 2), where each IV is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, and each Rf is independently alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl.
[0072] "Aryl" refers to a radical derived from an aromatic monocyclic or multicyclic hydrocarbon ring system by removing a hydrogen atom from a ring carbon atom.
The aromatic monocyclic or multicyclic hydrocarbon ring system contains only hydrogen and carbon from five to eighteen carbon atoms, where at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic, delocalized (4n+2) 7c¨electron system in accordance with the Htickel theory. The ring system from which aryl groups are derived include, but are not limited to, groups such as benzene, fluorene, indane, indene, tetralin, and naphthalene.
Unless stated otherwise specifically in the specification, the term "aryl" or the prefix "ar-" (such as in "aralkyl") is meant to include aryl radicals optionally substituted by one or more substituents independently selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -Rb-CN, -Rb-ORd, -Rb-OC(0)-Rd, -Rb-OC(0)-ORd, -Rb-OC(0)-N(Rd)2, -Rb-N(Rd)2, -Rb-C(0)Rd, -Rb-C(0)0Rd, -Rb-C(0)N(Rd)2, -Rb-O-Rc-C(0)N(Rd)2, -Rb-N(Ra)C(0)0Ra, -Rb-N(Ra)C(0)Ra, -Rb-N(Ra)S(0)tRa (where t is 1 or 2), -Rb-S(0)tORd (where t is 1 or 2), -Rb-S(0)tRa (where t is 1 or 2), and -Rb-S(0)tN(Rd)2 (where t is 1 or 2), where each Ra is independently hydrogen, alkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, aryl (optionally substituted with one or more halo groups), aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, each Rb is independently a direct bond or a straight or branched alkylene or alkenylene chain, and Rc is a straight or branched alkylene or alkenylene chain, and where each of the above substituents is unsubstituted unless otherwise indicated.
[0073] "Aryloxy" refers to a radical bonded through an oxygen atom of the formula ¨0-aryl, where aryl is as defined above.
[0074] "Aralkyl" refers to a radical of the formula -Rc-aryl where Rc is an alkylene chain as defined above, for example, methylene, ethylene, and the like. The alkylene chain part of the aralkyl radical is optionally substituted as described above for an alkylene chain. The aryl part of the aralkyl radical is optionally substituted as described above for an aryl group.
[0075] "Aralkenyl" refers to a radical of the formula ¨Rd-aryl where Rd is an alkenylene chain as defined above. The aryl part of the aralkenyl radical is optionally substituted as described above for an aryl group. The alkenylene chain part of the aralkenyl radical is optionally substituted as defined above for an alkenylene group.
[0076] "Aralkynyl" refers to a radical of the formula -Re-aryl, where Re is an alkynylene chain as defined above. The aryl part of the aralkynyl radical is optionally substituted as described above for an aryl group. The alkynylene chain part of the aralkynyl radical is optionally substituted as defined above for an alkynylene chain.
[0077] "Carbocycly1" refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, and in some embodiments, include fused or bridged ring systems, having from three to fifteen carbon atoms. In certain embodiments, a carbocyclyl comprises three to ten carbon atoms. In other embodiments, a carbocyclyl comprises five to seven carbon atoms. The carbocyclyl is attached to the rest of the molecule by a single bond. In some embodiments, the carbocyclyl is saturated, (i.e., containing single C-C bonds only) or unsaturated (i.e., containing one or more double bonds or triple bonds.) A fully saturated carbocyclyl radical is also referred to as "cycloalkyl." Examples of monocyclic cycloalkyls include, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. In certain embodiments, a cycloalkyl comprises three to eight carbon atoms (e.g., cycloalkyl). In other embodiments, a cycloalkyl comprises three to seven carbon atoms (e.g., C3-C7 cycloalkyl). In other embodiments, a cycloalkyl comprises three to six carbon atoms (e.g., C3-C6 cycloalkyl). In other embodiments, a cycloalkyl comprises three to five carbon atoms (e.g., C3-05 cycloalkyl). In other embodiments, a cycloalkyl comprises three to four carbon atoms (e.g., C3-C4 cycloalkyl). An unsaturated carbocyclyl is also referred to as "cycloalkenyl."
Examples of monocyclic cycloalkenyls include, e.g., cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. Polycyclic carbocyclyl radicals include, for example, adamantyl, norbornyl (i.e., bicyclo[2.2.11heptanyl), norbornenyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.11heptanyl, and the like. Unless otherwise stated specifically in the specification, the term "carbocyclyl" is meant to include carbocyclyl radicals that are optionally substituted by one or more substituents independently selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -CN, -R b-ORa, -Rb-OC(0)-Ra, -Rb-OC(0)-0Ra, -Rb-OC(0)-N(Ra)2, -Rb-N(Ra)2, -Rb-C(0)Ra, -kb-C(0)0Ra, -Rb-C(0)N(Ra)2, -Rb-O-Rc-C(0)N(Ra)2, -Rb-N(Ra)C(0)0Ra, -Rb-N(Ra)C(0)Ra, -Rb-N(Ra)S(0)tRa (where t is 1 or 2), -Rb-S(0)tORa (where t is 1 or 2), -Rb-S(0)tRa (where t is 1 or 2), and -Rb-S(0)tN(Ra)2 (where t is 1 or 2), where each Ra is independently hydrogen, alkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, each Rb is independently a direct bond or a straight or branched alkylene or alkenylene chain, and Rc is a straight or branched alkylene or alkenylene chain, and where each of the above substituents is unsubstituted unless otherwise indicated.
[0078] "Carbocyclylalkyl" refers to a radical of the formula ¨Rc-carbocycly1 where Rc is an alkylene chain as defined above. The alkylene chain and the carbocyclyl radical are optionally substituted as defined above.
[0079] "Halo" or "halogen" refers to bromo, chloro, fluoro, or iodo substituents.
[0080] "Fluoroalkyl" refers to an alkyl radical, as defined above, that is substituted by one or more fluoro radicals, as defined above, for example, trifluoromethyl, difluoromethyl, fluoromethyl, 2,2,2-trifluoroethyl, 1-fluoromethy1-2-fluoroethyl, and the like. In some embodiments, the alkyl part of the fluoroalkyl radical is optionally substituted as defined above for an alkyl group.
[0081] "Heterocycly1" or "heterocycle" refers to a stable 3- to 18-membered non-aromatic ring radical that comprises two to twelve carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen, and sulfur. Unless stated otherwise specifically in the specification, the heterocyclyl radical is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which include fused or bridged ring systems in some embodiments. The heteroatoms in the heterocyclyl radical are optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heterocyclyl radical is partially or fully saturated. In some embodiments, the heterocyclyl is attached to the rest of the molecule through any atom of the ring(s). In some embodiments, the heterocyclyl is saturated, (i.e., containing single bonds only) or unsaturated (i.e., containing one or more double bonds or triple bonds.) A fully saturated heterocyclyl radical is also referred to as "heterocycloalkyl." Examples of such heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[1,31dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Unless stated otherwise specifically in the specification, the term "heterocyclyl" is meant to include heterocyclyl radicals as defined above that are optionally substituted by one or more substituents selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -CN, -Rb-CN , -Rb-ORa, -Rb-OC(0)-Ra, -Rb-OC(0)-0Ra, -Rb-OC(0)-N(Ra)2, -Rb-N(Ra)2, -Rb-C(0)Ra, -kb-C(0)0Ra, -Rb-C(0)N(Ra)2, -Rb-O-Rc-C(0)N(Ra)2, -Rb-N(Ra)C(0)0Ra, -Rb-N(Ra)C(0)Ra, -Rb-N(Ra)S(0)tRa (where t is 1 or 2), -Rb-S(0)tORa (where t is 1 or 2), -Rb-S(0)tRa (where t is 1 or 2), and -Rb-S(0)tN(Ra)2 (where t is 1 or 2), where each Ra is independently hydrogen, alkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, each Rb is independently a direct bond or a straight or branched alkylene or alkenylene chain, and Rc is a straight or branched alkylene or alkenylene chain, and where each of the above substituents is unsubstituted unless otherwise indicated.
[0082] "Heteroalkyl" refers to an alkyl group in which one or more skeletal atoms of the alkyl are selected from an atom other than carbon, e.g., oxygen, nitrogen (e.g. ¨NH-, -N(alkyl)-, sulfur, or combinations thereof A heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalkyl. In one aspect, a heteroalkyl is a Ci-C6heteroalkyl. In some embodiments, the alkyl part of the heteroalkyl radical is optionally substituted as defined for an alkyl group.
[0083] "Heterocyclylalkyl" refers to a radical of the formula ¨Rc-heterocycly1 where Rc is an alkylene chain as defined above. If the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl is optionally attached to the alkyl radical at the nitrogen atom.
The alkylene chain of the heterocyclylalkyl radical is optionally substituted as defined above for an alkylene chain. The heterocyclyl part of the heterocyclylalkyl radical is optionally substituted as defined above for a heterocyclyl group.
[0084] "Heterocyclylalkoxy" refers to a radical bonded through an oxygen atom of the formula ¨
0-Rc-heterocycly1 where Rc is an alkylene chain as defined above. If the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl is optionally attached to the alkyl radical at the nitrogen atom. The alkylene chain of the heterocyclylalkoxy radical is optionally substituted as defined above for an alkylene chain. The heterocyclyl part of the heterocyclylalkoxy radical is optionally substituted as defined above for a heterocyclyl group.
[0085] "Heteroaryl" refers to a radical derived from a 3- to 18-membered aromatic ring radical that comprises two to seventeen carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen, and sulfur. As used herein, in some embodiments, the heteroaryl radical is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, wherein at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic, delocalized (4n+2) 7c¨electron system in accordance with the Htickel theory. Heteroaryl includes fused or bridged ring systems. The heteroatom(s) in the heteroaryl radical is optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heteroaryl is attached to the rest of the molecule through any atom of the ring(s). Examples of heteroaryls include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxolyl, benzofuranyl, benzooxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo [b][1,4] dioxepinyl, benzo[b][1,4]oxazinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzothieno[3,2-dlpyrimidinyl, benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, cyclopenta[d]pyrimidinyl, 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, 5,6-dihydrobenzo[h]quinazolinyl, 5,6-dihydrobenzo[h]cinnolinyl, 6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, furo[3,2-clpyridinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyrimidinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyridazinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyridinyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, 5,8-methano-5,6,7,8-tetrahydroquinazolinyl, naphthyridinyl, 1,6-naphthyridinonyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, ,6,6a,7, 8,9,10,10a-octahy drobenzo [h] quinazolinyl, 1-pheny1-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyrazolo[3,4-dlpyrimidinyl, pyridinyl, pyrido[3,2-dlpyrimidinyl, pyrido[3,4-dlpyrimidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, 5,6,7,8-tetrahydroquinazolinyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-dlpyrimidinyl, 6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-dlpyrimidinyl, 5,6,7,8-tetrahydropyrido[4,5-clpyridazinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, thieno[2,3-dlpyrimidinyl, thieno[3,2-dlpyrimidinyl, thieno[2,3-clpridinyl, and thiophenyl (i.e.
thienyl). Unless stated otherwise specifically in the specification, the term "heteroaryl" is meant to include heteroaryl radicals as defined above which are optionally substituted by one or more substituents selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R b-ORa, -Rb-OC(0)-Ra, -Rb-OC(0)-0Ra, -Rb-OC(0)-N(R)2, -Rb-N(R)2, -Rb-C(0)Ra, -Rb-C(0)0Ra, -Rb-C(0)N(Ra)2, -Rb-O-Rc-C(0)N(Ra)2, -Rb-N(Ra)C(0)0Ra, -Rb-N(Ra)C(0)Ra, -Rb-N(Ra)S(0)tRa (where t is 1 or 2), -Rb-S(0)tORa (where t is 1 or 2), -Rb-S(0)tRa (where t is 1 or 2), and -Rb-S(0)tN(Ra)2 (where t is 1 or 2), where each Ra is independently hydrogen, alkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, each Rb is independently a direct bond or a straight or branched alkylene or alkenylene chain, and Rc is a straight or branched alkylene or alkenylene chain, and where each of the above substituents is unsubstituted unless otherwise indicated.
[0086] "N-heteroaryl" refers to a heteroaryl radical as defined above containing at least one nitrogen and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a nitrogen atom in the heteroaryl radical. An N-heteroaryl radical is optionally substituted as described above for heteroaryl radicals.
[0087] "C-heteroaryl" refers to a heteroaryl radical as defined above and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a carbon atom in the heteroaryl radical. A C-heteroaryl radical is optionally substituted as described above for heteroaryl radicals.
[0088] "Heteroaryloxy" refers to radical bonded through an oxygen atom of the formula ¨0-heteroaryl, where heteroaryl is as defined above.
[0089] "Heteroarylalkyl" refers to a radical of the formula ¨Rc-heteroaryl, where Rc is an alkylene chain as defined above. If the heteroaryl is a nitrogen-containing heteroaryl, the heteroaryl is optionally attached to the alkyl radical at the nitrogen atom.
The alkylene chain of the heteroarylalkyl radical is optionally substituted as defined above for an alkylene chain. The heteroaryl part of the heteroarylalkyl radical is optionally substituted as defined above for a heteroaryl group.
[0090] "Heteroarylalkoxy" refers to a radical bonded through an oxygen atom of the formula ¨0-Rc-heteroaryl, where Rc is an alkylene chain as defined above. If the heteroaryl is a nitrogen-containing heteroaryl, the heteroaryl is optionally attached to the alkyl radical at the nitrogen atom. The alkylene chain of the heteroarylalkoxy radical is optionally substituted as defined above for an alkylene chain. The heteroaryl part of the heteroarylalkoxy radical is optionally substituted as defined above for a heteroaryl group.
[0091] In some embodiments, the compounds disclosed herein contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that are defined, in terms of absolute stereochemistry, as (R)- or (S)-. Unless stated otherwise, it is intended that all stereoisomeric forms of the compounds disclosed herein are contemplated by this disclosure. When the compounds described herein contain alkene double bonds, and unless specified otherwise, it is intended that this disclosure includes both E and Z
geometric isomers (e.g., cis or trans). Likewise, all possible isomers, as well as their racemic and optically pure forms, and all tautomeric forms are also intended to be included. The term "geometric isomer"
refers to E or Z geometric isomers (e.g., cis or trans) of an alkene double bond. The term "positional isomer" refers to structural isomers around a central ring, such as ortho-, meta-, and para- isomers around a benzene ring.
[0092] A "tautomer" refers to a molecule wherein a proton shift from one atom of a molecule to another atom of the same molecule is possible. The compounds presented herein, in certain embodiments, exist as tautomers. In circumstances where tautomerization is possible, a chemical equilibrium of the tautomers will exist. The exact ratio of the tautomers depends on several factors, including physical state, temperature, solvent, and pH. Some examples of tautomeric equilibrium include:
Nryµ = y (\
\ N
H H
\ NH2 N H \N \ N
isss N csss H
N N N ,N ¨ I NH
N HN N' N
N
csss\-- N 5 NH
N I
[0093] "Optional" or "optionally" means that a subsequently described event or circumstance may or may not occur and that the description includes instances when the event or circumstance occurs and instances in which it does not. For example, "optionally substituted aryl" means that the aryl radical may or may not be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution.
[0094] "Pharmaceutically acceptable salt" includes both acid and base addition salts. A
pharmaceutically acceptable salt of any one of the compounds described herein is intended to encompass any and all pharmaceutically suitable salt forms. Pharmaceutically acceptable salts of the compounds described herein are optionally pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
[0095] "Pharmaceutically acceptable acid addition salt" refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, phosphorous acid, and the like. Also included are salts that are formed with organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. and include, for example, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Exemplary salts thus include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, trifluoroacetates, propionates, caprylates, isobutyrates, oxalates, malonates, succinate suberates, sebacates, fumarates, maleates, mandelates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates, phenylacetates, citrates, lactates, malates, tartrates, methanesulfonates, and the like.
Also contemplated are salts of amino acids, such as arginates, gluconates, and galacturonates (see, for example, Berge S.M. et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 66:1-19 (1997), which is hereby incorporated by reference in its entirety). In some embodiments, acid addition salts of basic compounds are prepared by contacting the free base forms with a sufficient amount of the desired acid to produce the salt according to methods and techniques with which a skilled artisan is familiar.
[0096] "Pharmaceutically acceptable base addition salt" refers to those salts that retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. In some embodiments, pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines.
Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts, and the like. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, for example, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, /V,N-dibenzylethylenediamine, chloroprocaine, hydrabamine, choline, betaine, ethylenediamine, ethylenedianiline, N-methylglucamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like. See Berge et al., supra.
[0097] As used herein, "treatment" or "treating" or "palliating" or "ameliorating" are used interchangeably herein. These terms refer to an approach for obtaining beneficial or desired results including, but not limited to, therapeutic benefit and/or a prophylactic benefit. By "therapeutic benefit" is meant eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient is afflicted with the underlying disorder in some embodiments. For prophylactic benefit, in some embodiments, the compositions are administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease has not been made.
[0098] "Prodrug" is meant to indicate a compound that is converted under physiological conditions or by solvolysis to a biologically active compound described herein. Thus, the term "prodrug" refers to a precursor of a biologically active compound that is pharmaceutically acceptable. In some embodiments, a prodrug is inactive when administered to a subject, but is converted in vivo to an active compound, for example, by hydrolysis. The prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, e.g., Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam).
[0099] A discussion of prodrugs is provided in Higuchi, T., et al., "Pro-drugs as Novel Delivery Systems," A.C.S. Symposium Series, Vol. 14, and in Bioreversible Carriers in Drug Design, ed.
Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated in full by reference herein.
[00100] The term "prodrug" is also meant to include any covalently bonded carriers, which release the active compound in vivo when such prodrug is administered to a mammalian subject. In some embodiments, prodrugs of an active compound, as described herein, are prepared by modifying functional groups present in the active compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent active compound. Prodrugs include compounds wherein a hydroxy, amino, or mercapto group is
RN\ N , N \ Rz N ''22, A, 'C -RzrI ,Rz Rz I Rz NRz (Rz),¨ Z
0 [0026] In some embodiments, is Rz , Rz , Rz , Rz Rz N, A
Nrµ' &r TqN N
Rz Rz Rz , or Rz .
[0027] In some embodiments, each Rz is independently H, halogen, -CN, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In some embodiments, each Rz is independently H, halogen, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
In some embodiments, each Rz is independently H, -F, -Cl, -Br, -I, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or phenyl.
[0028] In some embodiments, each Rz is -L'-Y'. In some embodiments, LI is substituted or unsubstituted Ci-C4alkylene; and Y1 is substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cio heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
In some embodiments, each Rz is -L2-L3-Y2. In some embodiments, L2 is substituted or unsubstituted Ci-C6alkylene; L3 is -0-, -S-, -(S=0)-, -(SO2)-, -NR3-, -(C=0)-, -(C=0)0-, -0(C=0)-, -(C=0)NR3-, -(C=0)NR3-0-, -NR3(C=0)-, -NR3(C=0)NR3-, -0(C=0)NR3-, -NR3(C=0)0-, -NR3(S02)NR3-, -NR3(S02)-, -(S02)NR3-, -(S02)NR3-(C=0)-, -(S02)NR3-(C=0)0-, -NR3(S02)NR3-(C=0)-, or -NR3(S02)NR3-(C=0)0-; each R3 is independently H or substituted or unsubstituted Ci-C6alkyl; and Y2 is H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
[0029] In some embodiments, L2 is absent; L3 is -0-, -S-, -(S=0)-, -(SO2)-, -NR3-, -(C=0)-, -(C=0)0-, -0(C=0)-, -(C=0)NR3-, -(C=0)NR3-0-, -NR3(C=0)-, -NR3(C=0)NR3-, -0(C=0)NR3-, -NR3(C=0)0-, -NR3(502)NR3-, -NR3(S02)-, -(502)NR3-, -(S02)NR3-(C=0)-, -(502)NR3-(C=0)0-, -NR3(502)NR3-(C=0)-, or -NR3(502)NR3-(C=0)0-; each R3 is independently H or substituted or unsubstituted Ci-C6alkyl; and Y2 is H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
o,R
0- 0 0 0õ0 R
"S¨R ,s*
\SR HN,4 HN HN HN
[0030] In some embodiments, fr is .ss , or HN, R
o µI ,R
HN, [0031] In some embodiments, fr is [0032] In some embodiments, R is NHR1; and R1 is substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-C ioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
In some embodiments, RI is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or phenyl.
In some embodiments, R is RI; and RI is substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
In some embodiments, RI is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or phenyl.
7 7' HN 41:o HN
(R2), le (R2)r, [0033] In some embodiments, is [0034] In some embodiments, the compound has the structure of Formula (Ib), or a pharmaceutically acceptable salt thereof:
0- I, -S-R
HN
-(R2)r, Formula (Ib).
HN = (R2) HN i n [0035] In some embodiments, is IW .
'7 7' R2 -1- M
HN = (R2) is r or R2 HN i R2 HN 0 n 1W IW .
[0036] In some embodiments, is R2 7- R2 HN s HN HN
. (R2) r R2 HN 40 n R2 , R2 IW , [0037] In some embodiments, is , 7' 7' R HN
HN r R2 HN r HN R2 R2 IW R-, or R2 .
, 7 (R2) -1-In HN0 (R2)n [0038] In some embodiments, HN4, is [0039] In some embodiments, the compound has the structure of Formula (Ic), or a pharmaceutically acceptable salt thereof:
-S¨R
HN10(R2)n Formula (Ic).
¨1¨ ¨1¨
HN HNo (R2)n [0040] In some embodiments, is .
HNo HNt HN R2 FINO
________________________________ 2)n [0041] In some embodiments, (R is , or R2 HN HN
tR2 HN.(R2)n [0042] In some embodiments, is R2, R2 , M R HN HN R2 ,T, R2 R2 avr HNo_ HNb HN c(R2 HN HNI0 Z2 R2 or R2 , In some embodiments, each R2 is independently H, halogen, -N3, -CN, -SR4, -(S02)R4, -N(R4)2, -0O2R4, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Cr C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-C iocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
In some embodiments, the compound has the structure of Formula (Id), or a pharmaceutically acceptable salt thereof:
R
(Rz)õ,-HN =(R2)n Formula (Id).
[0043] In some embodiments, the compound has the structure of Formula (le), or a pharmaceutically acceptable salt thereof:
R
im HN
Formula (le).
[0044] In some embodiments, the compound has the structure of Formula (If), or a pharmaceutically acceptable salt thereof:
R
HN
______________________________________________ (R2), Formula (If).
[0045] In some embodiments, the compound has the structure of Formula (Ig), or a pharmaceutically acceptable salt thereof:
,R
(Rz)õ,-HN
Formula (Ig).
[0046] In some embodiments, the compound exhibits an IC50 of no more than about 3.000 .M.
[0047] Provided in another aspect is a compound, or pharmaceutically acceptable salt thereof, wherein the compound is a compound from Table 1, or a pharmaceutically acceptable salt thereof [0048] Provided in another aspect is a pharmaceutical composition comprising a pharmaceutically acceptable excipient and any one of the compounds disclosed herein or a pharmaceutically acceptable salt thereof [0049] Provided herein is a method for treating a cancer in a subject in need thereof comprising administering a therapeutically effective amount of a compound of any one of the compounds disclosed herein or a pharmaceutically acceptable salt thereof INCORPORATION BY REFERENCE
[0050] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
BRIEF DESCRIPTION OF THE DRAWINGS
[0051] Various aspects of the disclosure are set forth with particularity in the appended claims.
A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the disclosure are utilized, and the accompanying drawings of which:
[0052] FIG. 1 illustrates a schematic representation of the Hippo signaling network. Hippo pathway components shaded in dark gray indicate components that inhibit YAP/TAZ activity.
Hippo pathway components shaded in light gray indicate components that promote YAP/TAZ
activity. Pointed and blunt arrowheads indicate activating and inhibitory interactions, respectively. Abbreviations: a-CAT (a-Catenin), AJUB (Ajuba), AMOT
(Angiomotin), (3-TRCP
(0-transducing repeat containing protein), CK1 (Casein Kinase 1), CRB
(Crumbs), E-CAD (E-cadherin), EX (Expanded), GPCR (G-protein coupled receptor), HIPK (Homeodomain interacting protein kinase), KIBRA (Kidney brain), LATS (Large tumor suppressor), LGL
(Lethal giant larvae), MASK (Multiple ankyrin single KH), MER (Merlin), MOB
(Mps one binder), MST (Mammalian sterile 20 like), PALS (Protein Associated with Lin-7), PATJ (Pals 1-associated tight junction protein), PP2A (Protein phosphatase 2A), PTPN14 (Protein tyrosine phosphatase non-receptor type 14), RASSF (Ras associated factor), SAV
(Salvador), SCRIB
(Scribble), SIK (Salt inducible kinase), TAO (Thousand and one amino acid protein), TAZ
(transcriptional coactivator with PDZ-binding motif), TEAD (TEA domain protein), VGL4 (Vestigial-like 4), WBP2 (WW domain binding protein 2), YAP (Yes associated protein), ZO
(Zonula occludens), ZYX (Zyxin).
[0053] FIG. 2 illustrates a schematic representation of the Hippo signaling pathway regulated by G alpha proteins.
DETAILED DESCRIPTION OF THE DISCLOSURE
Certain Terminology [0054] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the claimed subject matter belongs. It is to be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of any subject matter claimed. In this application, the use of the singular includes the plural unless specifically stated otherwise. It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. In this application, the use of "or" means "and/or" unless stated otherwise.
Furthermore, use of the term "including" as well as other forms, such as "include", "includes,"
and "included," is not limiting.
[0055] As used herein, in some embodiments, ranges and amounts are expressed as "about" a particular value or range. About also includes the exact amount. Hence "about 5 uL" means "about 5 uL" and also "5 4." Generally, the term "about" includes an amount that is expected to be within experimental error.
[0056] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0057] As used herein, the terms "individual(s)", "subject(s)" and "patient(s)" mean any mammal. In some embodiments, the mammal is a human. In some embodiments, the mammal is anon-human. None of the terms require or are limited to situations characterized by the supervision (e.g. constant or intermittent) of a health care worker (e.g. a doctor, a registered nurse, a nurse practitioner, a physician's assistant, an orderly, or a hospice worker).
[0058] As used in the specification and appended claims, unless specified to the contrary, the following terms have the meaning indicated below.
[0059] "Amino" refers to the ¨NH2 radical.
[0060] "Cyano" refers to the -CN radical.
[0061] "Nitro" refers to the -NO2 radical.
[0062] "Oxa" refers to the -0- radical.
[0063] "Oxo" refers to the =0 radical.
[0064] "Thioxo" refers to the =S radical.
[0065] "Imino" refers to the =N-H radical.
[0066] "Oximo" refers to the =N-OH radical.
[0067] "Alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to fifteen carbon atoms (e.g., C1-C15 alkyl). In certain embodiments, an alkyl comprises one to thirteen carbon atoms (e.g., C1-C13 alkyl). In certain embodiments, an alkyl comprises one to eight carbon atoms (e.g., CI-Cs alkyl). In other embodiments, an alkyl comprises one to five carbon atoms (e.g., Ci-05 alkyl). In other embodiments, an alkyl comprises one to four carbon atoms (e.g., Ci-C4 alkyl). In other embodiments, an alkyl comprises one to three carbon atoms (e.g., Ci-C3 alkyl). In other embodiments, an alkyl comprises one to two carbon atoms (e.g., Ci-C2 alkyl).
In other embodiments, an alkyl comprises one carbon atom (e.g., C1 alkyl). In other embodiments, an alkyl comprises five to fifteen carbon atoms (e.g., C5-C15 alkyl). In other embodiments, an alkyl comprises five to eight carbon atoms (e.g., C5-C8 alkyl). In other embodiments, an alkyl comprises two to five carbon atoms (e.g., C2-05 alkyl). In other embodiments, an alkyl comprises three to five carbon atoms (e.g., C3-05 alkyl). In other embodiments, the alkyl group is selected from methyl, ethyl, 1-propyl (n-propyl), 1-methylethyl (iso-propyl), 1-butyl (n-butyl), 1-methylpropyl (sec-butyl), 2-methylpropyl (iso-butyl), 1,1-dimethylethyl (tert-butyl), 1-pentyl (n-penty1). The alkyl is attached to the rest of the molecule by a single bond.
Unless stated otherwise specifically in the specification, an alkyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -0Ra, -SRa, -0C(0)-Ra, -N(Ra)2, -C(0)Ra, -C(0)0Ra, -C(0)N(Ra)2, -N(Ra)C(0)0Rf, -0C(0)- NRaRf, -N(Ra)C(0)R, -N(Ra)S(0)tRf (where t is 1 or 2), -S(0)tORa (where t is 1 or 2), -S(0)tRf (where t is 1 or 2), and -S(0)N(Ra)2 (where t is 1 or 2), where each Ra is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, and each Rf is independently alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl.
[0068] "Alkoxy" refers to a radical bonded through an oxygen atom of the formula ¨0-alkyl, where alkyl is an alkyl chain as defined above.
[0069] "Alkenyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon double bond, and having from two to twelve carbon atoms. In certain embodiments, an alkenyl comprises two to eight carbon atoms. In other embodiments, an alkenyl comprises two to four carbon atoms. The alkenyl is attached to the rest of the molecule by a single bond, for example, ethenyl (i.e., vinyl), prop-l-enyl (i.e., allyl), but-l-enyl, pent-l-enyl, penta-1,4-dienyl, and the like. Unless stated otherwise specifically in the specification, an alkenyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -0Ra, -SRa, -0C(0)-Ra, -N(Ra)2, -C(0)Ra, -C(0)0Ra, -C(0)N(Ra)2, -N(Ra)C(0)0Rf, -0C(0)- NRaRf, -N(Ra)C(0)Rf, -N(Ra)S(0)tRf (where t is 1 or 2), -S(0)tORa (where t is 1 or 2), -S(0)tRf (where t is 1 or 2), and -S(0)N(Ra)2 (where t is 1 or 2), where each Ra is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, and each Rf is independently alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl.
[0070] "Alkynyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon triple bond, having from two to twelve carbon atoms. In certain embodiments, an alkynyl comprises two to eight carbon atoms. In other embodiments, an alkynyl has two to four carbon atoms.
The alkynyl is attached to the rest of the molecule by a single bond, for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like. Unless stated otherwise specifically in the specification, an alkynyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, oRa, -SR', -0C(0)-IV, -N(102, -C(0)1e, -C(0)01e, -C(0)N(102, -N(V)C(0)0Rf, -0C(0)- MeRf, -N(le)C(0)Rf, -N(10S(0)af (where t is 1 or 2), -S(0)tORa (where t is 1 or 2), -S(0)a (where t is 1 or 2), and -S(0)N(102 (where t is 1 or 2), where each IV is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, and each Rf is independently alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl.
[0071] "Alkylene" or "alkylene chain" refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing no unsaturation and having from one to twelve carbon atoms, for example, methylene, ethylene, propylene, n-butylene, and the like. The alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. In some embodiments, the points of attachment of the alkylene chain to the rest of the molecule and to the radical group are through one carbon in the alkylene chain or through any two carbons within the chain. In certain embodiments, an alkylene comprises one to eight carbon atoms (e.g., C i-C8 alkylene). In other embodiments, an alkylene comprises one to five carbon atoms (e.g., CI-05 alkylene). In other embodiments, an alkylene comprises one to four carbon atoms (e.g., C1-C4 alkylene). In other embodiments, an alkylene comprises one to three carbon atoms (e.g., C1-C3 alkylene). In other embodiments, an alkylene comprises one to two carbon atoms (e.g., C1-C2 alkylene). In other embodiments, an alkylene comprises one carbon atom (e.g., C1 alkylene). In other embodiments, an alkylene comprises five to eight carbon atoms (e.g., C5-C8 alkylene). In other embodiments, an alkylene comprises two to five carbon atoms (e.g., C2-05 alkylene). In other embodiments, an alkylene comprises three to five carbon atoms (e.g., C3-05 alkylene).
Unless stated otherwise specifically in the specification, an alkylene chain is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -01V, sRa,-0C(0)-Ra, -N(102, -C(0)Ra, -C(0)0IV, -C(0)N(102, -N(10C(0)0Rf, -0C(0)- NIZaRf, -N(V)C(0)Rf, -N(10S(0)af (where t is 1 or 2), -S(0)OW
(where t is 1 or 2), -S(0)tRf (where t is 1 or 2), and -S(0)N(102 (where t is 1 or 2), where each IV is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, and each Rf is independently alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl.
[0072] "Aryl" refers to a radical derived from an aromatic monocyclic or multicyclic hydrocarbon ring system by removing a hydrogen atom from a ring carbon atom.
The aromatic monocyclic or multicyclic hydrocarbon ring system contains only hydrogen and carbon from five to eighteen carbon atoms, where at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic, delocalized (4n+2) 7c¨electron system in accordance with the Htickel theory. The ring system from which aryl groups are derived include, but are not limited to, groups such as benzene, fluorene, indane, indene, tetralin, and naphthalene.
Unless stated otherwise specifically in the specification, the term "aryl" or the prefix "ar-" (such as in "aralkyl") is meant to include aryl radicals optionally substituted by one or more substituents independently selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -Rb-CN, -Rb-ORd, -Rb-OC(0)-Rd, -Rb-OC(0)-ORd, -Rb-OC(0)-N(Rd)2, -Rb-N(Rd)2, -Rb-C(0)Rd, -Rb-C(0)0Rd, -Rb-C(0)N(Rd)2, -Rb-O-Rc-C(0)N(Rd)2, -Rb-N(Ra)C(0)0Ra, -Rb-N(Ra)C(0)Ra, -Rb-N(Ra)S(0)tRa (where t is 1 or 2), -Rb-S(0)tORd (where t is 1 or 2), -Rb-S(0)tRa (where t is 1 or 2), and -Rb-S(0)tN(Rd)2 (where t is 1 or 2), where each Ra is independently hydrogen, alkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, aryl (optionally substituted with one or more halo groups), aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, each Rb is independently a direct bond or a straight or branched alkylene or alkenylene chain, and Rc is a straight or branched alkylene or alkenylene chain, and where each of the above substituents is unsubstituted unless otherwise indicated.
[0073] "Aryloxy" refers to a radical bonded through an oxygen atom of the formula ¨0-aryl, where aryl is as defined above.
[0074] "Aralkyl" refers to a radical of the formula -Rc-aryl where Rc is an alkylene chain as defined above, for example, methylene, ethylene, and the like. The alkylene chain part of the aralkyl radical is optionally substituted as described above for an alkylene chain. The aryl part of the aralkyl radical is optionally substituted as described above for an aryl group.
[0075] "Aralkenyl" refers to a radical of the formula ¨Rd-aryl where Rd is an alkenylene chain as defined above. The aryl part of the aralkenyl radical is optionally substituted as described above for an aryl group. The alkenylene chain part of the aralkenyl radical is optionally substituted as defined above for an alkenylene group.
[0076] "Aralkynyl" refers to a radical of the formula -Re-aryl, where Re is an alkynylene chain as defined above. The aryl part of the aralkynyl radical is optionally substituted as described above for an aryl group. The alkynylene chain part of the aralkynyl radical is optionally substituted as defined above for an alkynylene chain.
[0077] "Carbocycly1" refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, and in some embodiments, include fused or bridged ring systems, having from three to fifteen carbon atoms. In certain embodiments, a carbocyclyl comprises three to ten carbon atoms. In other embodiments, a carbocyclyl comprises five to seven carbon atoms. The carbocyclyl is attached to the rest of the molecule by a single bond. In some embodiments, the carbocyclyl is saturated, (i.e., containing single C-C bonds only) or unsaturated (i.e., containing one or more double bonds or triple bonds.) A fully saturated carbocyclyl radical is also referred to as "cycloalkyl." Examples of monocyclic cycloalkyls include, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. In certain embodiments, a cycloalkyl comprises three to eight carbon atoms (e.g., cycloalkyl). In other embodiments, a cycloalkyl comprises three to seven carbon atoms (e.g., C3-C7 cycloalkyl). In other embodiments, a cycloalkyl comprises three to six carbon atoms (e.g., C3-C6 cycloalkyl). In other embodiments, a cycloalkyl comprises three to five carbon atoms (e.g., C3-05 cycloalkyl). In other embodiments, a cycloalkyl comprises three to four carbon atoms (e.g., C3-C4 cycloalkyl). An unsaturated carbocyclyl is also referred to as "cycloalkenyl."
Examples of monocyclic cycloalkenyls include, e.g., cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. Polycyclic carbocyclyl radicals include, for example, adamantyl, norbornyl (i.e., bicyclo[2.2.11heptanyl), norbornenyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.11heptanyl, and the like. Unless otherwise stated specifically in the specification, the term "carbocyclyl" is meant to include carbocyclyl radicals that are optionally substituted by one or more substituents independently selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -CN, -R b-ORa, -Rb-OC(0)-Ra, -Rb-OC(0)-0Ra, -Rb-OC(0)-N(Ra)2, -Rb-N(Ra)2, -Rb-C(0)Ra, -kb-C(0)0Ra, -Rb-C(0)N(Ra)2, -Rb-O-Rc-C(0)N(Ra)2, -Rb-N(Ra)C(0)0Ra, -Rb-N(Ra)C(0)Ra, -Rb-N(Ra)S(0)tRa (where t is 1 or 2), -Rb-S(0)tORa (where t is 1 or 2), -Rb-S(0)tRa (where t is 1 or 2), and -Rb-S(0)tN(Ra)2 (where t is 1 or 2), where each Ra is independently hydrogen, alkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, each Rb is independently a direct bond or a straight or branched alkylene or alkenylene chain, and Rc is a straight or branched alkylene or alkenylene chain, and where each of the above substituents is unsubstituted unless otherwise indicated.
[0078] "Carbocyclylalkyl" refers to a radical of the formula ¨Rc-carbocycly1 where Rc is an alkylene chain as defined above. The alkylene chain and the carbocyclyl radical are optionally substituted as defined above.
[0079] "Halo" or "halogen" refers to bromo, chloro, fluoro, or iodo substituents.
[0080] "Fluoroalkyl" refers to an alkyl radical, as defined above, that is substituted by one or more fluoro radicals, as defined above, for example, trifluoromethyl, difluoromethyl, fluoromethyl, 2,2,2-trifluoroethyl, 1-fluoromethy1-2-fluoroethyl, and the like. In some embodiments, the alkyl part of the fluoroalkyl radical is optionally substituted as defined above for an alkyl group.
[0081] "Heterocycly1" or "heterocycle" refers to a stable 3- to 18-membered non-aromatic ring radical that comprises two to twelve carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen, and sulfur. Unless stated otherwise specifically in the specification, the heterocyclyl radical is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which include fused or bridged ring systems in some embodiments. The heteroatoms in the heterocyclyl radical are optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heterocyclyl radical is partially or fully saturated. In some embodiments, the heterocyclyl is attached to the rest of the molecule through any atom of the ring(s). In some embodiments, the heterocyclyl is saturated, (i.e., containing single bonds only) or unsaturated (i.e., containing one or more double bonds or triple bonds.) A fully saturated heterocyclyl radical is also referred to as "heterocycloalkyl." Examples of such heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[1,31dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Unless stated otherwise specifically in the specification, the term "heterocyclyl" is meant to include heterocyclyl radicals as defined above that are optionally substituted by one or more substituents selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -CN, -Rb-CN , -Rb-ORa, -Rb-OC(0)-Ra, -Rb-OC(0)-0Ra, -Rb-OC(0)-N(Ra)2, -Rb-N(Ra)2, -Rb-C(0)Ra, -kb-C(0)0Ra, -Rb-C(0)N(Ra)2, -Rb-O-Rc-C(0)N(Ra)2, -Rb-N(Ra)C(0)0Ra, -Rb-N(Ra)C(0)Ra, -Rb-N(Ra)S(0)tRa (where t is 1 or 2), -Rb-S(0)tORa (where t is 1 or 2), -Rb-S(0)tRa (where t is 1 or 2), and -Rb-S(0)tN(Ra)2 (where t is 1 or 2), where each Ra is independently hydrogen, alkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, each Rb is independently a direct bond or a straight or branched alkylene or alkenylene chain, and Rc is a straight or branched alkylene or alkenylene chain, and where each of the above substituents is unsubstituted unless otherwise indicated.
[0082] "Heteroalkyl" refers to an alkyl group in which one or more skeletal atoms of the alkyl are selected from an atom other than carbon, e.g., oxygen, nitrogen (e.g. ¨NH-, -N(alkyl)-, sulfur, or combinations thereof A heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalkyl. In one aspect, a heteroalkyl is a Ci-C6heteroalkyl. In some embodiments, the alkyl part of the heteroalkyl radical is optionally substituted as defined for an alkyl group.
[0083] "Heterocyclylalkyl" refers to a radical of the formula ¨Rc-heterocycly1 where Rc is an alkylene chain as defined above. If the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl is optionally attached to the alkyl radical at the nitrogen atom.
The alkylene chain of the heterocyclylalkyl radical is optionally substituted as defined above for an alkylene chain. The heterocyclyl part of the heterocyclylalkyl radical is optionally substituted as defined above for a heterocyclyl group.
[0084] "Heterocyclylalkoxy" refers to a radical bonded through an oxygen atom of the formula ¨
0-Rc-heterocycly1 where Rc is an alkylene chain as defined above. If the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl is optionally attached to the alkyl radical at the nitrogen atom. The alkylene chain of the heterocyclylalkoxy radical is optionally substituted as defined above for an alkylene chain. The heterocyclyl part of the heterocyclylalkoxy radical is optionally substituted as defined above for a heterocyclyl group.
[0085] "Heteroaryl" refers to a radical derived from a 3- to 18-membered aromatic ring radical that comprises two to seventeen carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen, and sulfur. As used herein, in some embodiments, the heteroaryl radical is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, wherein at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic, delocalized (4n+2) 7c¨electron system in accordance with the Htickel theory. Heteroaryl includes fused or bridged ring systems. The heteroatom(s) in the heteroaryl radical is optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heteroaryl is attached to the rest of the molecule through any atom of the ring(s). Examples of heteroaryls include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxolyl, benzofuranyl, benzooxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo [b][1,4] dioxepinyl, benzo[b][1,4]oxazinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzothieno[3,2-dlpyrimidinyl, benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, cyclopenta[d]pyrimidinyl, 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, 5,6-dihydrobenzo[h]quinazolinyl, 5,6-dihydrobenzo[h]cinnolinyl, 6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, furo[3,2-clpyridinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyrimidinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyridazinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyridinyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, 5,8-methano-5,6,7,8-tetrahydroquinazolinyl, naphthyridinyl, 1,6-naphthyridinonyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, ,6,6a,7, 8,9,10,10a-octahy drobenzo [h] quinazolinyl, 1-pheny1-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyrazolo[3,4-dlpyrimidinyl, pyridinyl, pyrido[3,2-dlpyrimidinyl, pyrido[3,4-dlpyrimidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, 5,6,7,8-tetrahydroquinazolinyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-dlpyrimidinyl, 6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-dlpyrimidinyl, 5,6,7,8-tetrahydropyrido[4,5-clpyridazinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, thieno[2,3-dlpyrimidinyl, thieno[3,2-dlpyrimidinyl, thieno[2,3-clpridinyl, and thiophenyl (i.e.
thienyl). Unless stated otherwise specifically in the specification, the term "heteroaryl" is meant to include heteroaryl radicals as defined above which are optionally substituted by one or more substituents selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R b-ORa, -Rb-OC(0)-Ra, -Rb-OC(0)-0Ra, -Rb-OC(0)-N(R)2, -Rb-N(R)2, -Rb-C(0)Ra, -Rb-C(0)0Ra, -Rb-C(0)N(Ra)2, -Rb-O-Rc-C(0)N(Ra)2, -Rb-N(Ra)C(0)0Ra, -Rb-N(Ra)C(0)Ra, -Rb-N(Ra)S(0)tRa (where t is 1 or 2), -Rb-S(0)tORa (where t is 1 or 2), -Rb-S(0)tRa (where t is 1 or 2), and -Rb-S(0)tN(Ra)2 (where t is 1 or 2), where each Ra is independently hydrogen, alkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, each Rb is independently a direct bond or a straight or branched alkylene or alkenylene chain, and Rc is a straight or branched alkylene or alkenylene chain, and where each of the above substituents is unsubstituted unless otherwise indicated.
[0086] "N-heteroaryl" refers to a heteroaryl radical as defined above containing at least one nitrogen and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a nitrogen atom in the heteroaryl radical. An N-heteroaryl radical is optionally substituted as described above for heteroaryl radicals.
[0087] "C-heteroaryl" refers to a heteroaryl radical as defined above and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a carbon atom in the heteroaryl radical. A C-heteroaryl radical is optionally substituted as described above for heteroaryl radicals.
[0088] "Heteroaryloxy" refers to radical bonded through an oxygen atom of the formula ¨0-heteroaryl, where heteroaryl is as defined above.
[0089] "Heteroarylalkyl" refers to a radical of the formula ¨Rc-heteroaryl, where Rc is an alkylene chain as defined above. If the heteroaryl is a nitrogen-containing heteroaryl, the heteroaryl is optionally attached to the alkyl radical at the nitrogen atom.
The alkylene chain of the heteroarylalkyl radical is optionally substituted as defined above for an alkylene chain. The heteroaryl part of the heteroarylalkyl radical is optionally substituted as defined above for a heteroaryl group.
[0090] "Heteroarylalkoxy" refers to a radical bonded through an oxygen atom of the formula ¨0-Rc-heteroaryl, where Rc is an alkylene chain as defined above. If the heteroaryl is a nitrogen-containing heteroaryl, the heteroaryl is optionally attached to the alkyl radical at the nitrogen atom. The alkylene chain of the heteroarylalkoxy radical is optionally substituted as defined above for an alkylene chain. The heteroaryl part of the heteroarylalkoxy radical is optionally substituted as defined above for a heteroaryl group.
[0091] In some embodiments, the compounds disclosed herein contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that are defined, in terms of absolute stereochemistry, as (R)- or (S)-. Unless stated otherwise, it is intended that all stereoisomeric forms of the compounds disclosed herein are contemplated by this disclosure. When the compounds described herein contain alkene double bonds, and unless specified otherwise, it is intended that this disclosure includes both E and Z
geometric isomers (e.g., cis or trans). Likewise, all possible isomers, as well as their racemic and optically pure forms, and all tautomeric forms are also intended to be included. The term "geometric isomer"
refers to E or Z geometric isomers (e.g., cis or trans) of an alkene double bond. The term "positional isomer" refers to structural isomers around a central ring, such as ortho-, meta-, and para- isomers around a benzene ring.
[0092] A "tautomer" refers to a molecule wherein a proton shift from one atom of a molecule to another atom of the same molecule is possible. The compounds presented herein, in certain embodiments, exist as tautomers. In circumstances where tautomerization is possible, a chemical equilibrium of the tautomers will exist. The exact ratio of the tautomers depends on several factors, including physical state, temperature, solvent, and pH. Some examples of tautomeric equilibrium include:
Nryµ = y (\
\ N
H H
\ NH2 N H \N \ N
isss N csss H
N N N ,N ¨ I NH
N HN N' N
N
csss\-- N 5 NH
N I
[0093] "Optional" or "optionally" means that a subsequently described event or circumstance may or may not occur and that the description includes instances when the event or circumstance occurs and instances in which it does not. For example, "optionally substituted aryl" means that the aryl radical may or may not be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution.
[0094] "Pharmaceutically acceptable salt" includes both acid and base addition salts. A
pharmaceutically acceptable salt of any one of the compounds described herein is intended to encompass any and all pharmaceutically suitable salt forms. Pharmaceutically acceptable salts of the compounds described herein are optionally pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
[0095] "Pharmaceutically acceptable acid addition salt" refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, phosphorous acid, and the like. Also included are salts that are formed with organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. and include, for example, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Exemplary salts thus include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, trifluoroacetates, propionates, caprylates, isobutyrates, oxalates, malonates, succinate suberates, sebacates, fumarates, maleates, mandelates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates, phenylacetates, citrates, lactates, malates, tartrates, methanesulfonates, and the like.
Also contemplated are salts of amino acids, such as arginates, gluconates, and galacturonates (see, for example, Berge S.M. et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 66:1-19 (1997), which is hereby incorporated by reference in its entirety). In some embodiments, acid addition salts of basic compounds are prepared by contacting the free base forms with a sufficient amount of the desired acid to produce the salt according to methods and techniques with which a skilled artisan is familiar.
[0096] "Pharmaceutically acceptable base addition salt" refers to those salts that retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. In some embodiments, pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines.
Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts, and the like. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, for example, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, /V,N-dibenzylethylenediamine, chloroprocaine, hydrabamine, choline, betaine, ethylenediamine, ethylenedianiline, N-methylglucamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like. See Berge et al., supra.
[0097] As used herein, "treatment" or "treating" or "palliating" or "ameliorating" are used interchangeably herein. These terms refer to an approach for obtaining beneficial or desired results including, but not limited to, therapeutic benefit and/or a prophylactic benefit. By "therapeutic benefit" is meant eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient is afflicted with the underlying disorder in some embodiments. For prophylactic benefit, in some embodiments, the compositions are administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease has not been made.
[0098] "Prodrug" is meant to indicate a compound that is converted under physiological conditions or by solvolysis to a biologically active compound described herein. Thus, the term "prodrug" refers to a precursor of a biologically active compound that is pharmaceutically acceptable. In some embodiments, a prodrug is inactive when administered to a subject, but is converted in vivo to an active compound, for example, by hydrolysis. The prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, e.g., Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam).
[0099] A discussion of prodrugs is provided in Higuchi, T., et al., "Pro-drugs as Novel Delivery Systems," A.C.S. Symposium Series, Vol. 14, and in Bioreversible Carriers in Drug Design, ed.
Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated in full by reference herein.
[00100] The term "prodrug" is also meant to include any covalently bonded carriers, which release the active compound in vivo when such prodrug is administered to a mammalian subject. In some embodiments, prodrugs of an active compound, as described herein, are prepared by modifying functional groups present in the active compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent active compound. Prodrugs include compounds wherein a hydroxy, amino, or mercapto group is
26 bonded to any group that, when the prodrug of the active compound is administered to a mammalian subject, cleaves to form a free hydroxy, free amino, or free mercapto group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate, and benzoate derivatives of alcohol or amine functional groups in the active compounds and the like.
Compounds [00101] In some embodiments, the compounds disclosed herein are benzosulfonyl compounds.
[00102] Provided in one aspect is a compound of Formula (I) or a pharmaceutically acceptable salt thereof:
HN,411 (R2), Formula (I) wherein, is a substituted or unsubstituted monocyclic 5-membered heterocyclic ring containing at least one N atom or a substituted or unsubstituted monocyclic 6-membered heteroaryl ring containing at least one N atom;
each Rz is independently H, halogen, -CN, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -L '-Y', or -L2-L3-Y2;
M iS 0, 1, 2, 3, 4, 0r5;
LI is substituted or unsubstituted Ci-C6alkylene, substituted or unsubstituted C2-Ciocyclolkylene, or substituted or unsubstituted C2- Cioheterocycloalkylene;
Y1 is substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cio heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
L2 is absent, substituted or unsubstituted Ci-C6alkylene, substituted or unsubstituted C2-
Compounds [00101] In some embodiments, the compounds disclosed herein are benzosulfonyl compounds.
[00102] Provided in one aspect is a compound of Formula (I) or a pharmaceutically acceptable salt thereof:
HN,411 (R2), Formula (I) wherein, is a substituted or unsubstituted monocyclic 5-membered heterocyclic ring containing at least one N atom or a substituted or unsubstituted monocyclic 6-membered heteroaryl ring containing at least one N atom;
each Rz is independently H, halogen, -CN, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -L '-Y', or -L2-L3-Y2;
M iS 0, 1, 2, 3, 4, 0r5;
LI is substituted or unsubstituted Ci-C6alkylene, substituted or unsubstituted C2-Ciocyclolkylene, or substituted or unsubstituted C2- Cioheterocycloalkylene;
Y1 is substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cio heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
L2 is absent, substituted or unsubstituted Ci-C6alkylene, substituted or unsubstituted C2-
27 Ciocyclolkylene, or substituted or unsubstituted C2-Cioheterocycloalkylene;
L3 is -0-, -S-, -(S=0)-, -(SO2)-, -NR3-, -(C=0)-, -(C=0)0-, -0(C=0)-, -(C=0)NR3-, -(C=0)NR3-0-, -0-NR3(C=0)-, -NR3(C=0)-, -NR3(C=0)NR3-, -0(C=0)NR3-, -NR3(C=0)0-, -NR3(S02)NR3-, -NR3(S02)-,-(S02)NR3-, -(S02)NR3-(C=0)-, -(C=0)-NR3(S02)-, -(S02)NR3-(C=0)0-, -0(C=0)-NR3(S02)-, -NR3(S02)NR3-(C=0)-, -(C=0)-NR3(S02)NR3-, -0(C=0)-NR3(S02)-NR3-, or -NR3(S02)NR3-(C=0)0-;
each R3 is independently H or substituted or unsubstituted Ci-C6alkyl;
Y2 is H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
or R3 and Y2 on the same N atom are taken together with the N atom to which they are attached to form a substituted or unsubstituted N-containing heterocycle;
R is NHR1 or R1;
R1 is substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
A (R2)n is substituted or unsubstituted phenyl or substituted or unsubstituted cyclohexyl;
each R2 is independently H, halogen, -N3, -CN, -(502)R4, -N(R4)2, -0O2R4, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, substituted or unsubstituted N=N
'24C( heteroaryl, or C F3 .
n is 0, 1, 2, 3, 4, or 5; and each R4 is independently H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted
L3 is -0-, -S-, -(S=0)-, -(SO2)-, -NR3-, -(C=0)-, -(C=0)0-, -0(C=0)-, -(C=0)NR3-, -(C=0)NR3-0-, -0-NR3(C=0)-, -NR3(C=0)-, -NR3(C=0)NR3-, -0(C=0)NR3-, -NR3(C=0)0-, -NR3(S02)NR3-, -NR3(S02)-,-(S02)NR3-, -(S02)NR3-(C=0)-, -(C=0)-NR3(S02)-, -(S02)NR3-(C=0)0-, -0(C=0)-NR3(S02)-, -NR3(S02)NR3-(C=0)-, -(C=0)-NR3(S02)NR3-, -0(C=0)-NR3(S02)-NR3-, or -NR3(S02)NR3-(C=0)0-;
each R3 is independently H or substituted or unsubstituted Ci-C6alkyl;
Y2 is H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
or R3 and Y2 on the same N atom are taken together with the N atom to which they are attached to form a substituted or unsubstituted N-containing heterocycle;
R is NHR1 or R1;
R1 is substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
A (R2)n is substituted or unsubstituted phenyl or substituted or unsubstituted cyclohexyl;
each R2 is independently H, halogen, -N3, -CN, -(502)R4, -N(R4)2, -0O2R4, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, substituted or unsubstituted N=N
'24C( heteroaryl, or C F3 .
n is 0, 1, 2, 3, 4, or 5; and each R4 is independently H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted
28 Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
(Rz),,¨.
[00103] In some embodiments, is a substituted or unsubstituted monocyclic 5-membered heterocyclic ring containing at least one N atom.
(Rz),,-410 [00104] In some embodiments, is a substituted or unsubstituted monocyclic 5-membered heterocyclic ring containing 1-4 N atoms, 0-2 0 atoms, and 0-2 S
atoms.
=
z2- A
-zi z2 .
(Rz),,¨. µ
, , is [00105] In some embodiments, , Z1 is ¨N-, ¨CH-, or -C-;
each Z2 is independently -CRz, -CHRz-, -C(Rz)2, -NRz-, -N-, -0-, or ¨S-, each - - is independently a single or double bond; and with the provision that the 5-membered heterocyclic ring contains at least one N atom.
[00106] In some embodiments, is substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted imidazolidinyl, substituted or unsubstituted pyrazolidinyl, substituted or unsubstituted oxazolidinyl, substituted or unsubstituted isoxazolidinyl, substituted or unsubstituted thiazolidinyl, or substituted or unsubstituted isothiazolidinyl.
Rz Rz \NV\
Rz--1j\IN>7 Rz (Rz),-410 Rz ¨----Rz [00107] In some embodiments, is Rz Rz , IR' Rz Rz Rz Rz IR' Rz-NV\ \N1V\
Rz ¨,...,...L Rz f -N Rz¨N, Rz-N\ Al Rz--<
Rz r -Rz ,N"-NRz Rz Rz Rz Rz Rz Rz , , , , ,
(Rz),,¨.
[00103] In some embodiments, is a substituted or unsubstituted monocyclic 5-membered heterocyclic ring containing at least one N atom.
(Rz),,-410 [00104] In some embodiments, is a substituted or unsubstituted monocyclic 5-membered heterocyclic ring containing 1-4 N atoms, 0-2 0 atoms, and 0-2 S
atoms.
=
z2- A
-zi z2 .
(Rz),,¨. µ
, , is [00105] In some embodiments, , Z1 is ¨N-, ¨CH-, or -C-;
each Z2 is independently -CRz, -CHRz-, -C(Rz)2, -NRz-, -N-, -0-, or ¨S-, each - - is independently a single or double bond; and with the provision that the 5-membered heterocyclic ring contains at least one N atom.
[00106] In some embodiments, is substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted imidazolidinyl, substituted or unsubstituted pyrazolidinyl, substituted or unsubstituted oxazolidinyl, substituted or unsubstituted isoxazolidinyl, substituted or unsubstituted thiazolidinyl, or substituted or unsubstituted isothiazolidinyl.
Rz Rz \NV\
Rz--1j\IN>7 Rz (Rz),-410 Rz ¨----Rz [00107] In some embodiments, is Rz Rz , IR' Rz Rz Rz Rz IR' Rz-NV\ \N1V\
Rz ¨,...,...L Rz f -N Rz¨N, Rz-N\ Al Rz--<
Rz r -Rz ,N"-NRz Rz Rz Rz Rz Rz Rz , , , , ,
29 Rz\
)7,1Rz Rz)......Nx N X R \N ,7\z? Rz Rz N 0 \N1)77 Rz ---e: Rz-y 0' Rz N-0 0\
Rz--Rz Rz )---Rz Rz-N I r Rz µONRz Rz , Rz , Rz Rz Rz 0--NRz , , Rzv x Rz )(\?Rz )N>z, Rz \ S-NX Rz\N,7\ Rz N
).
Rz-C-1 ' Rz____e? Rz......j, si )....õ,\ Rz S\
N-S a .....0 Rz )---"N Rz Rz-N \SNRz I r Rz Rz , Rz , Rz , Rz ' Rz Rz , Rz\ 1)..,1)17 Rz \N1)77 Rz Rz-N
Rz-< S )....-S
S---NRz Rz ,or Rz .
[00108] In some embodiments, is substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted pyrazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted isothiazolyl, substituted or unsubstituted triazoyl, substituted or unsubstituted tetrazoyl, substituted or unsubstituted oxadiazolyl, substituted or unsubstituted thiadiazolyl, or substituted or unsubstituted dithiazolyl.
Rz Rz \NI )17 Rz.......1_11N>Z7 RZ), J.N
(RZ)m -0 RZ RZ
[00109] In some embodiments, is Rz Rz , Rz Rz,\ RZ
,N -N >17 ,N-....217 N-..)17 Rz ),..._ >/.7 Rz\
N-õ,)1?
Rz-N Rz-....( Rz-N NI\ 1 )-----)11 N\_____Li N
)---- Rz Rz )---'NRz 1¨ Rz Rz-NsNRz Rz 'Rz Rz- I
N ---N Rz Rz Rz Rz , Rz , , , , Rz Rz-N ..._.?õ,õ Rz Nõ..-,,(\ N.,-,..,.21.? Rz).......,,>7 Rz R z -Sõ.. 0' N-}17 N:zzr\
N , Rz )...--Rz Nµi I Rz----1)11 Rz- I
Rz Rz Rz 0 Rz, N - 0--NRz Rz , , , ' , Rz>.,....?1, Rzv x N ......)1, Rz N . m A
N-......,.?"1 Ni-T ' S' N-.,277 N Rz-S__ s Rz-c_ ',"
)--0 kiW17 Rz' I
),---s --- N
Y---1---jRz "\c,.... SRz Rz Rz Rz , Rz , Rz , , , N. A, Rzõ, Rz\
N Rz-N: N Nf ,Nf, Rzy Rz_N' N
N'-1)2' Rz-N , ,i)z, N
X---"N Rz-N' '''. N's '71\
R/ 'Rz Rz N 'N
Rz Rz µ1\1:--N Rz V:N sN-N
, , Rz\ Rz NA N.N A, NI: - ,Nf ,,,Ps 1 f dN' N .1- Rz- =,- )...-.:-.:N Rz_iN-y)2' NY R,....µo--ii--A
s sz:
NN N o N --:-N Rz Rz Rz N-0 b-N N---1\1 , , Rz\
,omA, 0,,,A, N.N A Nf ,s_f2, s/N-Y4 Rz-N\ _i Rz--c., .,µ o' -Rz Rz NRz N'' I
\ Ns )------( µc I No I )---=-N
N
Dz Rz Rz Rz -, Rz Rz Rz , , '`
Rz, N:et, S' A s,mA, l'\1.,,, R A, z¨N' s y Ny2, Rz i -c_ - S/ - Rz--- ,S
N
S: \ ...._-_-..( il y"---Rz Rz Rz N-S , Rz Rz , Rz Rz , or NN
.
(Rz),¨.
[00110] In some embodiments, is a substituted or unsubstituted monocyclic 6-membered heteroaryl ring containing at least one N atom.
[00111] In some embodiments, is a substituted or unsubstituted monocyclic 6-membered heteroaryl ring containing 1 or 2 N atoms.
z2z2y\
"
ii (Rz6-0 = z2,z2-,z2 =
[00112] In some embodiments, is , each Z2 is independently CRz or N; and at least one Z2 is N.
(Rz),õ-0 [00113] In some embodiments, is substituted or unsubstituted pyridinyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted pyridazinyl.
Rz RzN}µ NA
I
(Rz),¨. RzThRz Rz-r Rz [00114] In some embodiments, is Rz Rz Rz Rz Rz,r\ Rz1\1 Rz Nrµ'22, Rz N) N Rz Rz Rz N Rz Rz N NRZ\, Rz Rz Rz Rz Rz Rz N Rz or Rz z&r N
Rz [00115] In some embodiments, the compound has the structure of Formula (Ia), or a pharmaceutically acceptable salt thereof:
(R z) -HN
- A (R2)n Formula (Ia) wherein Z1 is -N-, -CH-, or -C-.
Z1)4 (Rz),õ¨
In some embodiments, is a substituted or unsubstituted monocyclic membered heterocyclic ring containing at least one N atom, and the at least one N atom is adjacent to Z1.
Rzõ, i (Rz),- zoz2 , z2 , _z2 [00116] In some embodiments, is Z2_ or µZ2--Z2 =
Z1 is -N-, -CH-, or -C-;
each Z2 is independently CRz, NRz, N, 0, or S;
each - - is independently a single or double bond; and with the provision that the 5-membered heterocyclic ring contains at least one N atom.
A' (Rz),õ,-ZI
[00117] In some embodiments, is substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted imidazolidinyl, substituted or unsubstituted pyrazolidinyl, substituted or unsubstituted oxazolidinyl, substituted or unsubstituted isoxazolidinyl, substituted or unsubstituted thiazolidinyl, or substituted or unsubstituted isothiazolidinyl.
Rz\ Rz Rz [00118] In some embodiments, 01A is Rz-----NRz Rz -----1-\LIRz Rz , , i\j NI
Rz Rz Rz% Rz, z R
NI z \,V\ \,/\ ,,)17 j7.7 Rzõ, R\N7 s'\N,V\
Rz-N Rz- Rz i N-) Rz_ ......N 0' 0 )----Rz NRz µRz )-Rz Rz-<0, ----Rz Rz Rz , Rz , Rz Rz Rz Rz , , , Rz \
N Rz Rz--....e?
Rz-<
Rz ,or SRz .
z1)4 [00119] In some embodiments, is substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted pyrazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted isothiazolyl, substituted or unsubstituted triazoyl, substituted or unsubstituted tetrazoyl, substituted or unsubstituted oxadiazolyl, substituted or unsubstituted thiadiazolyl, or substituted or unsubstituted dithiazolyl.
Rz \N,7\ NN >7 A, (Rz),- Z
01 Rz).....L Rz-S__:__L
Rz Rz [00120] In some embodiments, is Rz Rz , Rz-N, Rz\ Rz Rz\
N-. R
..)17 N,...V\
, N I
IN-...7\i z-NY27 Rz-$.___IN 0' N--)17 -)--Rz r -Rz Rz1 -% )....,..N
Rz Rz- I
Rz , Rz N"-NRz Rz , Rz , Rz Cr-NRz , N-....I)11 Nz..õ..)11 N..,7\ Rf' % A
-.i NS___/
....... Rz-() Si z NsiNf -_ Rz Rz- I Rz-- N NI,NNA k R Rz N
Rz , Rz S"-NRz Rz , Rz Rz Rz , Rz y Rzy; Rz_N,Ny2, Rz\ Rz\
Ny2, N2, 9-., , A N, 1,1 A, Nµ I
Rz-N ):-'----N Rz-N' - N's I y N" 'I" Rz.-- i sN
Rz sNN Rz , 1\17----N , sNN , 1N , N=N , Rz I
Nf, /N-'' N.õ, Rz CL-NA ,N'NA
N ' I )N Rz.../N-fa' 0: _ -- 0) Rz Rz Rz NH) Rz Rz Rz Rz Rz N-41 , , , , Rz N s/NYa' Rzy2, S,õ)2, --<\ i S' - ,S
N, I_f2, )õ....s.-.N N
Rz -=-=N Rz--c\ )1);
µS
Rz Rz , \S"N , N'S , Rz µRz , Rz Rz , or N-N .
7 A, (Rz),--1 [00121] In some embodiments, 0 is a substituted or unsubstituted monocyclic 6-membered heteroaryl ring containing at least one N atom, and wherein the at least one N atom is adjacent to Z1.
(Rz),,,¨ Z2, -, Z2 [00122] In some embodiments, is Z2 ; and each Z2 is independently CRz or N.
A
(Rz),,,¨
[00123] In some embodiments, ZI
is substituted or unsubstituted pyridinyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted pyridazinyl.
Rz N),2a, q\
iA I
(Rz),,,- z RzRz Rz - Rz [00124] In some embodiments, O is Rz , Rz , Rz Rz N za, i Rz N Tjz2, RzN
N z z,- N
R R T
Rz , Rz ,or Rz .
[00125] In some embodiments, each Rz is independently H, halogen, -CN, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In some embodiments, each Rz is independently H, halogen, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
In some embodiments, each Rz is independently H, -F, -Cl, -Br, -I, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or phenyl.
[00126] In some embodiments, each Rz is -L'-Y'. In some embodiments, LI is substituted or unsubstituted Ci-C4alkylene; and Y1 is substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cio heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
In some embodiments, each Rz is -L2-L3-Y2. In some embodiments, L2 is substituted or unsubstituted Ci-C6alkylene; L3 is -0-, -S-, -(S=0)-, -(SO2)-, -NR3-, -(C=0)-, -(C=0)0-, -0(C=0)-, -(C=0)NR3-, -(C=0)NR3-0-, -NR3(C=0)-, -NR3(C=0)NR3-, -0(C=0)NR3-, -NR3(C=0)0-, -NR3(S02)NR3-, -NR3(S02)-, -(S02)NR3-, -(S02)NR3-(C=0)-, -(S02)NR3-(C=0)0-, -NR3(S02)NR3-(C=0)-, or -NR3(S02)NR3-(C=0)0-; each R3 is independently H or substituted or unsubstituted Ci-C6alkyl; and Y2 is H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
[00127] In some embodiments, L2 is absent; L3 is -0-, -S-, -(S=0)-, -(SO2)-, -NR3-, -(C=0)-, -(C=0)0-, -0(C=0)-, -(C=0)NR3-, -(C=0)NR3-0-, -NR3(C=0)-, -NR3(C=0)NR3-, -0(C=0)NR3-, -NR3(C=0)0-, -NR3(502)NR3-, -NR3(S02)-, -(502)NR3-, -(S02)NR3-(C=0)-, -(502)NR3-(C=0)0-, -NR3(502)NR3-(C=0)-, or -NR3(502)NR3-(C=0)0-; each R3 is independently H or substituted or unsubstituted Ci-C6alkyl; and Y2 is H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
R
"S-R
R
HN HN HN ,s [00128] In some embodiments, fr is 0õ0 \SR
lel 9 S
HN HN R
0- ,or µt R
"S-R
HN HN
[00129] In some embodiments, fr is .
[00130] In some embodiments, R is NHR1; and R1 is substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted CI-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-C ioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
In some embodiments, R1 is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or phenyl.
In some embodiments, R is R1; and R1 is substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-C10cyc1oa1ky1, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
In some embodiments, R1 is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or phenyl.
Ts"
HN 41:1 HN
(R2), (R2), [00131] In some embodiments, is [00132] In some embodiments, the compound has the structure of Formula (Ib), or a pharmaceutically acceptable salt thereof:
0-I, -S¨R
HN-Formula (Ib).
M -Tn.
HN 40 HN i&
(R2)n [00133] In some embodiments, is IW .
=nr ¨7 R2 'I¨
NN HN r& HN 40 R2 . (R2)n [00134] In some embodiments, is -nr-HN
or' R2.
40 (R2)n IW
[00135] In some embodiments, is , R2, HN 0 --r- R2 -1--- HN R2 HN t HN i R2 IW
R2 , R2 IW IW R 2 -, or R2 .
, 7 mHN 41:1 HN.-(R2)n ____ (R2)n [00136] In some embodiments, is [00137] In some embodiments, the compound has the structure of Formula (Ic), or a pharmaceutically acceptable salt thereof:
0-"
-S¨R
(Rz)m¨
HN
(R2)n Formula (Ic).
HNo HN10 (R2)n [00138] In some embodiments, is R2 7' HN HN b HN R2 ____________________________________ (R2)n [00139] In some embodiments, is HNaR2.
or ¨1¨ 7- R m R2 HN HN tR2 HN
____________________________________ (R2)n [00140] In some embodiments, is R2 -7- R2 s"7"
HNI)R2 HN R2 4¨rf, R2 R2 ar HNb HN1aR2 FINt HNIci IZ2R2 or HNIaR2 In some embodiments, each R2 is independently H, halogen, -N3, -CN, -SR4, -(S02)R4, -N(R4)2, -0O2R4, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Cr C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-C iocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
In some embodiments, the compound has the structure of Formula (Id), or a pharmaceutically acceptable salt thereof:
,R
(Rz)n,-HN =(R2)n Formula (Id).
[00141] In some embodiments, the compound has the structure of Formula (le), or a pharmaceutically acceptable salt thereof:
R
HN
Formula (le).
[00142] In some embodiments, the compound has the structure of Formula (If), or a pharmaceutically acceptable salt thereof:
,R
HN
______________________________________________ (R2),, Formula (If).
[00143] In some embodiments, the compound has the structure of Formula (Ig), or a pharmaceutically acceptable salt thereof:
,R
(Rz),¨
HN
Formula (Ig).
[00144] In some embodiments, the compound disclosed herein has the structure provided in Table 1.
Compound Structure Name No.
,N-NH
N' i'\I
H
N-(tert-butyl)-4-(cyclohexylamino)-1 CµI\ . NO 3-(2H-tetrazol-HN-S\ yl)benzenesulfonamide b (OH
) N-N
1\1' r'Ni N-(tert-buty1)-4-(cyclohexylamino)-2 H 3-(2-(2-hydroxyethyl)-2H-tetrazol-HN
'Rµ 0 -S 5-yl)benzenesulfonamide µµ * N
N I N-cyclohexy1-2-(5-methy1-1,2,4--- N
3 H oxadiazol-3-y1)-, 6 9,s = N
(methylsulfonyl)aniline ,N-NH
N ' 1 N
I-N-cyclohexy1-4-(methylsulfony1)-2-(:)=
N
*0 % (2H-tetrazol-5-y0aniline N-N/
NI' I
N N-cyclohexy1-2-(2-methy1-2H-H Atetrazol-5-y1)-4-*
N No (methylsulfonyl)aniline b \
N -N-cyclohexy1-2-(1-methy1-1H-1,2,3-6 H triazol-4-y1)-4-N
9µ Obt 0 (methylsulfonyl)aniline ,S
b Compound Structure Name No.
\
N-N
\ I N-cy clohexy1-2-(1-methy 1-1H-7 H py razol-4-y1)-4-(methylsulfonyl)aniline b --- N N-cy clohexy1-2-(1-methy 1-1H-8 H pyrazol-3-y1)-4-IcJJ N
0, (methylsulfonyl)aniline b 0 N
N',/
N
N-cy clohexy1-4-(methylsulfony1)-2-(1H-1,2,3-triazol-1-yl)aniline S, ' O
NO
N
H N-cy clohexy1-4-(methylsulfony1)-2-N
9% * 0 (1H-pyrazol-1-y0aniline ,s b N 11 H N-cyclohexy1-2-(1H-imidazol-1-y1)-N
9% * 0 4-(methylsulfonyl)aniline ,s b F-N
Ns )) N N-cy clohexy1-4-(methylsulfony1)-2-N
9% * 0 (1H-1,2,4-triazol-1-yl)aniline ,s b N, A
N
H N-cy clohexy1-4-(methylsulfony1)-2-9% * 0 (2H-1,2,3 -triazol-2-y0aniline ,s b Compound Structure Name No.
N¨N) 4-(cyclohexylamino)-3-(2-ethy1-2H-14 H tetrazol-5-y1)-N-0 methylbenzenesulfonamide \Sµ 40 NO
H N - \\
N¨N 4-(cyclohexylamino)-N-methy1-3-Ni , 15 H (2-propy1-2H-tetrazol-5-HN
0 0 41 NO yl)benzenesulfonamide \\
-S
\\
F
N¨N 4-(cyclohexylamino)-3-(2-(4-16 NI , N
fluoropheny1)-2H-tetrazol-5-y1)-N-SI H
N methylbenzenesulfonamide Os N- II
HO
p N¨N
N' ,N 3-(2-cyclobuty1-2H-tetrazol-5-y1)-4-17 H (cyclohexylamino)-N-N
CZµ 0 0 methylbenzenesulfonamide HN,Sµ`
I
N¨N
Ni , N 4-(cyclohexylamino)-3-(2-18 H cyclopenty1-2H-tetrazol-5-y1)-N-Rµ 0 N 0 methylbenzenesulfonamide HN,Sµ`
I
Compound Structure Name No.
Ai F
N¨N 4-(cyclohexylamino)-3-(2-(2-,, \
19 N , N
fluorobenzy1)-2H-tetrazol-5-y1)-N-No methylbenzenesulfonamide CZ%
,Sµ
HN
N 3-(2-benzy1-2H-tetrazol-5-y1)-4-¨.
,, IN
-- N (cyclohexylamino)-N-H methylbenzenesulfonamide N
HN-5)k *
i b 0 N-N 3-(2-butyltetrazol-5-y1)-4-21 N1N µi\I (cyclohexylamino)-N-methyl-õI NHo benzenesulfonamide \\
.S
NH µµ
/
N-N
N , N 4-(cyclohexylamino)-N-methy1-3-H
22 N (2-methyl-2H-tetrazol-5-Rµ 0 o yl)benzenesulfonamide -S
HN µ`
I
F II, N-N
4-(cyclohexylamino)-3-(2-(2-N ,N
fluoropheny1)-2H-tetrazol-5-y1)-N-N
methylbenzenesulfonamide C:Is la N II
HO
Compound Structure Name No.
01---:
tert-butyl 3-(5-(2-"
)------/ (cyclohexylamino)-5-(N-24 N-N methylsulfamoyl)pheny1)-2H-N' ' N
tetrazol-2-yOpyrrolidine-1-H
9µ 40 N0 carboxylate S
HN -µN
---\\/
C) / ,7N tert-butyl 34542------c (cyclohexylamino)-5-(N-NI II methylsulfamoyl)pheny1)-2H-\ N
H tetrazol-2-y0azetidine-1-carboxylate ,µ * No um-S
I IIN %\
).ss.
N¨N
NI' N 4-(cyclohexylamino)-3-(2-isopropyl-26 H 2H-tetrazol-5-y1)-N-9, 01 NO methylbenzenesulfonamide -S
HN
-----N-N 4-(cyclohexylamino)-3-(2-isobutyl-, 1 N N
27 2H-tetrazol-5-y1)-N-H
0µ 410 NO methylbenzenesulfonamide -S
HN
Compound Structure Name No.
)LX
01 tert-butyl 4-(5-(2-(cyclohexylamino)-5-(N-N¨N
28 N'' i'\I methylsulfamoyl)pheny1)-2H-H tetrazol-2-yOpiperidine-1-HN 0µ * NO carboxylate -S
µµ
N¨N 4-(cyclohexylamino)-N-methyl-3-29 H (2-(pyridin-3-ylmethyl)-2H-tetrazol-411 N...0 5-yl)benzenesulfonamide 0µ
;Sµ
HN `0 OH
(cyclohexylamino)-N-methy1-3-Ni ,N
)7,1Rz Rz)......Nx N X R \N ,7\z? Rz Rz N 0 \N1)77 Rz ---e: Rz-y 0' Rz N-0 0\
Rz--Rz Rz )---Rz Rz-N I r Rz µONRz Rz , Rz , Rz Rz Rz 0--NRz , , Rzv x Rz )(\?Rz )N>z, Rz \ S-NX Rz\N,7\ Rz N
).
Rz-C-1 ' Rz____e? Rz......j, si )....õ,\ Rz S\
N-S a .....0 Rz )---"N Rz Rz-N \SNRz I r Rz Rz , Rz , Rz , Rz ' Rz Rz , Rz\ 1)..,1)17 Rz \N1)77 Rz Rz-N
Rz-< S )....-S
S---NRz Rz ,or Rz .
[00108] In some embodiments, is substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted pyrazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted isothiazolyl, substituted or unsubstituted triazoyl, substituted or unsubstituted tetrazoyl, substituted or unsubstituted oxadiazolyl, substituted or unsubstituted thiadiazolyl, or substituted or unsubstituted dithiazolyl.
Rz Rz \NI )17 Rz.......1_11N>Z7 RZ), J.N
(RZ)m -0 RZ RZ
[00109] In some embodiments, is Rz Rz , Rz Rz,\ RZ
,N -N >17 ,N-....217 N-..)17 Rz ),..._ >/.7 Rz\
N-õ,)1?
Rz-N Rz-....( Rz-N NI\ 1 )-----)11 N\_____Li N
)---- Rz Rz )---'NRz 1¨ Rz Rz-NsNRz Rz 'Rz Rz- I
N ---N Rz Rz Rz Rz , Rz , , , , Rz Rz-N ..._.?õ,õ Rz Nõ..-,,(\ N.,-,..,.21.? Rz).......,,>7 Rz R z -Sõ.. 0' N-}17 N:zzr\
N , Rz )...--Rz Nµi I Rz----1)11 Rz- I
Rz Rz Rz 0 Rz, N - 0--NRz Rz , , , ' , Rz>.,....?1, Rzv x N ......)1, Rz N . m A
N-......,.?"1 Ni-T ' S' N-.,277 N Rz-S__ s Rz-c_ ',"
)--0 kiW17 Rz' I
),---s --- N
Y---1---jRz "\c,.... SRz Rz Rz Rz , Rz , Rz , , , N. A, Rzõ, Rz\
N Rz-N: N Nf ,Nf, Rzy Rz_N' N
N'-1)2' Rz-N , ,i)z, N
X---"N Rz-N' '''. N's '71\
R/ 'Rz Rz N 'N
Rz Rz µ1\1:--N Rz V:N sN-N
, , Rz\ Rz NA N.N A, NI: - ,Nf ,,,Ps 1 f dN' N .1- Rz- =,- )...-.:-.:N Rz_iN-y)2' NY R,....µo--ii--A
s sz:
NN N o N --:-N Rz Rz Rz N-0 b-N N---1\1 , , Rz\
,omA, 0,,,A, N.N A Nf ,s_f2, s/N-Y4 Rz-N\ _i Rz--c., .,µ o' -Rz Rz NRz N'' I
\ Ns )------( µc I No I )---=-N
N
Dz Rz Rz Rz -, Rz Rz Rz , , '`
Rz, N:et, S' A s,mA, l'\1.,,, R A, z¨N' s y Ny2, Rz i -c_ - S/ - Rz--- ,S
N
S: \ ...._-_-..( il y"---Rz Rz Rz N-S , Rz Rz , Rz Rz , or NN
.
(Rz),¨.
[00110] In some embodiments, is a substituted or unsubstituted monocyclic 6-membered heteroaryl ring containing at least one N atom.
[00111] In some embodiments, is a substituted or unsubstituted monocyclic 6-membered heteroaryl ring containing 1 or 2 N atoms.
z2z2y\
"
ii (Rz6-0 = z2,z2-,z2 =
[00112] In some embodiments, is , each Z2 is independently CRz or N; and at least one Z2 is N.
(Rz),õ-0 [00113] In some embodiments, is substituted or unsubstituted pyridinyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted pyridazinyl.
Rz RzN}µ NA
I
(Rz),¨. RzThRz Rz-r Rz [00114] In some embodiments, is Rz Rz Rz Rz Rz,r\ Rz1\1 Rz Nrµ'22, Rz N) N Rz Rz Rz N Rz Rz N NRZ\, Rz Rz Rz Rz Rz Rz N Rz or Rz z&r N
Rz [00115] In some embodiments, the compound has the structure of Formula (Ia), or a pharmaceutically acceptable salt thereof:
(R z) -HN
- A (R2)n Formula (Ia) wherein Z1 is -N-, -CH-, or -C-.
Z1)4 (Rz),õ¨
In some embodiments, is a substituted or unsubstituted monocyclic membered heterocyclic ring containing at least one N atom, and the at least one N atom is adjacent to Z1.
Rzõ, i (Rz),- zoz2 , z2 , _z2 [00116] In some embodiments, is Z2_ or µZ2--Z2 =
Z1 is -N-, -CH-, or -C-;
each Z2 is independently CRz, NRz, N, 0, or S;
each - - is independently a single or double bond; and with the provision that the 5-membered heterocyclic ring contains at least one N atom.
A' (Rz),õ,-ZI
[00117] In some embodiments, is substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted imidazolidinyl, substituted or unsubstituted pyrazolidinyl, substituted or unsubstituted oxazolidinyl, substituted or unsubstituted isoxazolidinyl, substituted or unsubstituted thiazolidinyl, or substituted or unsubstituted isothiazolidinyl.
Rz\ Rz Rz [00118] In some embodiments, 01A is Rz-----NRz Rz -----1-\LIRz Rz , , i\j NI
Rz Rz Rz% Rz, z R
NI z \,V\ \,/\ ,,)17 j7.7 Rzõ, R\N7 s'\N,V\
Rz-N Rz- Rz i N-) Rz_ ......N 0' 0 )----Rz NRz µRz )-Rz Rz-<0, ----Rz Rz Rz , Rz , Rz Rz Rz Rz , , , Rz \
N Rz Rz--....e?
Rz-<
Rz ,or SRz .
z1)4 [00119] In some embodiments, is substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted pyrazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted isothiazolyl, substituted or unsubstituted triazoyl, substituted or unsubstituted tetrazoyl, substituted or unsubstituted oxadiazolyl, substituted or unsubstituted thiadiazolyl, or substituted or unsubstituted dithiazolyl.
Rz \N,7\ NN >7 A, (Rz),- Z
01 Rz).....L Rz-S__:__L
Rz Rz [00120] In some embodiments, is Rz Rz , Rz-N, Rz\ Rz Rz\
N-. R
..)17 N,...V\
, N I
IN-...7\i z-NY27 Rz-$.___IN 0' N--)17 -)--Rz r -Rz Rz1 -% )....,..N
Rz Rz- I
Rz , Rz N"-NRz Rz , Rz , Rz Cr-NRz , N-....I)11 Nz..õ..)11 N..,7\ Rf' % A
-.i NS___/
....... Rz-() Si z NsiNf -_ Rz Rz- I Rz-- N NI,NNA k R Rz N
Rz , Rz S"-NRz Rz , Rz Rz Rz , Rz y Rzy; Rz_N,Ny2, Rz\ Rz\
Ny2, N2, 9-., , A N, 1,1 A, Nµ I
Rz-N ):-'----N Rz-N' - N's I y N" 'I" Rz.-- i sN
Rz sNN Rz , 1\17----N , sNN , 1N , N=N , Rz I
Nf, /N-'' N.õ, Rz CL-NA ,N'NA
N ' I )N Rz.../N-fa' 0: _ -- 0) Rz Rz Rz NH) Rz Rz Rz Rz Rz N-41 , , , , Rz N s/NYa' Rzy2, S,õ)2, --<\ i S' - ,S
N, I_f2, )õ....s.-.N N
Rz -=-=N Rz--c\ )1);
µS
Rz Rz , \S"N , N'S , Rz µRz , Rz Rz , or N-N .
7 A, (Rz),--1 [00121] In some embodiments, 0 is a substituted or unsubstituted monocyclic 6-membered heteroaryl ring containing at least one N atom, and wherein the at least one N atom is adjacent to Z1.
(Rz),,,¨ Z2, -, Z2 [00122] In some embodiments, is Z2 ; and each Z2 is independently CRz or N.
A
(Rz),,,¨
[00123] In some embodiments, ZI
is substituted or unsubstituted pyridinyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted pyridazinyl.
Rz N),2a, q\
iA I
(Rz),,,- z RzRz Rz - Rz [00124] In some embodiments, O is Rz , Rz , Rz Rz N za, i Rz N Tjz2, RzN
N z z,- N
R R T
Rz , Rz ,or Rz .
[00125] In some embodiments, each Rz is independently H, halogen, -CN, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In some embodiments, each Rz is independently H, halogen, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
In some embodiments, each Rz is independently H, -F, -Cl, -Br, -I, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or phenyl.
[00126] In some embodiments, each Rz is -L'-Y'. In some embodiments, LI is substituted or unsubstituted Ci-C4alkylene; and Y1 is substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cio heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
In some embodiments, each Rz is -L2-L3-Y2. In some embodiments, L2 is substituted or unsubstituted Ci-C6alkylene; L3 is -0-, -S-, -(S=0)-, -(SO2)-, -NR3-, -(C=0)-, -(C=0)0-, -0(C=0)-, -(C=0)NR3-, -(C=0)NR3-0-, -NR3(C=0)-, -NR3(C=0)NR3-, -0(C=0)NR3-, -NR3(C=0)0-, -NR3(S02)NR3-, -NR3(S02)-, -(S02)NR3-, -(S02)NR3-(C=0)-, -(S02)NR3-(C=0)0-, -NR3(S02)NR3-(C=0)-, or -NR3(S02)NR3-(C=0)0-; each R3 is independently H or substituted or unsubstituted Ci-C6alkyl; and Y2 is H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
[00127] In some embodiments, L2 is absent; L3 is -0-, -S-, -(S=0)-, -(SO2)-, -NR3-, -(C=0)-, -(C=0)0-, -0(C=0)-, -(C=0)NR3-, -(C=0)NR3-0-, -NR3(C=0)-, -NR3(C=0)NR3-, -0(C=0)NR3-, -NR3(C=0)0-, -NR3(502)NR3-, -NR3(S02)-, -(502)NR3-, -(S02)NR3-(C=0)-, -(502)NR3-(C=0)0-, -NR3(502)NR3-(C=0)-, or -NR3(502)NR3-(C=0)0-; each R3 is independently H or substituted or unsubstituted Ci-C6alkyl; and Y2 is H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
R
"S-R
R
HN HN HN ,s [00128] In some embodiments, fr is 0õ0 \SR
lel 9 S
HN HN R
0- ,or µt R
"S-R
HN HN
[00129] In some embodiments, fr is .
[00130] In some embodiments, R is NHR1; and R1 is substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted CI-C6heteroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, substituted or unsubstituted C2-C ioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
In some embodiments, R1 is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or phenyl.
In some embodiments, R is R1; and R1 is substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Ci-C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-C10cyc1oa1ky1, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
In some embodiments, R1 is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or phenyl.
Ts"
HN 41:1 HN
(R2), (R2), [00131] In some embodiments, is [00132] In some embodiments, the compound has the structure of Formula (Ib), or a pharmaceutically acceptable salt thereof:
0-I, -S¨R
HN-Formula (Ib).
M -Tn.
HN 40 HN i&
(R2)n [00133] In some embodiments, is IW .
=nr ¨7 R2 'I¨
NN HN r& HN 40 R2 . (R2)n [00134] In some embodiments, is -nr-HN
or' R2.
40 (R2)n IW
[00135] In some embodiments, is , R2, HN 0 --r- R2 -1--- HN R2 HN t HN i R2 IW
R2 , R2 IW IW R 2 -, or R2 .
, 7 mHN 41:1 HN.-(R2)n ____ (R2)n [00136] In some embodiments, is [00137] In some embodiments, the compound has the structure of Formula (Ic), or a pharmaceutically acceptable salt thereof:
0-"
-S¨R
(Rz)m¨
HN
(R2)n Formula (Ic).
HNo HN10 (R2)n [00138] In some embodiments, is R2 7' HN HN b HN R2 ____________________________________ (R2)n [00139] In some embodiments, is HNaR2.
or ¨1¨ 7- R m R2 HN HN tR2 HN
____________________________________ (R2)n [00140] In some embodiments, is R2 -7- R2 s"7"
HNI)R2 HN R2 4¨rf, R2 R2 ar HNb HN1aR2 FINt HNIci IZ2R2 or HNIaR2 In some embodiments, each R2 is independently H, halogen, -N3, -CN, -SR4, -(S02)R4, -N(R4)2, -0O2R4, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted Cr C6haloalkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-C iocycloalkyl, substituted or unsubstituted C2-Cioheterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
In some embodiments, the compound has the structure of Formula (Id), or a pharmaceutically acceptable salt thereof:
,R
(Rz)n,-HN =(R2)n Formula (Id).
[00141] In some embodiments, the compound has the structure of Formula (le), or a pharmaceutically acceptable salt thereof:
R
HN
Formula (le).
[00142] In some embodiments, the compound has the structure of Formula (If), or a pharmaceutically acceptable salt thereof:
,R
HN
______________________________________________ (R2),, Formula (If).
[00143] In some embodiments, the compound has the structure of Formula (Ig), or a pharmaceutically acceptable salt thereof:
,R
(Rz),¨
HN
Formula (Ig).
[00144] In some embodiments, the compound disclosed herein has the structure provided in Table 1.
Compound Structure Name No.
,N-NH
N' i'\I
H
N-(tert-butyl)-4-(cyclohexylamino)-1 CµI\ . NO 3-(2H-tetrazol-HN-S\ yl)benzenesulfonamide b (OH
) N-N
1\1' r'Ni N-(tert-buty1)-4-(cyclohexylamino)-2 H 3-(2-(2-hydroxyethyl)-2H-tetrazol-HN
'Rµ 0 -S 5-yl)benzenesulfonamide µµ * N
N I N-cyclohexy1-2-(5-methy1-1,2,4--- N
3 H oxadiazol-3-y1)-, 6 9,s = N
(methylsulfonyl)aniline ,N-NH
N ' 1 N
I-N-cyclohexy1-4-(methylsulfony1)-2-(:)=
N
*0 % (2H-tetrazol-5-y0aniline N-N/
NI' I
N N-cyclohexy1-2-(2-methy1-2H-H Atetrazol-5-y1)-4-*
N No (methylsulfonyl)aniline b \
N -N-cyclohexy1-2-(1-methy1-1H-1,2,3-6 H triazol-4-y1)-4-N
9µ Obt 0 (methylsulfonyl)aniline ,S
b Compound Structure Name No.
\
N-N
\ I N-cy clohexy1-2-(1-methy 1-1H-7 H py razol-4-y1)-4-(methylsulfonyl)aniline b --- N N-cy clohexy1-2-(1-methy 1-1H-8 H pyrazol-3-y1)-4-IcJJ N
0, (methylsulfonyl)aniline b 0 N
N',/
N
N-cy clohexy1-4-(methylsulfony1)-2-(1H-1,2,3-triazol-1-yl)aniline S, ' O
NO
N
H N-cy clohexy1-4-(methylsulfony1)-2-N
9% * 0 (1H-pyrazol-1-y0aniline ,s b N 11 H N-cyclohexy1-2-(1H-imidazol-1-y1)-N
9% * 0 4-(methylsulfonyl)aniline ,s b F-N
Ns )) N N-cy clohexy1-4-(methylsulfony1)-2-N
9% * 0 (1H-1,2,4-triazol-1-yl)aniline ,s b N, A
N
H N-cy clohexy1-4-(methylsulfony1)-2-9% * 0 (2H-1,2,3 -triazol-2-y0aniline ,s b Compound Structure Name No.
N¨N) 4-(cyclohexylamino)-3-(2-ethy1-2H-14 H tetrazol-5-y1)-N-0 methylbenzenesulfonamide \Sµ 40 NO
H N - \\
N¨N 4-(cyclohexylamino)-N-methy1-3-Ni , 15 H (2-propy1-2H-tetrazol-5-HN
0 0 41 NO yl)benzenesulfonamide \\
-S
\\
F
N¨N 4-(cyclohexylamino)-3-(2-(4-16 NI , N
fluoropheny1)-2H-tetrazol-5-y1)-N-SI H
N methylbenzenesulfonamide Os N- II
HO
p N¨N
N' ,N 3-(2-cyclobuty1-2H-tetrazol-5-y1)-4-17 H (cyclohexylamino)-N-N
CZµ 0 0 methylbenzenesulfonamide HN,Sµ`
I
N¨N
Ni , N 4-(cyclohexylamino)-3-(2-18 H cyclopenty1-2H-tetrazol-5-y1)-N-Rµ 0 N 0 methylbenzenesulfonamide HN,Sµ`
I
Compound Structure Name No.
Ai F
N¨N 4-(cyclohexylamino)-3-(2-(2-,, \
19 N , N
fluorobenzy1)-2H-tetrazol-5-y1)-N-No methylbenzenesulfonamide CZ%
,Sµ
HN
N 3-(2-benzy1-2H-tetrazol-5-y1)-4-¨.
,, IN
-- N (cyclohexylamino)-N-H methylbenzenesulfonamide N
HN-5)k *
i b 0 N-N 3-(2-butyltetrazol-5-y1)-4-21 N1N µi\I (cyclohexylamino)-N-methyl-õI NHo benzenesulfonamide \\
.S
NH µµ
/
N-N
N , N 4-(cyclohexylamino)-N-methy1-3-H
22 N (2-methyl-2H-tetrazol-5-Rµ 0 o yl)benzenesulfonamide -S
HN µ`
I
F II, N-N
4-(cyclohexylamino)-3-(2-(2-N ,N
fluoropheny1)-2H-tetrazol-5-y1)-N-N
methylbenzenesulfonamide C:Is la N II
HO
Compound Structure Name No.
01---:
tert-butyl 3-(5-(2-"
)------/ (cyclohexylamino)-5-(N-24 N-N methylsulfamoyl)pheny1)-2H-N' ' N
tetrazol-2-yOpyrrolidine-1-H
9µ 40 N0 carboxylate S
HN -µN
---\\/
C) / ,7N tert-butyl 34542------c (cyclohexylamino)-5-(N-NI II methylsulfamoyl)pheny1)-2H-\ N
H tetrazol-2-y0azetidine-1-carboxylate ,µ * No um-S
I IIN %\
).ss.
N¨N
NI' N 4-(cyclohexylamino)-3-(2-isopropyl-26 H 2H-tetrazol-5-y1)-N-9, 01 NO methylbenzenesulfonamide -S
HN
-----N-N 4-(cyclohexylamino)-3-(2-isobutyl-, 1 N N
27 2H-tetrazol-5-y1)-N-H
0µ 410 NO methylbenzenesulfonamide -S
HN
Compound Structure Name No.
)LX
01 tert-butyl 4-(5-(2-(cyclohexylamino)-5-(N-N¨N
28 N'' i'\I methylsulfamoyl)pheny1)-2H-H tetrazol-2-yOpiperidine-1-HN 0µ * NO carboxylate -S
µµ
N¨N 4-(cyclohexylamino)-N-methyl-3-29 H (2-(pyridin-3-ylmethyl)-2H-tetrazol-411 N...0 5-yl)benzenesulfonamide 0µ
;Sµ
HN `0 OH
(cyclohexylamino)-N-methy1-3-Ni ,N
30 H (2-(piperidin-4-y1)-2H-tetrazol-5-czµ 0 No yl)benzenesulfonamide -S
H LI
,,, Q, NN 3-(2-(1-acetylpiperidin-4-y1)-2H-
H LI
,,, Q, NN 3-(2-(1-acetylpiperidin-4-y1)-2H-
31 Nli , N tetrazol-5-y1)-4-(cyclohexylamino)-H N-methylbenzenesulfonamide \\
-S
HN \\
Compound Structure Name No.
0, /
µS, 0 µ0 4-(cyclohexylamino)-N-methy1-3-N¨N (2-(1-(methylsulfonyl)piperidin-4-
-S
HN \\
Compound Structure Name No.
0, /
µS, 0 µ0 4-(cyclohexylamino)-N-methy1-3-N¨N (2-(1-(methylsulfonyl)piperidin-4-
32 NI' , N
H y1)-2H-tetrazol-5-HN-Ot µ. ,..,µ µ0 No yl)benzenesulfonamide S
I `-' (cyclohexylamino)-N-methyl-3-
H y1)-2H-tetrazol-5-HN-Ot µ. ,..,µ µ0 No yl)benzenesulfonamide S
I `-' (cyclohexylamino)-N-methyl-3-
33 NN
(2-(1-(pyridin-3-yOpiperidin-4-y1)-1\11 i\I 2H-tetrazol-5-H
yl)benzenesulfonamide -S
N \\
N-N
N ,N 4-(cyclohexylamino)-N-methyl-3-
(2-(1-(pyridin-3-yOpiperidin-4-y1)-1\11 i\I 2H-tetrazol-5-H
yl)benzenesulfonamide -S
N \\
N-N
N ,N 4-(cyclohexylamino)-N-methyl-3-
34 H (2-pheny1-2H-tetrazo1-5-Rµ 0 N10 yl)benzenesulfonamide HN,Sµµ
I
N/1\1H
N-N
N, N 4-(cyclohexylamino)-N-methyl-3-I'
I
N/1\1H
N-N
N, N 4-(cyclohexylamino)-N-methyl-3-I'
35 H (2-(pyrrolidin-3-y1)-2H-tetrazol-5-c3,µµ el No yl)benzenesulfonamide -S
HN µµ
Compound Structure Name No.
¨N
Nii\l---4-(cyclohexylamino)-3-(2-(1-
HN µµ
Compound Structure Name No.
¨N
Nii\l---4-(cyclohexylamino)-3-(2-(1-
36 N
isopropylpyrrolidin-3-y1)-2H-H tetrazol-5-y1)-N-0µµ 0 No methylbenzenesulfonamide HN,S\\
N .
N¨N 4-(cyclohexylamino)-N-methyl-3-NI' N
isopropylpyrrolidin-3-y1)-2H-H tetrazol-5-y1)-N-0µµ 0 No methylbenzenesulfonamide HN,S\\
N .
N¨N 4-(cyclohexylamino)-N-methyl-3-NI' N
37 (2-(1-phenylpyrrolidin-3-y1)-2H-H
= No tetrazol-5-yObenzenesulfonamide \\
n IN \\
IIP
cf) 4-(cyclohexylamino)-N-methy1-3-N¨N
= No tetrazol-5-yObenzenesulfonamide \\
n IN \\
IIP
cf) 4-(cyclohexylamino)-N-methy1-3-N¨N
38 ,, , (2-(1-phenylpiperidin-4-y1)-2H-N ,N
H tetrazol-5-yObenzenesulfonamide HN,Sµ`
I
F
/ ( F
N-N F
/ 4-(cyclohexylamino)-N-methyl-3-N "
H tetrazol-5-yObenzenesulfonamide HN,Sµ`
I
F
/ ( F
N-N F
/ 4-(cyclohexylamino)-N-methyl-3-N "
39 H
N.....0 (2-(2,2,2-trifluoroethyl)-2H-tetrazol-5-yObenzenesulfonamide 0\ 40 :s\
N0---- µ
H
Compound Structure Name No.
N-N
4-(cyclohexylamino)-3-(2-(2-N "
N.....0 (2-(2,2,2-trifluoroethyl)-2H-tetrazol-5-yObenzenesulfonamide 0\ 40 :s\
N0---- µ
H
Compound Structure Name No.
N-N
4-(cyclohexylamino)-3-(2-(2-N "
40 fluoroethyl)-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide µ0 N--0 ,\Sµ
4-(cyclohexylamino)-3-(2-(4-N-N
4-(cyclohexylamino)-3-(2-(4-N-N
41 fluorobenzy1)-2H-tetrazol-5-y1)-N-H methylbenzenesulfonamide 0, is Nlo NS
HN-3-(2-(1-acetylpyrrolidin-3-y1)-2H-N
HN-3-(2-(1-acetylpyrrolidin-3-y1)-2H-N
42 tetrazol-5-y1)-4-(cyclohexylamino)-H
C3µ1µ * No N-methylbenzenesulfonamide -S
HN
(cyclohexylamino)-N-methy1-3-N-N
rt\I (2-(1-(methylsulfonyl)pyrrolidin-3-
C3µ1µ * No N-methylbenzenesulfonamide -S
HN
(cyclohexylamino)-N-methy1-3-N-N
rt\I (2-(1-(methylsulfonyl)pyrrolidin-3-
43 y1)-2H-tetrazol-5-o 40 yl)benzenesulfonamide n xx OH
N1' 4-(cyclohexylamino)-3-(2-(2-
N1' 4-(cyclohexylamino)-3-(2-(2-
44 H
hydroxyethyl)-2H-tetrazol-5-y1)-N-0µµs ei methylbenzenesulfonamide HN
Compound Structure Name No.
N
N¨N 4-(cyclohexylamino)-N-methy1-3-,, %
N ,N
hydroxyethyl)-2H-tetrazol-5-y1)-N-0µµs ei methylbenzenesulfonamide HN
Compound Structure Name No.
N
N¨N 4-(cyclohexylamino)-N-methy1-3-,, %
N ,N
45 1-N1 (2-(pyridin-3-y1)-2H-tetrazol-5-Cl 110 yl)benzenesulfonamide s 0 N II
HO
---4-(cyclohexylamino)-3-(2-(1-N¨N
isopropylpiperidin-4-y1)-2H-
HO
---4-(cyclohexylamino)-3-(2-(1-N¨N
isopropylpiperidin-4-y1)-2H-
46 I, INI
N ,N
H tetrazol-5-y1)-N-methylbenzenesulfonamide N No H
,-0 01 isopropyl 4-(5-(2-(cyclohexylamino)-5-(N-N¨N
N ,N
H tetrazol-5-y1)-N-methylbenzenesulfonamide N No H
,-0 01 isopropyl 4-(5-(2-(cyclohexylamino)-5-(N-N¨N
47 methylsulfamoyl)pheny1)-2H-NI ;N
H tetrazol-2-yOpiperidine-1-0, 41 NI..,0 carboxylate N b H
P--(N 1 \ 'NI 4-(cyclohexylamino)-N-methy1-3-
H tetrazol-2-yOpiperidine-1-0, 41 NI..,0 carboxylate N b H
P--(N 1 \ 'NI 4-(cyclohexylamino)-N-methy1-3-
48 H (5-methyl-1,2,4-oxadiazol-3-µN = No yl)benzenesulfonamide um-S
...., %%
...., %%
49 Compound Structure Name No.
)\----pl 3-(2-(1-acetylazetidin-3-y1)-2H-N¨N
NI' 1 49 N tetrazol-5-y1)-4-(cyclohexylamino)-H N-methylbenzenesulfonamide CµIµ . H 0 NO
N -S
N µN
0µ
S, N/II
Ti 0 4-(cyclohexylamino)-N-methy1-3-N¨N (2-(1-(methylsulfonyl)azetidin-3-y1)-
)\----pl 3-(2-(1-acetylazetidin-3-y1)-2H-N¨N
NI' 1 49 N tetrazol-5-y1)-4-(cyclohexylamino)-H N-methylbenzenesulfonamide CµIµ . H 0 NO
N -S
N µN
0µ
S, N/II
Ti 0 4-(cyclohexylamino)-N-methy1-3-N¨N (2-(1-(methylsulfonyl)azetidin-3-y1)-
50 NI' /1\I
2H-tetrazol-5-H
, . NO yl)benzenesulfonamide N -S
N \\
HO
¨N
4-(cyclohexylamino)-N-methy1-3-N¨N
2H-tetrazol-5-H
, . NO yl)benzenesulfonamide N -S
N \\
HO
¨N
4-(cyclohexylamino)-N-methy1-3-N¨N
51 Nii /1\1 (2-(1-phenylazetidin-3-y1)-2H-H tetrazol-5-yObenzenesulfonamide , ,s ,,,, iN µµ
)----pl 4-(cyclohexylamino)-3-(2-(1-N¨N
)----pl 4-(cyclohexylamino)-3-(2-(1-N¨N
52 Nii /1\1 isopropylazetidin-3-y1)-2H-tetrazol-H 5-y1)-N-methylbenzenesulfonamide 1::µ 410 NO
IN
Nõ,,S
\\
HO
Compound Structure Name No.
Q1-\( ,, N-N 0 3-(2-(1-acetylpiperidin-3-y1)-2H-, N N
IN
Nõ,,S
\\
HO
Compound Structure Name No.
Q1-\( ,, N-N 0 3-(2-(1-acetylpiperidin-3-y1)-2H-, N N
53 H tetrazol-5-y1)-4-(cyclohexylamino)-401 No N-methylbenzenesulfonamide (:)µµ
-S
N µµ
TT
NH
,11---N 3-(2-(azetidin-3-y1)-2H-tetrazol-5-H
-S
N µµ
TT
NH
,11---N 3-(2-(azetidin-3-y1)-2H-tetrazol-5-H
54 y1)-4-(cyclohexylamino)-N-(: N 40 o \ methylbenzenesulfonamide õ, H ,S
...., \\
NN
I
\
(cyclohexylamino)-N-methy1-3-
...., \\
NN
I
\
(cyclohexylamino)-N-methy1-3-
55 c:1µµ 0 No (pyrimidin-5-yl)benzenesulfonamide HN,Sµ`
I
n N N
(cyclohexylamino)-N-methyl-3-
I
n N N
(cyclohexylamino)-N-methyl-3-
56 c:zµ 0 No (pyrimidin-2-yl)benzenesulfonamide HN,Sµ`
I
/
/N
--.N 4-(cyclohexylamino)-N-methy1-3-
I
/
/N
--.N 4-(cyclohexylamino)-N-methy1-3-
57 H (1-methyl-1H-pyrazol-3-NH \\ * No Cµ)\
-S yl)benzenesulfonamide /
N-N
IT 4-(cyclohexylamino)-N-methy1-3-H
-S yl)benzenesulfonamide /
N-N
IT 4-(cyclohexylamino)-N-methy1-3-H
58 õI No (1-methyl-1H-1,2,3-triazol-4-(% yl)benzenesulfonamide -S
µµ
Compound Structure Name No.
QN--e N-N 0--E-- tert-butyl 34542-(cyclohexylamino)-5-(N-N, ,'N
µµ
Compound Structure Name No.
QN--e N-N 0--E-- tert-butyl 34542-(cyclohexylamino)-5-(N-N, ,'N
59 H methylsulfamoyl)pheny1)-2H-N
CZ\ 0 tetrazol-2-yOpiperidine-1-,Sµ carboxylate NH \o i .-..( tert-butyl 3-(5-(2-N=N
(cyclohexylamino)-5-(N-
CZ\ 0 tetrazol-2-yOpiperidine-1-,Sµ carboxylate NH \o i .-..( tert-butyl 3-(5-(2-N=N
(cyclohexylamino)-5-(N-
60 H methylsulfamoyl)pheny1)-1H-o 0 No tetrazol-1-yl)piperidine-1-NH,Sµ` carboxylate QN--( 4-(cyclohexylamino)-3-(2-(1-N-N
Ni µ
, 1\1 isopropylpiperidin-3-y1)-2H-
Ni µ
, 1\1 isopropylpiperidin-3-y1)-2H-
61 H
No tetrazol-5-y1)-N-CZµ lel methylbenzenesulfonamide ,S
N µ`
H
N- P
-N
S, 4-(cyc1ohexy1amino)-N-methy1-3-di ..- N (2-(1-(methylsulfonyl)piperidin-3-
No tetrazol-5-y1)-N-CZµ lel methylbenzenesulfonamide ,S
N µ`
H
N- P
-N
S, 4-(cyc1ohexy1amino)-N-methy1-3-di ..- N (2-(1-(methylsulfonyl)piperidin-3-
62 H y1)-2H-tetrazol-5-µ, * No yl)benzenesulfonamide "N -S
\\
HO
QN II
(cyclohexylamino)-N-methyl-3-N, ,N
\\
HO
QN II
(cyclohexylamino)-N-methyl-3-N, ,N
63 (2-(1-phenylpiperidin-3-y1)-2H-H
clµµ 0 No tetrazol-5-yObenzenesulfonamide ,S
N µµ
H
Compound Structure Name No.
---N \ /
4-(cyclohexylamino)-N-methyl-3-
clµµ 0 No tetrazol-5-yObenzenesulfonamide ,S
N µµ
H
Compound Structure Name No.
---N \ /
4-(cyclohexylamino)-N-methyl-3-
64 H
(:)% N (pyridin-2-yl)benzenesulfonamide µS
HN- %%
N
I
\
(cyclohexylamino)-N-methy1-3-
(:)% N (pyridin-2-yl)benzenesulfonamide µS
HN- %%
N
I
\
(cyclohexylamino)-N-methy1-3-
65 HNSµµ No R (pyridin-4-yl)benzenesulfonamide ,µ
,---NH
N 1 4-(cyclohexylamino)-N-methy1-3-.-- N
,---NH
N 1 4-(cyclohexylamino)-N-methy1-3-.-- N
66 H (5-methyl-1H-1,2,4-triazol-3-\NA * N0 yl)benzenesulfonamide H b ri N , N 4-(cyclohexylamino)-3-(1,5-H
67 dimethy1-1H-1,2,4-triazol-3-y1)-N-czµ 0 N
methylbenzenesulfonamide -S
N µõ`
H
NO-\N
4-(cyclohexylamino)-N-methy1-3-N¨N
methylbenzenesulfonamide -S
N µõ`
H
NO-\N
4-(cyclohexylamino)-N-methy1-3-N¨N
68 (2-(1-(pyridin-3-yOpyrrolidin-3-y1)-H 2H-tetrazol-5-yl)benzenesulfonamide -Sµµ
N
r I
N
(cyclohexylamino)-N-methy1-3-
N
r I
N
(cyclohexylamino)-N-methy1-3-
69 czµ 0 No (pyrimidin-4-yl)benzenesulfonamide -S
HN µ`
I
Compound Structure Name No.
N
pl 4-(cyclohexylamino)-N-methy1-3-N-N (2-(1-(py ri din-3 -yl)azeti din-3 -y1)-
HN µ`
I
Compound Structure Name No.
N
pl 4-(cyclohexylamino)-N-methy1-3-N-N (2-(1-(py ri din-3 -yl)azeti din-3 -y1)-
70 Ni 2H-tetrazol-5-H
. NO yl)benzenesulfonamide 0µµ
NS-N %\
HO
P' N-N
N" I 4-(cy clohexylamino)-3 -(2--- N
. NO yl)benzenesulfonamide 0µµ
NS-N %\
HO
P' N-N
N" I 4-(cy clohexylamino)-3 -(2--- N
71 cy cl opropy1-2H-tetrazol-5 -y1)-N-H
91 * No methy lbenzenes ulfonami de ,__, m -S
"" \ \
N-N/
N, , N 4-((4,4-difluorocyclohexyl)amino)-H
91 * No methy lbenzenes ulfonami de ,__, m -S
"" \ \
N-N/
N, , N 4-((4,4-difluorocyclohexyl)amino)-H
72 0 N0-N-methy1-3-(2-methy1-2H-tetrazol-\\ F 5-yl)benzenesulfonamide HN,Sµµ F
/
N-N
Ni , 1\1 4-((3,3-difluorocyclohexyl)amino)-H F
/
N-N
Ni , 1\1 4-((3,3-difluorocyclohexyl)amino)-H F
73 N N-methy1-3-(2-methy1-2H-tetrazol-5-yl)benzenesulfonamide S, HN
I
QNH
NN 4-(cyclohexylamino)-N-methyl-3-N" 1%\i
I
QNH
NN 4-(cyclohexylamino)-N-methyl-3-N" 1%\i
74 (2-(piperi din-3 -y 0-2H-tetrazol-5 -H
0 411 NO yl)benzenesulfonamide \\
, S
N \\
HO
Compound Structure Name No.
--N 4-(cy cl ohexylamino)-N-methy1-3 -
0 411 NO yl)benzenesulfonamide \\
, S
N \\
HO
Compound Structure Name No.
--N 4-(cy cl ohexylamino)-N-methy1-3 -
75 H (1 -(piperi din-3 -y1)-1H-tetrazol-% \ *
H N - S yl)benzenesulfonamide . ... "
/ \ N H2 -- N 3-(6-aminopyri din-2-y1)-4-
H N - S yl)benzenesulfonamide . ... "
/ \ N H2 -- N 3-(6-aminopyri din-2-y1)-4-
76 H (cyclohexylamino)-N-kim N
0, 'S methy lbenzenes ulfonami de . ..." "
I
\
H 4-(cy cl ohexylamino)-N-methy1-3 -
0, 'S methy lbenzenes ulfonami de . ..." "
I
\
H 4-(cy cl ohexylamino)-N-methy1-3 -
77 HNN 0 CZ\ (py ri din-3 -yl)b enzenes ul fonamide ,Sµµ
--N 4-(cyclohexylamino)-N-methy1-3-H
--N 4-(cyclohexylamino)-N-methy1-3-H
78 N (3 -methy 1py ri din-2-um 0, 2S yl)benzenesulfonamide . .. m µµ 0 F --- N 4-(cy clohexylamino)-3 -(3 -H
79 N 0 fluoropyridin-2-y1)-N-0, methy lbenzenes ulfonami de . ¨ \\
0 -- N 4-(cy clohexylamino)-3 -(3 -
0 -- N 4-(cy clohexylamino)-3 -(3 -
80 N 0 0 methoxy py ridin-2-y1)-N-, methy lbenzenes ulfonami de . ¨ \\
N, A
N 4-(cyclohexylamino)-N-methy1-3-H
N, A
N 4-(cyclohexylamino)-N-methy1-3-H
81 (2H-1,2,3 -tri azol-2-* o \\ N
mw-S yl)benzenesulfonamide "" \\
Compound Structure Name No.
N/
N 4-(cyclohexylamino)-N-methyl-3 -H
mw-S yl)benzenesulfonamide "" \\
Compound Structure Name No.
N/
N 4-(cyclohexylamino)-N-methyl-3 -H
82 0 No (1-methy1-1H-imidazol-4-µµ yl)benzenesulfonamide HN-%
1 o /
/ \ N
4-(cyclohexylamino)-3-(6---N
1 o /
/ \ N
4-(cyclohexylamino)-3-(6---N
83 H (dimethylamino)pyridin-2-y1)-N-R
HN N
-\Sµ methylbenzenesulfonamide / b 0 N N 1 3-(4-aminopyridin-2-y1)-4-
HN N
-\Sµ methylbenzenesulfonamide / b 0 N N 1 3-(4-aminopyridin-2-y1)-4-
84 N H (cyclohexylamino)-N-0µ
HN-\Sµ 0 methylbenzenesulfonamide / b i i \ NH
4-(cyc1ohexy1amino)-N-methy1-3---N
HN-\Sµ 0 methylbenzenesulfonamide / b i i \ NH
4-(cyc1ohexy1amino)-N-methy1-3---N
85 H (6-(methylamino)pyridin-2-N
NW' µ
'S yl)benzenesulfonamide µ
QN-0 4-(cyc1ohexy1amino)-N-methy1-3-N-N
NI , N (2-(1-(pyridin-3-yOpiperidin-3-y1)-
NW' µ
'S yl)benzenesulfonamide µ
QN-0 4-(cyc1ohexy1amino)-N-methy1-3-N-N
NI , N (2-(1-(pyridin-3-yOpiperidin-3-y1)-
86 H
2H-tetrazol-5-0µ 1410 N yl)benzenesulfonamide ,\Sµ
N b H
/
...-N
1 N 4-(cyclohexylamino)-3-(4--- N
2H-tetrazol-5-0µ 1410 N yl)benzenesulfonamide ,\Sµ
N b H
/
...-N
1 N 4-(cyclohexylamino)-3-(4--- N
87 H (dimethylamino)pyridin-2-y1)-N-N
0\
I_Im) methylbenzenesulfonamide . - \\
Compound Structure Name No.
I
NH
/
N I 4-(cyclohexylamino)-N-methyl-3-
0\
I_Im) methylbenzenesulfonamide . - \\
Compound Structure Name No.
I
NH
/
N I 4-(cyclohexylamino)-N-methyl-3-
88 H
No (4-(methylamino)pyridin-2-- yl)benzenesulfonamide µµ
HN Sµµ
n' (cyclohexylamino)-N-methy1-3-H
No (4-(methylamino)pyridin-2-- yl)benzenesulfonamide µµ
HN Sµµ
n' (cyclohexylamino)-N-methy1-3-H
89 * N (1H-1,2,3-triazol-1-9µ o HN yl)benzenesulfonamide yl)benzenesulfonamide / b N-N/
N" ,i;, N-methy1-3-(2-methy1-2H-tetrazol-
N" ,i;, N-methy1-3-(2-methy1-2H-tetrazol-
90 H
N
HN
RS \ it fill (phenylamino)benzenesulfonamide - \\
N=( O , N 4-(cyclohexylamino)-N-methy1-3-H
N
HN
RS \ it fill (phenylamino)benzenesulfonamide - \\
N=( O , N 4-(cyclohexylamino)-N-methy1-3-H
91 N (3-methy1-1,2,4-oxadiazol-5-Rµ el -13 yl)benzenesulfonamide ,S
N µ`,-, HL' N-N/
1\11 , i\J N-methy1-3-(2-methy1-2H-tetrazol-H F F
5-y1)-4-43-
N µ`,-, HL' N-N/
1\11 , i\J N-methy1-3-(2-methy1-2H-tetrazol-H F F
5-y1)-4-43-
92 N
I. el F (trifluoromethyl)phenyl)amino)benz (:)µµ
HN-Sµµ enesulfonamide N-methy1-3-(2-methy1-2H-tetrazol-NI' i'\I F
F F
I. el F (trifluoromethyl)phenyl)amino)benz (:)µµ
HN-Sµµ enesulfonamide N-methy1-3-(2-methy1-2H-tetrazol-NI' i'\I F
F F
93 H
HN
(trifluoromethyl)phenyl)amino)benz A 1#111 tip µµ enesulfonamide Compound Structure Name No.
/
N¨N
NI N-methy1-3-(2-methy1-2H-tetrazol-H 0F 5-y1)-4-((3-
HN
(trifluoromethyl)phenyl)amino)benz A 1#111 tip µµ enesulfonamide Compound Structure Name No.
/
N¨N
NI N-methy1-3-(2-methy1-2H-tetrazol-H 0F 5-y1)-4-((3-
94 N
q=40 µ IF (trifluoromethoxy)phenyl)amino)ben HN-Sµµ F
zenesulfonamide N¨N/
IT ,N N-methy1-3-(2-methy1-2H-tetrazol-H 5-y1)-4-((4-0 (trifluoromethyl)phenyl)amino)benz µs.
-S el N el F
HN \\ enesulfonamide FF
N=N
N ;N N-methy1-3-(1-methy1-1H-tetrazol-H
N 0 5-y1)-4-((4-CZµ SI F (trifluoromethyl)phenyl)amino)benz ,Sµ F
HN b F enesulfonamide I
N=N
--IV .,A N-methy1-3-(1-methy1-1H-tetrazol-H F
F
O. 1410 F (trifluoromethyl)phenyl)amino)benz -S
HN µµ enesulfonamide ,N-..z.N
N-methy1-3-(1-methy1-1H-tetrazol-----N
F F 5-y1)-4-((2-(trifluoromethyl)phenyl)amino)benz FIN'S%
/ b . enesulfonamide N=N
I\I i\1 N-methy1-3-(1-methy1-1H-tetrazol-H
F
CZµ 0 )< F
(trifluoromethoxy)phenyl)amino)ben ,S\ 0 F
HN b zenesulfonamide I
Compound Structure Name No.
N=N
'N /N
H 5-y1)-4-((3-100 . N eil c:IF
(Rµ IF
(trifluoromethoxy)phenyl)amino)ben ,S F
HN µµ zenesulfonamide ,N:---N
....j<F N-methy1-3-(1-methy1-1H-tetrazol-H 0 F 5-y1)-4-((2-101 401 N Isi Ci'µ
(trifluoromethoxy)phenyl)amino)ben ,S
HN \\ zenesulfonamide i 0 N /
¨N
Nii rµ\I F N-methy1-3-(2-methy1-2H-tetrazol-,kF
H 0 F 5-y1)-4-((2-102 N õI
Ci'µ
(trifluoromethoxy)phenyl)amino)ben um,S
n I sl \\ zenesulfonamide /
N¨N
N
,, x N % N-methy1-3-(2-methy1-2H-tetrazol-H 5-y1)-4-((4-F
0 )<F (trifluoromethoxy)phenyl)amino)ben HN,s,b 0 F
zenesulfonamide I
/
N¨N
Nis i\i 4-((2,3-difluorophenyl)amino)-N-H F
104 . N . F methy1-3-(2-methy1-2H-tetrazol-5-0\ yl)benzenesulfonamide HN-I '0 INI---( (cyclohexylamino)-N-methy1-3-µ
H
105 . No (5-methy1-1,3,4-oxadiazol-2-qµ yl)benzenesulfonamide ,S
HN µµ
Compound Structure Name No.
N=N
--IV
H F
4-((2,3-difluorophenyl)amino)-N-106 r F
methy1-3-(1-methy1-1H-tetrazol-5-µµ 4 .
HN-S yl)benzenesulfonamide \\
N=N
N
4-((3,5-difluorophenyl)amino)-N-H
107 0 0 N el F methy1-3-(1-methy1-1H-tetrazol-5-\\
HN-S\\ yl)benzenesulfonamide N¨N/
NI' N 4-((3,5-difluorophenyl)amino)-N-H
108 F methyl-3-(2-methy1-2H-tetrazol-5-0 el NO
\\
,S yl)benzenesulfonamide HN µµ
N=N
,NI i\1 F 4-((2,5-difluorophenyl)amino)-N-H
HN,S\\ methy1-3-(1-methy1-1H-tetrazol-5-yl)benzenesulfonamide I F
141 , N F 4-((2,5-difluorophenyl)amino)-N-H
110 N methy1-3-(2-methy1-2H-tetrazol-5-qµ 40 el HN,Sµµ yl)benzenesulfonamide P
r-N
//
N / 4-(cyclohexylamino)-3-(1-cyclopropy1-1H-imidazol-4-y1)-N-0, 401 N
methylbenzenesulfonamide ,\Sµ
HN `0 I
Compound Structure Name No.
NI¨
in N z 4-(cy cl ohexylamino)-3-(1-ethy 1-1H-H
Y ) 112 (:)µµ 0 No imidazol-4- 1 -N-methy lbenzenes ulfonami de HN,Sµ`
I
IF N
N / 4-(cyclohexylamino)-3-(1-isopropyl-H
113 N-0 1H-imidazol-4-y1)-N-0µ 41 methy lbenzenes ulfonami de ; S \
HN \ID
I
/=N
r" H
4-(cy cl ohexylamino)-3-(1-ethy 1-1H-114 czµ 0 NI) imidazol-5-y1)-N-methy lbenzenes ulfonami de I
3 -(2-(2-(benzyloxy)ethyl)-2H-tetrazol-5-y1)-N-methy1-4-44-;N (trifluoromethyl)phenyl)amino)benz H
N enesulfonami de 0µµ el SF
,S\ F
HN F
OH
3 -(2-(2-hy droxy ethyl)-2H-tetrazol-N-N
;N 5 -y1)-N-methy1-4-((4-czµ 0 N 0 F
(trifluoromethyl)phenyl)amino)benz enesulfonami de ,S\ F
HN F
I
Compound Structure Name No.
NN"
I, N /%\/ 4-((3-fluorophenyl)amino)-N-H
117 methyl-3-(2-methy1-2H-tetrazol-5-iN
yl)benzenesulfonamide S
HN -µµ
N¨N/
14 4-((4-fluorophenyl)amino)-N-H
118 methyl-3-(2-methy1-2H-tetrazol-5-HN \\ N
9µ = 411 yl)benzenesulfonamide -S
pz.-N
¨N rµ\/
4-((4-fluorophenyl)amino)-N-H
40 119 methyl-3-(1-methy1-1H-tetrazol-5-riN ) =
õ-S yl)benzenesulfonamide \\ N
N¨N/
1\11 l'\1 4-((2-fluorophenyl)amino)-N-H F
120 methyl-3-(2-methy1-2H-tetrazol-5-= N ei yl)benzenesulfonamide , ,õ,,S
riN \\
/
/i¨N
N-methy1-3-(1-methy1-1H-imidazol-N /
H 4-y1)-4-44-0µµ el F
(trifluoromethyl)phenyl)amino)benz HN,s\b F enesulfonamide F
I
N,,, /
¨N
Nii /µ\/ 4-((3,4-difluorophenyl)amino)-N-H
122 methyl-3-(2-methy1-2H-tetrazol-5-(R N
µ .
. F
yl)benzenesulfonamide iN H õõ, ...S
\\
Compound Structure Name No.
---\
N¨\\
3-(1 -ethyl- 1 H-imidazol-4-y1)-N-x N
methy1-4-((4-(trifluoromethyl)phenyl)amino)benz µµ 0 HN,Sµµ
F enesulfonami de \N¨\\
N N N-methy1-3-(1-methy 1-1H-imi dazol-H
czµ 4-y1)-4-((3-(trifluoromethyl)phenyl)amino)benz HN,Sµ` enesulfonami de F
----\
N-\\
N N 3-(1 -ethyl- 1 H-imidazol-4-y1)-N-H
N methyl-4-((3-(trifluoromethyl)phenyl)amino)benz .
HN,Sµ` enesulfonami de F
N¨\\ 3 -(1 -cy clopropy1-1H-imidazol-4-y1)-N N
N-methy1-4-((4-N (trifluoromethyl)phenyl)amino)benz F
-S enesulfonami de HN µ` F
.k N¨\\ 3 -(1 -cy clopropy1-1H-imidazol-4-y1)-x N
H N-methy1-4-((3 -127 (:)µµ 0 N s (trifluoromethyl)phenyl)amino)benz NH,Sµµ enesulfonami de F
Compound Structure Name No.
N¨N
N N N-methy1-3-(2-methyltetrazol-5-y1)-128 NH 4-(4-phenylanilino) (:)µµ NHS benzenesulfonamide I
N¨N
%\
N N
N,N-dimethy1-3-(2-methyltetrazol-5-129 el NH y1)-4-(4-CZµ
phenylanilino)benzenesulfonamide -Sµ
N
N-N
I\L
N-methy1-3-(2-methyltetrazol-5-y1)-R\ 40 4-(4-phenoxyanilino) NH"S\\ 0 benzenesulfonamide I
1.1 N¨N
N N N-methy1-3-(2-methyltetrazol-5-y1)-H
131 czµ N 4-(3-phenylanilino) benzenesulfonamide .S
NH µ`
I
N¨N
,µ
N N N, N-dimethy1-3-(2-methyltetrazol-H
132 zµ N 5-y1)-4-(3-phenylanilino) O
benzenesulfonamide ,S\
N
I -)=N 3-(5-amino-1,3,4-oxadiazol-2-y1)-N-methyl-4-[4-133 (:)µµ N
(trifluoromethyDanilinolbenzenesulf -S HN onamide F
Compound Structure Name No.
\
N¨N
N N N-methy1-3-(2-methyltetrazol-5-y1)-134 0 NH is 0 0 4-(3-Rµ phenoxyanilino)benzenesulfonamide .S
NH µ`
I
\
N-N
i %%
N N N,N-dimethy1-3-(2-methyltetrazol-5-135 0 NH 0 0 s y1)-4-(3-N" Rµ phenoxyanilino)benzenesulfonamide -S
F
40 3-[2-[(2-NI!
FluorophenyOmethylltetrazol-5-y11-N N
136 H N-methy1-443-Co4 (trifluoromethyDanilinolbenzenesulf ,s N b F F onamide H
F
F
3-[2-[(2-. N-N FluorophenyOmethylltetrazol-5-y11-Ni , Iv 137 H N-methyl-4-[4-N
0µµ 40 IS F (trifluoromethyDanilinolbenzenesulf ,s N µ` F onamide H F
\
N-N
Ni, Iv N-(tert-buty1)-3-(2-methy1-2H-H tetrazol-5-y1)-4-44-N
R\ 40 40 F (trifluoromethyl)phenyl)amino)benz HN,Sµ` F
0 F enesulfonamide Compound Structure Name No.
\N-\\
N N 4-(4-chloroanilino)-N-methy1-3-(1-H
139 N methylimidazol-CZ\ el el yl)benzenesulfonamide HN,Sµ` CI
I
\N-\\
N N 4-(3,4-dichloroanilino)-N-methy1-3-H
140 czµ 0 N 0 CI (1-methylimidazol-4-yl)benzenesulfonamide HN,Sµ` CI
I
\N-\\
N-methy1-3-(1-methylimidazol-4-N N
H y1)-4-13-IF (trifluoromethylsulfanyl)anilinolben µµ SI 1401 F
HN,S\\
zenesulfonamide \N--\\
N N 4-(3,5-dichloroanilino)-N-methy1-3-H
142 czµ N 0 CI (1-methylimidazol-4-yl)benzenesulfonamide HN,Sµ`
\N-\\
N N 4-(3-Chloroanilino)-N-methy1-3-(1-H
143 N 0 CI methylimidazol-yl)benzenesulfonamide HN,Sµµ
I 'D
\N-\\
N-methy1-3-(1-methylimidazol-4-x N
H y1)-4-14-144 0 N .
µµ
(trifluoromethylsulfanyl)anilinolben -S HN µ` SF
IF zenesulfonamide Compound Structure Name No.
\N¨\\
N N N-methy1-3-(1-methylimidazol-4-H
145 co.N.CI y1)-4-(3,4,5-trichloroanilino)benzenesulfonamide ,S CI
HN µ`
I CI
\N¨\\
NN
H
F F 443,5-Bis(trifluoromethypanilinol-N
146 40) F N-methy1-3-(1-methylimidazol-4-0Z\ 0 ,S yl)benzenesulfonamide HN µ`
F
\
N¨\\
x N 4-[4-Chloro-3-H
N
(trifluoromethyDanilinol-N-methyl-0µµ el 0 3-(1-methylimidazol-4-,S CI
HN µ` yl)benzenesulfonamide I F F
F
\N--\\
4-[3-Chloro-4-x N
H (trifluoromethyDanilinol-N-methyl-CZµ I. . F 3-(1-methylimidazol-4-,S
HN µ` I 0 F F yl)benzenesulfonamide \N¨\\
N N 4-((2,6-Difluorophenyl)amino)-N-F
H
149 0 N 0 methyl-3-(1-methy1-1H-imidazol-4-gµ
F yl)benzenesulfonamide ,S
HN µ`
I
Compound Structure Name No.
N¨\\
N-methy1-3-(1-methy1-1H-imidazol-N N
H H 4-y1)-4-4(1s,4s)-4-150 =
(trifluoromethyl)cyclohexyl)amino)b C}S N F
HN F enzenesulfonamide N¨\\
N-methy1-3-(1-methy1-1H-imidazol-x N
H H 4-y1)-4-4(1r,40-4-151 czµ Nq< (trifluoromethyl)cyclohexyl)amino)b -S
HN H F enzenesulfonamide 3-(2-Aminopyridin-4-y1)-N-methyl-4-((3-F (trifluoromethyl)phenyl)amino)benz CZ\
-S
HN enesulfonamide 3-(2-Aminopyridin-4-y1)-N-methyl-CZµ F (trifluoromethyl)phenyl)amino)benz -S
HN enesulfonamide Preparation of the Compounds [00145] The compounds used in the reactions described herein are made according to organic synthesis techniques known to those skilled in this art, starting from commercially available chemicals and/or from compounds described in the chemical literature. "Commercially available chemicals" are obtained from standard commercial sources including Acros Organics (Pittsburgh, PA), Aldrich Chemical (Milwaukee, WI, including Sigma Chemical and Fluka), Apin Chemicals Ltd. (Milton Park, UK), Avocado Research (Lancashire, U.K.), BDH
Inc. (Toronto, Canada), Bionet (Cornwall, U.K.), Chemservice Inc. (West Chester, PA), Crescent Chemical Co.
(Hauppauge, NY), Eastman Organic Chemicals, Eastman Kodak Company (Rochester, NY), Fisher Scientific Co. (Pittsburgh, PA), Fisons Chemicals (Leicestershire, UK), Frontier Scientific (Logan, UT), ICN Biomedicals, Inc. (Costa Mesa, CA), Key Organics (Cornwall, U.K.), Lancaster Synthesis (Windham, NH), Maybridge Chemical Co. Ltd. (Cornwall, U.K.), Parish Chemical Co.
(Orem, UT), Pfaltz & Bauer, Inc. (Waterbury, CN), Polyorganix (Houston, TX), Pierce Chemical Co. (Rockford, IL), Riedel de Haen AG (Hanover, Germany), Spectrum Quality Product, Inc.
(New Brunswick, NJ), TCI America (Portland, OR), Trans World Chemicals, Inc.
(Rockville, MD), and Wako Chemicals USA, Inc. (Richmond, VA).
[00146] Methods known to one of ordinary skill in the art are identified through various reference books and databases. Suitable reference books and treatise that detail the synthesis of reactants useful in the preparation of compounds described herein, or provide references to articles that describe the preparation, include for example, "Synthetic Organic Chemistry", John Wiley & Sons, Inc., New York; S. R. Sandler et al., "Organic Functional Group Preparations,"
2nd Ed., Academic Press, New York, 1983; H. 0. House, "Modern Synthetic Reactions", 2nd Ed., W. A. Benjamin, Inc. Menlo Park, Calif 1972; T. L. Gilchrist, "Heterocyclic Chemistry", 2nd Ed., John Wiley & Sons, New York, 1992; J. March, "Advanced Organic Chemistry:
Reactions, Mechanisms and Structure", 4th Ed., Wiley-Interscience, New York, 1992. Additional suitable reference books and treatise that detail the synthesis of reactants useful in the preparation of compounds described herein, or provide references to articles that describe the preparation, include for example, Fuhrhop, J. and Penzlin G. "Organic Synthesis: Concepts, Methods, Starting Materials", Second, Revised and Enlarged Edition (1994) John Wiley & Sons ISBN: 3-527-29074-5; Hoffman, R.V. "Organic Chemistry, An Intermediate Text"
(1996) Oxford University Press, ISBN 0-19-509618-5; Larock, R. C. "Comprehensive Organic Transformations: A Guide to Functional Group Preparations" 2nd Edition (1999) Wiley-VCH, ISBN: 0-471-19031-4; March, J. "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure" 4th Edition (1992) John Wiley & Sons, ISBN: 0-471-60180-2; Otera, J. (editor) "Modern Carbonyl Chemistry" (2000) Wiley-VCH, ISBN: 3-527-29871-1; Patai, S.
"Patai's 1992 Guide to the Chemistry of Functional Groups" (1992) Interscience ISBN: 0-471-93022-9;
Solomons, T. W. G. "Organic Chemistry" 7th Edition (2000) John Wiley & Sons, ISBN: 0-471-19095-0; Stowell, J.C., "Intermediate Organic Chemistry" 2nd Edition (1993) Wiley-Interscience, ISBN: 0-471-57456-2; "Industrial Organic Chemicals: Starting Materials and Intermediates: An Ullmann's Encyclopedia" (1999) John Wiley & Sons, ISBN: 3-527-29645-X, in 8 volumes; "Organic Reactions" (1942-2000) John Wiley & Sons, in over 55 volumes; and "Chemistry of Functional Groups" John Wiley & Sons, in 73 volumes.
[00147] In some instances, specific and analogous reactants are identified through the indices of known chemicals prepared by the Chemical Abstract Service of the American Chemical Society, which are available in most public and university libraries, as well as through on-line databases (the American Chemical Society, Washington, D.C., is contacted for more details). Chemicals that are known but not commercially available in catalogs are prepared by custom chemical synthesis houses, where many of the standard chemical supply houses (e.g., those listed above) provide custom synthesis services. A reference for the preparation and selection of pharmaceutical salts of the compounds described herein is P. H.
Stahl & C. G.
Wermuth "Handbook of Pharmaceutical Salts", Verlag Helvetica Chimica Acta, Zurich, 2002.
[00148] In some embodiments, the compounds disclosed herein are prepared as described in the Examples section.
Further Forms of Compounds Disclosed Herein Isomers [00149] Furthermore, in some embodiments, the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein possess one or more double bonds. The compounds presented herein include all cis, trans, syn, anti, entgegen (F), and zusammen (Z) isomers as well as the corresponding mixtures thereof In some situations, compounds exist as tautomers. The compounds described herein include all possible tautomers within the formulas described herein. In some situations, the compounds described herein possess one or more chiral centers and each center exists in the R
configuration, or S
configuration. The compounds described herein include all diastereomeric, enantiomeric, and epimeric forms as well as the corresponding mixtures thereof In additional embodiments of the compounds and methods provided herein, mixtures of enantiomers and/or diastereoisomers, resulting from a single preparative step, combination, or interconversion are useful for the applications described herein. In some embodiments, the compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers, and recovering the optically pure enantiomers. In some embodiments, disclosed herein are dissociable complexes (e.g., crystalline diastereomeric salts). In some embodiments, the diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and are separated by taking advantage of these dissimilarities. In some embodiments, the diastereomers are separated by chiral chromatography, or preferably, by separation/resolution techniques based upon differences in solubility. In some embodiments, the optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that does not result in racemization.
Labeled compounds [00150] In some embodiments, the compounds described herein exist in their isotopically-labeled forms. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such isotopically-labeled compounds. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such isotopically-labeled compounds as pharmaceutical compositions. Thus, in some embodiments, the compounds disclosed herein include isotopically-labeled compounds, which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. In some embodiments, examples of isotopes that are incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, and chlorine, such as 2H, 3H, 13C, 14C, 15N, 180, 170, 31p, 32p, 35s, 18F, and 36C1, respectively. Compounds described herein, and the metabolites, pharmaceutically acceptable salts, esters, prodrugs, solvates, hydrates, or derivatives thereof which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this disclosure. Certain isotopically-labeled compounds, for example those into which radioactive isotopes such as 3H and 14C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i. e., 3H and carbon-14, i. e., u isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavy isotopes such as deuterium, i.e. ,2H, produces certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements. In some embodiments, the isotopically labeled compounds, pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof is prepared by any suitable method.
[00151] In some embodiments, the compounds described herein are labeled by other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.
Pharmaceutically acceptable salts [00152] In some embodiments, the compounds described herein exist as their pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts as pharmaceutical compositions.
[00153] In some embodiments, the compounds described herein possess acidic or basic groups and therefore react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt. In some embodiments, these salts are prepared in situ during the final isolation and purification of the compounds of the disclosure, or by separately reacting a purified compound in its free form with a suitable acid or base, and isolating the salt thus formed.
Solvates [00154] In some embodiments, the compounds described herein exist as solvates. The disclosure provides for methods of treating diseases by administering such solvates. The disclosure further provides for methods of treating diseases by administering such solvates as pharmaceutical compositions.
[00155] Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and, in some embodiments, are formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, and the like.
Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. In some embodiments, solvates of the compounds described herein are conveniently prepared or formed during the processes described herein. By way of example only, hydrates of the compounds described herein are conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents including, but not limited to, dioxane, tetrahydrofuran, or methanol. In some embodiments, the compounds provided herein exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.
Prodrugs [00156] In some embodiments, the compounds described herein exist in prodrug form.
The disclosure provides for methods of treating diseases by administering such prodrugs. The disclosure further provides for methods of treating diseases by administering such prodrugs as pharmaceutical compositions.
[00157] In some embodiments, prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e. g., two, three, or four) amino acid residues is covalently joined through an amide or ester bond to a free amino, hydroxy, or carboxylic acid group of compounds of the present disclosure. The amino acid residues include, but are not limited to, the 20 naturally occurring amino acids and also includes 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvaline, beta-alanine, gamma-aminobutyric acid, cirtulline, homocysteine, homoserine, ornithine, and methionine sulfone. In other embodiments, prodrugs include compounds wherein a nucleic acid residue, or an oligonucleotide of two or more (e. g., two, three or four) nucleic acid residues is covalently joined to a compound of the present disclosure.
[00158] Pharmaceutically acceptable prodrugs of the compounds described herein also include, but are not limited to, esters, carbonates, thiocarbonates, N-acyl derivatives, N-acyloxyalkyl derivatives, quaternary derivatives of tertiary amines, N-Mannich bases, Schiff bases, amino acid conjugates, metal salts, and sulfonate esters. In some embodiments, compounds having free amino, amido, hydroxy, or carboxylic groups are converted into prodrugs. For instance, free carboxyl groups are derivatized as amides or alkyl esters. In certain instances, all of these prodrug moieties incorporate groups including, but not limited to, ether, amine, and carboxylic acid functionalities.
[00159] Hydroxy prodrugs include esters such as, though not limited to, acyloxyalkyl (e.g.
acyloxymethyl, acyloxyethyl) esters, alkoxycarbonyloxyalkyl esters, alkyl esters, aryl esters, sulfonate esters, sulfate esters and disulfide containing esters, ethers, amides, carbamates, hemisuccinates, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, as outlined in Advanced Drug Delivery Reviews 1996, 19, 115.
[00160] Amine derived prodrugs include, but are not limited to, the following groups and combinations of groups:
¨N)LR ¨N")"0".R ¨NAT. R ¨N)(0-R ¨NS'RR ¨Nr-LO)j"0-_NCIrk I I R ¨NI-1"S)1"R ¨NI-.1"0)1"R ¨NI-1"S)1"R
R R R ,1, R R
¨N 0 ¨N 0 0R ¨N 0 ¨N S 0 ¨N S
¨so as well as sulfonamides and phosphonamides.
[00161] In certain instances, sites on any aromatic ring portions are susceptible to various metabolic reactions, therefore incorporation of appropriate substituents on the aromatic ring structures reduce, minimize, or eliminate this metabolic pathway.
Metabolites [00162] In some embodiments, compounds described herein are susceptible to various metabolic reactions. Therefore, in some embodiments, incorporation of appropriate substituents into the structure will reduce, minimize, or eliminate a metabolic pathway. In specific embodiments, the appropriate substituent to decrease or eliminate the susceptibility of an aromatic ring to metabolic reactions is, by way of example only, a halogen or an alkyl group.
[00163] In additional or further embodiments, the compounds described herein are metabolized upon administration to an organism in need to produce a metabolite that is then used to produce a desired effect, including a desired therapeutic effect.
Pharmaceutical Compositions [00164] In certain embodiments, the compound as described herein is administered as a pure chemical. In other embodiments, the compound described herein is combined with a pharmaceutically suitable or acceptable carrier (also referred to herein as a pharmaceutically suitable (or acceptable) excipient, physiologically suitable (or acceptable) excipient, or physiologically suitable (or acceptable) carrier) selected on the basis of a chosen route of administration and standard pharmaceutical practice as described, for example, in Remington:
The Science and Practice of Pharmacy (Gennaro, 21st Ed. Mack Pub. Co., Easton, PA (2005)), the disclosure of which is hereby incorporated herein by reference in its entirety.
[00165] Accordingly, provided herein is a pharmaceutical composition comprising at least one compound described herein, or a stereoisomer, pharmaceutically acceptable salt, hydrate, solvate, or N-oxide thereof, together with one or more pharmaceutically acceptable carriers. The carrier(s) (or excipient(s)) is acceptable or suitable if the carrier is compatible with the other ingredients of the composition and not deleterious to the recipient (i.e., the subject) of the composition.
[00166] One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Formula (I), or a pharmaceutically acceptable salt thereof [00167] Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (I), or a pharmaceutically acceptable salt thereof [00168] In certain embodiments, the compound as described herein is substantially pure, in that it contains less than about 5%, or less than about 1%, or less than about 0.1%, of other organic small molecules, such as contaminating intermediates or by-products that are created, for example, in one or more of the steps of a synthesis method.
[00169] These formulations include those suitable for oral, rectal, topical, buccal, parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous), rectal, vaginal, or aerosol administration, although the most suitable form of administration in any given case will depend on the degree and severity of the condition being treated and on the nature of the particular compound being used. For example, disclosed compositions are formulated as a unit dose, and/or are formulated for oral or subcutaneous administration.
[00170] In some instances, exemplary pharmaceutical compositions are used in the form of a pharmaceutical preparation, for example, in solid, semisolid, or liquid form, which includes one or more of a disclosed compound, as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for external, enteral, or parenteral applications. In some embodiments, the active ingredient is compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use. The active object compound is included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or condition of the disease.
[00171] For preparing solid compositions such as tablets in some instances, the principal active ingredient is mixed with a pharmaceutical carrier, e.g., conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate, or gums, and other pharmaceutical diluents, e.g., water, to form a solid preformulation composition containing a homogeneous mixture of a disclosed compound or a non-toxic pharmaceutically acceptable salt thereof When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition is readily subdivided into equally effective unit dosage forms such as tablets, pills, and capsules.
[00172] In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the subject composition is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, acetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof and (10) coloring agents. In the case of capsules, tablets and pills, the compositions also comprise buffering agents in some embodiments. Solid compositions of a similar type are also employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
[00173] In some instances, a tablet is made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets are prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets are made by molding in a suitable machine a mixture of the subject composition moistened with an inert liquid diluent. Tablets, and other solid dosage forms, such as dragees, capsules, pills and granules, are optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art.
[00174] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the subject composition, the liquid dosage forms contain optionally inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, cyclodextrins and mixtures thereof [00175] Suspensions, in addition to the subject composition, optionally contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof [00176] In some embodiments, formulations for rectal or vaginal administration are presented as a suppository, which are prepared by mixing a subject composition with one or more suitable non-irritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the body cavity and release the active agent.
[00177] Dosage forms for transdermal administration of a subject composition include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active component is optionally mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which are required in some embodiments.
[00178] In some embodiments, the ointments, pastes, creams and gels contain, in addition to a subject composition, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof [00179] In some embodiments, powders and sprays contain, in addition to a subject composition, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
[00180] Compositions and compounds disclosed herein are alternatively administered by aerosol. This is accomplished by preparing an aqueous aerosol, liposomal preparation or solid particles containing the compound. A non-aqueous (e.g., fluorocarbon propellant) suspension could be used. Sonic nebulizers are used because they minimize exposing the agent to shear, which result in degradation of the compounds contained in the subject compositions in some embodiments. Ordinarily, an aqueous aerosol is made by formulating an aqueous solution or suspension of a subject composition together with conventional pharmaceutically acceptable carriers and stabilizers. The carriers and stabilizers vary with the requirements of the particular subject composition, but typically include non-ionic surfactants (Tweens, Pluronics, or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars or sugar alcohols.
Aerosols generally are prepared from isotonic solutions.
[00181] Pharmaceutical compositions suitable for parenteral administration comprise a subject composition in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders which are reconstituted into sterile injectable solutions or dispersions just prior to use, which optionally contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
[00182] Examples of suitable aqueous and non-aqueous carriers employed in the pharmaceutical compositions include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate and cyclodextrins. In some embodiments, proper fluidity is maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants [00183] Also contemplated are enteral pharmaceutical formulations including a disclosed compound and an enteric material; and a pharmaceutically acceptable carrier or excipient thereof Enteric materials refer to polymers that are substantially insoluble in the acidic environment of the stomach, and that are predominantly soluble in intestinal fluids at specific pHs. The small intestine is the part of the gastrointestinal tract (gut) between the stomach and the large intestine, and includes the duodenum, jejunum, and ileum. The pH of the duodenum is about 5.5, the pH of the jejunum is about 6.5 and the pH of the distal ileum is about 7.5.
Accordingly, enteric materials are not soluble, for example, until a pH of about 5.0, of about 5.2, of about 5.4, of about 5.6, of about 5.8, of about 6.0, of about 6.2, of about 6.4, of about 6.6, of about 6.8, of about 7.0, of about 7.2, of about 7.4, of about 7.6, of about 7.8, of about 8.0, of about 8.2, of about 8.4, of about 8.6, of about 8.8, of about 9.0, of about 9.2, of about 9.4, of about 9.6, of about 9.8, or of about 10Ø Exemplary enteric materials include cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (HPMCP), polyvinyl acetate phthalate (PVAP), hydroxypropyl methylcellulose acetate succinate (HPMCAS), cellulose acetate trimellitate, hydroxypropyl methylcellulose succinate, cellulose acetate succinate, cellulose acetate hexahydrophthalate, cellulose propionate phthalate, cellulose acetate maleate, cellulose acetate butyrate, cellulose acetate propionate, copolymer of methylmethacrylic acid and methyl methacrylate, copolymer of methyl acrylate, methylmethacrylate and methacrylic acid, copolymer of methylvinyl ether and maleic anhydride (Gantrez ES series), ethyl methyacrylate-methylmethacrylate-chlorotrimethylammonium ethyl acrylate copolymer, natural resins such as zein, shellac and copal collophorium, and several commercially available enteric dispersion systems (e.g., Eudragit L30D55, Eudragit FS30D, Eudragit L100, Eudragit S100, Kollicoat EMM30D, Estacryl 30D, Coateric, and Aquateric). The solubility of each of the above materials is either known or is readily determinable in vitro. The foregoing is a list of possible materials, but one of skill in the art with the benefit of the disclosure will recognize that it is not comprehensive and that there are other enteric materials that meet the objectives of the present disclosure.
[00184] In some embodiments, the dose of the composition comprising at least one compound as described herein differ, depending upon the patient's (e.g., human) condition, that is, stage of the disease, general health status, age, and other factors that a person skilled in the medical art will use to determine dose.
[00185] In some instances, pharmaceutical compositions are administered in a manner appropriate to the disease to be treated (or prevented) as determined by persons skilled in the medical arts. An appropriate dose and a suitable duration and frequency of administration will be determined by such factors as the condition of the patient, the type and severity of the patient's disease, the particular form of the active ingredient, and the method of administration. In general, an appropriate dose and treatment regimen provides the composition(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit (e.g., an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free and/or overall survival, or a lessening of symptom severity. Optimal doses are generally determined using experimental models and/or clinical trials. In some embodiments, the optimal dose depends upon the body mass, weight, or blood volume of the patient.
[00186] In some embodiments, oral doses typically range from about 1.0 mg to about 1000 mg, one to four times, or more, per day.
The Hippo Signaling Network [00187] The Hippo signaling network (also known as the Salvador/Warts/Hippo (SWH) pathway) is a master regulator of cell proliferation, death, and differentiation. In some embodiments, the main function of the Hippo signaling pathway is to regulate negatively the transcriptional co-activators Yes-associated protein (YAP) and its paralogue, the transcriptional co-activator with PDZ-binding motif (TAZ; also known as WWTR1) (FIG. 1). The Hippo kinase cascade phosphorylates and inhibits YAP/TAZ by promoting its cytoplasmic retention and degradation, thereby inhibiting the growth promoting function regulated under the YAP/TAZ control. In an un-phosphorylated/de-phosphorylated state, YAP, also known as YAP1 or YAP65, together with TAZ, are transported into the nucleus where they interact with TEAD
family of transcription factors to upregulate genes that promote proliferation and migration, and inhibit apoptosis. In some instances, unregulated upregulation of these genes involved in proliferation, migration, and anti-apoptosis leads to development of cancer.
In some instances, overexpression of YAP/TAZ is associated with cancer.
[00188] Additional core members of the Hippo signaling pathway comprise the serine/threonine kinases MST1/2 (homologues ofHippo/Hpo in Drosophila), Lats1/2 (homologues of Warts/Wts), and their adaptor proteins Savl (homologue of Salvador/Say) and Mob (MOBKL1A and MOBKL1B; homologues of Mats), respectively (FIG. 1). In general, MST1/2 kinase complexes with the scaffold protein Savl, which in turn phosphorylates and activates Lats1/2 kinase. Lats1/2 is also activated by the scaffold protein Mob. The activated Lats1/2 then phosphorylates and inactivates YAP or its paralog TAZ. The phosphorylation of YAP/TAZ leads to their nuclear export, retention within the cytoplasm, and degradation by the ubiquitin proteasome system.
[00189] In some instances, Lats1/2 phosphorylates YAP at the [HXRXXS]
consensus motifs. YAP comprises five [HXRXXS] consensus motifs, wherein X denotes any amino acid residue. In some instances, Lats1/2 phosphorylates YAP at one or more of the consensus motifs.
In some instances, Lats1/2 phosphorylates YAP at all five of the consensus motifs. In some instances, Lats1/2 phosphorylate at the S127 amino acid position. The phosphorylation of YAP
S127 promotes 14-3-3 protein binding and results in cytoplasmic sequestration of YAP.
Mutation of YAP at the S127 position thereby disrupts its interaction with 14-3-3 and subsequently promotes nuclear translocation.
[00190] Additional phosphorylation occurs at the S381 amino acid position in YAP.
Phosphorylation of YAP at the S381 position and on the corresponding site in TAZ primes both proteins for further phosphorylation events by CK16/6 in the degradation motif, which then signals for interaction with the (3-TRCP E3 ubiquitin ligase, leading to polyubiquitination and degradation of YAP.
[00191] In some instances, Lats1/2 phosphorylates TAZ at the [HXRXXS]
consensus motifs. TAZ comprises four [HXRXXS] consensus motifs, wherein X denotes any amino acid residues. In some instances, Lats1/2 phosphorylates TAZ at one or more of the consensus motifs.
In some instances, Lats1/2 phosphorylates TAZ at all four of the consensus motifs. In some instances, Lats1/2 phosphorylate at the S89 amino acid position. The phosphorylation of TAZ
S89 promotes 14-3-3 protein binding and results in cytoplasmic sequestration of TAZ. Mutation of TAZ at the S89 position thereby disrupts its interaction with 14-3-3 and subsequently promotes nuclear translocation.
[00192] In some embodiments, phosphorylated YAP/TAZ accumulates in the cytoplasm, and undergoes SCO-TRcP-mediated ubiquitination and subsequent proteasomal degradation. In some instances, the Skp, Cullin, F-box containing complex (SCF complex) is a multi-protein E3 ubiquitin ligase complex that comprises a F-box family member protein (e.g.
Cdc4), Skpl, a bridging protein, and RBX1, which contains a small RING Finger domain which interacts with E2-ubiquitin conjugating enzyme. In some cases, the F-box family comprises more than 40 members, in which exemplary members include F-box/WD repeat-containing protein lA
(FBXW1A, r3TrCP1, Fbxwl, hsSlimb, plkappaBalpha-E3 receptor subunit) and S-phase kinase-associated proteins 2 (SKP2). In some embodiments, the SCF complex (e.g.
SCF1mÃ131) interacts with an El ubiquitin-activating enzyme and an E2 ubiquitin-conjugating enzyme to catalyze the transfer of ubiquitin to the YAP/TAZ substrate. Exemplary El ubiquitin-activating enzymes include those encoded by the following genes: UBA1, UBA2, UBA3, UBA5, UBA5, UBA7, ATG7, NAE1, and SAE]. Exemplary E2 ubiquitin-conjugating enzymes include those encoded by the following genes: UBE2A, UBE2B, UBE2C, UBE2D1, UBE2D2, UBE2D3, UBE2E1, UBE2E2, UBE2E3, UBE2F, UBE2G1, UBE2G2, UBE2H, UBE2I, UBE211, UBE212, UBE2K, UBE2L3, UBE2L6, UBE2M, UBE2IV, UBE20, UBE2Q1, UBE2Q2, UBE2R1, UBE2R2, UBE2S, UBE2T, UBE2U, UBE2V1, UBE2V2, UBE2Z, ATG2, BIRC5, and UFC1. In some embodiments, the ubiquitinated YAP/TAZ further undergoes the degradation process through the 26S
proteasome.
[00193] In some embodiments, the Hippo pathway is regulated upstream by several different families of regulators (FIG. 1). In some instances, the Hippo pathway is regulated by the G-protein and its coupled receptors, the Crumbs complex, regulators upstream of the MST
kinases, and the adherens junction.
YAP/TAZ Interaction with TEAD
[00194] In some embodiments, un-phosphorylated and/or dephosphorylated YAP/TAZ
accumulates in the nucleus. Within the nucleus, YAP/TAZ interacts with the TEAD family of transcription factors (e.g. TEAD1, TEAD2, TEAD3, or TEAD4) to activate genes involved in anti-apoptosis and proliferation, such as for example CTFG, Cyr61, and FGF1.
[00195] In some embodiments, the compounds disclosed herein modulate the interaction between YAP/TAZ and TEAD. In some embodiments, the compounds disclosed herein bind to TEAD, YAP, or TAZ and prevent the interaction between YAP/TAZ and TEAD.
YAP/TAZ regulation mediated by G-proteins/GPCRs [00196] In some embodiments, the Hippo pathway is regulated by the G
protein-coupled receptor (GPCR) and G protein (also known as guanine nucleotide-binding proteins) family of proteins (FIG. 2). G proteins are molecular switches that transmit extracellular stimuli into the cell through GPCRs. In some instances, there are two classes of G proteins:
monomeric small GTPases and heterotrimeric G protein complexes. In some instances, the latter class of complexes comprise of alpha (G,), beta (G), and gamma (Gy) subunits. In some cases, there are several classes of Ga subunits: Goia, G12/13a, Gi/oa (G inhibitory, G other), and Gsa (G
stimulatory).
[00197] In some instances, Gia (G inhibitory), Goa (G other), Goia, and G12/13a coupled GPCRs activate YAP/TAZ and promote nuclear translocation. In other instances, Gsa (G
stimulatory) coupled GPCRs suppress YAP/TAZ activity, leading to YAP/TAZ
degradation.
[00198] In some cases, Gia (G inhibitory), Goa (G other), Goia, and G12/13a coupled GPCRs activate YAP/TAZ through repression of Lats1/2 activities. In contrast, Gsa, in some embodiments, induces Lats1/2 activity, thereby promoting YAP/TAZ degradation.
Gq Family [00199] Gqa (also known as Goi protein), participates in the inositol trisphosphate (IP3) signal transduction pathway and calcium (Ca2+) release from intracellular storage through the activation of phospholipase C (PLC). The activated PLC hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to diacyl glycerol (DAG) and IP3. In some instances, IP3 then diffuses through the cytoplasm into the ER or the sarcoplasmic reticulum (SR) in the case of muscle cells, and then binds to inositol trisphosphate receptor (InsP3R), which is a Ca2+
channel. In some cases, the binding triggers the opening of the Ca2+ channel, and thereby increases the release of Ca2+ into the cytoplasm.
[00200] In some embodiments, the GPCRs that interact with Gqa include, but are not limited to, 5-hydroxytryptamine receptor (5-HT receptor) types 5-HT2 and 5-HT3; alpha-1 adrenergic receptor; vasopressin type 1 receptors 1A and 1B; angiotensin II
receptor type 1;
calcitonin receptor; histamine H1 receptor; metabotropic glutamate receptor, group I; muscarinic receptors MI, M3, and M5; and trace amine-associated receptor 1.
[00201] In some instances, there are several types of Gqa: Gq, Gqin, Gq/14, and Gq/15. The Gq protein is encoded by GNAQ. Go' is encoded by GNA1 1 . Gq/14 is encoded by GNA14. Gq/15 is encoded by GNA15.
[00202] In some instances, mutations or modifications of the Gqa genes have been associated with cancer. Indeed, studies have shown that mutations in Gqa promote uveal melanoma (UM) tumorigenesis. In some instances, about 80% of UM cases have been detected to contain a mutation in GNAQ and/or GNA1 1 .
[00203] In some instances, mutations or modifications of the Gqa genes have been associated with congenital diseases. In some instances, mutations of Gqa have been observed in congenital diseases such as Port-Wine Stain and/or Sturge-Weber Syndrome. In some instances, about 92% of Port-Wine stain cases harbors a mutation in GNAQ. In some instances, about 88%
of Sturge-Weber Syndrome harbors a mutation in GNAQ.
G12/13 Family [00204] G12/13a modulates actin cytoskeletal remodeling in cells and regulates cell processes through guanine nucleotide exchange factors (GEFs). GEFs participate in the activation of small GTPases which acts as molecular switches in a variety of intracellular signaling pathways. Examples of small GTPases include the Ras-related GTPase superfamily (e.g. Rho family such as Cdc42), which is involved in cell differentiation, proliferation, cytoskeletal organization, vesicle trafficking, and nuclear transport.
[00205] In some embodiments, the GPCRs that interact with G12/13a include, but are not limited to, purinergic receptors (e.g. P2Y1, P2Y2, P2Y4, P2Y6); muscarinic acetylcholine receptors M1 and M3; receptors for thrombin [protease-activated receptor (PAR)-1, PAR-21;
thromboxane (TXA2); sphingosine 1-phosphate (e.g. S1P2, S1P3, S1P4 and S1P5);
lysophosphatidic acid (e.g. LP/6i', LPA2, LPA3); angiotensin II (AT1);
serotonin (5-HT2, and 5-HT4); somatostatin (55t5); endothelin (ETA and ETB); cholecystokinin (CCK1);
Via vasopressin receptors; D5 dopamine receptors; fMLP formyl peptide receptors; GAL2 galanin receptors; EP3 prostanoid receptors; Ai adenosine receptors; ai adrenergic receptors; BB2 bombesin receptors;
B2 bradykinin receptors; calcium-sensing receptors; KSHV-0RF74 chemokine receptors; NKI
tachykinin receptors; and thyroid-stimulating hormone (TSH) receptors.
[00206] In some instances, G12/1311 is further subdivided into Gi2 and Gi3 types which are encoded by GNA 1 2 and GNA 1 3, respectively.
G1/0 Family [00207] Guaa (G inhibitory, G other) (also known as Gi/Go or Gi protein) suppresses the production of 3',5'-cyclic AMP (cAMP) from adenosine triphosphate (ATP) through an inhibition of adenylate cyclase activity, which converts ATP to cAMP.
[00208] In some embodiments, the GPCRs that interact with Gia include, but are not limited to, 5-hydroxytryptamine receptor (5-HT receptor) types 5-HT1 and 5-HT5; muscarinic acetylcholine receptors such as M2 and M4; adenosine receptors such as Ai and A3; adrenergic receptors such as a2A, a2B, and a2c; apelin receptors; calcium-sensing receptor; cannabinoid receptors CB1 and CB2; chemokine CXCR4 receptor; dopamines D2, D3, and D4;
GABAB
receptor; glutamate receptors such as metabotropic glutamate receptor 2 (mGluR2), metabotropic glutamate receptor 3 (mGluR3), metabotropic glutamate receptor 4 (mGluR4), metabotropic glutamate receptor 6 (mGluR6), metabotropic glutamate receptor 7 (mGluR7), and metabotropic glutamate receptor 8 (mGluR8); histamine receptors such as H3 and H4 receptors; melatonin receptors such as melatonin receptor type 1 (MT1), melatonin receptor type 2 (MT2), and melatonin receptor type 3 (MT3); niacin receptors such as NIACR1 and NIACR2;
opioid receptors such as 6, K, jt, and nociceptin receptors; prostaglandin receptors such as prostaglandin E receptor 1 (EPA prostaglandin E receptor 3 (EP3), prostaglandin F receptor (FP), and thromboxane receptor (TP); somatostatin receptors sstl, sst2, sst3, sst4, and sst5; and trace amine-associated receptor 8.
[00209] In some instances, there are several types of Gta: Gal, Gia2, Gia3, Gia4, Goa, Gt, Ggust, and G. Gtal is encoded by GNAI Gia2 is encoded by GNAI2. Gta3 is encoded by GNAI3. Goa, the a, subunit, is encoded by GNA01. Gt is encoded by GNAT] and GNAT2. Ggust is encoded by GNAT3. Gz is encoded by GNAZ.
GsFamily [00210] Gsa (also known as G stimulatory, Gs alpha subunit, or Gs protein) activates the cAMP-dependent pathway through the activation of adenylate cyclase, which convers adenosine triphosphate (ATP) to 3',5'-cyclic AMP (cAMP) and pyrophosphate. In some embodiments, the GPCRs that interact with Gsa include, but are not limited to, 5-hydroxytryptamine receptor (5-HT receptor) types 5-HT4, 5-HT6, and 5-HT7; adrenocorticotropic hormone receptor (ACTH
receptor) (also known as melanocortin receptor 2 or MC2R); adenosine receptor types A2a and A2b; arginine vasopressin receptor 2 (AVPR2); 13-adrenergic receptors 131, 132, and 133; calcitonin receptor; calcitonin gene-related peptide receptor; corticotropin-releasing hormone receptor;
dopamine receptor D1-like family receptors such as D1 and D5; follicle-stimulating hormone receptor (FSH-receptor); gastric inhibitory polypeptide receptor; glucagon receptor; histamine H2 receptor; luteinizing hormone/choriogonadotropin receptor; melanocortin receptors such as MC1R, MC2R, MC3R, MC4R, and MC5R; parathyroid hormone receptor 1;
prostaglandin receptor types D2 and 12; secretin receptor; thyrotropin receptor; trace amine-associated receptor 1; and box jellyfish opsin.
[00211] In some instances, there are two types of Gsa: Gs and Golf. Gs is encoded by GNAS. Golf is encoded by GNAT.
Additional Regulators of the Hippo signaling network [00212] In some embodiments, the additional regulator of the Hippo signaling pathway is the Crumbs (Crb) complex. The Crumbs complex is a key regulator of cell polarity and cell shape. In some instances, the Crumbs complex comprises transmembrane CRB
proteins which assemble multi-protein complexes that function in cell polarity. In some instances, CRB
complexes recruit members of the Angiomotin (AMOT) family of adaptor proteins that interact with the Hippo pathway components. In some instances, studies have shown that AMOT directly binds to YAP, promotes YAP phosphorylation, and inhibits its nuclear localization.
[00213] In some instances, the additional regulator of the Hippo signaling pathway comprises regulators of the MST kinase family. MST kinases monitor actin cytoskeletal integrity. In some instances, the regulators include TAO kinases and cell polarity kinase PAR-1.
[00214] In some instances, the additional regulator of the Hippo signaling pathway comprises molecules of the adherens junction. In some instances, E-Cadherin (E-cad) suppresses YAP nuclear localization and activity through regulating MST activity. In some embodiments, E-cad-associated protein a-catenin regulates YAP through sequestering YAP/14-3-3 complexes in the cytoplasm. In other instances, Ajuba protein family members interact with Lats1/2 kinase activity, thereby preventing inactivation of YAP/TAZ.
[00215] In some embodiments, additional proteins that interact with YAP/TAZ
either directly or indirectly include, but are not limited to, Merlin, protocadherin Fat 1, MASK1/2, HIPK2, PTPN14, RASSF, PP2A, Salt-inducible kinases (SIKs), Scribble (SCRIB), the Scribble associated proteins Discs large (Dig), KIBRA, PTPN14, NPHP3, LKB1, Ajuba, and Z01/2.
[00216] In some embodiments, the compounds described herein are inhibitors of transcriptional coactivator with PDZ binding motif/Yes- associated protein transcriptional coactivator (TAZ/YAP). In some embodiments, the compounds described herein increase the phosphorylation of transcriptional coactivator with PDZ binding motif/ Yes-associated protein transcriptional coactivator (TAZ/YAP) or decrease the dephosphorylation of transcriptional coactivator with PDZ binding motif/ Yes- associated protein transcriptional coactivator (TAZ/YAP). In some embodiments, the compounds increase the ubiquitination of transcriptional coactivator with PDZ binding motif/ Yes- associated protein transcriptional coactivator (TAZ/YAP) or decrease the deubiquitination of transcriptional coactivator with PDZ
binding motif/ Yes- associated protein transcriptional coactivator (TAZ/YAP).
[00217] In some embodiments, the compounds disclosed herein are inhibitors of one or more of the proteins encompassed by, or related to, the Hippo pathway. In some instances, the one or more proteins comprise a protein shown in FIGs. 1 and/or 2. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of a G-protein and/or its coupled GPCR. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of a G-protein.
In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of the Gqa family proteins such as Gq, Got, Gq/14, and Gq/15; the G12/13a family of proteins such as G12 and G13; or the Gia family of proteins such as Gial, Gia2, Gia3, Gia4, Goa, Gt, Ggust, and G. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Gq. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Got. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Gq/14. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Gq/15. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of G12. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of G13. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Gal. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Gia2. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Gia3. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Gia4. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Goa. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Gt. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Ggust. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of G.
[00218] In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of a core protein of the Hippo pathway. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Savl. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Mob. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of YAP. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of TAZ. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of TEAD.
[00219] In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of a protein associated with the ubiquitination and proteasomal degradation pathway. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of a proteasomal degradation pathway protein (e.g. 26S proteasome).
[00220] In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of a protein of the Ras superfamily of proteins. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of a protein of the Rho family of proteins. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Cdc42.
[00221] Cdc42 is a member of the Ras superfamily of small GTPases.
Specifically, Cdc42 belongs to the Rho family of GTPases, in which the family members participate in diverse and critical cellular processes such as gene transcription, cell-cell adhesion, and cell cycle progression. Cdc42 is involved in cell growth and polarity, and in some instances, Cdc42 is activated by guanine nucleotide exchange factors (GEFs). In some cases, an inhibitor of Cdc42 is a compound disclosed herein.
[00222] In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of a deubiquitinating enzyme. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of a cysteine protease or a metalloprotease. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of an ubiquitin-specific protease. U5P47 is a member of the ubiquitin-specific protease (USP/UBP) superfamily of cysteine proteases. In some embodiments, the compounds disclosed herein are inhibitors of USP47.
[00223] Further embodiments provided herein include combinations of one or more of the particular embodiments set forth above.
Diseases Cancer [00224] In some embodiments, the compounds disclosed herein are useful for treating cancer. In some embodiments, the cancer is mediated by activation of transcriptional coactivator with PDZ binding motif/Yes- associated protein transcription coactivator (TAZ/YAP). In some embodiments, the cancer is mediated by modulation of the interaction of YAP/TAZ with TEAD.
In some embodiments, the cancer is characterized by a mutant Ga-protein. In some embodiments, the mutant Ga-protein is selected from G12, G13, Gq, G11, Gi, Go, and Gs. In some embodiments, the mutant Ga-protein is G12. In some embodiments, the mutant Ga-protein is G13. In some embodiments, the mutant Ga-protein is Gq. In some embodiments, the mutant Ga-protein is G11. In some embodiments, the mutant Ga-protein is Gi. In some embodiments, the mutant Ga-protein is Go. In some embodiments, the mutant Ga-protein is Gs.
[00225] In some embodiments, the cancer is a solid tumor. In some instances, the cancer is a hematologic malignancy. In some instances, the solid tumor is a sarcoma or carcinoma. In some instances, the solid tumor is a sarcoma. In some instances, the solid tumor is a carcinoma.
[00226] Exemplary sarcoma includes, but is not limited to, alveolar rhabdomyosarcoma, alveolar soft part sarcoma, ameloblastoma, angiosarcoma, chondrosarcoma, chordoma, clear cell sarcoma of soft tissue, dedifferentiated liposarcoma, desmoid, desmoplastic small round cell tumor, embryonal rhabdomyosarcoma, epithelioid fibrosarcoma, epithelioid hemangioendothelioma, epithelioid sarcoma, esthesioneuroblastoma, Ewing sarcoma, extrarenal rhabdoid tumor, extraskeletal myxoid chondrosarcoma, extraskeletal osteosarcoma, fibrosarcoma, giant cell tumor, hemangiopericytoma, infantile fibrosarcoma, inflammatory myofibroblastic tumor, Kaposi sarcoma, leiomyosarcoma of bone, liposarcoma, liposarcoma of bone, malignant fibrous histiocytoma (MFH), malignant fibrous histiocytoma (MFH) of bone, malignant mesenchymoma, malignant peripheral nerve sheath tumor, mesenchymal chondrosarcoma, myxofibrosarcoma, myxoid liposarcoma, myxoinflammatory fibroblastic sarcoma, neoplasms with perivascular epithelioid cell differentiation, osteosarcoma, parosteal osteosarcoma, neoplasm with perivascular epithelioid cell differentiation, periosteal osteosarcoma, pleomorphic liposarcoma, pleomorphic rhabdomyosarcoma, PNET/extraskeletal Ewing tumor, rhabdomyosarcoma, round cell liposarcoma, small cell osteosarcoma, solitary fibrous tumor, synovial sarcoma, and telangiectatic osteosarcoma.
[00227] Exemplary carcinoma includes, but is not limited to, adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, anaplastic carcinoma, large cell carcinoma, small cell carcinoma, anal cancer, appendix cancer, bile duct cancer (i.e., cholangiocarcinoma), bladder cancer, brain tumor, breast cancer, cervical cancer, colon cancer, cancer of Unknown Primary (CUP), esophageal cancer, eye cancer, fallopian tube cancer, gastroenterological cancer, kidney cancer, liver cancer, lung cancer, medulloblastoma, melanoma, oral cancer, ovarian cancer, pancreatic cancer, parathyroid disease, penile cancer, pituitary tumor, prostate cancer, rectal cancer, skin cancer, stomach cancer, testicular cancer, throat cancer, thyroid cancer, uterine cancer, vaginal cancer, and vulvar cancer. In some instances, the liver cancer is primary liver cancer.
[00228] In some instances, the cancer is selected from uveal melanoma, mesothelioma, esophageal cancer, liver cancer, breast cancer, hepatocellular carcinoma, lung adenocarcinoma, glioma, colon cancer, colorectal cancer, gastric cancer, medulloblastoma, ovarian cancer, esophageal squamous cell carcinoma, sarcoma, Ewing sarcoma, head and neck cancer, prostate cancer, and meningioma. In some cases, the cancer is uveal melanoma, mesothelioma, esophageal cancer, liver cancer, breast cancer, hepatocellular carcinoma, lung adenocarcinoma, glioma, colon cancer, colorectal cancer, gastric cancer, medulloblastoma, ovarian cancer, esophageal squamous cell carcinoma, sarcoma, Ewing sarcoma, head and neck cancer, prostate cancer, or meningioma. In some cases, the cancer is uveal melanoma, mesothelioma, esophageal cancer, or liver cancer. In some cases, the cancer is uveal melanoma. In some cases, the cancer is mesothelioma. In some cases, the cancer is esophageal cancer. In some cases, the cancer is liver cancer. In some cases, the cancer is primary liver cancer.
[00229] In some instances, the cancer is a hematologic malignancy. In some embodiments, a hematologic malignancy is a leukemia, a lymphoma, a myeloma, a non-Hodgkin's lymphoma, a Hodgkin's lymphoma, a T-cell malignancy, or a B-cell malignancy. In some instances, a hematologic malignancy is a T-cell malignancy. Exemplary T-cell malignancy includes, but is not limited to, peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), anaplastic large cell lymphoma, angioimmunoblastic lymphoma, cutaneous T-cell lymphoma, adult T-cell leukemia/lymphoma (ATLL), blastic NK-cell lymphoma, enteropathy-type T-cell lymphoma, hematosplenic gamma-delta T-cell lymphoma, lymphoblastic lymphoma, nasal NK/T-cell lymphomas, and treatment-related T-cell lymphomas.
[00230] In some instances, a hematologic malignancy is a B-cell malignancy.
Exemplary B-cell malignancy includes, but is not limited to, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), high risk CLL, and a non-CLL/SLL lymphoma. In some embodiments, the cancer is follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia, multiple myeloma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, Burkitt's lymphoma, non-Burkitt high grade B cell lymphoma, primary mediastinal B-cell lymphoma (PMBL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, B cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, or lymphomatoid granulomatosis.
[00231] In some instances, the cancer is a relapsed or refractory cancer.
In some embodiments, the relapsed or refractory cancer is a relapsed or refractory solid tumor. In some embodiments, the relapsed or refractory solid tumor is a relapsed or refractory sarcoma or a relapsed or refractory carcinoma. In some embodiments, the relapsed or refractory carcinoma includes adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, anaplastic carcinoma, large cell carcinoma, small cell carcinoma, anal cancer, appendix cancer, bile duct cancer (i.e., cholangiocarcinoma), bladder cancer, brain tumor, breast cancer, cervical cancer, colon cancer, cancer of Unknown Primary (CUP), esophageal cancer, eye cancer, fallopian tube cancer, gastroenterological cancer, kidney cancer, liver cancer, lung cancer, medulloblastoma, melanoma, oral cancer, ovarian cancer, pancreatic cancer, parathyroid disease, penile cancer, pituitary tumor, prostate cancer, rectal cancer, skin cancer, stomach cancer, testicular cancer, throat cancer, thyroid cancer, uterine cancer, vaginal cancer, and vulvar cancer.
[00232] In some instances, the relapsed or refractory cancer is selected from relapsed or refractory uveal melanoma, mesothelioma, esophageal cancer, liver cancer, breast cancer, hepatocellular carcinoma, lung adenocarcinoma, glioma, colon cancer, colorectal cancer, gastric cancer, medulloblastoma, ovarian cancer, esophageal squamous cell carcinoma, sarcoma, Ewing sarcoma, head and neck cancer, prostate cancer, and meningioma. In some cases, the relapsed or refractory cancer is relapsed or refractory uveal melanoma, mesothelioma, esophageal cancer, liver cancer, breast cancer, hepatocellular carcinoma, lung adenocarcinoma, glioma, colon cancer, colorectal cancer, gastric cancer, medulloblastoma, ovarian cancer, esophageal squamous cell carcinoma, sarcoma, Ewing sarcoma, head and neck cancer, prostate cancer, or meningioma.
In some cases, the relapsed or refractory cancer is relapsed or refractory uveal melanoma, mesothelioma, esophageal cancer, or liver cancer. In some cases, the relapsed or refractory cancer is relapsed or refractory uveal melanoma. In some cases, the relapsed or refractory cancer is relapsed or refractory mesothelioma. In some cases, the relapsed or refractory cancer is relapsed or refractory esophageal cancer. In some cases, the relapsed or refractory cancer is relapsed or refractory liver cancer. In some cases, the relapsed or refractory cancer is relapsed or refractory primary liver cancer.
[00233] In some instances, the relapsed or refractory cancer is a relapsed or refractory hematologic malignancy. In some embodiments, a relapsed or refractory hematologic malignancy is a relapsed or refractory leukemia, a relapsed or refractory lymphoma, a relapsed or refractory myeloma, a relapsed or refractory non-Hodgkin's lymphoma, a relapsed or refractory Hodgkin's lymphoma, a relapsed or refractory T-cell malignancy, or a relapsed or refractory B-cell malignancy. In some instances, a relapsed or refractory hematologic malignancy is a relapsed or refractory T-cell malignancy. In some instances, a relapsed or refractory hematologic malignancy is a relapsed or refractory B-cell malignancy, such as for example, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), high risk CLL, or a non-CLL/SLL lymphoma. In some embodiments, the cancer is follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia, multiple myeloma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, Burkitt's lymphoma, non-Burkitt high grade B
cell lymphoma, primary mediastinal B-cell lymphoma (PMBL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, B cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, or lymphomatoid granulomatosis.
[00234] In some instances, the cancer is a metastasized cancer. In some instances, the metastasized cancer is a metastasized solid tumor. In some instances, the metastasized solid tumor is a metastasized sarcoma or a metastasized carcinoma. In some embodiments, the metastasized carcinoma includes adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, anaplastic carcinoma, large cell carcinoma, small cell carcinoma, anal cancer, appendix cancer, bile duct cancer (i.e., cholangiocarcinoma), bladder cancer, brain tumor, breast cancer, cervical cancer, colon cancer, cancer of Unknown Primary (CUP), esophageal cancer, eye cancer, fallopian tube cancer, gastroenterological cancer, kidney cancer, liver cancer, lung cancer, medulloblastoma, melanoma, oral cancer, ovarian cancer, pancreatic cancer, parathyroid disease, penile cancer, pituitary tumor, prostate cancer, rectal cancer, skin cancer, stomach cancer, testicular cancer, throat cancer, thyroid cancer, uterine cancer, vaginal cancer, and vulvar cancer.
[00235] In some instances, the metastasized cancer is selected from metastasized uveal melanoma, mesothelioma, esophageal cancer, liver cancer, breast cancer, hepatocellular carcinoma, lung adenocarcinoma, glioma, colon cancer, colorectal cancer, gastric cancer, medulloblastoma, ovarian cancer, esophageal squamous cell carcinoma, sarcoma, Ewing sarcoma, head and neck cancer, prostate cancer, and meningioma. In some cases, the metastasized cancer is metastasized uveal melanoma, mesothelioma, esophageal cancer, liver cancer, breast cancer, hepatocellular carcinoma, lung adenocarcinoma, glioma, colon cancer, colorectal cancer, gastric cancer, medulloblastoma, ovarian cancer, esophageal squamous cell carcinoma, sarcoma, Ewing sarcoma, head and neck cancer, prostate cancer, or meningioma. In some cases, the metastasized cancer is metastasized uveal melanoma, mesothelioma, esophageal cancer, or liver cancer. In some cases, the metastasized cancer is metastasized uveal melanoma.
In some cases, the metastasized cancer is metastasized mesothelioma. In some cases, the metastasized cancer is metastasized esophageal cancer. In some cases, the metastasized cancer is metastasized liver cancer. In some cases, the metastasized cancer is metastasized primary liver cancer.
[00236] In some instances, the metastasized cancer is a metastasized hematologic malignancy. In some embodiments, the metastasized hematologic malignancy is a metastasized leukemia, a metastasized lymphoma, a metastasized myeloma, a metastasized non-Hodgkin's lymphoma, a metastasized Hodgkin's lymphoma, a metastasized T-cell malignancy, or a metastasized B-cell malignancy. In some instances, a metastasized hematologic malignancy is a metastasized T-cell malignancy. In some instances, a metastasized hematologic malignancy is a metastasized B-cell malignancy, such as for example, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), high risk CLL, or a non-CLL/SLL lymphoma. In some embodiments, the cancer is follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia, multiple myeloma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, Burkitt's lymphoma, non-Burkitt high grade B cell lymphoma, primary mediastinal B-cell lymphoma (PMBL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, B cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, or lymphomatoid granulomatosis.
Congenital Diseases [00237] In some embodiments, the compounds disclosed herein are useful for treating a congenital disease. In some embodiments, the congenital disease is mediated by activation of transcriptional coactivator with PDZ binding motif/Yes- associated protein transcription coactivator (TAZ/YAP). In some embodiments, the congenital disease is characterized by a mutant Ga-protein. In some embodiments, the mutant Ga-protein is selected from G12, G13, Gq, G11, Gi, Go, and Gs. In some embodiments, the mutant Ga-protein is G12. In some embodiments, the mutant Ga-protein is G13. In some embodiments, the mutant Ga-protein is Gq. In some embodiments, the mutant Ga-protein is G11. In some embodiments, the mutant Ga-protein is Gi. In some embodiments, the mutant Ga-protein is Go. In some embodiments, the mutant Ga-protein is Gs.
[00238] In some embodiments, the congenital disease is the result of a genetic abnormality, an intrauterine environment, errors related to morphogenesis, infection, epigenetic modifications on a parental germline, or a chromosomal abnormality. Exemplary congenital diseases include, but are not limited to, Sturge-Weber Syndrome, Port-Wine stain, Holt-Oram syndrome, abdominal wall defects, Becker muscular dystrophy (BMD), biotinidase deficiency, Charcot-Marie-Tooth (CMT), cleft lip, cleft palate, congenital adrenal hyperplasia, congenital heart defects, congenital hypothyroidism, congenital muscular dystrophy, cystic fibrosis, Down syndrome, Duchenne muscular dystrophy, Fragile X syndrome, Friedreich's ataxia, galactosemia, hemoglobinopathies, Krabbe disease, limb-girdle muscular dystrophy, medium chain acyl-CoA dehydrogenase deficiency, myasthenia gravis, neural tube defects, phenylketonuria, Pompe disease, severe combined immunodeficiency (SCID), Stickler syndrome (or hereditary progressive arthro-ophthalmopathy), spinal muscular atrophy, and trisomy 18. In some embodiments, the congenital disease is Sturge-Weber Syndrome or Port-Wine stain. In some embodiments, the congenital disease is Sturge-Weber Syndrome. In some embodiments, the congenital disease is Port-Wine stain.
EXAMPLES
[00239] These examples are provided for illustrative purposes only and not to limit the scope of the claims provided herein.
List of abbreviations [00240] As used above, and throughout the disclosure, the following abbreviations, unless otherwise indicated, shall be understood to have the following meanings:
ACN or MeCN acetonitrile Ac acetyl Bn benzyl BOC or Boc ter t-butyl carbamate t-Bu ter t-butyl Cy cyclohexyl C degrees Celsius DBA or dba dibenzylideneacetone DCE dichloroethane (C1CH2CH2C1) DCM dichloromethane (CH2C12) DIAD diisopropyl azodicarboxylate DIPEA or DIEA diisopropylethylamine DMAP 4-(N,N-dimethylamino)pyridine DMF dimethylformamide DMA /V,N-dimethylacetamide DMSO dimethylsulfoxide Dppf or dppf 1,1'-bis(diphenylphosphino)ferrocene EA or Et0Ac ethyl acetate eq equivalent(s) Et ethyl Et20 diethyl ether Et0H ethanol g gram(s) h hour(s) HPLC high performance liquid chromatography Hz hertz LAH lithium aluminum anhydride LCMS liquid chromatography mass spectrometry m/z mass-to-charge ratio M molar Me methyl MeI methyl iodide Me0H methanol mg milligram(s) MHz megahertz umol micromole(s) uL microliter(s) mL milliliter(s) mmol millimole(s) MS mass spectroscopy MsC1 methanesulfonyl chloride MW microwave radiation NCS N-chlorosuccinimide NMM N-methyl-morpholine NMP N-methyl-pyrrolidin-2-one NMR nuclear magnetic resonance PE petroleum ether Ph phenyl prep-HPLC preparative high pressure liquid chromatography prep-TLC preparative thin layer chromatography Py pyridine RP-HPLC reverse phase-high pressure liquid chromatography RT retention time TEA triethylamine TFA trifluoroacetic acid THF tetrahydrofuran TLC thin layer chromatography TMSC1 trimethylsilyl chloride Xantphos 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene XPhos 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl XPhos Pd G II chloro(2-dicyclohexylphosphino-2',4',6'-triisopropy1-1,1'-bipheny1)[2-(2'-amino-1,1'-biphenyOlpalladium(II) I. Chemical Synthesis [00241] Unless otherwise noted, reagents and solvents were used as received from commercial suppliers. Anhydrous solvents and oven-dried glassware were used for synthetic transformations sensitive to moisture and/or oxygen. Yields were not optimized. Reaction times were approximate and were not optimized. Column chromatography and thin layer chromatography (TLC) were performed on silica gel unless otherwise noted.
Example 1: N-(tert-buty1)-4-(cyclohexylarnino)-3-(2H-tetrazol-5-y1)benzenesulfonamide (Compound 1) 1;1¨NH
0µµ N 0 S
HN
Preparation of Compound 1:
CN ON CN
0 411 F H2Nk 2.0 eq = ______ NH2 F Cr :DMS0=1/1(v/v) N
HN¨S
CI' µµ
0 TEA (2.0 eq), DCM --7C 6 0 140 C, 2 h JNH
Aµ\1 NaN3(3 eq), NH4CI (3 eq) DMF, 140 C, 16 h =
NO
HN
Compound 1 Step 1: N-tert-butyl-3-cyano-4-fluoro-benzenesulfonamide [00242] To a solution of compound 1-1 (500 mg, 2.28 mmol, 1.0 eq) and 2-methylpropan-2-amine (334 mg, 4.56 mmol, 2.0 eq) in DCM (10 mL) was added TEA (461 mg, 4.56 mmol, 2.0 eq). The resulted mixture was stirred at 30 C for 16 hr. LCMS and TLC
(Petroleum ether: Ethyl acetate = 3/1) showed desired compound was found and all the starting material was consumed completely. The reaction mixture was poured into cold water (10 mL), extracted by DCM (3x10 mL). The combined organic layers were washed with brine (10 mL*2) dried over Na2SO4, concentrated under reduced pressure to give compound 1-2 (550 mg, 2.15 mmol, 94 % yield), which was directly used without further purification. 1HNMR (400 MHz, CDC13) 6 8.20 (dd, J =
2.3, 5.8 Hz, 1H), 8.15 (ddd, J= 2.4, 4.8, 8.8 Hz, 1H), 7.38 (t, J = 8.5 Hz, 1H), 1.29 (s, 9H).
Step 2: 5-12-13-(trifluoromethyl)phenoxy]pheny1]-2H-tetrazole [00243] A solution of compound 1-2 (450 mg, 1.76 mmol, 1.0 eq) and cyclohexylamine (870 mg, 8.76 mmol, 1 mL, 5.0 eq) in DMSO (1 mL) was heated to 140 C for 2 hr.
LCMS
showed 85% desired compound was found and the starting material was consumed completely.
The reaction mixture was combined and poured into cold water (10 mL), and then extracted by ethyl acetate (3x10 mL). The combined organic layers were washed with brine (10 mL*2) dried over Na2SO4, filtered, concentrated under reduced pressure to give the crude product. The crude product was purified by column chromatography (silica) to give compound 1-3 (580 mg, 1.69 mmol, 96% yield). LCMS (ESI): RT = 0.861 min, mass calc. for Ci7H25N302S
335.17, m/z found 335.7 [M+1-11+.
Step 3: N-tert-butyl-4-(cyclohexylamino)-3-(2H-tetrazol-5-yl)benzenesulfonamide [00244] To a solution of compound 1-3 (300 mg, 0.89 mmol, 1.0 eq) and NH4C1 (144 mg, 2.7 mmol, 3.0 eq) in DMF (2 mL) was added NaN3 (174 mg, 2.7 mmol, 3.0 eq). The resulted mixture was stirred at 140 C for 16 hr. LCMS showed 93% desired compound was found and the starting material was consumed completely. The reaction mixture was poured into cold water (10 mL), HC1 (1N, lmL) and then extracted by ethyl acetate (3 x10 mL). The combined organic layers were washed with brine (10 mL*2) dried over Na2SO4, concentrated under reduced pressure to give the crude product (350 mg, 0.83 mmol, 93 % yield). The crude product (230 mg) was directly used without further purification. 120 mg of crude product was purified by HPLC to give Compound 1 (90.52 mg). LCMS (ESI): RT =2.200 min, mass calc. for Ci7H26N602S
378.18, m/z found 379.1 [M+F11+; IFINMR (400 MHz, DMS0- d6) 6 8.52 (br s, 1H), 8.41 (d, J =
2.3 Hz, 1H), 7.63 (dd, J= 2.3, 8.8 Hz, 1H), 7.26 - 7.05 (m, 2H), 6.94 (d, J =
9.0 Hz, 1H), 3.59 (s, 1H), 2.04 - 1.94 (m, 2H), 1.79 - 1.68 (m, 2H), 1.64 - 1.54 (m, 1H), 1.50 -1.28 (m, 5H), 1.10 (s, 9H).
Example 2: N-(tert-butyl)-4-(cyclohexylamino)-3-(2-(2-hydroxyethyl)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 2) (OH
) ,'Rs% 0 HN *
__IN 0 Preparation of Compound 2:
(OH
11"-NH
N-N
"
IJ AI A 0 (1.5 eq) 0 40 No in, xµ
K2CO3 (2 eq), DMF, j V
100 C, 16 h Compound 2 [00245] To a solution of 2-1(80 mg, 0.21 mmol, 1.0 eq) and 2-bromoethanol (40 mg, 0.32 mmol, 1.5 eq) in DMF (2 mL) was added K2CO3 (58 mg, 0.42 mmol, 2.0 eq). The resulted mixture was stirred at 100 C for 16 hr. LCMS showed 75% desired compound was found and the starting material was consumed completely. The reaction mixture was poured into cold water (10 mL) and then extracted by ethyl acetate (3x10 mL). The combined organic layers were washed with brine (10 mL*2) dried over Na2SO4, concentrated under reduced pressure to give a brown solid. The crude product was purified by HPLC to give Compound 2 (23 mg, 54 umol, 26% yield). LCMS (ESI): RT =2.160 min, mass calc. for Ci9H301\1603S 422.21, m/z found 423.2 [M+H1+; IFINMR (400 MHz, DMS0- d6) 6 8.47 (d, J = 2.0 Hz, 1H), 7.69 (dd, J =
1.8, 8.8 Hz, 1H), 7.60 (d, J= 7.3 Hz, 1H), 7.30 (s, 1H), 7.01 (d, J = 9.0 Hz, 1H), 5.12 (t, J = 5.6 Hz, 1H), 4.81 (t, J = 4.9 Hz, 2H), 3.98 (q, J = 5.1 Hz, 2H), 3.69 - 3.59 (m, 1H), 2.04 -1.94 (m, 2H), 1.70 (s, 2H), 1.59 (d, J= 12.0 Hz, 1H), 1.50 - 1.28 (m, 5H), 1.09 (s, 9H).
Example 3: N-cyclohexy1-2-(5-methy1-1,2,4-oxadiazol-3-y1)-4-(methylsulfonyl)aniline (Compound 3) N
N
*
Preparation of Compound 3:
H2N OH )LCI
--N N I
--N
3-1A (2.0 eq) 9% *Py %
100 C, 2 hr 3-1 Compound 3 [00246] Compound 3-1A (10 mg, 0.13 mmol, 2.0 eq) was added to a solution of compound 3-1 (20 mg, 64 umol, 1.0 eq) in pyridine (1 mL). The reaction mixture was stirred at 100 C for 2 hours. The reaction mixture was concentrated under reduced pressure. The residue was purified by preparative high performance liquid chromatography.
The fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely and to obtain the title compound (2.16 mg, 9.4% yield). LCMS (ESI):
RT = 2.356 min, mass calcd. for Ci6H211\1303S 335.13, m/z found 358.0 [M+Nal+, NMR
(400MHz, CDC13) 6 8.64 (d, J = 2.2 Hz, 1H), 7.78 (dd, J = 2.2, 8.8 Hz, 1H), 7.35 (d, J=
7.3 Hz, 1H), 6.81 (d, J = 9.0 Hz, 1H), 3.60 - 3.48 (m, 1H), 3.03 (s, 3H), 2.65 (s, 3H), 2.08 -2.00 (m, 2H), 1.84 -1.73 (m, 2H), 1.69 - 1.59 (m, 1H), 1.47 - 1.31 (m, 5H).
Example 4: N-cyclohexy1-4-(methylsulfony1)-2-(2H-tetrazol-5-ypaniline (Compound 4) N-NH
NI' I
c?µ * N
--S
Preparation of Compound 4:
,N-NH
' CN NaN3 ( 3 eq) N
NH4CI (3 eq) 0 * DMF130 C
16h 4-1 Compound 4 [00247] To a mixture of 4-1 (145 mg, 0.52 mmol, 1.0 eq) and NaN3 (102 mg, 1.56 mmol, 3.0 eq) in DMF (3 mL) was added NH4C1 (84 mg, 1.56 mmol, 3.00 eq) in one portion at 25 C under N2. The mixture was heated to 130 C for 16 h. LCMS showed the compound 4-1 was consumed completely and one main peak with desired MS was detected. The reaction mixture was added EA (35 mL) and washed with water (30 mL) and then washed with brine (25 mL*2).The organic layer was dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC to obtain Compound 4 (80 mg, 0.25 mmol, 47.3% yield). LCMS (ESI): RT = 1.197 min, mass calcd. For C14HI9N502S, 321.15 m/z found 321.9[M+H1t 1H NMR (400MHz, CDC13) 6 8.45 -8.20 (m, 2H), 7.55 (br d, J= 9.20 Hz, 1H), 6.65 (br d, J= 9.20 Hz, 1H), 3.35 (br s, 1H), 2.92 (s, 3H), 2.00 - 1.85 (m, 2H), 1.80 - 1.65 (m, 2H), 1.65 - 1.50 (m, 1H), 1.36- 1.19 (m, 5H).
Example 5: N-cyclohexy1-2-(2-methy1-2H-tetrazol-5-y1)-4-(methylsulfonyl)aniline (Compound 5) N-N/
14' *
Preparation of Compound 5:
,N-NH
N N
K2CO3 (2.0 eq) Mel (1.5 eq) MeCN, rt, 2h ___________________________________________ oos *
5-1 Compound 5 [00248] To a mixture of 5-1 (30 mg, 93 umol, 1.00 eq) in CH3CN (5 mL) was added K2CO3 (26 mg, 0.19 mmol, 2.0 eq) and CH3I (20 mg, 0.14 mmol, 8.7 uL, 1.50 eq) in one portion at 20 C under N2. The mixture was stirred at 20 C for 2 h. LCMS
showed the starting material was consumed completely and one small peak with desired MS was detected. TCL
indicated one new spot was formed. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was diluted with water (10 mL) and extracted with EA
(20 mL * 3). The combined organic layers were washed with brine (40 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. LCMS showed 88% of desired product was found. The residue was purified by prep-HPLC to provide Compound 5 (8.84 mg, 26.4 umol, 28.2% yield). LCMS (ESI): RT = 0.810 min, mass calcd. For C15H211\15025, 335.14 m/z found 335.9[M+Hr 1H NMR (400MHz, CDC13) 6 8.68 (d, J= 2.00 Hz, 1H), 7.86 (br d, J= 7.20 Hz, 1H), 7.78 (dd, J= 9.20, 2.40 Hz, 1H), 6.84 (d, J= 9.20 Hz, 1H), 4.44 (s, 3H), 3.55 (br s, 1H), 3.06 (s, 3H), 2.14 - 2.04 (m, 2H), 1.88 - 1.77 (m, 2H), 1.72 - 1.64 (m, 1H), 1.50 - 1.27 (m, 5H).
Example 6: N-cyclohexy1-2-(1-methyl-1H-1,2,3-triazol-4-y1)-4-(methylsulfonyl)aniline (Compound 6) N-N
trI\
c)% * 0 Preparation of Compound 6:
N:m NN
0,13,0 Br trI\
6-la (1.3 eq) (:)µµ s I. Na2CO3 (2.7 eq),Pd(dPI30,-. 4102 (0.1 eq), dioxane/H20, 100 C, 16h 6-1 Compound 6 [00249] To a mixture of 6-1 (50 mg, 0.13 mmol, 1.0 eq) and 6-la (28 mg, 0.17 mmol, 1.30 eq) in dioxane (2 mL) and H20 (0.5 mL) was added Na2CO3 (38 mg, 0.36 mmol, 2.7 eq) and Pd(dppf)C12 (10 mg, 13 umol, 0.1 eq) in one portion under N2. The mixture was stirred at 100 C for 16 h. LCMS showed the starting material was consumed completely and one peak with desired MS was detected. The reaction mixture was concentrated under reduced pressure to remove solvent, and then added CH3CN (5 mL), filtered to give a black-brown liquid. The residue was purified by prep-HPLC. LCMS and 1HNMR confirmed Compound 6 was obtained (2.06 mg, 5.5 umol, 4.2% yield, HC1). LCMS (ESI): RT = 0.752 min, mass calcd.
For Ci6H22N4025, 334.15 m/z found 334.9[M+Hr 1H NMR (400MHz, DMSO-d6) 68.76 (s, 1H), 8.34 (br s, 1H), 7.95 (d, J=2.00 Hz, 1H), 7.60 (dd, J=8.80, 2.00 Hz, 1H), 6.91 (d, J=8.80 Hz, 1H), 4.13 (s, 3H), 3.11 (s, 3H), 2.60 -2.53 (m, 1H), 2.02 - 1.89 (m, 2H), 1.74 - 1.63 (m, 2H), 1.62- 1.51 (m, 1H), 1.49- 1.26 (m, 5H).
Example 7: N-cyclohexy1-2-(1-methy1-1H-pyrazol-4-y1)-4-(methylsulfonyl)aniline (Compound 7) N-N
\ I
*,s \c_)%
Preparation of Compound 7:
N-N
\ I
0õ0 Br 7-1a (1.4 eq) N
Na2003 (3.0 eq),Pd(dp130012 *
(0.1 eq), THF/H20, 70 C, 16h 7-1 Compound 7 1002501 To a mixture of 7-1 (50 mg, 0.13 mmol, 1.0 eq) and 7-la (30 mg, 0.18 mmol, 1.40 eq) in H20 (0.4 mL) and dioxane (2 mL) was added Pd(dppf)C12 (10 mg, 13.2 umol, 0.1 eq) and Na2CO3 (42 mg, 0.40 mmol, 3.0 eq) in one portion under N2.The mixture was stirred at 70 C
for 16 h. LCMS showed the compound 7-1 was consumed completely and one peak with desired MS was detected. The reaction mixture was concentrated under reduced pressure to remove solvent, and then added CH3CN (5 mL), filtered to give a black-brown liquid.
The residue was purified by prep-HPLC to obtain Compound 7 (4.70 mg, 12.7 umol, 9.6% yield, HC1). LCMS
(ESI): RT = 0.737 min, mass calcd. For C17H23N3025, 333.15 m/z found 333.9[M+Ht 1H NMR
(400MHz, DMSO-d6) 68.01 (s, 1H), 7.68 (s, 1H), 7.56 (dd, J = 8.40, 2.00 Hz, 1H), 7.49 (d, J =
2.00 Hz, 1H), 6.82 (d, J= 9.20 Hz, 1H), 3.90 (s, 3H), 3.45 - 3.35 (m, 1H), 3.08 (s, 3H), 1.97 -1.86 (m, 2H), 1.72 - 1.53 (m, 3H), 1.43 - 1.15 (m, 5H).
Example 8: N-cyclohexy1-2-(1-methyl-1H-pyrazol-3-y1)-4-(methylsulfonyl)aniline (Compound 8) /
N
0%
Preparation of Compound 8:
0 C 13-BP:
8-2a (2.0 eq) 8-la (1.2 eq) Br ACOK (3 eq) 0õ0 Br TMSCI (2.5 eq) Q * NH2 NaBH4 (1.0 el). 0. * Pd(dppf)Cl2 (0.1 eq) DMF, 0 C, 4h %% 1,4-dioxane, 100 C, 16h 0 N/
N Br /
8-3a (1.3 eq) I\ * No Na2003 (2.0 eq),Pd(dppf)012 R
(0.1 eq), dioxane/H20, 100 C, 16h Compound 8 Step 1: 2-bromo-N-cyclohexy1-4-methylsulfonyl-aniline [00251] To a mixture of 8-1 (500 mg, 2.0 mmol, 1.0 eq) and TMSC1 (543 mg, 5.0 mmol, 0.63 mL, 2.5 eq) and 8-la (235 mg, 2.4 mmol, 0.25 mL, 1.2 eq) in DMF (10 mL) was stirred at 0 C for 5 min under N2. The mixture was added NaBH4 (76 mg, 2.0 mmol, 1.0 eq) and stirred at 0 C for 3 h. LCMS showed no MS of the reactant 8-1, but one main peak with desired MS
was detected. The reaction mixture was quenched by addition sat.NaHCO3 (30 mL), and extracted with EA (30 mL * 3). The combined organic layers were washed with brine (30 mL *
2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography to provide 8-2 (750 mg, 2.3 mmol, 113 %
yield). LCMS
(ESI): RT = 0.829 min, mass calcd. For C131-118BrNO2S, 331.02 m/z found 331.9[M+H1+ and 333.9 [M+H+2]+.
Step 2: N-cyclohexy1-4-methylsulfony1-2-(4,4,5,5-tetramethyl-1,3,2-dioxab orolan-2-yl)aniline [00252] To a mixture of 8-2 (390 mg, 1.2 mmol, 1.0 eq) and 8-2a (594 mg, 2.3 mmol, 2.00 eq) in dioxane (7 mL) was added AcOK (344 mg, 3.5 mmol, 3.00 eq) in one portion at 14 C under N2. The mixture was degassed under vacuum and purged with N2 for 3 times. The resulted mixture was stirred at 100 C under N2 for 16 hour. LCMS showed the starting material was consumed completely and one main peak with desired MS was detected. TLC
showed many new spots were formed. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography to provide 8-3 (400 mg, 0.74 mmol, 63.1% yield) which was used next step without further purification. LCMS (ESI): RT = 0.931 min, mass calcd. For Ci9H3013N04S, 379.20 m/z found 380.1[M+H1+.
Step 3: N-cyclohexy1-2-(1-methylpyrazol-3-y1)-4-methylsulfonyl-aniline [00253] To a mixture of 8-3 (80 mg, 0.21 mmol, 1.0 eq) and 8-3a (44 mg, 0.27 mmol, 1.3 eq) in dioxane (3 mL) and H20 (0.15 mL) was added Na2CO3 (44 mg, 0.42 mmol, 2.0 eq) and Pd(dppf)C12 (16 mg, 21 umol, 0.1 eq) in one portion under N2. The mixture was stirred at 100 C
for 16 h. LCMS showed the starting material was consumed completely and one peak with desired MS was detected. The reaction mixture was concentrated under reduced pressure to remove solvent, and then added CH3CN (5 mL), filtered to give a black-brown liquid. The residue was purified by prep-HPLC. LCMS and 1HNMR confirmed that Compound 8 was obtained (2.20 mg, 6.4 umol, 3.0% yield). LCMS (ESI): RT = 0.835 min, mass calcd. For Ci7H23N3025, 333.15 m/z found 333.9[M+H1t 1H NMR (400MHz, CDC13) 6 8.44 (br d, J = 7.20 Hz, 1H), 8.04 (s, 1H), 7.64 (br d, J= 8.00 Hz, 1H), 7.41 (br s, 1H), 6.76 (br d, J = 8.80 Hz, 1H), 6.68 (s, 1H), 3.96 (s, 3H), 3.54 (br s, 1H), 3.04 (s, 3H), 2.10 - 2.00 (m, 2H), 1.87 - 1.75 (m, 2H), 1.68- 1.55 (m, 2H), 1.50- 1.42 (m, 3H).
Example 9: N-cyclohexy1-4-(methylsulfony1)-2-(1H-1,2,3-triazol-1-ypaniline (Compound 9) and N-cyclohexy1-4-(methylsulfony1)-2-(2H-1,2,3-triazol-2-ypaniline (Compound 13) = -NJ
czµ 1\10 0 ai N
sµ
Compound 9 Compound 13 Preparation of Compound 9 and Compound 13:
Br (NH
sl\l"N
0 *
9-2A (2 5 1\INT 0 ,S
*
Cu 1(0.4 eq), Cs2CO3(4.0 eq), CZ` WI
,S
DMF, 120 C, 16 h, 9-1 Compound 9 Compound 13 [00254] To a mixture of compound 9-1 (50 mg, 0.15 mmol, 1.0 eq), Cs2CO3 (196 mg, 0.60 mmol, 4.0 eq) and compound 9-2A (26 mg, 0.38 mmol, 22 uL, 2.5 eq) in DMF (2 mL) was added CuI (11 mg, 60 umol, 0.4 eq). The reaction mixture was heated at 120 C
for 16 hour under N2. LCMS and HPLC showed 18% +14% desired compound was found (m/z=320.9; RT:
0.743 and 0.834 min) and the starting material was consumed completely. The reaction mixture was poured into water (5 mL) and stirred for 5 min. The aqueous phase was extracted with ethyl acetate (5 mL*3). The combined organics phase were washed with brine (5 mL*2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a residue. The residue was purified by prep-HPLC to give Compound 9 (7 mg, 22 umol, 15% yield) and Compound 13 (6 mg, 19 umol, 12 % yield).
[00255] Compound 9: LCMS (ESI): RT = 0.754 min, mass calc. for C15H201\1402S 320.13, m/z found 320.9 [M+H1+; 1HNMR (400 MHz, CDC13) 6 7.93 (d, J= 6.3 Hz, 2H), 7.80 (dd, J=
1.9, 8.9 Hz, 1H), 7.75 (d, J= 2.0 Hz, 1H), 6.92 (d, J = 9.0 Hz, 1H), 6.27 (d, J = 7.3 Hz, 1H), 3.50 -3.39 (m, 1H), 3.05 (s, 3H), 2.01 (d, J= 11.5 Hz, 2H), 1.82 - 1.71 (m, 2H), 1.69- 1.61 (m, 1H), 1.46- 1.35 (m, 2H), 1.34- 1.23 (m, 3H).
[00256] Compound 13: LCMS (ESI): RT = 0.830 min, mass calc. for C15H201\1402S
320.13, m/z found 320.9 [M+H1+; 1HNMR (400 MHz, CDC13) 6 8.51 (d, J = 2.0 Hz, 1H), 7.86 (s, 2H), 7.73 (dd, J= 1.9, 8.7 Hz, 2H), 6.89 (d, J= 9.0 Hz, 1H), 3.56 - 3.45 (m, 1H), 3.07 (s, 3H), 2.06 (d, J= 11.5 Hz, 2H), 1.79 (dd, J= 3.9, 9.2 Hz, 2H), 1.71 - 1.62 (m, 1H), 1.48 - 1.30 (m, 5H).
Example 10: N-cyclohexy1-4-(methylsulfony1)-2-(1H-pyrazol-1-ypaniline (Compound 10) * No0 Preparation of Compound 10:
Br N=N
o w'N 10-2A (2.5 eq) Cul(0.4 eq), Cs2003(4.0 eq), = 0 DMF, 120 C, 16h NO%
10-1 Compound 10 [00257] To a mixture of compound 10-1 (100 mg, 0.3 mmol, 1.0 eq), Cs2CO3(392 mg, 1.2 mmol, 4.0 eq) and compound 10-2a (51 mg, 0.75 mmol, 2.5 eq) in DMF (2 mL) was added CuI
(23 mg, 0.12 mmol, 0.4 eq). The reaction mixture was heated at 120 C for 16 hour under N2.
LCMS showed 88% desired compound was found (m/z=320.0; RT: 0.803 min) and the starting material was consumed completely. The reaction mixture was poured into water (5 mL) and stirred for 5 min. The aqueous phase was extracted with ethyl acetate (5 mL*3). The combined organics phase were washed with brine (5 mL*2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a residue. The residue was purified by prep-HPLC to give Compound 10 (50 mg, 0.16 mmol, 52% yield). LCMS (ESI): RT = 0.820 min, mass calc. for C16H211\1302S 319.14, m/z found 319.9 [M+I-11+; IFINMR (400 MHz, CDC13) 6 7.78 (s, 2H), 7.74 - 7.68 (m, 2H), 6.82 (d, J = 8.5 Hz, 1H), 6.72 (d, J= 7.3 Hz, 1H), 6.50 (t, J=
2.0 Hz, 1H), 3.47 -3.37 (m, 1H), 3.03 (s, 3H), 2.05 - 1.96 (m, 2H), 1.79 - 1.70 (m, 2H), 1.68 -1.60 (m, 1H), 1.46 -1.25 (m, 5H).
Example 11: N-cyclohexy1-2-(1H-imidazol-1-y1)-4-(methylsulfonyl)aniline (Compound 11) 9s% * 11-\ II
Preparation of Compound 11:
NH
Br N 11-2A (2.5 eq) Cul(0.4 eq), Cs2003(4.0 eq), *
DMF, 120 C, 32 h, 11-1 Compound 11 [00258] To a mixture of compound 11-1 (50 mg, 0.15 mmol, 1.0 eq), compound 11-2A (26 mg, 0.38 mmol, 2.5 eq), and Cs2CO3 (196 mg, 0.60 mmol, 4.0 eq) in DMF (2 mL) was added Cul (15 mg, 60 umol, 0.4 eq). The reaction mixture was heated at 120 C for 32 hour under N2.
LCMS showed 50% of desired compound was found (m/z =319.9; RT: 0.642 min) and 39% of the starting material was remained. The reaction mixture was poured into water (5 mL) and stirred for 5 min. The aqueous phase was extracted with ethyl acetate (5 mL*3). The combined organics phase were washed with brine (5 mL*2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a residue. The residue was purified by HPLC to give Compound 11 (20 mg, 61 umol, 40 % yield). LCMS (EST): RT = 0.649 min, mass calc. for Ci6H211\1302S
319.14, m/z found 319.9 [M+I-11+; 1HNMR (400 MHz, CDC13) 6 7.82 (dd, J = 2.0, 8.8 Hz, 1H), 7.65 (d, J = 2.0 Hz, 1H), 7.62 (s, 1H), 7.31 (s, 1H), 7.08 (s, 1H), 6.82 (d, J= 8.8 Hz, 1H), 4.03 (d, J = 7.5 Hz, 1H), 3.42 - 3.31 (m, 1H), 3.05 (s, 3H), 1.95 (d, J= 12.3 Hz, 2H), 1.71 (d, J= 13.6 Hz, 2H), 1.64 (d, J= 13.3 Hz, 1H), 1.44 - 1.32 (m, 2H), 1.27 - 1.08 (m, 3H).
Example 12: N-cyclohexy1-4-(methylsulfony1)-2-(1H-1,2,4-triazol-1-ypaniline (Compound 12) N
Ns 9sx * No Preparation of Compound 12:
Br TN
N Ns õII
* N 12-2a (2.4 eq) CuI(0.2 eq), L-proline (0.4 eq), j) = 0 Cs2CO3(4.0 eq), DMSO, 120 C, 16h, 12-1 Compound [00259] To a mixture of compound 12-1 (50 mg, 0.15 mmol, 1.0 eq), Cs2CO3 (196 mg, 0.60 mmol, 4.0 eq) and compound 12-2a (25 mg, 0.36 mmol, 2.4 eq) in DMSO (2 mL) was added CuI (6 mg, 30 umol, 0.2 eq) and L-PROLINE (7 mg, 60 umol, 0.4 eq). The reaction mixture was heated at 120 C for 16 hour under N2. LCMS showed desired compound was found and the starting material was remained. The reaction mixture was poured into water (5 mL) and stirred for 5 min. The aqueous phase was extracted with ethyl acetate (5 mL*3). The combined organics phase were washed with brine (8 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a crude product. The crude product was combined and purified by prep-TLC to give Compound 12 (35 mg, 0.1 mmol, 34% yield). LCMS (EST): RT =
0.732 min, mass calc. for C15H20N402S 320.13, m/z found 320.9 [M+1-11+; 1HNMR (400 MHz, CDC13) 6 8.43 (s, 1H), 8.21 (s, 1H), 7.80 (dd, J = 2.0, 8.8 Hz, 1H), 7.73 (d, J = 2.0 Hz, 1H), 6.87 (d, J =
9.0 Hz, 1H), 6.08 (d, J= 7.5 Hz, 1H), 3.48 - 3.37 (m, 1H), 3.05 (s, 3H), 2.00 (d, J= 11.0 Hz, 2H), 1.80 - 1.70 (m, 2H), 1.65 (d, J= 12.5 Hz, 1H), 1.47 - 1.36 (m, 2H), 1.28 (d, J= 11.0 Hz, 3H).
Example 13: 4-(cyclohexylamino)-3-(2-ethy1-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 14) N-N
OµN gip NO
-S
HN
Preparation of Compound 14:
, NN
N-NH
Br 14-1a (1.5 eq) czN = NI) K2CO3 (2.0 eq) 'R% DMF, 80 C, 0.5 hr, MW
HN,Sµ`
14-1 Compound 14 [00260] To the solution of compound 14-1 (30 mg, 89 umol, 1.0 eq) in DMF (4 mL) was added compound 14-la (15 mg, 0.1mmol, 10 uL, 1.5 eq) and K2CO3 (24.65 mg, 0.18 mmol, 2.0 eq). The mixture was stirred at 80 C for 0.5 hr under microwave. The reaction was monitored by LCMS. The reaction was concentrated under reduced pressure. The residue was purified by prep-HPLC to give Compound 14 (6.13 mg, 16.8 umol, 18.9% yield). LCMS (EST): RT =
0.850 min, mass calcd. for C16H24N602S 364.17, m/z found 365.0 [M+H1+, NMR (400MHz, DMSO-d6) 6 8.41 (d, J= 2.3 Hz, 1H), 7.66 - 7.63 (m, 2H), 7.25 (br, , 1H), 7.04 (d, J=
9.0 Hz, 1H), 4.82 (q, J
= 7.4 Hz, 2H), 3.64 - 3.63 (m, 1H), 2.38 (s, 3H), 2.04 - 1.94 (m, 2H), 1.77 -1.67 (m, 2H), 1.60 (t, J = 7.3 Hz, 3H), 1.51 - 1.23 (m, 6H).
Example 14: 4-(cyclohexylamino)-N-methy1-3-(2-propy1-2H-tetrazol-5-yl)benzenesulfonamide (Compound 15) N-N
-S
HN
Preparation of Compound 15:
N-NH N-N
N ,NBr 15-1a (1.2 eq) czµ = NI) K2CO3 (1.5 eq) DMF, 80 C, 0.5 hr, MW 0 si HN,S ,S
NH \\
15-1 Compound 15 [00261] To the solution of 15-1 (30 mg, 89 umol, 1.0 eq) in DMF (4 mL) was added compound 15-la (12 mg, 98 umol, 9 uL, 1.1 eq) and K2CO3 (18 mg, 0.1 mmol, 1.5 eq). The mixture was stirred at 80 C for 0.5 hr under microwave. The reaction was monitored by LCMS.
The reaction was concentrated under reduced pressure. The residue was purified by prep-HPLC
to give Compound 15 (3.06 mg, 8.1 umol, 9.1% yield). LCMS (ESO: RT = 0.885 min, mass calcd. for C17H26N602S 378.18, m/z found 379.1 [M+141+, 1HNMR (400MHz, DMSO-d6) 6 8.42 (s, 1H), 7.69 - 7.60 (m, 2H), 7.28 - 7.19 (m, 1H), 7.05 (d, J= 8.8 Hz, 1H), 4.76 (t, J = 6.8 Hz, 2H), 3.69 - 3.58 (m, 1H), 2.38 (d, J= 5.0 Hz, 3H), 2.08 - 1.95 (m, 4H), 1.77 -1.68 (m, 2H), 1.64 - 1.54 (m, 1H), 1.46 - 1.23 (m, 5H), 0.91 (t, J= 7.3 Hz, 3H).
Example 15: 4-(cyclohexylamino)-3-(2-(4-fluoropheny1)-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 16) N-N
O. No ;S
N II
HO
Preparation of Compound 16:
N-N
N-NH B.oH
N,.N F z µ1\1 16-la (1.2 eq) 101 No Et3N (4 eq), Cu(OAc)2 (1 eq) DCM, 02, rt, 36h ;S N
N
Compound 16 [00262] A mixture of compound 16-1 (50 mg, 0.13 mmol, 1.00 eq, HC1), (4-fluorophenyl)boronic acid (24.4 mg, 0.17 mmol, 1.30 eq), DIEA (69.3 mg, 0.54 mmol, 93.7 uL, 4.0 eq) and Cu(0Ac)2 (24.4 mg, 0.13 mmol, 1.0 eq) was degassed under vacuum and purged with 02 several times. The mixture was stirred at 20 C for 20hr. LCMS showed that starting material was remained and no desired MS signal was detected. Additional of (4-fluorophenyl)boronic acid (24.4 mg, 0.17 mmol, 1.30 eq) was added. The reaction was stirred at 20 C for 16hr. LCMS showed that desired MS signal was detected. The reaction was filtered and concentrated. The residue was purified by Prep HPLC to give Compound 16 (3.10 mg, 7.1 umol, 5.3% yield). 1HNMR and LCMS confirmed that desired product was obtained.
LCMS
(ESI): RT = 0.890 min, mass calcd. for C20I-123N6502F 430.16, m/z found 431.1 [M+H1+.
NMR (400MHz, CDC13) 6 8.73 (d, J= 2.4 Hz, 1H), 8.25 - 8.10 (m, 2H), 7.90 -7.80 (m, 1H), 7.76 (dd, J = 8.8 Hz, 2.4 Hz, 1H), 7.40 - 7.25 (m, 2H), 6.86 (d, J= 9.2 Hz, 1H), 4.40 - 4.25 (m, 1H), 3.65 - 3.50 (m, 1H), 2.69 (d, J = 5.6 Hz, 3H), 2.10 - 2.00 (m, 2H), 1.90 -1.75 (m, 2H), 1.75 - 1.65 (m, 2H), 1.50 -1.40 (m, 4H).
Example 16: 3-(2-cyclobuty1-2H-tetrazol-5-y1)-4-(cyclohexylamino)-N-methylbenzene sulfonamide (Compound 17) N-N
,N
czµ N
NH,Sµ`
I
Preparation of Compound 17:
N-NH
BP N-N
oNN N
17-2 (1.5 eq) N
HN-SµN K2CO3 (2.0 eq), O,) DMF, 100 C, 8h HN,Sµ`
Compound 17 [00263] To a solution of compound 17-1 (30.0 mg, 89.2 umol, 1.0 eq) in DMF (2.0 mL) was added K2CO3 (24.7 mg, 0.18 mmol, 2.0 eq) and compound 17-2 (18.1 mg, 0.13 mmol, 12.6 uL, 1.5 eq). The mixture was stirred at 100 C for 16 hour at N2 atmosphere.
LCMS showed desired compound was found. The reaction was filtered to give a crude product.
The crude product was purified by prep-HPLC to give Compound 17 (2.01 mg, 5.2 umol, 5.8%
yield).
LCMS (EST): RT = 0.900 min, mass calc. for C18H26N602S 390.18, m/z found 391.1 [M+H1+;
1HNMR (400 MHz, CDC13) 6 8.64 (d, J= 2.3 Hz, 1H), 7.89 (d, J=7.0 Hz, 1H), 7.73 (dd, J = 2.1, 8.9 Hz, 1H), 6.82 (d, J= 9.0 Hz, 1H), 5.42 (q, J = 8.3 Hz, 1H), 4.26 (q, J =
5.3 Hz, 1H), 3.55 (s, 1H), 2.90 - 2.79 (m, 2H), 2.67 (d, J= 5.3 Hz, 5H), 2.16 - 1.99 (m, 4H), 1.87 -1.77 (m, 2H), 1.66 (d, J= 11.5 Hz, 1H), 1.51 - 1.35 (m, 5H).
Example 17: 4-(cyclohexylamino)-3-(2-cyclopenty1-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 18) N-N
czµ N o HN,Sµ`
I
Preparation of Compound 18:
N-NH
BrJD N-N
1\1 ;
18-la (1.2 eq) czµ = N czµ N
K2003 (2.0 eq), DMF, 80 C, 3 h HN HN
I I
18-1 Compound 18 [00264] To a stirred solution of compound 18-1 (50 mg, 0.15 mmol, 1.0 eq) and K2CO3 (41 mg, 0.30 mmol, 2.0 eq) in DMF (1 mL) was compound 18-la (27 mg, 0.18 mmol, 19 uL, 1.2 eq). The resulted mixture was heated to 80 C for 3 hours. LCMS showed 80%
desired compound was found and the starting material was consumed completely. The mixture was cooled. The reaction was diluted with DMF (2 mL), filtered to give a mixture. The mixture was purified by prep-HPLC to give Compound 18 (30 mg, 74 umol, 50% yield). LCMS (ESI): RT =
0.879 min, mass calc. for C19H281\1602S 404.20, m/z found 405.1 [M+H1+; 1HNMR (400 MHz, DMSO-d6) 6 8.41 (d, J= 2.0 Hz, 1H), 7.70 - 7.56 (m, 2H), 7.24 (d, J= 5.0 Hz, 1H), 7.04 (d, J= 9.0 Hz, 1H), 5.50 - 5.39 (m, 1H), 3.64 (d, J = 4.3 Hz, 1H), 2.38 (d, J= 5.0 Hz, 3H), 2.29 (td, J= 6.8, 13.4 Hz, 2H), 2.23 - 2.10 (m, 2H), 1.99 (d, J= 9.5 Hz, 2H), 1.90 - 1.67 (m, 6H), 1.58 (s, 1H), 1.51 -1.30 (m, 5H).
Example 18: 4-(cyclohexylamino)-3-(2-(2-fluorobenzy1)-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 19) N-N
NI' ;IV
No CZ\ 0101 HN
Preparation of Compound 19:
F Br FR
N-N "I-N-NH
i\J
i\J
19-la (1.2 eq) ei N0 HN,Sµ` K2CO3 (2.0 eq), DMF, 80 C, 3 h R` 40 F (:)µ\
,s ,s\ 401 L) Compound 19 19-2 [00265] To a stirred solution of compound 19-1 (50 mg, 0.15 mmol, 1.0 eq) and K2CO3 (41 mg, 0.30 mmol, 2.0 eq) in DMF (1 mL) was added compound 19-la (34 mg, 0.18 mmol, 21 uL, 1.2 eq). The resulted mixture was heated at 80 C for 3 hour. Reaction was monitored by LCMS and the starting material was consumed completely. The mixture was cooled and diluted with DMF (2 mL), filtered to give a mixture. The mixture was purified by prep-HPLC to give the Compound 19 (20 mg, 42.7 umol, 29% yield) and 19-2 crude (12 mg). The crude 19-2 was re-purified by prep-HPLC (7 mg, 11.9 umol, 7.99% yield, HC1 salt).
[00266] Compound 19: LCMS (EST): RT = 0.879 min, mass calc. for 444.17, m/z found 405.1 [M+H1+; NMR (400 MHz, DMSO-d6) 6 8.40 (d, J = 2.3 Hz, 1H), 7.64 (dd, J = 2.0, 8.8 Hz, 1H), 7.59 (t, J = 7.7 Hz, 1H), 7.54 - 7.45 (m, 2H), 7.34 - 7.21 (m, 3H), 7.02 (d, J = 9.0 Hz, 1H), 6.11 (s, 2H), 3.68 -3.55 (m, 1H), 2.36 (d, J= 5.0 Hz, 3H), 1.92 (d, J=
9.5 Hz, 2H), 1.62 (s, 2H), 1.56 (d, J = 11.5 Hz, 1H), 1.47 - 1.35 (m, 2H), 1.34 - 1.20 (m, 3H).
Example 19: 3-(2-benzy1-2H-tetrazol-5-y1)-4-(cyclohexylamino)-N-methylbenzenesulfonamide (Compound 20) =
N' --N
HN-2S1 *
Preparation of Compound 20:
N-NH 1.1 Br 20-2 (1.5 eq) N' N' No K2CO3 (4.0 eq) --N --N
HN DMF, 100 C 17 h *
\`
I HN-IS%
N=s, *
20-1 Compound 20 20-3 [00267] To a mixture of 20-1 (30.0 mg, 80.5 umol, 1.0 eq, HC1) and K2CO3 (44.5 mg, 0.3 mmol, 4.0 eq) in DMF (3.0 mL), was added 20-2 (20.6 mg, 0.1 mrnol, 14 uL, 1.5 eq). The resulted mixture was stirred at 100 C under N2 for 17 h. LCMS showed the reaction was completed. The mixture was filtered, and the solid was washed with DMF (1 mL).
The filtrate was purified by prep-HPLC. Compound 20 (2.07 mg, 4.8 umol, 6.0% yield) was obtained, which was confirmed by LCMS, 1HNMR and NOE. LCMS (ESI): RT = 0.906 min, mass calcd.
for C211-126N602S 426.18, m/z found 427.1 [M+H1+. 11-1 NMR (400MHz, DMSO-d6) 6 8.39 (d, J
= 2.3 Hz, 1H), 7.63 (dd, J= 2.0, 9.0 Hz, 1H), 7.54 (d, J= 7.3 Hz, 1H), 7.47 -7.37 (m, 5H), 7.20 (s, 1H), 7.02 (d, J= 9.0 Hz, 1H), 6.05 (s, 2H), 3.66 - 3.58 (m, 1H), 2.36 (s, 3H), 1.98 - 1.89 (m, 2H), 1.70 - 1.61 (m, 2H), 1.61 - 1.51 (m, 1H), 1.48 - 1.37 (m, 2H), 1.35 -1.25 (m, 3H).
[00268] Compound 20-3 (7.54 mg, 14.6 umol, 18.1% yield) was obtained, which was confirmed by LCMS and 1H NMR. LCMS (ESI): RT = 1.029 min, mass calcd. for 516.23, m/z found 517.2 [M+H1+. IFINMR (400MHz, CDC13) 6 8.61 (d, J = 2.3 Hz, 1H), 7.79 (d, J = 7.0 Hz, 1H), 7.70 (dd, J = 2.1, 8.9 Hz, 1H), 7.48 - 7.37 (m, 5H), 7.35 - 7.28 (m, 5H), 6.83 (d, J= 9.3 Hz, 1H), 5.83 (s, 2H), 4.14 (s, 2H), 3.58 - 3.50 (m, 1H), 2.59 (s, 3H), 2.09 - 2.01 (m, 2H), 1.84 - 1.75 (m, 2H), 1.70 - 1.62 (m, 1H), 1.47 - 1.41 (m, 3H).
Example 20: 3-(2-butyltetrazol-5-y1)-4-(cyclohexylamino)-N-methyl-benzenesulfonamide (Compound 21) N-N
1\1 NHo NH=S\µ
Preparation of Compound 21:
NH-N
1\1 N-N
I \I µi\J
NHo 21-1a(1.1eq) K2CO3(2.5 eq) NH.S DMF, 80 C, MW
µµ 0 0 , 0.5h NH .Sµ\ C) 21-1 Compound 21 [00269] To a solution of 21-1 (50.0 mg, 0.1 mmol, 1.0 eq) in DMF (3.0 mL) was added K2CO3 (41.0 mg, 0.3 mmol, 2.0 eq) and 1-bromobutane (20.3 mg, 0.1 mmol, 16.0 uL, 1.0 eq).
The mixture was stirred at 80 C under microwave condition for 0.5 hour. LCMS
showed 23% of 21-1 was remained. Several new peaks were shown on LCMS and 68% of desired compound was detected. The residue was purified by prep-HPLC to give Compound 21 (12.91 mg, 32.9 umol, 22% yield). LCMS (ESI): RT = 0.872 min, mass calc. for C18H28N6025 392.20, m/z found 393.1 [M+Na1+; 1HNMR (400MHz, CDC13) 6 8.62 (d, J = 2.3 Hz, 1H), 7.84 (d, J =
7.0 Hz, 1H), 7.74-7.71 (m, 1H), 6.82 (d, J = 9.0 Hz, 1H), 4.69 (t, J= 7.0 Hz, 2H), 4.23 (q, J= 5.4 Hz, 1H), 3.55 (s, 1H), 2.67 (d, J = 5.5 Hz, 3H), 2.13-2.01 (m, 4H), 1.88-1.78 (m, 2H), 1.67 (d, J= 11.8 Hz, 1H), 1.49-1.36 (m, 7H), 1.00 (t, J = 7.4 Hz, 3H).
Example 21: 4-(cyclohexylamino)-N-methyl-3-(2-methyl-2H-tetrazol-5-yl)benzenesulfonamide (Compound 22) N-N
µ1\1 HN,Sµ`
I
Preparation of Compound 22:
N-N/
N-NH N-N
;1\1 ,1\1 CH3I (1.5 eq) 0\µ 0 K2CO3 (2.0 eq), OP 0 HN'S\ DMF, 80 C, 0.5h I
HN,S µ` ,S - I N
I
Compound 22 Compound 22-2 [00270] Compound 22-1 (50.0 mg, 0.15 mmol, 1.0 eq), CH3I (31.6 mg, 0.22 mmol, 13.9 uL, 1.5 eq) and K2CO3 (41.1 mg, 0.30 mmol, 2.0 eq) were taken up into a microwave tube in DMF (2.0 mL). The sealed tube was heated at 100 C for 0.5 hour under microwave. LCMS
showed desired compound was found. The reaction was filtered to give a crude product. The crude product was purified by prep-HPLC to give two products. Compound 22 (14.5 mg, 41.3 umol, 27.8% yield) was obtained. LCMS (ESI): RT = 0.773 min, mass calc. for 350.15, m/z found 351.1 [M+F11+;IHNMR (400 MHz, CDC13) 6 8.61 (d, J = 2.3 Hz, 1H), 7.79 -7.70 (m, 2H), 6.82 (d, J = 9.0 Hz, 1H), 4.43 (s, 3H), 4.27 (q, J= 5.5 Hz, 1H), 3.59 - 3.49 (m, 1H), 2.67 (d, J= 5.5 Hz, 3H), 2.13 -2.04 (m, 2H), 1.86 - 1.78 (m, 2H), 1.67 (d, J= 11.8 Hz, 1H), 1.51 - 1.36 (m, 5H).
[00271] Compound 22-2 (2.3 mg, 6.4 umol, 4.3% yield) was obtained. LCMS
(ESI): RT
= 0.828 min, mass calc. for C16H24N602S 364.17, m/z found 365.1 [M+1-11;1HNMR
(400 MHz, CDC13) 6 8.53 (d, J = 2.3 Hz, 1H), 7.77 (d, J = 7.3 Hz, 1H), 7.66 (dd, J =
2.1, 8.9 Hz, 1H), 6.83 (d, J = 9.0 Hz, 1H), 4.44 (s, 3H), 3.54 (s, 1H), 2.72 (s, 6H), 2.09 (s, 2H), 1.82 (s, 2H), 1.66 (s, 1H), 1.52 - 1.40 (m, 5H).
Example 22: 4-(cyclohexylamino)-3-(2-(2-fluoropheny1)-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 23) F
N N
;S
N II
H
Preparation of Compound 23:
F
B.
OH
OH
N N N N
23-1a (1.2 eq) O. 110 No Et3N (4 eq), Cu(OAc)2 (1 eq) ;S
DCM, 02, rt, 36h 0. lel No ;S
N A
N
Compound 23 [00272] A mixture of compound 23-1 (50 mg, 0.13 mmol, 1.00 eq, HC1), 23-la (28.1 mg, 0.2 mmol, 1.5 eq) DIEA (69.3 mg, 0.54 mmol, 93.7 uL, 4.0 eq) and Cu(0Ac)2 (36.5 mg, 0.2 mmol, 1.5 eq) was degassed under vacuum and purged with 02 several times. The mixture was stirred at 20 C for 20 hr. LCMS showed that starting material was remained and no desired MS
signal was detected. Additional of 23-la (28.1 mg, 0.2 mmol, 1.5 eq) was added. The reaction was stirred at 20 C for another 16 hr. LCMS showed that 10% of desired MS
signal was detected. The reaction was filtered and concentrated. The residue was purified by prep-HPLC to give Compound 23 (1.90 mg, 4.4 umol, 3.3% yield). LCMS (ESI): RT = 0.884 min, mass calcd.
for C20I-123N6502F 430.16, m/z found 431.1 [M+H1+. IFINMR (400MHz, CDC13) 6 8.49 (d, J=
2.4 Hz, 1H), 8.07 (d, J= 7.6 Hz, 1H), 7.75 - 7.55 (m, 3H), 7.55 - 7.45 (m, 2H), 7.30 - 7.20 (m, 1H), 7.07 (d, J= 9.2 Hz, 1H), 3.60 - 3.50 (m, 1H), 2.36 (d, J = 5.2 Hz, 3H), 2.10 -2.00 (m, 2H), 1.90 - 1.75 (m, 2H), 1.75 - 1.65 (m, 1H), 1.50 -1.40 (m, 5H).
Example 23: tert-butyl 3-(5-(2-(cyclohexylamino)-5-(N-methylsulfamoyl)pheny1)-tetrazol-2-yl)pyrrolidine-1-carboxylate (Compound 24) 0*
N-N
/1\I
9% 40 NO
S
HN -Preparation of Compound 24:
r N-NH
Br)---/
NI' 24-la (1.2 eq) N
= N
K CO 1. e 2 3(5 q) * 0 HN -S
HN
24-1 Compound 24 [00273] To a solution of compound 24-1 (10 mg, 30 umol, 1.0 eq) in DMF (2 mL) was added 24-la (9 mg, 36 umol, 1.2 eq) and K2CO3 (6 mg, 45 umol, 1.5 eq). The mixture was stirred at 100 C for 16 hr. The reaction was monitored by LCMS. The reaction was concentrated under reduced pressure. The residue was purified by prep-HPLC to give Compound 24 (2.09 mg, 4.1 umol, 7.0% yield). LCMS (ESI): RT = 0.850 min, mass calcd. for C23H35N704S 505.25, miz found 528.1 [M+Nal+, 1HNMR (400MHz, CDC13) 6 8.61 (s, 1H), 7.74 (d, J= 7.8 Hz, 2H), 6.83 (d, J= 8.8 Hz, 1H), 5.51 - 5.44 (m, 1H), 4.27 (s, 1H), 4.00 (s, 2H), 3.79 - 3.63 (m, 2H), 3.54 (s, 1H), 2.77 - 2.69 (m, 1H), 2.67 (s, 3H), 2.60 - 2.52 (m, 1H), 2.08 (d, J=
7.5 Hz, 2H), 1.87 -1.79 (m, 2H), 1.71 - 1.63 (m, 3H), 1.49 (s, 9H), 1.44 (d, J = 8.8 Hz, 3H).
Example 24: tert-butyl 3-(5-(2-(cyclohexylamino)-5-(N-methylsulfamoyl)pheny1)-tetrazol-2-yl)azetidine-1-carboxylate (Compound 25) o N-N
N' N
No HN-S\ *
Preparation of Compound 25:
o N-NH
N N
N * o N-N
B
Boc oc N. Ni II
25-3 (1 eq) N
TsCI 25-la (1.2 eq) HO Py, 30 C, 20 h Ts0 K2CO3( 4 eq), DMF
80-120 C, 16 h N qk 25-1 25-2 Compound 25 Step 1: tert-butyl 3-(p-tolylsulfonyloxy)azetidine-l-carboxylate [00274] To a mixture of 25-1 (3.0 g, 17.3 mmol, 1.0 eq) in pyridine (16 mL) was added 25-la (3.96 g, 20.8 mmol, 1.2 eq) in one portion under N2.The mixture was stirred at 30 C and stirred for 20 h. LCMS showed compound 25-1 was consumed completely and one main peak with desired MS was detected. The reaction mixture was diluted with water (40 mL) and extracted with EA (30 mL * 3). The combined organic layers were washed with brine (30 mL *
3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. 25-2 (5.50 g, crude) was obtained as a red oil, which was used in the next step without further purification.
Step 2: 3-15-12-(cyclohexylamino)-5-(methylsulfamoyl)phenyl]tetrazol-2-yl]azetidine-1-carboxylate [00275] To a mixture of 25-2 (70 mg, 0.15 mmol, 1.2 eq) and 25-3 (50 mg, 0.13 mmol, 1.0 eq) in DMF (1 mL) was added K2CO3 (70 mg, 0.51 mmol, 4.0 eq) in one portion under N2.
The mixture was stirred at 80 C for 2.5 hr. LCMS showed only starting material was remained.
The reaction mixture was continued stirred at 120 C for 16 hr. LCMS showed one main peak with desired MS was detected. The reaction mixture was diluted with water (5 mL) and extracted with EA (5 mL * 4). The combined organic layers were dried with anhydrous Na2SO4, filtered and concentrated in vacuum. HPLC indicated 52% of desired product was found.
The residue was purified by prep-HPLC. LCMS and IFINMR confirmed Compound 25 (14.2 mg, 28.8 umol, 22.6% yield). LCMS (ESI): RT = 0.842 min, mass calcd. For C22H331\17045, 491.23 m/z found 514.1 [M+231+.1H NMR (400MHz, CDC13) 6 8.64 (d, J= 2.0 Hz, 1H), 7.82 -7.72 (m, 2H), 6.84 (d, J= 9.2 Hz, 1H), 5.75 - 5.66 (m, 1H), 4.60 - 4.51 (m, 4H), 4.27 -4.21 (m, 1H), 3.61 - 3.52 (m, 1H), 2.68 (d, J = 5.6 Hz, 3H), 2.11 -2.03 (m, 2H), 1.88 - 1.77 (m, 2H), 1.69 - 1.63 (m, 1H), 1.51 (s, 9H), 1.48 - 1.36 (m, 5H).
Example 25: 4-(cyclohexylamino)-3-(2-isopropy1-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 26) N-N
rµ\]
-S
HN
Preparation of Compound 26:
NH-N N-N
n= i, NHo 26-1a(1.0 eq) 0 9µ K2CO3(2.5 eq) = 0 NH-Sµ\ -S
DMF, 80 C, MW, 0.5 hr HN
26-1 Compound 26 1002761 To a solution of 26-1 (60.0 mg, 0.2 mmol, 1.0 eq) in DMF (3.0 mL) was added K2CO3 (49.3 mg, 0.4 mmol, 2.0 eq) and 2-iodopropane 26-la (30.3 mg, 0.2 mmol, 17.8 uL, 1.0 eq). The mixture was stirred at 80 C under microwave condition for 0.5 hr.
LCMS showed 39%
of 1 was remained. Several new peaks were shown on LCMS and 55% of desired compound was detected. The reaction mixture was purified by prep-HPLC to give Compound 26 (18.86 mg, 49.8 umol, 28% yield). LCMS (ESI): RT = 0.835 min, mass calc. for C17H26N6025 378.18, m/z found 379.0 [M+H1+; 1HNMR (400MHz, CDC13) 6 (ppm) 8.63 (d, J= 2.2 Hz, 1H), 7.90 (d, J=
7.1 Hz, 1H), 7.73-7.70 (m, 1H), 6.82 (d, J= 9.0 Hz, 1H), 5.19-5.09 (m, 1H), 4.28 (q, J = 5.3 Hz, 1H), 3.55 (s, 1H), 2.67 (d, J= 5.5 Hz, 3H), 2.15-2.02 (m, 2H), 1.86-1.78 (m, 2H), 1.73 (d, J = 6.6 Hz, 6H), 1.66 (d, J= 11.9 Hz, 1H), 1.52-1.36 (m, 5H) Example 26: 4-(cyclohexylamino)-3-(2-isobuty1-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 27) N-N
/1\I
0µµ 410'0i wm-S
Preparation of Compound 27:
NH-N
N-N
1\1N µi\I Brj N
27-1a(1.0eq) 1 NHo __________________________ K2CO3(2.5 eq) NH.S DMF, 80 C, 16h µµ NFI2S 410 0 27-1 Compound 27 [00277] To a solution of 27-1 (60.0 mg, 0.2 mmol, 1.0 eq) in DMF (2.0 mL) was added K2CO3 (49.3 mg, 0.4 mmol, 2.0 eq) and 27-la (24.4 mg, 0.2 mmol, 19.4 uL, 1.0 eq). The mixture was stirred at 80 C for 16h. LCMS showed 35% of 27-1 was remained.
Several new peaks were shown on LCMS and 40% of desired compound was detected. The mixture was purified by prep-HPLC to give Compound 27 (6.53 mg, 16.6 umol, 9% yield). LCMS
(ESI): RT
= 0.863 min, mass calc. for Ci8t128N6025 392.20, m/z found 393.1 [M+1-11+;
IFINMR (400MHz, CDC13) 6 8.63 (d, J = 2.3 Hz, 1H), 7.84 (d, J = 7.0 Hz, 1H), 7.74-7.71 (m, 1H), 7.27 (s, 1H), 6.82 (d, J = 9.0 Hz, 1H), 4.50 (d, J = 7.0 Hz, 2H), 4.28 (q, J= 5.4 Hz, 1H), 3.54 (s, 1H), 2.67 (d, J=
5.5 Hz, 3H), 2.50-2.40(m, 1H), 2.12-2.03 (m, 2H), 1.87-1.78 (m, 2H), 1.67 (d, J= 12.0 Hz, 1H), 1.53-1.35 (m, 5H), 1.02 (d, J= 6.8 Hz, 6H).
Example 27: tert-butyl 4-(5-(2-(cyclohexylamino)-5-(N-methylsulfamoyl)pheny1)-tetrazol-2-yl)piperidine-1-carboxylate (Compound 28) )L0) rI\J
40 No -S
HN
Preparation of Compound 28:
Br )L0) Ii o N N Boo' 28-la (1.2 eq) oNN N1 K2CO3 (2.0 eq), N
N
DMF, 100 C, 10 h HN-SµN
I -S
HN
Compound 28 [00278] To a stirring solution of compound 28-1 (200 mg, 0.60 mmol, 1.0 eq) and K2CO3 (247 mg, 1.78 mmol, 3.0 eq) in DMF (4 mL) was added compound 28-la (251 mg, 0.95 mmol, 1.6 eq). The resulting mixture was heated to 80 C for 16 h. LCMS showed 58% of desired compound was found and 35% of the starting material was remained. The resulted mixture was heated at 100 C for 16 hr. LCMS showed 58% of desired compound was found and 35% of the starting material was remained. The mixture was cooled and poured into water (8 mL) and stirred for 5 min. The aqueous phase was extracted with ethyl acetate (8 mL*3). The combined organic phases were washed with brine (8 mL*2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a residue which was purified by flash column chromatography to give the product (160 mg, 0.28 mmol, 47% yield). The product (30 mg) was re-purified by prep-HPLC to give Compound 28 (9.64 mg). LCMS (ESI): RT = 0.880 min, mass calc. for C24H37N704S 519.26, m/z found 542.1 [M+231+; 1HNMR (400 MHz, CDC13) 6 8.61 (d, J= 2.3 Hz, 1H), 7.82 (d, J= 7.0 Hz, 1H), 7.72 (dd, J= 2.3, 9.0 Hz, 1H), 6.82 (d, J =
9.0 Hz, 1H), 4.99 -4.87 (m, 1H), 4.26 - 4.20 (m, 2H), 3.54 (s, 1H), 3.08 (s, 2H), 2.66 (d, J= 5.5 Hz, 3H), 2.35 - 2.16 (m, 4H), 2.08 (d, J= 8.8 Hz, 2H), 1.81 (d, J= 5.0 Hz, 2H), 1.67 (d, J = 10.5 Hz, 1H), 1.50 (s, 9H), 1.48 - 1.34 (m, 5H).
Example 28: 4-(cyclohexylamino)-N-methyl-3-(2-(pyridin-3-ylmethyl)-2H-tetrazol-yl)benzenesulfonamide (Compound 29) Ni/
N-N, N N
N
S
HN
Preparation of Compound 29:
1,\J-NH HBr N N N,Br 29-la (1.2 eq) N
oµµ = No K2CO3 (2.0 eq),NQ
DMF, 80 C, 3 h HN-SµN 0111 I ,S, HN
Compound 29 [00279] To a stirring solution of compound 29-1 (50 mg, 0.15 mmol, 1.0 eq) and K2CO3 (62 mg, 0.45 mmol, 3.0 eq) in DMF (1 mL) was added compound 29-la (45 mg, 0.18 mmol, 1.2 eq). The resulting mixture was heated at 100 C for 16 hr. LCMS showed 66% of desired compound was found and the starting material was consumed completely. The mixture was cooled and diluted with DMF (2 mL) and filtered. The filtrate was purified by prep-HPLC to give Compound 29 (20 mg, 46 umol, 31% yield). LCMS (ESI): RT = 0.687 min, mass calc. for C20I-125N702S 427.18, m/z found 428.1 [M+H1+; IFINMR (400 MHz, CHLOROFORM-d) 6 8.88 - 8.53 (m, 3H), 7.86 - 7.66 (m, 3H), 7.36 (s, 1H), 6.80 (d, J= 8.5 Hz, 1H), 5.86 (s, 2H), 4.22 (s, 1H), 3.52 (s, 1H), 2.65 (d, J= 4.5 Hz, 3H), 2.05 (s, 2H), 1.77 (s, 2H), 1.59 (s, 3H), 1.42 (d, J =
9.3 Hz, 5H).
Example 29: 4-(cyclohexylamino)-N-methy1-3-(2-(piperidin-4-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 30) Nj\)--/NAN
czµ No -S
Preparation of Compound 30:
)LX QH
HCl/dioxane 20 C, 1 h N
czµ N o (RI\ *
,S
30-1 Compound 30 [00280] A solution of 30-1 (130 mg, 0.25 mmol, 1.0 eq) in HC1/dioxane (3 mL) was stirred at 20 C for 1 h. LCMS showed desired compound was found and the starting material was consumed completely. The mixture was concentrated to give the product (130 mg crude).
The product (100 mg) was directly used without further purification. The product (30 mg) was purified by prep-HPLC to give Compound 30 (11.26 mg). LCMS (ESI): RT = 0.655 min, mass calc. for Ci9H29N702S 419.21, m/z found 420.1 [M+1-11+; IFINMR (400 MHz, DMSO-d6) 6 9.51 - 9.06 (m, 2H), 8.41 (d, J = 1.8 Hz, 1H), 7.66 (d, J= 8.5 Hz, 1H), 7.58 (d, J=
7.3 Hz, 1H), 7.27 (d, J = 5.0 Hz, 1H), 7.06 (d, J = 9.0 Hz, 1H), 5.39 - 5.28 (m, 1H), 3.62 (s, 1H), 3.48 - 3.44 (m, 2H), 3.19 (s, 2H), 2.47 - 2.31 (m, 7H), 2.00 (d, J= 9.3 Hz, 2H), 1.71 (s, 2H), 1.59 (s, 1H), 1.52 -1.26 (m, 5H).
Example 30: 3-(2-(1-acetylpiperidin-4-y1)-2H-tetrazol-5-y1)-4-(cyclohexylamino)-N-methylbenzenesulfonamide (Compound 31) N¨N
Oxµ 411 -NHS %%
Preparation of Compound 31:
0)L./
( joi Boc -NI\
N-NH
Br 31-la (1.5 eq) 14' Dioxane-HCI
.s K2CO3 (2.0 eq), DMF, 120 C,3 hr N
20 C, lhr N *
HN
HCI
QI
N-N AcCI (1.0eq) TEA (3.0 eq) N¨N
N
DCM,0-20 C, 1 hr HN
NH xx Compound 31 Step 1: tert-Butyl 4-(5-(2-(cyclohexylamino)-5-(N-methylsulfamoyl)pheny1)-2H-tetrazol-2-yl) piperidine-l-carboxylate [00281] To a solution of compound 31-1 (300 mg, 0.89 mmol, 1.0 eq) and compound 31-la (353 mg, 1.34 mmol, 1.5 eq) in DMF (4 mL) was added K2CO3 (247 mg, 1.78 mmol, 2.0 eq).
The reaction mixture was stirred at 120 C for 3 hours. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (30 mL) and the resultant mixture was extracted with DCM (50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford 31-2 (410 mg, 78% yield). LCMS (ESI):
RT = 0.892 min, mass calcd. for C24H37N704S 519.26, m/z found 542.3 [M+Nal+.
Step 2: 4-(Cyclohexylamino)-N-methy1-3-(2-(piperidin-4-y1)-2H-tetrazol-5-yl)benzene sulfonamide hydrochloride [00282] A solution of compound 31-2 (410 mg, 0.79 mmol, 1.0 eq) in Dioxane/HC1 (8 mL) was stirred at 20 C for 1 hour. The reaction mixture was concentrated under reduced pressure to obtain 31-3 (350 mg, 97% yield). LCMS (ESI): RT = 0.646 min, mass calcd. for C19H29N702S 419.21, m/z found 420.2 [M+H1+.
Step 3: 3-(2-(1-Acetylpiperidin-4-y1)-2H-tetrazol-5-y1)-4-(cyclohexylamino)-N-methyl benzenesulfonamide [00283] To a solution of compound 31-3 (40 mg, 88 umol, 1.0 eq, HC1) and TEA (27 mg, 0.26 mmol, 3.0 eq) in DCM (1.5 mL) was added dropwise a solution of acetyl chloride (6.9 mg, 88 umol, 1.0 eq) in DCM (0.5 mL) at 0 C. The reaction mixture was allowed to warm up to 20 C and stirred at 20 C for 1 hour. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with DCM (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely.
Compound 31 (14.47 mg, 36% yield) was obtained. LCMS (ESI): RT = 0.747 min, mass calcd.
for C21-131N703S 461.22, m/z found 462.1 [M+H1+, 1HNMR (400MHz, DMSO-d6) 6 8.41 (d, J
= 1.8 Hz, 1H), 7.74 - 7.55 (m, 2H), 7.24 (d, J= 4.0 Hz, 1H), 7.05 (d, J= 9.0 Hz, 1H), 5.30 - 5.15 (m, 1H), 4.39 (d, J= 12.3 Hz, 1H), 3.94 (d, J= 13.6 Hz, 1H), 3.76 - 3.57 (m, 1H), 3.02 - 2.88 (m, 1H), 2.42 - 2.24 (m, 4H), 2.17 - 1.85 (m, 8H), 1.80 - 1.65 (m, 2H), 1.58 (br s, 1H), 1.53 - 1.20 (m, 6H).
Example 31: 4-(cyclohexylamino)-N-methy1-3-(2-(1-(methylsulfonyl)piperidin-4-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 32) µS, µ0 N-N
0 NoNH,sµ
Preparation of Compound 32:
HCI 0, /
NH
N-N MsCI (1.0eq) N-N
N TEA (3.0 eq) LI
DCM,0-20 C, 1 hr OµI 40 NO
HN
NH-%
I
Compound 32 [00284] To a solution of compound 32-1 (40 mg, 88 umol, 1.0 eq, HC1) and TEA (27 mg, 0.26 mmol, 3.0 eq) in DCM (1.5 mL) was added dropwise a solution of MsC1 (10 mg, 88 umol, 1.0 eq) in DCM (0.5 mL) at 0 C. The reaction mixture was allowed to warm up to 20 C and stirred at 20 C for 1 hour. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with DCM (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely.
Compound 32 (19.06 mg, 44% yield) was obtained. LCMS (ESI): RT = 0.774 min, mass calcd.
for C20I-1311\1704S2 497.19, m/z found 498.1 [M+H1+, 1HNMR (400MHz, DMSO-d6) 6 8.42 (s, 1H), 7.75 - 7.51 (m, 2H), 7.35 - 7.15 (m, 1H), 7.13 - 6.95 (m, 1H), 5.25 -5.05 (m, 1H), 3.74 -3.54 (m, 3H), 3.15 - 3.05 (m, 2H), 2.95 (s, 3H), 2.38 (s, 3H), 2.28 - 2.10 (m, 3H), 2.10 - 1.90 (m, 2H), 1.83 - 1.56 (m, 3H), 1.55 - 1.17 (m, 6H).
Example 32: 4-(cyclohexylamino)-N-methy1-3-(2-(1-(pyridin-3-yl)piperidin-4-y1)-tetrazol-5-yl)benzenesulfonamide (Compound 33) N-N
=
oµµ N
-S
N µ
H,`
Preparation of Compound 33:
HCI \1\0 I)0-Br N--N
N N-N
(1.5 eq) Pd2(dba)3 (0.05 eq) N N
9, N Xantphos (0.15 eq) NH-S Cs2CO3 (3.0 eq) (:)µµ No %\
I 0 Dioxane,100 C,16 hr el -S
N
H
33-1 Compound 33 [00285] A solution of compound 33-1 (40 mg, 88 umol, 1.0 eq, HC1), compound (21 mg, 0.13 mmol, 1.5 eq) and Pd2(dba)3 (4.0 mg, 4.4 umol, 0.05 eq), Xantphos (7.6 mg, 13 umol, 0.15 eq), Cs2CO3 (86 mg, 0.26 mmol, 3.0 eq) in Dioxane (2 mL) under N2.
The suspension was degassed under vacuum and purged with N2 several times. The reaction mixture was stirred at 100 C for 16 hours. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with DCM (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely. Compound 33 (5.12 mg, 11%
yield) was obtained. LCMS (ESI): RT = 0.685 min, mass calcd. for C24H321\1802S
496.24, m/z found 497.2 [M+H1+, 1HNMR (400MHz, CDC13) 6 8.62 (d, J= 2.0 Hz, 1H), 8.56 -8.30 (m, 1H), 8.28 - 8.00 (m, 1H), 7.83 (d, J= 7.0 Hz, 1H), 7.72 (dd, J = 2.3, 9.0 Hz, 1H), 7.31 - 7.27 (m, 1H), 7.25 - 7.17 (m, 1H), 6.82 (d, J = 9.0 Hz, 1H), 5.01 -4.91 (m, 1H), 4.26 (q, J=
5.4 Hz, 1H), 3.83 (d, J= 12.8 Hz, 2H), 3.60 - 3.48 (m, 1H), 3.19 - 3.06 (m, 2H), 2.66 (d, J= 5.5 Hz, 3H), 2.56 -2.42 (m, 4H), 2.13 - 2.02 (m, 2H), 1.86 - 1.76 (m, 2H), 1.71 - 1.66 (m, 1H), 1.52 - 1.24 (m, 5H).
Example 33: 4-(cyclohexylamino)-N-methy1-3-(2-pheny1-2H-tetrazol-5-yl)benzenesulfonamide (Compound 34) sit N-N
µ1\1 czµ N
NH,Sµ`
I
Preparation of Compound 34:
N-NH
;1\1 34-2 (1.5 eq) No IR\ el Cs2CO3 (2.0 eq), Cul(0.4 eq) ,Sµ
NH' MW, DMF, 120 C, 1h NH µ,-1 I
34-1 Compound 34 [00286] To a solution of compound 34-1 (50.0 mg, 0.15 mmol, 1.0 eq) and compound 34-2 (45.5 mg, 0.22 mmol, 24.9 uL, 1.5 eq) in DMF (2.0 mL) was added Cs2CO3 (193.7 mg, 0.59 mmol, 4.0 eq) and Cul (11.3 mg, 59.4 umol, 0.4 eq). The mixture was stirred at 100 C for 3 hour at N2 atmosphere. LCMS showed desired compound was found. The reaction was filtered to give a crude product which was purified by prep-HPLC to give Compound 34 (6.48 mg, 15.1 umol, 10.2% yield) was obtained. LCMS (EST): RT = 0.839 min, mass calc. for 412.17, m/z found 413.1 [M+F11+;IHNMR (400 MHz, CDC13) 6 8.11 (s, 1H), 7.48 (dd, J = 1.8, 9.0 Hz, 1H), 7.34 - 7.24 (m, 4H), 7.22 - 7.15 (m, 2H), 6.88 (d, J= 9.0 Hz, 1H), 3.57 (s, 1H), 3.20 (s, 3H), 2.11 (d, J= 10.8 Hz, 2H), 1.88 (d, J= 8.5 Hz, 2H), 1.71 (d, J= 10.5 Hz, 1H), 1.58 - 1.52 (m, 1H), 1.49 - 1.28 (m, 4H).
Example 34: 4-(cyclohexylamino)-N-methy1-3-(2-(pyrrolidin-3-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 35) N/1\1H
N-N
NH-Sµµ
I
Preparation of Compound 35:
0 *
.N/1\1H
1\1 N-N
N
N-N HCl/dioxane NI' )1.=
N
2000, 2 h (:)µµ ei -Sµµ
0 * NH
µµ
-S
NH \\
cJ
Compound 35 [00287] A mixture of compound 35-1 (0.31 g, 0.61 mmol, 1.0 eq) in HC1/dioxane (4 M, 4 mL, 26.1 eq) stirred at 20 C for 1 hour. LCMS showed the desired compound was found. TLC
showed desired compound was found and the starting material was consumed completely. The reaction mixture was concentrated to give the crude Compound 35 (0.23 g, 0.52 mmol, 84.9%
yield, HC1). The residue was directly used without further purification. The crude product (15.0 mg) was purified by prep-HPLC to give the title compound (2.60 mg). LCMS
(ESI): RT = 0.643 min, mass calc. for C18H27N702S 405.19, m/z found 406.1 [M+1-1I;1HNMR (400 MHz, DMSO-d6) 6 9.92 (s, 1H), 9.68 (s, 1H), 8.42 (s, 1H), 7.71 - 7.45 (m, 2H), 7.30 (s, 1H), 7.05 (d, J= 8.8 Hz, 1H), 5.86 (s, 1H), 3.85 (s, 2H), 3.46 (d, J= 15.6 Hz, 2H), 2.72 - 2.57 (m, 2H), 2.36 (s, 3H), 1.99 (s, 2H), 1.70 (s, 2H), 1.58 (s, 1H), 1.49 - 1.27 (m, 5H). 1HNMR (400 MHz, Me0D-d4) 6 8.56 (d, J= 2.3 Hz, 1H), 7.72 (dd, J= 2.3, 9.0 Hz, 1H), 7.01 (d, J = 9.0 Hz, 1H), 5.96 - 5.89 (m, 1H), 4.11 -4.05 (m, 1H), 4.01 -3.93 (m, 1H), 3.70 - 3.61 (m, 3H), 2.81 -2.74 (m, 2H), 2.51 (s, 3H), 2.14 - 2.04 (m, 2H), 1.82 (dd, J= 4.5, 8.8 Hz, 2H), 1.67 (s, 1H), 1.57 -1.37 (m, 5H).
Example 35: 4-(cyclohexylamino)-3-(2-(1-isopropylpyrrolidin-3-y1)-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 36) N N
oµµ N 0 NH-Sµµ
I
Preparation of Compound 36:
/1\1H
N N N N
36-2 (1.5 eq) (:)µµ = No _______________________________________ = No K2CO3 (2.0 eq), 10µµ
HN-S DMF, 80 C, 1h NH-%
Compound 36 [00288] To a solution of compound 36-1 (30 mg, 73.9 umol, 1.0 eq) in DMF
(2.0 mL) was added K2CO3 (20.5 mg, 0.15 mmol, 2.0 eq) and compound 36-2 (18.9 mg, 0.11 mmol, 11.1 uL, 1.5 eq). The mixture was stirred at 80 C for 2 hr at N2 atmosphere. LCMS
showed desired compound was found. The reaction was filtered to give a crude product which was purified by prep-HPLC to give Compound 36 (2.48 mg, 5.3 umol, 7.2% yield) was obtained.
LCMS (ESI):
RT = 0.659 min, mass calc. for C21H331\1702S 447.60, m/z found 448.1 [M+F11+;IHNMR (400 MHz, CDC13) 6 8.62 (d, J= 2.3 Hz, 1H), 7.86 (d, J= 7.5 Hz, 1H), 7.73 (dd, J =
2.3, 9.0 Hz, 1H), 6.82 (d, J= 9.0 Hz, 1H), 5.46 (s, 1H), 4.24 (q, J= 5.4 Hz, 1H), 3.59 - 3.41 (m, 2H), 3.14 - 3.05 (m, 1H), 3.01 - 2.87 (m, 2H), 2.67 (d, J= 5.5 Hz, 3H), 2.63 - 2.52 (m, 3H), 2.07 (d, J= 5.3 Hz, 2H), 1.81 (s, 2H), 1.64 (s, 1H), 1.51 - 1.29 (m, 5H), 1.17 (d, J = 6.3 Hz, 6H).
Example 36: 4-(cyclohexylamino)-N-methy1-3-(2-(1-phenylpyrrolidin-3-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 37) N N
u m-S
Pan \\
Preparation of Compound 37:
HO-B
OH
N N N õ N
37-2(1.5 eq) (:)µµ N No DI EA (4.0 eq),Cu(OAc)2(1.5 eq) DCM, 02, rt, 24h ei No H,sµ`
Compound 37 [00289] To a solution of compound 37-1 (30 mg, 73.9 umol, 1.0 eq) and compound 37-2 (18.0 mg, 0.15 mmol, 2.0 eq) in DCM (5.0 mL) was added DIEA (38.2 mg, 0.30 mmol, 51.5 uL, 4.0 eq) and Cu(OAc)2 (20.1 mg, 0.11 mmol, 1.5 eq). The mixture was stirred at 20 C for 16 hr at 02 atmosphere. LCMS showed desired compound was found. The reaction was filtered to give a crude product. The crude product was purified by prep-HPLC to give Compound 37 (4.9 mg, 10.2 umol, 13.8% yield) was obtained. LCMS (ESI): RT = 0.912 min, mass calc.
for C24H311\1702S 481.23, m/z found 482.1 [M+F11+;IHNMR (400 MHz, CDC13-d) 6 8.61 (d, J= 2.0 Hz, 1H), 7.75 - 7.65 (m, 2H), 7.30 (s, 2H), 6.82 - 6.74 (m, 2H), 6.63 (d, J =
8.3 Hz, 2H), 5.65 (d, J = 3.3 Hz, 1H), 4.20 (d, J = 5.5 Hz, 1H), 4.06 - 3.93 (m, 2H), 3.74 (q, J=
7.9 Hz, 1H), 3.62 (dt, J = 4.1, 8.7 Hz, 1H), 3.48 (s, 1H), 2.94 - 2.85 (m, 1H), 2.78 - 2.69 (m, 1H), 2.65 (d, J= 5.5 Hz, 3H), 2.02 (s, 2H), 1.77 (s, 2H), 1.63 (s, 1H), 1.45 - 1.27 (m, 5H).
Example 37: 4-(cyclohexylamino)-N-methy1-3-(2-(1-phenylpiperidin-4-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 38) c_N)1 N-N
czµ N
NH
I
Preparation of Compound 38:
NH N
NN HOB NN
N OH 38-2(2.0 eq) (:)µµ No DIEA (4D.Oe9i),0 rt 4 Cu(OAcg(1.5 eq) czµ N
civ o -Sµ µ0 NH HCI NH
I
38-1 Compound 38 [00290] To a solution of compound 38-1 (50.0 mg, 0.12 mmol, 1.0 eq) and compound 38-2 (43.6 mg, 0.36 mmol, 3.0 eq) in DCM (5.0 mL) was added DIEA (61.6 mg, 0.47 mmol, 83.3 uL, 4.0 eq) and Cu(OAc)2 (32.5 mg, 0.18 mmol, 1.5 eq). The mixture was stirred at 25 C for 16 hr at 02 atmosphere. LCMS showed desired compound was found. The reaction was filtered to give a crude product which was purified by prep-HPLC to give Compound 38 (9.24 mg, 18.6 umol, 15.6% yield) was obtained. LCMS (ESI): RT = 0.845 min, mass calc. for 495.24, m/z found 496.2 [M+F11+;IHNMR (400 MHz, CDC13-d) 6 8.63 (d, J=2.3 Hz, 1H), 7.83 (d, J= 7.0 Hz, 1H), 7.73 (dd, J = 2.1, 8.9 Hz, 1H), 7.31 (t, J= 7.9 Hz, 2H), 7.01 (d, J= 8.0 Hz, 2H), 6.92 (t, J= 7.3 Hz, 1H), 6.82 (d, J= 9.0 Hz, 1H), 4.93 (if, J= 5.0, 10.0 Hz, 1H), 4.28 (q, J =
5.5 Hz, 1H), 3.83 (d, J= 12.8 Hz, 2H), 3.54 (s, 1H), 3.12 - 3.01 (m, 2H), 2.67 (d, J = 5.5 Hz, 3H), 2.54 - 2.42 (m, 4H), 2.08 (d, J= 9.3 Hz, 2H), 1.87 - 1.78 (m, 2H), 1.67 (d, J= 12.8 Hz, 1H), 1.50- 1.34 (m, 5H).
Example 38: 4-(cyclohexylamino)-N-methyl-3-(2-(2,2,2-trifluoroethyl)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 39) /
N-N, F
II
0õ
N
Preparation of Compound 39:
( F
Tf0 F
N-NH \-(-F ( F F
39-2 (3.6 eq) N1' N
µµ o Cs2CO3 (3.0 eq) sµ N... 0 CH3CN, 0 C-rt, 40 h 0õ N..õ(1) HN N
,S, F->r-N
N F
39-1 Compound 39 Compound 39-[00291] To a mixture of 39-1 (40.0 mg, 0.1 mmol, 1.0 eq, HC1) and Cs2CO3 (104.9 mg, 0.3 mmol, 3.0 eq) in CH3CN (3.0 mL) was added 39-2 (29.9 mg, 0.1 mmol, 1.2 eq) at 0 C. The resulted mixture was stirred at 15 C for 20 h. LCMS showed there's 16%
desired compound, and 66% starting material remained. Another 39-2 (60 mg) was added. The mixture was stirred at 15 C for 20 h. LCMS and HPLC showed the reaction was completed. The mixture was filtered, and the solid was washed with DMF (1 mL). The filtrate was purified by prep-HPLC.
Compound 39 (2.20 mg, 5.3 umol, 4.9% yield) was obtained. LCMS (ESI): RT =
0.828 min, mass calcd. for Ci6H2iF3N602S 418.14, m/z found 419.1 [M+1-11+.'H NMR (400MHz, CDC13) 6 8.67 (d, J= 2.5 Hz, 1H), 7.76 (dd, J= 2.3, 8.8 Hz, 1H), 7.60 (d, J = 7.0 Hz, 1H), 6.85 (d, J = 9.0 Hz, 1H), 5.34 - 5.28 (m, 2H), 4.25 (q, J= 5.3 Hz, 1H), 3.58 - 3.55 (m, 1H), 2.68 (d, J = 5.5 Hz, 3H), 2.08 (d, J= 10.3 Hz, 2H), 1.86 - 1.78 (m, 2H), 1.71 - 1.63 (m, 1H), 1.53 -1.36 (m, 5H).
[00292]
Compound 39-3 (6.43 mg, 12.8 umol, 12.0% yield) was obtained. LCMS (ESI):
RT = 0.910 min, mass calcd. for Ci8H22F6N602S 500.14, m/z found 501.1 [M+1-11+. NMR
(400MHz, CDC13) 6 8.63 (d, J= 2.3 Hz, 1H), 7.73 - 7.63 (m, 2H), 6.85 (d, J =
9.0 Hz, 1H), 5.32 (q, J= 7.6 Hz, 2H), 3.76 (q, J= 8.7 Hz, 2H), 3.61 - 3.51 (m, 1H), 2.92 (s, 3H), 2.09 - 2.07 (m, 2H), 1.87 - 1.76 (m, 2H), 1.69 - 1.67 (m, 1H), 1.53 - 1.35 (m, 5H).
Example 39: 4-(cyclohexylamino)-3-(2-(2-fluoroethyl)-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 40) N-NII , ,N
0 N, 4110 Preparation of Compound 40:
N-NH
z BrF
40-la (1.2 eq) Uz N
K2003 (3.0 eq) (:)µ DMF, 80 C, 2 h HN
`0 40-1 Compound 40 [00293] To a mixture of 40-1 (40.0 mg, 0.1 mmol, 1.0 eq, HC1) and K2CO3 (44.5 mg, 0.3 mmol, 3.0 eq) in DMF (2.0 mL) was added 40-la (16.3 mg, 0.1 mmol, 1.2 eq). The resulted mixture was stirred at 80 C for 2 h. The reaction was monitored by LCMS. The mixture was filtered, and the solid was washed with DMF (1 mL). The filtrate was checked by HPLC. The filtrate was purified by prep-HPLC. Compound 40 (4.48 mg, 11.7 umol, 10.9%
yield,) was obtained. LCMS (ESI): RT = 0.779 min, mass calcd. for Ci6H23FN602S 382.16, m/z found 383.1 [M+H1+. 1HNMR (400MHz, DMSO-d6) 6 8.41 (d, J = 2.0 Hz, 1H), 7.66 (dd, J= 2.0, 8.8 Hz, 1H), 7.60 (d, J= 7.5 Hz, 1H), 7.26 (q, J= 5.0 Hz, 1H), 7.05 (d, J = 9.0 Hz, 1H), 5.21 (t, J = 4.5 Hz, 1H), 5.14 (t, J= 4.5 Hz, 1H), 5.09 - 5.04 (m, 1H), 4.95 (t, J= 4.5 Hz, 1H), 3.69 - 3.60 (m, 1H), 2.37 (d, J= 4.8 Hz, 3H), 2.03 - 1.95 (m, 2H), 1.76 - 1.67 (m, 2H), 1.63 -1.55 (m, 1H), 1.51 - 1.32 (m, 5H).
Example 40: 4-(cyclohexylamino)-3-(2-(4-fluorobenzy1)-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 41) N-N
1\1, 0, N10 Preparation of Compound 41:
Br 11, N 41-2 (1.5 eq) N-N
N-N
K2CO3 (4.0 eq) IT ;1 0 DMF, 40 C,17 h N1c) H 0. ao 0õs Nr8 41-1 HN'il Compound 41 Compound 41-3 [00294] To a mixture of 41-1 (40.0 mg, 0.1 mmol, 1.0 eq, HC1) and K2CO3 (59.3 mg, 0.4 mmol, 4.0 eq) in DMF (3.0 mL), was added 41-2 (30.4 mg, 0.2 mmol, 20 uL, 1.5 eq). The resultant mixture was stirred at 40 C under N2 for 17 h. The reaction was monitored by LCMS.
The mixture was filtered, and the solid was washed with DMF (1 mL) and checked by HPLC.
The filtrate was purified by prep-HPLC. Compound 41 (6.61 mg, 14.9 umol, 13.9%
yield) was obtained. LCMS (ESI): RT = 0.868 min, mass calcd. for C21H25FN602S 444.17, m/z found 445.0 [M+H1+. 1HNMR (400MHz, DMSO-d6) 6 8.38 (d, J = 2.3 Hz, 1H), 7.63 (dd, J= 2.0, 8.8 Hz, 1H), 7.56 - 7.50 (m, 3H), 7.30 - 7.20 (m, 3H), 7.02 (d, J= 9.3 Hz, 1H), 6.05 (s, 2H), 3.66 - 3.57 (m, 1H), 2.35 (d, J= 5.0 Hz, 3H), 1.97 - 1.89 (m, 2H), 1.65 (td, J = 3.2, 6.1 Hz, 2H), 1.60 - 1.52 (m, 1H), 1.47 - 1.36 (m, 2H) , 1.35 - 1.22 (m, 3H).
[00295] Compound 41-3 (6.72 mg, 12.2 umol, 11.3% yield) was obtained, which was confirmed by LCMS and 1HNMR. LCMS (ESI): RT = 0.988 min, mass calcd. for C28H30F2N602S 552.21, m/z found 553.1 [M+H1+. NMR (400MHz, DMSO-d6) 6 8.38 (d, J =
2.3 Hz, 1H), 7.70 (dd, J= 1.9, 8.9 Hz, 1H), 7.59 (d, J= 7.5 Hz, 1H), 7.54 (dd, J = 5.6, 8.4 Hz, 2H), 7.34 (dd, J= 5.6, 8.2 Hz, 2H), 7.26 (t, J= 8.8 Hz, 2H), 7.16 (t, J = 8.8 Hz, 2H), 7.05 (d, J =
9.0 Hz, 1H), 6.06 (s, 2H), 4.06 (s, 2H), 3.69 - 3.59 (m, 1H), 1.98 - 1.89 (m, 2H), 1.65 (dd, J=
3.5, 8.8 Hz, 2H), 1.60 - 1.52 (m, 1H), 1.47 - 1.37 (m, 2H), 1.36 - 1.25 (m, 3H).
Example 41: 3-(2-(1-acetylpyrrolidin-3-y1)-2H-tetrazol-5-y1)-4-(cyclohexylamino)-N-methylbenzenesulfonamide (Compound 42) No -S
NH \\ *
Preparation of Compound 42:
/1\1H
Nr,N 0 N )(CI
N
(1.2 eq) am No __________________________________ TEA (2.5 eq) HNSN0 DCM, 10 C, 0.5 hr ` NH *
Compound 42 [00296] To the solution of compound 42-1 (30 mg, 68 umol, 1 eq, HC1) in DCM
(3 mL) was added TEA (17 mg, 0.17 mmol, 24 uL, 2.5 eq). Then acetyl chloride (6 mg, 81 umol, 6 uL, 1.2 eq) was added to the mixture. The solution was stirred at 10 C for 0.5 hr. The reaction was monitored by LCMS. The reaction was concentrated under reduced pressure.
The residue was purified by prep-HPLC to give Compound 42 (9.21 mg, 20.6 umol, 30.3%
yield). LCMS
(ESI): RT = 0.722 min, mass calcd. for C20I-129N703S 447.21, m/z found 448.1 [M+1-11+, 1HNMR
(400MHz, CHLOROFORM-d) 6 8.59 (br, 1H), 7.73 (d, J=7.8 Hz, 2H), 6.83 (d, J=8.3 Hz, 1H), 5.65 - 5.44 (m, 1H), 4.39 - 3.71 (m, 5H), 3.58 - 3.44 (m, 1H), 2.91 - 2.59 (m, 5H), 2.23 - 2.03 (m, 5H), 1.89 - 1.76 (m, 2H), 1.71 - 1.67 (m, 1H), 1.48 - 1.35 (m, 5H).
Example 42: 4-(cyclohexylamino)-N-methy1-3-(2-(1-(methylsulfonyl)pyrrolidin-3-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 43) N -N
NH
(Rµ
-S
NH µµ
Preparation of Compound 43:
N N
MsCI 11\1 (1.2 eq) CZµ la No TEA (2.5 eq) NHsµ
DCM, 10 C, 0.5 hr ifibl No , -µs µ
0 NH \µ
Compound 43 [00297] To the solution of compound 43-1 (30 mg, 68 umol, 1 eq, HC1) in DCM (3 mL) was added TEA (17 mg, 0.17 mmol, 24 uL, 2.5 eq). Then methanesulfonyl chloride (9 mg, 81 umol, 6 uL, 1.2 eq) was added to the mixture. The solution was stirred at 10 C for 0.5 hr. The reaction was monitored by LCMS. The reaction was concentrated under reduced pressure. The residue was purified by prep-HPLC to give Compound 43 (3.71 mg, 7.7 umol, 11.3%
yield). LCMS (ESI): RT = 0.754 min, mass calcd. for C19H29N704S2 483.17, m/z found 484.1 [M+H]+, 1HNMR (400MHz, CHLOROFORM-d) 6 8.57 (d, J=2.3 Hz, 1H), 7.78 - 7.71 (m, 2H), 6.84 (d, J=9.0 Hz, 1H), 5.61 -5.54 (m, 1H), 4.30 - 4.22 (m, 1H), 4.10 - 4.02 (m, 2H), 3.81 -3.73 (m, 1H), 3.70 - 3.62 (m, 1H), 3.59 - 3.50 (m, 1H), 2.95 (s, 3H), 2.79 - 2.69 (m, 2H), 2.68 - 2.66 (m, 3H), 2.13 -2.03 (m, 2H), 1.87 -1.78 (m, 2H), 1.72- 1.64 (m, 1H), 1.51 -1.41 (m, 5H).
Example 43: 4-(cyclohexylamino)-3-(2-(2-hydroxyethyl)-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 44) OH
1\11 µµ No NHS
I
Preparation of Compound 44:
OH
N-NH OH
N N Br Ck K2CO3 (2.0 eq), DMF, NH
HN-Sµµ 100 C, 16 h No 44-1 Compound 44 [00298] To a solution of compound 44-1 (30.0 mg, 89.2 umol, 1.0 eq) in DMF (2.0 mL) was added K2CO3 (24.7 mg, 0.18 mmol, 2.0 eq) and compound 44-2 (16.7 mg, 0.13 mmol, 9.5 uL, 1.5 eq). The mixture was stirred at 100 C for 16 hour at N2 atmosphere.
LCMS showed desired compound was found. The reaction was filtered to give a crude product.
The crude product was purified by prep-HPLC to give Compound 44 (6.16 mg, 16.2 umol, 18.2% yield) was obtained. LCMS (ESI): RT = 0.725 min, mass calc. for C16H24N603S 380.16, m/z found 381.0 [M+F11+;IHNMR (400 MHz, CDC13) 6 8.60 (d, J= 2.3 Hz, 1H), 7.82 (d, J =
7.0 Hz, 1H), 7.73 (dd, J = 2.3, 9.0 Hz, 1H), 6.82 (d, J = 9.0 Hz, 1H), 4.88 - 4.80 (m, 2H), 4.33 - 4.24 (m, 3H), 3.54 (s, 1H), 2.66 (d, J = 5.5 Hz, 3H), 2.30 (t, J= 6.3 Hz, 1H), 2.08 (d, J=
8.0 Hz, 2H), 1.86 -1.77 (m, 2H), 1.67 (d, J= 12.3 Hz, 1H), 1.52 - 1.35 (m, 5H).
Example 44: 4-(cyclohexylamino)-N-methy1-3-(2-(pyridin-3-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 45) N N
Nc)ICN
N I
H
Preparation of Compound 45:
OH
N-N
N-NH n'b OH
;1\1 NI' ;IV
45-la (1.2 eq) No Cou2010(00c;c052e0qh),DMSO, O.
;S
Compound 45 [00299] A solution of compound 45-1 (50 mg, 0.13 mmol, 1.0 eq, HC1), 45-la (33 mg, 0.27 mmol, 2.0 eq) and Cu20 (1 mg, 6.70 umol, 0.05 eq) in DMSO (3 mL) was degassed under vacuum and purged with 02 several times. The mixture was stirred at 100 C for 20hr. LCMS
showed that -60% of desired MS signal was detected. The reaction was filtered and concentrated. The residue was purified by prep-HPLC to give Compound 45 (2.30 mg, 5.6 umol, 4.2% yield). The HNMR and LCMS confirmed that desired product was obtained. LCMS
(ESI): RT = 2.779 min, mass calcd. for Ci9H23N7502 413.16, m/z found 414.0 [M+H1+. IFINMR
(400MHz, CDC13) 6 9.39 (s, 1H), 8.85 (s, 1H), 8.75 - 8.50 (m, 2H), 7.80 (dd, J
= 8.0 Hz, 4.8 Hz, 1H), 7.71 (dd, J= 9.2 Hz, 2.0 Hz, 1H), 7.40 - 7.25 (m, 2H), 6.86 (d, J = 9.2 Hz, 1H), 7.40 - 7.25 (m, 1H), 7.11 (d, J= 9.2 Hz, 1H), 3.65 - 3.50 (m, 1H), 2.41 (d, J = 4.8 Hz, 3H), 2.10 -2.00 (m, 2H), 1.90 - 1.75 (m, 2H), 1.75 - 1.65 (m, 2H), 1.50 -1.40 (m, 4H).
Example 45: 4-(cyclohexylamino)-3-(2-(1-isopropylpiperidin-4-y1)-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 46) and isopropyl 4-(5-(2-(cyclohexylamino)-5-(N-methylsulfamoyl)pheny1)-2H-tetrazol-2-yl)piperidine-1-carboxylate (Compound 47) o N-N N-N
;N NI ;NI
H H
011 ON =
,µS
N `0 Compound 46 Compound 47 Preparation of Compound 46 and Compound 47:
NH N
,-0 N-N
ii ;N 46-2a (1.0 1.2) N N-N
K2CO3 (2.0 eq), DMF, 80 C, 5h N-NS 0 ,NS
N ,Ns 46-1 Compound 46 ri Compound 47 [00300] To a stirred solution of 46-1 (30 mg, 66 umol, 1.0 eq, HC1) and K2CO3 (18.2 mg, 0.13 mmol, 2.0 eq) in DMF (1 mL) was added compound 46-2a (11 mg, 66 umol, 7 uL, 1.0 eq).
The resulting mixture was heated at 80 C for 5 hr. The reaction was monitored by LCMS. The reaction mixture was poured into water (3 mL) and the resulting mixture was stirred for 5 min.
The aqueous phase was extracted with ethyl acetate (3 mL*3). The combined organic phase were washed with brine (3 mL*2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a residue. The residue was purified by prep-HPLC to give Compound 46 (6 mg, 13 umol, 20 % yield) and Compound 47 (1.49 mg, 3 umol, 5% yield).
[00301] Compound 46: LCMS (EST): RT = 0.647 min, mass calc. for C22H35N702S
461.26, m/z found 462.2 [M+H]+; NMR (400 MHz, CDC13) 6 8.61 (d, J = 2.0 Hz, 1H), 7.82 (d, J = 7.3 Hz, 1H), 7.71 (dd, J = 2.1, 8.9 Hz, 1H), 6.81 (d, J= 9.0 Hz, 1H), 4.72 (quin, J= 7.5 Hz, 1H), 4.24 (q, J= 5.3 Hz, 1H), 3.52 (s, 1H), 3.03 (d, J = 11.5 Hz, 2H), 2.84 (td, J = 6.5, 13.1 Hz, 1H), 2.66 (d, J= 5.5 Hz, 3H), 2.48 - 2.37 (m, 2H), 2.33 (d, J = 3.3 Hz, 4H), 2.08 (d, J = 8.5 Hz, 2H), 1.87 - 1.75 (m, 2H), 1.66 (s, 1H), 1.51 - 1.33 (m, 5H), 1.09 (d, J =
6.5 Hz, 6H).
[00302] Compound 47: LCMS (EST): RT = 0.8648 min, mass calc. for 505.25, m/z found 528.1 [M+23]+; 1H NMR (400 MHz, CDC13) 6 8.60 (d, J = 2.3 Hz, 1H), 7.82 ( d, J = 7.3 Hz, 1H), 7.72 (dd, J = 2.3, 8.8 Hz, 1H), 6.82 (d, J = 9.0 Hz, 1H), 5.01 - 4.89 (m, 2H), 4.34 - 4.16 (m, 3H), 3.53 (s, 1H), 3.13 (t, J = 11.2 Hz, 2H), 2.66 (d, J= 5.5 Hz, 3H), 2.35 - 2.20 (m, 4H), 2.07 (d, J = 9.3 Hz, 2H), 1.81 (s, 2H), 1.65 (s, 1H), 1.50 - 1.39 (m, 5H), 1.29 (d, J = 6.3 Hz, 6H).
Example 46: 4-(cyclohexylamino)-N-methyl-3-(5-methyl-1,2,4-oxadiazol-3-yl)benzene sulfonamide (Compound 48) N9-( \ N
411, -S
HN
Preparation of Compound 48:
OH
CN
NH2OH-HCI (5.0 eq) N NH2 N N
Na2CO3 (5.0 eq) __________________________ to. AcC1 (1.1 eq) -S 0 pyridine HN 0 HN 40 Et0H,80 C, 3 hr A 100 C, 16 hr No ___________________________________________________________ 40 No -S
HN
48-2 Compound 48 Step 1: 2-(Cyclohexylamino)-N'-hydroxy-5-(N-methylsulfamoyl)benzimidamide [00303] To a solution of compound 48-1 (100 mg, 0.34 mmol, 1.0 eq) and hydroxylamine (118 mg, 1.7 mmol, 5.0 eq, HC1) in Et0H (4 mL) was added Na2CO3 (181 mg, 1.7 mmol, 5.0 eq) and then stirred at 80 C for 3 hours. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure to obtain 48-2 (90 mg, 81%
yield). LCMS (ESI):
RT = 0.604 min, mass calcd. for C14H22N403S 326.14, m/z found 326.9 [M+H1+.
Step 2: 4-(Cyclohexylamino)-N-methy1-3-(5-methy1-1,2,4-oxadiazol-3-yObenzenesulfonamide [00304] Acetyl chloride (11 mg, 0.13 mmol, 1.1 eq) was added to a solution of compound 48-2 (40 mg, 0.12 mmol, 1.0 eq) in Pyridine (1 mL). The reaction mixture was stirred at 100 C
for 16 hours. The reaction mixture was concentrated under reduced pressure.
The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely. Compound 48 (12.18 mg, 28% yield) was obtained. LCMS (ESI): RT =
1.242 min, mass calcd. for C16H22N403S 350.14, m/z found 351.0 [M+1-11+, 1HNMR (400MHz, CDC13) 6 8.59 (d, J= 2.3 Hz, 1H), 7.75 (dd, J= 2.3, 9.0 Hz, 1H), 7.29 (d, J = 7.3 Hz, 1H), 6.81 (d, J = 9.0 Hz, 1H), 4.23 (q, J= 5.2 Hz, 1H), 3.62 - 3.48 (m, 1H), 2.68 -2.63 (m, 6H), 2.12 -2.02 (m, 2H), 1.86 - 1.76 (m, 2H), 1.70 - 1.62 (m, 1H), 1.51 - 1.34 (m, 5H).
Example 47: 3-(2-(1-acetylazetidin-3-y1)-2H-tetrazol-5-y1)-4-(cyclohexylamino)-N-methylbenzenesulfonamide (Compound 49) 0)L.
/1\1 *N -S
N
Preparation of Compound 49:
p1H
N /1\I 49-la AcCI (2 eq) N /1\I
44,0 Et3N (4 eq), DCM 40 15, 2h No N N
49-1 Compound 49 [00305] To a mixture of 49-1 (25 mg, 58 umol, 1 eq, HC1) and Et3N (24 mg, 0.23 mmol, 33 uL, 4 eq) in DCM (1 mL) was added 49-la (9 mg, 0.12 mmol, 9 uL, 2 eq) in one portion at 15 C under N2. The mixture was stirred at 15 C for 2 h. LCMS showed the compound 1 was consumed completely and one main peak with desired MS was detected. The reaction mixture was concentrated under reduced pressure to remove solvent. HPLC showed 64% of desired product was formed. The residue was purified by prep-HPLC. LCMS and IFINMR
confirmed the product was Compound 49 (2.13 mg, 4.7 umol, 8.0% yield). LCMS (ESI): RT =
0.709 min, mass calcd. For Ci9H27N7035, 433.19 m/z found 434.1[M+1-11+ and 456.1[M+231+.11-1NMR
(400MHz, DMSO-d6) 6 8.43 (d, J= 2.00 Hz, 1H), 7.66 (dd, J= 8.80, 2.00 Hz, 1H), 7.60 (br s, 1H), 7.27 (br s, 1H), 7.05 (d, J= 9.20 Hz, 1H), 6.02 - 5.87 (m, 1H), 4.78 (t, J= 8.80 Hz, 1H), 4.66 - 4.56 (m, 1H), 4.53 - 4.43 (m, 1H), 4.37 - 4.27 (m, 1H), 2.37 (s, 3H), 2.36 - 2.28 (m, 1H), 2.01 - 1.91 (m, 2H), 1.85 (s, 3H), 1.74-1.64 (m, 2H), 1.61 - 1.51 (m, 1H), 1.50 - 1.31 (m, 5H).
Example 48: 4-(cyclohexylamino)-N-methyl-3-(2-(1-(methylsulfonyl)azetidin-3-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 50) tS, ONµ *N -S
N
Preparation of Compound 50:
tS, N¨N N¨N
/1\1 50-la MsCI (2 eq) 1\11 Et3N (4 eq), DCM
ON% 40 NO 15 C, 2h 9, = 0 N N
50-1 Compound 50 [00306] To a mixture of 50-1 (25 mg, 58 umol, 1 eq, HC1) and Et3N (24 mg, 0.23 mmol, 33 uL, 4 eq) in DCM (1 mL) was added 50-la (70 mg, 0.61 mmol, 47 uL, 10.5 eq) in one portion at 15 C under N2. The mixture was stirred at 15 C for 2 h. LCMS showed compound 50-1 was consumed completely and one main peak with desired MS was detected. The reaction mixture was concentrated under reduced pressure to remove solvent. HPLC showed 54% of desired product was formed. The residue was purified by prep-HPLC. LCMS and 11-1NMR
confirmed that the product was Compound 50 (4.39 mg, 9.4 umol, 16.0% yield). LCMS (ESI):
RT = 0.749 min, mass calcd. For C181-127N70452, 469.16 m/z found 470.0[M+Hr 1H NMR
(400MHz, DMSO-d6) 6 8.43 (d, J= 2.00 Hz, 1H), 7.66 (dd, J= 8.80, 2.00 Hz, 1H), 7.59 -7.46 (m, 1H), 7.30 - 7.22 (m, 1H), 7.06 (d, J = 8.80 Hz, 1H), 6.04 - 5.95 (m, 1H), 4.59 -4.41 (m, 4H), 3.70 -3.60(m, 1H), 3.17 (s, 3H), 2.38 (d, J= 4.40 Hz, 3H), 2.02- 1.94(m, 2H), 1.76 -1.67 (m, 2H), 1.64- 1.54 (m, 1H), 1.51 - 1.30 (m, 5H) Example 49: 4-(cyclohexylamino)-N-methy1-3-(2-(1-phenylazetidin-3-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 51) N-N
0%1 *Nm-S
Preparation of Compound 49:
OH
[-NH
NN
/1\1 51-1a (2 eq) N-N
DIEA (4 eq), CupAc)2 (1 eq) \1 0 = 02(15Psi),DCM,20 C, 50h Nm-S 0õ = NO
µµ
H 0 Nõ,,S
µµ
HO
51-1 Compound 51 [00307] To a mixture of 51-1 (50 mg, 0.12 mmol, 1 eq, HC1) and DIPEA (60 mg, 0.47 mmol, 4 eq) in DCM (1.5 mL) was added Cu(OAc)2 (21 mg, 0.12 mmol, 1 eq) and 51-la (29 mg, 0.23 mmol, 2 eq) in one portion under N2. The mixture was stirred at 20 C
for 50 h.
LCMS showed 24% of compound 51-1 was remained. Several new peaks were shown on LCMS
and 40% of desired compound was detected. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was diluted with water (5 mL) and extracted with EA (5 mL*3), the combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum. HPLC indicated 35% of desired product was formed. The residue was purified by prep-HPLC. LCMS and 1HNMR confirmed the product was Compound 51 (2.04 mg, 4.3 umol, 3.7% yield). LCMS (ESI): RT = 0.885 min, mass calcd. For C23H29N7025, 467.21 miz found 468.1[MA-1]-1.1H NMR (400MHz, CDC13) 6 8.63 (d, J= 2.00 Hz, 1H), 7.81 - 7.70 (m, 2H), 7.34 - 7.27(m, 2H), 6.91 - 6.78 (m, 2H), 6.59 (d, J= 8.00 Hz, 2H), 5.93 - 5.83 (m, 1H), 4.56 (t, J = 8.00 Hzõ 2H), 4.50 - 4.43 (m, 2H), 4.35 - 4.28 (m, 1H), 3.53 (br s, 1H), 2.66 (d, J=
5.20 Hz, 3H), 2.05 - 1.96 (m, 2H), 1.82 - 1.72 (m, 2H), 1.62 - 1.56 (m, 1H), 1.45 - 1.28 (m, 5H).
Example 50: 4-(cyclohexylamino)-3-(2-(1-isopropylazetidin-3-y1)-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 52) N¨N
ON\ *N -S
N
Preparation of Compound 52:
TyH
N¨N N¨N
/1\I
52-1a(1.5 eq) OIN 4110 K2000,3 (4 eq), DMF 0µµ 40 NO
60 C 2h N -S
N N
52-1 Compound 52 [00308] To a mixture of 52-1 (30 mg, 70 umol, 1 eq, HC1) and K2CO3 (39 mg, 0.28 mmol, 4 eq) in CH3CN (2 mL) was added 52-la (18 mg, 0.10 mmol, 1.5 eq) in one portion under N2.
The mixture was stirred at 40 C for 2 h. LCMS showed the starting material was remained and no desired MS was detected. The reaction mixture was added DMF (1 mL) and heated to 60 C
for 2 h. LCMS showed 30% of compound 52-1 was remained. Several new peaks were shown on LCMS and 25%of desired compound was detected. The reaction mixture was concentrated under reduced pressure to remove CH3CN. The residue was diluted with water (3 mL) and extracted with EA(5 mL * 3). The combined organic layers were dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC. LCMS and 1HNMR confirmed the product was Compound 52 (3.55 mg, 8.2 umol, 11.7% yield).
LCMS
(ESI): RT = 0.663 min, mass calcd. For C201-131N7025, 433.23 m/z found 434.1[M+H1+.1H NMR
(400MHz, CDC13) 6 13.39 (br s, 1H), 8.60 (br s, 1H), 7.75 (br d, J = 8.40 Hz, 2H), 6.84 (br d, J
= 8.40 Hz, 1H), 6.17 (br s, 1H), 4.96 (br s, 2H), 4.48 (br s, 2H), 3.67 (br s, 1H), 3.54 (br s, 1H), 2.65 (br s, 3H), 2.10 -2.04 (m, 2H), 1.87 - 1.78 (m, 2H), 1.69 - 1.66 (m, 1H), 1.51 - 1.40 (m, 11H).
Example 51: 3-(2-(1-acetylpiperidin-3-y1)-2H-tetrazol-5-y1)-4-(cyclohexylamino)-N-methylbenzenesulfonamide (Compound 53) N N
-S
N
Preparation of Compound 53:
QN1--C) N-N
N N HCl/dioxane (4 eq) N Ac20 (1 eq), TEA (3 eq), N ,N
HNS\,r, Nko DCM,15 C, = 0 DCM, 0-15 C, 1 25 h N N
53-1 53-2 Compound 53 Step 1: 4-(cyclohexylamino)-N-methy1-3-(2-(piperidin-3-y1)-2H-tetrazol-5-yl)benzenesulfonamide [00309] To a mixture of compound 53-1 (0.26 g, 500 umol, 1 eq) in DCM (2 mL) was added HC1/dioxane (1 M, 2 mL, 4.0 eq). The mixture was stirred at 15 C for 1 h. The crude LCMS showed 95% of desired product was detected. The reaction mixture was concentrated under reduced pressure to give a residue as a light yellow solid. The residue was diluted with Me0H (5 mL) and water (5 mL), and the most of Me0H was removed under reduced pressure, the remaining aqueous was lyophilized to give compound 53-2 (210 mg, 460 umol, 92% yield, HC1). 20 mg of the solid was purified by prep-HPLC to give 53-2 (2.19 mg).
LCMS (ESI): RT =
2.089 min, mass calc. for C19H29N702S 419.54, m/z found 420.0 [M+11+. 1HNMR
(400 MHz, METHANOL-d4) 6 1.23 - 2.27 (m, 16 H), 2.33 - 2.58 (m, 4 H), 2.90 (s, 1 H), 3.36 - 3.52 (m, 3 H), 3.65 (br s, 1 H), 4.29 (br s, 1 H), 5.04 - 5.46 (m, 2 H), 7.01 (br d, J=
9.29 Hz, 1 H), 7.72 (br d, J = 7.03 Hz, 1 H), 8.58 (s, 1 H).
Step 2: 3-(2-(1-acetylpiperidin-3-y1)-2H-tetrazol-5-y1)-4-(cyclohexylamino)-N-methylbenzenesulfonamide [00310] To a mixture of compound 53-2 (30 mg, 65.8 umol, 1 eq, HC1) and TEA (20.0 mg, 197 umol, 27.5 uL, 3 eq) in DCM (1 mL) was added Ac20 (6.7 mg, 65.8 umol, 6.2 uL, 1 eq) in one portion at 0 C and stirred for 15 min. The mixture was stirred at 15 C for 1 h. The crude LCMS showed 85% of desired product was detected. The reaction mixture was quenched by water (10 mL) and extracted with DCM (10 mL* 4). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue (25 mg) as colorless oil. The residue was purified by prep-HPLC to give Compound 53 (2.41 mg, 5.1 umol, 7.8% yield). LCMS (ESI): RT = 2.047 min, mass calc. for C2,H311\1703S 461.58, m/z found 462.1 [M+11+. 1HNMR (400 MHz, DMSO-d6, t=80 C) 6 1.29 - 1.54 (m, 6 H), 1.57 - 1.76 (m, 4 H), 1.79 - 1.93 (m, 1 H), 1.95 - 2.07 (m, 5 H), 2.23 - 2.36 (m, 1 H), 2.44 (s, 4 H), 3.27 -3.51 (m, 1 H), 3.59 - 3.80 (m, 2 H), 4.88 - 5.17 (m, 1 H), 6.89 - 7.05 (m, 2 H), 7.48 (br d, J=
7.53 Hz, 1 H), 7.67 (dd, J = 8.78, 2.26 Hz, 1 H), 8.44 (d, J= 2.26 Hz, 1 H).
Example 52: 3-(2-(azetidin-3-y1)-2H-tetrazol-5-y1)-4-(cyclohexylamino)-N-methylbenzenesulfonamide (Compound 54) TTH
0õ 40-S
HN
Preparation of Compound 54:
o ,7N
HCl/dioxane N--N
rt, 2h N
0õ = 9 NO % * -S
HN
HN NO -S% / 0 54-1 Compound 54 [00311] To a mixture of 54-1 (12 mg, 24.4 umol, 1.0 eq) in Me0H (1 mL) was added HC1/dioxane (4 M, 3 mL, 492 eq). The reaction mixture was stirred at 15 C
for 2 h. LCMS showed the starting material was consumed completely and one main peak with desired MS was detected. The reaction mixture was concentrated under reduced pressure to remove solvent. HPLC showed 92% of desired product was formed. The residue was purified by prep-HPLC. LCMS and 1HNMR confirmed the product was Compound 54 (4.30 mg, 10.1 umol, 41.2% yield, HC1). LCMS (ESI): RT = 0.646 min, mass calcd. For Ci7H25N7025, 391.18 m/z found 392.1[M+Hr1H NMR (400MHz, DMSO-d6) 6 9.96 - 9.57 (m, 2H), 8.43 (d, J= 2.40 Hz, 1H), 7.73 - 7.63 (m, 1H), 7.60 - 7.42 (m, 1H), 7.36 - 7.22 (m, 1H), 7.07 (d, J= 9.20 Hz, 1H), 6.15 - 6.02 (m, 1H), 4.61 - 4.51 (m, 4H), 3.67 - 3.63 (m, 1H), 2.37 (s, 3H), 2.04 - 1.94 (m, 2H), 1.79 - 1.67 (m, 2H), 1.64 - 1.53 (m, 1H), 1.50 - 1.29 (m, 5H).
Example 53: 4-(cyclohexylamino)-N-methyl-3-(pyrimidin-5-yl)benzenesulfonamide (Compound 55) N N
HN,sµ`
I
Preparation of Compound 55:
NN
, NN
0õ0 Br No 55-2(1.5 eq) ________________________________________ )1. (:)µµ
Na2003(2.0 eq), el No HN-S\` Pd(dppf)c12(0.1 eq) I HN(Sµ) 55-1 .., dioxane/H20, 90 C,1 6 h 1 ""
Compound 55 [00312] To a solution of compound 55-1 (50.0 mg, 0.13 mmol, 1.0 eq) and compound 2 (30.2 mg, 0.19 mmol, 1.5 eq) in dioxane (5.0 mL) was added H20 (0.5 mL), Pd(dppf)C12 (9.3 mg, 12.7 umol, 0.1 eq) and Na2CO3 (26.9 mg, 0.25 mmol, 2.0 eq). The mixture was stirred at 90 C for 16 hours under N2 atmosphere. LCMS showed desired compound was found.
The reaction was filtered through Celite and concentrated under reduced pressure to give a residue. The crude product was purified by prep-HPLC to give Compound 55 (5.25 mg, 14.7 umol, 11.6% yield).
LCMS (EST): RT = 0.695 min, mass calc. for C17H22N402S 346.15, m/z found 347.0 [M+H1+;
1HNMR (400 MHz, CDC13-d) 6 9.28 (s, 1H), 8.82 (s, 2H), 7.76 (dd, J= 2.3, 8.8 Hz, 1H), 7.51 (d, J= 2.3 Hz, 1H), 6.78 (d, J= 8.8 Hz, 1H), 4.34 (q, J = 5.3 Hz, 1H), 3.99 (d, J
= 7.5 Hz, 1H), 3.43 - 3.32 (m, 1H), 2.68 (d, J = 5.5 Hz, 3H), 2.04 - 1.97 (m, 2H), 1.78 - 1.70 (m, 2H), 1.45 - 1.32 (m, 2H), 1.29 - 1.06 (m, 4H).
Example 54: 4-(cyclohexylamino)-N-methyl-3-(pyrimidin-2-yl)benzenesulfonamide (Compound 56) N N
oµµ No HN,Sµ`
I
Preparation of Compound 56:
Nõ.1 N
0õ0 CI N N
56-2 (1.5 eq) µµ N10 HN,sµ` Na2CO3(2.0 eq), O\ =
No Pd(dpp0c12(0.1 eq) HN-S\r`
56-1 , THF/H20, 70 C,16 h '-Compound 56 [00313] To a solution of compound 56-1 (50.0 mg, 0.13 mmol, 1.0 eq) and compound 56-2 (21.8 mg, 0.19 mmol, 1.5 eq) in H20 (0.5 mL) was added THF (3.0 mL), Pd(dppf)C12 (9.3 mg, 12.7 umol, 0.1 eq) and Na2CO3 (26.9 mg, 0.25 mmol, 2.0 eq). The mixture was stirred at 70 C
for 16 hours under N2 atmosphere. LCMS showed desired compound was found. The reaction was filtered through Celite and concentrated under reduced pressure to give a residue. The crude product was purified by prep-HPLC to give Compound 56 (2.51 mg, 7.2 umol, 5.7%
yield).
LCMS (EST): RT = 0.793 min, mass calc. for C17H22N402S 346.15, m/z found 347.0 [M+H1+;
1HNMR (400 MHz, CDC13-d) 6 9.76 (d, J= 6.8 Hz, 1H), 9.11 (d, J = 2.3 Hz, 1H), 8.78 (d, J =
5.0 Hz, 2H), 7.72 (dd, J= 2.4, 8.9 Hz, 1H), 7.16 (t, J = 4.9 Hz, 1H), 6.81 (d, J = 9.0 Hz, 1H), 4.20 (q, J = 5.4 Hz, 1H), 3.56 (s, 1H), 2.67 (d, J= 5.5 Hz, 3H), 2.07 (d, J=
5.5 Hz, 2H), 1.85 -1.76 (m, 2H), 1.67 (d, J= 11.5 Hz, 1H), 1.53 - 1.36 (m, 5H).
Example 55: 4-(cyclohexylamino)-N-methyl-3-(1-methyl-1H-pyrazol-3-yl)benzenesulfonamide (Compound 57) /
N
0µµ *-S
NH µµ
Preparation of Compound 57:
0,,0 /
B157-1a (1.3 eq) µN No __________________ Na2CO3 (2.0 eq)). 0 *
Pd(dppf)C12 (0.1 eq) NH H20/Dioxane -SµN NH-S\
100 C, 4 hr I b 57-1 Compound 57 [00314] To the solution of compound 57-1 (50 mg, 0.13 mmol, 1 eq) in dioxane (3 mL) and H20 (0.15 mL) was added compound 57-la (27 mg, 0.16 mmol, 1.3 eq), Na2CO3 (27 mg, 0.25 mmol, 2 eq) and Pd(dppf)C12 (9 mg, 12.7 umol, 0.1 eq). The mixture was stirred at 100 C for 4 hr under N2 atmosphere. The reaction was monitored by LCMS. The reaction was concentrated under reduced pressure. The reaction solution was concentrated under reduced pressure. The residue was purified by prep-HPLC to give Compound 57 (2.06 mg, 5.9 umol, 4.7% yield). LCMS (ESI): RT = 0.784 min, mass calcd. for C17H24N402S 348.16, m/z found 349.1 [M+H1+, 1HNMR (400MHz, CDC13) 6 8.33 (d, J= 7.5 Hz, 1H), 7.99 (d, J =
2.3 Hz, 1H), 7.63 - 7.56 (m, 1H), 7.41 (d, J = 2.5 Hz, 1H), 6.74 (d, J= 9.0 Hz, 1H), 6.66 (d, J= 2.5 Hz, 1H), 4.15 (q, J= 5.4 Hz, 1H), 3.96 (s, 3H), 3.58 - 3.46 (m, 1H), 2.64 (d, J= 5.5 Hz, 3H), 2.08 - 2.01 (m, 2H), 1.84 - 1.74 (m, 2H), 1.68 - 1.61 (m, 1H), 1.51 - 1.36 (m, 5H).
Example 56: 4-(cyclohexylamino)-N-methyl-3-(1-methyl-1H-1,2,3-triazol-4-yl)benzenesulfonamide (Compound 58) N-N
0õ 40 N
-S
HN O
Preparation of Compound 58:
________________________________________________________________ B-13 --( Br cr NH2 Br MeNH2, 2M solution Br 0 F inTHF (2.0 eq) 0 58-2A (1.5 eq) 58-3A (1.5 eq) ti HN¨S = HN-1 DMSO, 140 C, 2 hr Pd(dppf)Cl2 (0.05 eq) Cl' DCM, 20 C, 4 hr / 6 0 AcOK
(2.0 eq) Dioxane,95 C, 16 hr N-Kr Ny-) N¨N/
0õ0 Br 58-4A (1.0 eq) 140 NO Pd(dppf)Cl2 (0.05 eq) HN' NO
Na2CO3 (2.0 eq) Dioxane:H20 = 10 :1 0 I 100 C, 16 hr 584 Compound 58 Step 1: 3-Bromo-4-fluoro-N-methylbenzenesulfonamide [00315] To a solution of compound 58-1 (1.0 g, 3.7 mmol, 1.0 eq) in DCM (8 mL) was added MeNH2 (2 M, 3.7 mL, 2.0 eq). The reaction mixture was stirred at 20 C
for 4 hours. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (15 mL) and the resultant mixture was extracted with DCM (30 mL * 2). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure to obtain the title compound (950 mg, 97 % yield).
Step 2: 3-Bromo-4-(cyclohexylamino)-N-methylbenzenesulfonamide [00316] A solution of compound 58-2 (950 mg, 3.54 mmol, 1.0 eq) and compound 58-2A
(879 mg, 8.86 mmol, 1.0 mL, 2.5 eq) in DMSO (6 mL) was stirred at 140 C for 2 hours. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (20 mL) and the resultant mixture was extracted with EA (40 mL * 2). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound (1.2 g, 98% yield). LCMS (ESI): RT = 0.801 min, mass calcd. for C13H19BrN202S
347.27, m/z found 348.9 [M+H]+.
Step 3: 4-(Cyclohexylamino)-N-methy1-3-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-yl)benzenesulfonamide [00317] A solution of compound 58-3 (230 mg, 0.662 mmol, 1.0 eq), compound (252 mg, 0.993 mmol, 1.5 eq), Pd(dppf)C12 (24 mg, 33 umol, 0.05 eq) and AcOK
(130 mg, 1.32 mmol, 2.0 eq) in dioxane (4 mL) was heated to 95 C and stirred at 95 C for 16 hours under N2.
The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (20 mL) and the resultant mixture was extracted with EA (50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel (to afford the title compound (240 mg, 92% yield). LCMS (ESI): RT = 0.886 min, mass calcd. for 394.34, m/z found 395.1 [M+H1+.
Step 4: 4-(Cyclohexylamino)-N-methy1-3-(5-methy1-1,2,4-oxadiazol-3-yl)benzenesulfonamide [00318] Compound 58-4 (50 mg, 0.13 mmol, 1.0 eq), compound 58-4A (21 mg, 0.13 mmol, 1.0 eq), Pd(dppf)C12 (4.6 mg, 6.3 umol, 0.05 eq) and Na2CO3 (27 mg, 0.26 mmol, 2.0 eq) in Dioxane (2 mL) and H20 (0.2 mL) was de-gassed and then stirred at 100 C
for 16 hours under N2. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (25 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (5 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely.
Compound 58 (2.13 mg, 4.8% yield) was obtained. LCMS (ESI): RT = 0.740 min, mass calcd.
for C16H23N502S 349.45, m/z found 350.0 [M+H1+, 1HNMR (400MHz, CDC13-d) 6 8.29 (d, J=
7.3 Hz, 1H), 7.89 (s, 1H), 7.83 (d, J = 2.3 Hz, 1H), 7.60 (dd, J= 2.1, 8.9 Hz, 1H), 6.77 (d, J= 8.8 Hz, 1H), 4.25 - 4.20 (m, 1H), 4.18 (s, 3H), 3.56 - 3.44 (m, 1H), 2.63 (d, J =
5.5 Hz, 3H), 2.11 -2.00 (m, 2H), 1.86 - 1.77 (m, 2H), 1.69 - 1.61 (m, 1H), 1.50 - 1.28 (m, 5H).
Example 57: tert-butyl 3-(5-(2-(cyclohexylamino)-5-(N-methylsulfamoyl)pheny1)-tetrazol-2-yl)piperidine-1-carboxylate (Compound 59) and tert-butyl 34542-(cyclohexylamino)-5-(N-methylsulfamoyl)pheny1)-1H-tetrazol-1-yl)piperidine-1-carboxylate (Compound 60) QN--e 0\ N=N
NI ;NI
laN1 czµ N
No CZ\ SI
NH"
,Sµ
NH o Compound 59 Compound 60 Preparation of Compound 59 and Compound 60:
QN--e 0 0 TsCI (1.05 eq) TEA (2 eq), NaBH4 (1.1 eq)).._ DMAP (0.1 eq) HO Me0H, 0-15 C, HO DCM, 0-15 C 17h Ts0 0-+
59-1 18 h 59-2 59-3 N-N
N ,N 0 Q. = N,0 S. N-N 0-+
0\NO-NN=
NH :N
0 /1\1 59-3a(1 eq) N
59-3 (1.2 eq), K2CO3 (4 eq), N , = o DMF,120 C, MW, 1 h Rµ 40 .s NH µ`
,S
NH 'b 0 Compound 59 Compound 60 Step 1: tert-butyl 3-hydroxypiperidine-1-carboxylate [00319] Compound 59-1 (3.50 g, 17.57 mmol, 1.0 eq) was dissolved in Me0H
(150 mL) and cooled to 0 C, NaBH4 (731.1 mg, 19.3 mmol, 1.1 eq) was added. The mixture was stirred at 0 C for 2 hours and then at 15 C for 16 h. The crude LCMS showed the desired product MS value was detected. The reaction mixture was quenched by saturated aq. NH4C1 (20 mL) and water (30 mL) and then extracted with DCM (50 mL* 4). The combined organic layers were dried over Na2SO4, filtered and concentrated under pressure to give a residue. The residue was purified by flash silica gel chromatography to give compound 59-2 (1.80 g, 8.94 mmol, 50.9% yield) as a colorless oil, which solidified upon standing. 1HNMR (400 MHz, CDC13) 6 1.17 - 1.58 (m, 12 H), 1.74 (m, 1 H), 1.88 (s, 1 H), 2.94 - 3.16 (m, 2 H), 3.55 (br s, 1 H), 3.64 -3.82 (m, 2 H).
Step 2: tert-butyl 3-(tosyloxy)piperidine-1-carboxylate [00320] A mixture of compound 59-2 (1.0 g, 4.97 mmol, 1.0 eq), 4-methylbenzenesulfonyl chloride (995 mg, 5.22 mmol, 1.05 eq) and TEA (1.01 g, 9.94 mmol, 1.38 mL, 2.00 eq) in DCM (50.00 mL) was stirred at 0 C for 5 min under N2.
Then DMAP (60.7 mg, 0.50 mmol, 0.10 eq) was added, and the mixture was stirred at 0 C for 1 h.
Then the mixture was stirred at 15 C for 16 h. The crude LCMS showed the desired product MS
value was detected. The reaction mixture was quenched by water (35 mL) and extracted with DCM (10 mL
*3). The combined organic layer was washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography to give compound 59-3 (0.5 g, 1.41 mmol, 28.3%
yield) as colorless oil. 1HNMR (400 MHz, CDC13) 6 1.38- 1.47 (m, 11 H) 1.67- 1.86 (m, 3 H) 2.43 (s, 3 H) 3.14 -3.45 (m, 3 H) 3.54 (d, J= 13.01 Hz, 1 H) 4.44 (s, 1 H) 7.33 (d, J= 7.94 Hz, 2 H) 7.79 (d, J=
8.16 Hz, 2H).
Step 3: tert-butyl 3-(5-(2-(cyclohexylamino)-5-(N-methylsulfamoyl)pheny1)-2H-tetrazol-2-yl)piperidine-1-carboxylate (Compound 59) and tert-butyl 3-(5-(2-(cyclohexylamino)-5-(N-methylsulfamoyl)pheny1)-1H-tetrazol-1-yl)piperidine-1-carboxylate (Compound 60) [00321] Compound 59-3a (0.05 g, 0.15 mmol, 1.0 eq), compound 59-3 (63.4 mg, 0.18 mmol, 1.2 eq) and K2CO3 (82.2 mg, 0.59 mmol, 4.0 eq) were taken up into a microwave tube in DMF (2 mL) .The sealed tube was heated at 80 C for 1 h under microwave.
Then the sealed tube was heated at 120 C for 1 h under microwave. TLC indicated compound 3 was consumed completely and one new spot formed. The reaction mixture was filtered. The filtrate was quenched by water (15 ml) and extracted with Et0Ac (15 mL* 3). The combined organic layers were washed with brine (10 mL*2), dried over with anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC
to give Compound 59 (4.33 mg, 8.0 umol, 5.4% yield) and Compound 60 (5.47 mg, 10.5 umol, 7.1% yield).
[00322] Compound 59: LCMS (ESI): RT = 2.405 min, mass calc. for C24H37N704S
519.66, m/z found 464.0 [M-551+; NMR (400 MHz, CDC13) 6 1.27 - 1.57 (m, 17 H), 1.66 (s, 1 H), 1.83 - 1.93 (m, 2 H), 1.94 - 2.03 (m, 1 H), 2.09 (s, 2 H), 2.67 (d, J=
5.52 Hz, 3 H), 3.22 -3.48 (m, 2 H), 3.53 (br s, 1 H), 4.23 (s, 1 H), 4.29 - 4.51 (m, 1 H), 4.66 ( d, J= 12.55 Hz, 1 H), 4.77 - 4.99 (m, 2 H), 6.82 (d, J= 9.03 Hz, 1 H), 7.70 - 7.75 (m, 1 H), 7.80 (s, 1 H) 8.62 (br s, 1 H).
[00323] Compound 60: LCMS (ESI): RT = 2.485 min, mass calc. for C24H37N704S
519.66, m/z found 464.0 [M-551+; IFINMR (400 MHz, CDC13) 6 1.45 (s, 14 H), 1.69 (s, 2 H), 1.81 (s, 2 H), 1.91 - 2.16 (m, 3 H), 2.27 (s, 1 H), 2.40 (s, 1 H), 2.66 (d, J=
5.27 Hz, 3 H), 3.05 (s, 1 H), 3.53 (br s, 2 H), 4.00 (d, J= 13.05 Hz, 1 H), 4.15 -4.55 (m, 2 H), 4.85 (s, 1 H), 6.81 (d, J=
9.03 Hz, 1 H), 7.72 (d, J= 7.78 Hz, 1 H), 7.83 (d, J= 6.27 Hz, 1 H), 8.61 (br s, 1 H).
Example 58: 4-(cyclohexylamino)-3-(2-(1-isopropylpiperidin-3-y1)-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 61) QN--( N-N
N
czµ scN
,S
N
H
Preparation of Compound 61:
I y QN--( QNH
61-la (1.2 eq) N-N
N N K2CO3 (4 eq) N N
DMF, 60 C, 1 h.
N1c) CZµ
S
HO N
H
61-1 Compound 61 [00324] To a mixture of compound 61-1 (30 mg, 65.8 umol, 1.0 eq, HC1) and K2CO3 (36.4 mg, 0.26 mmol, 4.0 eq) in DMF (1 mL) was added compound 61-la (16.8 mg, 98.7 umol, 9.9 uL, 1.5 eq) in one portion at 15 C under N2. The mixture was stirred at 60 C
for 2 h. The crude LCMS showed 84% of the desired product was detected. The reaction mixture was filtered. The filtrate was quenched by water (10 mL) and extracted with Et0Ac (15 mL* 3).
The combined organic layer was washed with brine (10 mL* 2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue (18 mg) as colorless oil. The residue was purified by prep-HPLC to give Compound 61 (2.10 mg, 4.4 umol, 6.7% yield).
LCMS (ESI):
RT = 2.457 min, mass calc. for C22H35N702S 461.62, m/z found 462.1 [M+11+.
Example 59: 4-(cyclohexylamino)-N-methyl-3-(2-(1-(methylsulfonyl)piperidin-3-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 62) s,.
* NO
0\
\m Preparation of Compound 62:
s, MsCI (31.85 eq), N j TEA (3 eq) N I
N
411 DCM, 000, 1 h S
x NJ' *
62-1 Compound 62 [00325] To a mixture of compound 62-1 (20 mg, 43.9 umol, 1.0 eq, HC1) and TEA (13.3 mg, 0.13 mmol, 18.3 uL, 3.0 eq) in DCM (1 mL) was added MsC1 (0.16 g, 1.40 mmol, 0.11 mL, 31.8 eq) in one portion at 0 C.The mixture was stirred at 0 C for 1 h. The crude LCMS showed 62% of the desired product was detected. The reaction mixture was diluted with DCM (20 mL), washed with brine (15 mL) and concentrated under reduced pressure to give a residue (21 mg). The residue was purified by prep-HPLC to give Compound 62 (2.49 mg, 5.0 umol, 11.4%
yield). LCMS (ESI): RT = 2.171 min, mass calc. for C201-131N704S2 497.63, m/z found 498.0 [M+1]+; 1H NMR (400 MHz, DMSO-d6) 6 1.24- 1.51 (m, 5 H), 1.58 (s, 1 H), 1.67-1.85 (m, 3 H), 1.98 (s, 3 H), 2.24 - 2.33 (m, 1 H), 2.37 (d, J= 5.02 Hz, 4 H), 2.94 (s, 3 H), 3.09 (t, J = 9.03 Hz, 1 H), 3.36 - 3.46 (m, 2 H), 3.53 -3.72 (m, 2 H), 3.92 (dd, J= 11.80, 3.26 Hz, 1 H), 5.17 (dt, J = 7.97, 4.17 Hz, 1 H), 7.05 (d, J = 9.29 Hz, 1 H), 7.25 (q, J= 5.02 Hz, 1 H), 7.59 (d, J= 7.53 Hz, 1 H), 7.65 (dd, J= 8.91, 2.13 Hz, 1 H), 8.42 (d, J = 2.26 Hz, 1 H).
Example 60: 4-(cyclohexylamino)-N-methy1-3-(2-(1-phenylpiperidin-3-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 63) N-NoN 411 N N
oµN N
-S
N
H
Preparation of Compound 63:
QNH HO , OH N-No N-N N 63-la (3 eq) I' Cu(OAc)2 (1.2 eq) _________________________________________ )1-o Nio iDjcIPmEA40( 40ceq)1,60h2, clµx 1.1 0 N -NS
N
63-1 Compound 63 [00326] To a mixture of compound 63-1 (40 mg, 87.7 umol, 1.0 eq, HC1) and compound 63-la (32.1 mg, 0.26 mmol, 3 eq) in DCM (1 mL) were added Cu(0Ac)2 (19.1 mg, 0.11 mmol, 1.2 eq) and DIPEA (45.4 mg, 0.35 mol, 61.1 uL, 4 eq) in one portion at 15 C
under 02. The mixture was stirred at 40 C for 16 h. The crude LCMS showed 40% of the desired product was detected. The reaction mixture was purified by flash silica gel chromatography to give a product (34 mg), which was further purified by prep-HPLC to still give an impure product (9 mg). The impure product was further purified by prep-HPLC to give Compound 63 (2.23 mg, 4.5 umol, 5.1% yield). LCMS (ESI): RT = 2.070 min, mass calc. for C25H33N702S 495.64, m/z found 496.1 [M+11+. 1HNMR (400 MHz, CDC13) 6 1.33 - 1.44 (m, 3 H), 1.48 - 1.72 (m, 4 H), 1.81 (br s, 2 H), 1.88 -2.01 (m, 1 H), 2.02 - 2.14 (m, 3 H), 2.29 - 2.41 (m, 1 H), 2.42 -2.53 (m, 1 H), 2.67 (d, J = 5.27 Hz, 3 H), 2.94 - 3.06 (m, 1 H), 3.41 - 3.60 (m, 2 H), 3.65 (br d, J=
12.30 Hz, 1 H), 4.05 (br d, J = 12.05 Hz, 1 H), 4.23 (q, J = 5.44 Hz, 1 H), 4.98 - 5.12 (m, 1 H), 6.83 (d, J= 9.03 Hz, 1 H), 6.91 (t, J= 7.28 Hz, 1 H), 7.00 (d, J= 8.28 Hz, 2 H), 7.27 - 7.34 (m, 2 H), 7.73 (dd, J = 8.78, 2.01 Hz, 1 H), 7.87 (br d, J= 7.03 Hz, 1 H), 8.64 (d, J = 2.01 Hz, 1 H).
Example 61: 4-(cyclohexylamino)-N-methyl-3-(pyridin-2-yl)benzenesulfonamide (Compound 64) NQ
CI%
NH-µS%
Preparation of Compound 64:
N)1 NI /
Br 64-1a (1.5 eq) µµ Nlo XPhos Pd G 11 (0.1 eq) OSJ
dioxane, 80 C, 22 h ___________________________ c N0 ,S m N
64-1 Compound 64 [00327] To a mixture of compound 64-1 (40 mg, 0.12 mmol, 1.0 eq) and compound 64-la (63.6 mg, 0.17 mmol, 1.5 eq) in dioxane (1 mL) was added XPhos Pd G II (9.1 mg, 11.5 umol, 0.1 eq) in one portion at 15 C under N2. The mixture was stirred at 80 C for 22 hours. The crude LCMS showed 43% of the desired product was detected. The reaction mixture was quenched by water (10 mL) and extracted with Et0Ac (15 mL*3). The combined organic layer was washed with brine (15 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC to give Compound 64 (2.34 mg, 6.8 umol, 4.7% yield). LCMS (ESI): RT = 2.280 min, mass calc. for C18H23N302S 345.46, miz found 346.0 [M+11+.1HNMR (400 MHz, CDC13) 6 1.24 - 1.50 (m, 5 H), 1.64 (br d, J=
12.55 Hz, 1 H), 1.71 - 1.84 (m, 2 H), 2.04 (br d, J= 8.78 Hz, 2 H), 2.64 (d, J= 5.52 Hz, 3 H), 3.43 - 3.55 (m, 1 H), 4.28 (q, J = 5.44 Hz, 1 H), 6.78 (d, J= 9.03 Hz, 1 H), 7.24 (ddd, J= 6.59, 4.83, 1.88 Hz, 1 H), 7.66 (dd, J = 8.91, 2.13 Hz, 1 H), 7.74 - 7.84 (m, 2 H), 8.07 (d, J= 2.26 Hz, 1 H), 8.53 - 8.69 (m, 1 H), 9.25 (br d, J= 6.78 Hz, 1 H).
Example 62: 4-(cyclohexylamino)-N-methyl-3-(pyridin-4-yl)benzenesulfonamide (Compound 65) NH,\S0µµ
Preparation of Compound 65:
1\1 Ho BL
Br OH 65-1a(1.5 eq) N10K3PO4 (4 eq), XPhos Pd G11(0.1 eq) H20, Dioxane, 80 C, 16 h NHµ HN,µSµµ
I
65-1 Compound 65 [00328] To a mixture of compound 65-1 (40 mg, 0.12 mmol, 1.0 eq) and compound 65-la (21.2 mg, 0.18 mmol, 1.5 eq) in dioxane (1 mL) was added K3PO4 (3 M, 0.15 mL, 4.0 eq) in one portion at 15 C under N2. The mixture was stirred at 15 C for 5 min, then XPhos Pd G 11 (9.1 mg, 11.5 umol, 0.1 eq) was added, and the mixture was heated to 80 C and stirred for 16 hours. The crude LCMS showed 31% of the compound 1 was remained and 22% of the desired product was detected. The resulting reaction mixture was quenched by water (15 mL), and then extracted with Et0Ac (20 mL*3). The combined organic layer was washed with brine (15 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC to give Compound 65 (3.34 mg, 9.8 umol, 4.2% yield). LCMS (ESI): RT = 1.933 min, mass calc. for C181-123N302S 345.46, m/z found 346.0 [M+11+; 1HNMR (400 MHz, CDC13) 6 1.09 - 1.28 (m, 3 H), 1.33 - 1.46 (m, 2 H), 1.63 (br d, J =
4.02 Hz, 1 H), 1.69 - 1.78 (m, 2 H), 2.00 (br dd, J= 12.55, 3.01 Hz, 2 H), 2.67 (d, J= 5.52 Hz, 3 H), 3.30 - 3.43 (m, 1 H), 4.27 (br d, J= 7.53 Hz, 1 H), 4.37 (q, J= 5.27 Hz, 1 H), 6.74 (d, J =
9.03 Hz, 1 H), 7.32 - 7.40 (m, 2 H), 7.52 (d, J = 2.26 Hz, 1 H), 7.72 (dd, J=
8.78, 2.26 Hz, 1 H), 8.72 (d, J = 5.77 Hz, 2 H).
Example 63: 4-(cyclohexylamino)-N-methyl-3-(5-methyl-1H-1,2,4-triazol-3-yl)benzenesulfonamide (Compound 66) N
\NA *
H
NO
Preparation of Compound 66:
NH
CN )(NH2 HCI
N
NN No o 66-1A (1.5 eq) N
,S CuBr (0.05 eq) * No H Cs2003 (3.0 eq) \m S
DMSO, 120 C, 4 hr 66-1 Compound 66 [00329] To a solution of compound 66-1 (100 mg, 0.34 mmol, 1.0 eq), compound 66-1A
(48 mg, 0.51 mmol, 1.5 eq, HC1) and Cs2CO3 (333 mg, 1.02 mmol, 3.0 eq) in DMSO
(2 mL) was added CuBr (2.4 mg, 17 umol, 0.05 eq). The reaction mixture was stirred at 120 C for 4 hours under air. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL * 2). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely.
Compound 66 (28.07 mg, 24% yield) was obtained. LCMS (ESO: RT = 0.705 min, mass calcd. for C16H23N502S 349.45, m/z found 349.9 [M+H1+, 1HNMR (400MHz, DMSO-d6) 6 13.92 (s, 1H), 8.42 (s, 1H), 8.35 - 8.16 (m, 1H), 7.53 (dd, J= 2.1, 8.9 Hz, 1H), 7.13 - 7.05 (m, 1H), 6.89 (d, J=
9.0 Hz, 1H), 3.64 - 3.53 (m, 1H), 2.44 (s, 3H), 2.36 (d, J= 5.0 Hz, 3H), 2.02 -1.92 (m, 2H), 1.76 - 1.66 (m, 2H), 1.63 - 1.52 (m, 1H), 1.49 - 1.39 (m, 2H), 1.38 - 1.28 (m, 3H).
Example 64: 4-(cyclohexylamino)-3-(1,5-dimethy1-1H-1,2,4-triazol-3-y1)-N-methylbenzenesulfonamide (Compound 67) rN( N ,N
czN No ,S
N
H
Preparation of Compound 67:
N,õN
0õ0 tiN
Br N
67-1A (1.0 eq) = No czµ N o 0, Pd(dppf)C12 (0.05 eq)=
,S Na2CO3 (2.0 eq) N ,S
H o Dioxane:H20 = 10 :1 N
100 C, 16 hr H
67-1 Compound 67 [00330] Compound 67-1 (50 mg, 0.13 mmol, 1.0 eq), compound 67-1A (22 mg, 0.13 mmol, 1.0 eq), Pd(dppf)C12 (4.6 mg, 6.3 umol, 0.05 eq) and Na2CO3 (27 mg, 0.25 mmol, 2.0 eq) in Dioxane (2 mL) and H20 (0.2 mL) was degassed and then stirred at 100 C for 16 hours under N2. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA
(25 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (5 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely. Compound 67 (6.75 mg, 15%
yield) was obtained. LCMS (ESI): RT = 0.742 min, mass calcd. for C17H25N502S
363.48, m/z found 364.0 [M+H1+, 1HNMR (400MHz, DMSO-d6) 6 8.38 (d, J= 2.3 Hz, 1H), 8.22 (d, J= 7.5 Hz, 1H), 7.52 (dd, J= 2.3, 8.8 Hz, 1H), 7.14 - 7.07 (m, 1H), 6.89 (d, J = 8.8 Hz, 1H), 3.86 (s, 3H), 3.64 - 3.53 (m, 1H), 2.48 (s, 3H), 2.36 (d, J= 5.0 Hz, 3H), 2.02 - 1.92 (m, 2H), 1.76 - 1.66 (m, 2H), 1.63 - 1.53 (m, 1H), 1.50 - 1.29 (m, 5H).
Example 65: 4-(cyclohexylamino)-N-methy1-3-(2-(1-(pyridin-3-yl)pyrrolidin-3-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 68) _01\
0 No NH-S0µµ
Preparation of Compound 68:
NF\J
N
I-Boc N-N, ,H p-Boc N-N
N
Br 68-la (1.2 eq) N N HCl/Dioxane (4M, 6mL) C lei No ________________________ K2CO3 (1.5 eq) NoDioxane, 10 C, 1 hr Z\ KI (0.3 eq) 0 ,S
NH µ` DMF, 100 C, 16 hr µ`s H
N N Br j\l-N
(1.3eq) N N
No _____________________________________ Pd2(dba)3 (0.02 eq) CZµ Xantphos (0.06 eq) 4/1 ,S HN Cs2CO3 (3.0 eq) 0 I Dioxane, 100 C, 16 hr NH-%
68-3 Compound 68 Step 1: tert-butyl 3-(5-(2-(cyclohexylamino)-5-(N-methylsulfamoyl)pheny1)-2H-tetrazol-2-yppyrrolidine-1-carboxylate [00331] To the solution of compound 68-1 (200 mg, 0.59 mmol, 1.0 eq) in DMF
(2 mL) was added compound 68-la (178 mg, 0.71 mmol, 1.2 eq), KI (30 mg, 0.18 mmol, 0.3 eq) and K2CO3 (123 mg, 0.89 mmol, 1.5 eq). The mixture was stirred at 100 C for 16 hr. The reaction was monitored by TLC. The reaction solution was washed with H20 (10 mL). The mixture was extracted with Et0Ac (10 mL). The organic layer was washed with H20 (10 mL).
The organic layer was dried with Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography) to give compound 68-2 (180 mg, 0.35 mmol, 58%
yield).
Step 2: 4-(cyclohexylamino)-N-methy1-3-(2-(pyrrolidin-3-y1)-2H-tetrazol-5-yl)benzene sulfonamide [00332] To the solution of compound 68-2 (180 mg, 0.36 mmol, 1 eq) in dioxane (6 mL) was added HC1/dioxane (4 M, 6 mL, 67 eq). The mixture was stirred at 10 C
for 1 hr. The reaction was monitored by TLC. TLC showed that the starting material was consumed and a new spot with larger polarity was observed. The reaction solution was concentrated under reduced pressure to give compound 68-3 (170 mg, crude, HC1).
Step 3: 4-(cyclohexylamino)-N-methy1-3-(2-(1-(pyridin-3-yl)pyrrolidin-3-y1)-2H-tetrazol-5-yl)benzenesulfonamide [00333] To the solution of compound 68-3 (170 mg, 0.38 mmol, 1 eq, HC1) in dioxane (5 mL) was added 3-bromopyridine (79 mg, 0.5 mmol, 48 uL, 1.3 eq), Pd2(dba)3 (7 mg, 7.7 umol, 0.02 eq), Cs2CO3 (376 mg, 1.2 mmol, 3 eq), Xantphos (13 mg, 23 umol, 0.06 eq).
The mixture was stirred at 100 C for 16 hr. The reaction was monitored by LCMS. The reaction was concentrated under reduced pressure. The reaction solution was concentrated under reduced pressure. The residue was purified by prep-HPLC to give Compound 68 (8.66 mg, 17.9 umol, 4.7% yield). LCMS (EST): RT = 0.670 min, mass calcd. for C23H30N802S 482.22, m/z found 483.1 [M+H1+,1HNMR (400MHz, CDC13) 6 8.60 (d, J=2.3 Hz, 1H), 8.10 - 8.02 (m, 2H), 7.75 -7.65 (m, 2H), 7.18 (dd, J = 4.5, 8.3 Hz, 1H), 6.93 - 6.89 (m, 1H), 6.81 (d, J=
9.0 Hz, 1H), 5.72 -5.63 (m, 1H), 4.27 (q, J= 5.5 Hz, 1H), 4.05 - 3.95 (m, 2H), 3.80 - 3.72 (m, 1H), 3.68 - 3.61 (m, 1H), 3.56 - 3.45 (m, 1H), 2.96 - 2.87 (m, 1H), 2.82 - 2.70 (m, 1H), 2.65 (d, J= 5.5 Hz, 3H), 2.09 - 1.97 (m, 2H), 1.83 - 1.72 (m, 2H), 1.49 - 1.23 (m, 6H).
Example 66: 4-(cyclohexylamino)-N-methy1-3-(pyrimidin-4-yl)benzenesulfonamide (Compound 69) N
czµ N
NH,SµN
I
Preparation of Compound 69:
ryN
0,13'0 CI N
10µµ N 69-2 (1.5 eq) µµQ
Na2003(2.0 eq), (:) = N
NH,Sµ` Pd(dppf)Cl2(0.1 eq) I
69-1 THF/H20, 90 C,16 h I L' Compound 69 [00334] To a solution of compound 69-1 (50.0 mg, 0.13 mmol, 1.0 eq) and compound 69-2 (21.8 mg, 0.19 mmol, 1.5 eq) in H20 (0.5 mL) was added dioxane (5 mL), Pd(dppf)C12 (9.3 mg, 12.7 umol, 0.1 eq) and Na2CO3 (26.9 mg, 0.25 mmol, 2.0 eq). The mixture was stirred at 90 C for 16 hour under N2 atmosphere. LCMS showed desired compound was found. The reaction was filtered through Celite and concentrated under reduced pressure to give a residue. The crude product was purified by prep-HPLC to give Compound 69 (4.99 mg, 14.4 umol, 11.4% yield).
LCMS (EST): RT = 0.748 min, mass calc. for Ci7H22N402S 346.15, m/z found 346.9 [M+H1+;
1HNMR (400 MHz, CDC13-d) 6 9.71 (d, J= 7.0 Hz, 1H), 9.18 (d, J = 1.0 Hz, 1H), 8.76 (d, J =
5.8 Hz, 1H), 8.21 (d, J = 2.0 Hz, 1H), 7.79 (dd, J= 1.0, 5.8 Hz, 1H), 7.70 (dd, J= 2.0, 9.0 Hz, 1H), 6.83 (d, J= 9.3 Hz, 1H), 4.29 (q, J= 5.5 Hz, 1H), 3.54 (s, 1H), 2.66 (d, J= 5.5 Hz, 3H), 2.09- 2.02(m, 2H), 1.80 (d, J= 4.8 Hz, 2H), 1.66 (d, J= 11.0 Hz, 1H), 1.52-1.35 (m, 5H).
Example 67: 4-(cyclohexylamino)-N-methy1-3-(2-(1-(pyridin-3-yl)azetidin-3-y1)-tetrazol-5-yl)benzenesulfonamide (Compound 70) N-N
OµN
N -S
N
Preparation of Compound 70:
NH
Br N
1;1*---N 1\1*
Al\I N-N
70-1a(1.5 eq) Al\I
Cs2CO3 (4.0 eq), Xantphos (0.15 eq) , 410 Pd2dba3 (0.08 eq),dioxane,100 C, 16h 4/10 0, N
N
HO
70-1 Compound 70 [00335] To a mixture of 70-1 (80 mg, 0.19 mmol, 1 eq, HC1) and Cs2CO3 (244 mg, 0.748 mmol, 4 eq) in dioxane (4 mL) was added Pd2(dba)3 (14 mg, 15 umol, 0.08 eq) and Xantphos (16 mg, 28 umol, 0.15 eq) and 3-bromopyridine (70-1a) (44 mg, 0.28 mmol, 1.5 eq) in one portion under N2.The mixture was stirred at 100 C for 16 h. The reaction was monitored by LCMS. The reaction mixture was diluted with water (10 mL) and extracted with EA (15 mL *
3). The combined organic layers were dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The reaction was monitored by LCMS. The residue was purified by prep-HPLC. LCMS
and 1HNMR confirmed the product was Compound 70 (2.73 mg, 5.8 umol, 3.1%
yield). LCMS
(ESI): RT = 2.083 min, mass calcd. For C22H28N802S, 468.21 m/z found 469.0[M+Hr 1H NMR
(400MHz, CDC13) 6 8.64 (d, J= 2.40 Hz, 1H), 8.19- 8.12(m, 1H), 8.01 (d, J=
2.40 Hz, 1H), 7.80 - 7.70 (m, 2H), 7.24 - 7.17 (m, 1H), 6.92 - 6.85 (m, 1H), 6.82 (d, J=
9.20 Hz, 1H), 6.00 -5.86 (m, 1H), 4.63 (t, J = 8.00 Hz, 2H), 4.58 - 4.50 (m, 2H), 4.32 - 4.24 (m, 1H), 3.60 - 3.49 (m, 1H), 2.66 (d, J= 5.60 Hz, 3H), 2.05 - 1.98 (m, 2H), 1.82 - 1.71 (m, 2H), 1.66 -1.62 (m, 1H), 1.46- 1.27 (m, 5H).
Example 68: 4-(cyclohexylamino)-3-(2-cyclopropy1-2H-tetrazol-5-y1)-N-methylbenzene sulfonamide (Compound 71) N ' N
HN-S*%
Preparation of Compound 71:
N-NH (H0)2B NN
71-2 (1.5 eq) N
N Na2CO23,(B41.0eRq),D,CiuN(Ecri5 c)2e(q1.
2 py )5 eq), CZ\
HN
HN DOE,,µ` *
60 C, 4 h /
71-1 Compound 71 [00336] To a solution of compound 71-1 (0.1 g, 0.30 mmol, 1.0 eq) and compound 71-2 (30.6 mg, 0.36 mmol, 1.2 eq) in DCE (5.0 mL) was added Cu(OAc)2 (81.0 mg, 0.45 mmol, 1.5 eq) Na2CO3 (74.0 mg, 0.89 mmol, 3.0 eq) and 2,21-BIPYRIDINE (69.6 mg, 0.45 mmol, 1.5 eq).
The mixture was stirred at 60 C for 4 hr at N2 atmosphere. LCMS showed the desired compound. The reaction was filtered through Celite and concentrated under reduced pressure to give a residue. The crude product was purified by prep-HPLC to give Compound 71 (2.33 mg, 6.2 umol, 2.1% yield). LCMS (ESI): RT = 0.813 min, mass calc. for C17H24N602S
376.17, m/z found 377.2 [M+F11+;IHNMR (400 MHz, CDC13) 6 8.41 (s, 2H), 7.69 (d, J= 8.0 Hz, 1H), 6.87 (d, J = 7.0 Hz, 1H), 4.60 (s, 1H), 3.53 (s, 1H), 2.70 (s, 3H), 2.13 - 1.97 (m, 2H), 1.84 (s, 3H), 1.65 (s, 1H), 1.44 (s, 5H), 0.85 - 0.57 (m, 4H). 1HNMR (400 MHz, DMSO-d6) 6 8.47 (s, 2H), 7.71 - 7.61 (m, 1H), 7.11 - 7.02 (m, 1H), 3.64 (s, 1H), 2.65 (s, 3H), 2.00 (s, 2H), 1.82 (s, 1H), 1.74 (d, J= 15.6 Hz, 2H), 1.58 (s, 1H), 1.50 - 1.29 (m, 5H), 0.75 - 0.63 (m, 4H).
Example 69: 4-((4,4-difluorocyclohexyl)amino)-N-methy1-3-(2-methyl-2H-tetrazol-yl)benzenesulfonamide (Compound 72) N-N
lel 07F
-S
HN
Preparation of Compound 72:
ON -FON
eµµ F HCI H2N
72-1A(1.2eq) _________________________________________________ 0 l 07 NaN3(3.0 eq) ,S F NH4CI (3.0 eq), -S
N
TEA (1.2 eq) HN F DMF, 120 C, 16 hr DMS0,140 C, 2h I
N-N
N-NH
N N
N N
Mel(1.0 eq) Si 0- K2CO3(1.5 eq), HN
,S
,S
HN F DMF, 80 C, 0.5 h MW I 0 I
72-3 Compound 72 Step 1: 3-Cyano-4-((4,4-difluorocyclohexyl)amino)-N-methylbenzenesulfonamide [00337] To a stirring solution of compound 72-1A (96 mg, 0.56 mmol, 1.2 eq, HC1) and TEA (57 mg, 0.56 mmol, 1.2 eq) in DMSO (1.5 mL) was added compound 72-1 (100 mg, 0.47 mmol, 1.0 eq). The reaction mixture was stirred at 140 C for 16 hours. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (50 mL *
3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound (100 mg, 65% yield).
Step 2: 4-((4,4-Difluorocyclohexyl)amino)-N-methy1-3-(2H-tetrazol-5-yl)benzenesulfonamide [00338] A
solution of compound 72-2 (100 mg, 0.30 mmol, 1.0 eq), NaN3 (59 mg, 0.91 mmol, 3.0 eq) and NH4C1 (49 mg, 0.91 mmol, 3.0 eq) in DMF (4 mL) was stirred at 120 C for 16 hours. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. LCMS (ESI): RT = 0.697 min, mass calcd. for C14HI8F2N602S 372.12, m/z found 373.0 [M+1-11+.
Step 3: 4-((4,4-Difluorocyclohexyl)amino)-N-methyl-3-(2-methyl-2H-tetrazol-5-yl)benzenesulfonamide [00339] Compound 72-3 (90 mg, 0.24 mmol, 1.0 eq), CH3I (34 mg, 0.24 mmol, 1.0 eq) and K2CO3 (50 mg, 0.36 mmol, 1.5 eq) were taken up into a microwave tube in DMF (3 mL).
The sealed tube was heated at 80 C for 30 min under microwave. The reaction mixture was concentrated under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely. Compound 72 (15.34 mg, 16%
yield) was obtained. LCMS (ESI): RT = 0.735 min, mass calcd. for C15H20F2N602S
386.13, m/z found 387.0 [M+H1+, 1HNMR (400MHz, DMSO-d6) 6 8.40 (d, J= 2.3 Hz, 1H), 7.68 (dd, J=
2.3, 8.8 Hz, 1H), 7.56 (d, J= 7.5 Hz, 1H), 7.32 - 7.22 (m, 1H), 7.16 - 7.09 (m, 1H), 4.48 (s, 3H), 3.92 - 3.80 (m, 1H), 2.38 (d, J= 3.3 Hz, 3H), 2.15 - 2.01 (m, 6H), 1.68 - 1.54 (m, 2H).
Example 70: 4-((3,3-difluorocyclohexyl)amino)-N-methyl-3-(2-methyl-2H-tetrazol-yl)benzenesulfonamide (Compound 73) N-N
Ii LF
ON N
HNS\No Preparation of Compound 73:
CN
N o/_F F _____________________________________________________________ µµ 73-la (1.2eq) NaN3(3.0 eq) ,S
,S NH4CI (3.0 eq), HN
I TEA (1.2eq) HN
0 DMF, 120 C, 5 hr DMS0,140 C, 16 hr N-N
N-NH
ii N
N N
01 NI0(_ Mel (15 eq) ____________________________________________ v=- 0µ
µµ K2CO3 (1.5 eq), HN,\Sµ`
,S
HN DMF, 80 C, 0.5 h MW 0 73-3 Compound 73 Step 1: 3-Cyano-4-((3,3-difluorocyclohexyl)amino)-N-methylbenzenesulfonamide [00340] To a stirring solution of compound 73-la (53 mg, 0.39 mmol, 1.2 eq, HC1) and TEA (40 mg, 0.39 mmol, 1.2 eq) in DMS0 (1.5 mL) was added compound 73-1 (70 mg, 0.32 mmol, 1.0 eq). The reaction mixture was stirred at 140 C for 16 hours. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (50 mL *
3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound (70 mg, 65% yield) as a light yellow solid. LCMS (ESI): RT = 0.700 min, mass calcd.
for C14H17F2N302S 329.10, m/z found 329.9 [M+H1+.
Step 2: 4-((3,3-Difluorocyclohexyl)amino)-N-methyl-3-(2H-tetrazol-5-yObenzenesulfonamide [00341] A solution of compound 73-2 (70 mg, 0.21 mmol, 1.0 eq), NaN3 (41 mg, 0.64 mmol, 3.0 eq) and NH4C1 (34 mg, 0.64 mmol, 3.0 eq) in DMF (4 mL) was stirred at 120 C for 5 hours. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. LCMS (ESI): RT = 0.701 min, mass calcd. for C14H18F2N602S 372.12, m/z found 373.0 [M+H1+.
Step 3: 4-((3,3-Difluorocyclohexyl)amino)-N-methyl-3-(2-methyl-2H-tetrazol-5-yObenzenesulfonamide [00342] Compound 73-3 (70 mg, 0.24 mmol, 1.0 eq), CH3I (400 mg, 2.82 mmol, eq) and K2CO3 (39 mg, 0.28 mmol, 1.5 eq) were taken up into a microwave tube in DMF (3 mL).
The sealed tube was heated at 80 C for 30 min under microwave. The reaction mixture was concentrated under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely. Compound 73 (9.83 mg, 14%
yield) was obtained. LCMS (ESI): RT = 0.733 min, mass calcd. for C15H20F2N602S
386.13, m/z found 387.0 [M+H1+, 1HNMR (400MHz, DMSO-d6) 6 8.40 (d, J= 2.3 Hz, 1H), 7.72 -7.61 (m, 2H), 7.32 - 7.22 (m, 1H), 7.07 (d, J= 9.0 Hz, 1H), 4.48 (s, 3H), 3.98 - 3.85 (m, 1H), 2.46 - 2.36 (m, 4H), 2.11 - 1.74 (m, 5H), 1.70 - 1.56 (m, 1H), 1.56 - 1.44 (m, 1H).
Example 71: 4-(cyclohexylamino)-N-methy1-3-(2-(piperidin-3-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 74) and 4-(cyclohexylamino)-N-methy1-3-(1-(piperidin-3-y1)-1H-tetrazol-5-yl)benzenesulfonamide (Compound 75) QNH
N-N HN-\
_________________________________________________ N I
14' 1%\1 r --N
0 N *
N H
-S /
N
H
Compound 74 Compound 75 Preparation of Compound 74 and Compound 75:
N-N
N , N
.0 N'O
0 S.
TsCI (1.05 eq),TEA (2 eq), Q C) NH0 o*. DMAP (0.1 eq) N¨
I 74-2a (1 eq) HO DCM, 0-25 C, 38 h Ts0 74-2 (1.4 eq), K2CO3 (4 eq), 74-1 74-2 DMF,120 C, 17 h N-N
N HCl/dioxane (47.24 eq) ____________________________________________ )1-N1c) DCM,15 C, 1 h C\lµ 4111 S
NHb NN
HO
74-3 Compound 74 HN¨)¨
N=N
N
--N
HCl/dioxane (15.99 eq) 10µµ DCM,15 C, 1 h NH-2S%
-S
NH µ`
Compound 75 Step 1: tert-butyl 3-(tosyloxy)piperidine-1-carboxylate [00343] A mixture of compound 74-1 (0.75 g, 3.73 mmol, 1.00 eq), 4-methylbenzenesulfonyl chloride (0.74 g, 3.91 mmol, 1.05 eq) and TEA (0.75 g, 7.45 mmol, 1.03 mL, 2.0 eq) in DCM (20 mL) was stirred at 0 C for 5 min under N2. Then DMAP
(45.5 mg, 0.37 mmol, 0.1 eq) was added, and the mixture was stirred at 0 C. The mixture was stirred at 15 C
for 16 h. Reaction was monitored by LCMS and TLC. 373 mg of 4-methylbenzenesulfonyl chloride and TEA (0.5 mL) were added, and then the mixture was stirred at 15 C for 2 h. The mixture was stirred at 25 C for 20 h.. The reaction mixture was quenched by water (10 mL) and brine (20 mL), and then extracted with DCM (10 mL *3). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography to give the compound 74-2 (841 mg, 2.37 mmol, 63.5% yield) as a colorless oil, which solidified upon standing.
1HNMR (400 MHz, CDC13) 6 1.39 - 1.51 (m, 10 H), 1.65 - 1.99 (m, 3 H), 2.45 (s, 3 H), 3.28 (s, 1 H), 3.33 - 3.48 (m, 2 H), 3.56 (d, J= 12.05 Hz, 1 H), 4.46 (s, 1 H), 7.35 (d, J= 8.28 Hz, 2 H), 7.81 (d, J= 8.28 Hz, 2 H).
Step 2: tert-butyl 3-(5-(2-(cyclohexylamino)-5-(N-methylsulfamoyl)pheny1)-2H-tetrazol-2-yl)piperidine-1-carboxylate and tert-butyl 3-(5-(2-(cyclohexylamino)-5-(N-methylsulfamoyl)pheny1)-1H-tetrazol-1-yl)piperidine-1-carboxylate [00344] To a mixture of compound 74-2a (0.2 g, 0.59 mmol, 1 eq) and compound 74-2 (295.8 mg, 0.83 mmol, 1.4 eq) in DMF (5 mL) was added K2CO3 (328.7 mg, 2.38 mmol, 4 eq) in one portion. The mixture was stirred at 120 C for 17 hours. The reaction mixture was filtered off, and then quenched by water (20 mL), extracted with Et0Ac (20 mL* 3). The combined organic layer was washed with brine (20 mL*2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography to give the product as light yellow oil (175 mg), which was further purified by prep-HPLC to give compound 74-3 (11 mg, 20.1 umol, 3.4% yield) and compound 74-4 (65 mg, 121.3 umol, 20.4% yield).
[00345] Compound 74-3: LCMS (ESI): RT = 2.405 min, mass calc. for 519.66, m/z found 464.0 [M-551+; 1HNMR (400 MHz, CDC13) 6 1.28 - 1.53 (m, 14 H), 1.67 (d, J
= 11.80 Hz, 2 H), 1.82 (s, 3 H), 1.88 (s, 1 H), 1.97 (d, J = 7.03 Hz, 1 H), 2.08 (d, J = 4.52 Hz, 2 H), 2.67 (d, J= 5.52 Hz, 3 H), 3.24 - 3.48 (m, 2 H), 3.53 (br s, 1 H), 4.19 -4.45 (m, 2 H), 4.61 -4.73 (m, 1 H), 4.79 - 5.01 (m, 2 H), 6.82 (d, J = 9.03 Hz, 1 H), 7.73 (dd, J=
9.03, 2.26 Hz, 1 H), 7.79 (d, J= 5.77 Hz, 1 H), 8.62 (br s, 1 H).
[00346] Compound 74-4: LCMS (ESI): RT = 2.461 min, mass calc. for 519.66, m/z found 464.0 [M-551+; 1HNMR (400 MHz, CDC13) 6 1.35 - 1.53 (m, 15 H), 1.63 -1.75 (m, 2 H), 1.78 - 1.88 (m, 2 H), 1.98 (s, 1 H), 2.08 (d, J= 5.52 Hz, 2 H), 2.27 (d, J= 11.04 Hz, 1 H), 2.36 - 2.50 (m, 1 H), 2.67 (d, J = 5.52 Hz, 3 H), 3.06 (t, J = 11.04 Hz, 1 H), 3.54 (br s, 2 H), 3.91 - 4.07 (m, 1 H), 4.24 (q, J= 5.52 Hz, 1 H), 4.33 (s, 1 H), 4.80 -4.95 (m, 1 H), 6.82 (d, J = 9.03 Hz, 1 H), 7.73 (dd, J = 9.03, 2.26 Hz, 1 H), 7.83 (br d, J= 7.03 Hz, 1 H), 8.62 (d, J=
2.51 Hz, 1 H).
Step 3: 4-(cyclohexylamino)-N-methy1-3-(2-(piperidin-3-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 74) [00347] To a mixture of compound 74-3 (11 mg, 21.2 umol, 1 eq) in DCM (1 mL) was added HC1/Me0H (1 M, 1 mL, 47.2 eq). The mixture was stirred at 15 C for 1 h.
The crude LCMS showed 98% of the desired product was detected. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC to give Compound 74 (2.47 mg, 5.2 umol, 24.6% yield, HC1). LCMS (ESI): RT = 2.083 min, mass calc.
for C19H29N702S 419.54, m/z found 420.0 [M+F11+;IHNMR (400 MHz, METHANOL-d4) 6 1.28 - 1.59 (m, 5 H), 1.62 - 1.73 (m, 1 H), 1.82 (dd, J= 9.03, 3.76 Hz, 2 H), 1.90 -2.03 (m, 1 H), 2.03 - 2.26 (m, 4 H), 2.37 - 2.49 (m, 1 H), 2.51 (s, 3 H), 3.35 - 3.51 (m, 2 H), 3.60 - 3.71 (m, 1 H), 4.29 (br d, J = 9.03 Hz, 1 H), 5.11 (dd, J = 14.93, 9.41 Hz, 1 H), 5.30 (dd, J= 15.06, 3.26 Hz, 1 H), 7.00 (d, J= 9.03 Hz, 1 H), 7.71 (dd, J= 9.03, 2.26 Hz, 1 H), 8.57 (d, J =
2.26 Hz, 1 H).
Step 4: 4-(cyclohexylamino)-N-methy1-3-(1-(piperidin-3-y1)-1H-tetrazol-5-yl)benzenesulfonamide (Compound 75) [00348] To a mixture of compound 74-4 (65 mg, 0.12 mmol, 1 eq) in DCM (2 mL) was added HC1/Me0H (1 M, 2 mL, 16.0 eq) in one portion. The mixture was stirred at 15 C for 1 hour. The crude LCMS showed 99% of the desired product was detected and HPLC
showed the reaction was completed. The reaction mixture was concentrated under reduced pressure to give Compound 75 (62 mg, crude, HC1). 12 mg of the product was diluted with Me0H
(0.2 mL) and water (2 mL), then the most of the solvent was removed under reduced pressure, the remaining aqueous layer was lyophilized to give Compound 75 (2.32 mg, HC1). The remaining product (50 mg) was used in the next step without further purification.
[00349] Compound 75: LCMS (ESI): RT = 2.053 min, mass calc. for C19H29N702S
419.54, m/z found 420.0 [M+H1+; 1HNMR (400MHz, METHANOL-d4) 6 1.60- 1.39 (m, 5H), 1.70 (d, J= 12.5 Hz, 1H), 1.84 (dd, J= 4.0, 9.5 Hz, 2H), 1.96 (td, J = 4.7, 9.2 Hz, 1H), 2.15 -2.03 (m, 3H), 2.53 (s, 3H), 2.52 - 2.40 (m, 2H), 3.18 - 3.08 (m, 1H), 3.30 (br s, 1H), 3.75 - 3.63 (m, 2H), 3.86 - 3.77 (m, 1H), 5.23 (dd, J= 3.8, 7.8 Hz, 1H), 7.02 (d, J = 9.0 Hz, 1H) , 7.73 (dd, J
= 2.5, 9.0 Hz, 1H), 8.58 (d, J = 2.5 Hz, 1H).
Example 72: 3-(6-aminopyridin-2-y1)-4-(cyclohexylamino)-N-methylbenzenesulfonamide (Compound 76) \ NH2 N
1_,K1-µS
Preparation of Compound 76:
c,NH2 Br 76-la (1.3 eq) \ NH2 / \ Na2CO3 (3.0 eq) --N
0,13,0 Pd(dppf)C12 (0.1 eq) R la NO H20/dioxane(1/10) -\S
80 C,16 h HN
HN-Sµ` / 0 76-1 Compound 76 [00350] To a suspension of compound 76-1 (50 mg, 0.13 mmol, 1 eq) and 76-la (29 mg, 0.16 mmol, 1.3 eq) in mix solution of dioxane (1.5 mL) and H20 (0.15 mL) were added Pd(dppf)C12 (9 mg, 13 umol, 0.1 eq) and Na2CO3 (40 mg, 0.38 mmol, 3 eq) in one portion under N2. The resulting mixture was stirred at 80 C for 16 h. LCMS showed the starting material was consumed completely and 44% of desired product was formed. The reaction mixture was diluted with water (10 mL) and extracted with EA (10 mL * 4). The combined organic layers were concentrated under reduced pressure to give a residue.
HPLC indicated 61%
of desired product was detected. The residue was purified by prep-HPLC. LCMS
and 1HNMR
confirmed Compound 76 (6.76 mg, 18.6 umol, 14.6% yield). LCMS (ESI): RT =
0.632 min, mass calcd. For Ci8H24N402S, 360.16 m/z found 361.0[M+231+. 1HNMR (400MHz, CDC13) 6 8.53 (br d, J= 6.00 Hz, 1H), 7.94 (d, J = 2.00 Hz, 1H), 7.63 (dd, J = 2.00, 8.40 Hz, 1H), 7.56 (t, J = 7.60 Hz, 1H), 7.04 (d, J = 7.60 Hz, 1H), 6.72 (d, J= 9.20 Hz, 1H), 6.47 (d, J= 8.40 Hz, 1H), 4.44 (br s, 2H), 4.23 - 4.14 (m, 1H), 3.53 - 3.40 (m, 1H), 2.61 (d, J= 5.60 Hz, 3H), 2.08 - 2.01 (m, 2H), 1.82 - 1.72 (m, 2H), 1.67 - 1.61 (m, 1H), 1.48 - 1.27 (m, 5H).
Example 73: 4-(cyclohexylamino)-N-methyl-3-(pyridin-3-yl)benzenesulfonamide (Compound 77) N
COHN,\Sµµ
Preparation of Compound 77:
N' / \
00 Br Ii 77-la (1.5 eq) Cs2CO3 (4 eq), Pd(dppf)C12 (0.1 eq) CZ\
NH" H20, Dioxane, 100 C, 16 h HN-S
77-1 Compound 77 [00351] To a mixture of compound 77-1 (50 mg, 0.13 mmol, 1 eq) and compound 77-la (30.1 mg, 0.19 mmol, 18.3 uL, 1.5 eq) in a solution of dioxane (2 mL) and H20 (0.3 mL) was added Pd(dppf)C12 (9.3 mg, 12.7 umol, 0.1 eq) and Cs2CO3 (165.3 mg, 0.51 mmol, 4 eq) in one portion under N2. The mixture was stirred at 100 C for 16 hours. The crude LCMS showed 49%
of the desired product was detected. The reaction mixture was quenched by water (15 mL), and then extracted with Et0Ac (20 mL*3). The combined organic layer was washed with brine (15 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography to give the product (92 mg), which was further purified by prep-HPLC to provide the product (15.54 mg), which was further purified by prep-HPLC to give the Compound 77 (6.9 mg, 18.1 umol, 7.1% yield, HC1 salt).
LCMS (ESI): RT = 1.941 min, mass calc. for C181-123N302S 345.46, m/z found 346.0 [M+H1+.
1HNMR (400 MHz, DMSO-d6) 6 8.60 (td, J= 5.02, 1.51 Hz, 2H), 7.84 (dt, J= 7.78, 1.88 Hz, 1H), 7.56 (dd, J= 8.78, 2.26 Hz, 1H), 7.51 (dd, J= 7.65, 4.89 Hz, 1H), 7.32 (d, J = 2.26 Hz, 1H), 7.11 (q, J = 5.02 Hz, 1H), 6.86 (d, J = 8.78 Hz, 1H), 4.99 (d, J= 8.03 Hz, 1H), 2.52 (d, J= 1.76 Hz, 1H), 2.37 (d, J= 5.02 Hz, 3H), 1.85 (d, J= 10.29 Hz, 2H), 1.51 - 1.70 (m, 3H), 1.32 (q, J =
12.21 Hz, 2H), 1.04 - 1.24 (m, 3H).
Example 74: 4-(cyclohexylamino)-N-methyl-3-(3-methylpyridin-2-yl)benzenesulfonamide (Compound 78) N
N
0, HNOO
Preparation of Compound 78:
Br 78-la (1.5 eq) \
Pd(dppf)0I2 (0.1 eq) --N
Cs2003 (4 eq) HN
,µ 40 dioxane, H20, 100 C, 16 h -S
78-1 Compound 78 [00352] To a mixture of compound 78-1 (25 mg, 63.4 umol, 1 eq) and compound 78-la (16.4 mg, 95.1 umol, 10.6 uL, 1.5 eq) in a solution of dioxane (0.7 mL) and H20 (0.3 mL) were added Pd(dppf)C12 (4.6 mg, 6.3 umol, 0.1 eq) and Cs2CO3 (82.6 mg, 0.25 mmol, 4 eq) in one portion at room temperature (15 C) under N2. The mixture was stirred at 100 C
for 16 h. The crude LCMS showed 33% of the desired product was detected and the compound 78-1 was consumed completely. The mixture was quenched by water (15 mL), extracted with Et0Ac (10 mL * 3). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue (46 mg). The residue was purified by prep-HPLC to give Compound 78 (10.5 mg, 29.3 umol, 33.0% yield). LCMS (ESI): RT =
2.055 min, mass calc. for Ci9H25N302S 359.17, m/z found 360.0 [M+1-11+; NMR (400 MHz, CDC13) 6 8.54 (br d, J= 4.02 Hz, 1H), 7.64 - 7.73 (m, 2H), 7.54 (d, J = 2.26 Hz, 1H), 7.21 - 7.27 (m, 1H), 6.76 (d, J= 8.78 Hz, 1H), 4.91 (br d, J= 7.28 Hz, 1H), 4.30 (q, J = 5.52 Hz, 1H), 3.28 - 3.44 (m, 1H), 2.60 (d, J= 5.52 Hz, 3H), 2.25 (s, 3H), 1.93 - 2.06 (m, 2H), 1.62 - 1.76 (m, 3H), 1.28 - 1.43 (m, 2H), 1.07 - 1.27 (m, 3H).
Example 75: 4-(cyclohexylamino)-3-(3-fluoropyridin-2-y1)-N-methylbenzenesulfonamide (Compound 79) F N
0µ
HN
Preparation of Compound 79:
F -N
Br 79-1a (1.5 eq) \
0, ,0 Pd(dppf)C12 (0.1 eq) F
Cs2003 (4 eq) 01%* NU H20, -S -NS
HN 100 C, 16 h HN
79-1 Compound 79 [00353] To a mixture of compound 79-1 (25 mg, 63.4 umol, 1 eq) and compound 79-la (16.7 mg, 95.1 umol, 1.5 eq) in a solution of dioxane (0.7 mL) and H20 (0.3 mL) were added Pd(dppf)C12 (4.6 mg, 6.3 umol, 0.1 eq) and Cs2CO3 (82.6 mg, 0.25 mmol, 4 eq) in one portion at room temperature (15 C) under N2. The mixture was stirred at 100 C for 16 h. The crude LCMS showed 33% of the desired product was detected and the compound 79-1 was consumed completely. The reaction mixture was combined with another batch, the mixture was quenched by water (15 mL), extracted with Et0Ac (10 mL * 4). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue (51 mg). The residue was purified by prep-HPLC to give the Compound 79 (15.2 mg, 41.7 umol, 47.0% yield). LCMS (ESI): RT = 2.172 min, mass calc. for C18H22FN302S 363.14, m/z found 364.0 [M+H1+; 1HNMR (400 MHz, CDC13) 6 8.46 (d, J=4.77 Hz, 1H), 8.02 (t, J=
2.64 Hz, 1H), 7.70 (dd, J= 8.91, 2.13 Hz, 1H), 7.49 - 7.61 (m, 2H), 7.32 (dt, J = 8.34, 4.24 Hz, 1H), 6.80 (d, J
= 9.03 Hz, 1H), 4.21 (q, J = 5.35 Hz, 1H), 3.38 - 3.50 (m, 1H), 2.66 (d, J=
5.52 Hz, 3H), 1.97 -2.08 (m, 2H), 1.70 - 1.80 (m, 2H), 1.64 (br dd, J= 8.28, 4.27 Hz, 1H), 1.36 -1.49 (m, 2H), 1.23 -1.35 (m, 3H).
Example 76: 4-(cyclohexylamino)-3-(3-methoxypyridin-2-y1)-N-methylbenzenesulfonamide (Compound 80) o N
0µ
HN
Preparation of Compound 80:
Br 80-la (1.5 eq) Os ,0 Pd(dPPf)2C12 (0.1 eq) Cs2003 (4 eq) 0,µ HN NU dioxane, H20, ,S% 410 100 C, 16 h HN
80-1 Compound 80 [00354] To a mixture of compound 80-1 (25 mg, 63.4 umol, 1 eq) and compound 80-la (17.9 mg, 95.1 umol, 1.5 eq) in a solution of dioxane (0.7 mL) and H20 (0.3 mL) were added Pd(dppf)C12 (4.6 mg, 6.3 umol, 0.1 eq) and Cs2CO3 (82.6 mg, 0.25 mmol, 4 eq) in one portion at room temperature (15 C) under N2. The mixture was stirred at 100 C for 16 h. The crude LCMS showed 39% of the desired product was detected and the compound 80-1 was consumed completely. The mixture was quenched by water (15 mL), extracted with Et0Ac (10 mL * 3).
The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue (42 mg). The residue was purified by prep-HPLC to give the Compound 80 (8.2 mg, 21.7 umol, 24.5% yield). LCMS (ESI): RT = 2.049 min, mass calc. for Ci9H25N303S 375.16, m/z found 376.0 [M+H1+; IFINMR (400 MHz, CDC13) 6 8.26 (dd, J =
4.64, 1.13 Hz, 1H), 7.98 (d, J= 2.26 Hz, 1H), 7.65 (dd, J= 8.91, 2.13 Hz, 1H), 7.32 - 7.38 (m, 1H), 7.25 - 7.31 (m, 1H), 6.76 (d, J= 9.03 Hz, 1H), 6.59 (br d, J = 7.03 Hz, 1H), 4.27 (q, J =
5.35 Hz, 1H), 3.83 (s, 3H), 3.29 - 3.50 (m, 1H), 2.64 (d, J= 5.52 Hz, 3H), 1.93 -2.10 (m, 3H), 1.72 (br dd, J= 9.16, 4.14 Hz, 2H), 1.61 (d, J= 4.52 Hz, 1H), 1.33 - 1.46 (m, 2H), 1.17 - 1.31 (m, 3H).
Example 77: 4-(cyclohexylamino)-N-methy1-3-(2H-1,2,3-triazol-2-yl)benzenesulfonamide (Compound 81) ,N, N
o 40 No S
NH -µN
Preparation of Compound 81:
ain = -NI Fe (5.0 eq) N/11 =N NO2 81-la (1.0 eq) N
NH4CI (5.0 eq) 81-3a (1.2 eq) KF (1.0 eq) * NO2 Et0H:H20 = 2:1 * NH2 __________________ I DMSO, 70 C, 2 h 80 C, 4 hr I
TMSCI (2.5 eq), NaBH4 (1.0 eq), DMF, 0 C, 3h =N-N
=N
Na0"Sr ' IR, N 1) 1.Na0Me(3.0eq),THF Me0H, 81-4a (3.0eq) jpe.-Cul(5.0eq)/DMS0/0 2.methanamine (3.0eq), TEA(5.0eq), MW, 110 C, 1 h NCS(2.0eq), THF, 20 C, 3h 81-4 81-5 Compound 81 Step 1: 2-(5-Iodo-2-nitropheny1)-2H-1,2,3-triazole [00355] To a solution of compound 81-1 (450 mg, 1.69 mmol, 1.0 eq) in DMSO
(5 mL) were added compound 81-la (116 mg, 1.69 mmol, 1.0 eq) and KF (98 mg, 1.7 mmol, 1.0 eq).
The reaction mixture was stirred at 70 C for 2 hours. The mixture was diluted with water (30 mL) and the resultant mixture was extracted with EA (50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound 81-2 (150 mg, 28% yield). 1HNMR (400MHz, DMSO-d6) 6 8.35 (s, 1H), 8.23 (s, 2H), 8.13 (d, J = 8.3 Hz, 1H), 7.86 (d, J= 8.3 Hz, 1H).
Step 2: 4-Iodo-2-(2H-1,2,3-triazol-2-yl)aniline [00356] A solution of compound 81-2 (100 mg, 0.316 mmol, 1.0 eq), Fe (88 mg, 1.6 mmol, 5.0 eq) and NH4C1 (85 mg, 1.6 mmol, 5.0 eq) in Et0H (4 mL) and H20 (2 mL) was stirred at 80 C for 4 hours. The mixture was diluted with water (30 mL) and the resultant mixture was extracted with EA (50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure to obtain compound 81-3 (85 mg, 94% yield). LCMS (ESI): RT = 0.735 min, mass calcd. for C8H7IN4 285.97, m/z found 286.7 [M+H]+.
Step 3: N-Cyclohexy1-4-iodo-2-(2H-1,2,3-triazol-2-yl)aniline [00357] A mixture of compound 81-3 (60 mg, 0.21 mmol, 1.0 eq), compound 81-3a (25 mg, 0.25 mmol, 1.2 eq) and TMSC1 (57 mg, 0.52 mmol, 2.5 eq) in DMF (2 mL) was stirred at 0 C for 10 min under N2. NaBH4 (8.0 mg, 0.21 mmol, 1.0 eq) was added, the reaction mixture was stirred at 0 C for 2 hours. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound 81-4 (50 mg, crude) as a white solid.
Step 4: Methyl 3-44-(cyclohexylamino)-3-(2H-1,2,3-triazol-2-yl)phenyl)sulfonyl)propanoate [00358] Compound 81-4 (50 mg, 0.14 mmol, 1.0 eq), compound 81-4a (71 mg, 0.41 mmol, 3.0 eq) and Cul (129 mg, 0.679 mmol, 5.0 eq) were taken up into a microwave tube in DMSO (1.5 mL). The sealed tube was heated at 110 C for 1 hour under microwave. The mixture was diluted with water (10 mL) and EA (30 mL). The suspension was filtered and the filtrate was separation, the water layer was extracted with EA (20 mL * 2).
The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound 81-5 (40 mg, 75% yield). LCMS (EST): RT = 0.813 min, mass calcd. for C18I-124N404S 392.15, m/z found 393.0 [M+I-11+.
Step 5: 4-(Cyclohexylamino)-N-methyl-3-(2H-1,2,3-triazol-2-yl)benzenesulfonamide [00359] To a solution of compound 81-5 (40 mg, 0.10 mmol, 1.0 eq) in Me0H
(1 mL) and THF (2 mL) was added Na0Me (17 mg, 0.31 mmol, 3.0 eq). The reaction mixture was stirred at 20 C for 1 hour, and then removed solvent to give a residue. The residue was dissolved with THF (2 mL). After MeNH2 (2 M, 0.15 mL, 3.0 eq), TEA (52 mg, 0.51 mmol, 5.0 eq) and NCS
(27 mg, 0.20 mmol, 2.0 eq) were added, the reaction mixture was stirred at 20 C for 3 hours. The mixture was diluted with water (30 mL) and the resultant mixture was extracted with EA (50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely.
Compound 81 (26.59 mg, 77% yield) was obtained. LCMS (EST): RT = 0.792 min, mass calcd.
for C15H211\1502S 335.14, m/z found 335.9 [M+I-11+, 1HNMR (400MHz, CDC13) 6 = 8.43 (d, J= 2.0 Hz, 1H), 7.85 (s, 2H), 7.67 (dd, J= 2.3, 8.8 Hz, 1H), 7.64 - 7.57 (m, 1H), 6.86 (d, J = 9.0 Hz, 1H), 4.26 (q, J= 5.4 Hz, 1H), 3.54 - 3.43 (m, 1H), 2.67 (d, J = 5.3 Hz, 3H), 2.10 - 2.02 (m, 2H), 1.83 - 1.74 (m, 2H), 1.70 - 1.62 (m, 1H), 1.49 - 1.28 (m, 5H).
Example 78: 4-(cyclohexylamino)-N-methyl-3-(1-methyl-1H-imidazol-4-yl)benzenesulfonamide (Compound 82) N/
N
HN,S
I
Preparation of Compound 82:
0,13,0 N
Br 82-2(1.5 eq) 0 = NO (:)µµ
Na2003(2.0 eq), I. 0 ,S
eq) I
82-1 dioxane/H20, 80 C,5 h Compound 82 [00360] To a solution of compound 82-1 (0.04 g, 0.10 mmol, 1.0 eq) and compound 82-2 (16.3 mg, 0.10 mmol, 1.0 eq) in dioxane (5.0 mL) was added H20 (0.5 mL) Pd(dppf)C12 (7.4 mg, 10.14 umol, 0.1 eq) and Na2CO3 (21.5 mg, 0.20 mmol, 2.0 eq). The mixture was stirred at 80 C
for 16 hour under N2 atmosphere. LCMS showed desired compound was found. The reaction was filtered through Celite and concentrated under reduced pressure to give a residue. The crude product was purified by prep-HPLC to give Compound 82 (6.64 mg, 18.86 umol, 18.60%
yield). LCMS (ESI): RT = 0.634 min, mass calc. for C17H24N402S 348.16, m/z found 348.9 [M+F11+;IHNMR (400 MHz, CDC13) 6 8.55 (s, 1H), 7.81 (d, J = 2.0 Hz, 1H), 7.54 (dd, J = 2.3, 8.8 Hz, 1H), 7.47 (s, 1H), 7.24 (s, 1H), 6.69 (d, J= 9.0 Hz, 1H), 4.24 (q, J =
5.4 Hz, 1H), 3.75 (s, 3H), 3.44 (s, 1H), 2.62 (d, J= 5.5 Hz, 3H), 2.12 -2.00 (m, 2H), 1.86 - 1.75 (m, 2H), 1.69 - 1.64 (m, 1H), 1.48 - 1.25 (m, 5H).
Example 79: 4-(cyclohexylamino)-3-(6-(dimethylamino)pyridin-2-y1)-N-methylbenzenesulfonamide (Compound 83) \
()%
H m Preparation of Compound 83:
/
-N
Br /
83-la (1.3 eq) Na2003 (3.0 eq) / \ N
--N
0õ0 B Pd(dppf)012 (0.1 eq) I H
H ________________________________________ il. N
µ.. N
lei H20/dioxane(1/10) 80 C,16 h 0 HN -S %%
HN µ`
I
83-1 Compound 83 2, /
/ \ NH2 NaH (3.0 eq) c)...-N
CH3I (3.0 eq) \
DMF, 0-15, 16h Br Br 83-lb 83-la Step 1: 6-bromo-N,N-dimethyl-pyridin-2-amine [00361] To a mixture of the compound 83-lb (100 mg, 0.578 mmol, 1 eq) in DMF (2 mL) was added NaH (69 mg, 1.73 mmol, 60% purity, 3 eq) in one portion at 0 C
under N2. The reaction mixture was stirred at 0 C for 15 min, then CH3I (246 mg, 1.73 mmol, 3 eq) was added at 0 C and the mixture was warmed to 15 C and stirred for 16 h. LCMS showed one main peak with desired MS was detected. TLC indicated the starting material was consumed completely.
The reaction mixture was diluted with water (15 mL) and extracted with EA (15 mL * 4). The combined organic layers were dried with anhydrous Na2SO4, filtered and concentrated in vacuum to provide compound 83-la (130 mg, crude), which was used next step without further purification Step 2: 4-(cyclohexylamino)-3-16-(dimethylamino)-2-pyridy1]-N-methyl-benzenesulfonamide [00362] To a suspension of the compound 83-la (33 mg, 0.132 mmol, 1.3 eq) and the compound 83-1 (40 mg, 0.101 mmol, 1 eq) in mix solution of H20 (0.1 mL) and dioxane (1 mL) were added Pd(dppf)C12 (7.5 mg, 10 umol, 0.1 eq) and Na2CO3 (32 mg, 0.304 mmol, 3 eq) in one portion under N2. The mixture was stirred at 80 C for 16 h. LCMS
showed the starting material was consumed completely and one main peak with desired MS
was detected.
The reaction mixture was diluted with water (10 mL) and extracted with EA (10 mL * 3). The combined organic layers were concentrated under reduced pressure to give a residue. HPLC
showed 68% of desired product was detected. The residue was purified by prep-HPLC. LCMS
and 1HNMR that the Compound 83 (4.81 mg, 12 umol, 11.8% yield). LCMS (ESI): RT
= 0.755 min, mass calcd. For C20I-128N402S, 388.19 m/z found 389.1[M+1-11+. IFINMR
(400MHz, CDC13) 6 8.62 (br d, J= 6.80 Hz, 1H), 7.96 (d, J = 2.40 Hz, 1H), 7.68 - 7.52 (m, 2H), 6.94 (d, J = 7.60 Hz, 1H), 6.74 (d, J= 9.20 Hz, 1H), 6.48 (d, J= 8.40 Hz, 1H), 4.18 -4.09 (m, 1H), 3.47 - 3.35 (m, 1H), 3.14 (s, 6H), 2.64 (d, J= 5.60 Hz, 3H), 2.17 -2.06 (m, 2H), 1.84 -1.75 (m, 2H), 1.73 -1.66 (m, 1H), 1.45 - 1.35 (m, 2H), 1.29 - 1.20 (m, 3H).
Example 80: 3-(4-aminopyridin-2-y1)-4-(cyclohexylamino)-N-methylbenzenesulfonamide (Compound 84) N
HN
Preparation of Compound 84:
N
Br NH2 NflT
0,6,0 84-la (1.3 eq) Na2CO3 (3.0 eq) Pd(dppf)012 (0.1 eq) 0 CZµ
HN-S, HN,Sµµ H20/dioxane(1/10) 80 C,16 h 84-1 Compound 84 [00363] To a suspension of the compound 84-1 (40 mg, 0.101 mmol, 1 eq) and the compound 84-la (22 mg, 0.131 mmol, 1.3 eq) in mix solvent of dioxane (1 mL) and H20 (0.15) were added Pd(dppf)C12 (7 mg, 10 umol, 0.1 eq) and Na2CO3 (32 mg, 0.304 mmol, 3 eq) in one portion under N2. The mixture was stirred at 80 C for 16 h. LCMS showed the starting material was consumed completely and 40% of desired product was formed. The reaction mixture was diluted with water (10 mL) and extracted with EA (10 mL * 4). The combined organic layers were concentrated under reduced pressure to give a residue. HPLC indicated 60%
of desired product was detected. The residue was purified by prep-HPLC. LCMS and IFINMR
confirmed the white solid was the Compound 84 (14.25 mg, 39 umol, 39% yield). LCMS
(ESI): RT =
0.618 min, mass calcd. For Ci8H24N402S, 360.16 m/z found 361.0[M+Hr IFINMR
(400MHz, CDC13) 6 9.19 (br s, 1H), 8.19 (d, J = 5.60 Hz, 1H), 8.02 (d, J= 2.40 Hz, 1H), 7.63 (dd, J= 2.00, 8.80 Hz, 1H), 7.03 (d, J= 2.00 Hz, 1H), 6.72 (d, J = 8.80 Hz, 1H), 6.47 (dd, J
= 2.00, 5.60 Hz, 1H), 4.69 (q, J= 5.30 Hz, 1H), 4.36 (s, 2H), 3.45 (br s, 1H), 2.60 (d, J= 5.20 Hz, 3H), 2.05 -1.98 (m, 2H), 1.80 - 1.71 (m, 2H), 1.64 - 1.58 (m, 1H), 1.44 - 1.25 (m, 4H).
Example 81: 4-(cyclohexylamino)-N-methyl-3-(6-(methylamino)pyridin-2-yl)benzenesulfonamide (Compound 85) /
i \ NH
--N
H
µNI H N
µS
....--Preparation of Compound 85:
/
c,NH
I .N
Br /
85-1a (1.3 eq) Na2CO3 (3.0 eq) / NH \
---N
0õ0 B Pd(dppf)C12 (0.1 eq) H
H
H20/dioxane(1/10) 'S
ON\ el NO NW- 1%
80 C,16 h 1 85-1 Compound 85 OH
'e.OH H
2/ \ NH2 85-1 b (1.0 eq) --N
...- N
________________________________________ ).- N
Br Py (1.4 eq), Cu(OAc)2 (1.0 eq), 85-1c (0.4 eq) dioxane, 02 (15 Psi), 20 00,2 h Br 85-la Step 1: 6-bromo-N-methyl-pyridin-2-amine [00364] Cu(0Ac)2 (303 mg, 1.67 mmol, 1 eq) was added to a solution of the compound 85-1c (116 mg, 0.67 mmol, 0.4 eq) and pyridine (185 mg, 2.34 mmol, 1.40 eq) in dioxane (6 mL). The reaction mixture was stirred at 15 C for 15 min. The compound 85-lb (100 mg, 1.67 mmol, 1 eq) was added and the reaction was heated to 100 C, and stirred at 100 C under 02(15 Psi) for 16 h. LCMS showed no desired MS was detected. TLC indicated the compound 85-1c was remained and two new spots were formed. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography. NMR confirmed that the product was compound 85-la (37 mg, 0.20 mmol, 11.9% yield). NMR
(400MHz, CDC13) 6 7.31 - 7.27 (m, 1H), 6.74 (d, J = 7.60 Hz, 1H), 6.29 (d, J= 8.00 Hz, 1H), 4.69 (br s, 1H), 2.91 (d, J = 5.20 Hz, 3H).
Step 2: 4-(cyclohexylamino)-N-methy1-346-(methylamino)-2-pyridyl]benzenesulfonamide [00365] To a suspension of the compound 85-la (31 mg, 0.131 mmol, 1.3 eq) and the compound 85-1 (40 mg, 0.10 mmol, 1 eq) in mix solvent of H20 (0.1 mL) and dioxane (1 mL) were added Na2CO3 (32 mg, 0.304 mmol, 3 eq) and Pd(dppf)C12 (7 mg, 10 umol, 0.1 eq) in one portion under N2. The mixture was stirred at 80 C for 16 h. LCMS showed the starting material was consumed completely and one main peak with desired MS was detected. The reaction mixture was diluted with water (10 mL) and extracted with EA (10 mL *
3). The combined organic layers were concentrated under reduced pressure to give a residue. HPLC
showed 66% of desired product was detected. The residue was purified by prep-HPLC. LCMS and NMR confirmed that the product was the Compound 85 (9.94 mg, 26 umol, 26.2% yield). LCMS (ESI): RT = 0.664 min, mass calcd. For Ci9H26N4025 374.18 m/z found 375.0 [M+F11+. NMR
(400MHz, CDC13) 6 8.70 (d, J= 6.5 Hz, 1H), 7.97 (d, J= 2.3 .. Hz, 1H), 7.63 (dd, J= 2.3, 8.8 Hz, 1H), 7.54 (t, J= 7.9 Hz, 1H), 6.98 (d, J = 7.5 Hz, 1H), 6.73 (d, J =
9.0 Hz, 1H), 6.36 (d, J = 8.3 Hz, 1H), 4.53 - 4.45 (m, 1H), 4.13 (q, J= 5.7 Hz, 1H), 3.48 - 3.37 (m, 1H), 3.00 (d, J= 5.0 Hz, 3H), 2.63 (d, J= 5.5 Hz, 3H), 2.17 - 2.05 (m, 2H), 1.85 - 1.74 (m, 2H), 1.73 - 1.62 (m, 1H), 1.47 - 1.38 (m, 2H), 1.33 - 1.24 (m, 3H).
Example 82: 4-(cyclohexylamino)-N-methy1-3-(2-(1-(pyridin-3-yl)piperidin-3-y1)-tetrazol-5-yl)benzenesulfonamide (Compound 86) N N
oNN N
,S
Preparation of Compound 86:
HO B.IL N--01 QNH OH
864a (2 eq) N-NQ
N-N Cu(OAc)2 (1 eq), ii ,1\1 DIPEA (4 eq) 02, DCM, 30 C, 104 h czµ N
N N
HO
86-1 Compound 86 [00366] To a mixture of 86-1 (50 mg, 0.110 mmol, 1 eq, HC1 salt) and compound 86-la (27.0 mg, 0.219 mmol, 2 eq) in DCM (1 mL) were added Cu(0Ac)2 (19.9 mg, 0.110 umol, 1 eq) and DIPEA (56.7 mg, 0.439 mmol, 76.4 uL, 4 eq) in one portion at 15 C
under 02. The mixture was stirred at 30 C for 88 h. The mixture was stirred at 30 C for 16 h. The reaction mixture was diluted with DCM (15 mL), and then concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography to give the product as yellow oil (37 mg), which was further purified by prep-HPLC to give the impure product (6.53 mg), which was further purified by prep-HPLC to give the Compound 86 (2.91 mg, 5.9 umol, 5.3% yield). LCMS (ESI): RT = 2.247 min, mass calc. for C24H32N802S 496.24, m/z found 497.1 [M+H1+; IFINMR (400 MHz, CDC13) 6 8.61 (br s, 1H), 8.41 (s, 1H), 8.05 (s, 1H), 7.59 - 7.92 (m, 3H), 6.80 (d, J= 8.53 Hz, 1H), 5.07 (s, 1H), 4.51 (s, 1H), 3.88 - 4.24 (m, 1H), 3.53 (br s, 3H), 2.78 (s, 1H), 2.63 (s, 3H), 2.46 (s, 1H), 2.07 (s, 2H), 1.60 - 1.99 (m, 7H), 1.22 - 1.44 (m, 4H).
Example 83: 4-(cyclohexylamino)-3-(4-(dimethylamino)pyridin-2-y1)-N-methylbenzenesulfonamide (Compound 87) X
,\
HNS
Preparation of Compound 87:
cNN
Br 87-la (1.3 eq) N
Na2003 (3.0 eq) 0,6,0 Pd(dppf)C12 (0.1 eq) H20/dioxane(1 /1 0) ON, O
80 C,16 h HN
HN
I
87-1 Compound 87 H2Nc NaH
CH31 (2.5 eq) N
DMF, 0-it, 16h Br Br 87-lb 87-la Step 1: 2-bromo-N,N-dimethyl-pyridin-4-amine [00367] To a mixture of the compound 87-lb (100 mg, 0.578 mmol, 1 eq) in DMF (2 mL) was added NaH (92 mg, 2.31 mmol, 4 eq) in one portion at 0 C under N2. The mixture was stirred at 0 C for 15 min, then CH3I (0.63 g, 4.44 mmol, 0.27 mL, 7.68 eq) was added at 0 C
and then the mixture was warmed to 15 C and stirred for 16 h. The reaction was monitored by LCMS. The reaction mixture was diluted with water (15 mL) and extracted with EA (15 mL *
4). The combined organic layers were dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give the compound 87-la (130 mg, crude), which was used next step without further purification. NMR (400MHz, CDC13) 6 7.95 (d, J= 6.00 Hz, 1H), 6.65 (d, J =
2.40 Hz, 1H), 6.44 (dd, J= 2.50, 6.10 Hz, 1H), 3.00 (s, 6H).
Step 2: 4-(cyclohexylamino)-3-14-(dimethylamino)-2-pyridy1]-N-methyl-benzenesulfonamide [00368] To a suspension of the compound 87-la (38 mg, 0.132 mmol, 1.3 eq) and the compound 1 (40 mg, 0.101 mmol, 1 eq) in mix solvent of H20 (0.1 mL) and dioxane (1 mL) were added Pd(dppf)C12 (7 mg, 10 umol, 0.1 eq) and Na2CO3 (38 mg, 0.355 mmol, 3.5 eq) in one portion under N2. The mixture was stirred at 80 C for 16 h. LCMS
showed the starting material was consumed completely and one main peak with desired MS
was detected.
The reaction mixture was diluted with water (10 mL) and extracted with EA (10 mL * 3). The combined organic layers were concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC. LCMS and NMR confirmed the Compound 87 (5.88 mg, 15 umol, 14.9% yield). LCMS (ESI): RT = 0.642 min, mass calcd. For C20I-128N402S, 388.19 m/z found 389.1[M+H1 IFINMR (400MHz, CDC13) 6 8.60 (br d, J= 6.00 Hz, 1H), 8.22 (d, J= 6.00 Hz, 1H), 7.90 (d, J= 2.00 Hz, 1H), 7.63 (dd, J = 2.40, 8.80 Hz, 1H), 6.77 (d, J = 2.40 Hz, 1H), 6.71 (d, J= 8.80 Hz, 1H), 6.48 (dd, J= 2.40, 6.00 Hz, 1H), 4.40 - 4.27 (m, 1H), 3.49 - 3.35 (m, 1H), 3.07 (s, 6H), 2.60 (d, J= 5.60 Hz, 3H), 2.06 - 1.99 (m, 2H), 1.81 - 1.71 (m, 2H), 1.62 - 1.57 (m, 1H), 1.49 - 1.31 (m, 5H).
Example 84: 4-(cyclohexylamino)-N-methyl-3-(4-(methylamino)pyridin-2-yl)benzenesulfonamide (Compound 88) I
NH
N
kloON
HN,µSµµ
I
Preparation of Compound 88:
I
N,NH
I
Br NH
88-la (1.3 eq) Na2003 (3.0 eq) /
N I
0õ0 B H Pd(dppf)C12 (0.1 eq) H
No (:)µµ 0 No ________________________________ v.--H20/dioxane(1/10) \\
HN-Sµµ
80 C,16 h HN,Sµ` I
I
88-1 Compound 88 'I'OH I
NH2 88-1 b (1 0 eq) I ' __ 88-1c (0.4 eq) g NH
N I
Py (1.4 eq), Cu(OAc)2 (1.0 eq), Nr Br dioxane,02(15 Psi), Br 15-100 C,16 h 88-1c 88-1a Step 1: 2-bromo-N-methyl-pyridin-4-amine [00369] Cu(OAc)2 (303 mg, 1.67 mmol, 1 eq) was added to a solution of the compound 88-1c (116 mg, 0.668 mmol, 0.4 eq) and pyridine (185 mg, 2.34 mmol, 0.19 mL, 1.40 eq) in dioxane (6 mL). The reaction mixture was stirred at 15 C for 15 min.
The compound 88-lb (100 mg, 1.67 mmol, 1 eq) was added and the reaction was heated to 100 C
and stirred at 100 C under 02(15 Psi) for 16 h. LCMS showed no desired MS was detected. TLC
indicated the compound 88-1c was remained and one new spot was formed. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography. IFINMR confirmed that the product was 88-la (35 mg, 0.187 mmol, 11.2% yield). IFINMR (400MHz, CDC13) 6 7.93 (d, J = 5.60 Hz, 1H), 6.62 (d, J=2.00 Hz, 1H), 6.39 (dd, J= 2.20, 5.60 Hz, 1H), 4.32 (br s, 1H), 2.87 (d, J= 5.20 Hz, 3H).
Step 2: 4-(cyclohexylamino)-N-methyl-3-14-(methylamino)-2-pyridyl]benzenesulfonamide [00370] To a suspension of the compound 88-la (29 mg, 0.132 mmol, 1.3 eq) and the compound 88-1 (40 mg, 101.44 umol, 1 eq) in a mix solvent of H20 (0.1 mL) and dioxane (1 mL) were added Na2CO3 (32 mg, 0.304 mmol, 3 eq) and Pd(dppf)C12 (7.4 mg, 10 umol, 0.1 eq) in one portion under N2. The mixture was stirred at 80 C for 16 h. LCMS
showed the starting material was consumed completely and one main peak with desired MS was detected. The reaction mixture was diluted with water (5 mL) and extracted with EA (7 mL *
3). The combined organic layers were concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC. LCMS and IFINMR confirmed that the product was Compound (8.07 mg, 20.9 umol, 20.6% yield). LCMS (ESI): RT = 0.630 min, mass calcd. For Ci9H26N4025, 374.18 m/z found 375.0[M+Hr NMR (400MHz, CDC13) 6 8.97 (br d, J=
7.60 Hz, 1H), 8.20 (d, J= 6.00 Hz, 1H), 7.96 (d, J = 2.00 Hz, 1H), 7.63 (dd, J =
2.10, 8.90 Hz, 1H), 6.82 (d, J = 2.00 Hz, 1H), 6.72 (d, J = 8.80 Hz, 1H), 6.41 (dd, J = 2.00, 5.80 Hz, 1H), 4.47 - 4.35 (m, 2H), 3.50 - 3.37 (m, 1H), 2.92 (d, J= 5.20 Hz, 3H), 2.61 (d, J = 5.60 Hz, 3H), 2.06 - 2.00 (m, 2H), 1.81 - 1.73 (m, 2H), 1.68- 1.61 (m, 1H), 1.45 - 1.30 (m, 5H).
Example 85: 4-(cyclohexylamino)-N-methyl-3-(1H-1,2,3-triazol-1-yl)benzenesulfonamide (Compound 89) N
No -S
HN *
Preparation of Compound 89:
N.N ffN
Fe (5.0 eq) NO2 89-la (1.0 eq) N NH4CI (5.0 eq) N 89-3a (1.2 eq) KF (1.0 eq) * W NO Et0H:H20 = 2:1 * NH
DMSO70C2 h 2 80 C, 4 hr TMSCI (2.5 eq), NaBH4 (1.0 eq), I , DMF, 0 C, 1 hand 10 min (,11 Na0Sr ' N
1 . Na0Me(3.0 eq),THF Me0H, iN
*N 89-4a (3.0eq) 20 C, 1 hr U 1(5.0eq)/DMS0/ 0 -S *
2. methanamine (3.0 eq), TEA(5.0 eq), HN
MW, 110 C, 1 h 0 89-4 o NCS(2.0 eq), THF, 20 C, 16 hr Compound 89 Step 1: 1-(5-Iodo-2-nitropheny1)-1H-1,2,3-triazole [00371] To a solution of compound 89-1 (450 mg, 1.69 mmol, 1.0 eq) in DMSO (5 mL) were added compound 89-la (116 mg, 1.69 mmol, 1.0 eq) and KF (98 mg, 1.7 mmol, 1.0 eq).
The reaction mixture was stirred at 70 C for 2 hours. The mixture was diluted with water (30 mL) and the resultant mixture was extracted with EA (50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound 89-2 (200 mg, 37% yield). 1HNMR (400MHz, DMSO-d6) 6 8.75 (s, 1H), 8.33 (s, 1H), 8.23 (d, J= 8.3 Hz, 1H), 8.01 (s, 1H), 7.97 (d, J= 8.3 Hz, 1H).
Step 2: 4-Iodo-2-(1H-1,2,3-triazol-2-yl)aniline [00372] A solution of compound 89-2 (200 mg, 0.633 mmol, 1.0 eq), Fe (177 mg, 3.16 mmol, 5.0 eq) and NH4C1 (169 mg, 3.16 mmol, 5.0 eq) in Et0H (5 mL) and H20 (2.5 mL) was stirred at 80 C for 4 hours. The mixture was diluted with water (30 mL) and the resultant mixture was extracted with EA (50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure to obtain the title compound 89-3 (180 mg, 99% yield). LCMS (ESI): RT = 0.654 min, mass calcd. for C8H7IN4 285.97, m/z found 286.8 [M+H1+.
Step 3: N-Cyclohexy1-4-iodo-2-(1H-1,2,3-triazol-2-yl)aniline [00373] A mixture of compound 89-3 (100 mg, 0.350 mmol, 1.0 eq), compound 89-3a (41 mg, 0.42 mmol, 1.2 eq) and TMSC1 (95 mg, 0.87 mmol, 2.5 eq) in DMF (2 mL) was stirred at 0 C for 10 min under N2. NaBH4 (13 mg, 0.35 mmol, 1.0 eq) was added, the reaction mixture was stirred at 0 C for 1 hour. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound 89-4 (120 mg, crude). LCMS (ESI):
RT = 0.868 min, mass calcd. for C14H17IN4 368.05, m/z found 368.9 [M+1-11+.
Step 4: Methyl 3-44-(cyclohexylamino)-3-(1H-1,2,3-triazol-2-yl)phenyl)sulfonyl)propanoate [00374] Compound 89-4 (60 mg, 0.16 mmol, 1.0 eq) , compound 89-4a (85 mg, 0.49 mmol, 3.0 eq) and Cul (155 mg, 0.815 mmol, 5.0 eq) were taken up into a microwave tube in DMSO (1.5 mL). The sealed tube was heated at 110 C for 1 hour under microwave. The mixture was diluted with water (10 mL) and EA (30 mL).The suspension was filtered and the filtrate was separation, the water layer was extracted with EA (20 mL * 2).
The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford compound 89-5 (60 mg, 94% yield). LCMS (EST): RT = 0.748 min, mass calcd. for C18I-124N404S 392.15, m/z found 393.0 [M+I-11+.
Step 5: 4-(Cyclohexylamino)-N-methy1-3-(1H-1,2,3-triazol-2-yl)benzenesulfonamide [00375] To a solution of compound 89-5 (60 mg, 0.15 mmol, 1.0 eq) in Me0H
(1 mL) and THF (2 mL) was added Na0Me (25 mg, 0.46 mmol, 3.0 eq). The reaction mixture was stirred at 20 C for 1 hour, and then removed solvent to give a residue. The residue was dissolved with THF (2 mL). After MeNH2 (2 M, 0.23 mL, 3.0 eq), TEA (77 mg, 0.76 mmol, 5.0 eq) and NCS
(41 mg, 0.31 mmol, 2.0 eq) were added, the reaction mixture was stirred at 20 C for 3 hours. The mixture was diluted with water (30 mL) and the resultant mixture was extracted with EA (50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely.
Compound 89 (16.13 mg, 31% yield) was obtained. LCMS (EST): RT = 0.739 min, mass calcd.
for C15H211\1502S 335.14, m/z found 335.9 [M-411+, 1HNMR (400MHz, DMSO-d6) 6 8.59 (d, J= 1.0 Hz, 1H), 8.03 (d, J= 1.0 Hz, 1H), 7.67 (dd, J= 2.3, 8.8 Hz, 1H), 7.58 (d, J =
2.3 Hz, 1H), 7.09 (d, J = 8.8 Hz, 1H), 5.91 (d, J = 8.0 Hz, 1H), 3.51 - 3.41 (m, 1H), 2.53 -2.51 (m, 1H), 2.40 (s, 3H), 1.93 - 1.83 (m, 2H), 1.71 - 1.61 (m, 2H), 1.61 - 1.52 (m, 1H), 1.43 -1.28 (m, 2H), 1.28 -1.11 (m, 3H).
Example 86: N-methy1-3-(2-methy1-2H-tetrazol-5-y1)-4-(phenylamino)benzenesulfonamide (Compound 90) /
N-N
NI, H
40 N to 9\
,S
HN µµ
Preparation of Compound 90:
I
BnNH2(1.2eq), I 0 NN, _0 I 0 TEA (1 2eq) NH', S
NH, * NaN3(3.0 eq) iSS- al S DMS0,120 C, 3 h (3( 0 io Mel (1.0 eq) e 0 ______________ ,... ______________________ ,.. N
H
I IN.-F N io NH4C1(3.0 eq), N, N K2CO3 (1.5 eq) I I N DMF, 130 C, 16 hr N-N DMF, 80 C, N 25 min, MW
Phi (2 eq) I I Pd2(dba)3(0.1 eq) N-N/
NH, _0 dry Pd/C(0.2 eq) S- 1-1N, _0 Xantphos(0.2 eq) N , r' \I
d 0 Me0H, HCI(cat) S-K3PO4 (3 eq) H
N = H2, 30 C, 45 Psi 01 0 To1, 110 C, 16 h H NH2 _____________________ N .
1.-N ' N
N, N HN N%
N-N i 0 / N-N
/ 90-5 Compound 90 Step 1: 4-(benzylamino)-3-cyano-N-methylbenzenesulfonamide [00376] To a solution of 3-cyano-4-fluoro-N-methyl-benzenesulfonamide 90-1 (1 g, 4.67 mmol, 1 eq) and BnNH2 (600.2 mg, 5.6 mmol, 610.63 uL, 1.2 eq) in DMSO (5 mL) was added TEA (566.8 mg, 5.6 mmol, 779.71 uL, 1.2 eq) in one portion at 15 C. The mixture was stirred at 120 C for 3 h. LCMS showed the reaction was complete and 93% of desired product was formed. The resulting yellow mixture was combined with other batches and diluted with water (15 mL) and EA (80 mL) and separated. The separated organic layer was washed with brine (10 mL*6), dried over anhydrous Na2SO4, filtered and concentrated under vacuum to give a white residue A. The residue A was triturated with a mixture solution of EA:PE = 1:2 solvent (15 mL) and then filtered. The filter cake was washed with a mixture solution of EA:PE
= 1:2 solvent (25 mL) and dried to give compound 90-2 (1 g, 3.32 mmol, 71.12% yield). The filtrate was concentrated to give a residue B. The residue B was purified by flash silica gel chromatography to give compound 90-2 (0.3 g, 0.99 mmol, 21.32% yield). Iti NMR (400MHz, DMSO-d6) 6 7.81 (d, J = 2.5 Hz, 1H), 7.71 (t, J = 6.0 Hz, 1H), 7.62 (dd, J= 2.0, 9.0 Hz, 1H), 7.39 - 7.31 (m, 4H), 7.29 - 7.18 (m, 2H), 6.78 (d, J = 9.0 Hz, 1H), 4.51 (d, J= 6.0 Hz, 2H), 2.37 -2.33 (m, 3H).
Step 2: 4-(benzylamino)-N-methyl-3-(2H-tetrazol-5-yl)benzenesulfonamide [00377] To a mixture of compound 90-2(1 g, 3.32 mmol, 1 eq) and NaN3 (647.2 mg, 9.95 mmol, 3 eq) in DMF (15 mL) was added NH4C1 (532.5 mg, 9.95 mmol, 0.35 mL, 3 eq) in one portion at 15 C under N2. The mixture was heated to 130 C for 16 h. LCMS
showed the reaction was complete and 90% of desired product was formed. The mixture was diluted with water (20 mL). The resulting solution was added into a 0.5 M HC1 solution (50 mL), along with lots of solid formed. Then the mixture was filtered. The filter cake was washed with water (25 mL) and dried to give compound 90-3 (1.2 g, crude).
Step 3: 4-(benzylamino)-N-methy1-3-(2-methy1-2H-tetrazol-5-yObenzenesulfonamide [00378] To a mixture of compound 90-3 (0.66 g, 1.92 mmol, 1 eq) and K2CO3 (397.3 mg, 2.87 mmol, 1.5 eq) in DMF (12 mL) was added Mel (272 mg, 1.92 mmol, 0.12 mL, 1 eq) in one portion at 15 C under N2. The mixture was heated at 80 C under microwave for 25 min. LCMS
showed the reaction was complete and 71% of desired product was formed. The mixture was combined with another batch and diluted with water (15 mL) and EA (100 mL) and separated, along with some solid formed. Then the mixture was filtered. The filter cake was washed with water (15 mL) and dried under vacuum to give compound 90-4 (0.29 g, 0.81 mmol, 42.22%
yield). The filtrate was washed with brine (15 mL*3), dried over anhydrous Na2SO4, filtered and concentrated under vacuum to give compound 90-4 (0.9 g, crude), which was used for next step without further purification. NMR
(400MHz, DMSO-d6) 6 8.40 (d, J= 2.5 Hz, 1H), 8.08 (t, J
= 5.8 Hz, 1H), 7.64 - 7.58 (m, 1H), 7.42 - 7.33 (m, 4H), 7.31 - 7.20 (m, 2H), 6.93 (d, J = 9.0 Hz, 1H), 4.66 (d, J = 6.0 Hz, 2H), 4.49 (s, 3H), 2.37 (d, J = 5.0 Hz, 3H).
Step 4: 4-amino-N-methy1-3-(2-methy1-2H-tetrazol-5-yObenzenesulfonamide [00379] To a solution of compound 90-4 (0.9 g, 2.51 mmol, 1 eq) in Me0H (20 mL) were added dry Pd/C (0.45 g, 0.42 mmol, 10% purity, 0.5 eq) and HC1 (12 M, 0.21 mL, 1 eq) at 15 C.
The resulting dark mixture was degassed and refilled with H2 for three times and then stirred at 30 C for 16 h under 45 Psi H2. TLC showed the mixture was complete and new spots were formed. The dark mixture was filtered via a pad of Celite. The filter cake was washed with methanol (10 mL). The filtrate was concentrated to give compound 90-5 (0.55 g, 1.80 mmol, 71.87% yield, HC1), which was used for next step without further purification.
(400MHz, DMSO-d6) 6 8.34 (d, J= 2.0 Hz, 1H), 7.58 - 7.53 (m, 1H), 7.24 - 7.17 (m, 1H), 7.00 (d, J = 9.0 Hz, 1H), 4.47 (s, 3H), 2.38 (d, J= 4.0 Hz, 3H).
Step 5: N-methy1-3-(2-methy1-2H-tetrazol-5-y1)-4-(phenylamino)benzenesulfonamide [00380] To a solution of compound 90-5 (20 mg, 74.5 umol, 1 eq), iodobenzene (30.4 mg, 0.15 mmol, 16 uL, 2 eq) and K3PO4 (47.5 mg, 0.22 mmol, 3 eq) in toluene (1 mL) were added Pd2(dba)3 (6.8 mg, 7.4 umol, 0.1 eq) and Xantphos (8.6 mg, 14.9 umol, 0.2 eq) at 15 C
under nitrogen. The resulting mixture was degassed and refilled with nitrogen for three times and then stirred at 110 C for 16 h under N2. LCMS showed the reaction was complete and 38% of desired product was formed. TLC showed the reaction was complete and new spots were formed.
The mixture was combined with another batch and filtered via a pad of Celite.
The filter cake was washed with EA (30 mL). The filtrate was concentrated to give a residue.
The residue was purified by prep-TLC and then purified by prep-HPLC to give Compound 90 (5.46 mg, 15.9 umol, 21.27% yield). LCMS (ESI): RT = 1.465 min, mass calc. for C15tl16N602S
344.11, m/z found 345.0 [M+11+. 1H NMR (400MHz, DMSO-d6) 6 9.14 (s, 1H), 8.45 (d, J= 2.5 Hz, 1H), 7.69 (dd, J = 2.0, 9.0 Hz, 1H), 7.50 - 7.40 (m, 2H), 7.40 - 7.31 (m, 4H), 7.23 - 7.13 (m, 1H), 4.51 (s, 3H), 2.42 (d, J = 4.5 Hz, 3H).
Example 87: 4-(cyclohexylamino)-N-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)benzenesulfonamide (Compound 91) N=( ,N
C}S
N
H
Preparation of Compound 91:
HO o H2N¨
HO o 0 0 F 91-1a (3 eq) H2SO4(cat) F 91-3a (2.0 eq) (Rµ 411 DCM,0 C, 20 min (Rµ 140 Me0H, Rµ DMF
,S CI \\ ,S 80 C, 120 C, 4 hr N ,S
18hr H
OH N=( HN , N
91-4a (2.0 eq) R\= -0 ____________ NaH(2.0 eq) R\
THF, 0 C-r.t. 16h ,S
,S N
N H
H
91-4 Compound 91 Step 1: 2-fluoro-5-(methylsulfamoyl)benzoic acid [00381] To a solution of 91-1 (1 g, 4.2 mmol, 1 eq) in DCM (10 mL) was added 91-la (2 M, 6.3mL, 3 eq) at 0 C under N2 atmosphere. The mixture was stirred at this temperature for 20 min. LCMS showed reactant 1 was consumed completely and one main peak with MS
of 247 was detected(the sample was dissolved in Me0H). The reaction was quenched by adding HC1 (5 mL, 2M) and separated. The organic layer was washed with brine (10 mL), dried over Na2SO4 and filtered. The filtrate was concentrated to give a residue 91-2 (910 mg, crude). The crude product was used in next step directly without further purification. 1HNMR
(400MHz, DMSO-d6) 6 8.26 (dd, J= 2.3, 6.8 Hz, 1H), 8.02 (ddd, J=2.5, 4.4, 8.7 Hz, 1H), 7.66 (q, J= 4.8 Hz, 1H), 7.58 (dd, J = 8.8, 10.5 Hz, 1H), 2.43 (d, J = 4.8 Hz, 3H).
Step 2: methyl 2-fluoro-5-(methylsulfamoyl)benzoate [00382] To a solution of 91-2 (910 mg, 3.90 mmol, 1 eq) in Me0H (10 mL) was added H2SO4 (38.27 mg, 0.39 mmol, 20.8 uL, 0.1 eq). The mixture was stirred at 80 C
for 4 hr. TLC
showed reactant was consumed completely and one new spot was formed. The reaction mixture was concentrated and the residue was poured into water (20 mL). The aqueous layer was extracted with Et0Ac (5 mL*3), the combined organic layer was washed with brine (10 mL), dried over Na2SO4 and filtered. The filtrate was concentrated to give crude product 91-3 (900 mg, 3.64 mmol, 93.3% yield). The crude product was used in next step directly without further purification. IFINMR (400MHz, DMSO-d6) 6 8.27 (dd, J = 2.4, 6.7 Hz, 1H), 8.05 (ddd, J = 2.5, 4.3, 8.8 Hz, 1H), 7.70 (br d, J = 4.8 Hz, 1H), 7.63 (dd, J= 8.8, 10.5 Hz, 1H), 3.91 (s, 3H), 2.43 (d, J= 5.0 Hz, 3H).
Step 3: methyl 2-(cyclohexylamino)-5-(methylsulfamoyl)benzoate [00383] To a solution of methyl 91-3 (900 mg, 3.64 mmol, 1 eq) in DMSO (4 mL) was added 91-3a (722.0 mg, 7.3 mmol, 833.3 uL, 2.0 eq). The mixture was stirred at 130 C for 4h.
TLC showed reactant was consumed completely and one new spot was formed. LCMS
showed 50% desired MS. The reaction mixture was poured into water (20 mL) and extracted with Et0Ac(10 mL*3). The combined organic layer was washed with brine (10 mL), dried over Na2SO4 and filtered. The filtrate was concentrated to give a residue. The residue was purified by flash silica gel chromatography to give compound 91-4 (750 mg, 2.16 mmol, 59.3% yield).
LCMS (ESI): RT = 0.824 min, mass calc. for Ci5H22N2045 326.13, m/z found 326.9[M+H1+; 11-1 NMR (400MHz, DMSO-d6) 6 8.23 - 8.18 (m, 2H), 7.67 (dd, J = 2.3, 9.0 Hz, 1H), 7.21 (q, J = 5.2 Hz, 1H), 7.00 (d, J= 9.3 Hz, 1H), 3.84 (s, 3H), 3.64 - 3.52 (m, 1H), 2.35 (d, J = 5.3 Hz, 3H), 1.94 (br dd, J= 3.5, 8.8 Hz, 2H), 1.68 (br dd, J= 4.3, 9.0 Hz, 2H), 1.58 (br dd, J = 4.0, 8.5 Hz, 1H), 1.49 - 1.36 (m, 2H), 1.36 - 1.21 (m, 3H).
Step 4: 4-(cyclohexylamino)-N-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)benzenesulfonamide [00384] To a solution of 91-4 (100 mg, 0.31 mmol, 1 eq) in THF (5 mL) was added NaH
(24.5 mg, 0.61 mmol, 60% purity, 2.0 eq) at 0 C, the mixture was stirred for 30 min at this temperature. Then, 91-4a (45.4 mg, 0.61 mmol, 2.0 eq) was added and the mixture was allowed warmed to 10-15 C and stirred for 16hr. LCMS showed -39% of Reactant 91-4 was remained.
Several new peaks were shown on LCMS and -37% of desired compound was detected. The reaction was poured into sat. aq. NH4C1 (10 mL) and extracted with Et0Ac(5 mL*3). The combined organic layer was washed with brine (10 mL), dried over Na2SO4 and filtered to give a residue. The residue was purified by prep-HPLC to give Compound 91 (19.10 mg, 45.91 umol, 15% yield, HC1). LCMS (ESI): RT = 1.234 min, mass calc. for Ci6H22N4035 350.14, m/z found 351.0 [M+H1+; 1HNMR (400MHz, DMSO-d6) 6 8.23 (d, J= 2.3 Hz, 1H), 8.19 ( d, J=
7.5 Hz, 1H), 7.73 (dd, J= 2.3, 9.0 Hz, 1H), 7.30 (d, J= 5.3 Hz, 1H), 7.12 (d, J= 9.3 Hz, 1H), 3.85 (s, 1H), 3.73 - 3.62 (m, 1H), 2.46 (s, 3H), 2.39 (d, J= 5.3 Hz, 3H), 1.99 (d, J =
9.5 Hz, 2H), 1.70 (s, 2H), 1.61-1.58 (m, 1H), 1.49- 1.30 (m, 5H).
Example 88: N-methy1-3-(2-methy1-2H-tetrazol-5-y1)-4-43-(trifluoromethyl)phenyl)amino)benzenesulfonamide (Compound 92) N-N/
HFF
(Rµ N
F
HN-S
Preparation of Compound 92:
N-N/ OH /
F NI-N
HO I.F 1\11 92-la (2.25 eq) N
NH2 __________________________________________________________ F
µµ DIPEA (3.36 eq), 0 C:1 HN-Sµµ Cu(OAc)2 (2.27 eq), HN,Sµµ
0 02 (15 Psi),DCM,25 C,42 h I
92-1 Compound 92 [00385] To a suspension of the compound 92-1 (40 mg, 0.131 mmol, 1 eq, HC1), DIPEA
(57 mg, 0.441 mmol, 3.36 eq) and the compound 92-la (56 mg, 0.295 mmol, 2.25 eq) in DCM
(1 mL) was added Cu(OAc)2 (54 mg, 0.297 mmol, 2.27 eq) in one portion under 02(15 Psi). The reaction mixture was stirred at 25 C for 42 h. LCMS showed 26% of the starting material was remained and 32% of desired product was formed. The reaction mixture was filtered and concentrated in vacuum. LCMS showed 30 % of desired product was detected. HPLC
indicated 39% of desired product was formed. The residue was purified by prep-HPLC. LCMS
and NMR and HMBC confirmed that the product was Compound 92 (9.64 mg, 22.9 umol, 17.5%
yield). LCMS (ESI): RT = 0.808 min, mass calcd. For Ci6H15F3N602S, 412.09 m/z found 413.0[M+H1t 1HNMR (400MHz, CDC13) 6 9.55 (s, 1H), 8.71 (d, J = 2.40 Hz, 1H), 7.76 (dd, J
= 2.40, 9.20 Hz, 1H), 7.58 - 7.49 (m, 3H), 7.46 - 7.41 (m, 1H), 7.35 (d, J =
8.40 Hz, 1H), 4.48 (s, 3H), 4.43 - 4.35 (m, 1H), 2.72 (d, J= 5.60 Hz, 3H).
Example 89: N-methy1-3-(2-methy1-2H-tetrazol-5-y1)-4-42-(trifluoromethyl)phenyl)amino)benzenesulfonamide (Compound 93) N-N
N
,_,m,s , 0 Preparation of Compound 93:
N-N/ F F OH m /
Nii * OH N4 FFF
si c NH2 93-1 a (2.25 eq) C3µ1µ l N
õ HN
HN-S\µ DIPEA (3.36 eq), -S
Cu(OAc)2 (2.27 eq), / 0 1 02 (15 Psi),DCM,25 C,42 h 93-1 Compound 93 [00386] To a suspension of the compound 93-1 (40 mg, 0.13 mmol, 1 eq, HC1) ,DIPEA
(57 mg, 0.441 mmol, 3.36 eq) and the compound 93-la (56 mg, 0.295 mmol, 2.25 eq) in DCM
(1 mL) was added Cu(0Ac)2 (54 mg, 0.297 mmol, 2.27 eq) in one portion under 02(15 Psi). The reaction mixture was stirred at 25 C for 42 h. LCMS showed 47% of the starting material was remained and 23% of desired product was formed. The reaction mixture was filtered and concentrated in vacuum. LCMS showed 18% of desired product was detected. HPLC
indicated 26% of desired product was formed. The residue was purified by prep-HPLC. LCMS
and 1HNMR confirmed the product was Compound 93 (6.06 mg, 14.7 umol, 11.2%
yield). LCMS (ESI): RT = 0.789 min, mass calcd. For Ci6H15F3N602S, 412.09 m/z found 413.0[M+Hr 1HNMR (400MHz, CDC13) 6 9.54 (s, 1H), 8.76 (d, J = 2.00 Hz, 1H), 7.76 (d, J=
8.00 Hz, 1H), 7.72 (dd, J= 2.30, 8.80 Hz, 1H), 7.62 - 7.54 (m, 2H), 7.35 -7.28 (m, 1H), 7.21 (d, J= 8.80 Hz, 1H), 4.46 (s, 3H), 4.39 (br d, J= 5.50 Hz, 1H), 2.71 (d, J= 5.50 Hz, 3H).
Example 90: N-methy1-3-(2-methy1-2H-tetrazol-5-y1)-4-43-(trifluoromethoxy)phenyl)amino)benzenesulfonamide (Compound 94) 1-1\-11 0 F
µµ = )<F
HN-Sµµ
Preparation of Compound 94:
OH
N/
¨N HO N¨N/
' 410 0õF
rF
94-1a (2.25 eq) 0 F lei NH2 _____ DIPEA (3.36 eq), (R\ ei = )<F
HN,\Sµµ -Sµ
Cu(OAc)2 (2.27 eq), HN b 02 (15 Psi),DCM,rt,64 h 94-1 Compound 94 [00387] To a suspension of the compound 94-1 (40 mg, 0.131 mmol, 1 eq, HC1), DIPEA
(57 mg, 0.441 mmol, 3.36 eq) and the compound 94-la (61 mg, 0.296 mmol, 2.26 eq) in DCM
(1.5 mL) was added Cu(0Ac)2(54 mg, 0.297 mmol, 2.27 eq) in one portion under 02(15 Psi).
The mixture was stirred at 12 C for 64 h. LCMS showed 36% of the starting material was remained and 23% of desired product was formed. The reaction mixture was filtered and concentrated in vacuum. LCMS showed 17% of desired product was detected. HPLC
indicated 18% of desired product was formed. The residue was purified by prep-HPLC. LCMS
and NMR confirmed that the product was Compound 94 (5.35 mg, 12.5 umol, 9.5% yield).
LCMS (EST): RT = 0.815 min, mass calcd. For Ci6H15F3N603S, 428.09 m/z found 429.0[M+Ht 1HNMR (400MHz, CDC13) 6 9.52 (s, 1H), 8.71 (d, J = 2.2 Hz, 1H), 7.75 (dd, J =
2.20, 9.00 Hz, 1H), 7.47 - 7.35 (m, 2H), 7.24 (s, 1H), 7.19 (s, 1H), 7.07 - 7.00 (m, 1H), 4.48 (s, 3H), 4.31 (br d, J = 5.30 Hz, 1H), 2.72 (d, J = 5.50 Hz, 3H).
Example 91: N-methy1-3-(2-methy1-2H-tetrazol-5-y1)-4-44-(trifluoromethyl)phenyl)amino)benzenesulfonamide (Compound 95) N-N
N
F
HN,Sµµ
I F F
Preparation of Compound 95:
pH
N-N/ `1 .B
HO Ai =11 N=N
F
NN --N N FE NN
--N N
40 NH, 40 0 NH2 DIPEA (3.0 eq), 0 N
HNSµµ HNSµµ F N
F
Cu(OAc)2 (1.5 eq), HN HN
02(15 Psi),DCM,25 C,16 h F F
q=40 µ IF (trifluoromethoxy)phenyl)amino)ben HN-Sµµ F
zenesulfonamide N¨N/
IT ,N N-methy1-3-(2-methy1-2H-tetrazol-H 5-y1)-4-((4-0 (trifluoromethyl)phenyl)amino)benz µs.
-S el N el F
HN \\ enesulfonamide FF
N=N
N ;N N-methy1-3-(1-methy1-1H-tetrazol-H
N 0 5-y1)-4-((4-CZµ SI F (trifluoromethyl)phenyl)amino)benz ,Sµ F
HN b F enesulfonamide I
N=N
--IV .,A N-methy1-3-(1-methy1-1H-tetrazol-H F
F
O. 1410 F (trifluoromethyl)phenyl)amino)benz -S
HN µµ enesulfonamide ,N-..z.N
N-methy1-3-(1-methy1-1H-tetrazol-----N
F F 5-y1)-4-((2-(trifluoromethyl)phenyl)amino)benz FIN'S%
/ b . enesulfonamide N=N
I\I i\1 N-methy1-3-(1-methy1-1H-tetrazol-H
F
CZµ 0 )< F
(trifluoromethoxy)phenyl)amino)ben ,S\ 0 F
HN b zenesulfonamide I
Compound Structure Name No.
N=N
'N /N
H 5-y1)-4-((3-100 . N eil c:IF
(Rµ IF
(trifluoromethoxy)phenyl)amino)ben ,S F
HN µµ zenesulfonamide ,N:---N
....j<F N-methy1-3-(1-methy1-1H-tetrazol-H 0 F 5-y1)-4-((2-101 401 N Isi Ci'µ
(trifluoromethoxy)phenyl)amino)ben ,S
HN \\ zenesulfonamide i 0 N /
¨N
Nii rµ\I F N-methy1-3-(2-methy1-2H-tetrazol-,kF
H 0 F 5-y1)-4-((2-102 N õI
Ci'µ
(trifluoromethoxy)phenyl)amino)ben um,S
n I sl \\ zenesulfonamide /
N¨N
N
,, x N % N-methy1-3-(2-methy1-2H-tetrazol-H 5-y1)-4-((4-F
0 )<F (trifluoromethoxy)phenyl)amino)ben HN,s,b 0 F
zenesulfonamide I
/
N¨N
Nis i\i 4-((2,3-difluorophenyl)amino)-N-H F
104 . N . F methy1-3-(2-methy1-2H-tetrazol-5-0\ yl)benzenesulfonamide HN-I '0 INI---( (cyclohexylamino)-N-methy1-3-µ
H
105 . No (5-methy1-1,3,4-oxadiazol-2-qµ yl)benzenesulfonamide ,S
HN µµ
Compound Structure Name No.
N=N
--IV
H F
4-((2,3-difluorophenyl)amino)-N-106 r F
methy1-3-(1-methy1-1H-tetrazol-5-µµ 4 .
HN-S yl)benzenesulfonamide \\
N=N
N
4-((3,5-difluorophenyl)amino)-N-H
107 0 0 N el F methy1-3-(1-methy1-1H-tetrazol-5-\\
HN-S\\ yl)benzenesulfonamide N¨N/
NI' N 4-((3,5-difluorophenyl)amino)-N-H
108 F methyl-3-(2-methy1-2H-tetrazol-5-0 el NO
\\
,S yl)benzenesulfonamide HN µµ
N=N
,NI i\1 F 4-((2,5-difluorophenyl)amino)-N-H
HN,S\\ methy1-3-(1-methy1-1H-tetrazol-5-yl)benzenesulfonamide I F
141 , N F 4-((2,5-difluorophenyl)amino)-N-H
110 N methy1-3-(2-methy1-2H-tetrazol-5-qµ 40 el HN,Sµµ yl)benzenesulfonamide P
r-N
//
N / 4-(cyclohexylamino)-3-(1-cyclopropy1-1H-imidazol-4-y1)-N-0, 401 N
methylbenzenesulfonamide ,\Sµ
HN `0 I
Compound Structure Name No.
NI¨
in N z 4-(cy cl ohexylamino)-3-(1-ethy 1-1H-H
Y ) 112 (:)µµ 0 No imidazol-4- 1 -N-methy lbenzenes ulfonami de HN,Sµ`
I
IF N
N / 4-(cyclohexylamino)-3-(1-isopropyl-H
113 N-0 1H-imidazol-4-y1)-N-0µ 41 methy lbenzenes ulfonami de ; S \
HN \ID
I
/=N
r" H
4-(cy cl ohexylamino)-3-(1-ethy 1-1H-114 czµ 0 NI) imidazol-5-y1)-N-methy lbenzenes ulfonami de I
3 -(2-(2-(benzyloxy)ethyl)-2H-tetrazol-5-y1)-N-methy1-4-44-;N (trifluoromethyl)phenyl)amino)benz H
N enesulfonami de 0µµ el SF
,S\ F
HN F
OH
3 -(2-(2-hy droxy ethyl)-2H-tetrazol-N-N
;N 5 -y1)-N-methy1-4-((4-czµ 0 N 0 F
(trifluoromethyl)phenyl)amino)benz enesulfonami de ,S\ F
HN F
I
Compound Structure Name No.
NN"
I, N /%\/ 4-((3-fluorophenyl)amino)-N-H
117 methyl-3-(2-methy1-2H-tetrazol-5-iN
yl)benzenesulfonamide S
HN -µµ
N¨N/
14 4-((4-fluorophenyl)amino)-N-H
118 methyl-3-(2-methy1-2H-tetrazol-5-HN \\ N
9µ = 411 yl)benzenesulfonamide -S
pz.-N
¨N rµ\/
4-((4-fluorophenyl)amino)-N-H
40 119 methyl-3-(1-methy1-1H-tetrazol-5-riN ) =
õ-S yl)benzenesulfonamide \\ N
N¨N/
1\11 l'\1 4-((2-fluorophenyl)amino)-N-H F
120 methyl-3-(2-methy1-2H-tetrazol-5-= N ei yl)benzenesulfonamide , ,õ,,S
riN \\
/
/i¨N
N-methy1-3-(1-methy1-1H-imidazol-N /
H 4-y1)-4-44-0µµ el F
(trifluoromethyl)phenyl)amino)benz HN,s\b F enesulfonamide F
I
N,,, /
¨N
Nii /µ\/ 4-((3,4-difluorophenyl)amino)-N-H
122 methyl-3-(2-methy1-2H-tetrazol-5-(R N
µ .
. F
yl)benzenesulfonamide iN H õõ, ...S
\\
Compound Structure Name No.
---\
N¨\\
3-(1 -ethyl- 1 H-imidazol-4-y1)-N-x N
methy1-4-((4-(trifluoromethyl)phenyl)amino)benz µµ 0 HN,Sµµ
F enesulfonami de \N¨\\
N N N-methy1-3-(1-methy 1-1H-imi dazol-H
czµ 4-y1)-4-((3-(trifluoromethyl)phenyl)amino)benz HN,Sµ` enesulfonami de F
----\
N-\\
N N 3-(1 -ethyl- 1 H-imidazol-4-y1)-N-H
N methyl-4-((3-(trifluoromethyl)phenyl)amino)benz .
HN,Sµ` enesulfonami de F
N¨\\ 3 -(1 -cy clopropy1-1H-imidazol-4-y1)-N N
N-methy1-4-((4-N (trifluoromethyl)phenyl)amino)benz F
-S enesulfonami de HN µ` F
.k N¨\\ 3 -(1 -cy clopropy1-1H-imidazol-4-y1)-x N
H N-methy1-4-((3 -127 (:)µµ 0 N s (trifluoromethyl)phenyl)amino)benz NH,Sµµ enesulfonami de F
Compound Structure Name No.
N¨N
N N N-methy1-3-(2-methyltetrazol-5-y1)-128 NH 4-(4-phenylanilino) (:)µµ NHS benzenesulfonamide I
N¨N
%\
N N
N,N-dimethy1-3-(2-methyltetrazol-5-129 el NH y1)-4-(4-CZµ
phenylanilino)benzenesulfonamide -Sµ
N
N-N
I\L
N-methy1-3-(2-methyltetrazol-5-y1)-R\ 40 4-(4-phenoxyanilino) NH"S\\ 0 benzenesulfonamide I
1.1 N¨N
N N N-methy1-3-(2-methyltetrazol-5-y1)-H
131 czµ N 4-(3-phenylanilino) benzenesulfonamide .S
NH µ`
I
N¨N
,µ
N N N, N-dimethy1-3-(2-methyltetrazol-H
132 zµ N 5-y1)-4-(3-phenylanilino) O
benzenesulfonamide ,S\
N
I -)=N 3-(5-amino-1,3,4-oxadiazol-2-y1)-N-methyl-4-[4-133 (:)µµ N
(trifluoromethyDanilinolbenzenesulf -S HN onamide F
Compound Structure Name No.
\
N¨N
N N N-methy1-3-(2-methyltetrazol-5-y1)-134 0 NH is 0 0 4-(3-Rµ phenoxyanilino)benzenesulfonamide .S
NH µ`
I
\
N-N
i %%
N N N,N-dimethy1-3-(2-methyltetrazol-5-135 0 NH 0 0 s y1)-4-(3-N" Rµ phenoxyanilino)benzenesulfonamide -S
F
40 3-[2-[(2-NI!
FluorophenyOmethylltetrazol-5-y11-N N
136 H N-methy1-443-Co4 (trifluoromethyDanilinolbenzenesulf ,s N b F F onamide H
F
F
3-[2-[(2-. N-N FluorophenyOmethylltetrazol-5-y11-Ni , Iv 137 H N-methyl-4-[4-N
0µµ 40 IS F (trifluoromethyDanilinolbenzenesulf ,s N µ` F onamide H F
\
N-N
Ni, Iv N-(tert-buty1)-3-(2-methy1-2H-H tetrazol-5-y1)-4-44-N
R\ 40 40 F (trifluoromethyl)phenyl)amino)benz HN,Sµ` F
0 F enesulfonamide Compound Structure Name No.
\N-\\
N N 4-(4-chloroanilino)-N-methy1-3-(1-H
139 N methylimidazol-CZ\ el el yl)benzenesulfonamide HN,Sµ` CI
I
\N-\\
N N 4-(3,4-dichloroanilino)-N-methy1-3-H
140 czµ 0 N 0 CI (1-methylimidazol-4-yl)benzenesulfonamide HN,Sµ` CI
I
\N-\\
N-methy1-3-(1-methylimidazol-4-N N
H y1)-4-13-IF (trifluoromethylsulfanyl)anilinolben µµ SI 1401 F
HN,S\\
zenesulfonamide \N--\\
N N 4-(3,5-dichloroanilino)-N-methy1-3-H
142 czµ N 0 CI (1-methylimidazol-4-yl)benzenesulfonamide HN,Sµ`
\N-\\
N N 4-(3-Chloroanilino)-N-methy1-3-(1-H
143 N 0 CI methylimidazol-yl)benzenesulfonamide HN,Sµµ
I 'D
\N-\\
N-methy1-3-(1-methylimidazol-4-x N
H y1)-4-14-144 0 N .
µµ
(trifluoromethylsulfanyl)anilinolben -S HN µ` SF
IF zenesulfonamide Compound Structure Name No.
\N¨\\
N N N-methy1-3-(1-methylimidazol-4-H
145 co.N.CI y1)-4-(3,4,5-trichloroanilino)benzenesulfonamide ,S CI
HN µ`
I CI
\N¨\\
NN
H
F F 443,5-Bis(trifluoromethypanilinol-N
146 40) F N-methy1-3-(1-methylimidazol-4-0Z\ 0 ,S yl)benzenesulfonamide HN µ`
F
\
N¨\\
x N 4-[4-Chloro-3-H
N
(trifluoromethyDanilinol-N-methyl-0µµ el 0 3-(1-methylimidazol-4-,S CI
HN µ` yl)benzenesulfonamide I F F
F
\N--\\
4-[3-Chloro-4-x N
H (trifluoromethyDanilinol-N-methyl-CZµ I. . F 3-(1-methylimidazol-4-,S
HN µ` I 0 F F yl)benzenesulfonamide \N¨\\
N N 4-((2,6-Difluorophenyl)amino)-N-F
H
149 0 N 0 methyl-3-(1-methy1-1H-imidazol-4-gµ
F yl)benzenesulfonamide ,S
HN µ`
I
Compound Structure Name No.
N¨\\
N-methy1-3-(1-methy1-1H-imidazol-N N
H H 4-y1)-4-4(1s,4s)-4-150 =
(trifluoromethyl)cyclohexyl)amino)b C}S N F
HN F enzenesulfonamide N¨\\
N-methy1-3-(1-methy1-1H-imidazol-x N
H H 4-y1)-4-4(1r,40-4-151 czµ Nq< (trifluoromethyl)cyclohexyl)amino)b -S
HN H F enzenesulfonamide 3-(2-Aminopyridin-4-y1)-N-methyl-4-((3-F (trifluoromethyl)phenyl)amino)benz CZ\
-S
HN enesulfonamide 3-(2-Aminopyridin-4-y1)-N-methyl-CZµ F (trifluoromethyl)phenyl)amino)benz -S
HN enesulfonamide Preparation of the Compounds [00145] The compounds used in the reactions described herein are made according to organic synthesis techniques known to those skilled in this art, starting from commercially available chemicals and/or from compounds described in the chemical literature. "Commercially available chemicals" are obtained from standard commercial sources including Acros Organics (Pittsburgh, PA), Aldrich Chemical (Milwaukee, WI, including Sigma Chemical and Fluka), Apin Chemicals Ltd. (Milton Park, UK), Avocado Research (Lancashire, U.K.), BDH
Inc. (Toronto, Canada), Bionet (Cornwall, U.K.), Chemservice Inc. (West Chester, PA), Crescent Chemical Co.
(Hauppauge, NY), Eastman Organic Chemicals, Eastman Kodak Company (Rochester, NY), Fisher Scientific Co. (Pittsburgh, PA), Fisons Chemicals (Leicestershire, UK), Frontier Scientific (Logan, UT), ICN Biomedicals, Inc. (Costa Mesa, CA), Key Organics (Cornwall, U.K.), Lancaster Synthesis (Windham, NH), Maybridge Chemical Co. Ltd. (Cornwall, U.K.), Parish Chemical Co.
(Orem, UT), Pfaltz & Bauer, Inc. (Waterbury, CN), Polyorganix (Houston, TX), Pierce Chemical Co. (Rockford, IL), Riedel de Haen AG (Hanover, Germany), Spectrum Quality Product, Inc.
(New Brunswick, NJ), TCI America (Portland, OR), Trans World Chemicals, Inc.
(Rockville, MD), and Wako Chemicals USA, Inc. (Richmond, VA).
[00146] Methods known to one of ordinary skill in the art are identified through various reference books and databases. Suitable reference books and treatise that detail the synthesis of reactants useful in the preparation of compounds described herein, or provide references to articles that describe the preparation, include for example, "Synthetic Organic Chemistry", John Wiley & Sons, Inc., New York; S. R. Sandler et al., "Organic Functional Group Preparations,"
2nd Ed., Academic Press, New York, 1983; H. 0. House, "Modern Synthetic Reactions", 2nd Ed., W. A. Benjamin, Inc. Menlo Park, Calif 1972; T. L. Gilchrist, "Heterocyclic Chemistry", 2nd Ed., John Wiley & Sons, New York, 1992; J. March, "Advanced Organic Chemistry:
Reactions, Mechanisms and Structure", 4th Ed., Wiley-Interscience, New York, 1992. Additional suitable reference books and treatise that detail the synthesis of reactants useful in the preparation of compounds described herein, or provide references to articles that describe the preparation, include for example, Fuhrhop, J. and Penzlin G. "Organic Synthesis: Concepts, Methods, Starting Materials", Second, Revised and Enlarged Edition (1994) John Wiley & Sons ISBN: 3-527-29074-5; Hoffman, R.V. "Organic Chemistry, An Intermediate Text"
(1996) Oxford University Press, ISBN 0-19-509618-5; Larock, R. C. "Comprehensive Organic Transformations: A Guide to Functional Group Preparations" 2nd Edition (1999) Wiley-VCH, ISBN: 0-471-19031-4; March, J. "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure" 4th Edition (1992) John Wiley & Sons, ISBN: 0-471-60180-2; Otera, J. (editor) "Modern Carbonyl Chemistry" (2000) Wiley-VCH, ISBN: 3-527-29871-1; Patai, S.
"Patai's 1992 Guide to the Chemistry of Functional Groups" (1992) Interscience ISBN: 0-471-93022-9;
Solomons, T. W. G. "Organic Chemistry" 7th Edition (2000) John Wiley & Sons, ISBN: 0-471-19095-0; Stowell, J.C., "Intermediate Organic Chemistry" 2nd Edition (1993) Wiley-Interscience, ISBN: 0-471-57456-2; "Industrial Organic Chemicals: Starting Materials and Intermediates: An Ullmann's Encyclopedia" (1999) John Wiley & Sons, ISBN: 3-527-29645-X, in 8 volumes; "Organic Reactions" (1942-2000) John Wiley & Sons, in over 55 volumes; and "Chemistry of Functional Groups" John Wiley & Sons, in 73 volumes.
[00147] In some instances, specific and analogous reactants are identified through the indices of known chemicals prepared by the Chemical Abstract Service of the American Chemical Society, which are available in most public and university libraries, as well as through on-line databases (the American Chemical Society, Washington, D.C., is contacted for more details). Chemicals that are known but not commercially available in catalogs are prepared by custom chemical synthesis houses, where many of the standard chemical supply houses (e.g., those listed above) provide custom synthesis services. A reference for the preparation and selection of pharmaceutical salts of the compounds described herein is P. H.
Stahl & C. G.
Wermuth "Handbook of Pharmaceutical Salts", Verlag Helvetica Chimica Acta, Zurich, 2002.
[00148] In some embodiments, the compounds disclosed herein are prepared as described in the Examples section.
Further Forms of Compounds Disclosed Herein Isomers [00149] Furthermore, in some embodiments, the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein possess one or more double bonds. The compounds presented herein include all cis, trans, syn, anti, entgegen (F), and zusammen (Z) isomers as well as the corresponding mixtures thereof In some situations, compounds exist as tautomers. The compounds described herein include all possible tautomers within the formulas described herein. In some situations, the compounds described herein possess one or more chiral centers and each center exists in the R
configuration, or S
configuration. The compounds described herein include all diastereomeric, enantiomeric, and epimeric forms as well as the corresponding mixtures thereof In additional embodiments of the compounds and methods provided herein, mixtures of enantiomers and/or diastereoisomers, resulting from a single preparative step, combination, or interconversion are useful for the applications described herein. In some embodiments, the compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers, and recovering the optically pure enantiomers. In some embodiments, disclosed herein are dissociable complexes (e.g., crystalline diastereomeric salts). In some embodiments, the diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and are separated by taking advantage of these dissimilarities. In some embodiments, the diastereomers are separated by chiral chromatography, or preferably, by separation/resolution techniques based upon differences in solubility. In some embodiments, the optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that does not result in racemization.
Labeled compounds [00150] In some embodiments, the compounds described herein exist in their isotopically-labeled forms. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such isotopically-labeled compounds. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such isotopically-labeled compounds as pharmaceutical compositions. Thus, in some embodiments, the compounds disclosed herein include isotopically-labeled compounds, which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. In some embodiments, examples of isotopes that are incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, and chlorine, such as 2H, 3H, 13C, 14C, 15N, 180, 170, 31p, 32p, 35s, 18F, and 36C1, respectively. Compounds described herein, and the metabolites, pharmaceutically acceptable salts, esters, prodrugs, solvates, hydrates, or derivatives thereof which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this disclosure. Certain isotopically-labeled compounds, for example those into which radioactive isotopes such as 3H and 14C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i. e., 3H and carbon-14, i. e., u isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavy isotopes such as deuterium, i.e. ,2H, produces certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements. In some embodiments, the isotopically labeled compounds, pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof is prepared by any suitable method.
[00151] In some embodiments, the compounds described herein are labeled by other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.
Pharmaceutically acceptable salts [00152] In some embodiments, the compounds described herein exist as their pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts as pharmaceutical compositions.
[00153] In some embodiments, the compounds described herein possess acidic or basic groups and therefore react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt. In some embodiments, these salts are prepared in situ during the final isolation and purification of the compounds of the disclosure, or by separately reacting a purified compound in its free form with a suitable acid or base, and isolating the salt thus formed.
Solvates [00154] In some embodiments, the compounds described herein exist as solvates. The disclosure provides for methods of treating diseases by administering such solvates. The disclosure further provides for methods of treating diseases by administering such solvates as pharmaceutical compositions.
[00155] Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and, in some embodiments, are formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, and the like.
Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. In some embodiments, solvates of the compounds described herein are conveniently prepared or formed during the processes described herein. By way of example only, hydrates of the compounds described herein are conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents including, but not limited to, dioxane, tetrahydrofuran, or methanol. In some embodiments, the compounds provided herein exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.
Prodrugs [00156] In some embodiments, the compounds described herein exist in prodrug form.
The disclosure provides for methods of treating diseases by administering such prodrugs. The disclosure further provides for methods of treating diseases by administering such prodrugs as pharmaceutical compositions.
[00157] In some embodiments, prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e. g., two, three, or four) amino acid residues is covalently joined through an amide or ester bond to a free amino, hydroxy, or carboxylic acid group of compounds of the present disclosure. The amino acid residues include, but are not limited to, the 20 naturally occurring amino acids and also includes 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvaline, beta-alanine, gamma-aminobutyric acid, cirtulline, homocysteine, homoserine, ornithine, and methionine sulfone. In other embodiments, prodrugs include compounds wherein a nucleic acid residue, or an oligonucleotide of two or more (e. g., two, three or four) nucleic acid residues is covalently joined to a compound of the present disclosure.
[00158] Pharmaceutically acceptable prodrugs of the compounds described herein also include, but are not limited to, esters, carbonates, thiocarbonates, N-acyl derivatives, N-acyloxyalkyl derivatives, quaternary derivatives of tertiary amines, N-Mannich bases, Schiff bases, amino acid conjugates, metal salts, and sulfonate esters. In some embodiments, compounds having free amino, amido, hydroxy, or carboxylic groups are converted into prodrugs. For instance, free carboxyl groups are derivatized as amides or alkyl esters. In certain instances, all of these prodrug moieties incorporate groups including, but not limited to, ether, amine, and carboxylic acid functionalities.
[00159] Hydroxy prodrugs include esters such as, though not limited to, acyloxyalkyl (e.g.
acyloxymethyl, acyloxyethyl) esters, alkoxycarbonyloxyalkyl esters, alkyl esters, aryl esters, sulfonate esters, sulfate esters and disulfide containing esters, ethers, amides, carbamates, hemisuccinates, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, as outlined in Advanced Drug Delivery Reviews 1996, 19, 115.
[00160] Amine derived prodrugs include, but are not limited to, the following groups and combinations of groups:
¨N)LR ¨N")"0".R ¨NAT. R ¨N)(0-R ¨NS'RR ¨Nr-LO)j"0-_NCIrk I I R ¨NI-1"S)1"R ¨NI-.1"0)1"R ¨NI-1"S)1"R
R R R ,1, R R
¨N 0 ¨N 0 0R ¨N 0 ¨N S 0 ¨N S
¨so as well as sulfonamides and phosphonamides.
[00161] In certain instances, sites on any aromatic ring portions are susceptible to various metabolic reactions, therefore incorporation of appropriate substituents on the aromatic ring structures reduce, minimize, or eliminate this metabolic pathway.
Metabolites [00162] In some embodiments, compounds described herein are susceptible to various metabolic reactions. Therefore, in some embodiments, incorporation of appropriate substituents into the structure will reduce, minimize, or eliminate a metabolic pathway. In specific embodiments, the appropriate substituent to decrease or eliminate the susceptibility of an aromatic ring to metabolic reactions is, by way of example only, a halogen or an alkyl group.
[00163] In additional or further embodiments, the compounds described herein are metabolized upon administration to an organism in need to produce a metabolite that is then used to produce a desired effect, including a desired therapeutic effect.
Pharmaceutical Compositions [00164] In certain embodiments, the compound as described herein is administered as a pure chemical. In other embodiments, the compound described herein is combined with a pharmaceutically suitable or acceptable carrier (also referred to herein as a pharmaceutically suitable (or acceptable) excipient, physiologically suitable (or acceptable) excipient, or physiologically suitable (or acceptable) carrier) selected on the basis of a chosen route of administration and standard pharmaceutical practice as described, for example, in Remington:
The Science and Practice of Pharmacy (Gennaro, 21st Ed. Mack Pub. Co., Easton, PA (2005)), the disclosure of which is hereby incorporated herein by reference in its entirety.
[00165] Accordingly, provided herein is a pharmaceutical composition comprising at least one compound described herein, or a stereoisomer, pharmaceutically acceptable salt, hydrate, solvate, or N-oxide thereof, together with one or more pharmaceutically acceptable carriers. The carrier(s) (or excipient(s)) is acceptable or suitable if the carrier is compatible with the other ingredients of the composition and not deleterious to the recipient (i.e., the subject) of the composition.
[00166] One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Formula (I), or a pharmaceutically acceptable salt thereof [00167] Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (I), or a pharmaceutically acceptable salt thereof [00168] In certain embodiments, the compound as described herein is substantially pure, in that it contains less than about 5%, or less than about 1%, or less than about 0.1%, of other organic small molecules, such as contaminating intermediates or by-products that are created, for example, in one or more of the steps of a synthesis method.
[00169] These formulations include those suitable for oral, rectal, topical, buccal, parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous), rectal, vaginal, or aerosol administration, although the most suitable form of administration in any given case will depend on the degree and severity of the condition being treated and on the nature of the particular compound being used. For example, disclosed compositions are formulated as a unit dose, and/or are formulated for oral or subcutaneous administration.
[00170] In some instances, exemplary pharmaceutical compositions are used in the form of a pharmaceutical preparation, for example, in solid, semisolid, or liquid form, which includes one or more of a disclosed compound, as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for external, enteral, or parenteral applications. In some embodiments, the active ingredient is compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use. The active object compound is included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or condition of the disease.
[00171] For preparing solid compositions such as tablets in some instances, the principal active ingredient is mixed with a pharmaceutical carrier, e.g., conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate, or gums, and other pharmaceutical diluents, e.g., water, to form a solid preformulation composition containing a homogeneous mixture of a disclosed compound or a non-toxic pharmaceutically acceptable salt thereof When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition is readily subdivided into equally effective unit dosage forms such as tablets, pills, and capsules.
[00172] In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the subject composition is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, acetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof and (10) coloring agents. In the case of capsules, tablets and pills, the compositions also comprise buffering agents in some embodiments. Solid compositions of a similar type are also employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
[00173] In some instances, a tablet is made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets are prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets are made by molding in a suitable machine a mixture of the subject composition moistened with an inert liquid diluent. Tablets, and other solid dosage forms, such as dragees, capsules, pills and granules, are optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art.
[00174] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the subject composition, the liquid dosage forms contain optionally inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, cyclodextrins and mixtures thereof [00175] Suspensions, in addition to the subject composition, optionally contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof [00176] In some embodiments, formulations for rectal or vaginal administration are presented as a suppository, which are prepared by mixing a subject composition with one or more suitable non-irritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the body cavity and release the active agent.
[00177] Dosage forms for transdermal administration of a subject composition include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active component is optionally mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which are required in some embodiments.
[00178] In some embodiments, the ointments, pastes, creams and gels contain, in addition to a subject composition, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof [00179] In some embodiments, powders and sprays contain, in addition to a subject composition, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
[00180] Compositions and compounds disclosed herein are alternatively administered by aerosol. This is accomplished by preparing an aqueous aerosol, liposomal preparation or solid particles containing the compound. A non-aqueous (e.g., fluorocarbon propellant) suspension could be used. Sonic nebulizers are used because they minimize exposing the agent to shear, which result in degradation of the compounds contained in the subject compositions in some embodiments. Ordinarily, an aqueous aerosol is made by formulating an aqueous solution or suspension of a subject composition together with conventional pharmaceutically acceptable carriers and stabilizers. The carriers and stabilizers vary with the requirements of the particular subject composition, but typically include non-ionic surfactants (Tweens, Pluronics, or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars or sugar alcohols.
Aerosols generally are prepared from isotonic solutions.
[00181] Pharmaceutical compositions suitable for parenteral administration comprise a subject composition in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders which are reconstituted into sterile injectable solutions or dispersions just prior to use, which optionally contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
[00182] Examples of suitable aqueous and non-aqueous carriers employed in the pharmaceutical compositions include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate and cyclodextrins. In some embodiments, proper fluidity is maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants [00183] Also contemplated are enteral pharmaceutical formulations including a disclosed compound and an enteric material; and a pharmaceutically acceptable carrier or excipient thereof Enteric materials refer to polymers that are substantially insoluble in the acidic environment of the stomach, and that are predominantly soluble in intestinal fluids at specific pHs. The small intestine is the part of the gastrointestinal tract (gut) between the stomach and the large intestine, and includes the duodenum, jejunum, and ileum. The pH of the duodenum is about 5.5, the pH of the jejunum is about 6.5 and the pH of the distal ileum is about 7.5.
Accordingly, enteric materials are not soluble, for example, until a pH of about 5.0, of about 5.2, of about 5.4, of about 5.6, of about 5.8, of about 6.0, of about 6.2, of about 6.4, of about 6.6, of about 6.8, of about 7.0, of about 7.2, of about 7.4, of about 7.6, of about 7.8, of about 8.0, of about 8.2, of about 8.4, of about 8.6, of about 8.8, of about 9.0, of about 9.2, of about 9.4, of about 9.6, of about 9.8, or of about 10Ø Exemplary enteric materials include cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (HPMCP), polyvinyl acetate phthalate (PVAP), hydroxypropyl methylcellulose acetate succinate (HPMCAS), cellulose acetate trimellitate, hydroxypropyl methylcellulose succinate, cellulose acetate succinate, cellulose acetate hexahydrophthalate, cellulose propionate phthalate, cellulose acetate maleate, cellulose acetate butyrate, cellulose acetate propionate, copolymer of methylmethacrylic acid and methyl methacrylate, copolymer of methyl acrylate, methylmethacrylate and methacrylic acid, copolymer of methylvinyl ether and maleic anhydride (Gantrez ES series), ethyl methyacrylate-methylmethacrylate-chlorotrimethylammonium ethyl acrylate copolymer, natural resins such as zein, shellac and copal collophorium, and several commercially available enteric dispersion systems (e.g., Eudragit L30D55, Eudragit FS30D, Eudragit L100, Eudragit S100, Kollicoat EMM30D, Estacryl 30D, Coateric, and Aquateric). The solubility of each of the above materials is either known or is readily determinable in vitro. The foregoing is a list of possible materials, but one of skill in the art with the benefit of the disclosure will recognize that it is not comprehensive and that there are other enteric materials that meet the objectives of the present disclosure.
[00184] In some embodiments, the dose of the composition comprising at least one compound as described herein differ, depending upon the patient's (e.g., human) condition, that is, stage of the disease, general health status, age, and other factors that a person skilled in the medical art will use to determine dose.
[00185] In some instances, pharmaceutical compositions are administered in a manner appropriate to the disease to be treated (or prevented) as determined by persons skilled in the medical arts. An appropriate dose and a suitable duration and frequency of administration will be determined by such factors as the condition of the patient, the type and severity of the patient's disease, the particular form of the active ingredient, and the method of administration. In general, an appropriate dose and treatment regimen provides the composition(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit (e.g., an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free and/or overall survival, or a lessening of symptom severity. Optimal doses are generally determined using experimental models and/or clinical trials. In some embodiments, the optimal dose depends upon the body mass, weight, or blood volume of the patient.
[00186] In some embodiments, oral doses typically range from about 1.0 mg to about 1000 mg, one to four times, or more, per day.
The Hippo Signaling Network [00187] The Hippo signaling network (also known as the Salvador/Warts/Hippo (SWH) pathway) is a master regulator of cell proliferation, death, and differentiation. In some embodiments, the main function of the Hippo signaling pathway is to regulate negatively the transcriptional co-activators Yes-associated protein (YAP) and its paralogue, the transcriptional co-activator with PDZ-binding motif (TAZ; also known as WWTR1) (FIG. 1). The Hippo kinase cascade phosphorylates and inhibits YAP/TAZ by promoting its cytoplasmic retention and degradation, thereby inhibiting the growth promoting function regulated under the YAP/TAZ control. In an un-phosphorylated/de-phosphorylated state, YAP, also known as YAP1 or YAP65, together with TAZ, are transported into the nucleus where they interact with TEAD
family of transcription factors to upregulate genes that promote proliferation and migration, and inhibit apoptosis. In some instances, unregulated upregulation of these genes involved in proliferation, migration, and anti-apoptosis leads to development of cancer.
In some instances, overexpression of YAP/TAZ is associated with cancer.
[00188] Additional core members of the Hippo signaling pathway comprise the serine/threonine kinases MST1/2 (homologues ofHippo/Hpo in Drosophila), Lats1/2 (homologues of Warts/Wts), and their adaptor proteins Savl (homologue of Salvador/Say) and Mob (MOBKL1A and MOBKL1B; homologues of Mats), respectively (FIG. 1). In general, MST1/2 kinase complexes with the scaffold protein Savl, which in turn phosphorylates and activates Lats1/2 kinase. Lats1/2 is also activated by the scaffold protein Mob. The activated Lats1/2 then phosphorylates and inactivates YAP or its paralog TAZ. The phosphorylation of YAP/TAZ leads to their nuclear export, retention within the cytoplasm, and degradation by the ubiquitin proteasome system.
[00189] In some instances, Lats1/2 phosphorylates YAP at the [HXRXXS]
consensus motifs. YAP comprises five [HXRXXS] consensus motifs, wherein X denotes any amino acid residue. In some instances, Lats1/2 phosphorylates YAP at one or more of the consensus motifs.
In some instances, Lats1/2 phosphorylates YAP at all five of the consensus motifs. In some instances, Lats1/2 phosphorylate at the S127 amino acid position. The phosphorylation of YAP
S127 promotes 14-3-3 protein binding and results in cytoplasmic sequestration of YAP.
Mutation of YAP at the S127 position thereby disrupts its interaction with 14-3-3 and subsequently promotes nuclear translocation.
[00190] Additional phosphorylation occurs at the S381 amino acid position in YAP.
Phosphorylation of YAP at the S381 position and on the corresponding site in TAZ primes both proteins for further phosphorylation events by CK16/6 in the degradation motif, which then signals for interaction with the (3-TRCP E3 ubiquitin ligase, leading to polyubiquitination and degradation of YAP.
[00191] In some instances, Lats1/2 phosphorylates TAZ at the [HXRXXS]
consensus motifs. TAZ comprises four [HXRXXS] consensus motifs, wherein X denotes any amino acid residues. In some instances, Lats1/2 phosphorylates TAZ at one or more of the consensus motifs.
In some instances, Lats1/2 phosphorylates TAZ at all four of the consensus motifs. In some instances, Lats1/2 phosphorylate at the S89 amino acid position. The phosphorylation of TAZ
S89 promotes 14-3-3 protein binding and results in cytoplasmic sequestration of TAZ. Mutation of TAZ at the S89 position thereby disrupts its interaction with 14-3-3 and subsequently promotes nuclear translocation.
[00192] In some embodiments, phosphorylated YAP/TAZ accumulates in the cytoplasm, and undergoes SCO-TRcP-mediated ubiquitination and subsequent proteasomal degradation. In some instances, the Skp, Cullin, F-box containing complex (SCF complex) is a multi-protein E3 ubiquitin ligase complex that comprises a F-box family member protein (e.g.
Cdc4), Skpl, a bridging protein, and RBX1, which contains a small RING Finger domain which interacts with E2-ubiquitin conjugating enzyme. In some cases, the F-box family comprises more than 40 members, in which exemplary members include F-box/WD repeat-containing protein lA
(FBXW1A, r3TrCP1, Fbxwl, hsSlimb, plkappaBalpha-E3 receptor subunit) and S-phase kinase-associated proteins 2 (SKP2). In some embodiments, the SCF complex (e.g.
SCF1mÃ131) interacts with an El ubiquitin-activating enzyme and an E2 ubiquitin-conjugating enzyme to catalyze the transfer of ubiquitin to the YAP/TAZ substrate. Exemplary El ubiquitin-activating enzymes include those encoded by the following genes: UBA1, UBA2, UBA3, UBA5, UBA5, UBA7, ATG7, NAE1, and SAE]. Exemplary E2 ubiquitin-conjugating enzymes include those encoded by the following genes: UBE2A, UBE2B, UBE2C, UBE2D1, UBE2D2, UBE2D3, UBE2E1, UBE2E2, UBE2E3, UBE2F, UBE2G1, UBE2G2, UBE2H, UBE2I, UBE211, UBE212, UBE2K, UBE2L3, UBE2L6, UBE2M, UBE2IV, UBE20, UBE2Q1, UBE2Q2, UBE2R1, UBE2R2, UBE2S, UBE2T, UBE2U, UBE2V1, UBE2V2, UBE2Z, ATG2, BIRC5, and UFC1. In some embodiments, the ubiquitinated YAP/TAZ further undergoes the degradation process through the 26S
proteasome.
[00193] In some embodiments, the Hippo pathway is regulated upstream by several different families of regulators (FIG. 1). In some instances, the Hippo pathway is regulated by the G-protein and its coupled receptors, the Crumbs complex, regulators upstream of the MST
kinases, and the adherens junction.
YAP/TAZ Interaction with TEAD
[00194] In some embodiments, un-phosphorylated and/or dephosphorylated YAP/TAZ
accumulates in the nucleus. Within the nucleus, YAP/TAZ interacts with the TEAD family of transcription factors (e.g. TEAD1, TEAD2, TEAD3, or TEAD4) to activate genes involved in anti-apoptosis and proliferation, such as for example CTFG, Cyr61, and FGF1.
[00195] In some embodiments, the compounds disclosed herein modulate the interaction between YAP/TAZ and TEAD. In some embodiments, the compounds disclosed herein bind to TEAD, YAP, or TAZ and prevent the interaction between YAP/TAZ and TEAD.
YAP/TAZ regulation mediated by G-proteins/GPCRs [00196] In some embodiments, the Hippo pathway is regulated by the G
protein-coupled receptor (GPCR) and G protein (also known as guanine nucleotide-binding proteins) family of proteins (FIG. 2). G proteins are molecular switches that transmit extracellular stimuli into the cell through GPCRs. In some instances, there are two classes of G proteins:
monomeric small GTPases and heterotrimeric G protein complexes. In some instances, the latter class of complexes comprise of alpha (G,), beta (G), and gamma (Gy) subunits. In some cases, there are several classes of Ga subunits: Goia, G12/13a, Gi/oa (G inhibitory, G other), and Gsa (G
stimulatory).
[00197] In some instances, Gia (G inhibitory), Goa (G other), Goia, and G12/13a coupled GPCRs activate YAP/TAZ and promote nuclear translocation. In other instances, Gsa (G
stimulatory) coupled GPCRs suppress YAP/TAZ activity, leading to YAP/TAZ
degradation.
[00198] In some cases, Gia (G inhibitory), Goa (G other), Goia, and G12/13a coupled GPCRs activate YAP/TAZ through repression of Lats1/2 activities. In contrast, Gsa, in some embodiments, induces Lats1/2 activity, thereby promoting YAP/TAZ degradation.
Gq Family [00199] Gqa (also known as Goi protein), participates in the inositol trisphosphate (IP3) signal transduction pathway and calcium (Ca2+) release from intracellular storage through the activation of phospholipase C (PLC). The activated PLC hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to diacyl glycerol (DAG) and IP3. In some instances, IP3 then diffuses through the cytoplasm into the ER or the sarcoplasmic reticulum (SR) in the case of muscle cells, and then binds to inositol trisphosphate receptor (InsP3R), which is a Ca2+
channel. In some cases, the binding triggers the opening of the Ca2+ channel, and thereby increases the release of Ca2+ into the cytoplasm.
[00200] In some embodiments, the GPCRs that interact with Gqa include, but are not limited to, 5-hydroxytryptamine receptor (5-HT receptor) types 5-HT2 and 5-HT3; alpha-1 adrenergic receptor; vasopressin type 1 receptors 1A and 1B; angiotensin II
receptor type 1;
calcitonin receptor; histamine H1 receptor; metabotropic glutamate receptor, group I; muscarinic receptors MI, M3, and M5; and trace amine-associated receptor 1.
[00201] In some instances, there are several types of Gqa: Gq, Gqin, Gq/14, and Gq/15. The Gq protein is encoded by GNAQ. Go' is encoded by GNA1 1 . Gq/14 is encoded by GNA14. Gq/15 is encoded by GNA15.
[00202] In some instances, mutations or modifications of the Gqa genes have been associated with cancer. Indeed, studies have shown that mutations in Gqa promote uveal melanoma (UM) tumorigenesis. In some instances, about 80% of UM cases have been detected to contain a mutation in GNAQ and/or GNA1 1 .
[00203] In some instances, mutations or modifications of the Gqa genes have been associated with congenital diseases. In some instances, mutations of Gqa have been observed in congenital diseases such as Port-Wine Stain and/or Sturge-Weber Syndrome. In some instances, about 92% of Port-Wine stain cases harbors a mutation in GNAQ. In some instances, about 88%
of Sturge-Weber Syndrome harbors a mutation in GNAQ.
G12/13 Family [00204] G12/13a modulates actin cytoskeletal remodeling in cells and regulates cell processes through guanine nucleotide exchange factors (GEFs). GEFs participate in the activation of small GTPases which acts as molecular switches in a variety of intracellular signaling pathways. Examples of small GTPases include the Ras-related GTPase superfamily (e.g. Rho family such as Cdc42), which is involved in cell differentiation, proliferation, cytoskeletal organization, vesicle trafficking, and nuclear transport.
[00205] In some embodiments, the GPCRs that interact with G12/13a include, but are not limited to, purinergic receptors (e.g. P2Y1, P2Y2, P2Y4, P2Y6); muscarinic acetylcholine receptors M1 and M3; receptors for thrombin [protease-activated receptor (PAR)-1, PAR-21;
thromboxane (TXA2); sphingosine 1-phosphate (e.g. S1P2, S1P3, S1P4 and S1P5);
lysophosphatidic acid (e.g. LP/6i', LPA2, LPA3); angiotensin II (AT1);
serotonin (5-HT2, and 5-HT4); somatostatin (55t5); endothelin (ETA and ETB); cholecystokinin (CCK1);
Via vasopressin receptors; D5 dopamine receptors; fMLP formyl peptide receptors; GAL2 galanin receptors; EP3 prostanoid receptors; Ai adenosine receptors; ai adrenergic receptors; BB2 bombesin receptors;
B2 bradykinin receptors; calcium-sensing receptors; KSHV-0RF74 chemokine receptors; NKI
tachykinin receptors; and thyroid-stimulating hormone (TSH) receptors.
[00206] In some instances, G12/1311 is further subdivided into Gi2 and Gi3 types which are encoded by GNA 1 2 and GNA 1 3, respectively.
G1/0 Family [00207] Guaa (G inhibitory, G other) (also known as Gi/Go or Gi protein) suppresses the production of 3',5'-cyclic AMP (cAMP) from adenosine triphosphate (ATP) through an inhibition of adenylate cyclase activity, which converts ATP to cAMP.
[00208] In some embodiments, the GPCRs that interact with Gia include, but are not limited to, 5-hydroxytryptamine receptor (5-HT receptor) types 5-HT1 and 5-HT5; muscarinic acetylcholine receptors such as M2 and M4; adenosine receptors such as Ai and A3; adrenergic receptors such as a2A, a2B, and a2c; apelin receptors; calcium-sensing receptor; cannabinoid receptors CB1 and CB2; chemokine CXCR4 receptor; dopamines D2, D3, and D4;
GABAB
receptor; glutamate receptors such as metabotropic glutamate receptor 2 (mGluR2), metabotropic glutamate receptor 3 (mGluR3), metabotropic glutamate receptor 4 (mGluR4), metabotropic glutamate receptor 6 (mGluR6), metabotropic glutamate receptor 7 (mGluR7), and metabotropic glutamate receptor 8 (mGluR8); histamine receptors such as H3 and H4 receptors; melatonin receptors such as melatonin receptor type 1 (MT1), melatonin receptor type 2 (MT2), and melatonin receptor type 3 (MT3); niacin receptors such as NIACR1 and NIACR2;
opioid receptors such as 6, K, jt, and nociceptin receptors; prostaglandin receptors such as prostaglandin E receptor 1 (EPA prostaglandin E receptor 3 (EP3), prostaglandin F receptor (FP), and thromboxane receptor (TP); somatostatin receptors sstl, sst2, sst3, sst4, and sst5; and trace amine-associated receptor 8.
[00209] In some instances, there are several types of Gta: Gal, Gia2, Gia3, Gia4, Goa, Gt, Ggust, and G. Gtal is encoded by GNAI Gia2 is encoded by GNAI2. Gta3 is encoded by GNAI3. Goa, the a, subunit, is encoded by GNA01. Gt is encoded by GNAT] and GNAT2. Ggust is encoded by GNAT3. Gz is encoded by GNAZ.
GsFamily [00210] Gsa (also known as G stimulatory, Gs alpha subunit, or Gs protein) activates the cAMP-dependent pathway through the activation of adenylate cyclase, which convers adenosine triphosphate (ATP) to 3',5'-cyclic AMP (cAMP) and pyrophosphate. In some embodiments, the GPCRs that interact with Gsa include, but are not limited to, 5-hydroxytryptamine receptor (5-HT receptor) types 5-HT4, 5-HT6, and 5-HT7; adrenocorticotropic hormone receptor (ACTH
receptor) (also known as melanocortin receptor 2 or MC2R); adenosine receptor types A2a and A2b; arginine vasopressin receptor 2 (AVPR2); 13-adrenergic receptors 131, 132, and 133; calcitonin receptor; calcitonin gene-related peptide receptor; corticotropin-releasing hormone receptor;
dopamine receptor D1-like family receptors such as D1 and D5; follicle-stimulating hormone receptor (FSH-receptor); gastric inhibitory polypeptide receptor; glucagon receptor; histamine H2 receptor; luteinizing hormone/choriogonadotropin receptor; melanocortin receptors such as MC1R, MC2R, MC3R, MC4R, and MC5R; parathyroid hormone receptor 1;
prostaglandin receptor types D2 and 12; secretin receptor; thyrotropin receptor; trace amine-associated receptor 1; and box jellyfish opsin.
[00211] In some instances, there are two types of Gsa: Gs and Golf. Gs is encoded by GNAS. Golf is encoded by GNAT.
Additional Regulators of the Hippo signaling network [00212] In some embodiments, the additional regulator of the Hippo signaling pathway is the Crumbs (Crb) complex. The Crumbs complex is a key regulator of cell polarity and cell shape. In some instances, the Crumbs complex comprises transmembrane CRB
proteins which assemble multi-protein complexes that function in cell polarity. In some instances, CRB
complexes recruit members of the Angiomotin (AMOT) family of adaptor proteins that interact with the Hippo pathway components. In some instances, studies have shown that AMOT directly binds to YAP, promotes YAP phosphorylation, and inhibits its nuclear localization.
[00213] In some instances, the additional regulator of the Hippo signaling pathway comprises regulators of the MST kinase family. MST kinases monitor actin cytoskeletal integrity. In some instances, the regulators include TAO kinases and cell polarity kinase PAR-1.
[00214] In some instances, the additional regulator of the Hippo signaling pathway comprises molecules of the adherens junction. In some instances, E-Cadherin (E-cad) suppresses YAP nuclear localization and activity through regulating MST activity. In some embodiments, E-cad-associated protein a-catenin regulates YAP through sequestering YAP/14-3-3 complexes in the cytoplasm. In other instances, Ajuba protein family members interact with Lats1/2 kinase activity, thereby preventing inactivation of YAP/TAZ.
[00215] In some embodiments, additional proteins that interact with YAP/TAZ
either directly or indirectly include, but are not limited to, Merlin, protocadherin Fat 1, MASK1/2, HIPK2, PTPN14, RASSF, PP2A, Salt-inducible kinases (SIKs), Scribble (SCRIB), the Scribble associated proteins Discs large (Dig), KIBRA, PTPN14, NPHP3, LKB1, Ajuba, and Z01/2.
[00216] In some embodiments, the compounds described herein are inhibitors of transcriptional coactivator with PDZ binding motif/Yes- associated protein transcriptional coactivator (TAZ/YAP). In some embodiments, the compounds described herein increase the phosphorylation of transcriptional coactivator with PDZ binding motif/ Yes-associated protein transcriptional coactivator (TAZ/YAP) or decrease the dephosphorylation of transcriptional coactivator with PDZ binding motif/ Yes- associated protein transcriptional coactivator (TAZ/YAP). In some embodiments, the compounds increase the ubiquitination of transcriptional coactivator with PDZ binding motif/ Yes- associated protein transcriptional coactivator (TAZ/YAP) or decrease the deubiquitination of transcriptional coactivator with PDZ
binding motif/ Yes- associated protein transcriptional coactivator (TAZ/YAP).
[00217] In some embodiments, the compounds disclosed herein are inhibitors of one or more of the proteins encompassed by, or related to, the Hippo pathway. In some instances, the one or more proteins comprise a protein shown in FIGs. 1 and/or 2. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of a G-protein and/or its coupled GPCR. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of a G-protein.
In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of the Gqa family proteins such as Gq, Got, Gq/14, and Gq/15; the G12/13a family of proteins such as G12 and G13; or the Gia family of proteins such as Gial, Gia2, Gia3, Gia4, Goa, Gt, Ggust, and G. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Gq. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Got. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Gq/14. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Gq/15. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of G12. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of G13. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Gal. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Gia2. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Gia3. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Gia4. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Goa. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Gt. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Ggust. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of G.
[00218] In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of a core protein of the Hippo pathway. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Savl. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Mob. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of YAP. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of TAZ. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of TEAD.
[00219] In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of a protein associated with the ubiquitination and proteasomal degradation pathway. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of a proteasomal degradation pathway protein (e.g. 26S proteasome).
[00220] In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of a protein of the Ras superfamily of proteins. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of a protein of the Rho family of proteins. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of Cdc42.
[00221] Cdc42 is a member of the Ras superfamily of small GTPases.
Specifically, Cdc42 belongs to the Rho family of GTPases, in which the family members participate in diverse and critical cellular processes such as gene transcription, cell-cell adhesion, and cell cycle progression. Cdc42 is involved in cell growth and polarity, and in some instances, Cdc42 is activated by guanine nucleotide exchange factors (GEFs). In some cases, an inhibitor of Cdc42 is a compound disclosed herein.
[00222] In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of a deubiquitinating enzyme. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of a cysteine protease or a metalloprotease. In some embodiments, an inhibitor of the Hippo pathway is an inhibitor of an ubiquitin-specific protease. U5P47 is a member of the ubiquitin-specific protease (USP/UBP) superfamily of cysteine proteases. In some embodiments, the compounds disclosed herein are inhibitors of USP47.
[00223] Further embodiments provided herein include combinations of one or more of the particular embodiments set forth above.
Diseases Cancer [00224] In some embodiments, the compounds disclosed herein are useful for treating cancer. In some embodiments, the cancer is mediated by activation of transcriptional coactivator with PDZ binding motif/Yes- associated protein transcription coactivator (TAZ/YAP). In some embodiments, the cancer is mediated by modulation of the interaction of YAP/TAZ with TEAD.
In some embodiments, the cancer is characterized by a mutant Ga-protein. In some embodiments, the mutant Ga-protein is selected from G12, G13, Gq, G11, Gi, Go, and Gs. In some embodiments, the mutant Ga-protein is G12. In some embodiments, the mutant Ga-protein is G13. In some embodiments, the mutant Ga-protein is Gq. In some embodiments, the mutant Ga-protein is G11. In some embodiments, the mutant Ga-protein is Gi. In some embodiments, the mutant Ga-protein is Go. In some embodiments, the mutant Ga-protein is Gs.
[00225] In some embodiments, the cancer is a solid tumor. In some instances, the cancer is a hematologic malignancy. In some instances, the solid tumor is a sarcoma or carcinoma. In some instances, the solid tumor is a sarcoma. In some instances, the solid tumor is a carcinoma.
[00226] Exemplary sarcoma includes, but is not limited to, alveolar rhabdomyosarcoma, alveolar soft part sarcoma, ameloblastoma, angiosarcoma, chondrosarcoma, chordoma, clear cell sarcoma of soft tissue, dedifferentiated liposarcoma, desmoid, desmoplastic small round cell tumor, embryonal rhabdomyosarcoma, epithelioid fibrosarcoma, epithelioid hemangioendothelioma, epithelioid sarcoma, esthesioneuroblastoma, Ewing sarcoma, extrarenal rhabdoid tumor, extraskeletal myxoid chondrosarcoma, extraskeletal osteosarcoma, fibrosarcoma, giant cell tumor, hemangiopericytoma, infantile fibrosarcoma, inflammatory myofibroblastic tumor, Kaposi sarcoma, leiomyosarcoma of bone, liposarcoma, liposarcoma of bone, malignant fibrous histiocytoma (MFH), malignant fibrous histiocytoma (MFH) of bone, malignant mesenchymoma, malignant peripheral nerve sheath tumor, mesenchymal chondrosarcoma, myxofibrosarcoma, myxoid liposarcoma, myxoinflammatory fibroblastic sarcoma, neoplasms with perivascular epithelioid cell differentiation, osteosarcoma, parosteal osteosarcoma, neoplasm with perivascular epithelioid cell differentiation, periosteal osteosarcoma, pleomorphic liposarcoma, pleomorphic rhabdomyosarcoma, PNET/extraskeletal Ewing tumor, rhabdomyosarcoma, round cell liposarcoma, small cell osteosarcoma, solitary fibrous tumor, synovial sarcoma, and telangiectatic osteosarcoma.
[00227] Exemplary carcinoma includes, but is not limited to, adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, anaplastic carcinoma, large cell carcinoma, small cell carcinoma, anal cancer, appendix cancer, bile duct cancer (i.e., cholangiocarcinoma), bladder cancer, brain tumor, breast cancer, cervical cancer, colon cancer, cancer of Unknown Primary (CUP), esophageal cancer, eye cancer, fallopian tube cancer, gastroenterological cancer, kidney cancer, liver cancer, lung cancer, medulloblastoma, melanoma, oral cancer, ovarian cancer, pancreatic cancer, parathyroid disease, penile cancer, pituitary tumor, prostate cancer, rectal cancer, skin cancer, stomach cancer, testicular cancer, throat cancer, thyroid cancer, uterine cancer, vaginal cancer, and vulvar cancer. In some instances, the liver cancer is primary liver cancer.
[00228] In some instances, the cancer is selected from uveal melanoma, mesothelioma, esophageal cancer, liver cancer, breast cancer, hepatocellular carcinoma, lung adenocarcinoma, glioma, colon cancer, colorectal cancer, gastric cancer, medulloblastoma, ovarian cancer, esophageal squamous cell carcinoma, sarcoma, Ewing sarcoma, head and neck cancer, prostate cancer, and meningioma. In some cases, the cancer is uveal melanoma, mesothelioma, esophageal cancer, liver cancer, breast cancer, hepatocellular carcinoma, lung adenocarcinoma, glioma, colon cancer, colorectal cancer, gastric cancer, medulloblastoma, ovarian cancer, esophageal squamous cell carcinoma, sarcoma, Ewing sarcoma, head and neck cancer, prostate cancer, or meningioma. In some cases, the cancer is uveal melanoma, mesothelioma, esophageal cancer, or liver cancer. In some cases, the cancer is uveal melanoma. In some cases, the cancer is mesothelioma. In some cases, the cancer is esophageal cancer. In some cases, the cancer is liver cancer. In some cases, the cancer is primary liver cancer.
[00229] In some instances, the cancer is a hematologic malignancy. In some embodiments, a hematologic malignancy is a leukemia, a lymphoma, a myeloma, a non-Hodgkin's lymphoma, a Hodgkin's lymphoma, a T-cell malignancy, or a B-cell malignancy. In some instances, a hematologic malignancy is a T-cell malignancy. Exemplary T-cell malignancy includes, but is not limited to, peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), anaplastic large cell lymphoma, angioimmunoblastic lymphoma, cutaneous T-cell lymphoma, adult T-cell leukemia/lymphoma (ATLL), blastic NK-cell lymphoma, enteropathy-type T-cell lymphoma, hematosplenic gamma-delta T-cell lymphoma, lymphoblastic lymphoma, nasal NK/T-cell lymphomas, and treatment-related T-cell lymphomas.
[00230] In some instances, a hematologic malignancy is a B-cell malignancy.
Exemplary B-cell malignancy includes, but is not limited to, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), high risk CLL, and a non-CLL/SLL lymphoma. In some embodiments, the cancer is follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia, multiple myeloma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, Burkitt's lymphoma, non-Burkitt high grade B cell lymphoma, primary mediastinal B-cell lymphoma (PMBL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, B cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, or lymphomatoid granulomatosis.
[00231] In some instances, the cancer is a relapsed or refractory cancer.
In some embodiments, the relapsed or refractory cancer is a relapsed or refractory solid tumor. In some embodiments, the relapsed or refractory solid tumor is a relapsed or refractory sarcoma or a relapsed or refractory carcinoma. In some embodiments, the relapsed or refractory carcinoma includes adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, anaplastic carcinoma, large cell carcinoma, small cell carcinoma, anal cancer, appendix cancer, bile duct cancer (i.e., cholangiocarcinoma), bladder cancer, brain tumor, breast cancer, cervical cancer, colon cancer, cancer of Unknown Primary (CUP), esophageal cancer, eye cancer, fallopian tube cancer, gastroenterological cancer, kidney cancer, liver cancer, lung cancer, medulloblastoma, melanoma, oral cancer, ovarian cancer, pancreatic cancer, parathyroid disease, penile cancer, pituitary tumor, prostate cancer, rectal cancer, skin cancer, stomach cancer, testicular cancer, throat cancer, thyroid cancer, uterine cancer, vaginal cancer, and vulvar cancer.
[00232] In some instances, the relapsed or refractory cancer is selected from relapsed or refractory uveal melanoma, mesothelioma, esophageal cancer, liver cancer, breast cancer, hepatocellular carcinoma, lung adenocarcinoma, glioma, colon cancer, colorectal cancer, gastric cancer, medulloblastoma, ovarian cancer, esophageal squamous cell carcinoma, sarcoma, Ewing sarcoma, head and neck cancer, prostate cancer, and meningioma. In some cases, the relapsed or refractory cancer is relapsed or refractory uveal melanoma, mesothelioma, esophageal cancer, liver cancer, breast cancer, hepatocellular carcinoma, lung adenocarcinoma, glioma, colon cancer, colorectal cancer, gastric cancer, medulloblastoma, ovarian cancer, esophageal squamous cell carcinoma, sarcoma, Ewing sarcoma, head and neck cancer, prostate cancer, or meningioma.
In some cases, the relapsed or refractory cancer is relapsed or refractory uveal melanoma, mesothelioma, esophageal cancer, or liver cancer. In some cases, the relapsed or refractory cancer is relapsed or refractory uveal melanoma. In some cases, the relapsed or refractory cancer is relapsed or refractory mesothelioma. In some cases, the relapsed or refractory cancer is relapsed or refractory esophageal cancer. In some cases, the relapsed or refractory cancer is relapsed or refractory liver cancer. In some cases, the relapsed or refractory cancer is relapsed or refractory primary liver cancer.
[00233] In some instances, the relapsed or refractory cancer is a relapsed or refractory hematologic malignancy. In some embodiments, a relapsed or refractory hematologic malignancy is a relapsed or refractory leukemia, a relapsed or refractory lymphoma, a relapsed or refractory myeloma, a relapsed or refractory non-Hodgkin's lymphoma, a relapsed or refractory Hodgkin's lymphoma, a relapsed or refractory T-cell malignancy, or a relapsed or refractory B-cell malignancy. In some instances, a relapsed or refractory hematologic malignancy is a relapsed or refractory T-cell malignancy. In some instances, a relapsed or refractory hematologic malignancy is a relapsed or refractory B-cell malignancy, such as for example, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), high risk CLL, or a non-CLL/SLL lymphoma. In some embodiments, the cancer is follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia, multiple myeloma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, Burkitt's lymphoma, non-Burkitt high grade B
cell lymphoma, primary mediastinal B-cell lymphoma (PMBL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, B cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, or lymphomatoid granulomatosis.
[00234] In some instances, the cancer is a metastasized cancer. In some instances, the metastasized cancer is a metastasized solid tumor. In some instances, the metastasized solid tumor is a metastasized sarcoma or a metastasized carcinoma. In some embodiments, the metastasized carcinoma includes adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, anaplastic carcinoma, large cell carcinoma, small cell carcinoma, anal cancer, appendix cancer, bile duct cancer (i.e., cholangiocarcinoma), bladder cancer, brain tumor, breast cancer, cervical cancer, colon cancer, cancer of Unknown Primary (CUP), esophageal cancer, eye cancer, fallopian tube cancer, gastroenterological cancer, kidney cancer, liver cancer, lung cancer, medulloblastoma, melanoma, oral cancer, ovarian cancer, pancreatic cancer, parathyroid disease, penile cancer, pituitary tumor, prostate cancer, rectal cancer, skin cancer, stomach cancer, testicular cancer, throat cancer, thyroid cancer, uterine cancer, vaginal cancer, and vulvar cancer.
[00235] In some instances, the metastasized cancer is selected from metastasized uveal melanoma, mesothelioma, esophageal cancer, liver cancer, breast cancer, hepatocellular carcinoma, lung adenocarcinoma, glioma, colon cancer, colorectal cancer, gastric cancer, medulloblastoma, ovarian cancer, esophageal squamous cell carcinoma, sarcoma, Ewing sarcoma, head and neck cancer, prostate cancer, and meningioma. In some cases, the metastasized cancer is metastasized uveal melanoma, mesothelioma, esophageal cancer, liver cancer, breast cancer, hepatocellular carcinoma, lung adenocarcinoma, glioma, colon cancer, colorectal cancer, gastric cancer, medulloblastoma, ovarian cancer, esophageal squamous cell carcinoma, sarcoma, Ewing sarcoma, head and neck cancer, prostate cancer, or meningioma. In some cases, the metastasized cancer is metastasized uveal melanoma, mesothelioma, esophageal cancer, or liver cancer. In some cases, the metastasized cancer is metastasized uveal melanoma.
In some cases, the metastasized cancer is metastasized mesothelioma. In some cases, the metastasized cancer is metastasized esophageal cancer. In some cases, the metastasized cancer is metastasized liver cancer. In some cases, the metastasized cancer is metastasized primary liver cancer.
[00236] In some instances, the metastasized cancer is a metastasized hematologic malignancy. In some embodiments, the metastasized hematologic malignancy is a metastasized leukemia, a metastasized lymphoma, a metastasized myeloma, a metastasized non-Hodgkin's lymphoma, a metastasized Hodgkin's lymphoma, a metastasized T-cell malignancy, or a metastasized B-cell malignancy. In some instances, a metastasized hematologic malignancy is a metastasized T-cell malignancy. In some instances, a metastasized hematologic malignancy is a metastasized B-cell malignancy, such as for example, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), high risk CLL, or a non-CLL/SLL lymphoma. In some embodiments, the cancer is follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia, multiple myeloma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, Burkitt's lymphoma, non-Burkitt high grade B cell lymphoma, primary mediastinal B-cell lymphoma (PMBL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, B cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, or lymphomatoid granulomatosis.
Congenital Diseases [00237] In some embodiments, the compounds disclosed herein are useful for treating a congenital disease. In some embodiments, the congenital disease is mediated by activation of transcriptional coactivator with PDZ binding motif/Yes- associated protein transcription coactivator (TAZ/YAP). In some embodiments, the congenital disease is characterized by a mutant Ga-protein. In some embodiments, the mutant Ga-protein is selected from G12, G13, Gq, G11, Gi, Go, and Gs. In some embodiments, the mutant Ga-protein is G12. In some embodiments, the mutant Ga-protein is G13. In some embodiments, the mutant Ga-protein is Gq. In some embodiments, the mutant Ga-protein is G11. In some embodiments, the mutant Ga-protein is Gi. In some embodiments, the mutant Ga-protein is Go. In some embodiments, the mutant Ga-protein is Gs.
[00238] In some embodiments, the congenital disease is the result of a genetic abnormality, an intrauterine environment, errors related to morphogenesis, infection, epigenetic modifications on a parental germline, or a chromosomal abnormality. Exemplary congenital diseases include, but are not limited to, Sturge-Weber Syndrome, Port-Wine stain, Holt-Oram syndrome, abdominal wall defects, Becker muscular dystrophy (BMD), biotinidase deficiency, Charcot-Marie-Tooth (CMT), cleft lip, cleft palate, congenital adrenal hyperplasia, congenital heart defects, congenital hypothyroidism, congenital muscular dystrophy, cystic fibrosis, Down syndrome, Duchenne muscular dystrophy, Fragile X syndrome, Friedreich's ataxia, galactosemia, hemoglobinopathies, Krabbe disease, limb-girdle muscular dystrophy, medium chain acyl-CoA dehydrogenase deficiency, myasthenia gravis, neural tube defects, phenylketonuria, Pompe disease, severe combined immunodeficiency (SCID), Stickler syndrome (or hereditary progressive arthro-ophthalmopathy), spinal muscular atrophy, and trisomy 18. In some embodiments, the congenital disease is Sturge-Weber Syndrome or Port-Wine stain. In some embodiments, the congenital disease is Sturge-Weber Syndrome. In some embodiments, the congenital disease is Port-Wine stain.
EXAMPLES
[00239] These examples are provided for illustrative purposes only and not to limit the scope of the claims provided herein.
List of abbreviations [00240] As used above, and throughout the disclosure, the following abbreviations, unless otherwise indicated, shall be understood to have the following meanings:
ACN or MeCN acetonitrile Ac acetyl Bn benzyl BOC or Boc ter t-butyl carbamate t-Bu ter t-butyl Cy cyclohexyl C degrees Celsius DBA or dba dibenzylideneacetone DCE dichloroethane (C1CH2CH2C1) DCM dichloromethane (CH2C12) DIAD diisopropyl azodicarboxylate DIPEA or DIEA diisopropylethylamine DMAP 4-(N,N-dimethylamino)pyridine DMF dimethylformamide DMA /V,N-dimethylacetamide DMSO dimethylsulfoxide Dppf or dppf 1,1'-bis(diphenylphosphino)ferrocene EA or Et0Ac ethyl acetate eq equivalent(s) Et ethyl Et20 diethyl ether Et0H ethanol g gram(s) h hour(s) HPLC high performance liquid chromatography Hz hertz LAH lithium aluminum anhydride LCMS liquid chromatography mass spectrometry m/z mass-to-charge ratio M molar Me methyl MeI methyl iodide Me0H methanol mg milligram(s) MHz megahertz umol micromole(s) uL microliter(s) mL milliliter(s) mmol millimole(s) MS mass spectroscopy MsC1 methanesulfonyl chloride MW microwave radiation NCS N-chlorosuccinimide NMM N-methyl-morpholine NMP N-methyl-pyrrolidin-2-one NMR nuclear magnetic resonance PE petroleum ether Ph phenyl prep-HPLC preparative high pressure liquid chromatography prep-TLC preparative thin layer chromatography Py pyridine RP-HPLC reverse phase-high pressure liquid chromatography RT retention time TEA triethylamine TFA trifluoroacetic acid THF tetrahydrofuran TLC thin layer chromatography TMSC1 trimethylsilyl chloride Xantphos 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene XPhos 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl XPhos Pd G II chloro(2-dicyclohexylphosphino-2',4',6'-triisopropy1-1,1'-bipheny1)[2-(2'-amino-1,1'-biphenyOlpalladium(II) I. Chemical Synthesis [00241] Unless otherwise noted, reagents and solvents were used as received from commercial suppliers. Anhydrous solvents and oven-dried glassware were used for synthetic transformations sensitive to moisture and/or oxygen. Yields were not optimized. Reaction times were approximate and were not optimized. Column chromatography and thin layer chromatography (TLC) were performed on silica gel unless otherwise noted.
Example 1: N-(tert-buty1)-4-(cyclohexylarnino)-3-(2H-tetrazol-5-y1)benzenesulfonamide (Compound 1) 1;1¨NH
0µµ N 0 S
HN
Preparation of Compound 1:
CN ON CN
0 411 F H2Nk 2.0 eq = ______ NH2 F Cr :DMS0=1/1(v/v) N
HN¨S
CI' µµ
0 TEA (2.0 eq), DCM --7C 6 0 140 C, 2 h JNH
Aµ\1 NaN3(3 eq), NH4CI (3 eq) DMF, 140 C, 16 h =
NO
HN
Compound 1 Step 1: N-tert-butyl-3-cyano-4-fluoro-benzenesulfonamide [00242] To a solution of compound 1-1 (500 mg, 2.28 mmol, 1.0 eq) and 2-methylpropan-2-amine (334 mg, 4.56 mmol, 2.0 eq) in DCM (10 mL) was added TEA (461 mg, 4.56 mmol, 2.0 eq). The resulted mixture was stirred at 30 C for 16 hr. LCMS and TLC
(Petroleum ether: Ethyl acetate = 3/1) showed desired compound was found and all the starting material was consumed completely. The reaction mixture was poured into cold water (10 mL), extracted by DCM (3x10 mL). The combined organic layers were washed with brine (10 mL*2) dried over Na2SO4, concentrated under reduced pressure to give compound 1-2 (550 mg, 2.15 mmol, 94 % yield), which was directly used without further purification. 1HNMR (400 MHz, CDC13) 6 8.20 (dd, J =
2.3, 5.8 Hz, 1H), 8.15 (ddd, J= 2.4, 4.8, 8.8 Hz, 1H), 7.38 (t, J = 8.5 Hz, 1H), 1.29 (s, 9H).
Step 2: 5-12-13-(trifluoromethyl)phenoxy]pheny1]-2H-tetrazole [00243] A solution of compound 1-2 (450 mg, 1.76 mmol, 1.0 eq) and cyclohexylamine (870 mg, 8.76 mmol, 1 mL, 5.0 eq) in DMSO (1 mL) was heated to 140 C for 2 hr.
LCMS
showed 85% desired compound was found and the starting material was consumed completely.
The reaction mixture was combined and poured into cold water (10 mL), and then extracted by ethyl acetate (3x10 mL). The combined organic layers were washed with brine (10 mL*2) dried over Na2SO4, filtered, concentrated under reduced pressure to give the crude product. The crude product was purified by column chromatography (silica) to give compound 1-3 (580 mg, 1.69 mmol, 96% yield). LCMS (ESI): RT = 0.861 min, mass calc. for Ci7H25N302S
335.17, m/z found 335.7 [M+1-11+.
Step 3: N-tert-butyl-4-(cyclohexylamino)-3-(2H-tetrazol-5-yl)benzenesulfonamide [00244] To a solution of compound 1-3 (300 mg, 0.89 mmol, 1.0 eq) and NH4C1 (144 mg, 2.7 mmol, 3.0 eq) in DMF (2 mL) was added NaN3 (174 mg, 2.7 mmol, 3.0 eq). The resulted mixture was stirred at 140 C for 16 hr. LCMS showed 93% desired compound was found and the starting material was consumed completely. The reaction mixture was poured into cold water (10 mL), HC1 (1N, lmL) and then extracted by ethyl acetate (3 x10 mL). The combined organic layers were washed with brine (10 mL*2) dried over Na2SO4, concentrated under reduced pressure to give the crude product (350 mg, 0.83 mmol, 93 % yield). The crude product (230 mg) was directly used without further purification. 120 mg of crude product was purified by HPLC to give Compound 1 (90.52 mg). LCMS (ESI): RT =2.200 min, mass calc. for Ci7H26N602S
378.18, m/z found 379.1 [M+F11+; IFINMR (400 MHz, DMS0- d6) 6 8.52 (br s, 1H), 8.41 (d, J =
2.3 Hz, 1H), 7.63 (dd, J= 2.3, 8.8 Hz, 1H), 7.26 - 7.05 (m, 2H), 6.94 (d, J =
9.0 Hz, 1H), 3.59 (s, 1H), 2.04 - 1.94 (m, 2H), 1.79 - 1.68 (m, 2H), 1.64 - 1.54 (m, 1H), 1.50 -1.28 (m, 5H), 1.10 (s, 9H).
Example 2: N-(tert-butyl)-4-(cyclohexylamino)-3-(2-(2-hydroxyethyl)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 2) (OH
) ,'Rs% 0 HN *
__IN 0 Preparation of Compound 2:
(OH
11"-NH
N-N
"
IJ AI A 0 (1.5 eq) 0 40 No in, xµ
K2CO3 (2 eq), DMF, j V
100 C, 16 h Compound 2 [00245] To a solution of 2-1(80 mg, 0.21 mmol, 1.0 eq) and 2-bromoethanol (40 mg, 0.32 mmol, 1.5 eq) in DMF (2 mL) was added K2CO3 (58 mg, 0.42 mmol, 2.0 eq). The resulted mixture was stirred at 100 C for 16 hr. LCMS showed 75% desired compound was found and the starting material was consumed completely. The reaction mixture was poured into cold water (10 mL) and then extracted by ethyl acetate (3x10 mL). The combined organic layers were washed with brine (10 mL*2) dried over Na2SO4, concentrated under reduced pressure to give a brown solid. The crude product was purified by HPLC to give Compound 2 (23 mg, 54 umol, 26% yield). LCMS (ESI): RT =2.160 min, mass calc. for Ci9H301\1603S 422.21, m/z found 423.2 [M+H1+; IFINMR (400 MHz, DMS0- d6) 6 8.47 (d, J = 2.0 Hz, 1H), 7.69 (dd, J =
1.8, 8.8 Hz, 1H), 7.60 (d, J= 7.3 Hz, 1H), 7.30 (s, 1H), 7.01 (d, J = 9.0 Hz, 1H), 5.12 (t, J = 5.6 Hz, 1H), 4.81 (t, J = 4.9 Hz, 2H), 3.98 (q, J = 5.1 Hz, 2H), 3.69 - 3.59 (m, 1H), 2.04 -1.94 (m, 2H), 1.70 (s, 2H), 1.59 (d, J= 12.0 Hz, 1H), 1.50 - 1.28 (m, 5H), 1.09 (s, 9H).
Example 3: N-cyclohexy1-2-(5-methy1-1,2,4-oxadiazol-3-y1)-4-(methylsulfonyl)aniline (Compound 3) N
N
*
Preparation of Compound 3:
H2N OH )LCI
--N N I
--N
3-1A (2.0 eq) 9% *Py %
100 C, 2 hr 3-1 Compound 3 [00246] Compound 3-1A (10 mg, 0.13 mmol, 2.0 eq) was added to a solution of compound 3-1 (20 mg, 64 umol, 1.0 eq) in pyridine (1 mL). The reaction mixture was stirred at 100 C for 2 hours. The reaction mixture was concentrated under reduced pressure. The residue was purified by preparative high performance liquid chromatography.
The fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely and to obtain the title compound (2.16 mg, 9.4% yield). LCMS (ESI):
RT = 2.356 min, mass calcd. for Ci6H211\1303S 335.13, m/z found 358.0 [M+Nal+, NMR
(400MHz, CDC13) 6 8.64 (d, J = 2.2 Hz, 1H), 7.78 (dd, J = 2.2, 8.8 Hz, 1H), 7.35 (d, J=
7.3 Hz, 1H), 6.81 (d, J = 9.0 Hz, 1H), 3.60 - 3.48 (m, 1H), 3.03 (s, 3H), 2.65 (s, 3H), 2.08 -2.00 (m, 2H), 1.84 -1.73 (m, 2H), 1.69 - 1.59 (m, 1H), 1.47 - 1.31 (m, 5H).
Example 4: N-cyclohexy1-4-(methylsulfony1)-2-(2H-tetrazol-5-ypaniline (Compound 4) N-NH
NI' I
c?µ * N
--S
Preparation of Compound 4:
,N-NH
' CN NaN3 ( 3 eq) N
NH4CI (3 eq) 0 * DMF130 C
16h 4-1 Compound 4 [00247] To a mixture of 4-1 (145 mg, 0.52 mmol, 1.0 eq) and NaN3 (102 mg, 1.56 mmol, 3.0 eq) in DMF (3 mL) was added NH4C1 (84 mg, 1.56 mmol, 3.00 eq) in one portion at 25 C under N2. The mixture was heated to 130 C for 16 h. LCMS showed the compound 4-1 was consumed completely and one main peak with desired MS was detected. The reaction mixture was added EA (35 mL) and washed with water (30 mL) and then washed with brine (25 mL*2).The organic layer was dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC to obtain Compound 4 (80 mg, 0.25 mmol, 47.3% yield). LCMS (ESI): RT = 1.197 min, mass calcd. For C14HI9N502S, 321.15 m/z found 321.9[M+H1t 1H NMR (400MHz, CDC13) 6 8.45 -8.20 (m, 2H), 7.55 (br d, J= 9.20 Hz, 1H), 6.65 (br d, J= 9.20 Hz, 1H), 3.35 (br s, 1H), 2.92 (s, 3H), 2.00 - 1.85 (m, 2H), 1.80 - 1.65 (m, 2H), 1.65 - 1.50 (m, 1H), 1.36- 1.19 (m, 5H).
Example 5: N-cyclohexy1-2-(2-methy1-2H-tetrazol-5-y1)-4-(methylsulfonyl)aniline (Compound 5) N-N/
14' *
Preparation of Compound 5:
,N-NH
N N
K2CO3 (2.0 eq) Mel (1.5 eq) MeCN, rt, 2h ___________________________________________ oos *
5-1 Compound 5 [00248] To a mixture of 5-1 (30 mg, 93 umol, 1.00 eq) in CH3CN (5 mL) was added K2CO3 (26 mg, 0.19 mmol, 2.0 eq) and CH3I (20 mg, 0.14 mmol, 8.7 uL, 1.50 eq) in one portion at 20 C under N2. The mixture was stirred at 20 C for 2 h. LCMS
showed the starting material was consumed completely and one small peak with desired MS was detected. TCL
indicated one new spot was formed. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was diluted with water (10 mL) and extracted with EA
(20 mL * 3). The combined organic layers were washed with brine (40 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. LCMS showed 88% of desired product was found. The residue was purified by prep-HPLC to provide Compound 5 (8.84 mg, 26.4 umol, 28.2% yield). LCMS (ESI): RT = 0.810 min, mass calcd. For C15H211\15025, 335.14 m/z found 335.9[M+Hr 1H NMR (400MHz, CDC13) 6 8.68 (d, J= 2.00 Hz, 1H), 7.86 (br d, J= 7.20 Hz, 1H), 7.78 (dd, J= 9.20, 2.40 Hz, 1H), 6.84 (d, J= 9.20 Hz, 1H), 4.44 (s, 3H), 3.55 (br s, 1H), 3.06 (s, 3H), 2.14 - 2.04 (m, 2H), 1.88 - 1.77 (m, 2H), 1.72 - 1.64 (m, 1H), 1.50 - 1.27 (m, 5H).
Example 6: N-cyclohexy1-2-(1-methyl-1H-1,2,3-triazol-4-y1)-4-(methylsulfonyl)aniline (Compound 6) N-N
trI\
c)% * 0 Preparation of Compound 6:
N:m NN
0,13,0 Br trI\
6-la (1.3 eq) (:)µµ s I. Na2CO3 (2.7 eq),Pd(dPI30,-. 4102 (0.1 eq), dioxane/H20, 100 C, 16h 6-1 Compound 6 [00249] To a mixture of 6-1 (50 mg, 0.13 mmol, 1.0 eq) and 6-la (28 mg, 0.17 mmol, 1.30 eq) in dioxane (2 mL) and H20 (0.5 mL) was added Na2CO3 (38 mg, 0.36 mmol, 2.7 eq) and Pd(dppf)C12 (10 mg, 13 umol, 0.1 eq) in one portion under N2. The mixture was stirred at 100 C for 16 h. LCMS showed the starting material was consumed completely and one peak with desired MS was detected. The reaction mixture was concentrated under reduced pressure to remove solvent, and then added CH3CN (5 mL), filtered to give a black-brown liquid. The residue was purified by prep-HPLC. LCMS and 1HNMR confirmed Compound 6 was obtained (2.06 mg, 5.5 umol, 4.2% yield, HC1). LCMS (ESI): RT = 0.752 min, mass calcd.
For Ci6H22N4025, 334.15 m/z found 334.9[M+Hr 1H NMR (400MHz, DMSO-d6) 68.76 (s, 1H), 8.34 (br s, 1H), 7.95 (d, J=2.00 Hz, 1H), 7.60 (dd, J=8.80, 2.00 Hz, 1H), 6.91 (d, J=8.80 Hz, 1H), 4.13 (s, 3H), 3.11 (s, 3H), 2.60 -2.53 (m, 1H), 2.02 - 1.89 (m, 2H), 1.74 - 1.63 (m, 2H), 1.62- 1.51 (m, 1H), 1.49- 1.26 (m, 5H).
Example 7: N-cyclohexy1-2-(1-methy1-1H-pyrazol-4-y1)-4-(methylsulfonyl)aniline (Compound 7) N-N
\ I
*,s \c_)%
Preparation of Compound 7:
N-N
\ I
0õ0 Br 7-1a (1.4 eq) N
Na2003 (3.0 eq),Pd(dp130012 *
(0.1 eq), THF/H20, 70 C, 16h 7-1 Compound 7 1002501 To a mixture of 7-1 (50 mg, 0.13 mmol, 1.0 eq) and 7-la (30 mg, 0.18 mmol, 1.40 eq) in H20 (0.4 mL) and dioxane (2 mL) was added Pd(dppf)C12 (10 mg, 13.2 umol, 0.1 eq) and Na2CO3 (42 mg, 0.40 mmol, 3.0 eq) in one portion under N2.The mixture was stirred at 70 C
for 16 h. LCMS showed the compound 7-1 was consumed completely and one peak with desired MS was detected. The reaction mixture was concentrated under reduced pressure to remove solvent, and then added CH3CN (5 mL), filtered to give a black-brown liquid.
The residue was purified by prep-HPLC to obtain Compound 7 (4.70 mg, 12.7 umol, 9.6% yield, HC1). LCMS
(ESI): RT = 0.737 min, mass calcd. For C17H23N3025, 333.15 m/z found 333.9[M+Ht 1H NMR
(400MHz, DMSO-d6) 68.01 (s, 1H), 7.68 (s, 1H), 7.56 (dd, J = 8.40, 2.00 Hz, 1H), 7.49 (d, J =
2.00 Hz, 1H), 6.82 (d, J= 9.20 Hz, 1H), 3.90 (s, 3H), 3.45 - 3.35 (m, 1H), 3.08 (s, 3H), 1.97 -1.86 (m, 2H), 1.72 - 1.53 (m, 3H), 1.43 - 1.15 (m, 5H).
Example 8: N-cyclohexy1-2-(1-methyl-1H-pyrazol-3-y1)-4-(methylsulfonyl)aniline (Compound 8) /
N
0%
Preparation of Compound 8:
0 C 13-BP:
8-2a (2.0 eq) 8-la (1.2 eq) Br ACOK (3 eq) 0õ0 Br TMSCI (2.5 eq) Q * NH2 NaBH4 (1.0 el). 0. * Pd(dppf)Cl2 (0.1 eq) DMF, 0 C, 4h %% 1,4-dioxane, 100 C, 16h 0 N/
N Br /
8-3a (1.3 eq) I\ * No Na2003 (2.0 eq),Pd(dppf)012 R
(0.1 eq), dioxane/H20, 100 C, 16h Compound 8 Step 1: 2-bromo-N-cyclohexy1-4-methylsulfonyl-aniline [00251] To a mixture of 8-1 (500 mg, 2.0 mmol, 1.0 eq) and TMSC1 (543 mg, 5.0 mmol, 0.63 mL, 2.5 eq) and 8-la (235 mg, 2.4 mmol, 0.25 mL, 1.2 eq) in DMF (10 mL) was stirred at 0 C for 5 min under N2. The mixture was added NaBH4 (76 mg, 2.0 mmol, 1.0 eq) and stirred at 0 C for 3 h. LCMS showed no MS of the reactant 8-1, but one main peak with desired MS
was detected. The reaction mixture was quenched by addition sat.NaHCO3 (30 mL), and extracted with EA (30 mL * 3). The combined organic layers were washed with brine (30 mL *
2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography to provide 8-2 (750 mg, 2.3 mmol, 113 %
yield). LCMS
(ESI): RT = 0.829 min, mass calcd. For C131-118BrNO2S, 331.02 m/z found 331.9[M+H1+ and 333.9 [M+H+2]+.
Step 2: N-cyclohexy1-4-methylsulfony1-2-(4,4,5,5-tetramethyl-1,3,2-dioxab orolan-2-yl)aniline [00252] To a mixture of 8-2 (390 mg, 1.2 mmol, 1.0 eq) and 8-2a (594 mg, 2.3 mmol, 2.00 eq) in dioxane (7 mL) was added AcOK (344 mg, 3.5 mmol, 3.00 eq) in one portion at 14 C under N2. The mixture was degassed under vacuum and purged with N2 for 3 times. The resulted mixture was stirred at 100 C under N2 for 16 hour. LCMS showed the starting material was consumed completely and one main peak with desired MS was detected. TLC
showed many new spots were formed. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography to provide 8-3 (400 mg, 0.74 mmol, 63.1% yield) which was used next step without further purification. LCMS (ESI): RT = 0.931 min, mass calcd. For Ci9H3013N04S, 379.20 m/z found 380.1[M+H1+.
Step 3: N-cyclohexy1-2-(1-methylpyrazol-3-y1)-4-methylsulfonyl-aniline [00253] To a mixture of 8-3 (80 mg, 0.21 mmol, 1.0 eq) and 8-3a (44 mg, 0.27 mmol, 1.3 eq) in dioxane (3 mL) and H20 (0.15 mL) was added Na2CO3 (44 mg, 0.42 mmol, 2.0 eq) and Pd(dppf)C12 (16 mg, 21 umol, 0.1 eq) in one portion under N2. The mixture was stirred at 100 C
for 16 h. LCMS showed the starting material was consumed completely and one peak with desired MS was detected. The reaction mixture was concentrated under reduced pressure to remove solvent, and then added CH3CN (5 mL), filtered to give a black-brown liquid. The residue was purified by prep-HPLC. LCMS and 1HNMR confirmed that Compound 8 was obtained (2.20 mg, 6.4 umol, 3.0% yield). LCMS (ESI): RT = 0.835 min, mass calcd. For Ci7H23N3025, 333.15 m/z found 333.9[M+H1t 1H NMR (400MHz, CDC13) 6 8.44 (br d, J = 7.20 Hz, 1H), 8.04 (s, 1H), 7.64 (br d, J= 8.00 Hz, 1H), 7.41 (br s, 1H), 6.76 (br d, J = 8.80 Hz, 1H), 6.68 (s, 1H), 3.96 (s, 3H), 3.54 (br s, 1H), 3.04 (s, 3H), 2.10 - 2.00 (m, 2H), 1.87 - 1.75 (m, 2H), 1.68- 1.55 (m, 2H), 1.50- 1.42 (m, 3H).
Example 9: N-cyclohexy1-4-(methylsulfony1)-2-(1H-1,2,3-triazol-1-ypaniline (Compound 9) and N-cyclohexy1-4-(methylsulfony1)-2-(2H-1,2,3-triazol-2-ypaniline (Compound 13) = -NJ
czµ 1\10 0 ai N
sµ
Compound 9 Compound 13 Preparation of Compound 9 and Compound 13:
Br (NH
sl\l"N
0 *
9-2A (2 5 1\INT 0 ,S
*
Cu 1(0.4 eq), Cs2CO3(4.0 eq), CZ` WI
,S
DMF, 120 C, 16 h, 9-1 Compound 9 Compound 13 [00254] To a mixture of compound 9-1 (50 mg, 0.15 mmol, 1.0 eq), Cs2CO3 (196 mg, 0.60 mmol, 4.0 eq) and compound 9-2A (26 mg, 0.38 mmol, 22 uL, 2.5 eq) in DMF (2 mL) was added CuI (11 mg, 60 umol, 0.4 eq). The reaction mixture was heated at 120 C
for 16 hour under N2. LCMS and HPLC showed 18% +14% desired compound was found (m/z=320.9; RT:
0.743 and 0.834 min) and the starting material was consumed completely. The reaction mixture was poured into water (5 mL) and stirred for 5 min. The aqueous phase was extracted with ethyl acetate (5 mL*3). The combined organics phase were washed with brine (5 mL*2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a residue. The residue was purified by prep-HPLC to give Compound 9 (7 mg, 22 umol, 15% yield) and Compound 13 (6 mg, 19 umol, 12 % yield).
[00255] Compound 9: LCMS (ESI): RT = 0.754 min, mass calc. for C15H201\1402S 320.13, m/z found 320.9 [M+H1+; 1HNMR (400 MHz, CDC13) 6 7.93 (d, J= 6.3 Hz, 2H), 7.80 (dd, J=
1.9, 8.9 Hz, 1H), 7.75 (d, J= 2.0 Hz, 1H), 6.92 (d, J = 9.0 Hz, 1H), 6.27 (d, J = 7.3 Hz, 1H), 3.50 -3.39 (m, 1H), 3.05 (s, 3H), 2.01 (d, J= 11.5 Hz, 2H), 1.82 - 1.71 (m, 2H), 1.69- 1.61 (m, 1H), 1.46- 1.35 (m, 2H), 1.34- 1.23 (m, 3H).
[00256] Compound 13: LCMS (ESI): RT = 0.830 min, mass calc. for C15H201\1402S
320.13, m/z found 320.9 [M+H1+; 1HNMR (400 MHz, CDC13) 6 8.51 (d, J = 2.0 Hz, 1H), 7.86 (s, 2H), 7.73 (dd, J= 1.9, 8.7 Hz, 2H), 6.89 (d, J= 9.0 Hz, 1H), 3.56 - 3.45 (m, 1H), 3.07 (s, 3H), 2.06 (d, J= 11.5 Hz, 2H), 1.79 (dd, J= 3.9, 9.2 Hz, 2H), 1.71 - 1.62 (m, 1H), 1.48 - 1.30 (m, 5H).
Example 10: N-cyclohexy1-4-(methylsulfony1)-2-(1H-pyrazol-1-ypaniline (Compound 10) * No0 Preparation of Compound 10:
Br N=N
o w'N 10-2A (2.5 eq) Cul(0.4 eq), Cs2003(4.0 eq), = 0 DMF, 120 C, 16h NO%
10-1 Compound 10 [00257] To a mixture of compound 10-1 (100 mg, 0.3 mmol, 1.0 eq), Cs2CO3(392 mg, 1.2 mmol, 4.0 eq) and compound 10-2a (51 mg, 0.75 mmol, 2.5 eq) in DMF (2 mL) was added CuI
(23 mg, 0.12 mmol, 0.4 eq). The reaction mixture was heated at 120 C for 16 hour under N2.
LCMS showed 88% desired compound was found (m/z=320.0; RT: 0.803 min) and the starting material was consumed completely. The reaction mixture was poured into water (5 mL) and stirred for 5 min. The aqueous phase was extracted with ethyl acetate (5 mL*3). The combined organics phase were washed with brine (5 mL*2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a residue. The residue was purified by prep-HPLC to give Compound 10 (50 mg, 0.16 mmol, 52% yield). LCMS (ESI): RT = 0.820 min, mass calc. for C16H211\1302S 319.14, m/z found 319.9 [M+I-11+; IFINMR (400 MHz, CDC13) 6 7.78 (s, 2H), 7.74 - 7.68 (m, 2H), 6.82 (d, J = 8.5 Hz, 1H), 6.72 (d, J= 7.3 Hz, 1H), 6.50 (t, J=
2.0 Hz, 1H), 3.47 -3.37 (m, 1H), 3.03 (s, 3H), 2.05 - 1.96 (m, 2H), 1.79 - 1.70 (m, 2H), 1.68 -1.60 (m, 1H), 1.46 -1.25 (m, 5H).
Example 11: N-cyclohexy1-2-(1H-imidazol-1-y1)-4-(methylsulfonyl)aniline (Compound 11) 9s% * 11-\ II
Preparation of Compound 11:
NH
Br N 11-2A (2.5 eq) Cul(0.4 eq), Cs2003(4.0 eq), *
DMF, 120 C, 32 h, 11-1 Compound 11 [00258] To a mixture of compound 11-1 (50 mg, 0.15 mmol, 1.0 eq), compound 11-2A (26 mg, 0.38 mmol, 2.5 eq), and Cs2CO3 (196 mg, 0.60 mmol, 4.0 eq) in DMF (2 mL) was added Cul (15 mg, 60 umol, 0.4 eq). The reaction mixture was heated at 120 C for 32 hour under N2.
LCMS showed 50% of desired compound was found (m/z =319.9; RT: 0.642 min) and 39% of the starting material was remained. The reaction mixture was poured into water (5 mL) and stirred for 5 min. The aqueous phase was extracted with ethyl acetate (5 mL*3). The combined organics phase were washed with brine (5 mL*2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a residue. The residue was purified by HPLC to give Compound 11 (20 mg, 61 umol, 40 % yield). LCMS (EST): RT = 0.649 min, mass calc. for Ci6H211\1302S
319.14, m/z found 319.9 [M+I-11+; 1HNMR (400 MHz, CDC13) 6 7.82 (dd, J = 2.0, 8.8 Hz, 1H), 7.65 (d, J = 2.0 Hz, 1H), 7.62 (s, 1H), 7.31 (s, 1H), 7.08 (s, 1H), 6.82 (d, J= 8.8 Hz, 1H), 4.03 (d, J = 7.5 Hz, 1H), 3.42 - 3.31 (m, 1H), 3.05 (s, 3H), 1.95 (d, J= 12.3 Hz, 2H), 1.71 (d, J= 13.6 Hz, 2H), 1.64 (d, J= 13.3 Hz, 1H), 1.44 - 1.32 (m, 2H), 1.27 - 1.08 (m, 3H).
Example 12: N-cyclohexy1-4-(methylsulfony1)-2-(1H-1,2,4-triazol-1-ypaniline (Compound 12) N
Ns 9sx * No Preparation of Compound 12:
Br TN
N Ns õII
* N 12-2a (2.4 eq) CuI(0.2 eq), L-proline (0.4 eq), j) = 0 Cs2CO3(4.0 eq), DMSO, 120 C, 16h, 12-1 Compound [00259] To a mixture of compound 12-1 (50 mg, 0.15 mmol, 1.0 eq), Cs2CO3 (196 mg, 0.60 mmol, 4.0 eq) and compound 12-2a (25 mg, 0.36 mmol, 2.4 eq) in DMSO (2 mL) was added CuI (6 mg, 30 umol, 0.2 eq) and L-PROLINE (7 mg, 60 umol, 0.4 eq). The reaction mixture was heated at 120 C for 16 hour under N2. LCMS showed desired compound was found and the starting material was remained. The reaction mixture was poured into water (5 mL) and stirred for 5 min. The aqueous phase was extracted with ethyl acetate (5 mL*3). The combined organics phase were washed with brine (8 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a crude product. The crude product was combined and purified by prep-TLC to give Compound 12 (35 mg, 0.1 mmol, 34% yield). LCMS (EST): RT =
0.732 min, mass calc. for C15H20N402S 320.13, m/z found 320.9 [M+1-11+; 1HNMR (400 MHz, CDC13) 6 8.43 (s, 1H), 8.21 (s, 1H), 7.80 (dd, J = 2.0, 8.8 Hz, 1H), 7.73 (d, J = 2.0 Hz, 1H), 6.87 (d, J =
9.0 Hz, 1H), 6.08 (d, J= 7.5 Hz, 1H), 3.48 - 3.37 (m, 1H), 3.05 (s, 3H), 2.00 (d, J= 11.0 Hz, 2H), 1.80 - 1.70 (m, 2H), 1.65 (d, J= 12.5 Hz, 1H), 1.47 - 1.36 (m, 2H), 1.28 (d, J= 11.0 Hz, 3H).
Example 13: 4-(cyclohexylamino)-3-(2-ethy1-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 14) N-N
OµN gip NO
-S
HN
Preparation of Compound 14:
, NN
N-NH
Br 14-1a (1.5 eq) czN = NI) K2CO3 (2.0 eq) 'R% DMF, 80 C, 0.5 hr, MW
HN,Sµ`
14-1 Compound 14 [00260] To the solution of compound 14-1 (30 mg, 89 umol, 1.0 eq) in DMF (4 mL) was added compound 14-la (15 mg, 0.1mmol, 10 uL, 1.5 eq) and K2CO3 (24.65 mg, 0.18 mmol, 2.0 eq). The mixture was stirred at 80 C for 0.5 hr under microwave. The reaction was monitored by LCMS. The reaction was concentrated under reduced pressure. The residue was purified by prep-HPLC to give Compound 14 (6.13 mg, 16.8 umol, 18.9% yield). LCMS (EST): RT =
0.850 min, mass calcd. for C16H24N602S 364.17, m/z found 365.0 [M+H1+, NMR (400MHz, DMSO-d6) 6 8.41 (d, J= 2.3 Hz, 1H), 7.66 - 7.63 (m, 2H), 7.25 (br, , 1H), 7.04 (d, J=
9.0 Hz, 1H), 4.82 (q, J
= 7.4 Hz, 2H), 3.64 - 3.63 (m, 1H), 2.38 (s, 3H), 2.04 - 1.94 (m, 2H), 1.77 -1.67 (m, 2H), 1.60 (t, J = 7.3 Hz, 3H), 1.51 - 1.23 (m, 6H).
Example 14: 4-(cyclohexylamino)-N-methy1-3-(2-propy1-2H-tetrazol-5-yl)benzenesulfonamide (Compound 15) N-N
-S
HN
Preparation of Compound 15:
N-NH N-N
N ,NBr 15-1a (1.2 eq) czµ = NI) K2CO3 (1.5 eq) DMF, 80 C, 0.5 hr, MW 0 si HN,S ,S
NH \\
15-1 Compound 15 [00261] To the solution of 15-1 (30 mg, 89 umol, 1.0 eq) in DMF (4 mL) was added compound 15-la (12 mg, 98 umol, 9 uL, 1.1 eq) and K2CO3 (18 mg, 0.1 mmol, 1.5 eq). The mixture was stirred at 80 C for 0.5 hr under microwave. The reaction was monitored by LCMS.
The reaction was concentrated under reduced pressure. The residue was purified by prep-HPLC
to give Compound 15 (3.06 mg, 8.1 umol, 9.1% yield). LCMS (ESO: RT = 0.885 min, mass calcd. for C17H26N602S 378.18, m/z found 379.1 [M+141+, 1HNMR (400MHz, DMSO-d6) 6 8.42 (s, 1H), 7.69 - 7.60 (m, 2H), 7.28 - 7.19 (m, 1H), 7.05 (d, J= 8.8 Hz, 1H), 4.76 (t, J = 6.8 Hz, 2H), 3.69 - 3.58 (m, 1H), 2.38 (d, J= 5.0 Hz, 3H), 2.08 - 1.95 (m, 4H), 1.77 -1.68 (m, 2H), 1.64 - 1.54 (m, 1H), 1.46 - 1.23 (m, 5H), 0.91 (t, J= 7.3 Hz, 3H).
Example 15: 4-(cyclohexylamino)-3-(2-(4-fluoropheny1)-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 16) N-N
O. No ;S
N II
HO
Preparation of Compound 16:
N-N
N-NH B.oH
N,.N F z µ1\1 16-la (1.2 eq) 101 No Et3N (4 eq), Cu(OAc)2 (1 eq) DCM, 02, rt, 36h ;S N
N
Compound 16 [00262] A mixture of compound 16-1 (50 mg, 0.13 mmol, 1.00 eq, HC1), (4-fluorophenyl)boronic acid (24.4 mg, 0.17 mmol, 1.30 eq), DIEA (69.3 mg, 0.54 mmol, 93.7 uL, 4.0 eq) and Cu(0Ac)2 (24.4 mg, 0.13 mmol, 1.0 eq) was degassed under vacuum and purged with 02 several times. The mixture was stirred at 20 C for 20hr. LCMS showed that starting material was remained and no desired MS signal was detected. Additional of (4-fluorophenyl)boronic acid (24.4 mg, 0.17 mmol, 1.30 eq) was added. The reaction was stirred at 20 C for 16hr. LCMS showed that desired MS signal was detected. The reaction was filtered and concentrated. The residue was purified by Prep HPLC to give Compound 16 (3.10 mg, 7.1 umol, 5.3% yield). 1HNMR and LCMS confirmed that desired product was obtained.
LCMS
(ESI): RT = 0.890 min, mass calcd. for C20I-123N6502F 430.16, m/z found 431.1 [M+H1+.
NMR (400MHz, CDC13) 6 8.73 (d, J= 2.4 Hz, 1H), 8.25 - 8.10 (m, 2H), 7.90 -7.80 (m, 1H), 7.76 (dd, J = 8.8 Hz, 2.4 Hz, 1H), 7.40 - 7.25 (m, 2H), 6.86 (d, J= 9.2 Hz, 1H), 4.40 - 4.25 (m, 1H), 3.65 - 3.50 (m, 1H), 2.69 (d, J = 5.6 Hz, 3H), 2.10 - 2.00 (m, 2H), 1.90 -1.75 (m, 2H), 1.75 - 1.65 (m, 2H), 1.50 -1.40 (m, 4H).
Example 16: 3-(2-cyclobuty1-2H-tetrazol-5-y1)-4-(cyclohexylamino)-N-methylbenzene sulfonamide (Compound 17) N-N
,N
czµ N
NH,Sµ`
I
Preparation of Compound 17:
N-NH
BP N-N
oNN N
17-2 (1.5 eq) N
HN-SµN K2CO3 (2.0 eq), O,) DMF, 100 C, 8h HN,Sµ`
Compound 17 [00263] To a solution of compound 17-1 (30.0 mg, 89.2 umol, 1.0 eq) in DMF (2.0 mL) was added K2CO3 (24.7 mg, 0.18 mmol, 2.0 eq) and compound 17-2 (18.1 mg, 0.13 mmol, 12.6 uL, 1.5 eq). The mixture was stirred at 100 C for 16 hour at N2 atmosphere.
LCMS showed desired compound was found. The reaction was filtered to give a crude product.
The crude product was purified by prep-HPLC to give Compound 17 (2.01 mg, 5.2 umol, 5.8%
yield).
LCMS (EST): RT = 0.900 min, mass calc. for C18H26N602S 390.18, m/z found 391.1 [M+H1+;
1HNMR (400 MHz, CDC13) 6 8.64 (d, J= 2.3 Hz, 1H), 7.89 (d, J=7.0 Hz, 1H), 7.73 (dd, J = 2.1, 8.9 Hz, 1H), 6.82 (d, J= 9.0 Hz, 1H), 5.42 (q, J = 8.3 Hz, 1H), 4.26 (q, J =
5.3 Hz, 1H), 3.55 (s, 1H), 2.90 - 2.79 (m, 2H), 2.67 (d, J= 5.3 Hz, 5H), 2.16 - 1.99 (m, 4H), 1.87 -1.77 (m, 2H), 1.66 (d, J= 11.5 Hz, 1H), 1.51 - 1.35 (m, 5H).
Example 17: 4-(cyclohexylamino)-3-(2-cyclopenty1-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 18) N-N
czµ N o HN,Sµ`
I
Preparation of Compound 18:
N-NH
BrJD N-N
1\1 ;
18-la (1.2 eq) czµ = N czµ N
K2003 (2.0 eq), DMF, 80 C, 3 h HN HN
I I
18-1 Compound 18 [00264] To a stirred solution of compound 18-1 (50 mg, 0.15 mmol, 1.0 eq) and K2CO3 (41 mg, 0.30 mmol, 2.0 eq) in DMF (1 mL) was compound 18-la (27 mg, 0.18 mmol, 19 uL, 1.2 eq). The resulted mixture was heated to 80 C for 3 hours. LCMS showed 80%
desired compound was found and the starting material was consumed completely. The mixture was cooled. The reaction was diluted with DMF (2 mL), filtered to give a mixture. The mixture was purified by prep-HPLC to give Compound 18 (30 mg, 74 umol, 50% yield). LCMS (ESI): RT =
0.879 min, mass calc. for C19H281\1602S 404.20, m/z found 405.1 [M+H1+; 1HNMR (400 MHz, DMSO-d6) 6 8.41 (d, J= 2.0 Hz, 1H), 7.70 - 7.56 (m, 2H), 7.24 (d, J= 5.0 Hz, 1H), 7.04 (d, J= 9.0 Hz, 1H), 5.50 - 5.39 (m, 1H), 3.64 (d, J = 4.3 Hz, 1H), 2.38 (d, J= 5.0 Hz, 3H), 2.29 (td, J= 6.8, 13.4 Hz, 2H), 2.23 - 2.10 (m, 2H), 1.99 (d, J= 9.5 Hz, 2H), 1.90 - 1.67 (m, 6H), 1.58 (s, 1H), 1.51 -1.30 (m, 5H).
Example 18: 4-(cyclohexylamino)-3-(2-(2-fluorobenzy1)-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 19) N-N
NI' ;IV
No CZ\ 0101 HN
Preparation of Compound 19:
F Br FR
N-N "I-N-NH
i\J
i\J
19-la (1.2 eq) ei N0 HN,Sµ` K2CO3 (2.0 eq), DMF, 80 C, 3 h R` 40 F (:)µ\
,s ,s\ 401 L) Compound 19 19-2 [00265] To a stirred solution of compound 19-1 (50 mg, 0.15 mmol, 1.0 eq) and K2CO3 (41 mg, 0.30 mmol, 2.0 eq) in DMF (1 mL) was added compound 19-la (34 mg, 0.18 mmol, 21 uL, 1.2 eq). The resulted mixture was heated at 80 C for 3 hour. Reaction was monitored by LCMS and the starting material was consumed completely. The mixture was cooled and diluted with DMF (2 mL), filtered to give a mixture. The mixture was purified by prep-HPLC to give the Compound 19 (20 mg, 42.7 umol, 29% yield) and 19-2 crude (12 mg). The crude 19-2 was re-purified by prep-HPLC (7 mg, 11.9 umol, 7.99% yield, HC1 salt).
[00266] Compound 19: LCMS (EST): RT = 0.879 min, mass calc. for 444.17, m/z found 405.1 [M+H1+; NMR (400 MHz, DMSO-d6) 6 8.40 (d, J = 2.3 Hz, 1H), 7.64 (dd, J = 2.0, 8.8 Hz, 1H), 7.59 (t, J = 7.7 Hz, 1H), 7.54 - 7.45 (m, 2H), 7.34 - 7.21 (m, 3H), 7.02 (d, J = 9.0 Hz, 1H), 6.11 (s, 2H), 3.68 -3.55 (m, 1H), 2.36 (d, J= 5.0 Hz, 3H), 1.92 (d, J=
9.5 Hz, 2H), 1.62 (s, 2H), 1.56 (d, J = 11.5 Hz, 1H), 1.47 - 1.35 (m, 2H), 1.34 - 1.20 (m, 3H).
Example 19: 3-(2-benzy1-2H-tetrazol-5-y1)-4-(cyclohexylamino)-N-methylbenzenesulfonamide (Compound 20) =
N' --N
HN-2S1 *
Preparation of Compound 20:
N-NH 1.1 Br 20-2 (1.5 eq) N' N' No K2CO3 (4.0 eq) --N --N
HN DMF, 100 C 17 h *
\`
I HN-IS%
N=s, *
20-1 Compound 20 20-3 [00267] To a mixture of 20-1 (30.0 mg, 80.5 umol, 1.0 eq, HC1) and K2CO3 (44.5 mg, 0.3 mmol, 4.0 eq) in DMF (3.0 mL), was added 20-2 (20.6 mg, 0.1 mrnol, 14 uL, 1.5 eq). The resulted mixture was stirred at 100 C under N2 for 17 h. LCMS showed the reaction was completed. The mixture was filtered, and the solid was washed with DMF (1 mL).
The filtrate was purified by prep-HPLC. Compound 20 (2.07 mg, 4.8 umol, 6.0% yield) was obtained, which was confirmed by LCMS, 1HNMR and NOE. LCMS (ESI): RT = 0.906 min, mass calcd.
for C211-126N602S 426.18, m/z found 427.1 [M+H1+. 11-1 NMR (400MHz, DMSO-d6) 6 8.39 (d, J
= 2.3 Hz, 1H), 7.63 (dd, J= 2.0, 9.0 Hz, 1H), 7.54 (d, J= 7.3 Hz, 1H), 7.47 -7.37 (m, 5H), 7.20 (s, 1H), 7.02 (d, J= 9.0 Hz, 1H), 6.05 (s, 2H), 3.66 - 3.58 (m, 1H), 2.36 (s, 3H), 1.98 - 1.89 (m, 2H), 1.70 - 1.61 (m, 2H), 1.61 - 1.51 (m, 1H), 1.48 - 1.37 (m, 2H), 1.35 -1.25 (m, 3H).
[00268] Compound 20-3 (7.54 mg, 14.6 umol, 18.1% yield) was obtained, which was confirmed by LCMS and 1H NMR. LCMS (ESI): RT = 1.029 min, mass calcd. for 516.23, m/z found 517.2 [M+H1+. IFINMR (400MHz, CDC13) 6 8.61 (d, J = 2.3 Hz, 1H), 7.79 (d, J = 7.0 Hz, 1H), 7.70 (dd, J = 2.1, 8.9 Hz, 1H), 7.48 - 7.37 (m, 5H), 7.35 - 7.28 (m, 5H), 6.83 (d, J= 9.3 Hz, 1H), 5.83 (s, 2H), 4.14 (s, 2H), 3.58 - 3.50 (m, 1H), 2.59 (s, 3H), 2.09 - 2.01 (m, 2H), 1.84 - 1.75 (m, 2H), 1.70 - 1.62 (m, 1H), 1.47 - 1.41 (m, 3H).
Example 20: 3-(2-butyltetrazol-5-y1)-4-(cyclohexylamino)-N-methyl-benzenesulfonamide (Compound 21) N-N
1\1 NHo NH=S\µ
Preparation of Compound 21:
NH-N
1\1 N-N
I \I µi\J
NHo 21-1a(1.1eq) K2CO3(2.5 eq) NH.S DMF, 80 C, MW
µµ 0 0 , 0.5h NH .Sµ\ C) 21-1 Compound 21 [00269] To a solution of 21-1 (50.0 mg, 0.1 mmol, 1.0 eq) in DMF (3.0 mL) was added K2CO3 (41.0 mg, 0.3 mmol, 2.0 eq) and 1-bromobutane (20.3 mg, 0.1 mmol, 16.0 uL, 1.0 eq).
The mixture was stirred at 80 C under microwave condition for 0.5 hour. LCMS
showed 23% of 21-1 was remained. Several new peaks were shown on LCMS and 68% of desired compound was detected. The residue was purified by prep-HPLC to give Compound 21 (12.91 mg, 32.9 umol, 22% yield). LCMS (ESI): RT = 0.872 min, mass calc. for C18H28N6025 392.20, m/z found 393.1 [M+Na1+; 1HNMR (400MHz, CDC13) 6 8.62 (d, J = 2.3 Hz, 1H), 7.84 (d, J =
7.0 Hz, 1H), 7.74-7.71 (m, 1H), 6.82 (d, J = 9.0 Hz, 1H), 4.69 (t, J= 7.0 Hz, 2H), 4.23 (q, J= 5.4 Hz, 1H), 3.55 (s, 1H), 2.67 (d, J = 5.5 Hz, 3H), 2.13-2.01 (m, 4H), 1.88-1.78 (m, 2H), 1.67 (d, J= 11.8 Hz, 1H), 1.49-1.36 (m, 7H), 1.00 (t, J = 7.4 Hz, 3H).
Example 21: 4-(cyclohexylamino)-N-methyl-3-(2-methyl-2H-tetrazol-5-yl)benzenesulfonamide (Compound 22) N-N
µ1\1 HN,Sµ`
I
Preparation of Compound 22:
N-N/
N-NH N-N
;1\1 ,1\1 CH3I (1.5 eq) 0\µ 0 K2CO3 (2.0 eq), OP 0 HN'S\ DMF, 80 C, 0.5h I
HN,S µ` ,S - I N
I
Compound 22 Compound 22-2 [00270] Compound 22-1 (50.0 mg, 0.15 mmol, 1.0 eq), CH3I (31.6 mg, 0.22 mmol, 13.9 uL, 1.5 eq) and K2CO3 (41.1 mg, 0.30 mmol, 2.0 eq) were taken up into a microwave tube in DMF (2.0 mL). The sealed tube was heated at 100 C for 0.5 hour under microwave. LCMS
showed desired compound was found. The reaction was filtered to give a crude product. The crude product was purified by prep-HPLC to give two products. Compound 22 (14.5 mg, 41.3 umol, 27.8% yield) was obtained. LCMS (ESI): RT = 0.773 min, mass calc. for 350.15, m/z found 351.1 [M+F11+;IHNMR (400 MHz, CDC13) 6 8.61 (d, J = 2.3 Hz, 1H), 7.79 -7.70 (m, 2H), 6.82 (d, J = 9.0 Hz, 1H), 4.43 (s, 3H), 4.27 (q, J= 5.5 Hz, 1H), 3.59 - 3.49 (m, 1H), 2.67 (d, J= 5.5 Hz, 3H), 2.13 -2.04 (m, 2H), 1.86 - 1.78 (m, 2H), 1.67 (d, J= 11.8 Hz, 1H), 1.51 - 1.36 (m, 5H).
[00271] Compound 22-2 (2.3 mg, 6.4 umol, 4.3% yield) was obtained. LCMS
(ESI): RT
= 0.828 min, mass calc. for C16H24N602S 364.17, m/z found 365.1 [M+1-11;1HNMR
(400 MHz, CDC13) 6 8.53 (d, J = 2.3 Hz, 1H), 7.77 (d, J = 7.3 Hz, 1H), 7.66 (dd, J =
2.1, 8.9 Hz, 1H), 6.83 (d, J = 9.0 Hz, 1H), 4.44 (s, 3H), 3.54 (s, 1H), 2.72 (s, 6H), 2.09 (s, 2H), 1.82 (s, 2H), 1.66 (s, 1H), 1.52 - 1.40 (m, 5H).
Example 22: 4-(cyclohexylamino)-3-(2-(2-fluoropheny1)-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 23) F
N N
;S
N II
H
Preparation of Compound 23:
F
B.
OH
OH
N N N N
23-1a (1.2 eq) O. 110 No Et3N (4 eq), Cu(OAc)2 (1 eq) ;S
DCM, 02, rt, 36h 0. lel No ;S
N A
N
Compound 23 [00272] A mixture of compound 23-1 (50 mg, 0.13 mmol, 1.00 eq, HC1), 23-la (28.1 mg, 0.2 mmol, 1.5 eq) DIEA (69.3 mg, 0.54 mmol, 93.7 uL, 4.0 eq) and Cu(0Ac)2 (36.5 mg, 0.2 mmol, 1.5 eq) was degassed under vacuum and purged with 02 several times. The mixture was stirred at 20 C for 20 hr. LCMS showed that starting material was remained and no desired MS
signal was detected. Additional of 23-la (28.1 mg, 0.2 mmol, 1.5 eq) was added. The reaction was stirred at 20 C for another 16 hr. LCMS showed that 10% of desired MS
signal was detected. The reaction was filtered and concentrated. The residue was purified by prep-HPLC to give Compound 23 (1.90 mg, 4.4 umol, 3.3% yield). LCMS (ESI): RT = 0.884 min, mass calcd.
for C20I-123N6502F 430.16, m/z found 431.1 [M+H1+. IFINMR (400MHz, CDC13) 6 8.49 (d, J=
2.4 Hz, 1H), 8.07 (d, J= 7.6 Hz, 1H), 7.75 - 7.55 (m, 3H), 7.55 - 7.45 (m, 2H), 7.30 - 7.20 (m, 1H), 7.07 (d, J= 9.2 Hz, 1H), 3.60 - 3.50 (m, 1H), 2.36 (d, J = 5.2 Hz, 3H), 2.10 -2.00 (m, 2H), 1.90 - 1.75 (m, 2H), 1.75 - 1.65 (m, 1H), 1.50 -1.40 (m, 5H).
Example 23: tert-butyl 3-(5-(2-(cyclohexylamino)-5-(N-methylsulfamoyl)pheny1)-tetrazol-2-yl)pyrrolidine-1-carboxylate (Compound 24) 0*
N-N
/1\I
9% 40 NO
S
HN -Preparation of Compound 24:
r N-NH
Br)---/
NI' 24-la (1.2 eq) N
= N
K CO 1. e 2 3(5 q) * 0 HN -S
HN
24-1 Compound 24 [00273] To a solution of compound 24-1 (10 mg, 30 umol, 1.0 eq) in DMF (2 mL) was added 24-la (9 mg, 36 umol, 1.2 eq) and K2CO3 (6 mg, 45 umol, 1.5 eq). The mixture was stirred at 100 C for 16 hr. The reaction was monitored by LCMS. The reaction was concentrated under reduced pressure. The residue was purified by prep-HPLC to give Compound 24 (2.09 mg, 4.1 umol, 7.0% yield). LCMS (ESI): RT = 0.850 min, mass calcd. for C23H35N704S 505.25, miz found 528.1 [M+Nal+, 1HNMR (400MHz, CDC13) 6 8.61 (s, 1H), 7.74 (d, J= 7.8 Hz, 2H), 6.83 (d, J= 8.8 Hz, 1H), 5.51 - 5.44 (m, 1H), 4.27 (s, 1H), 4.00 (s, 2H), 3.79 - 3.63 (m, 2H), 3.54 (s, 1H), 2.77 - 2.69 (m, 1H), 2.67 (s, 3H), 2.60 - 2.52 (m, 1H), 2.08 (d, J=
7.5 Hz, 2H), 1.87 -1.79 (m, 2H), 1.71 - 1.63 (m, 3H), 1.49 (s, 9H), 1.44 (d, J = 8.8 Hz, 3H).
Example 24: tert-butyl 3-(5-(2-(cyclohexylamino)-5-(N-methylsulfamoyl)pheny1)-tetrazol-2-yl)azetidine-1-carboxylate (Compound 25) o N-N
N' N
No HN-S\ *
Preparation of Compound 25:
o N-NH
N N
N * o N-N
B
Boc oc N. Ni II
25-3 (1 eq) N
TsCI 25-la (1.2 eq) HO Py, 30 C, 20 h Ts0 K2CO3( 4 eq), DMF
80-120 C, 16 h N qk 25-1 25-2 Compound 25 Step 1: tert-butyl 3-(p-tolylsulfonyloxy)azetidine-l-carboxylate [00274] To a mixture of 25-1 (3.0 g, 17.3 mmol, 1.0 eq) in pyridine (16 mL) was added 25-la (3.96 g, 20.8 mmol, 1.2 eq) in one portion under N2.The mixture was stirred at 30 C and stirred for 20 h. LCMS showed compound 25-1 was consumed completely and one main peak with desired MS was detected. The reaction mixture was diluted with water (40 mL) and extracted with EA (30 mL * 3). The combined organic layers were washed with brine (30 mL *
3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. 25-2 (5.50 g, crude) was obtained as a red oil, which was used in the next step without further purification.
Step 2: 3-15-12-(cyclohexylamino)-5-(methylsulfamoyl)phenyl]tetrazol-2-yl]azetidine-1-carboxylate [00275] To a mixture of 25-2 (70 mg, 0.15 mmol, 1.2 eq) and 25-3 (50 mg, 0.13 mmol, 1.0 eq) in DMF (1 mL) was added K2CO3 (70 mg, 0.51 mmol, 4.0 eq) in one portion under N2.
The mixture was stirred at 80 C for 2.5 hr. LCMS showed only starting material was remained.
The reaction mixture was continued stirred at 120 C for 16 hr. LCMS showed one main peak with desired MS was detected. The reaction mixture was diluted with water (5 mL) and extracted with EA (5 mL * 4). The combined organic layers were dried with anhydrous Na2SO4, filtered and concentrated in vacuum. HPLC indicated 52% of desired product was found.
The residue was purified by prep-HPLC. LCMS and IFINMR confirmed Compound 25 (14.2 mg, 28.8 umol, 22.6% yield). LCMS (ESI): RT = 0.842 min, mass calcd. For C22H331\17045, 491.23 m/z found 514.1 [M+231+.1H NMR (400MHz, CDC13) 6 8.64 (d, J= 2.0 Hz, 1H), 7.82 -7.72 (m, 2H), 6.84 (d, J= 9.2 Hz, 1H), 5.75 - 5.66 (m, 1H), 4.60 - 4.51 (m, 4H), 4.27 -4.21 (m, 1H), 3.61 - 3.52 (m, 1H), 2.68 (d, J = 5.6 Hz, 3H), 2.11 -2.03 (m, 2H), 1.88 - 1.77 (m, 2H), 1.69 - 1.63 (m, 1H), 1.51 (s, 9H), 1.48 - 1.36 (m, 5H).
Example 25: 4-(cyclohexylamino)-3-(2-isopropy1-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 26) N-N
rµ\]
-S
HN
Preparation of Compound 26:
NH-N N-N
n= i, NHo 26-1a(1.0 eq) 0 9µ K2CO3(2.5 eq) = 0 NH-Sµ\ -S
DMF, 80 C, MW, 0.5 hr HN
26-1 Compound 26 1002761 To a solution of 26-1 (60.0 mg, 0.2 mmol, 1.0 eq) in DMF (3.0 mL) was added K2CO3 (49.3 mg, 0.4 mmol, 2.0 eq) and 2-iodopropane 26-la (30.3 mg, 0.2 mmol, 17.8 uL, 1.0 eq). The mixture was stirred at 80 C under microwave condition for 0.5 hr.
LCMS showed 39%
of 1 was remained. Several new peaks were shown on LCMS and 55% of desired compound was detected. The reaction mixture was purified by prep-HPLC to give Compound 26 (18.86 mg, 49.8 umol, 28% yield). LCMS (ESI): RT = 0.835 min, mass calc. for C17H26N6025 378.18, m/z found 379.0 [M+H1+; 1HNMR (400MHz, CDC13) 6 (ppm) 8.63 (d, J= 2.2 Hz, 1H), 7.90 (d, J=
7.1 Hz, 1H), 7.73-7.70 (m, 1H), 6.82 (d, J= 9.0 Hz, 1H), 5.19-5.09 (m, 1H), 4.28 (q, J = 5.3 Hz, 1H), 3.55 (s, 1H), 2.67 (d, J= 5.5 Hz, 3H), 2.15-2.02 (m, 2H), 1.86-1.78 (m, 2H), 1.73 (d, J = 6.6 Hz, 6H), 1.66 (d, J= 11.9 Hz, 1H), 1.52-1.36 (m, 5H) Example 26: 4-(cyclohexylamino)-3-(2-isobuty1-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 27) N-N
/1\I
0µµ 410'0i wm-S
Preparation of Compound 27:
NH-N
N-N
1\1N µi\I Brj N
27-1a(1.0eq) 1 NHo __________________________ K2CO3(2.5 eq) NH.S DMF, 80 C, 16h µµ NFI2S 410 0 27-1 Compound 27 [00277] To a solution of 27-1 (60.0 mg, 0.2 mmol, 1.0 eq) in DMF (2.0 mL) was added K2CO3 (49.3 mg, 0.4 mmol, 2.0 eq) and 27-la (24.4 mg, 0.2 mmol, 19.4 uL, 1.0 eq). The mixture was stirred at 80 C for 16h. LCMS showed 35% of 27-1 was remained.
Several new peaks were shown on LCMS and 40% of desired compound was detected. The mixture was purified by prep-HPLC to give Compound 27 (6.53 mg, 16.6 umol, 9% yield). LCMS
(ESI): RT
= 0.863 min, mass calc. for Ci8t128N6025 392.20, m/z found 393.1 [M+1-11+;
IFINMR (400MHz, CDC13) 6 8.63 (d, J = 2.3 Hz, 1H), 7.84 (d, J = 7.0 Hz, 1H), 7.74-7.71 (m, 1H), 7.27 (s, 1H), 6.82 (d, J = 9.0 Hz, 1H), 4.50 (d, J = 7.0 Hz, 2H), 4.28 (q, J= 5.4 Hz, 1H), 3.54 (s, 1H), 2.67 (d, J=
5.5 Hz, 3H), 2.50-2.40(m, 1H), 2.12-2.03 (m, 2H), 1.87-1.78 (m, 2H), 1.67 (d, J= 12.0 Hz, 1H), 1.53-1.35 (m, 5H), 1.02 (d, J= 6.8 Hz, 6H).
Example 27: tert-butyl 4-(5-(2-(cyclohexylamino)-5-(N-methylsulfamoyl)pheny1)-tetrazol-2-yl)piperidine-1-carboxylate (Compound 28) )L0) rI\J
40 No -S
HN
Preparation of Compound 28:
Br )L0) Ii o N N Boo' 28-la (1.2 eq) oNN N1 K2CO3 (2.0 eq), N
N
DMF, 100 C, 10 h HN-SµN
I -S
HN
Compound 28 [00278] To a stirring solution of compound 28-1 (200 mg, 0.60 mmol, 1.0 eq) and K2CO3 (247 mg, 1.78 mmol, 3.0 eq) in DMF (4 mL) was added compound 28-la (251 mg, 0.95 mmol, 1.6 eq). The resulting mixture was heated to 80 C for 16 h. LCMS showed 58% of desired compound was found and 35% of the starting material was remained. The resulted mixture was heated at 100 C for 16 hr. LCMS showed 58% of desired compound was found and 35% of the starting material was remained. The mixture was cooled and poured into water (8 mL) and stirred for 5 min. The aqueous phase was extracted with ethyl acetate (8 mL*3). The combined organic phases were washed with brine (8 mL*2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a residue which was purified by flash column chromatography to give the product (160 mg, 0.28 mmol, 47% yield). The product (30 mg) was re-purified by prep-HPLC to give Compound 28 (9.64 mg). LCMS (ESI): RT = 0.880 min, mass calc. for C24H37N704S 519.26, m/z found 542.1 [M+231+; 1HNMR (400 MHz, CDC13) 6 8.61 (d, J= 2.3 Hz, 1H), 7.82 (d, J= 7.0 Hz, 1H), 7.72 (dd, J= 2.3, 9.0 Hz, 1H), 6.82 (d, J =
9.0 Hz, 1H), 4.99 -4.87 (m, 1H), 4.26 - 4.20 (m, 2H), 3.54 (s, 1H), 3.08 (s, 2H), 2.66 (d, J= 5.5 Hz, 3H), 2.35 - 2.16 (m, 4H), 2.08 (d, J= 8.8 Hz, 2H), 1.81 (d, J= 5.0 Hz, 2H), 1.67 (d, J = 10.5 Hz, 1H), 1.50 (s, 9H), 1.48 - 1.34 (m, 5H).
Example 28: 4-(cyclohexylamino)-N-methyl-3-(2-(pyridin-3-ylmethyl)-2H-tetrazol-yl)benzenesulfonamide (Compound 29) Ni/
N-N, N N
N
S
HN
Preparation of Compound 29:
1,\J-NH HBr N N N,Br 29-la (1.2 eq) N
oµµ = No K2CO3 (2.0 eq),NQ
DMF, 80 C, 3 h HN-SµN 0111 I ,S, HN
Compound 29 [00279] To a stirring solution of compound 29-1 (50 mg, 0.15 mmol, 1.0 eq) and K2CO3 (62 mg, 0.45 mmol, 3.0 eq) in DMF (1 mL) was added compound 29-la (45 mg, 0.18 mmol, 1.2 eq). The resulting mixture was heated at 100 C for 16 hr. LCMS showed 66% of desired compound was found and the starting material was consumed completely. The mixture was cooled and diluted with DMF (2 mL) and filtered. The filtrate was purified by prep-HPLC to give Compound 29 (20 mg, 46 umol, 31% yield). LCMS (ESI): RT = 0.687 min, mass calc. for C20I-125N702S 427.18, m/z found 428.1 [M+H1+; IFINMR (400 MHz, CHLOROFORM-d) 6 8.88 - 8.53 (m, 3H), 7.86 - 7.66 (m, 3H), 7.36 (s, 1H), 6.80 (d, J= 8.5 Hz, 1H), 5.86 (s, 2H), 4.22 (s, 1H), 3.52 (s, 1H), 2.65 (d, J= 4.5 Hz, 3H), 2.05 (s, 2H), 1.77 (s, 2H), 1.59 (s, 3H), 1.42 (d, J =
9.3 Hz, 5H).
Example 29: 4-(cyclohexylamino)-N-methy1-3-(2-(piperidin-4-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 30) Nj\)--/NAN
czµ No -S
Preparation of Compound 30:
)LX QH
HCl/dioxane 20 C, 1 h N
czµ N o (RI\ *
,S
30-1 Compound 30 [00280] A solution of 30-1 (130 mg, 0.25 mmol, 1.0 eq) in HC1/dioxane (3 mL) was stirred at 20 C for 1 h. LCMS showed desired compound was found and the starting material was consumed completely. The mixture was concentrated to give the product (130 mg crude).
The product (100 mg) was directly used without further purification. The product (30 mg) was purified by prep-HPLC to give Compound 30 (11.26 mg). LCMS (ESI): RT = 0.655 min, mass calc. for Ci9H29N702S 419.21, m/z found 420.1 [M+1-11+; IFINMR (400 MHz, DMSO-d6) 6 9.51 - 9.06 (m, 2H), 8.41 (d, J = 1.8 Hz, 1H), 7.66 (d, J= 8.5 Hz, 1H), 7.58 (d, J=
7.3 Hz, 1H), 7.27 (d, J = 5.0 Hz, 1H), 7.06 (d, J = 9.0 Hz, 1H), 5.39 - 5.28 (m, 1H), 3.62 (s, 1H), 3.48 - 3.44 (m, 2H), 3.19 (s, 2H), 2.47 - 2.31 (m, 7H), 2.00 (d, J= 9.3 Hz, 2H), 1.71 (s, 2H), 1.59 (s, 1H), 1.52 -1.26 (m, 5H).
Example 30: 3-(2-(1-acetylpiperidin-4-y1)-2H-tetrazol-5-y1)-4-(cyclohexylamino)-N-methylbenzenesulfonamide (Compound 31) N¨N
Oxµ 411 -NHS %%
Preparation of Compound 31:
0)L./
( joi Boc -NI\
N-NH
Br 31-la (1.5 eq) 14' Dioxane-HCI
.s K2CO3 (2.0 eq), DMF, 120 C,3 hr N
20 C, lhr N *
HN
HCI
QI
N-N AcCI (1.0eq) TEA (3.0 eq) N¨N
N
DCM,0-20 C, 1 hr HN
NH xx Compound 31 Step 1: tert-Butyl 4-(5-(2-(cyclohexylamino)-5-(N-methylsulfamoyl)pheny1)-2H-tetrazol-2-yl) piperidine-l-carboxylate [00281] To a solution of compound 31-1 (300 mg, 0.89 mmol, 1.0 eq) and compound 31-la (353 mg, 1.34 mmol, 1.5 eq) in DMF (4 mL) was added K2CO3 (247 mg, 1.78 mmol, 2.0 eq).
The reaction mixture was stirred at 120 C for 3 hours. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (30 mL) and the resultant mixture was extracted with DCM (50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford 31-2 (410 mg, 78% yield). LCMS (ESI):
RT = 0.892 min, mass calcd. for C24H37N704S 519.26, m/z found 542.3 [M+Nal+.
Step 2: 4-(Cyclohexylamino)-N-methy1-3-(2-(piperidin-4-y1)-2H-tetrazol-5-yl)benzene sulfonamide hydrochloride [00282] A solution of compound 31-2 (410 mg, 0.79 mmol, 1.0 eq) in Dioxane/HC1 (8 mL) was stirred at 20 C for 1 hour. The reaction mixture was concentrated under reduced pressure to obtain 31-3 (350 mg, 97% yield). LCMS (ESI): RT = 0.646 min, mass calcd. for C19H29N702S 419.21, m/z found 420.2 [M+H1+.
Step 3: 3-(2-(1-Acetylpiperidin-4-y1)-2H-tetrazol-5-y1)-4-(cyclohexylamino)-N-methyl benzenesulfonamide [00283] To a solution of compound 31-3 (40 mg, 88 umol, 1.0 eq, HC1) and TEA (27 mg, 0.26 mmol, 3.0 eq) in DCM (1.5 mL) was added dropwise a solution of acetyl chloride (6.9 mg, 88 umol, 1.0 eq) in DCM (0.5 mL) at 0 C. The reaction mixture was allowed to warm up to 20 C and stirred at 20 C for 1 hour. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with DCM (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely.
Compound 31 (14.47 mg, 36% yield) was obtained. LCMS (ESI): RT = 0.747 min, mass calcd.
for C21-131N703S 461.22, m/z found 462.1 [M+H1+, 1HNMR (400MHz, DMSO-d6) 6 8.41 (d, J
= 1.8 Hz, 1H), 7.74 - 7.55 (m, 2H), 7.24 (d, J= 4.0 Hz, 1H), 7.05 (d, J= 9.0 Hz, 1H), 5.30 - 5.15 (m, 1H), 4.39 (d, J= 12.3 Hz, 1H), 3.94 (d, J= 13.6 Hz, 1H), 3.76 - 3.57 (m, 1H), 3.02 - 2.88 (m, 1H), 2.42 - 2.24 (m, 4H), 2.17 - 1.85 (m, 8H), 1.80 - 1.65 (m, 2H), 1.58 (br s, 1H), 1.53 - 1.20 (m, 6H).
Example 31: 4-(cyclohexylamino)-N-methy1-3-(2-(1-(methylsulfonyl)piperidin-4-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 32) µS, µ0 N-N
0 NoNH,sµ
Preparation of Compound 32:
HCI 0, /
NH
N-N MsCI (1.0eq) N-N
N TEA (3.0 eq) LI
DCM,0-20 C, 1 hr OµI 40 NO
HN
NH-%
I
Compound 32 [00284] To a solution of compound 32-1 (40 mg, 88 umol, 1.0 eq, HC1) and TEA (27 mg, 0.26 mmol, 3.0 eq) in DCM (1.5 mL) was added dropwise a solution of MsC1 (10 mg, 88 umol, 1.0 eq) in DCM (0.5 mL) at 0 C. The reaction mixture was allowed to warm up to 20 C and stirred at 20 C for 1 hour. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with DCM (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely.
Compound 32 (19.06 mg, 44% yield) was obtained. LCMS (ESI): RT = 0.774 min, mass calcd.
for C20I-1311\1704S2 497.19, m/z found 498.1 [M+H1+, 1HNMR (400MHz, DMSO-d6) 6 8.42 (s, 1H), 7.75 - 7.51 (m, 2H), 7.35 - 7.15 (m, 1H), 7.13 - 6.95 (m, 1H), 5.25 -5.05 (m, 1H), 3.74 -3.54 (m, 3H), 3.15 - 3.05 (m, 2H), 2.95 (s, 3H), 2.38 (s, 3H), 2.28 - 2.10 (m, 3H), 2.10 - 1.90 (m, 2H), 1.83 - 1.56 (m, 3H), 1.55 - 1.17 (m, 6H).
Example 32: 4-(cyclohexylamino)-N-methy1-3-(2-(1-(pyridin-3-yl)piperidin-4-y1)-tetrazol-5-yl)benzenesulfonamide (Compound 33) N-N
=
oµµ N
-S
N µ
H,`
Preparation of Compound 33:
HCI \1\0 I)0-Br N--N
N N-N
(1.5 eq) Pd2(dba)3 (0.05 eq) N N
9, N Xantphos (0.15 eq) NH-S Cs2CO3 (3.0 eq) (:)µµ No %\
I 0 Dioxane,100 C,16 hr el -S
N
H
33-1 Compound 33 [00285] A solution of compound 33-1 (40 mg, 88 umol, 1.0 eq, HC1), compound (21 mg, 0.13 mmol, 1.5 eq) and Pd2(dba)3 (4.0 mg, 4.4 umol, 0.05 eq), Xantphos (7.6 mg, 13 umol, 0.15 eq), Cs2CO3 (86 mg, 0.26 mmol, 3.0 eq) in Dioxane (2 mL) under N2.
The suspension was degassed under vacuum and purged with N2 several times. The reaction mixture was stirred at 100 C for 16 hours. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with DCM (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely. Compound 33 (5.12 mg, 11%
yield) was obtained. LCMS (ESI): RT = 0.685 min, mass calcd. for C24H321\1802S
496.24, m/z found 497.2 [M+H1+, 1HNMR (400MHz, CDC13) 6 8.62 (d, J= 2.0 Hz, 1H), 8.56 -8.30 (m, 1H), 8.28 - 8.00 (m, 1H), 7.83 (d, J= 7.0 Hz, 1H), 7.72 (dd, J = 2.3, 9.0 Hz, 1H), 7.31 - 7.27 (m, 1H), 7.25 - 7.17 (m, 1H), 6.82 (d, J = 9.0 Hz, 1H), 5.01 -4.91 (m, 1H), 4.26 (q, J=
5.4 Hz, 1H), 3.83 (d, J= 12.8 Hz, 2H), 3.60 - 3.48 (m, 1H), 3.19 - 3.06 (m, 2H), 2.66 (d, J= 5.5 Hz, 3H), 2.56 -2.42 (m, 4H), 2.13 - 2.02 (m, 2H), 1.86 - 1.76 (m, 2H), 1.71 - 1.66 (m, 1H), 1.52 - 1.24 (m, 5H).
Example 33: 4-(cyclohexylamino)-N-methy1-3-(2-pheny1-2H-tetrazol-5-yl)benzenesulfonamide (Compound 34) sit N-N
µ1\1 czµ N
NH,Sµ`
I
Preparation of Compound 34:
N-NH
;1\1 34-2 (1.5 eq) No IR\ el Cs2CO3 (2.0 eq), Cul(0.4 eq) ,Sµ
NH' MW, DMF, 120 C, 1h NH µ,-1 I
34-1 Compound 34 [00286] To a solution of compound 34-1 (50.0 mg, 0.15 mmol, 1.0 eq) and compound 34-2 (45.5 mg, 0.22 mmol, 24.9 uL, 1.5 eq) in DMF (2.0 mL) was added Cs2CO3 (193.7 mg, 0.59 mmol, 4.0 eq) and Cul (11.3 mg, 59.4 umol, 0.4 eq). The mixture was stirred at 100 C for 3 hour at N2 atmosphere. LCMS showed desired compound was found. The reaction was filtered to give a crude product which was purified by prep-HPLC to give Compound 34 (6.48 mg, 15.1 umol, 10.2% yield) was obtained. LCMS (EST): RT = 0.839 min, mass calc. for 412.17, m/z found 413.1 [M+F11+;IHNMR (400 MHz, CDC13) 6 8.11 (s, 1H), 7.48 (dd, J = 1.8, 9.0 Hz, 1H), 7.34 - 7.24 (m, 4H), 7.22 - 7.15 (m, 2H), 6.88 (d, J= 9.0 Hz, 1H), 3.57 (s, 1H), 3.20 (s, 3H), 2.11 (d, J= 10.8 Hz, 2H), 1.88 (d, J= 8.5 Hz, 2H), 1.71 (d, J= 10.5 Hz, 1H), 1.58 - 1.52 (m, 1H), 1.49 - 1.28 (m, 4H).
Example 34: 4-(cyclohexylamino)-N-methy1-3-(2-(pyrrolidin-3-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 35) N/1\1H
N-N
NH-Sµµ
I
Preparation of Compound 35:
0 *
.N/1\1H
1\1 N-N
N
N-N HCl/dioxane NI' )1.=
N
2000, 2 h (:)µµ ei -Sµµ
0 * NH
µµ
-S
NH \\
cJ
Compound 35 [00287] A mixture of compound 35-1 (0.31 g, 0.61 mmol, 1.0 eq) in HC1/dioxane (4 M, 4 mL, 26.1 eq) stirred at 20 C for 1 hour. LCMS showed the desired compound was found. TLC
showed desired compound was found and the starting material was consumed completely. The reaction mixture was concentrated to give the crude Compound 35 (0.23 g, 0.52 mmol, 84.9%
yield, HC1). The residue was directly used without further purification. The crude product (15.0 mg) was purified by prep-HPLC to give the title compound (2.60 mg). LCMS
(ESI): RT = 0.643 min, mass calc. for C18H27N702S 405.19, m/z found 406.1 [M+1-1I;1HNMR (400 MHz, DMSO-d6) 6 9.92 (s, 1H), 9.68 (s, 1H), 8.42 (s, 1H), 7.71 - 7.45 (m, 2H), 7.30 (s, 1H), 7.05 (d, J= 8.8 Hz, 1H), 5.86 (s, 1H), 3.85 (s, 2H), 3.46 (d, J= 15.6 Hz, 2H), 2.72 - 2.57 (m, 2H), 2.36 (s, 3H), 1.99 (s, 2H), 1.70 (s, 2H), 1.58 (s, 1H), 1.49 - 1.27 (m, 5H). 1HNMR (400 MHz, Me0D-d4) 6 8.56 (d, J= 2.3 Hz, 1H), 7.72 (dd, J= 2.3, 9.0 Hz, 1H), 7.01 (d, J = 9.0 Hz, 1H), 5.96 - 5.89 (m, 1H), 4.11 -4.05 (m, 1H), 4.01 -3.93 (m, 1H), 3.70 - 3.61 (m, 3H), 2.81 -2.74 (m, 2H), 2.51 (s, 3H), 2.14 - 2.04 (m, 2H), 1.82 (dd, J= 4.5, 8.8 Hz, 2H), 1.67 (s, 1H), 1.57 -1.37 (m, 5H).
Example 35: 4-(cyclohexylamino)-3-(2-(1-isopropylpyrrolidin-3-y1)-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 36) N N
oµµ N 0 NH-Sµµ
I
Preparation of Compound 36:
/1\1H
N N N N
36-2 (1.5 eq) (:)µµ = No _______________________________________ = No K2CO3 (2.0 eq), 10µµ
HN-S DMF, 80 C, 1h NH-%
Compound 36 [00288] To a solution of compound 36-1 (30 mg, 73.9 umol, 1.0 eq) in DMF
(2.0 mL) was added K2CO3 (20.5 mg, 0.15 mmol, 2.0 eq) and compound 36-2 (18.9 mg, 0.11 mmol, 11.1 uL, 1.5 eq). The mixture was stirred at 80 C for 2 hr at N2 atmosphere. LCMS
showed desired compound was found. The reaction was filtered to give a crude product which was purified by prep-HPLC to give Compound 36 (2.48 mg, 5.3 umol, 7.2% yield) was obtained.
LCMS (ESI):
RT = 0.659 min, mass calc. for C21H331\1702S 447.60, m/z found 448.1 [M+F11+;IHNMR (400 MHz, CDC13) 6 8.62 (d, J= 2.3 Hz, 1H), 7.86 (d, J= 7.5 Hz, 1H), 7.73 (dd, J =
2.3, 9.0 Hz, 1H), 6.82 (d, J= 9.0 Hz, 1H), 5.46 (s, 1H), 4.24 (q, J= 5.4 Hz, 1H), 3.59 - 3.41 (m, 2H), 3.14 - 3.05 (m, 1H), 3.01 - 2.87 (m, 2H), 2.67 (d, J= 5.5 Hz, 3H), 2.63 - 2.52 (m, 3H), 2.07 (d, J= 5.3 Hz, 2H), 1.81 (s, 2H), 1.64 (s, 1H), 1.51 - 1.29 (m, 5H), 1.17 (d, J = 6.3 Hz, 6H).
Example 36: 4-(cyclohexylamino)-N-methy1-3-(2-(1-phenylpyrrolidin-3-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 37) N N
u m-S
Pan \\
Preparation of Compound 37:
HO-B
OH
N N N õ N
37-2(1.5 eq) (:)µµ N No DI EA (4.0 eq),Cu(OAc)2(1.5 eq) DCM, 02, rt, 24h ei No H,sµ`
Compound 37 [00289] To a solution of compound 37-1 (30 mg, 73.9 umol, 1.0 eq) and compound 37-2 (18.0 mg, 0.15 mmol, 2.0 eq) in DCM (5.0 mL) was added DIEA (38.2 mg, 0.30 mmol, 51.5 uL, 4.0 eq) and Cu(OAc)2 (20.1 mg, 0.11 mmol, 1.5 eq). The mixture was stirred at 20 C for 16 hr at 02 atmosphere. LCMS showed desired compound was found. The reaction was filtered to give a crude product. The crude product was purified by prep-HPLC to give Compound 37 (4.9 mg, 10.2 umol, 13.8% yield) was obtained. LCMS (ESI): RT = 0.912 min, mass calc.
for C24H311\1702S 481.23, m/z found 482.1 [M+F11+;IHNMR (400 MHz, CDC13-d) 6 8.61 (d, J= 2.0 Hz, 1H), 7.75 - 7.65 (m, 2H), 7.30 (s, 2H), 6.82 - 6.74 (m, 2H), 6.63 (d, J =
8.3 Hz, 2H), 5.65 (d, J = 3.3 Hz, 1H), 4.20 (d, J = 5.5 Hz, 1H), 4.06 - 3.93 (m, 2H), 3.74 (q, J=
7.9 Hz, 1H), 3.62 (dt, J = 4.1, 8.7 Hz, 1H), 3.48 (s, 1H), 2.94 - 2.85 (m, 1H), 2.78 - 2.69 (m, 1H), 2.65 (d, J= 5.5 Hz, 3H), 2.02 (s, 2H), 1.77 (s, 2H), 1.63 (s, 1H), 1.45 - 1.27 (m, 5H).
Example 37: 4-(cyclohexylamino)-N-methy1-3-(2-(1-phenylpiperidin-4-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 38) c_N)1 N-N
czµ N
NH
I
Preparation of Compound 38:
NH N
NN HOB NN
N OH 38-2(2.0 eq) (:)µµ No DIEA (4D.Oe9i),0 rt 4 Cu(OAcg(1.5 eq) czµ N
civ o -Sµ µ0 NH HCI NH
I
38-1 Compound 38 [00290] To a solution of compound 38-1 (50.0 mg, 0.12 mmol, 1.0 eq) and compound 38-2 (43.6 mg, 0.36 mmol, 3.0 eq) in DCM (5.0 mL) was added DIEA (61.6 mg, 0.47 mmol, 83.3 uL, 4.0 eq) and Cu(OAc)2 (32.5 mg, 0.18 mmol, 1.5 eq). The mixture was stirred at 25 C for 16 hr at 02 atmosphere. LCMS showed desired compound was found. The reaction was filtered to give a crude product which was purified by prep-HPLC to give Compound 38 (9.24 mg, 18.6 umol, 15.6% yield) was obtained. LCMS (ESI): RT = 0.845 min, mass calc. for 495.24, m/z found 496.2 [M+F11+;IHNMR (400 MHz, CDC13-d) 6 8.63 (d, J=2.3 Hz, 1H), 7.83 (d, J= 7.0 Hz, 1H), 7.73 (dd, J = 2.1, 8.9 Hz, 1H), 7.31 (t, J= 7.9 Hz, 2H), 7.01 (d, J= 8.0 Hz, 2H), 6.92 (t, J= 7.3 Hz, 1H), 6.82 (d, J= 9.0 Hz, 1H), 4.93 (if, J= 5.0, 10.0 Hz, 1H), 4.28 (q, J =
5.5 Hz, 1H), 3.83 (d, J= 12.8 Hz, 2H), 3.54 (s, 1H), 3.12 - 3.01 (m, 2H), 2.67 (d, J = 5.5 Hz, 3H), 2.54 - 2.42 (m, 4H), 2.08 (d, J= 9.3 Hz, 2H), 1.87 - 1.78 (m, 2H), 1.67 (d, J= 12.8 Hz, 1H), 1.50- 1.34 (m, 5H).
Example 38: 4-(cyclohexylamino)-N-methyl-3-(2-(2,2,2-trifluoroethyl)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 39) /
N-N, F
II
0õ
N
Preparation of Compound 39:
( F
Tf0 F
N-NH \-(-F ( F F
39-2 (3.6 eq) N1' N
µµ o Cs2CO3 (3.0 eq) sµ N... 0 CH3CN, 0 C-rt, 40 h 0õ N..õ(1) HN N
,S, F->r-N
N F
39-1 Compound 39 Compound 39-[00291] To a mixture of 39-1 (40.0 mg, 0.1 mmol, 1.0 eq, HC1) and Cs2CO3 (104.9 mg, 0.3 mmol, 3.0 eq) in CH3CN (3.0 mL) was added 39-2 (29.9 mg, 0.1 mmol, 1.2 eq) at 0 C. The resulted mixture was stirred at 15 C for 20 h. LCMS showed there's 16%
desired compound, and 66% starting material remained. Another 39-2 (60 mg) was added. The mixture was stirred at 15 C for 20 h. LCMS and HPLC showed the reaction was completed. The mixture was filtered, and the solid was washed with DMF (1 mL). The filtrate was purified by prep-HPLC.
Compound 39 (2.20 mg, 5.3 umol, 4.9% yield) was obtained. LCMS (ESI): RT =
0.828 min, mass calcd. for Ci6H2iF3N602S 418.14, m/z found 419.1 [M+1-11+.'H NMR (400MHz, CDC13) 6 8.67 (d, J= 2.5 Hz, 1H), 7.76 (dd, J= 2.3, 8.8 Hz, 1H), 7.60 (d, J = 7.0 Hz, 1H), 6.85 (d, J = 9.0 Hz, 1H), 5.34 - 5.28 (m, 2H), 4.25 (q, J= 5.3 Hz, 1H), 3.58 - 3.55 (m, 1H), 2.68 (d, J = 5.5 Hz, 3H), 2.08 (d, J= 10.3 Hz, 2H), 1.86 - 1.78 (m, 2H), 1.71 - 1.63 (m, 1H), 1.53 -1.36 (m, 5H).
[00292]
Compound 39-3 (6.43 mg, 12.8 umol, 12.0% yield) was obtained. LCMS (ESI):
RT = 0.910 min, mass calcd. for Ci8H22F6N602S 500.14, m/z found 501.1 [M+1-11+. NMR
(400MHz, CDC13) 6 8.63 (d, J= 2.3 Hz, 1H), 7.73 - 7.63 (m, 2H), 6.85 (d, J =
9.0 Hz, 1H), 5.32 (q, J= 7.6 Hz, 2H), 3.76 (q, J= 8.7 Hz, 2H), 3.61 - 3.51 (m, 1H), 2.92 (s, 3H), 2.09 - 2.07 (m, 2H), 1.87 - 1.76 (m, 2H), 1.69 - 1.67 (m, 1H), 1.53 - 1.35 (m, 5H).
Example 39: 4-(cyclohexylamino)-3-(2-(2-fluoroethyl)-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 40) N-NII , ,N
0 N, 4110 Preparation of Compound 40:
N-NH
z BrF
40-la (1.2 eq) Uz N
K2003 (3.0 eq) (:)µ DMF, 80 C, 2 h HN
`0 40-1 Compound 40 [00293] To a mixture of 40-1 (40.0 mg, 0.1 mmol, 1.0 eq, HC1) and K2CO3 (44.5 mg, 0.3 mmol, 3.0 eq) in DMF (2.0 mL) was added 40-la (16.3 mg, 0.1 mmol, 1.2 eq). The resulted mixture was stirred at 80 C for 2 h. The reaction was monitored by LCMS. The mixture was filtered, and the solid was washed with DMF (1 mL). The filtrate was checked by HPLC. The filtrate was purified by prep-HPLC. Compound 40 (4.48 mg, 11.7 umol, 10.9%
yield,) was obtained. LCMS (ESI): RT = 0.779 min, mass calcd. for Ci6H23FN602S 382.16, m/z found 383.1 [M+H1+. 1HNMR (400MHz, DMSO-d6) 6 8.41 (d, J = 2.0 Hz, 1H), 7.66 (dd, J= 2.0, 8.8 Hz, 1H), 7.60 (d, J= 7.5 Hz, 1H), 7.26 (q, J= 5.0 Hz, 1H), 7.05 (d, J = 9.0 Hz, 1H), 5.21 (t, J = 4.5 Hz, 1H), 5.14 (t, J= 4.5 Hz, 1H), 5.09 - 5.04 (m, 1H), 4.95 (t, J= 4.5 Hz, 1H), 3.69 - 3.60 (m, 1H), 2.37 (d, J= 4.8 Hz, 3H), 2.03 - 1.95 (m, 2H), 1.76 - 1.67 (m, 2H), 1.63 -1.55 (m, 1H), 1.51 - 1.32 (m, 5H).
Example 40: 4-(cyclohexylamino)-3-(2-(4-fluorobenzy1)-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 41) N-N
1\1, 0, N10 Preparation of Compound 41:
Br 11, N 41-2 (1.5 eq) N-N
N-N
K2CO3 (4.0 eq) IT ;1 0 DMF, 40 C,17 h N1c) H 0. ao 0õs Nr8 41-1 HN'il Compound 41 Compound 41-3 [00294] To a mixture of 41-1 (40.0 mg, 0.1 mmol, 1.0 eq, HC1) and K2CO3 (59.3 mg, 0.4 mmol, 4.0 eq) in DMF (3.0 mL), was added 41-2 (30.4 mg, 0.2 mmol, 20 uL, 1.5 eq). The resultant mixture was stirred at 40 C under N2 for 17 h. The reaction was monitored by LCMS.
The mixture was filtered, and the solid was washed with DMF (1 mL) and checked by HPLC.
The filtrate was purified by prep-HPLC. Compound 41 (6.61 mg, 14.9 umol, 13.9%
yield) was obtained. LCMS (ESI): RT = 0.868 min, mass calcd. for C21H25FN602S 444.17, m/z found 445.0 [M+H1+. 1HNMR (400MHz, DMSO-d6) 6 8.38 (d, J = 2.3 Hz, 1H), 7.63 (dd, J= 2.0, 8.8 Hz, 1H), 7.56 - 7.50 (m, 3H), 7.30 - 7.20 (m, 3H), 7.02 (d, J= 9.3 Hz, 1H), 6.05 (s, 2H), 3.66 - 3.57 (m, 1H), 2.35 (d, J= 5.0 Hz, 3H), 1.97 - 1.89 (m, 2H), 1.65 (td, J = 3.2, 6.1 Hz, 2H), 1.60 - 1.52 (m, 1H), 1.47 - 1.36 (m, 2H) , 1.35 - 1.22 (m, 3H).
[00295] Compound 41-3 (6.72 mg, 12.2 umol, 11.3% yield) was obtained, which was confirmed by LCMS and 1HNMR. LCMS (ESI): RT = 0.988 min, mass calcd. for C28H30F2N602S 552.21, m/z found 553.1 [M+H1+. NMR (400MHz, DMSO-d6) 6 8.38 (d, J =
2.3 Hz, 1H), 7.70 (dd, J= 1.9, 8.9 Hz, 1H), 7.59 (d, J= 7.5 Hz, 1H), 7.54 (dd, J = 5.6, 8.4 Hz, 2H), 7.34 (dd, J= 5.6, 8.2 Hz, 2H), 7.26 (t, J= 8.8 Hz, 2H), 7.16 (t, J = 8.8 Hz, 2H), 7.05 (d, J =
9.0 Hz, 1H), 6.06 (s, 2H), 4.06 (s, 2H), 3.69 - 3.59 (m, 1H), 1.98 - 1.89 (m, 2H), 1.65 (dd, J=
3.5, 8.8 Hz, 2H), 1.60 - 1.52 (m, 1H), 1.47 - 1.37 (m, 2H), 1.36 - 1.25 (m, 3H).
Example 41: 3-(2-(1-acetylpyrrolidin-3-y1)-2H-tetrazol-5-y1)-4-(cyclohexylamino)-N-methylbenzenesulfonamide (Compound 42) No -S
NH \\ *
Preparation of Compound 42:
/1\1H
Nr,N 0 N )(CI
N
(1.2 eq) am No __________________________________ TEA (2.5 eq) HNSN0 DCM, 10 C, 0.5 hr ` NH *
Compound 42 [00296] To the solution of compound 42-1 (30 mg, 68 umol, 1 eq, HC1) in DCM
(3 mL) was added TEA (17 mg, 0.17 mmol, 24 uL, 2.5 eq). Then acetyl chloride (6 mg, 81 umol, 6 uL, 1.2 eq) was added to the mixture. The solution was stirred at 10 C for 0.5 hr. The reaction was monitored by LCMS. The reaction was concentrated under reduced pressure.
The residue was purified by prep-HPLC to give Compound 42 (9.21 mg, 20.6 umol, 30.3%
yield). LCMS
(ESI): RT = 0.722 min, mass calcd. for C20I-129N703S 447.21, m/z found 448.1 [M+1-11+, 1HNMR
(400MHz, CHLOROFORM-d) 6 8.59 (br, 1H), 7.73 (d, J=7.8 Hz, 2H), 6.83 (d, J=8.3 Hz, 1H), 5.65 - 5.44 (m, 1H), 4.39 - 3.71 (m, 5H), 3.58 - 3.44 (m, 1H), 2.91 - 2.59 (m, 5H), 2.23 - 2.03 (m, 5H), 1.89 - 1.76 (m, 2H), 1.71 - 1.67 (m, 1H), 1.48 - 1.35 (m, 5H).
Example 42: 4-(cyclohexylamino)-N-methy1-3-(2-(1-(methylsulfonyl)pyrrolidin-3-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 43) N -N
NH
(Rµ
-S
NH µµ
Preparation of Compound 43:
N N
MsCI 11\1 (1.2 eq) CZµ la No TEA (2.5 eq) NHsµ
DCM, 10 C, 0.5 hr ifibl No , -µs µ
0 NH \µ
Compound 43 [00297] To the solution of compound 43-1 (30 mg, 68 umol, 1 eq, HC1) in DCM (3 mL) was added TEA (17 mg, 0.17 mmol, 24 uL, 2.5 eq). Then methanesulfonyl chloride (9 mg, 81 umol, 6 uL, 1.2 eq) was added to the mixture. The solution was stirred at 10 C for 0.5 hr. The reaction was monitored by LCMS. The reaction was concentrated under reduced pressure. The residue was purified by prep-HPLC to give Compound 43 (3.71 mg, 7.7 umol, 11.3%
yield). LCMS (ESI): RT = 0.754 min, mass calcd. for C19H29N704S2 483.17, m/z found 484.1 [M+H]+, 1HNMR (400MHz, CHLOROFORM-d) 6 8.57 (d, J=2.3 Hz, 1H), 7.78 - 7.71 (m, 2H), 6.84 (d, J=9.0 Hz, 1H), 5.61 -5.54 (m, 1H), 4.30 - 4.22 (m, 1H), 4.10 - 4.02 (m, 2H), 3.81 -3.73 (m, 1H), 3.70 - 3.62 (m, 1H), 3.59 - 3.50 (m, 1H), 2.95 (s, 3H), 2.79 - 2.69 (m, 2H), 2.68 - 2.66 (m, 3H), 2.13 -2.03 (m, 2H), 1.87 -1.78 (m, 2H), 1.72- 1.64 (m, 1H), 1.51 -1.41 (m, 5H).
Example 43: 4-(cyclohexylamino)-3-(2-(2-hydroxyethyl)-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 44) OH
1\11 µµ No NHS
I
Preparation of Compound 44:
OH
N-NH OH
N N Br Ck K2CO3 (2.0 eq), DMF, NH
HN-Sµµ 100 C, 16 h No 44-1 Compound 44 [00298] To a solution of compound 44-1 (30.0 mg, 89.2 umol, 1.0 eq) in DMF (2.0 mL) was added K2CO3 (24.7 mg, 0.18 mmol, 2.0 eq) and compound 44-2 (16.7 mg, 0.13 mmol, 9.5 uL, 1.5 eq). The mixture was stirred at 100 C for 16 hour at N2 atmosphere.
LCMS showed desired compound was found. The reaction was filtered to give a crude product.
The crude product was purified by prep-HPLC to give Compound 44 (6.16 mg, 16.2 umol, 18.2% yield) was obtained. LCMS (ESI): RT = 0.725 min, mass calc. for C16H24N603S 380.16, m/z found 381.0 [M+F11+;IHNMR (400 MHz, CDC13) 6 8.60 (d, J= 2.3 Hz, 1H), 7.82 (d, J =
7.0 Hz, 1H), 7.73 (dd, J = 2.3, 9.0 Hz, 1H), 6.82 (d, J = 9.0 Hz, 1H), 4.88 - 4.80 (m, 2H), 4.33 - 4.24 (m, 3H), 3.54 (s, 1H), 2.66 (d, J = 5.5 Hz, 3H), 2.30 (t, J= 6.3 Hz, 1H), 2.08 (d, J=
8.0 Hz, 2H), 1.86 -1.77 (m, 2H), 1.67 (d, J= 12.3 Hz, 1H), 1.52 - 1.35 (m, 5H).
Example 44: 4-(cyclohexylamino)-N-methy1-3-(2-(pyridin-3-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 45) N N
Nc)ICN
N I
H
Preparation of Compound 45:
OH
N-N
N-NH n'b OH
;1\1 NI' ;IV
45-la (1.2 eq) No Cou2010(00c;c052e0qh),DMSO, O.
;S
Compound 45 [00299] A solution of compound 45-1 (50 mg, 0.13 mmol, 1.0 eq, HC1), 45-la (33 mg, 0.27 mmol, 2.0 eq) and Cu20 (1 mg, 6.70 umol, 0.05 eq) in DMSO (3 mL) was degassed under vacuum and purged with 02 several times. The mixture was stirred at 100 C for 20hr. LCMS
showed that -60% of desired MS signal was detected. The reaction was filtered and concentrated. The residue was purified by prep-HPLC to give Compound 45 (2.30 mg, 5.6 umol, 4.2% yield). The HNMR and LCMS confirmed that desired product was obtained. LCMS
(ESI): RT = 2.779 min, mass calcd. for Ci9H23N7502 413.16, m/z found 414.0 [M+H1+. IFINMR
(400MHz, CDC13) 6 9.39 (s, 1H), 8.85 (s, 1H), 8.75 - 8.50 (m, 2H), 7.80 (dd, J
= 8.0 Hz, 4.8 Hz, 1H), 7.71 (dd, J= 9.2 Hz, 2.0 Hz, 1H), 7.40 - 7.25 (m, 2H), 6.86 (d, J = 9.2 Hz, 1H), 7.40 - 7.25 (m, 1H), 7.11 (d, J= 9.2 Hz, 1H), 3.65 - 3.50 (m, 1H), 2.41 (d, J = 4.8 Hz, 3H), 2.10 -2.00 (m, 2H), 1.90 - 1.75 (m, 2H), 1.75 - 1.65 (m, 2H), 1.50 -1.40 (m, 4H).
Example 45: 4-(cyclohexylamino)-3-(2-(1-isopropylpiperidin-4-y1)-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 46) and isopropyl 4-(5-(2-(cyclohexylamino)-5-(N-methylsulfamoyl)pheny1)-2H-tetrazol-2-yl)piperidine-1-carboxylate (Compound 47) o N-N N-N
;N NI ;NI
H H
011 ON =
,µS
N `0 Compound 46 Compound 47 Preparation of Compound 46 and Compound 47:
NH N
,-0 N-N
ii ;N 46-2a (1.0 1.2) N N-N
K2CO3 (2.0 eq), DMF, 80 C, 5h N-NS 0 ,NS
N ,Ns 46-1 Compound 46 ri Compound 47 [00300] To a stirred solution of 46-1 (30 mg, 66 umol, 1.0 eq, HC1) and K2CO3 (18.2 mg, 0.13 mmol, 2.0 eq) in DMF (1 mL) was added compound 46-2a (11 mg, 66 umol, 7 uL, 1.0 eq).
The resulting mixture was heated at 80 C for 5 hr. The reaction was monitored by LCMS. The reaction mixture was poured into water (3 mL) and the resulting mixture was stirred for 5 min.
The aqueous phase was extracted with ethyl acetate (3 mL*3). The combined organic phase were washed with brine (3 mL*2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give a residue. The residue was purified by prep-HPLC to give Compound 46 (6 mg, 13 umol, 20 % yield) and Compound 47 (1.49 mg, 3 umol, 5% yield).
[00301] Compound 46: LCMS (EST): RT = 0.647 min, mass calc. for C22H35N702S
461.26, m/z found 462.2 [M+H]+; NMR (400 MHz, CDC13) 6 8.61 (d, J = 2.0 Hz, 1H), 7.82 (d, J = 7.3 Hz, 1H), 7.71 (dd, J = 2.1, 8.9 Hz, 1H), 6.81 (d, J= 9.0 Hz, 1H), 4.72 (quin, J= 7.5 Hz, 1H), 4.24 (q, J= 5.3 Hz, 1H), 3.52 (s, 1H), 3.03 (d, J = 11.5 Hz, 2H), 2.84 (td, J = 6.5, 13.1 Hz, 1H), 2.66 (d, J= 5.5 Hz, 3H), 2.48 - 2.37 (m, 2H), 2.33 (d, J = 3.3 Hz, 4H), 2.08 (d, J = 8.5 Hz, 2H), 1.87 - 1.75 (m, 2H), 1.66 (s, 1H), 1.51 - 1.33 (m, 5H), 1.09 (d, J =
6.5 Hz, 6H).
[00302] Compound 47: LCMS (EST): RT = 0.8648 min, mass calc. for 505.25, m/z found 528.1 [M+23]+; 1H NMR (400 MHz, CDC13) 6 8.60 (d, J = 2.3 Hz, 1H), 7.82 ( d, J = 7.3 Hz, 1H), 7.72 (dd, J = 2.3, 8.8 Hz, 1H), 6.82 (d, J = 9.0 Hz, 1H), 5.01 - 4.89 (m, 2H), 4.34 - 4.16 (m, 3H), 3.53 (s, 1H), 3.13 (t, J = 11.2 Hz, 2H), 2.66 (d, J= 5.5 Hz, 3H), 2.35 - 2.20 (m, 4H), 2.07 (d, J = 9.3 Hz, 2H), 1.81 (s, 2H), 1.65 (s, 1H), 1.50 - 1.39 (m, 5H), 1.29 (d, J = 6.3 Hz, 6H).
Example 46: 4-(cyclohexylamino)-N-methyl-3-(5-methyl-1,2,4-oxadiazol-3-yl)benzene sulfonamide (Compound 48) N9-( \ N
411, -S
HN
Preparation of Compound 48:
OH
CN
NH2OH-HCI (5.0 eq) N NH2 N N
Na2CO3 (5.0 eq) __________________________ to. AcC1 (1.1 eq) -S 0 pyridine HN 0 HN 40 Et0H,80 C, 3 hr A 100 C, 16 hr No ___________________________________________________________ 40 No -S
HN
48-2 Compound 48 Step 1: 2-(Cyclohexylamino)-N'-hydroxy-5-(N-methylsulfamoyl)benzimidamide [00303] To a solution of compound 48-1 (100 mg, 0.34 mmol, 1.0 eq) and hydroxylamine (118 mg, 1.7 mmol, 5.0 eq, HC1) in Et0H (4 mL) was added Na2CO3 (181 mg, 1.7 mmol, 5.0 eq) and then stirred at 80 C for 3 hours. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure to obtain 48-2 (90 mg, 81%
yield). LCMS (ESI):
RT = 0.604 min, mass calcd. for C14H22N403S 326.14, m/z found 326.9 [M+H1+.
Step 2: 4-(Cyclohexylamino)-N-methy1-3-(5-methy1-1,2,4-oxadiazol-3-yObenzenesulfonamide [00304] Acetyl chloride (11 mg, 0.13 mmol, 1.1 eq) was added to a solution of compound 48-2 (40 mg, 0.12 mmol, 1.0 eq) in Pyridine (1 mL). The reaction mixture was stirred at 100 C
for 16 hours. The reaction mixture was concentrated under reduced pressure.
The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely. Compound 48 (12.18 mg, 28% yield) was obtained. LCMS (ESI): RT =
1.242 min, mass calcd. for C16H22N403S 350.14, m/z found 351.0 [M+1-11+, 1HNMR (400MHz, CDC13) 6 8.59 (d, J= 2.3 Hz, 1H), 7.75 (dd, J= 2.3, 9.0 Hz, 1H), 7.29 (d, J = 7.3 Hz, 1H), 6.81 (d, J = 9.0 Hz, 1H), 4.23 (q, J= 5.2 Hz, 1H), 3.62 - 3.48 (m, 1H), 2.68 -2.63 (m, 6H), 2.12 -2.02 (m, 2H), 1.86 - 1.76 (m, 2H), 1.70 - 1.62 (m, 1H), 1.51 - 1.34 (m, 5H).
Example 47: 3-(2-(1-acetylazetidin-3-y1)-2H-tetrazol-5-y1)-4-(cyclohexylamino)-N-methylbenzenesulfonamide (Compound 49) 0)L.
/1\1 *N -S
N
Preparation of Compound 49:
p1H
N /1\I 49-la AcCI (2 eq) N /1\I
44,0 Et3N (4 eq), DCM 40 15, 2h No N N
49-1 Compound 49 [00305] To a mixture of 49-1 (25 mg, 58 umol, 1 eq, HC1) and Et3N (24 mg, 0.23 mmol, 33 uL, 4 eq) in DCM (1 mL) was added 49-la (9 mg, 0.12 mmol, 9 uL, 2 eq) in one portion at 15 C under N2. The mixture was stirred at 15 C for 2 h. LCMS showed the compound 1 was consumed completely and one main peak with desired MS was detected. The reaction mixture was concentrated under reduced pressure to remove solvent. HPLC showed 64% of desired product was formed. The residue was purified by prep-HPLC. LCMS and IFINMR
confirmed the product was Compound 49 (2.13 mg, 4.7 umol, 8.0% yield). LCMS (ESI): RT =
0.709 min, mass calcd. For Ci9H27N7035, 433.19 m/z found 434.1[M+1-11+ and 456.1[M+231+.11-1NMR
(400MHz, DMSO-d6) 6 8.43 (d, J= 2.00 Hz, 1H), 7.66 (dd, J= 8.80, 2.00 Hz, 1H), 7.60 (br s, 1H), 7.27 (br s, 1H), 7.05 (d, J= 9.20 Hz, 1H), 6.02 - 5.87 (m, 1H), 4.78 (t, J= 8.80 Hz, 1H), 4.66 - 4.56 (m, 1H), 4.53 - 4.43 (m, 1H), 4.37 - 4.27 (m, 1H), 2.37 (s, 3H), 2.36 - 2.28 (m, 1H), 2.01 - 1.91 (m, 2H), 1.85 (s, 3H), 1.74-1.64 (m, 2H), 1.61 - 1.51 (m, 1H), 1.50 - 1.31 (m, 5H).
Example 48: 4-(cyclohexylamino)-N-methyl-3-(2-(1-(methylsulfonyl)azetidin-3-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 50) tS, ONµ *N -S
N
Preparation of Compound 50:
tS, N¨N N¨N
/1\1 50-la MsCI (2 eq) 1\11 Et3N (4 eq), DCM
ON% 40 NO 15 C, 2h 9, = 0 N N
50-1 Compound 50 [00306] To a mixture of 50-1 (25 mg, 58 umol, 1 eq, HC1) and Et3N (24 mg, 0.23 mmol, 33 uL, 4 eq) in DCM (1 mL) was added 50-la (70 mg, 0.61 mmol, 47 uL, 10.5 eq) in one portion at 15 C under N2. The mixture was stirred at 15 C for 2 h. LCMS showed compound 50-1 was consumed completely and one main peak with desired MS was detected. The reaction mixture was concentrated under reduced pressure to remove solvent. HPLC showed 54% of desired product was formed. The residue was purified by prep-HPLC. LCMS and 11-1NMR
confirmed that the product was Compound 50 (4.39 mg, 9.4 umol, 16.0% yield). LCMS (ESI):
RT = 0.749 min, mass calcd. For C181-127N70452, 469.16 m/z found 470.0[M+Hr 1H NMR
(400MHz, DMSO-d6) 6 8.43 (d, J= 2.00 Hz, 1H), 7.66 (dd, J= 8.80, 2.00 Hz, 1H), 7.59 -7.46 (m, 1H), 7.30 - 7.22 (m, 1H), 7.06 (d, J = 8.80 Hz, 1H), 6.04 - 5.95 (m, 1H), 4.59 -4.41 (m, 4H), 3.70 -3.60(m, 1H), 3.17 (s, 3H), 2.38 (d, J= 4.40 Hz, 3H), 2.02- 1.94(m, 2H), 1.76 -1.67 (m, 2H), 1.64- 1.54 (m, 1H), 1.51 - 1.30 (m, 5H) Example 49: 4-(cyclohexylamino)-N-methy1-3-(2-(1-phenylazetidin-3-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 51) N-N
0%1 *Nm-S
Preparation of Compound 49:
OH
[-NH
NN
/1\1 51-1a (2 eq) N-N
DIEA (4 eq), CupAc)2 (1 eq) \1 0 = 02(15Psi),DCM,20 C, 50h Nm-S 0õ = NO
µµ
H 0 Nõ,,S
µµ
HO
51-1 Compound 51 [00307] To a mixture of 51-1 (50 mg, 0.12 mmol, 1 eq, HC1) and DIPEA (60 mg, 0.47 mmol, 4 eq) in DCM (1.5 mL) was added Cu(OAc)2 (21 mg, 0.12 mmol, 1 eq) and 51-la (29 mg, 0.23 mmol, 2 eq) in one portion under N2. The mixture was stirred at 20 C
for 50 h.
LCMS showed 24% of compound 51-1 was remained. Several new peaks were shown on LCMS
and 40% of desired compound was detected. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was diluted with water (5 mL) and extracted with EA (5 mL*3), the combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum. HPLC indicated 35% of desired product was formed. The residue was purified by prep-HPLC. LCMS and 1HNMR confirmed the product was Compound 51 (2.04 mg, 4.3 umol, 3.7% yield). LCMS (ESI): RT = 0.885 min, mass calcd. For C23H29N7025, 467.21 miz found 468.1[MA-1]-1.1H NMR (400MHz, CDC13) 6 8.63 (d, J= 2.00 Hz, 1H), 7.81 - 7.70 (m, 2H), 7.34 - 7.27(m, 2H), 6.91 - 6.78 (m, 2H), 6.59 (d, J= 8.00 Hz, 2H), 5.93 - 5.83 (m, 1H), 4.56 (t, J = 8.00 Hzõ 2H), 4.50 - 4.43 (m, 2H), 4.35 - 4.28 (m, 1H), 3.53 (br s, 1H), 2.66 (d, J=
5.20 Hz, 3H), 2.05 - 1.96 (m, 2H), 1.82 - 1.72 (m, 2H), 1.62 - 1.56 (m, 1H), 1.45 - 1.28 (m, 5H).
Example 50: 4-(cyclohexylamino)-3-(2-(1-isopropylazetidin-3-y1)-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 52) N¨N
ON\ *N -S
N
Preparation of Compound 52:
TyH
N¨N N¨N
/1\I
52-1a(1.5 eq) OIN 4110 K2000,3 (4 eq), DMF 0µµ 40 NO
60 C 2h N -S
N N
52-1 Compound 52 [00308] To a mixture of 52-1 (30 mg, 70 umol, 1 eq, HC1) and K2CO3 (39 mg, 0.28 mmol, 4 eq) in CH3CN (2 mL) was added 52-la (18 mg, 0.10 mmol, 1.5 eq) in one portion under N2.
The mixture was stirred at 40 C for 2 h. LCMS showed the starting material was remained and no desired MS was detected. The reaction mixture was added DMF (1 mL) and heated to 60 C
for 2 h. LCMS showed 30% of compound 52-1 was remained. Several new peaks were shown on LCMS and 25%of desired compound was detected. The reaction mixture was concentrated under reduced pressure to remove CH3CN. The residue was diluted with water (3 mL) and extracted with EA(5 mL * 3). The combined organic layers were dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC. LCMS and 1HNMR confirmed the product was Compound 52 (3.55 mg, 8.2 umol, 11.7% yield).
LCMS
(ESI): RT = 0.663 min, mass calcd. For C201-131N7025, 433.23 m/z found 434.1[M+H1+.1H NMR
(400MHz, CDC13) 6 13.39 (br s, 1H), 8.60 (br s, 1H), 7.75 (br d, J = 8.40 Hz, 2H), 6.84 (br d, J
= 8.40 Hz, 1H), 6.17 (br s, 1H), 4.96 (br s, 2H), 4.48 (br s, 2H), 3.67 (br s, 1H), 3.54 (br s, 1H), 2.65 (br s, 3H), 2.10 -2.04 (m, 2H), 1.87 - 1.78 (m, 2H), 1.69 - 1.66 (m, 1H), 1.51 - 1.40 (m, 11H).
Example 51: 3-(2-(1-acetylpiperidin-3-y1)-2H-tetrazol-5-y1)-4-(cyclohexylamino)-N-methylbenzenesulfonamide (Compound 53) N N
-S
N
Preparation of Compound 53:
QN1--C) N-N
N N HCl/dioxane (4 eq) N Ac20 (1 eq), TEA (3 eq), N ,N
HNS\,r, Nko DCM,15 C, = 0 DCM, 0-15 C, 1 25 h N N
53-1 53-2 Compound 53 Step 1: 4-(cyclohexylamino)-N-methy1-3-(2-(piperidin-3-y1)-2H-tetrazol-5-yl)benzenesulfonamide [00309] To a mixture of compound 53-1 (0.26 g, 500 umol, 1 eq) in DCM (2 mL) was added HC1/dioxane (1 M, 2 mL, 4.0 eq). The mixture was stirred at 15 C for 1 h. The crude LCMS showed 95% of desired product was detected. The reaction mixture was concentrated under reduced pressure to give a residue as a light yellow solid. The residue was diluted with Me0H (5 mL) and water (5 mL), and the most of Me0H was removed under reduced pressure, the remaining aqueous was lyophilized to give compound 53-2 (210 mg, 460 umol, 92% yield, HC1). 20 mg of the solid was purified by prep-HPLC to give 53-2 (2.19 mg).
LCMS (ESI): RT =
2.089 min, mass calc. for C19H29N702S 419.54, m/z found 420.0 [M+11+. 1HNMR
(400 MHz, METHANOL-d4) 6 1.23 - 2.27 (m, 16 H), 2.33 - 2.58 (m, 4 H), 2.90 (s, 1 H), 3.36 - 3.52 (m, 3 H), 3.65 (br s, 1 H), 4.29 (br s, 1 H), 5.04 - 5.46 (m, 2 H), 7.01 (br d, J=
9.29 Hz, 1 H), 7.72 (br d, J = 7.03 Hz, 1 H), 8.58 (s, 1 H).
Step 2: 3-(2-(1-acetylpiperidin-3-y1)-2H-tetrazol-5-y1)-4-(cyclohexylamino)-N-methylbenzenesulfonamide [00310] To a mixture of compound 53-2 (30 mg, 65.8 umol, 1 eq, HC1) and TEA (20.0 mg, 197 umol, 27.5 uL, 3 eq) in DCM (1 mL) was added Ac20 (6.7 mg, 65.8 umol, 6.2 uL, 1 eq) in one portion at 0 C and stirred for 15 min. The mixture was stirred at 15 C for 1 h. The crude LCMS showed 85% of desired product was detected. The reaction mixture was quenched by water (10 mL) and extracted with DCM (10 mL* 4). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue (25 mg) as colorless oil. The residue was purified by prep-HPLC to give Compound 53 (2.41 mg, 5.1 umol, 7.8% yield). LCMS (ESI): RT = 2.047 min, mass calc. for C2,H311\1703S 461.58, m/z found 462.1 [M+11+. 1HNMR (400 MHz, DMSO-d6, t=80 C) 6 1.29 - 1.54 (m, 6 H), 1.57 - 1.76 (m, 4 H), 1.79 - 1.93 (m, 1 H), 1.95 - 2.07 (m, 5 H), 2.23 - 2.36 (m, 1 H), 2.44 (s, 4 H), 3.27 -3.51 (m, 1 H), 3.59 - 3.80 (m, 2 H), 4.88 - 5.17 (m, 1 H), 6.89 - 7.05 (m, 2 H), 7.48 (br d, J=
7.53 Hz, 1 H), 7.67 (dd, J = 8.78, 2.26 Hz, 1 H), 8.44 (d, J= 2.26 Hz, 1 H).
Example 52: 3-(2-(azetidin-3-y1)-2H-tetrazol-5-y1)-4-(cyclohexylamino)-N-methylbenzenesulfonamide (Compound 54) TTH
0õ 40-S
HN
Preparation of Compound 54:
o ,7N
HCl/dioxane N--N
rt, 2h N
0õ = 9 NO % * -S
HN
HN NO -S% / 0 54-1 Compound 54 [00311] To a mixture of 54-1 (12 mg, 24.4 umol, 1.0 eq) in Me0H (1 mL) was added HC1/dioxane (4 M, 3 mL, 492 eq). The reaction mixture was stirred at 15 C
for 2 h. LCMS showed the starting material was consumed completely and one main peak with desired MS was detected. The reaction mixture was concentrated under reduced pressure to remove solvent. HPLC showed 92% of desired product was formed. The residue was purified by prep-HPLC. LCMS and 1HNMR confirmed the product was Compound 54 (4.30 mg, 10.1 umol, 41.2% yield, HC1). LCMS (ESI): RT = 0.646 min, mass calcd. For Ci7H25N7025, 391.18 m/z found 392.1[M+Hr1H NMR (400MHz, DMSO-d6) 6 9.96 - 9.57 (m, 2H), 8.43 (d, J= 2.40 Hz, 1H), 7.73 - 7.63 (m, 1H), 7.60 - 7.42 (m, 1H), 7.36 - 7.22 (m, 1H), 7.07 (d, J= 9.20 Hz, 1H), 6.15 - 6.02 (m, 1H), 4.61 - 4.51 (m, 4H), 3.67 - 3.63 (m, 1H), 2.37 (s, 3H), 2.04 - 1.94 (m, 2H), 1.79 - 1.67 (m, 2H), 1.64 - 1.53 (m, 1H), 1.50 - 1.29 (m, 5H).
Example 53: 4-(cyclohexylamino)-N-methyl-3-(pyrimidin-5-yl)benzenesulfonamide (Compound 55) N N
HN,sµ`
I
Preparation of Compound 55:
NN
, NN
0õ0 Br No 55-2(1.5 eq) ________________________________________ )1. (:)µµ
Na2003(2.0 eq), el No HN-S\` Pd(dppf)c12(0.1 eq) I HN(Sµ) 55-1 .., dioxane/H20, 90 C,1 6 h 1 ""
Compound 55 [00312] To a solution of compound 55-1 (50.0 mg, 0.13 mmol, 1.0 eq) and compound 2 (30.2 mg, 0.19 mmol, 1.5 eq) in dioxane (5.0 mL) was added H20 (0.5 mL), Pd(dppf)C12 (9.3 mg, 12.7 umol, 0.1 eq) and Na2CO3 (26.9 mg, 0.25 mmol, 2.0 eq). The mixture was stirred at 90 C for 16 hours under N2 atmosphere. LCMS showed desired compound was found.
The reaction was filtered through Celite and concentrated under reduced pressure to give a residue. The crude product was purified by prep-HPLC to give Compound 55 (5.25 mg, 14.7 umol, 11.6% yield).
LCMS (EST): RT = 0.695 min, mass calc. for C17H22N402S 346.15, m/z found 347.0 [M+H1+;
1HNMR (400 MHz, CDC13-d) 6 9.28 (s, 1H), 8.82 (s, 2H), 7.76 (dd, J= 2.3, 8.8 Hz, 1H), 7.51 (d, J= 2.3 Hz, 1H), 6.78 (d, J= 8.8 Hz, 1H), 4.34 (q, J = 5.3 Hz, 1H), 3.99 (d, J
= 7.5 Hz, 1H), 3.43 - 3.32 (m, 1H), 2.68 (d, J = 5.5 Hz, 3H), 2.04 - 1.97 (m, 2H), 1.78 - 1.70 (m, 2H), 1.45 - 1.32 (m, 2H), 1.29 - 1.06 (m, 4H).
Example 54: 4-(cyclohexylamino)-N-methyl-3-(pyrimidin-2-yl)benzenesulfonamide (Compound 56) N N
oµµ No HN,Sµ`
I
Preparation of Compound 56:
Nõ.1 N
0õ0 CI N N
56-2 (1.5 eq) µµ N10 HN,sµ` Na2CO3(2.0 eq), O\ =
No Pd(dpp0c12(0.1 eq) HN-S\r`
56-1 , THF/H20, 70 C,16 h '-Compound 56 [00313] To a solution of compound 56-1 (50.0 mg, 0.13 mmol, 1.0 eq) and compound 56-2 (21.8 mg, 0.19 mmol, 1.5 eq) in H20 (0.5 mL) was added THF (3.0 mL), Pd(dppf)C12 (9.3 mg, 12.7 umol, 0.1 eq) and Na2CO3 (26.9 mg, 0.25 mmol, 2.0 eq). The mixture was stirred at 70 C
for 16 hours under N2 atmosphere. LCMS showed desired compound was found. The reaction was filtered through Celite and concentrated under reduced pressure to give a residue. The crude product was purified by prep-HPLC to give Compound 56 (2.51 mg, 7.2 umol, 5.7%
yield).
LCMS (EST): RT = 0.793 min, mass calc. for C17H22N402S 346.15, m/z found 347.0 [M+H1+;
1HNMR (400 MHz, CDC13-d) 6 9.76 (d, J= 6.8 Hz, 1H), 9.11 (d, J = 2.3 Hz, 1H), 8.78 (d, J =
5.0 Hz, 2H), 7.72 (dd, J= 2.4, 8.9 Hz, 1H), 7.16 (t, J = 4.9 Hz, 1H), 6.81 (d, J = 9.0 Hz, 1H), 4.20 (q, J = 5.4 Hz, 1H), 3.56 (s, 1H), 2.67 (d, J= 5.5 Hz, 3H), 2.07 (d, J=
5.5 Hz, 2H), 1.85 -1.76 (m, 2H), 1.67 (d, J= 11.5 Hz, 1H), 1.53 - 1.36 (m, 5H).
Example 55: 4-(cyclohexylamino)-N-methyl-3-(1-methyl-1H-pyrazol-3-yl)benzenesulfonamide (Compound 57) /
N
0µµ *-S
NH µµ
Preparation of Compound 57:
0,,0 /
B157-1a (1.3 eq) µN No __________________ Na2CO3 (2.0 eq)). 0 *
Pd(dppf)C12 (0.1 eq) NH H20/Dioxane -SµN NH-S\
100 C, 4 hr I b 57-1 Compound 57 [00314] To the solution of compound 57-1 (50 mg, 0.13 mmol, 1 eq) in dioxane (3 mL) and H20 (0.15 mL) was added compound 57-la (27 mg, 0.16 mmol, 1.3 eq), Na2CO3 (27 mg, 0.25 mmol, 2 eq) and Pd(dppf)C12 (9 mg, 12.7 umol, 0.1 eq). The mixture was stirred at 100 C for 4 hr under N2 atmosphere. The reaction was monitored by LCMS. The reaction was concentrated under reduced pressure. The reaction solution was concentrated under reduced pressure. The residue was purified by prep-HPLC to give Compound 57 (2.06 mg, 5.9 umol, 4.7% yield). LCMS (ESI): RT = 0.784 min, mass calcd. for C17H24N402S 348.16, m/z found 349.1 [M+H1+, 1HNMR (400MHz, CDC13) 6 8.33 (d, J= 7.5 Hz, 1H), 7.99 (d, J =
2.3 Hz, 1H), 7.63 - 7.56 (m, 1H), 7.41 (d, J = 2.5 Hz, 1H), 6.74 (d, J= 9.0 Hz, 1H), 6.66 (d, J= 2.5 Hz, 1H), 4.15 (q, J= 5.4 Hz, 1H), 3.96 (s, 3H), 3.58 - 3.46 (m, 1H), 2.64 (d, J= 5.5 Hz, 3H), 2.08 - 2.01 (m, 2H), 1.84 - 1.74 (m, 2H), 1.68 - 1.61 (m, 1H), 1.51 - 1.36 (m, 5H).
Example 56: 4-(cyclohexylamino)-N-methyl-3-(1-methyl-1H-1,2,3-triazol-4-yl)benzenesulfonamide (Compound 58) N-N
0õ 40 N
-S
HN O
Preparation of Compound 58:
________________________________________________________________ B-13 --( Br cr NH2 Br MeNH2, 2M solution Br 0 F inTHF (2.0 eq) 0 58-2A (1.5 eq) 58-3A (1.5 eq) ti HN¨S = HN-1 DMSO, 140 C, 2 hr Pd(dppf)Cl2 (0.05 eq) Cl' DCM, 20 C, 4 hr / 6 0 AcOK
(2.0 eq) Dioxane,95 C, 16 hr N-Kr Ny-) N¨N/
0õ0 Br 58-4A (1.0 eq) 140 NO Pd(dppf)Cl2 (0.05 eq) HN' NO
Na2CO3 (2.0 eq) Dioxane:H20 = 10 :1 0 I 100 C, 16 hr 584 Compound 58 Step 1: 3-Bromo-4-fluoro-N-methylbenzenesulfonamide [00315] To a solution of compound 58-1 (1.0 g, 3.7 mmol, 1.0 eq) in DCM (8 mL) was added MeNH2 (2 M, 3.7 mL, 2.0 eq). The reaction mixture was stirred at 20 C
for 4 hours. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (15 mL) and the resultant mixture was extracted with DCM (30 mL * 2). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure to obtain the title compound (950 mg, 97 % yield).
Step 2: 3-Bromo-4-(cyclohexylamino)-N-methylbenzenesulfonamide [00316] A solution of compound 58-2 (950 mg, 3.54 mmol, 1.0 eq) and compound 58-2A
(879 mg, 8.86 mmol, 1.0 mL, 2.5 eq) in DMSO (6 mL) was stirred at 140 C for 2 hours. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (20 mL) and the resultant mixture was extracted with EA (40 mL * 2). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound (1.2 g, 98% yield). LCMS (ESI): RT = 0.801 min, mass calcd. for C13H19BrN202S
347.27, m/z found 348.9 [M+H]+.
Step 3: 4-(Cyclohexylamino)-N-methy1-3-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-yl)benzenesulfonamide [00317] A solution of compound 58-3 (230 mg, 0.662 mmol, 1.0 eq), compound (252 mg, 0.993 mmol, 1.5 eq), Pd(dppf)C12 (24 mg, 33 umol, 0.05 eq) and AcOK
(130 mg, 1.32 mmol, 2.0 eq) in dioxane (4 mL) was heated to 95 C and stirred at 95 C for 16 hours under N2.
The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (20 mL) and the resultant mixture was extracted with EA (50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel (to afford the title compound (240 mg, 92% yield). LCMS (ESI): RT = 0.886 min, mass calcd. for 394.34, m/z found 395.1 [M+H1+.
Step 4: 4-(Cyclohexylamino)-N-methy1-3-(5-methy1-1,2,4-oxadiazol-3-yl)benzenesulfonamide [00318] Compound 58-4 (50 mg, 0.13 mmol, 1.0 eq), compound 58-4A (21 mg, 0.13 mmol, 1.0 eq), Pd(dppf)C12 (4.6 mg, 6.3 umol, 0.05 eq) and Na2CO3 (27 mg, 0.26 mmol, 2.0 eq) in Dioxane (2 mL) and H20 (0.2 mL) was de-gassed and then stirred at 100 C
for 16 hours under N2. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (25 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (5 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely.
Compound 58 (2.13 mg, 4.8% yield) was obtained. LCMS (ESI): RT = 0.740 min, mass calcd.
for C16H23N502S 349.45, m/z found 350.0 [M+H1+, 1HNMR (400MHz, CDC13-d) 6 8.29 (d, J=
7.3 Hz, 1H), 7.89 (s, 1H), 7.83 (d, J = 2.3 Hz, 1H), 7.60 (dd, J= 2.1, 8.9 Hz, 1H), 6.77 (d, J= 8.8 Hz, 1H), 4.25 - 4.20 (m, 1H), 4.18 (s, 3H), 3.56 - 3.44 (m, 1H), 2.63 (d, J =
5.5 Hz, 3H), 2.11 -2.00 (m, 2H), 1.86 - 1.77 (m, 2H), 1.69 - 1.61 (m, 1H), 1.50 - 1.28 (m, 5H).
Example 57: tert-butyl 3-(5-(2-(cyclohexylamino)-5-(N-methylsulfamoyl)pheny1)-tetrazol-2-yl)piperidine-1-carboxylate (Compound 59) and tert-butyl 34542-(cyclohexylamino)-5-(N-methylsulfamoyl)pheny1)-1H-tetrazol-1-yl)piperidine-1-carboxylate (Compound 60) QN--e 0\ N=N
NI ;NI
laN1 czµ N
No CZ\ SI
NH"
,Sµ
NH o Compound 59 Compound 60 Preparation of Compound 59 and Compound 60:
QN--e 0 0 TsCI (1.05 eq) TEA (2 eq), NaBH4 (1.1 eq)).._ DMAP (0.1 eq) HO Me0H, 0-15 C, HO DCM, 0-15 C 17h Ts0 0-+
59-1 18 h 59-2 59-3 N-N
N ,N 0 Q. = N,0 S. N-N 0-+
0\NO-NN=
NH :N
0 /1\1 59-3a(1 eq) N
59-3 (1.2 eq), K2CO3 (4 eq), N , = o DMF,120 C, MW, 1 h Rµ 40 .s NH µ`
,S
NH 'b 0 Compound 59 Compound 60 Step 1: tert-butyl 3-hydroxypiperidine-1-carboxylate [00319] Compound 59-1 (3.50 g, 17.57 mmol, 1.0 eq) was dissolved in Me0H
(150 mL) and cooled to 0 C, NaBH4 (731.1 mg, 19.3 mmol, 1.1 eq) was added. The mixture was stirred at 0 C for 2 hours and then at 15 C for 16 h. The crude LCMS showed the desired product MS value was detected. The reaction mixture was quenched by saturated aq. NH4C1 (20 mL) and water (30 mL) and then extracted with DCM (50 mL* 4). The combined organic layers were dried over Na2SO4, filtered and concentrated under pressure to give a residue. The residue was purified by flash silica gel chromatography to give compound 59-2 (1.80 g, 8.94 mmol, 50.9% yield) as a colorless oil, which solidified upon standing. 1HNMR (400 MHz, CDC13) 6 1.17 - 1.58 (m, 12 H), 1.74 (m, 1 H), 1.88 (s, 1 H), 2.94 - 3.16 (m, 2 H), 3.55 (br s, 1 H), 3.64 -3.82 (m, 2 H).
Step 2: tert-butyl 3-(tosyloxy)piperidine-1-carboxylate [00320] A mixture of compound 59-2 (1.0 g, 4.97 mmol, 1.0 eq), 4-methylbenzenesulfonyl chloride (995 mg, 5.22 mmol, 1.05 eq) and TEA (1.01 g, 9.94 mmol, 1.38 mL, 2.00 eq) in DCM (50.00 mL) was stirred at 0 C for 5 min under N2.
Then DMAP (60.7 mg, 0.50 mmol, 0.10 eq) was added, and the mixture was stirred at 0 C for 1 h.
Then the mixture was stirred at 15 C for 16 h. The crude LCMS showed the desired product MS
value was detected. The reaction mixture was quenched by water (35 mL) and extracted with DCM (10 mL
*3). The combined organic layer was washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography to give compound 59-3 (0.5 g, 1.41 mmol, 28.3%
yield) as colorless oil. 1HNMR (400 MHz, CDC13) 6 1.38- 1.47 (m, 11 H) 1.67- 1.86 (m, 3 H) 2.43 (s, 3 H) 3.14 -3.45 (m, 3 H) 3.54 (d, J= 13.01 Hz, 1 H) 4.44 (s, 1 H) 7.33 (d, J= 7.94 Hz, 2 H) 7.79 (d, J=
8.16 Hz, 2H).
Step 3: tert-butyl 3-(5-(2-(cyclohexylamino)-5-(N-methylsulfamoyl)pheny1)-2H-tetrazol-2-yl)piperidine-1-carboxylate (Compound 59) and tert-butyl 3-(5-(2-(cyclohexylamino)-5-(N-methylsulfamoyl)pheny1)-1H-tetrazol-1-yl)piperidine-1-carboxylate (Compound 60) [00321] Compound 59-3a (0.05 g, 0.15 mmol, 1.0 eq), compound 59-3 (63.4 mg, 0.18 mmol, 1.2 eq) and K2CO3 (82.2 mg, 0.59 mmol, 4.0 eq) were taken up into a microwave tube in DMF (2 mL) .The sealed tube was heated at 80 C for 1 h under microwave.
Then the sealed tube was heated at 120 C for 1 h under microwave. TLC indicated compound 3 was consumed completely and one new spot formed. The reaction mixture was filtered. The filtrate was quenched by water (15 ml) and extracted with Et0Ac (15 mL* 3). The combined organic layers were washed with brine (10 mL*2), dried over with anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC
to give Compound 59 (4.33 mg, 8.0 umol, 5.4% yield) and Compound 60 (5.47 mg, 10.5 umol, 7.1% yield).
[00322] Compound 59: LCMS (ESI): RT = 2.405 min, mass calc. for C24H37N704S
519.66, m/z found 464.0 [M-551+; NMR (400 MHz, CDC13) 6 1.27 - 1.57 (m, 17 H), 1.66 (s, 1 H), 1.83 - 1.93 (m, 2 H), 1.94 - 2.03 (m, 1 H), 2.09 (s, 2 H), 2.67 (d, J=
5.52 Hz, 3 H), 3.22 -3.48 (m, 2 H), 3.53 (br s, 1 H), 4.23 (s, 1 H), 4.29 - 4.51 (m, 1 H), 4.66 ( d, J= 12.55 Hz, 1 H), 4.77 - 4.99 (m, 2 H), 6.82 (d, J= 9.03 Hz, 1 H), 7.70 - 7.75 (m, 1 H), 7.80 (s, 1 H) 8.62 (br s, 1 H).
[00323] Compound 60: LCMS (ESI): RT = 2.485 min, mass calc. for C24H37N704S
519.66, m/z found 464.0 [M-551+; IFINMR (400 MHz, CDC13) 6 1.45 (s, 14 H), 1.69 (s, 2 H), 1.81 (s, 2 H), 1.91 - 2.16 (m, 3 H), 2.27 (s, 1 H), 2.40 (s, 1 H), 2.66 (d, J=
5.27 Hz, 3 H), 3.05 (s, 1 H), 3.53 (br s, 2 H), 4.00 (d, J= 13.05 Hz, 1 H), 4.15 -4.55 (m, 2 H), 4.85 (s, 1 H), 6.81 (d, J=
9.03 Hz, 1 H), 7.72 (d, J= 7.78 Hz, 1 H), 7.83 (d, J= 6.27 Hz, 1 H), 8.61 (br s, 1 H).
Example 58: 4-(cyclohexylamino)-3-(2-(1-isopropylpiperidin-3-y1)-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide (Compound 61) QN--( N-N
N
czµ scN
,S
N
H
Preparation of Compound 61:
I y QN--( QNH
61-la (1.2 eq) N-N
N N K2CO3 (4 eq) N N
DMF, 60 C, 1 h.
N1c) CZµ
S
HO N
H
61-1 Compound 61 [00324] To a mixture of compound 61-1 (30 mg, 65.8 umol, 1.0 eq, HC1) and K2CO3 (36.4 mg, 0.26 mmol, 4.0 eq) in DMF (1 mL) was added compound 61-la (16.8 mg, 98.7 umol, 9.9 uL, 1.5 eq) in one portion at 15 C under N2. The mixture was stirred at 60 C
for 2 h. The crude LCMS showed 84% of the desired product was detected. The reaction mixture was filtered. The filtrate was quenched by water (10 mL) and extracted with Et0Ac (15 mL* 3).
The combined organic layer was washed with brine (10 mL* 2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue (18 mg) as colorless oil. The residue was purified by prep-HPLC to give Compound 61 (2.10 mg, 4.4 umol, 6.7% yield).
LCMS (ESI):
RT = 2.457 min, mass calc. for C22H35N702S 461.62, m/z found 462.1 [M+11+.
Example 59: 4-(cyclohexylamino)-N-methyl-3-(2-(1-(methylsulfonyl)piperidin-3-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 62) s,.
* NO
0\
\m Preparation of Compound 62:
s, MsCI (31.85 eq), N j TEA (3 eq) N I
N
411 DCM, 000, 1 h S
x NJ' *
62-1 Compound 62 [00325] To a mixture of compound 62-1 (20 mg, 43.9 umol, 1.0 eq, HC1) and TEA (13.3 mg, 0.13 mmol, 18.3 uL, 3.0 eq) in DCM (1 mL) was added MsC1 (0.16 g, 1.40 mmol, 0.11 mL, 31.8 eq) in one portion at 0 C.The mixture was stirred at 0 C for 1 h. The crude LCMS showed 62% of the desired product was detected. The reaction mixture was diluted with DCM (20 mL), washed with brine (15 mL) and concentrated under reduced pressure to give a residue (21 mg). The residue was purified by prep-HPLC to give Compound 62 (2.49 mg, 5.0 umol, 11.4%
yield). LCMS (ESI): RT = 2.171 min, mass calc. for C201-131N704S2 497.63, m/z found 498.0 [M+1]+; 1H NMR (400 MHz, DMSO-d6) 6 1.24- 1.51 (m, 5 H), 1.58 (s, 1 H), 1.67-1.85 (m, 3 H), 1.98 (s, 3 H), 2.24 - 2.33 (m, 1 H), 2.37 (d, J= 5.02 Hz, 4 H), 2.94 (s, 3 H), 3.09 (t, J = 9.03 Hz, 1 H), 3.36 - 3.46 (m, 2 H), 3.53 -3.72 (m, 2 H), 3.92 (dd, J= 11.80, 3.26 Hz, 1 H), 5.17 (dt, J = 7.97, 4.17 Hz, 1 H), 7.05 (d, J = 9.29 Hz, 1 H), 7.25 (q, J= 5.02 Hz, 1 H), 7.59 (d, J= 7.53 Hz, 1 H), 7.65 (dd, J= 8.91, 2.13 Hz, 1 H), 8.42 (d, J = 2.26 Hz, 1 H).
Example 60: 4-(cyclohexylamino)-N-methy1-3-(2-(1-phenylpiperidin-3-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 63) N-NoN 411 N N
oµN N
-S
N
H
Preparation of Compound 63:
QNH HO , OH N-No N-N N 63-la (3 eq) I' Cu(OAc)2 (1.2 eq) _________________________________________ )1-o Nio iDjcIPmEA40( 40ceq)1,60h2, clµx 1.1 0 N -NS
N
63-1 Compound 63 [00326] To a mixture of compound 63-1 (40 mg, 87.7 umol, 1.0 eq, HC1) and compound 63-la (32.1 mg, 0.26 mmol, 3 eq) in DCM (1 mL) were added Cu(0Ac)2 (19.1 mg, 0.11 mmol, 1.2 eq) and DIPEA (45.4 mg, 0.35 mol, 61.1 uL, 4 eq) in one portion at 15 C
under 02. The mixture was stirred at 40 C for 16 h. The crude LCMS showed 40% of the desired product was detected. The reaction mixture was purified by flash silica gel chromatography to give a product (34 mg), which was further purified by prep-HPLC to still give an impure product (9 mg). The impure product was further purified by prep-HPLC to give Compound 63 (2.23 mg, 4.5 umol, 5.1% yield). LCMS (ESI): RT = 2.070 min, mass calc. for C25H33N702S 495.64, m/z found 496.1 [M+11+. 1HNMR (400 MHz, CDC13) 6 1.33 - 1.44 (m, 3 H), 1.48 - 1.72 (m, 4 H), 1.81 (br s, 2 H), 1.88 -2.01 (m, 1 H), 2.02 - 2.14 (m, 3 H), 2.29 - 2.41 (m, 1 H), 2.42 -2.53 (m, 1 H), 2.67 (d, J = 5.27 Hz, 3 H), 2.94 - 3.06 (m, 1 H), 3.41 - 3.60 (m, 2 H), 3.65 (br d, J=
12.30 Hz, 1 H), 4.05 (br d, J = 12.05 Hz, 1 H), 4.23 (q, J = 5.44 Hz, 1 H), 4.98 - 5.12 (m, 1 H), 6.83 (d, J= 9.03 Hz, 1 H), 6.91 (t, J= 7.28 Hz, 1 H), 7.00 (d, J= 8.28 Hz, 2 H), 7.27 - 7.34 (m, 2 H), 7.73 (dd, J = 8.78, 2.01 Hz, 1 H), 7.87 (br d, J= 7.03 Hz, 1 H), 8.64 (d, J = 2.01 Hz, 1 H).
Example 61: 4-(cyclohexylamino)-N-methyl-3-(pyridin-2-yl)benzenesulfonamide (Compound 64) NQ
CI%
NH-µS%
Preparation of Compound 64:
N)1 NI /
Br 64-1a (1.5 eq) µµ Nlo XPhos Pd G 11 (0.1 eq) OSJ
dioxane, 80 C, 22 h ___________________________ c N0 ,S m N
64-1 Compound 64 [00327] To a mixture of compound 64-1 (40 mg, 0.12 mmol, 1.0 eq) and compound 64-la (63.6 mg, 0.17 mmol, 1.5 eq) in dioxane (1 mL) was added XPhos Pd G II (9.1 mg, 11.5 umol, 0.1 eq) in one portion at 15 C under N2. The mixture was stirred at 80 C for 22 hours. The crude LCMS showed 43% of the desired product was detected. The reaction mixture was quenched by water (10 mL) and extracted with Et0Ac (15 mL*3). The combined organic layer was washed with brine (15 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC to give Compound 64 (2.34 mg, 6.8 umol, 4.7% yield). LCMS (ESI): RT = 2.280 min, mass calc. for C18H23N302S 345.46, miz found 346.0 [M+11+.1HNMR (400 MHz, CDC13) 6 1.24 - 1.50 (m, 5 H), 1.64 (br d, J=
12.55 Hz, 1 H), 1.71 - 1.84 (m, 2 H), 2.04 (br d, J= 8.78 Hz, 2 H), 2.64 (d, J= 5.52 Hz, 3 H), 3.43 - 3.55 (m, 1 H), 4.28 (q, J = 5.44 Hz, 1 H), 6.78 (d, J= 9.03 Hz, 1 H), 7.24 (ddd, J= 6.59, 4.83, 1.88 Hz, 1 H), 7.66 (dd, J = 8.91, 2.13 Hz, 1 H), 7.74 - 7.84 (m, 2 H), 8.07 (d, J= 2.26 Hz, 1 H), 8.53 - 8.69 (m, 1 H), 9.25 (br d, J= 6.78 Hz, 1 H).
Example 62: 4-(cyclohexylamino)-N-methyl-3-(pyridin-4-yl)benzenesulfonamide (Compound 65) NH,\S0µµ
Preparation of Compound 65:
1\1 Ho BL
Br OH 65-1a(1.5 eq) N10K3PO4 (4 eq), XPhos Pd G11(0.1 eq) H20, Dioxane, 80 C, 16 h NHµ HN,µSµµ
I
65-1 Compound 65 [00328] To a mixture of compound 65-1 (40 mg, 0.12 mmol, 1.0 eq) and compound 65-la (21.2 mg, 0.18 mmol, 1.5 eq) in dioxane (1 mL) was added K3PO4 (3 M, 0.15 mL, 4.0 eq) in one portion at 15 C under N2. The mixture was stirred at 15 C for 5 min, then XPhos Pd G 11 (9.1 mg, 11.5 umol, 0.1 eq) was added, and the mixture was heated to 80 C and stirred for 16 hours. The crude LCMS showed 31% of the compound 1 was remained and 22% of the desired product was detected. The resulting reaction mixture was quenched by water (15 mL), and then extracted with Et0Ac (20 mL*3). The combined organic layer was washed with brine (15 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC to give Compound 65 (3.34 mg, 9.8 umol, 4.2% yield). LCMS (ESI): RT = 1.933 min, mass calc. for C181-123N302S 345.46, m/z found 346.0 [M+11+; 1HNMR (400 MHz, CDC13) 6 1.09 - 1.28 (m, 3 H), 1.33 - 1.46 (m, 2 H), 1.63 (br d, J =
4.02 Hz, 1 H), 1.69 - 1.78 (m, 2 H), 2.00 (br dd, J= 12.55, 3.01 Hz, 2 H), 2.67 (d, J= 5.52 Hz, 3 H), 3.30 - 3.43 (m, 1 H), 4.27 (br d, J= 7.53 Hz, 1 H), 4.37 (q, J= 5.27 Hz, 1 H), 6.74 (d, J =
9.03 Hz, 1 H), 7.32 - 7.40 (m, 2 H), 7.52 (d, J = 2.26 Hz, 1 H), 7.72 (dd, J=
8.78, 2.26 Hz, 1 H), 8.72 (d, J = 5.77 Hz, 2 H).
Example 63: 4-(cyclohexylamino)-N-methyl-3-(5-methyl-1H-1,2,4-triazol-3-yl)benzenesulfonamide (Compound 66) N
\NA *
H
NO
Preparation of Compound 66:
NH
CN )(NH2 HCI
N
NN No o 66-1A (1.5 eq) N
,S CuBr (0.05 eq) * No H Cs2003 (3.0 eq) \m S
DMSO, 120 C, 4 hr 66-1 Compound 66 [00329] To a solution of compound 66-1 (100 mg, 0.34 mmol, 1.0 eq), compound 66-1A
(48 mg, 0.51 mmol, 1.5 eq, HC1) and Cs2CO3 (333 mg, 1.02 mmol, 3.0 eq) in DMSO
(2 mL) was added CuBr (2.4 mg, 17 umol, 0.05 eq). The reaction mixture was stirred at 120 C for 4 hours under air. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL * 2). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely.
Compound 66 (28.07 mg, 24% yield) was obtained. LCMS (ESO: RT = 0.705 min, mass calcd. for C16H23N502S 349.45, m/z found 349.9 [M+H1+, 1HNMR (400MHz, DMSO-d6) 6 13.92 (s, 1H), 8.42 (s, 1H), 8.35 - 8.16 (m, 1H), 7.53 (dd, J= 2.1, 8.9 Hz, 1H), 7.13 - 7.05 (m, 1H), 6.89 (d, J=
9.0 Hz, 1H), 3.64 - 3.53 (m, 1H), 2.44 (s, 3H), 2.36 (d, J= 5.0 Hz, 3H), 2.02 -1.92 (m, 2H), 1.76 - 1.66 (m, 2H), 1.63 - 1.52 (m, 1H), 1.49 - 1.39 (m, 2H), 1.38 - 1.28 (m, 3H).
Example 64: 4-(cyclohexylamino)-3-(1,5-dimethy1-1H-1,2,4-triazol-3-y1)-N-methylbenzenesulfonamide (Compound 67) rN( N ,N
czN No ,S
N
H
Preparation of Compound 67:
N,õN
0õ0 tiN
Br N
67-1A (1.0 eq) = No czµ N o 0, Pd(dppf)C12 (0.05 eq)=
,S Na2CO3 (2.0 eq) N ,S
H o Dioxane:H20 = 10 :1 N
100 C, 16 hr H
67-1 Compound 67 [00330] Compound 67-1 (50 mg, 0.13 mmol, 1.0 eq), compound 67-1A (22 mg, 0.13 mmol, 1.0 eq), Pd(dppf)C12 (4.6 mg, 6.3 umol, 0.05 eq) and Na2CO3 (27 mg, 0.25 mmol, 2.0 eq) in Dioxane (2 mL) and H20 (0.2 mL) was degassed and then stirred at 100 C for 16 hours under N2. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA
(25 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (5 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely. Compound 67 (6.75 mg, 15%
yield) was obtained. LCMS (ESI): RT = 0.742 min, mass calcd. for C17H25N502S
363.48, m/z found 364.0 [M+H1+, 1HNMR (400MHz, DMSO-d6) 6 8.38 (d, J= 2.3 Hz, 1H), 8.22 (d, J= 7.5 Hz, 1H), 7.52 (dd, J= 2.3, 8.8 Hz, 1H), 7.14 - 7.07 (m, 1H), 6.89 (d, J = 8.8 Hz, 1H), 3.86 (s, 3H), 3.64 - 3.53 (m, 1H), 2.48 (s, 3H), 2.36 (d, J= 5.0 Hz, 3H), 2.02 - 1.92 (m, 2H), 1.76 - 1.66 (m, 2H), 1.63 - 1.53 (m, 1H), 1.50 - 1.29 (m, 5H).
Example 65: 4-(cyclohexylamino)-N-methy1-3-(2-(1-(pyridin-3-yl)pyrrolidin-3-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 68) _01\
0 No NH-S0µµ
Preparation of Compound 68:
NF\J
N
I-Boc N-N, ,H p-Boc N-N
N
Br 68-la (1.2 eq) N N HCl/Dioxane (4M, 6mL) C lei No ________________________ K2CO3 (1.5 eq) NoDioxane, 10 C, 1 hr Z\ KI (0.3 eq) 0 ,S
NH µ` DMF, 100 C, 16 hr µ`s H
N N Br j\l-N
(1.3eq) N N
No _____________________________________ Pd2(dba)3 (0.02 eq) CZµ Xantphos (0.06 eq) 4/1 ,S HN Cs2CO3 (3.0 eq) 0 I Dioxane, 100 C, 16 hr NH-%
68-3 Compound 68 Step 1: tert-butyl 3-(5-(2-(cyclohexylamino)-5-(N-methylsulfamoyl)pheny1)-2H-tetrazol-2-yppyrrolidine-1-carboxylate [00331] To the solution of compound 68-1 (200 mg, 0.59 mmol, 1.0 eq) in DMF
(2 mL) was added compound 68-la (178 mg, 0.71 mmol, 1.2 eq), KI (30 mg, 0.18 mmol, 0.3 eq) and K2CO3 (123 mg, 0.89 mmol, 1.5 eq). The mixture was stirred at 100 C for 16 hr. The reaction was monitored by TLC. The reaction solution was washed with H20 (10 mL). The mixture was extracted with Et0Ac (10 mL). The organic layer was washed with H20 (10 mL).
The organic layer was dried with Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography) to give compound 68-2 (180 mg, 0.35 mmol, 58%
yield).
Step 2: 4-(cyclohexylamino)-N-methy1-3-(2-(pyrrolidin-3-y1)-2H-tetrazol-5-yl)benzene sulfonamide [00332] To the solution of compound 68-2 (180 mg, 0.36 mmol, 1 eq) in dioxane (6 mL) was added HC1/dioxane (4 M, 6 mL, 67 eq). The mixture was stirred at 10 C
for 1 hr. The reaction was monitored by TLC. TLC showed that the starting material was consumed and a new spot with larger polarity was observed. The reaction solution was concentrated under reduced pressure to give compound 68-3 (170 mg, crude, HC1).
Step 3: 4-(cyclohexylamino)-N-methy1-3-(2-(1-(pyridin-3-yl)pyrrolidin-3-y1)-2H-tetrazol-5-yl)benzenesulfonamide [00333] To the solution of compound 68-3 (170 mg, 0.38 mmol, 1 eq, HC1) in dioxane (5 mL) was added 3-bromopyridine (79 mg, 0.5 mmol, 48 uL, 1.3 eq), Pd2(dba)3 (7 mg, 7.7 umol, 0.02 eq), Cs2CO3 (376 mg, 1.2 mmol, 3 eq), Xantphos (13 mg, 23 umol, 0.06 eq).
The mixture was stirred at 100 C for 16 hr. The reaction was monitored by LCMS. The reaction was concentrated under reduced pressure. The reaction solution was concentrated under reduced pressure. The residue was purified by prep-HPLC to give Compound 68 (8.66 mg, 17.9 umol, 4.7% yield). LCMS (EST): RT = 0.670 min, mass calcd. for C23H30N802S 482.22, m/z found 483.1 [M+H1+,1HNMR (400MHz, CDC13) 6 8.60 (d, J=2.3 Hz, 1H), 8.10 - 8.02 (m, 2H), 7.75 -7.65 (m, 2H), 7.18 (dd, J = 4.5, 8.3 Hz, 1H), 6.93 - 6.89 (m, 1H), 6.81 (d, J=
9.0 Hz, 1H), 5.72 -5.63 (m, 1H), 4.27 (q, J= 5.5 Hz, 1H), 4.05 - 3.95 (m, 2H), 3.80 - 3.72 (m, 1H), 3.68 - 3.61 (m, 1H), 3.56 - 3.45 (m, 1H), 2.96 - 2.87 (m, 1H), 2.82 - 2.70 (m, 1H), 2.65 (d, J= 5.5 Hz, 3H), 2.09 - 1.97 (m, 2H), 1.83 - 1.72 (m, 2H), 1.49 - 1.23 (m, 6H).
Example 66: 4-(cyclohexylamino)-N-methy1-3-(pyrimidin-4-yl)benzenesulfonamide (Compound 69) N
czµ N
NH,SµN
I
Preparation of Compound 69:
ryN
0,13'0 CI N
10µµ N 69-2 (1.5 eq) µµQ
Na2003(2.0 eq), (:) = N
NH,Sµ` Pd(dppf)Cl2(0.1 eq) I
69-1 THF/H20, 90 C,16 h I L' Compound 69 [00334] To a solution of compound 69-1 (50.0 mg, 0.13 mmol, 1.0 eq) and compound 69-2 (21.8 mg, 0.19 mmol, 1.5 eq) in H20 (0.5 mL) was added dioxane (5 mL), Pd(dppf)C12 (9.3 mg, 12.7 umol, 0.1 eq) and Na2CO3 (26.9 mg, 0.25 mmol, 2.0 eq). The mixture was stirred at 90 C for 16 hour under N2 atmosphere. LCMS showed desired compound was found. The reaction was filtered through Celite and concentrated under reduced pressure to give a residue. The crude product was purified by prep-HPLC to give Compound 69 (4.99 mg, 14.4 umol, 11.4% yield).
LCMS (EST): RT = 0.748 min, mass calc. for Ci7H22N402S 346.15, m/z found 346.9 [M+H1+;
1HNMR (400 MHz, CDC13-d) 6 9.71 (d, J= 7.0 Hz, 1H), 9.18 (d, J = 1.0 Hz, 1H), 8.76 (d, J =
5.8 Hz, 1H), 8.21 (d, J = 2.0 Hz, 1H), 7.79 (dd, J= 1.0, 5.8 Hz, 1H), 7.70 (dd, J= 2.0, 9.0 Hz, 1H), 6.83 (d, J= 9.3 Hz, 1H), 4.29 (q, J= 5.5 Hz, 1H), 3.54 (s, 1H), 2.66 (d, J= 5.5 Hz, 3H), 2.09- 2.02(m, 2H), 1.80 (d, J= 4.8 Hz, 2H), 1.66 (d, J= 11.0 Hz, 1H), 1.52-1.35 (m, 5H).
Example 67: 4-(cyclohexylamino)-N-methy1-3-(2-(1-(pyridin-3-yl)azetidin-3-y1)-tetrazol-5-yl)benzenesulfonamide (Compound 70) N-N
OµN
N -S
N
Preparation of Compound 70:
NH
Br N
1;1*---N 1\1*
Al\I N-N
70-1a(1.5 eq) Al\I
Cs2CO3 (4.0 eq), Xantphos (0.15 eq) , 410 Pd2dba3 (0.08 eq),dioxane,100 C, 16h 4/10 0, N
N
HO
70-1 Compound 70 [00335] To a mixture of 70-1 (80 mg, 0.19 mmol, 1 eq, HC1) and Cs2CO3 (244 mg, 0.748 mmol, 4 eq) in dioxane (4 mL) was added Pd2(dba)3 (14 mg, 15 umol, 0.08 eq) and Xantphos (16 mg, 28 umol, 0.15 eq) and 3-bromopyridine (70-1a) (44 mg, 0.28 mmol, 1.5 eq) in one portion under N2.The mixture was stirred at 100 C for 16 h. The reaction was monitored by LCMS. The reaction mixture was diluted with water (10 mL) and extracted with EA (15 mL *
3). The combined organic layers were dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The reaction was monitored by LCMS. The residue was purified by prep-HPLC. LCMS
and 1HNMR confirmed the product was Compound 70 (2.73 mg, 5.8 umol, 3.1%
yield). LCMS
(ESI): RT = 2.083 min, mass calcd. For C22H28N802S, 468.21 m/z found 469.0[M+Hr 1H NMR
(400MHz, CDC13) 6 8.64 (d, J= 2.40 Hz, 1H), 8.19- 8.12(m, 1H), 8.01 (d, J=
2.40 Hz, 1H), 7.80 - 7.70 (m, 2H), 7.24 - 7.17 (m, 1H), 6.92 - 6.85 (m, 1H), 6.82 (d, J=
9.20 Hz, 1H), 6.00 -5.86 (m, 1H), 4.63 (t, J = 8.00 Hz, 2H), 4.58 - 4.50 (m, 2H), 4.32 - 4.24 (m, 1H), 3.60 - 3.49 (m, 1H), 2.66 (d, J= 5.60 Hz, 3H), 2.05 - 1.98 (m, 2H), 1.82 - 1.71 (m, 2H), 1.66 -1.62 (m, 1H), 1.46- 1.27 (m, 5H).
Example 68: 4-(cyclohexylamino)-3-(2-cyclopropy1-2H-tetrazol-5-y1)-N-methylbenzene sulfonamide (Compound 71) N ' N
HN-S*%
Preparation of Compound 71:
N-NH (H0)2B NN
71-2 (1.5 eq) N
N Na2CO23,(B41.0eRq),D,CiuN(Ecri5 c)2e(q1.
2 py )5 eq), CZ\
HN
HN DOE,,µ` *
60 C, 4 h /
71-1 Compound 71 [00336] To a solution of compound 71-1 (0.1 g, 0.30 mmol, 1.0 eq) and compound 71-2 (30.6 mg, 0.36 mmol, 1.2 eq) in DCE (5.0 mL) was added Cu(OAc)2 (81.0 mg, 0.45 mmol, 1.5 eq) Na2CO3 (74.0 mg, 0.89 mmol, 3.0 eq) and 2,21-BIPYRIDINE (69.6 mg, 0.45 mmol, 1.5 eq).
The mixture was stirred at 60 C for 4 hr at N2 atmosphere. LCMS showed the desired compound. The reaction was filtered through Celite and concentrated under reduced pressure to give a residue. The crude product was purified by prep-HPLC to give Compound 71 (2.33 mg, 6.2 umol, 2.1% yield). LCMS (ESI): RT = 0.813 min, mass calc. for C17H24N602S
376.17, m/z found 377.2 [M+F11+;IHNMR (400 MHz, CDC13) 6 8.41 (s, 2H), 7.69 (d, J= 8.0 Hz, 1H), 6.87 (d, J = 7.0 Hz, 1H), 4.60 (s, 1H), 3.53 (s, 1H), 2.70 (s, 3H), 2.13 - 1.97 (m, 2H), 1.84 (s, 3H), 1.65 (s, 1H), 1.44 (s, 5H), 0.85 - 0.57 (m, 4H). 1HNMR (400 MHz, DMSO-d6) 6 8.47 (s, 2H), 7.71 - 7.61 (m, 1H), 7.11 - 7.02 (m, 1H), 3.64 (s, 1H), 2.65 (s, 3H), 2.00 (s, 2H), 1.82 (s, 1H), 1.74 (d, J= 15.6 Hz, 2H), 1.58 (s, 1H), 1.50 - 1.29 (m, 5H), 0.75 - 0.63 (m, 4H).
Example 69: 4-((4,4-difluorocyclohexyl)amino)-N-methy1-3-(2-methyl-2H-tetrazol-yl)benzenesulfonamide (Compound 72) N-N
lel 07F
-S
HN
Preparation of Compound 72:
ON -FON
eµµ F HCI H2N
72-1A(1.2eq) _________________________________________________ 0 l 07 NaN3(3.0 eq) ,S F NH4CI (3.0 eq), -S
N
TEA (1.2 eq) HN F DMF, 120 C, 16 hr DMS0,140 C, 2h I
N-N
N-NH
N N
N N
Mel(1.0 eq) Si 0- K2CO3(1.5 eq), HN
,S
,S
HN F DMF, 80 C, 0.5 h MW I 0 I
72-3 Compound 72 Step 1: 3-Cyano-4-((4,4-difluorocyclohexyl)amino)-N-methylbenzenesulfonamide [00337] To a stirring solution of compound 72-1A (96 mg, 0.56 mmol, 1.2 eq, HC1) and TEA (57 mg, 0.56 mmol, 1.2 eq) in DMSO (1.5 mL) was added compound 72-1 (100 mg, 0.47 mmol, 1.0 eq). The reaction mixture was stirred at 140 C for 16 hours. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (50 mL *
3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound (100 mg, 65% yield).
Step 2: 4-((4,4-Difluorocyclohexyl)amino)-N-methy1-3-(2H-tetrazol-5-yl)benzenesulfonamide [00338] A
solution of compound 72-2 (100 mg, 0.30 mmol, 1.0 eq), NaN3 (59 mg, 0.91 mmol, 3.0 eq) and NH4C1 (49 mg, 0.91 mmol, 3.0 eq) in DMF (4 mL) was stirred at 120 C for 16 hours. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. LCMS (ESI): RT = 0.697 min, mass calcd. for C14HI8F2N602S 372.12, m/z found 373.0 [M+1-11+.
Step 3: 4-((4,4-Difluorocyclohexyl)amino)-N-methyl-3-(2-methyl-2H-tetrazol-5-yl)benzenesulfonamide [00339] Compound 72-3 (90 mg, 0.24 mmol, 1.0 eq), CH3I (34 mg, 0.24 mmol, 1.0 eq) and K2CO3 (50 mg, 0.36 mmol, 1.5 eq) were taken up into a microwave tube in DMF (3 mL).
The sealed tube was heated at 80 C for 30 min under microwave. The reaction mixture was concentrated under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely. Compound 72 (15.34 mg, 16%
yield) was obtained. LCMS (ESI): RT = 0.735 min, mass calcd. for C15H20F2N602S
386.13, m/z found 387.0 [M+H1+, 1HNMR (400MHz, DMSO-d6) 6 8.40 (d, J= 2.3 Hz, 1H), 7.68 (dd, J=
2.3, 8.8 Hz, 1H), 7.56 (d, J= 7.5 Hz, 1H), 7.32 - 7.22 (m, 1H), 7.16 - 7.09 (m, 1H), 4.48 (s, 3H), 3.92 - 3.80 (m, 1H), 2.38 (d, J= 3.3 Hz, 3H), 2.15 - 2.01 (m, 6H), 1.68 - 1.54 (m, 2H).
Example 70: 4-((3,3-difluorocyclohexyl)amino)-N-methyl-3-(2-methyl-2H-tetrazol-yl)benzenesulfonamide (Compound 73) N-N
Ii LF
ON N
HNS\No Preparation of Compound 73:
CN
N o/_F F _____________________________________________________________ µµ 73-la (1.2eq) NaN3(3.0 eq) ,S
,S NH4CI (3.0 eq), HN
I TEA (1.2eq) HN
0 DMF, 120 C, 5 hr DMS0,140 C, 16 hr N-N
N-NH
ii N
N N
01 NI0(_ Mel (15 eq) ____________________________________________ v=- 0µ
µµ K2CO3 (1.5 eq), HN,\Sµ`
,S
HN DMF, 80 C, 0.5 h MW 0 73-3 Compound 73 Step 1: 3-Cyano-4-((3,3-difluorocyclohexyl)amino)-N-methylbenzenesulfonamide [00340] To a stirring solution of compound 73-la (53 mg, 0.39 mmol, 1.2 eq, HC1) and TEA (40 mg, 0.39 mmol, 1.2 eq) in DMS0 (1.5 mL) was added compound 73-1 (70 mg, 0.32 mmol, 1.0 eq). The reaction mixture was stirred at 140 C for 16 hours. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (50 mL *
3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound (70 mg, 65% yield) as a light yellow solid. LCMS (ESI): RT = 0.700 min, mass calcd.
for C14H17F2N302S 329.10, m/z found 329.9 [M+H1+.
Step 2: 4-((3,3-Difluorocyclohexyl)amino)-N-methyl-3-(2H-tetrazol-5-yObenzenesulfonamide [00341] A solution of compound 73-2 (70 mg, 0.21 mmol, 1.0 eq), NaN3 (41 mg, 0.64 mmol, 3.0 eq) and NH4C1 (34 mg, 0.64 mmol, 3.0 eq) in DMF (4 mL) was stirred at 120 C for 5 hours. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. LCMS (ESI): RT = 0.701 min, mass calcd. for C14H18F2N602S 372.12, m/z found 373.0 [M+H1+.
Step 3: 4-((3,3-Difluorocyclohexyl)amino)-N-methyl-3-(2-methyl-2H-tetrazol-5-yObenzenesulfonamide [00342] Compound 73-3 (70 mg, 0.24 mmol, 1.0 eq), CH3I (400 mg, 2.82 mmol, eq) and K2CO3 (39 mg, 0.28 mmol, 1.5 eq) were taken up into a microwave tube in DMF (3 mL).
The sealed tube was heated at 80 C for 30 min under microwave. The reaction mixture was concentrated under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely. Compound 73 (9.83 mg, 14%
yield) was obtained. LCMS (ESI): RT = 0.733 min, mass calcd. for C15H20F2N602S
386.13, m/z found 387.0 [M+H1+, 1HNMR (400MHz, DMSO-d6) 6 8.40 (d, J= 2.3 Hz, 1H), 7.72 -7.61 (m, 2H), 7.32 - 7.22 (m, 1H), 7.07 (d, J= 9.0 Hz, 1H), 4.48 (s, 3H), 3.98 - 3.85 (m, 1H), 2.46 - 2.36 (m, 4H), 2.11 - 1.74 (m, 5H), 1.70 - 1.56 (m, 1H), 1.56 - 1.44 (m, 1H).
Example 71: 4-(cyclohexylamino)-N-methy1-3-(2-(piperidin-3-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 74) and 4-(cyclohexylamino)-N-methy1-3-(1-(piperidin-3-y1)-1H-tetrazol-5-yl)benzenesulfonamide (Compound 75) QNH
N-N HN-\
_________________________________________________ N I
14' 1%\1 r --N
0 N *
N H
-S /
N
H
Compound 74 Compound 75 Preparation of Compound 74 and Compound 75:
N-N
N , N
.0 N'O
0 S.
TsCI (1.05 eq),TEA (2 eq), Q C) NH0 o*. DMAP (0.1 eq) N¨
I 74-2a (1 eq) HO DCM, 0-25 C, 38 h Ts0 74-2 (1.4 eq), K2CO3 (4 eq), 74-1 74-2 DMF,120 C, 17 h N-N
N HCl/dioxane (47.24 eq) ____________________________________________ )1-N1c) DCM,15 C, 1 h C\lµ 4111 S
NHb NN
HO
74-3 Compound 74 HN¨)¨
N=N
N
--N
HCl/dioxane (15.99 eq) 10µµ DCM,15 C, 1 h NH-2S%
-S
NH µ`
Compound 75 Step 1: tert-butyl 3-(tosyloxy)piperidine-1-carboxylate [00343] A mixture of compound 74-1 (0.75 g, 3.73 mmol, 1.00 eq), 4-methylbenzenesulfonyl chloride (0.74 g, 3.91 mmol, 1.05 eq) and TEA (0.75 g, 7.45 mmol, 1.03 mL, 2.0 eq) in DCM (20 mL) was stirred at 0 C for 5 min under N2. Then DMAP
(45.5 mg, 0.37 mmol, 0.1 eq) was added, and the mixture was stirred at 0 C. The mixture was stirred at 15 C
for 16 h. Reaction was monitored by LCMS and TLC. 373 mg of 4-methylbenzenesulfonyl chloride and TEA (0.5 mL) were added, and then the mixture was stirred at 15 C for 2 h. The mixture was stirred at 25 C for 20 h.. The reaction mixture was quenched by water (10 mL) and brine (20 mL), and then extracted with DCM (10 mL *3). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography to give the compound 74-2 (841 mg, 2.37 mmol, 63.5% yield) as a colorless oil, which solidified upon standing.
1HNMR (400 MHz, CDC13) 6 1.39 - 1.51 (m, 10 H), 1.65 - 1.99 (m, 3 H), 2.45 (s, 3 H), 3.28 (s, 1 H), 3.33 - 3.48 (m, 2 H), 3.56 (d, J= 12.05 Hz, 1 H), 4.46 (s, 1 H), 7.35 (d, J= 8.28 Hz, 2 H), 7.81 (d, J= 8.28 Hz, 2 H).
Step 2: tert-butyl 3-(5-(2-(cyclohexylamino)-5-(N-methylsulfamoyl)pheny1)-2H-tetrazol-2-yl)piperidine-1-carboxylate and tert-butyl 3-(5-(2-(cyclohexylamino)-5-(N-methylsulfamoyl)pheny1)-1H-tetrazol-1-yl)piperidine-1-carboxylate [00344] To a mixture of compound 74-2a (0.2 g, 0.59 mmol, 1 eq) and compound 74-2 (295.8 mg, 0.83 mmol, 1.4 eq) in DMF (5 mL) was added K2CO3 (328.7 mg, 2.38 mmol, 4 eq) in one portion. The mixture was stirred at 120 C for 17 hours. The reaction mixture was filtered off, and then quenched by water (20 mL), extracted with Et0Ac (20 mL* 3). The combined organic layer was washed with brine (20 mL*2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography to give the product as light yellow oil (175 mg), which was further purified by prep-HPLC to give compound 74-3 (11 mg, 20.1 umol, 3.4% yield) and compound 74-4 (65 mg, 121.3 umol, 20.4% yield).
[00345] Compound 74-3: LCMS (ESI): RT = 2.405 min, mass calc. for 519.66, m/z found 464.0 [M-551+; 1HNMR (400 MHz, CDC13) 6 1.28 - 1.53 (m, 14 H), 1.67 (d, J
= 11.80 Hz, 2 H), 1.82 (s, 3 H), 1.88 (s, 1 H), 1.97 (d, J = 7.03 Hz, 1 H), 2.08 (d, J = 4.52 Hz, 2 H), 2.67 (d, J= 5.52 Hz, 3 H), 3.24 - 3.48 (m, 2 H), 3.53 (br s, 1 H), 4.19 -4.45 (m, 2 H), 4.61 -4.73 (m, 1 H), 4.79 - 5.01 (m, 2 H), 6.82 (d, J = 9.03 Hz, 1 H), 7.73 (dd, J=
9.03, 2.26 Hz, 1 H), 7.79 (d, J= 5.77 Hz, 1 H), 8.62 (br s, 1 H).
[00346] Compound 74-4: LCMS (ESI): RT = 2.461 min, mass calc. for 519.66, m/z found 464.0 [M-551+; 1HNMR (400 MHz, CDC13) 6 1.35 - 1.53 (m, 15 H), 1.63 -1.75 (m, 2 H), 1.78 - 1.88 (m, 2 H), 1.98 (s, 1 H), 2.08 (d, J= 5.52 Hz, 2 H), 2.27 (d, J= 11.04 Hz, 1 H), 2.36 - 2.50 (m, 1 H), 2.67 (d, J = 5.52 Hz, 3 H), 3.06 (t, J = 11.04 Hz, 1 H), 3.54 (br s, 2 H), 3.91 - 4.07 (m, 1 H), 4.24 (q, J= 5.52 Hz, 1 H), 4.33 (s, 1 H), 4.80 -4.95 (m, 1 H), 6.82 (d, J = 9.03 Hz, 1 H), 7.73 (dd, J = 9.03, 2.26 Hz, 1 H), 7.83 (br d, J= 7.03 Hz, 1 H), 8.62 (d, J=
2.51 Hz, 1 H).
Step 3: 4-(cyclohexylamino)-N-methy1-3-(2-(piperidin-3-y1)-2H-tetrazol-5-yl)benzenesulfonamide (Compound 74) [00347] To a mixture of compound 74-3 (11 mg, 21.2 umol, 1 eq) in DCM (1 mL) was added HC1/Me0H (1 M, 1 mL, 47.2 eq). The mixture was stirred at 15 C for 1 h.
The crude LCMS showed 98% of the desired product was detected. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC to give Compound 74 (2.47 mg, 5.2 umol, 24.6% yield, HC1). LCMS (ESI): RT = 2.083 min, mass calc.
for C19H29N702S 419.54, m/z found 420.0 [M+F11+;IHNMR (400 MHz, METHANOL-d4) 6 1.28 - 1.59 (m, 5 H), 1.62 - 1.73 (m, 1 H), 1.82 (dd, J= 9.03, 3.76 Hz, 2 H), 1.90 -2.03 (m, 1 H), 2.03 - 2.26 (m, 4 H), 2.37 - 2.49 (m, 1 H), 2.51 (s, 3 H), 3.35 - 3.51 (m, 2 H), 3.60 - 3.71 (m, 1 H), 4.29 (br d, J = 9.03 Hz, 1 H), 5.11 (dd, J = 14.93, 9.41 Hz, 1 H), 5.30 (dd, J= 15.06, 3.26 Hz, 1 H), 7.00 (d, J= 9.03 Hz, 1 H), 7.71 (dd, J= 9.03, 2.26 Hz, 1 H), 8.57 (d, J =
2.26 Hz, 1 H).
Step 4: 4-(cyclohexylamino)-N-methy1-3-(1-(piperidin-3-y1)-1H-tetrazol-5-yl)benzenesulfonamide (Compound 75) [00348] To a mixture of compound 74-4 (65 mg, 0.12 mmol, 1 eq) in DCM (2 mL) was added HC1/Me0H (1 M, 2 mL, 16.0 eq) in one portion. The mixture was stirred at 15 C for 1 hour. The crude LCMS showed 99% of the desired product was detected and HPLC
showed the reaction was completed. The reaction mixture was concentrated under reduced pressure to give Compound 75 (62 mg, crude, HC1). 12 mg of the product was diluted with Me0H
(0.2 mL) and water (2 mL), then the most of the solvent was removed under reduced pressure, the remaining aqueous layer was lyophilized to give Compound 75 (2.32 mg, HC1). The remaining product (50 mg) was used in the next step without further purification.
[00349] Compound 75: LCMS (ESI): RT = 2.053 min, mass calc. for C19H29N702S
419.54, m/z found 420.0 [M+H1+; 1HNMR (400MHz, METHANOL-d4) 6 1.60- 1.39 (m, 5H), 1.70 (d, J= 12.5 Hz, 1H), 1.84 (dd, J= 4.0, 9.5 Hz, 2H), 1.96 (td, J = 4.7, 9.2 Hz, 1H), 2.15 -2.03 (m, 3H), 2.53 (s, 3H), 2.52 - 2.40 (m, 2H), 3.18 - 3.08 (m, 1H), 3.30 (br s, 1H), 3.75 - 3.63 (m, 2H), 3.86 - 3.77 (m, 1H), 5.23 (dd, J= 3.8, 7.8 Hz, 1H), 7.02 (d, J = 9.0 Hz, 1H) , 7.73 (dd, J
= 2.5, 9.0 Hz, 1H), 8.58 (d, J = 2.5 Hz, 1H).
Example 72: 3-(6-aminopyridin-2-y1)-4-(cyclohexylamino)-N-methylbenzenesulfonamide (Compound 76) \ NH2 N
1_,K1-µS
Preparation of Compound 76:
c,NH2 Br 76-la (1.3 eq) \ NH2 / \ Na2CO3 (3.0 eq) --N
0,13,0 Pd(dppf)C12 (0.1 eq) R la NO H20/dioxane(1/10) -\S
80 C,16 h HN
HN-Sµ` / 0 76-1 Compound 76 [00350] To a suspension of compound 76-1 (50 mg, 0.13 mmol, 1 eq) and 76-la (29 mg, 0.16 mmol, 1.3 eq) in mix solution of dioxane (1.5 mL) and H20 (0.15 mL) were added Pd(dppf)C12 (9 mg, 13 umol, 0.1 eq) and Na2CO3 (40 mg, 0.38 mmol, 3 eq) in one portion under N2. The resulting mixture was stirred at 80 C for 16 h. LCMS showed the starting material was consumed completely and 44% of desired product was formed. The reaction mixture was diluted with water (10 mL) and extracted with EA (10 mL * 4). The combined organic layers were concentrated under reduced pressure to give a residue.
HPLC indicated 61%
of desired product was detected. The residue was purified by prep-HPLC. LCMS
and 1HNMR
confirmed Compound 76 (6.76 mg, 18.6 umol, 14.6% yield). LCMS (ESI): RT =
0.632 min, mass calcd. For Ci8H24N402S, 360.16 m/z found 361.0[M+231+. 1HNMR (400MHz, CDC13) 6 8.53 (br d, J= 6.00 Hz, 1H), 7.94 (d, J = 2.00 Hz, 1H), 7.63 (dd, J = 2.00, 8.40 Hz, 1H), 7.56 (t, J = 7.60 Hz, 1H), 7.04 (d, J = 7.60 Hz, 1H), 6.72 (d, J= 9.20 Hz, 1H), 6.47 (d, J= 8.40 Hz, 1H), 4.44 (br s, 2H), 4.23 - 4.14 (m, 1H), 3.53 - 3.40 (m, 1H), 2.61 (d, J= 5.60 Hz, 3H), 2.08 - 2.01 (m, 2H), 1.82 - 1.72 (m, 2H), 1.67 - 1.61 (m, 1H), 1.48 - 1.27 (m, 5H).
Example 73: 4-(cyclohexylamino)-N-methyl-3-(pyridin-3-yl)benzenesulfonamide (Compound 77) N
COHN,\Sµµ
Preparation of Compound 77:
N' / \
00 Br Ii 77-la (1.5 eq) Cs2CO3 (4 eq), Pd(dppf)C12 (0.1 eq) CZ\
NH" H20, Dioxane, 100 C, 16 h HN-S
77-1 Compound 77 [00351] To a mixture of compound 77-1 (50 mg, 0.13 mmol, 1 eq) and compound 77-la (30.1 mg, 0.19 mmol, 18.3 uL, 1.5 eq) in a solution of dioxane (2 mL) and H20 (0.3 mL) was added Pd(dppf)C12 (9.3 mg, 12.7 umol, 0.1 eq) and Cs2CO3 (165.3 mg, 0.51 mmol, 4 eq) in one portion under N2. The mixture was stirred at 100 C for 16 hours. The crude LCMS showed 49%
of the desired product was detected. The reaction mixture was quenched by water (15 mL), and then extracted with Et0Ac (20 mL*3). The combined organic layer was washed with brine (15 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography to give the product (92 mg), which was further purified by prep-HPLC to provide the product (15.54 mg), which was further purified by prep-HPLC to give the Compound 77 (6.9 mg, 18.1 umol, 7.1% yield, HC1 salt).
LCMS (ESI): RT = 1.941 min, mass calc. for C181-123N302S 345.46, m/z found 346.0 [M+H1+.
1HNMR (400 MHz, DMSO-d6) 6 8.60 (td, J= 5.02, 1.51 Hz, 2H), 7.84 (dt, J= 7.78, 1.88 Hz, 1H), 7.56 (dd, J= 8.78, 2.26 Hz, 1H), 7.51 (dd, J= 7.65, 4.89 Hz, 1H), 7.32 (d, J = 2.26 Hz, 1H), 7.11 (q, J = 5.02 Hz, 1H), 6.86 (d, J = 8.78 Hz, 1H), 4.99 (d, J= 8.03 Hz, 1H), 2.52 (d, J= 1.76 Hz, 1H), 2.37 (d, J= 5.02 Hz, 3H), 1.85 (d, J= 10.29 Hz, 2H), 1.51 - 1.70 (m, 3H), 1.32 (q, J =
12.21 Hz, 2H), 1.04 - 1.24 (m, 3H).
Example 74: 4-(cyclohexylamino)-N-methyl-3-(3-methylpyridin-2-yl)benzenesulfonamide (Compound 78) N
N
0, HNOO
Preparation of Compound 78:
Br 78-la (1.5 eq) \
Pd(dppf)0I2 (0.1 eq) --N
Cs2003 (4 eq) HN
,µ 40 dioxane, H20, 100 C, 16 h -S
78-1 Compound 78 [00352] To a mixture of compound 78-1 (25 mg, 63.4 umol, 1 eq) and compound 78-la (16.4 mg, 95.1 umol, 10.6 uL, 1.5 eq) in a solution of dioxane (0.7 mL) and H20 (0.3 mL) were added Pd(dppf)C12 (4.6 mg, 6.3 umol, 0.1 eq) and Cs2CO3 (82.6 mg, 0.25 mmol, 4 eq) in one portion at room temperature (15 C) under N2. The mixture was stirred at 100 C
for 16 h. The crude LCMS showed 33% of the desired product was detected and the compound 78-1 was consumed completely. The mixture was quenched by water (15 mL), extracted with Et0Ac (10 mL * 3). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue (46 mg). The residue was purified by prep-HPLC to give Compound 78 (10.5 mg, 29.3 umol, 33.0% yield). LCMS (ESI): RT =
2.055 min, mass calc. for Ci9H25N302S 359.17, m/z found 360.0 [M+1-11+; NMR (400 MHz, CDC13) 6 8.54 (br d, J= 4.02 Hz, 1H), 7.64 - 7.73 (m, 2H), 7.54 (d, J = 2.26 Hz, 1H), 7.21 - 7.27 (m, 1H), 6.76 (d, J= 8.78 Hz, 1H), 4.91 (br d, J= 7.28 Hz, 1H), 4.30 (q, J = 5.52 Hz, 1H), 3.28 - 3.44 (m, 1H), 2.60 (d, J= 5.52 Hz, 3H), 2.25 (s, 3H), 1.93 - 2.06 (m, 2H), 1.62 - 1.76 (m, 3H), 1.28 - 1.43 (m, 2H), 1.07 - 1.27 (m, 3H).
Example 75: 4-(cyclohexylamino)-3-(3-fluoropyridin-2-y1)-N-methylbenzenesulfonamide (Compound 79) F N
0µ
HN
Preparation of Compound 79:
F -N
Br 79-1a (1.5 eq) \
0, ,0 Pd(dppf)C12 (0.1 eq) F
Cs2003 (4 eq) 01%* NU H20, -S -NS
HN 100 C, 16 h HN
79-1 Compound 79 [00353] To a mixture of compound 79-1 (25 mg, 63.4 umol, 1 eq) and compound 79-la (16.7 mg, 95.1 umol, 1.5 eq) in a solution of dioxane (0.7 mL) and H20 (0.3 mL) were added Pd(dppf)C12 (4.6 mg, 6.3 umol, 0.1 eq) and Cs2CO3 (82.6 mg, 0.25 mmol, 4 eq) in one portion at room temperature (15 C) under N2. The mixture was stirred at 100 C for 16 h. The crude LCMS showed 33% of the desired product was detected and the compound 79-1 was consumed completely. The reaction mixture was combined with another batch, the mixture was quenched by water (15 mL), extracted with Et0Ac (10 mL * 4). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue (51 mg). The residue was purified by prep-HPLC to give the Compound 79 (15.2 mg, 41.7 umol, 47.0% yield). LCMS (ESI): RT = 2.172 min, mass calc. for C18H22FN302S 363.14, m/z found 364.0 [M+H1+; 1HNMR (400 MHz, CDC13) 6 8.46 (d, J=4.77 Hz, 1H), 8.02 (t, J=
2.64 Hz, 1H), 7.70 (dd, J= 8.91, 2.13 Hz, 1H), 7.49 - 7.61 (m, 2H), 7.32 (dt, J = 8.34, 4.24 Hz, 1H), 6.80 (d, J
= 9.03 Hz, 1H), 4.21 (q, J = 5.35 Hz, 1H), 3.38 - 3.50 (m, 1H), 2.66 (d, J=
5.52 Hz, 3H), 1.97 -2.08 (m, 2H), 1.70 - 1.80 (m, 2H), 1.64 (br dd, J= 8.28, 4.27 Hz, 1H), 1.36 -1.49 (m, 2H), 1.23 -1.35 (m, 3H).
Example 76: 4-(cyclohexylamino)-3-(3-methoxypyridin-2-y1)-N-methylbenzenesulfonamide (Compound 80) o N
0µ
HN
Preparation of Compound 80:
Br 80-la (1.5 eq) Os ,0 Pd(dPPf)2C12 (0.1 eq) Cs2003 (4 eq) 0,µ HN NU dioxane, H20, ,S% 410 100 C, 16 h HN
80-1 Compound 80 [00354] To a mixture of compound 80-1 (25 mg, 63.4 umol, 1 eq) and compound 80-la (17.9 mg, 95.1 umol, 1.5 eq) in a solution of dioxane (0.7 mL) and H20 (0.3 mL) were added Pd(dppf)C12 (4.6 mg, 6.3 umol, 0.1 eq) and Cs2CO3 (82.6 mg, 0.25 mmol, 4 eq) in one portion at room temperature (15 C) under N2. The mixture was stirred at 100 C for 16 h. The crude LCMS showed 39% of the desired product was detected and the compound 80-1 was consumed completely. The mixture was quenched by water (15 mL), extracted with Et0Ac (10 mL * 3).
The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue (42 mg). The residue was purified by prep-HPLC to give the Compound 80 (8.2 mg, 21.7 umol, 24.5% yield). LCMS (ESI): RT = 2.049 min, mass calc. for Ci9H25N303S 375.16, m/z found 376.0 [M+H1+; IFINMR (400 MHz, CDC13) 6 8.26 (dd, J =
4.64, 1.13 Hz, 1H), 7.98 (d, J= 2.26 Hz, 1H), 7.65 (dd, J= 8.91, 2.13 Hz, 1H), 7.32 - 7.38 (m, 1H), 7.25 - 7.31 (m, 1H), 6.76 (d, J= 9.03 Hz, 1H), 6.59 (br d, J = 7.03 Hz, 1H), 4.27 (q, J =
5.35 Hz, 1H), 3.83 (s, 3H), 3.29 - 3.50 (m, 1H), 2.64 (d, J= 5.52 Hz, 3H), 1.93 -2.10 (m, 3H), 1.72 (br dd, J= 9.16, 4.14 Hz, 2H), 1.61 (d, J= 4.52 Hz, 1H), 1.33 - 1.46 (m, 2H), 1.17 - 1.31 (m, 3H).
Example 77: 4-(cyclohexylamino)-N-methy1-3-(2H-1,2,3-triazol-2-yl)benzenesulfonamide (Compound 81) ,N, N
o 40 No S
NH -µN
Preparation of Compound 81:
ain = -NI Fe (5.0 eq) N/11 =N NO2 81-la (1.0 eq) N
NH4CI (5.0 eq) 81-3a (1.2 eq) KF (1.0 eq) * NO2 Et0H:H20 = 2:1 * NH2 __________________ I DMSO, 70 C, 2 h 80 C, 4 hr I
TMSCI (2.5 eq), NaBH4 (1.0 eq), DMF, 0 C, 3h =N-N
=N
Na0"Sr ' IR, N 1) 1.Na0Me(3.0eq),THF Me0H, 81-4a (3.0eq) jpe.-Cul(5.0eq)/DMS0/0 2.methanamine (3.0eq), TEA(5.0eq), MW, 110 C, 1 h NCS(2.0eq), THF, 20 C, 3h 81-4 81-5 Compound 81 Step 1: 2-(5-Iodo-2-nitropheny1)-2H-1,2,3-triazole [00355] To a solution of compound 81-1 (450 mg, 1.69 mmol, 1.0 eq) in DMSO
(5 mL) were added compound 81-la (116 mg, 1.69 mmol, 1.0 eq) and KF (98 mg, 1.7 mmol, 1.0 eq).
The reaction mixture was stirred at 70 C for 2 hours. The mixture was diluted with water (30 mL) and the resultant mixture was extracted with EA (50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound 81-2 (150 mg, 28% yield). 1HNMR (400MHz, DMSO-d6) 6 8.35 (s, 1H), 8.23 (s, 2H), 8.13 (d, J = 8.3 Hz, 1H), 7.86 (d, J= 8.3 Hz, 1H).
Step 2: 4-Iodo-2-(2H-1,2,3-triazol-2-yl)aniline [00356] A solution of compound 81-2 (100 mg, 0.316 mmol, 1.0 eq), Fe (88 mg, 1.6 mmol, 5.0 eq) and NH4C1 (85 mg, 1.6 mmol, 5.0 eq) in Et0H (4 mL) and H20 (2 mL) was stirred at 80 C for 4 hours. The mixture was diluted with water (30 mL) and the resultant mixture was extracted with EA (50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure to obtain compound 81-3 (85 mg, 94% yield). LCMS (ESI): RT = 0.735 min, mass calcd. for C8H7IN4 285.97, m/z found 286.7 [M+H]+.
Step 3: N-Cyclohexy1-4-iodo-2-(2H-1,2,3-triazol-2-yl)aniline [00357] A mixture of compound 81-3 (60 mg, 0.21 mmol, 1.0 eq), compound 81-3a (25 mg, 0.25 mmol, 1.2 eq) and TMSC1 (57 mg, 0.52 mmol, 2.5 eq) in DMF (2 mL) was stirred at 0 C for 10 min under N2. NaBH4 (8.0 mg, 0.21 mmol, 1.0 eq) was added, the reaction mixture was stirred at 0 C for 2 hours. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound 81-4 (50 mg, crude) as a white solid.
Step 4: Methyl 3-44-(cyclohexylamino)-3-(2H-1,2,3-triazol-2-yl)phenyl)sulfonyl)propanoate [00358] Compound 81-4 (50 mg, 0.14 mmol, 1.0 eq), compound 81-4a (71 mg, 0.41 mmol, 3.0 eq) and Cul (129 mg, 0.679 mmol, 5.0 eq) were taken up into a microwave tube in DMSO (1.5 mL). The sealed tube was heated at 110 C for 1 hour under microwave. The mixture was diluted with water (10 mL) and EA (30 mL). The suspension was filtered and the filtrate was separation, the water layer was extracted with EA (20 mL * 2).
The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound 81-5 (40 mg, 75% yield). LCMS (EST): RT = 0.813 min, mass calcd. for C18I-124N404S 392.15, m/z found 393.0 [M+I-11+.
Step 5: 4-(Cyclohexylamino)-N-methyl-3-(2H-1,2,3-triazol-2-yl)benzenesulfonamide [00359] To a solution of compound 81-5 (40 mg, 0.10 mmol, 1.0 eq) in Me0H
(1 mL) and THF (2 mL) was added Na0Me (17 mg, 0.31 mmol, 3.0 eq). The reaction mixture was stirred at 20 C for 1 hour, and then removed solvent to give a residue. The residue was dissolved with THF (2 mL). After MeNH2 (2 M, 0.15 mL, 3.0 eq), TEA (52 mg, 0.51 mmol, 5.0 eq) and NCS
(27 mg, 0.20 mmol, 2.0 eq) were added, the reaction mixture was stirred at 20 C for 3 hours. The mixture was diluted with water (30 mL) and the resultant mixture was extracted with EA (50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely.
Compound 81 (26.59 mg, 77% yield) was obtained. LCMS (EST): RT = 0.792 min, mass calcd.
for C15H211\1502S 335.14, m/z found 335.9 [M+I-11+, 1HNMR (400MHz, CDC13) 6 = 8.43 (d, J= 2.0 Hz, 1H), 7.85 (s, 2H), 7.67 (dd, J= 2.3, 8.8 Hz, 1H), 7.64 - 7.57 (m, 1H), 6.86 (d, J = 9.0 Hz, 1H), 4.26 (q, J= 5.4 Hz, 1H), 3.54 - 3.43 (m, 1H), 2.67 (d, J = 5.3 Hz, 3H), 2.10 - 2.02 (m, 2H), 1.83 - 1.74 (m, 2H), 1.70 - 1.62 (m, 1H), 1.49 - 1.28 (m, 5H).
Example 78: 4-(cyclohexylamino)-N-methyl-3-(1-methyl-1H-imidazol-4-yl)benzenesulfonamide (Compound 82) N/
N
HN,S
I
Preparation of Compound 82:
0,13,0 N
Br 82-2(1.5 eq) 0 = NO (:)µµ
Na2003(2.0 eq), I. 0 ,S
eq) I
82-1 dioxane/H20, 80 C,5 h Compound 82 [00360] To a solution of compound 82-1 (0.04 g, 0.10 mmol, 1.0 eq) and compound 82-2 (16.3 mg, 0.10 mmol, 1.0 eq) in dioxane (5.0 mL) was added H20 (0.5 mL) Pd(dppf)C12 (7.4 mg, 10.14 umol, 0.1 eq) and Na2CO3 (21.5 mg, 0.20 mmol, 2.0 eq). The mixture was stirred at 80 C
for 16 hour under N2 atmosphere. LCMS showed desired compound was found. The reaction was filtered through Celite and concentrated under reduced pressure to give a residue. The crude product was purified by prep-HPLC to give Compound 82 (6.64 mg, 18.86 umol, 18.60%
yield). LCMS (ESI): RT = 0.634 min, mass calc. for C17H24N402S 348.16, m/z found 348.9 [M+F11+;IHNMR (400 MHz, CDC13) 6 8.55 (s, 1H), 7.81 (d, J = 2.0 Hz, 1H), 7.54 (dd, J = 2.3, 8.8 Hz, 1H), 7.47 (s, 1H), 7.24 (s, 1H), 6.69 (d, J= 9.0 Hz, 1H), 4.24 (q, J =
5.4 Hz, 1H), 3.75 (s, 3H), 3.44 (s, 1H), 2.62 (d, J= 5.5 Hz, 3H), 2.12 -2.00 (m, 2H), 1.86 - 1.75 (m, 2H), 1.69 - 1.64 (m, 1H), 1.48 - 1.25 (m, 5H).
Example 79: 4-(cyclohexylamino)-3-(6-(dimethylamino)pyridin-2-y1)-N-methylbenzenesulfonamide (Compound 83) \
()%
H m Preparation of Compound 83:
/
-N
Br /
83-la (1.3 eq) Na2003 (3.0 eq) / \ N
--N
0õ0 B Pd(dppf)012 (0.1 eq) I H
H ________________________________________ il. N
µ.. N
lei H20/dioxane(1/10) 80 C,16 h 0 HN -S %%
HN µ`
I
83-1 Compound 83 2, /
/ \ NH2 NaH (3.0 eq) c)...-N
CH3I (3.0 eq) \
DMF, 0-15, 16h Br Br 83-lb 83-la Step 1: 6-bromo-N,N-dimethyl-pyridin-2-amine [00361] To a mixture of the compound 83-lb (100 mg, 0.578 mmol, 1 eq) in DMF (2 mL) was added NaH (69 mg, 1.73 mmol, 60% purity, 3 eq) in one portion at 0 C
under N2. The reaction mixture was stirred at 0 C for 15 min, then CH3I (246 mg, 1.73 mmol, 3 eq) was added at 0 C and the mixture was warmed to 15 C and stirred for 16 h. LCMS showed one main peak with desired MS was detected. TLC indicated the starting material was consumed completely.
The reaction mixture was diluted with water (15 mL) and extracted with EA (15 mL * 4). The combined organic layers were dried with anhydrous Na2SO4, filtered and concentrated in vacuum to provide compound 83-la (130 mg, crude), which was used next step without further purification Step 2: 4-(cyclohexylamino)-3-16-(dimethylamino)-2-pyridy1]-N-methyl-benzenesulfonamide [00362] To a suspension of the compound 83-la (33 mg, 0.132 mmol, 1.3 eq) and the compound 83-1 (40 mg, 0.101 mmol, 1 eq) in mix solution of H20 (0.1 mL) and dioxane (1 mL) were added Pd(dppf)C12 (7.5 mg, 10 umol, 0.1 eq) and Na2CO3 (32 mg, 0.304 mmol, 3 eq) in one portion under N2. The mixture was stirred at 80 C for 16 h. LCMS
showed the starting material was consumed completely and one main peak with desired MS
was detected.
The reaction mixture was diluted with water (10 mL) and extracted with EA (10 mL * 3). The combined organic layers were concentrated under reduced pressure to give a residue. HPLC
showed 68% of desired product was detected. The residue was purified by prep-HPLC. LCMS
and 1HNMR that the Compound 83 (4.81 mg, 12 umol, 11.8% yield). LCMS (ESI): RT
= 0.755 min, mass calcd. For C20I-128N402S, 388.19 m/z found 389.1[M+1-11+. IFINMR
(400MHz, CDC13) 6 8.62 (br d, J= 6.80 Hz, 1H), 7.96 (d, J = 2.40 Hz, 1H), 7.68 - 7.52 (m, 2H), 6.94 (d, J = 7.60 Hz, 1H), 6.74 (d, J= 9.20 Hz, 1H), 6.48 (d, J= 8.40 Hz, 1H), 4.18 -4.09 (m, 1H), 3.47 - 3.35 (m, 1H), 3.14 (s, 6H), 2.64 (d, J= 5.60 Hz, 3H), 2.17 -2.06 (m, 2H), 1.84 -1.75 (m, 2H), 1.73 -1.66 (m, 1H), 1.45 - 1.35 (m, 2H), 1.29 - 1.20 (m, 3H).
Example 80: 3-(4-aminopyridin-2-y1)-4-(cyclohexylamino)-N-methylbenzenesulfonamide (Compound 84) N
HN
Preparation of Compound 84:
N
Br NH2 NflT
0,6,0 84-la (1.3 eq) Na2CO3 (3.0 eq) Pd(dppf)012 (0.1 eq) 0 CZµ
HN-S, HN,Sµµ H20/dioxane(1/10) 80 C,16 h 84-1 Compound 84 [00363] To a suspension of the compound 84-1 (40 mg, 0.101 mmol, 1 eq) and the compound 84-la (22 mg, 0.131 mmol, 1.3 eq) in mix solvent of dioxane (1 mL) and H20 (0.15) were added Pd(dppf)C12 (7 mg, 10 umol, 0.1 eq) and Na2CO3 (32 mg, 0.304 mmol, 3 eq) in one portion under N2. The mixture was stirred at 80 C for 16 h. LCMS showed the starting material was consumed completely and 40% of desired product was formed. The reaction mixture was diluted with water (10 mL) and extracted with EA (10 mL * 4). The combined organic layers were concentrated under reduced pressure to give a residue. HPLC indicated 60%
of desired product was detected. The residue was purified by prep-HPLC. LCMS and IFINMR
confirmed the white solid was the Compound 84 (14.25 mg, 39 umol, 39% yield). LCMS
(ESI): RT =
0.618 min, mass calcd. For Ci8H24N402S, 360.16 m/z found 361.0[M+Hr IFINMR
(400MHz, CDC13) 6 9.19 (br s, 1H), 8.19 (d, J = 5.60 Hz, 1H), 8.02 (d, J= 2.40 Hz, 1H), 7.63 (dd, J= 2.00, 8.80 Hz, 1H), 7.03 (d, J= 2.00 Hz, 1H), 6.72 (d, J = 8.80 Hz, 1H), 6.47 (dd, J
= 2.00, 5.60 Hz, 1H), 4.69 (q, J= 5.30 Hz, 1H), 4.36 (s, 2H), 3.45 (br s, 1H), 2.60 (d, J= 5.20 Hz, 3H), 2.05 -1.98 (m, 2H), 1.80 - 1.71 (m, 2H), 1.64 - 1.58 (m, 1H), 1.44 - 1.25 (m, 4H).
Example 81: 4-(cyclohexylamino)-N-methyl-3-(6-(methylamino)pyridin-2-yl)benzenesulfonamide (Compound 85) /
i \ NH
--N
H
µNI H N
µS
....--Preparation of Compound 85:
/
c,NH
I .N
Br /
85-1a (1.3 eq) Na2CO3 (3.0 eq) / NH \
---N
0õ0 B Pd(dppf)C12 (0.1 eq) H
H
H20/dioxane(1/10) 'S
ON\ el NO NW- 1%
80 C,16 h 1 85-1 Compound 85 OH
'e.OH H
2/ \ NH2 85-1 b (1.0 eq) --N
...- N
________________________________________ ).- N
Br Py (1.4 eq), Cu(OAc)2 (1.0 eq), 85-1c (0.4 eq) dioxane, 02 (15 Psi), 20 00,2 h Br 85-la Step 1: 6-bromo-N-methyl-pyridin-2-amine [00364] Cu(0Ac)2 (303 mg, 1.67 mmol, 1 eq) was added to a solution of the compound 85-1c (116 mg, 0.67 mmol, 0.4 eq) and pyridine (185 mg, 2.34 mmol, 1.40 eq) in dioxane (6 mL). The reaction mixture was stirred at 15 C for 15 min. The compound 85-lb (100 mg, 1.67 mmol, 1 eq) was added and the reaction was heated to 100 C, and stirred at 100 C under 02(15 Psi) for 16 h. LCMS showed no desired MS was detected. TLC indicated the compound 85-1c was remained and two new spots were formed. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography. NMR confirmed that the product was compound 85-la (37 mg, 0.20 mmol, 11.9% yield). NMR
(400MHz, CDC13) 6 7.31 - 7.27 (m, 1H), 6.74 (d, J = 7.60 Hz, 1H), 6.29 (d, J= 8.00 Hz, 1H), 4.69 (br s, 1H), 2.91 (d, J = 5.20 Hz, 3H).
Step 2: 4-(cyclohexylamino)-N-methy1-346-(methylamino)-2-pyridyl]benzenesulfonamide [00365] To a suspension of the compound 85-la (31 mg, 0.131 mmol, 1.3 eq) and the compound 85-1 (40 mg, 0.10 mmol, 1 eq) in mix solvent of H20 (0.1 mL) and dioxane (1 mL) were added Na2CO3 (32 mg, 0.304 mmol, 3 eq) and Pd(dppf)C12 (7 mg, 10 umol, 0.1 eq) in one portion under N2. The mixture was stirred at 80 C for 16 h. LCMS showed the starting material was consumed completely and one main peak with desired MS was detected. The reaction mixture was diluted with water (10 mL) and extracted with EA (10 mL *
3). The combined organic layers were concentrated under reduced pressure to give a residue. HPLC
showed 66% of desired product was detected. The residue was purified by prep-HPLC. LCMS and NMR confirmed that the product was the Compound 85 (9.94 mg, 26 umol, 26.2% yield). LCMS (ESI): RT = 0.664 min, mass calcd. For Ci9H26N4025 374.18 m/z found 375.0 [M+F11+. NMR
(400MHz, CDC13) 6 8.70 (d, J= 6.5 Hz, 1H), 7.97 (d, J= 2.3 .. Hz, 1H), 7.63 (dd, J= 2.3, 8.8 Hz, 1H), 7.54 (t, J= 7.9 Hz, 1H), 6.98 (d, J = 7.5 Hz, 1H), 6.73 (d, J =
9.0 Hz, 1H), 6.36 (d, J = 8.3 Hz, 1H), 4.53 - 4.45 (m, 1H), 4.13 (q, J= 5.7 Hz, 1H), 3.48 - 3.37 (m, 1H), 3.00 (d, J= 5.0 Hz, 3H), 2.63 (d, J= 5.5 Hz, 3H), 2.17 - 2.05 (m, 2H), 1.85 - 1.74 (m, 2H), 1.73 - 1.62 (m, 1H), 1.47 - 1.38 (m, 2H), 1.33 - 1.24 (m, 3H).
Example 82: 4-(cyclohexylamino)-N-methy1-3-(2-(1-(pyridin-3-yl)piperidin-3-y1)-tetrazol-5-yl)benzenesulfonamide (Compound 86) N N
oNN N
,S
Preparation of Compound 86:
HO B.IL N--01 QNH OH
864a (2 eq) N-NQ
N-N Cu(OAc)2 (1 eq), ii ,1\1 DIPEA (4 eq) 02, DCM, 30 C, 104 h czµ N
N N
HO
86-1 Compound 86 [00366] To a mixture of 86-1 (50 mg, 0.110 mmol, 1 eq, HC1 salt) and compound 86-la (27.0 mg, 0.219 mmol, 2 eq) in DCM (1 mL) were added Cu(0Ac)2 (19.9 mg, 0.110 umol, 1 eq) and DIPEA (56.7 mg, 0.439 mmol, 76.4 uL, 4 eq) in one portion at 15 C
under 02. The mixture was stirred at 30 C for 88 h. The mixture was stirred at 30 C for 16 h. The reaction mixture was diluted with DCM (15 mL), and then concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography to give the product as yellow oil (37 mg), which was further purified by prep-HPLC to give the impure product (6.53 mg), which was further purified by prep-HPLC to give the Compound 86 (2.91 mg, 5.9 umol, 5.3% yield). LCMS (ESI): RT = 2.247 min, mass calc. for C24H32N802S 496.24, m/z found 497.1 [M+H1+; IFINMR (400 MHz, CDC13) 6 8.61 (br s, 1H), 8.41 (s, 1H), 8.05 (s, 1H), 7.59 - 7.92 (m, 3H), 6.80 (d, J= 8.53 Hz, 1H), 5.07 (s, 1H), 4.51 (s, 1H), 3.88 - 4.24 (m, 1H), 3.53 (br s, 3H), 2.78 (s, 1H), 2.63 (s, 3H), 2.46 (s, 1H), 2.07 (s, 2H), 1.60 - 1.99 (m, 7H), 1.22 - 1.44 (m, 4H).
Example 83: 4-(cyclohexylamino)-3-(4-(dimethylamino)pyridin-2-y1)-N-methylbenzenesulfonamide (Compound 87) X
,\
HNS
Preparation of Compound 87:
cNN
Br 87-la (1.3 eq) N
Na2003 (3.0 eq) 0,6,0 Pd(dppf)C12 (0.1 eq) H20/dioxane(1 /1 0) ON, O
80 C,16 h HN
HN
I
87-1 Compound 87 H2Nc NaH
CH31 (2.5 eq) N
DMF, 0-it, 16h Br Br 87-lb 87-la Step 1: 2-bromo-N,N-dimethyl-pyridin-4-amine [00367] To a mixture of the compound 87-lb (100 mg, 0.578 mmol, 1 eq) in DMF (2 mL) was added NaH (92 mg, 2.31 mmol, 4 eq) in one portion at 0 C under N2. The mixture was stirred at 0 C for 15 min, then CH3I (0.63 g, 4.44 mmol, 0.27 mL, 7.68 eq) was added at 0 C
and then the mixture was warmed to 15 C and stirred for 16 h. The reaction was monitored by LCMS. The reaction mixture was diluted with water (15 mL) and extracted with EA (15 mL *
4). The combined organic layers were dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give the compound 87-la (130 mg, crude), which was used next step without further purification. NMR (400MHz, CDC13) 6 7.95 (d, J= 6.00 Hz, 1H), 6.65 (d, J =
2.40 Hz, 1H), 6.44 (dd, J= 2.50, 6.10 Hz, 1H), 3.00 (s, 6H).
Step 2: 4-(cyclohexylamino)-3-14-(dimethylamino)-2-pyridy1]-N-methyl-benzenesulfonamide [00368] To a suspension of the compound 87-la (38 mg, 0.132 mmol, 1.3 eq) and the compound 1 (40 mg, 0.101 mmol, 1 eq) in mix solvent of H20 (0.1 mL) and dioxane (1 mL) were added Pd(dppf)C12 (7 mg, 10 umol, 0.1 eq) and Na2CO3 (38 mg, 0.355 mmol, 3.5 eq) in one portion under N2. The mixture was stirred at 80 C for 16 h. LCMS
showed the starting material was consumed completely and one main peak with desired MS
was detected.
The reaction mixture was diluted with water (10 mL) and extracted with EA (10 mL * 3). The combined organic layers were concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC. LCMS and NMR confirmed the Compound 87 (5.88 mg, 15 umol, 14.9% yield). LCMS (ESI): RT = 0.642 min, mass calcd. For C20I-128N402S, 388.19 m/z found 389.1[M+H1 IFINMR (400MHz, CDC13) 6 8.60 (br d, J= 6.00 Hz, 1H), 8.22 (d, J= 6.00 Hz, 1H), 7.90 (d, J= 2.00 Hz, 1H), 7.63 (dd, J = 2.40, 8.80 Hz, 1H), 6.77 (d, J = 2.40 Hz, 1H), 6.71 (d, J= 8.80 Hz, 1H), 6.48 (dd, J= 2.40, 6.00 Hz, 1H), 4.40 - 4.27 (m, 1H), 3.49 - 3.35 (m, 1H), 3.07 (s, 6H), 2.60 (d, J= 5.60 Hz, 3H), 2.06 - 1.99 (m, 2H), 1.81 - 1.71 (m, 2H), 1.62 - 1.57 (m, 1H), 1.49 - 1.31 (m, 5H).
Example 84: 4-(cyclohexylamino)-N-methyl-3-(4-(methylamino)pyridin-2-yl)benzenesulfonamide (Compound 88) I
NH
N
kloON
HN,µSµµ
I
Preparation of Compound 88:
I
N,NH
I
Br NH
88-la (1.3 eq) Na2003 (3.0 eq) /
N I
0õ0 B H Pd(dppf)C12 (0.1 eq) H
No (:)µµ 0 No ________________________________ v.--H20/dioxane(1/10) \\
HN-Sµµ
80 C,16 h HN,Sµ` I
I
88-1 Compound 88 'I'OH I
NH2 88-1 b (1 0 eq) I ' __ 88-1c (0.4 eq) g NH
N I
Py (1.4 eq), Cu(OAc)2 (1.0 eq), Nr Br dioxane,02(15 Psi), Br 15-100 C,16 h 88-1c 88-1a Step 1: 2-bromo-N-methyl-pyridin-4-amine [00369] Cu(OAc)2 (303 mg, 1.67 mmol, 1 eq) was added to a solution of the compound 88-1c (116 mg, 0.668 mmol, 0.4 eq) and pyridine (185 mg, 2.34 mmol, 0.19 mL, 1.40 eq) in dioxane (6 mL). The reaction mixture was stirred at 15 C for 15 min.
The compound 88-lb (100 mg, 1.67 mmol, 1 eq) was added and the reaction was heated to 100 C
and stirred at 100 C under 02(15 Psi) for 16 h. LCMS showed no desired MS was detected. TLC
indicated the compound 88-1c was remained and one new spot was formed. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography. IFINMR confirmed that the product was 88-la (35 mg, 0.187 mmol, 11.2% yield). IFINMR (400MHz, CDC13) 6 7.93 (d, J = 5.60 Hz, 1H), 6.62 (d, J=2.00 Hz, 1H), 6.39 (dd, J= 2.20, 5.60 Hz, 1H), 4.32 (br s, 1H), 2.87 (d, J= 5.20 Hz, 3H).
Step 2: 4-(cyclohexylamino)-N-methyl-3-14-(methylamino)-2-pyridyl]benzenesulfonamide [00370] To a suspension of the compound 88-la (29 mg, 0.132 mmol, 1.3 eq) and the compound 88-1 (40 mg, 101.44 umol, 1 eq) in a mix solvent of H20 (0.1 mL) and dioxane (1 mL) were added Na2CO3 (32 mg, 0.304 mmol, 3 eq) and Pd(dppf)C12 (7.4 mg, 10 umol, 0.1 eq) in one portion under N2. The mixture was stirred at 80 C for 16 h. LCMS
showed the starting material was consumed completely and one main peak with desired MS was detected. The reaction mixture was diluted with water (5 mL) and extracted with EA (7 mL *
3). The combined organic layers were concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC. LCMS and IFINMR confirmed that the product was Compound (8.07 mg, 20.9 umol, 20.6% yield). LCMS (ESI): RT = 0.630 min, mass calcd. For Ci9H26N4025, 374.18 m/z found 375.0[M+Hr NMR (400MHz, CDC13) 6 8.97 (br d, J=
7.60 Hz, 1H), 8.20 (d, J= 6.00 Hz, 1H), 7.96 (d, J = 2.00 Hz, 1H), 7.63 (dd, J =
2.10, 8.90 Hz, 1H), 6.82 (d, J = 2.00 Hz, 1H), 6.72 (d, J = 8.80 Hz, 1H), 6.41 (dd, J = 2.00, 5.80 Hz, 1H), 4.47 - 4.35 (m, 2H), 3.50 - 3.37 (m, 1H), 2.92 (d, J= 5.20 Hz, 3H), 2.61 (d, J = 5.60 Hz, 3H), 2.06 - 2.00 (m, 2H), 1.81 - 1.73 (m, 2H), 1.68- 1.61 (m, 1H), 1.45 - 1.30 (m, 5H).
Example 85: 4-(cyclohexylamino)-N-methyl-3-(1H-1,2,3-triazol-1-yl)benzenesulfonamide (Compound 89) N
No -S
HN *
Preparation of Compound 89:
N.N ffN
Fe (5.0 eq) NO2 89-la (1.0 eq) N NH4CI (5.0 eq) N 89-3a (1.2 eq) KF (1.0 eq) * W NO Et0H:H20 = 2:1 * NH
DMSO70C2 h 2 80 C, 4 hr TMSCI (2.5 eq), NaBH4 (1.0 eq), I , DMF, 0 C, 1 hand 10 min (,11 Na0Sr ' N
1 . Na0Me(3.0 eq),THF Me0H, iN
*N 89-4a (3.0eq) 20 C, 1 hr U 1(5.0eq)/DMS0/ 0 -S *
2. methanamine (3.0 eq), TEA(5.0 eq), HN
MW, 110 C, 1 h 0 89-4 o NCS(2.0 eq), THF, 20 C, 16 hr Compound 89 Step 1: 1-(5-Iodo-2-nitropheny1)-1H-1,2,3-triazole [00371] To a solution of compound 89-1 (450 mg, 1.69 mmol, 1.0 eq) in DMSO (5 mL) were added compound 89-la (116 mg, 1.69 mmol, 1.0 eq) and KF (98 mg, 1.7 mmol, 1.0 eq).
The reaction mixture was stirred at 70 C for 2 hours. The mixture was diluted with water (30 mL) and the resultant mixture was extracted with EA (50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound 89-2 (200 mg, 37% yield). 1HNMR (400MHz, DMSO-d6) 6 8.75 (s, 1H), 8.33 (s, 1H), 8.23 (d, J= 8.3 Hz, 1H), 8.01 (s, 1H), 7.97 (d, J= 8.3 Hz, 1H).
Step 2: 4-Iodo-2-(1H-1,2,3-triazol-2-yl)aniline [00372] A solution of compound 89-2 (200 mg, 0.633 mmol, 1.0 eq), Fe (177 mg, 3.16 mmol, 5.0 eq) and NH4C1 (169 mg, 3.16 mmol, 5.0 eq) in Et0H (5 mL) and H20 (2.5 mL) was stirred at 80 C for 4 hours. The mixture was diluted with water (30 mL) and the resultant mixture was extracted with EA (50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure to obtain the title compound 89-3 (180 mg, 99% yield). LCMS (ESI): RT = 0.654 min, mass calcd. for C8H7IN4 285.97, m/z found 286.8 [M+H1+.
Step 3: N-Cyclohexy1-4-iodo-2-(1H-1,2,3-triazol-2-yl)aniline [00373] A mixture of compound 89-3 (100 mg, 0.350 mmol, 1.0 eq), compound 89-3a (41 mg, 0.42 mmol, 1.2 eq) and TMSC1 (95 mg, 0.87 mmol, 2.5 eq) in DMF (2 mL) was stirred at 0 C for 10 min under N2. NaBH4 (13 mg, 0.35 mmol, 1.0 eq) was added, the reaction mixture was stirred at 0 C for 1 hour. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound 89-4 (120 mg, crude). LCMS (ESI):
RT = 0.868 min, mass calcd. for C14H17IN4 368.05, m/z found 368.9 [M+1-11+.
Step 4: Methyl 3-44-(cyclohexylamino)-3-(1H-1,2,3-triazol-2-yl)phenyl)sulfonyl)propanoate [00374] Compound 89-4 (60 mg, 0.16 mmol, 1.0 eq) , compound 89-4a (85 mg, 0.49 mmol, 3.0 eq) and Cul (155 mg, 0.815 mmol, 5.0 eq) were taken up into a microwave tube in DMSO (1.5 mL). The sealed tube was heated at 110 C for 1 hour under microwave. The mixture was diluted with water (10 mL) and EA (30 mL).The suspension was filtered and the filtrate was separation, the water layer was extracted with EA (20 mL * 2).
The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford compound 89-5 (60 mg, 94% yield). LCMS (EST): RT = 0.748 min, mass calcd. for C18I-124N404S 392.15, m/z found 393.0 [M+I-11+.
Step 5: 4-(Cyclohexylamino)-N-methy1-3-(1H-1,2,3-triazol-2-yl)benzenesulfonamide [00375] To a solution of compound 89-5 (60 mg, 0.15 mmol, 1.0 eq) in Me0H
(1 mL) and THF (2 mL) was added Na0Me (25 mg, 0.46 mmol, 3.0 eq). The reaction mixture was stirred at 20 C for 1 hour, and then removed solvent to give a residue. The residue was dissolved with THF (2 mL). After MeNH2 (2 M, 0.23 mL, 3.0 eq), TEA (77 mg, 0.76 mmol, 5.0 eq) and NCS
(41 mg, 0.31 mmol, 2.0 eq) were added, the reaction mixture was stirred at 20 C for 3 hours. The mixture was diluted with water (30 mL) and the resultant mixture was extracted with EA (50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely.
Compound 89 (16.13 mg, 31% yield) was obtained. LCMS (EST): RT = 0.739 min, mass calcd.
for C15H211\1502S 335.14, m/z found 335.9 [M-411+, 1HNMR (400MHz, DMSO-d6) 6 8.59 (d, J= 1.0 Hz, 1H), 8.03 (d, J= 1.0 Hz, 1H), 7.67 (dd, J= 2.3, 8.8 Hz, 1H), 7.58 (d, J =
2.3 Hz, 1H), 7.09 (d, J = 8.8 Hz, 1H), 5.91 (d, J = 8.0 Hz, 1H), 3.51 - 3.41 (m, 1H), 2.53 -2.51 (m, 1H), 2.40 (s, 3H), 1.93 - 1.83 (m, 2H), 1.71 - 1.61 (m, 2H), 1.61 - 1.52 (m, 1H), 1.43 -1.28 (m, 2H), 1.28 -1.11 (m, 3H).
Example 86: N-methy1-3-(2-methy1-2H-tetrazol-5-y1)-4-(phenylamino)benzenesulfonamide (Compound 90) /
N-N
NI, H
40 N to 9\
,S
HN µµ
Preparation of Compound 90:
I
BnNH2(1.2eq), I 0 NN, _0 I 0 TEA (1 2eq) NH', S
NH, * NaN3(3.0 eq) iSS- al S DMS0,120 C, 3 h (3( 0 io Mel (1.0 eq) e 0 ______________ ,... ______________________ ,.. N
H
I IN.-F N io NH4C1(3.0 eq), N, N K2CO3 (1.5 eq) I I N DMF, 130 C, 16 hr N-N DMF, 80 C, N 25 min, MW
Phi (2 eq) I I Pd2(dba)3(0.1 eq) N-N/
NH, _0 dry Pd/C(0.2 eq) S- 1-1N, _0 Xantphos(0.2 eq) N , r' \I
d 0 Me0H, HCI(cat) S-K3PO4 (3 eq) H
N = H2, 30 C, 45 Psi 01 0 To1, 110 C, 16 h H NH2 _____________________ N .
1.-N ' N
N, N HN N%
N-N i 0 / N-N
/ 90-5 Compound 90 Step 1: 4-(benzylamino)-3-cyano-N-methylbenzenesulfonamide [00376] To a solution of 3-cyano-4-fluoro-N-methyl-benzenesulfonamide 90-1 (1 g, 4.67 mmol, 1 eq) and BnNH2 (600.2 mg, 5.6 mmol, 610.63 uL, 1.2 eq) in DMSO (5 mL) was added TEA (566.8 mg, 5.6 mmol, 779.71 uL, 1.2 eq) in one portion at 15 C. The mixture was stirred at 120 C for 3 h. LCMS showed the reaction was complete and 93% of desired product was formed. The resulting yellow mixture was combined with other batches and diluted with water (15 mL) and EA (80 mL) and separated. The separated organic layer was washed with brine (10 mL*6), dried over anhydrous Na2SO4, filtered and concentrated under vacuum to give a white residue A. The residue A was triturated with a mixture solution of EA:PE = 1:2 solvent (15 mL) and then filtered. The filter cake was washed with a mixture solution of EA:PE
= 1:2 solvent (25 mL) and dried to give compound 90-2 (1 g, 3.32 mmol, 71.12% yield). The filtrate was concentrated to give a residue B. The residue B was purified by flash silica gel chromatography to give compound 90-2 (0.3 g, 0.99 mmol, 21.32% yield). Iti NMR (400MHz, DMSO-d6) 6 7.81 (d, J = 2.5 Hz, 1H), 7.71 (t, J = 6.0 Hz, 1H), 7.62 (dd, J= 2.0, 9.0 Hz, 1H), 7.39 - 7.31 (m, 4H), 7.29 - 7.18 (m, 2H), 6.78 (d, J = 9.0 Hz, 1H), 4.51 (d, J= 6.0 Hz, 2H), 2.37 -2.33 (m, 3H).
Step 2: 4-(benzylamino)-N-methyl-3-(2H-tetrazol-5-yl)benzenesulfonamide [00377] To a mixture of compound 90-2(1 g, 3.32 mmol, 1 eq) and NaN3 (647.2 mg, 9.95 mmol, 3 eq) in DMF (15 mL) was added NH4C1 (532.5 mg, 9.95 mmol, 0.35 mL, 3 eq) in one portion at 15 C under N2. The mixture was heated to 130 C for 16 h. LCMS
showed the reaction was complete and 90% of desired product was formed. The mixture was diluted with water (20 mL). The resulting solution was added into a 0.5 M HC1 solution (50 mL), along with lots of solid formed. Then the mixture was filtered. The filter cake was washed with water (25 mL) and dried to give compound 90-3 (1.2 g, crude).
Step 3: 4-(benzylamino)-N-methy1-3-(2-methy1-2H-tetrazol-5-yObenzenesulfonamide [00378] To a mixture of compound 90-3 (0.66 g, 1.92 mmol, 1 eq) and K2CO3 (397.3 mg, 2.87 mmol, 1.5 eq) in DMF (12 mL) was added Mel (272 mg, 1.92 mmol, 0.12 mL, 1 eq) in one portion at 15 C under N2. The mixture was heated at 80 C under microwave for 25 min. LCMS
showed the reaction was complete and 71% of desired product was formed. The mixture was combined with another batch and diluted with water (15 mL) and EA (100 mL) and separated, along with some solid formed. Then the mixture was filtered. The filter cake was washed with water (15 mL) and dried under vacuum to give compound 90-4 (0.29 g, 0.81 mmol, 42.22%
yield). The filtrate was washed with brine (15 mL*3), dried over anhydrous Na2SO4, filtered and concentrated under vacuum to give compound 90-4 (0.9 g, crude), which was used for next step without further purification. NMR
(400MHz, DMSO-d6) 6 8.40 (d, J= 2.5 Hz, 1H), 8.08 (t, J
= 5.8 Hz, 1H), 7.64 - 7.58 (m, 1H), 7.42 - 7.33 (m, 4H), 7.31 - 7.20 (m, 2H), 6.93 (d, J = 9.0 Hz, 1H), 4.66 (d, J = 6.0 Hz, 2H), 4.49 (s, 3H), 2.37 (d, J = 5.0 Hz, 3H).
Step 4: 4-amino-N-methy1-3-(2-methy1-2H-tetrazol-5-yObenzenesulfonamide [00379] To a solution of compound 90-4 (0.9 g, 2.51 mmol, 1 eq) in Me0H (20 mL) were added dry Pd/C (0.45 g, 0.42 mmol, 10% purity, 0.5 eq) and HC1 (12 M, 0.21 mL, 1 eq) at 15 C.
The resulting dark mixture was degassed and refilled with H2 for three times and then stirred at 30 C for 16 h under 45 Psi H2. TLC showed the mixture was complete and new spots were formed. The dark mixture was filtered via a pad of Celite. The filter cake was washed with methanol (10 mL). The filtrate was concentrated to give compound 90-5 (0.55 g, 1.80 mmol, 71.87% yield, HC1), which was used for next step without further purification.
(400MHz, DMSO-d6) 6 8.34 (d, J= 2.0 Hz, 1H), 7.58 - 7.53 (m, 1H), 7.24 - 7.17 (m, 1H), 7.00 (d, J = 9.0 Hz, 1H), 4.47 (s, 3H), 2.38 (d, J= 4.0 Hz, 3H).
Step 5: N-methy1-3-(2-methy1-2H-tetrazol-5-y1)-4-(phenylamino)benzenesulfonamide [00380] To a solution of compound 90-5 (20 mg, 74.5 umol, 1 eq), iodobenzene (30.4 mg, 0.15 mmol, 16 uL, 2 eq) and K3PO4 (47.5 mg, 0.22 mmol, 3 eq) in toluene (1 mL) were added Pd2(dba)3 (6.8 mg, 7.4 umol, 0.1 eq) and Xantphos (8.6 mg, 14.9 umol, 0.2 eq) at 15 C
under nitrogen. The resulting mixture was degassed and refilled with nitrogen for three times and then stirred at 110 C for 16 h under N2. LCMS showed the reaction was complete and 38% of desired product was formed. TLC showed the reaction was complete and new spots were formed.
The mixture was combined with another batch and filtered via a pad of Celite.
The filter cake was washed with EA (30 mL). The filtrate was concentrated to give a residue.
The residue was purified by prep-TLC and then purified by prep-HPLC to give Compound 90 (5.46 mg, 15.9 umol, 21.27% yield). LCMS (ESI): RT = 1.465 min, mass calc. for C15tl16N602S
344.11, m/z found 345.0 [M+11+. 1H NMR (400MHz, DMSO-d6) 6 9.14 (s, 1H), 8.45 (d, J= 2.5 Hz, 1H), 7.69 (dd, J = 2.0, 9.0 Hz, 1H), 7.50 - 7.40 (m, 2H), 7.40 - 7.31 (m, 4H), 7.23 - 7.13 (m, 1H), 4.51 (s, 3H), 2.42 (d, J = 4.5 Hz, 3H).
Example 87: 4-(cyclohexylamino)-N-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)benzenesulfonamide (Compound 91) N=( ,N
C}S
N
H
Preparation of Compound 91:
HO o H2N¨
HO o 0 0 F 91-1a (3 eq) H2SO4(cat) F 91-3a (2.0 eq) (Rµ 411 DCM,0 C, 20 min (Rµ 140 Me0H, Rµ DMF
,S CI \\ ,S 80 C, 120 C, 4 hr N ,S
18hr H
OH N=( HN , N
91-4a (2.0 eq) R\= -0 ____________ NaH(2.0 eq) R\
THF, 0 C-r.t. 16h ,S
,S N
N H
H
91-4 Compound 91 Step 1: 2-fluoro-5-(methylsulfamoyl)benzoic acid [00381] To a solution of 91-1 (1 g, 4.2 mmol, 1 eq) in DCM (10 mL) was added 91-la (2 M, 6.3mL, 3 eq) at 0 C under N2 atmosphere. The mixture was stirred at this temperature for 20 min. LCMS showed reactant 1 was consumed completely and one main peak with MS
of 247 was detected(the sample was dissolved in Me0H). The reaction was quenched by adding HC1 (5 mL, 2M) and separated. The organic layer was washed with brine (10 mL), dried over Na2SO4 and filtered. The filtrate was concentrated to give a residue 91-2 (910 mg, crude). The crude product was used in next step directly without further purification. 1HNMR
(400MHz, DMSO-d6) 6 8.26 (dd, J= 2.3, 6.8 Hz, 1H), 8.02 (ddd, J=2.5, 4.4, 8.7 Hz, 1H), 7.66 (q, J= 4.8 Hz, 1H), 7.58 (dd, J = 8.8, 10.5 Hz, 1H), 2.43 (d, J = 4.8 Hz, 3H).
Step 2: methyl 2-fluoro-5-(methylsulfamoyl)benzoate [00382] To a solution of 91-2 (910 mg, 3.90 mmol, 1 eq) in Me0H (10 mL) was added H2SO4 (38.27 mg, 0.39 mmol, 20.8 uL, 0.1 eq). The mixture was stirred at 80 C
for 4 hr. TLC
showed reactant was consumed completely and one new spot was formed. The reaction mixture was concentrated and the residue was poured into water (20 mL). The aqueous layer was extracted with Et0Ac (5 mL*3), the combined organic layer was washed with brine (10 mL), dried over Na2SO4 and filtered. The filtrate was concentrated to give crude product 91-3 (900 mg, 3.64 mmol, 93.3% yield). The crude product was used in next step directly without further purification. IFINMR (400MHz, DMSO-d6) 6 8.27 (dd, J = 2.4, 6.7 Hz, 1H), 8.05 (ddd, J = 2.5, 4.3, 8.8 Hz, 1H), 7.70 (br d, J = 4.8 Hz, 1H), 7.63 (dd, J= 8.8, 10.5 Hz, 1H), 3.91 (s, 3H), 2.43 (d, J= 5.0 Hz, 3H).
Step 3: methyl 2-(cyclohexylamino)-5-(methylsulfamoyl)benzoate [00383] To a solution of methyl 91-3 (900 mg, 3.64 mmol, 1 eq) in DMSO (4 mL) was added 91-3a (722.0 mg, 7.3 mmol, 833.3 uL, 2.0 eq). The mixture was stirred at 130 C for 4h.
TLC showed reactant was consumed completely and one new spot was formed. LCMS
showed 50% desired MS. The reaction mixture was poured into water (20 mL) and extracted with Et0Ac(10 mL*3). The combined organic layer was washed with brine (10 mL), dried over Na2SO4 and filtered. The filtrate was concentrated to give a residue. The residue was purified by flash silica gel chromatography to give compound 91-4 (750 mg, 2.16 mmol, 59.3% yield).
LCMS (ESI): RT = 0.824 min, mass calc. for Ci5H22N2045 326.13, m/z found 326.9[M+H1+; 11-1 NMR (400MHz, DMSO-d6) 6 8.23 - 8.18 (m, 2H), 7.67 (dd, J = 2.3, 9.0 Hz, 1H), 7.21 (q, J = 5.2 Hz, 1H), 7.00 (d, J= 9.3 Hz, 1H), 3.84 (s, 3H), 3.64 - 3.52 (m, 1H), 2.35 (d, J = 5.3 Hz, 3H), 1.94 (br dd, J= 3.5, 8.8 Hz, 2H), 1.68 (br dd, J= 4.3, 9.0 Hz, 2H), 1.58 (br dd, J = 4.0, 8.5 Hz, 1H), 1.49 - 1.36 (m, 2H), 1.36 - 1.21 (m, 3H).
Step 4: 4-(cyclohexylamino)-N-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)benzenesulfonamide [00384] To a solution of 91-4 (100 mg, 0.31 mmol, 1 eq) in THF (5 mL) was added NaH
(24.5 mg, 0.61 mmol, 60% purity, 2.0 eq) at 0 C, the mixture was stirred for 30 min at this temperature. Then, 91-4a (45.4 mg, 0.61 mmol, 2.0 eq) was added and the mixture was allowed warmed to 10-15 C and stirred for 16hr. LCMS showed -39% of Reactant 91-4 was remained.
Several new peaks were shown on LCMS and -37% of desired compound was detected. The reaction was poured into sat. aq. NH4C1 (10 mL) and extracted with Et0Ac(5 mL*3). The combined organic layer was washed with brine (10 mL), dried over Na2SO4 and filtered to give a residue. The residue was purified by prep-HPLC to give Compound 91 (19.10 mg, 45.91 umol, 15% yield, HC1). LCMS (ESI): RT = 1.234 min, mass calc. for Ci6H22N4035 350.14, m/z found 351.0 [M+H1+; 1HNMR (400MHz, DMSO-d6) 6 8.23 (d, J= 2.3 Hz, 1H), 8.19 ( d, J=
7.5 Hz, 1H), 7.73 (dd, J= 2.3, 9.0 Hz, 1H), 7.30 (d, J= 5.3 Hz, 1H), 7.12 (d, J= 9.3 Hz, 1H), 3.85 (s, 1H), 3.73 - 3.62 (m, 1H), 2.46 (s, 3H), 2.39 (d, J= 5.3 Hz, 3H), 1.99 (d, J =
9.5 Hz, 2H), 1.70 (s, 2H), 1.61-1.58 (m, 1H), 1.49- 1.30 (m, 5H).
Example 88: N-methy1-3-(2-methy1-2H-tetrazol-5-y1)-4-43-(trifluoromethyl)phenyl)amino)benzenesulfonamide (Compound 92) N-N/
HFF
(Rµ N
F
HN-S
Preparation of Compound 92:
N-N/ OH /
F NI-N
HO I.F 1\11 92-la (2.25 eq) N
NH2 __________________________________________________________ F
µµ DIPEA (3.36 eq), 0 C:1 HN-Sµµ Cu(OAc)2 (2.27 eq), HN,Sµµ
0 02 (15 Psi),DCM,25 C,42 h I
92-1 Compound 92 [00385] To a suspension of the compound 92-1 (40 mg, 0.131 mmol, 1 eq, HC1), DIPEA
(57 mg, 0.441 mmol, 3.36 eq) and the compound 92-la (56 mg, 0.295 mmol, 2.25 eq) in DCM
(1 mL) was added Cu(OAc)2 (54 mg, 0.297 mmol, 2.27 eq) in one portion under 02(15 Psi). The reaction mixture was stirred at 25 C for 42 h. LCMS showed 26% of the starting material was remained and 32% of desired product was formed. The reaction mixture was filtered and concentrated in vacuum. LCMS showed 30 % of desired product was detected. HPLC
indicated 39% of desired product was formed. The residue was purified by prep-HPLC. LCMS
and NMR and HMBC confirmed that the product was Compound 92 (9.64 mg, 22.9 umol, 17.5%
yield). LCMS (ESI): RT = 0.808 min, mass calcd. For Ci6H15F3N602S, 412.09 m/z found 413.0[M+H1t 1HNMR (400MHz, CDC13) 6 9.55 (s, 1H), 8.71 (d, J = 2.40 Hz, 1H), 7.76 (dd, J
= 2.40, 9.20 Hz, 1H), 7.58 - 7.49 (m, 3H), 7.46 - 7.41 (m, 1H), 7.35 (d, J =
8.40 Hz, 1H), 4.48 (s, 3H), 4.43 - 4.35 (m, 1H), 2.72 (d, J= 5.60 Hz, 3H).
Example 89: N-methy1-3-(2-methy1-2H-tetrazol-5-y1)-4-42-(trifluoromethyl)phenyl)amino)benzenesulfonamide (Compound 93) N-N
N
,_,m,s , 0 Preparation of Compound 93:
N-N/ F F OH m /
Nii * OH N4 FFF
si c NH2 93-1 a (2.25 eq) C3µ1µ l N
õ HN
HN-S\µ DIPEA (3.36 eq), -S
Cu(OAc)2 (2.27 eq), / 0 1 02 (15 Psi),DCM,25 C,42 h 93-1 Compound 93 [00386] To a suspension of the compound 93-1 (40 mg, 0.13 mmol, 1 eq, HC1) ,DIPEA
(57 mg, 0.441 mmol, 3.36 eq) and the compound 93-la (56 mg, 0.295 mmol, 2.25 eq) in DCM
(1 mL) was added Cu(0Ac)2 (54 mg, 0.297 mmol, 2.27 eq) in one portion under 02(15 Psi). The reaction mixture was stirred at 25 C for 42 h. LCMS showed 47% of the starting material was remained and 23% of desired product was formed. The reaction mixture was filtered and concentrated in vacuum. LCMS showed 18% of desired product was detected. HPLC
indicated 26% of desired product was formed. The residue was purified by prep-HPLC. LCMS
and 1HNMR confirmed the product was Compound 93 (6.06 mg, 14.7 umol, 11.2%
yield). LCMS (ESI): RT = 0.789 min, mass calcd. For Ci6H15F3N602S, 412.09 m/z found 413.0[M+Hr 1HNMR (400MHz, CDC13) 6 9.54 (s, 1H), 8.76 (d, J = 2.00 Hz, 1H), 7.76 (d, J=
8.00 Hz, 1H), 7.72 (dd, J= 2.30, 8.80 Hz, 1H), 7.62 - 7.54 (m, 2H), 7.35 -7.28 (m, 1H), 7.21 (d, J= 8.80 Hz, 1H), 4.46 (s, 3H), 4.39 (br d, J= 5.50 Hz, 1H), 2.71 (d, J= 5.50 Hz, 3H).
Example 90: N-methy1-3-(2-methy1-2H-tetrazol-5-y1)-4-43-(trifluoromethoxy)phenyl)amino)benzenesulfonamide (Compound 94) 1-1\-11 0 F
µµ = )<F
HN-Sµµ
Preparation of Compound 94:
OH
N/
¨N HO N¨N/
' 410 0õF
rF
94-1a (2.25 eq) 0 F lei NH2 _____ DIPEA (3.36 eq), (R\ ei = )<F
HN,\Sµµ -Sµ
Cu(OAc)2 (2.27 eq), HN b 02 (15 Psi),DCM,rt,64 h 94-1 Compound 94 [00387] To a suspension of the compound 94-1 (40 mg, 0.131 mmol, 1 eq, HC1), DIPEA
(57 mg, 0.441 mmol, 3.36 eq) and the compound 94-la (61 mg, 0.296 mmol, 2.26 eq) in DCM
(1.5 mL) was added Cu(0Ac)2(54 mg, 0.297 mmol, 2.27 eq) in one portion under 02(15 Psi).
The mixture was stirred at 12 C for 64 h. LCMS showed 36% of the starting material was remained and 23% of desired product was formed. The reaction mixture was filtered and concentrated in vacuum. LCMS showed 17% of desired product was detected. HPLC
indicated 18% of desired product was formed. The residue was purified by prep-HPLC. LCMS
and NMR confirmed that the product was Compound 94 (5.35 mg, 12.5 umol, 9.5% yield).
LCMS (EST): RT = 0.815 min, mass calcd. For Ci6H15F3N603S, 428.09 m/z found 429.0[M+Ht 1HNMR (400MHz, CDC13) 6 9.52 (s, 1H), 8.71 (d, J = 2.2 Hz, 1H), 7.75 (dd, J =
2.20, 9.00 Hz, 1H), 7.47 - 7.35 (m, 2H), 7.24 (s, 1H), 7.19 (s, 1H), 7.07 - 7.00 (m, 1H), 4.48 (s, 3H), 4.31 (br d, J = 5.30 Hz, 1H), 2.72 (d, J = 5.50 Hz, 3H).
Example 91: N-methy1-3-(2-methy1-2H-tetrazol-5-y1)-4-44-(trifluoromethyl)phenyl)amino)benzenesulfonamide (Compound 95) N-N
N
F
HN,Sµµ
I F F
Preparation of Compound 95:
pH
N-N/ `1 .B
HO Ai =11 N=N
F
NN --N N FE NN
--N N
40 NH, 40 0 NH2 DIPEA (3.0 eq), 0 N
HNSµµ HNSµµ F N
F
Cu(OAc)2 (1.5 eq), HN HN
02(15 Psi),DCM,25 C,16 h F F
95-1 95-2 Compound 95 95-3 [00388] To a mixture of compound 95-1 and compound 95-2 (350 mg, 1.30 mmol, 1 eq), compound 95-la (370.4 mg, 1.95 mmol, 1.5 eq) in DCM (10 mL) was added Cu(0Ac)2 (354.2 mg, 1.95 mmol, 1.5 eq) followed by DIEA (504 mg, 3.90 mmol, 0.68 mL, 3 eq) under N2. The suspension was degassed under vacuum and purged with 02 several times. The mixture was stirred under 02 (15psi) at 25 C for 16 hours. LCMS showed that desired product was detected.
The reaction was filtered and concentrated. The crude product was purified by prep-HPLC to give Compound 95 (38.35 mg, 92.99 umol, 7.15% yield). 1HNMR and LCMS confirmed that desired product was obtained. LCMS (ESI): RT = 0.784 min, mass calcd. For Ci6H15F3N602S, 412.09 m/z found 412.9[M+Hr IFINMR (400MHz, CDC13) 6 9.62 (s, 1H), 8.71 (d, J
= 2.0 Hz, 1H), 7.77 (dd, J= 8.80, 2.40 Hz, 1H), 7.65 (d, J= 8.80 Hz, 2H), 7.48 (d, J =
8.40 Hz, 1H), 7.40 (d, J = 8.40 Hz, 2H), 4.48 (s, 3H), 4.33 (q, J = 5.60 Hz, 1H), 2.71 (d, J=
5.60 Hz, 3H).
Example 92: N-methy1-3-(1-methy1-1H-tetrazol-5-y1)-4-44-(trifluoromethyl)phenyl)amino)benzenesulfonamide (Compound 96) N=N
%
c2,),µ 110 010 F
HNb Preparation of Compound 96:
OH
HO
N=N 00 N=N
N F F
NH 96-1a (2.0 eq) C:\ Cu(OAc)2 (1.2 eq) (:)µµ 0101 .SNb DIPEA(3.0 eq) HN
DCM, 30 C, 16 h, HN,sb
The reaction was filtered and concentrated. The crude product was purified by prep-HPLC to give Compound 95 (38.35 mg, 92.99 umol, 7.15% yield). 1HNMR and LCMS confirmed that desired product was obtained. LCMS (ESI): RT = 0.784 min, mass calcd. For Ci6H15F3N602S, 412.09 m/z found 412.9[M+Hr IFINMR (400MHz, CDC13) 6 9.62 (s, 1H), 8.71 (d, J
= 2.0 Hz, 1H), 7.77 (dd, J= 8.80, 2.40 Hz, 1H), 7.65 (d, J= 8.80 Hz, 2H), 7.48 (d, J =
8.40 Hz, 1H), 7.40 (d, J = 8.40 Hz, 2H), 4.48 (s, 3H), 4.33 (q, J = 5.60 Hz, 1H), 2.71 (d, J=
5.60 Hz, 3H).
Example 92: N-methy1-3-(1-methy1-1H-tetrazol-5-y1)-4-44-(trifluoromethyl)phenyl)amino)benzenesulfonamide (Compound 96) N=N
%
c2,),µ 110 010 F
HNb Preparation of Compound 96:
OH
HO
N=N 00 N=N
N F F
NH 96-1a (2.0 eq) C:\ Cu(OAc)2 (1.2 eq) (:)µµ 0101 .SNb DIPEA(3.0 eq) HN
DCM, 30 C, 16 h, HN,sb
96-1 Compound 96 [00389] A solution of compound 96-1 (100 mg, 0.328 mmol, 1.0 eq, HC1), compound 96-la (125 mg, 0.656 mmol, 2.0 eq), Cu(0Ac)2 (72 mg, 0.39 mmol, 1.2 eq) and DIPEA
(127 mg, 0.984 mmol, 3.0 eq) in DCM (4 mL) was stirred at 30 C for 16 hours under 02.
The mixture was diluted with water (20 mL) and the resultant mixture was extracted with DCM (50 mL * 3).
The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the residue. The residue was purified by preparative high performance liquid chromatography.
The pure fractions were collected and the volatiles were removed under vacuum.
The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely. Compound 96 (14.04 mg, 10% yield) was obtained.
LCMS (ESI): RT = 0.784 min, mass calcd. for C16H15F3N602S 412.09, m/z found 413.0 [M+H1+, 1HNMR (400MHz, CDC13) 6 9.24 (s, 1H), 8.02 (d, J= 2.3 Hz, 1H), 7.82 (dd, J=
2.0, 8.8 Hz, 1H), 7.64 (d, J= 8.5 Hz, 2H), 7.55 (d, J= 9.0 Hz, 1H), 7.34 (d, J= 8.3 Hz, 2H), 4.41 - 4.34 (m, 1H), 4.32 (s, 3H), 2.70 (d, J= 5.3 Hz, 3H).
Example 93: N-methy1-3-(1-methy1-1H-tetrazol-5-y1)-4-43-(trifluoromethyl)phenyl)amino)benzenesulfonamide (Compound 97) N=N
--N 1\1 CZ\ N
F
HN-Sµµ
Preparation of Compound 97:
N OH F N NN
(127 mg, 0.984 mmol, 3.0 eq) in DCM (4 mL) was stirred at 30 C for 16 hours under 02.
The mixture was diluted with water (20 mL) and the resultant mixture was extracted with DCM (50 mL * 3).
The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the residue. The residue was purified by preparative high performance liquid chromatography.
The pure fractions were collected and the volatiles were removed under vacuum.
The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely. Compound 96 (14.04 mg, 10% yield) was obtained.
LCMS (ESI): RT = 0.784 min, mass calcd. for C16H15F3N602S 412.09, m/z found 413.0 [M+H1+, 1HNMR (400MHz, CDC13) 6 9.24 (s, 1H), 8.02 (d, J= 2.3 Hz, 1H), 7.82 (dd, J=
2.0, 8.8 Hz, 1H), 7.64 (d, J= 8.5 Hz, 2H), 7.55 (d, J= 9.0 Hz, 1H), 7.34 (d, J= 8.3 Hz, 2H), 4.41 - 4.34 (m, 1H), 4.32 (s, 3H), 2.70 (d, J= 5.3 Hz, 3H).
Example 93: N-methy1-3-(1-methy1-1H-tetrazol-5-y1)-4-43-(trifluoromethyl)phenyl)amino)benzenesulfonamide (Compound 97) N=N
--N 1\1 CZ\ N
F
HN-Sµµ
Preparation of Compound 97:
N OH F N NN
97-la 41 (2.25 eq) 1 NH2 F
DIPEA (3.36 eq), 0µµ
HN,µSµµ HN-%
Cu(OAc)2 (2.27 eq), I 02 (15 Psi),00M,25 C,42 h I
97-1 Compound 97 [00390] To a suspension of compound 97-1 (40 mg, 0.131 mmol, 1 eq, HC1), DIPEA (57 mg, 0.441 mmol, 3.36 eq) and compound 97-la (56 mg, 0.295 mmol, 2.25 eq) in DCM (1 mL) was added Cu(0Ac)2 (54 mg, 0.297 mmol, 2.27 eq) in one portion under 02(15 Psi). The reaction mixture was stirred at 25 C for 42 h. LCMS showed 26% of the starting material was remained and 32% of desired product was formed. The reaction mixture was filtered and concentrated in vacuum. LCMS showed 30% of desired product was detected. HPLC
indicated 39% of desired product was formed. The residue was purified by prep-HPLC to give Compound 97 (2.80 mg, 6.7 umol, 5.1% yield). LCMS (ESI): RT = 0.748 min, mass calcd.
For Ci6H15F3N602S, 412.09 m/z found 412.9[M+H1t IFINMR (400MHz, CDC13) 6 9.21 (s, 1H), 8.03 (d, J= 2.00 Hz, 1H), 7.82 (dd, J= 2.00, 8.80 Hz, 1H), 7.57 - 7.50 (m, 2H), 7.47 - 7.40 (m, 3H), 4.43 - 4.35 (br d, J= 5.3 Hz, 1H), 4.33 (s, 3H), 2.70 (d, J = 5.60 Hz, 3H).
Example 94: N-methyl-3-(1-methyl-1H-tetrazol-5-y1)-4-42-(trifluoromethyl)phenyl)amino)benzenesulfonamide (Compound 98) -N I
F F
1-1N-S%
*
Preparation of Compound 98:
N=N F F OH
B.OH
-N I
F F e F i NH2 98-la (2.25 eq) HN,µ% DIPEA (3.36 eq), __ ).
FIN'S%
I o Cu(OAc)2 (2.27 eq), /
02 (15 Psi),DCM,25 C,42 h
DIPEA (3.36 eq), 0µµ
HN,µSµµ HN-%
Cu(OAc)2 (2.27 eq), I 02 (15 Psi),00M,25 C,42 h I
97-1 Compound 97 [00390] To a suspension of compound 97-1 (40 mg, 0.131 mmol, 1 eq, HC1), DIPEA (57 mg, 0.441 mmol, 3.36 eq) and compound 97-la (56 mg, 0.295 mmol, 2.25 eq) in DCM (1 mL) was added Cu(0Ac)2 (54 mg, 0.297 mmol, 2.27 eq) in one portion under 02(15 Psi). The reaction mixture was stirred at 25 C for 42 h. LCMS showed 26% of the starting material was remained and 32% of desired product was formed. The reaction mixture was filtered and concentrated in vacuum. LCMS showed 30% of desired product was detected. HPLC
indicated 39% of desired product was formed. The residue was purified by prep-HPLC to give Compound 97 (2.80 mg, 6.7 umol, 5.1% yield). LCMS (ESI): RT = 0.748 min, mass calcd.
For Ci6H15F3N602S, 412.09 m/z found 412.9[M+H1t IFINMR (400MHz, CDC13) 6 9.21 (s, 1H), 8.03 (d, J= 2.00 Hz, 1H), 7.82 (dd, J= 2.00, 8.80 Hz, 1H), 7.57 - 7.50 (m, 2H), 7.47 - 7.40 (m, 3H), 4.43 - 4.35 (br d, J= 5.3 Hz, 1H), 4.33 (s, 3H), 2.70 (d, J = 5.60 Hz, 3H).
Example 94: N-methyl-3-(1-methyl-1H-tetrazol-5-y1)-4-42-(trifluoromethyl)phenyl)amino)benzenesulfonamide (Compound 98) -N I
F F
1-1N-S%
*
Preparation of Compound 98:
N=N F F OH
B.OH
-N I
F F e F i NH2 98-la (2.25 eq) HN,µ% DIPEA (3.36 eq), __ ).
FIN'S%
I o Cu(OAc)2 (2.27 eq), /
02 (15 Psi),DCM,25 C,42 h
98-1 Compound 98 [00391] To a suspension of compound 98-1 (40 mg, 0.131 mmol, 1 eq, HC1), DIPEA (57 mg, 0.441 mmol, 3.36 eq) and compound 98-la (56 mg, 0.295 mmol, 2.25 eq) in DCM (1 mL) was added Cu(0Ac)2 (54 mg, 0.297 mmol, 2.27 eq) in one portion under 02(15 Psi). The reaction mixture was stirred at 25 C for 42 h. LCMS showed 47% of the starting material was remained and 23% of desired product was formed. The reaction mixture was filtered and concentrated in vacuum. LCMS showed 18% of desired product was detected. HPLC
indicated 26% of desired product was formed. The residue was purified by prep-HPLC to give Compound 98 (2.22 mg, 5.4 umol, 4.1% yield). LCMS (ESI): RT = 0.749 min, mass calcd. For C16H15F3N602S, 412.09 m/z found 413.1[M+H1 1HNMR (400MHz, CDC13) 6 9.22 (s, 1H), 8.04 (d, J= 2.00 Hz, 1H), 7.79 - 7.73 (m, 2H), 7.63 - 7.56 (m, 1H), 7.45 (d, J
= 8.00 Hz, 1H), 7.35 (t, J = 7.50 Hz, 1H), 7.17 (d, J = 9.00 Hz, 1H), 4.38 -4.32 (m, 4H), 2.70 (d, J= 5.50 Hz, 3H).
Example 95: N-methyl-3-(1-methyl-1H-tetrazol-5-y1)-4-44-(trifluoromethoxy)phenyl)amino)benzenesulfonamide (Compound 99) N=N
,-N N
czµ N
HN,Sµ`
I
Preparation of Compound 99:
OH
N=I\; HOB io F
,F N=N;
I* NH2 99-la (2.25 eq) czµ N
0 )<F
DIPEA (3.36 eq), HN,Sµµ HN,Sµ` 0 F
Cu(OAc)2 (2.27 eq), 0 02 (15 Psi),00M,rt,64 h
indicated 26% of desired product was formed. The residue was purified by prep-HPLC to give Compound 98 (2.22 mg, 5.4 umol, 4.1% yield). LCMS (ESI): RT = 0.749 min, mass calcd. For C16H15F3N602S, 412.09 m/z found 413.1[M+H1 1HNMR (400MHz, CDC13) 6 9.22 (s, 1H), 8.04 (d, J= 2.00 Hz, 1H), 7.79 - 7.73 (m, 2H), 7.63 - 7.56 (m, 1H), 7.45 (d, J
= 8.00 Hz, 1H), 7.35 (t, J = 7.50 Hz, 1H), 7.17 (d, J = 9.00 Hz, 1H), 4.38 -4.32 (m, 4H), 2.70 (d, J= 5.50 Hz, 3H).
Example 95: N-methyl-3-(1-methyl-1H-tetrazol-5-y1)-4-44-(trifluoromethoxy)phenyl)amino)benzenesulfonamide (Compound 99) N=N
,-N N
czµ N
HN,Sµ`
I
Preparation of Compound 99:
OH
N=I\; HOB io F
,F N=N;
I* NH2 99-la (2.25 eq) czµ N
0 )<F
DIPEA (3.36 eq), HN,Sµµ HN,Sµ` 0 F
Cu(OAc)2 (2.27 eq), 0 02 (15 Psi),00M,rt,64 h
99-1 Compound 99 [00392] To a suspension of compound 99-1 (40 mg, 0.131 mmol, 1 eq, HC1), DIPEA (57 mg, 0.441mmo1, 3.36 eq) and compound 99-la (61 mg, 0.296 mmol, 2.26 eq) in DCM
(1.5 mL) was added Cu(0Ac)2 (54 mg, 0.297 mmol, 2.27 eq) in one portion under 02(15 Psi). The mixture was stirred at 12 C for 64 h. LCMS showed 46% of the starting material was remained and 15% of desired product was formed. The reaction mixture was filtered and concentrated in vacuum. LCMS showed 11% of desired product was detected. HPLC indicated 9% of desired product was formed. The residue was purified by prep-HPLC to give Compound 99 (2.89 mg, 6.3 umol, 4.8% yield). LCMS (ESI): RT = 0.769 min, mass calcd. For Ci6H15F3N603S, 428.09 m/z found 429.0[M+H1t 1FINMR (400MHz, CDC13) 6 9.08 (s, 1H), 8.01 (d, J= 2.00 Hz, 1H), 7.78 (dd, J= 2.30, 9.00 Hz, 1H), 7.36 (d, J= 9.00 Hz, 1H), 7.28 (s, 2H), 4.43 (d, J= 5.00 Hz, 1H), 4.33 (s, 3H), 2.69 (d, J= 5.30 Hz, 3H).
Example 96: N-methyl-3-(1-methyl-1H-tetrazol-5-y1)-4-43-(trifluoromethoxy)phenyl)amino)benzenesulfonamide (Compound 100) N=N
õ-N zN
= N (:)F
(:)µµ
HN,Sµµ
Preparation of Compound 100:
OH
HOB OF
N.nt --N NN
4/ NH2 100-1a (2.25 eq) N 1::3F 1 Ciµµ DIPEA (3.36 eq), HN,Sµµ Cu(OAc)2 (2.27 eq), HN,Sµµ
I 0 02 (15 Psi),DCM,rt,64 h I0
(1.5 mL) was added Cu(0Ac)2 (54 mg, 0.297 mmol, 2.27 eq) in one portion under 02(15 Psi). The mixture was stirred at 12 C for 64 h. LCMS showed 46% of the starting material was remained and 15% of desired product was formed. The reaction mixture was filtered and concentrated in vacuum. LCMS showed 11% of desired product was detected. HPLC indicated 9% of desired product was formed. The residue was purified by prep-HPLC to give Compound 99 (2.89 mg, 6.3 umol, 4.8% yield). LCMS (ESI): RT = 0.769 min, mass calcd. For Ci6H15F3N603S, 428.09 m/z found 429.0[M+H1t 1FINMR (400MHz, CDC13) 6 9.08 (s, 1H), 8.01 (d, J= 2.00 Hz, 1H), 7.78 (dd, J= 2.30, 9.00 Hz, 1H), 7.36 (d, J= 9.00 Hz, 1H), 7.28 (s, 2H), 4.43 (d, J= 5.00 Hz, 1H), 4.33 (s, 3H), 2.69 (d, J= 5.30 Hz, 3H).
Example 96: N-methyl-3-(1-methyl-1H-tetrazol-5-y1)-4-43-(trifluoromethoxy)phenyl)amino)benzenesulfonamide (Compound 100) N=N
õ-N zN
= N (:)F
(:)µµ
HN,Sµµ
Preparation of Compound 100:
OH
HOB OF
N.nt --N NN
4/ NH2 100-1a (2.25 eq) N 1::3F 1 Ciµµ DIPEA (3.36 eq), HN,Sµµ Cu(OAc)2 (2.27 eq), HN,Sµµ
I 0 02 (15 Psi),DCM,rt,64 h I0
100-1 Compound 100 [00393] To a suspension of compound 100-1 (40 mg, 0.131 mmol, 1 eq, HC1), DIPEA (57 mg, 0.441 mmol, 3.36 eq) and compound 100-la (61 mg, 0.296 mmol, 2.26 eq) in DCM (1.5 mL) was added Cu(0Ac)2 (54 mg, 0.297 mmol, 2.27 eq) in one portion under 02(15 Psi). The mixture was stirred at 12 C for 64 h. LCMS showed 36% of the starting material was remained and 23% of desired product was formed. The reaction mixture was filtered and concentrated in vacuum. LCMS showed 17% of desired product was detected. HPLC indicated 18% of desired product was formed. The residue was purified by prep-HPLC to provide Compound 100 (2.61 mg, 5.73 umol, 4.4% yield). LCMS (ESI): RT = 0.764 min, mass calcd. For Ci6H15F3N603S, 428.09 m/z found 429.0[M+Hr 1H NMR (400MHz, CDC13) 6 9.15 (s, 1H), 8.02 (d, J
= 2.3 Hz, 1H), 7.81 (dd, J= 2.10, 8.90 Hz, 1H), 7.49 - 7.39 (m, 2H), 7.22 - 7.16 (m, 1H), 7.13 (s, 1H), 7.05 (br d, J= 8.30 Hz, 1H), 4.44 - 4.36 (m, 1H), 4.33 (s, 3H), 2.70 (d, J= 5.30 Hz, 3H).
Example 97: N-methyl-3-(1-methyl-1H-tetrazol-5-y1)-4-42-(trifluoromethoxy)phenyl)amino)benzenesulfonamide (Compound 101) NN F
-N N
H F
= s/ n N
,õ,- S
I
Preparation of Compound 101:
1`1=1`; HO'la -N N
--N N F
NH2 101-1a (2.25 eq) 1NF
õ-S
HN-S \µ DIPEA (3.36 eq), n IN \\
I Cu(OAc)2 (2.27 eq), 1 0 02 (15 Psi),00MA,64 h
= 2.3 Hz, 1H), 7.81 (dd, J= 2.10, 8.90 Hz, 1H), 7.49 - 7.39 (m, 2H), 7.22 - 7.16 (m, 1H), 7.13 (s, 1H), 7.05 (br d, J= 8.30 Hz, 1H), 4.44 - 4.36 (m, 1H), 4.33 (s, 3H), 2.70 (d, J= 5.30 Hz, 3H).
Example 97: N-methyl-3-(1-methyl-1H-tetrazol-5-y1)-4-42-(trifluoromethoxy)phenyl)amino)benzenesulfonamide (Compound 101) NN F
-N N
H F
= s/ n N
,õ,- S
I
Preparation of Compound 101:
1`1=1`; HO'la -N N
--N N F
NH2 101-1a (2.25 eq) 1NF
õ-S
HN-S \µ DIPEA (3.36 eq), n IN \\
I Cu(OAc)2 (2.27 eq), 1 0 02 (15 Psi),00MA,64 h
101-1 Compound 101 [00394] To a suspension of compound 101-1 (40 mg, 0.131 mmol, 1 eq, HC1) ,DIPEA (57 mg, 0.441 mmol, 3.36 eq) and compound 101-la (61 mg, 0.296 mmol, 2.26 eq) in DCM (1.5 mL) was added Cu(0Ac)2 (54 mg, 0297 mmol, 2.27 eq) in one portion under 02(15 Psi). The reaction mixture was stirred at 12 C for 64 h. LCMS showed 45% of the starting material was remained and 16% of desired product was formed. The reaction mixture was filtered and concentrated in vacuum. LCMS showed 12% of desired product was detected. HPLC
indicated 14% of desired product was formed. The residue was purified by prep-HPLC to provide Compound 101 (2.86 mg, 6.3 umol, 4.8% yield). LCMS (ESI): RT = 0.754 min, mass calcd. For Ci6H15F3N603S, 428.09 m/z found 429.0[M+Ht IFINMR (400MHz, CDC13) 6 9.06 (s, 1H), 8.01 (d, J= 2.30 Hz, 1H), 7.80 (dd, J = 2.10, 8.90 Hz, 1H), 7.44 (dd, J = 1.50, 8.00 Hz, 1H), 7.38 (br d, J= 8.00 Hz, 1H), 7.36 - 7.28 (m, 2H), 7.26 - 7.21 (m, 1H), 4.46 - 4.39 (m, 1H), 4.31 (s, 3H), 2.69 (d, J = 5.30 Hz, 3H).
Example 98: N-methy1-3-(2-methy1-2H-tetrazol-5-y1)-4-42-(trifluoromethoxy)phenyl)amino)benzenesulfonamide (Compound 102) N-N
N
H F
(Rµ N
-S
HN
Preparation of Compound 102:
/ OHO
N¨N F
N¨N
HO -e N"
NH2 102-la (2.25 eq) IR\ 41" N 411 HN,Sµµ DIPEA (3.36 eq), n IN/ \\
I o CU(OAC)2 (2.27 eq), I 0 02 (15 Psi),DCM,rt,64 h
indicated 14% of desired product was formed. The residue was purified by prep-HPLC to provide Compound 101 (2.86 mg, 6.3 umol, 4.8% yield). LCMS (ESI): RT = 0.754 min, mass calcd. For Ci6H15F3N603S, 428.09 m/z found 429.0[M+Ht IFINMR (400MHz, CDC13) 6 9.06 (s, 1H), 8.01 (d, J= 2.30 Hz, 1H), 7.80 (dd, J = 2.10, 8.90 Hz, 1H), 7.44 (dd, J = 1.50, 8.00 Hz, 1H), 7.38 (br d, J= 8.00 Hz, 1H), 7.36 - 7.28 (m, 2H), 7.26 - 7.21 (m, 1H), 4.46 - 4.39 (m, 1H), 4.31 (s, 3H), 2.69 (d, J = 5.30 Hz, 3H).
Example 98: N-methy1-3-(2-methy1-2H-tetrazol-5-y1)-4-42-(trifluoromethoxy)phenyl)amino)benzenesulfonamide (Compound 102) N-N
N
H F
(Rµ N
-S
HN
Preparation of Compound 102:
/ OHO
N¨N F
N¨N
HO -e N"
NH2 102-la (2.25 eq) IR\ 41" N 411 HN,Sµµ DIPEA (3.36 eq), n IN/ \\
I o CU(OAC)2 (2.27 eq), I 0 02 (15 Psi),DCM,rt,64 h
102-1 Compound 102 [00395] To a suspension of compound 102-1 (40 mg, 0.131 mmol, 1 eq, HC1) ,DIPEA (57 mg, 0.441 mmol, 3.36 eq) and compound 102-la (61 mg, 0.296 mmol, 2.26 eq) in DCM (1.5 mL) was added Cu(0Ac)2 (54 mg, 0297 mmol, 2.27 eq) in one portion under 02(15 Psi).The reaction mixture was stirred at 12 C for 64 h. LCMS showed 45% of the starting material was remained and 16% of desired product was formed. The reaction mixture was filtered and concentrated in vacuum. LCMS showed 12% of desired product was detected. HPLC
indicated 14% of desired product was formed. The residue was purified by prep-HPLC to provide Compound 102 (4.84 mg, 11.3 umol, 8.6% yield). LCMS (ESI): RT = 0.808 min, mass calcd. For Ci6H15F3N603S, 428.09 m/z found 429.0[M+Ht IFINMR (400MHz, CDC13) 6 9.52 (s, 1H), 8.71 (d, J= 2.30 Hz, 1H), 7.75 (dd, J= 2.10, 8.90 Hz, 1H), 7.46 -7.37 (m, 2H), 7.25 (br d, J = 1.30 Hz, 1H), 7.19 (s, 1H), 7.04 (br d, J = 8.30 Hz, 1H), 4.48 (s, 3H), 4.31 (br d, J= 5.50 Hz, 1H), 2.72 (d, J = 5.50 Hz, 3H).
Example 99: N-methy1-3-(2-methy1-2H-tetrazol-5-y1)-4-44-(trifluoromethoxy)phenyl)amino)benzenesulfonamide (Compound 103) N¨N
/1\1 czµ N
)<F
HN,Sµ` 0 F
I
Preparation of Compound 103:
/ OH
N¨N
HO = )F<F N¨N
, F
NH 2 103-la (2.25 eq) µµ N
=C'µµ DIPEA (3.36 eq), (:)=
)<F
HN,S\0 Cu(OAc)2 (2.27 eq), ,Sµb 0 F
02 (15 Psi),DCM,rt,64 h
indicated 14% of desired product was formed. The residue was purified by prep-HPLC to provide Compound 102 (4.84 mg, 11.3 umol, 8.6% yield). LCMS (ESI): RT = 0.808 min, mass calcd. For Ci6H15F3N603S, 428.09 m/z found 429.0[M+Ht IFINMR (400MHz, CDC13) 6 9.52 (s, 1H), 8.71 (d, J= 2.30 Hz, 1H), 7.75 (dd, J= 2.10, 8.90 Hz, 1H), 7.46 -7.37 (m, 2H), 7.25 (br d, J = 1.30 Hz, 1H), 7.19 (s, 1H), 7.04 (br d, J = 8.30 Hz, 1H), 4.48 (s, 3H), 4.31 (br d, J= 5.50 Hz, 1H), 2.72 (d, J = 5.50 Hz, 3H).
Example 99: N-methy1-3-(2-methy1-2H-tetrazol-5-y1)-4-44-(trifluoromethoxy)phenyl)amino)benzenesulfonamide (Compound 103) N¨N
/1\1 czµ N
)<F
HN,Sµ` 0 F
I
Preparation of Compound 103:
/ OH
N¨N
HO = )F<F N¨N
, F
NH 2 103-la (2.25 eq) µµ N
=C'µµ DIPEA (3.36 eq), (:)=
)<F
HN,S\0 Cu(OAc)2 (2.27 eq), ,Sµb 0 F
02 (15 Psi),DCM,rt,64 h
103-1 Compound 103 [00396] To a suspension of the compound 103-1 (40 mg, 0.131 mmol, 1 eq, HC1), DIPEA
(57 mg, 0.441 mmol, 3.36 eq) and the compound 103-la (61 mg, 0.296 mmol, 2.26 eq) in DCM
(1.5 mL) was added Cu(0Ac)2 (54 mg, 0.297 mmol, 2.27 eq) in one portion under 02(15 Psi).
The mixture was stirred at 12 C for 64 h. LCMS showed 46% of the starting material was remained and 15% of desired product was formed. The reaction mixture was filtered and concentrated in vacuum. LCMS showed 11% of desired product was detected. HPLC
indicated 9% of desired product was formed. The residue was purified by prep-HPLC to provide Compound 103 (3.65 mg, 8.5 umol, 6.5% yield). LCMS (ESI): RT = 0.824 min, mass calcd. For Ci6H15F3N603S, 428.09 m/z found 429.0[M+Hr 1HNMR (400MHz, CDC13) 6 9.45 (s, 1H), 8.70 (d, J= 2.30 Hz, 1H), 7.73 (dd, J= 2.30, 8.80 Hz, 1H), 7.37 - 7.33 (m, 2H), 7.29 (d, J = 3.80 Hz, 3H), 4.48 (s, 3H), 4.29 (br d, J= 5.50 Hz, 1H), 2.71 (d, J = 5.50 Hz, 3H).
Example 100: 4-((2,3-difluorophenyl)amino)-N-methyl-3-(2-methyl-2H-tetrazol-5-yl)benzenesulfonamide (Compound 104) and 4-((2,3-difluorophenyl)amino)-N-methyl-3-(1-methyl-1H-tetrazol-5-yl)benzenesulfonamide (Compound 106) N¨N
--N N
N F N F
-S HN-S
HN
Compound 104 Compound 106 Preparation of Compound 104 and Compound 106:
OH F
N-j{ H0B * F N-N/
--N
N Ni' N=N
N
(57 mg, 0.441 mmol, 3.36 eq) and the compound 103-la (61 mg, 0.296 mmol, 2.26 eq) in DCM
(1.5 mL) was added Cu(0Ac)2 (54 mg, 0.297 mmol, 2.27 eq) in one portion under 02(15 Psi).
The mixture was stirred at 12 C for 64 h. LCMS showed 46% of the starting material was remained and 15% of desired product was formed. The reaction mixture was filtered and concentrated in vacuum. LCMS showed 11% of desired product was detected. HPLC
indicated 9% of desired product was formed. The residue was purified by prep-HPLC to provide Compound 103 (3.65 mg, 8.5 umol, 6.5% yield). LCMS (ESI): RT = 0.824 min, mass calcd. For Ci6H15F3N603S, 428.09 m/z found 429.0[M+Hr 1HNMR (400MHz, CDC13) 6 9.45 (s, 1H), 8.70 (d, J= 2.30 Hz, 1H), 7.73 (dd, J= 2.30, 8.80 Hz, 1H), 7.37 - 7.33 (m, 2H), 7.29 (d, J = 3.80 Hz, 3H), 4.48 (s, 3H), 4.29 (br d, J= 5.50 Hz, 1H), 2.71 (d, J = 5.50 Hz, 3H).
Example 100: 4-((2,3-difluorophenyl)amino)-N-methyl-3-(2-methyl-2H-tetrazol-5-yl)benzenesulfonamide (Compound 104) and 4-((2,3-difluorophenyl)amino)-N-methyl-3-(1-methyl-1H-tetrazol-5-yl)benzenesulfonamide (Compound 106) N¨N
--N N
N F N F
-S HN-S
HN
Compound 104 Compound 106 Preparation of Compound 104 and Compound 106:
OH F
N-j{ H0B * F N-N/
--N
N Ni' N=N
N
104-la (2 eq) 0 Ahl HN0 NH2 + NH2 CU(OAC)2 (1 eq), DIPEA
(3 eq) HN N F HN c3µs = N F
___________________________________________ 0µ =
Compound 104 Compound 106 [00397] To a mixture of compound 104-1 (0.1 g, 0.22 mmol, 1.0 eq, HC1) and compound 104-la (70 mg, 0.45 mmol, 2.0 eq) in DCM (4 mL) were added Cu(0Ac)2 (41 mg, 0.22 mmol, 1.0 eq) and DIPEA (87 mg, 0.67 mmol, 117 uL, 3.0 eq) under 02(15 psi). The mixture was stirred at 25 C for 16 h. LCMS showed 6% of the desired product was detected and 30% of the starting material was remained. Compound 104-la (70 mg, 0.45 mmol, 2.0 eq), Cu(0Ac)2 (41 mg, 0.22 mmol, 1.0 eq) and DIPEA (87 mg, 0.67 mmol, 116 uL, 3.0 eq) were added. The mixture was stirred at 35 C for 36 h under 02 (15 psi). The reaction was monitored by LCMS.
The product was isolated and the filtrate was concentrated. The residue was purified by prep-HPLC to give Compound 104 (4 mg, 11 umol, 5% yield) and Compound 106 (10 mg).
Compound 106 was re-purified by prep-TLC to give Compound 106 (6.0 mg, 16 umol, 7%
yield).
[00398] Compound 104: LCMS (ESI): RT = 0.749 min, mass calc. for Ci5Hi4F2N602S
380.09, m/z found 380.9 [M+H1+; 1HNMR (400 MHz, CDC13) 6 9.39 (s, 1H), 8.73 (d, J = 2.3 Hz, 1H), 7.76 (dd, J= 2.3, 8.8 Hz, 1H), 7.22 (d, J= 8.8 Hz, 2H), 7.16 - 7.07 (m, 1H), 7.06 - 6.96 (m, 1H), 4.48 (s, 3H), 4.27 (d, J= 5.5 Hz, 1H), 2.71 (d, J = 5.5 Hz, 3H).
[00399] Compound 106: LCMS (ESI): RT = 0.677 min, mass calc. for Ci5Hi4F2N602S
380.09, m/z found 380.9 [M+H1+; 1HNMR (400 MHz, CDC13) 6 9.03 (s, 1H), 8.02 (d, J = 2.0 Hz, 1H), 7.81 (d, J= 8.8 Hz, 1H), 7.20 (d, J= 8.8 Hz, 1H), 7.15 - 7.10 (m, 2H), 7.09 - 7.00 (m, 1H), 4.33 (s, 4H), 2.69 (d, J= 5.5 Hz, 3H).
Example 101: 4-(cyclohexylamino)-N-methyl-3-(5-methyl-1,3,4-oxadiazol-2-yl)benzenesulfonamide (Compound 105) -S
HN
Preparation of Compound 105:
NH2NH2H20 (2.0 mL) NH2 2LCI
(3 eq) HN N F HN c3µs = N F
___________________________________________ 0µ =
Compound 104 Compound 106 [00397] To a mixture of compound 104-1 (0.1 g, 0.22 mmol, 1.0 eq, HC1) and compound 104-la (70 mg, 0.45 mmol, 2.0 eq) in DCM (4 mL) were added Cu(0Ac)2 (41 mg, 0.22 mmol, 1.0 eq) and DIPEA (87 mg, 0.67 mmol, 117 uL, 3.0 eq) under 02(15 psi). The mixture was stirred at 25 C for 16 h. LCMS showed 6% of the desired product was detected and 30% of the starting material was remained. Compound 104-la (70 mg, 0.45 mmol, 2.0 eq), Cu(0Ac)2 (41 mg, 0.22 mmol, 1.0 eq) and DIPEA (87 mg, 0.67 mmol, 116 uL, 3.0 eq) were added. The mixture was stirred at 35 C for 36 h under 02 (15 psi). The reaction was monitored by LCMS.
The product was isolated and the filtrate was concentrated. The residue was purified by prep-HPLC to give Compound 104 (4 mg, 11 umol, 5% yield) and Compound 106 (10 mg).
Compound 106 was re-purified by prep-TLC to give Compound 106 (6.0 mg, 16 umol, 7%
yield).
[00398] Compound 104: LCMS (ESI): RT = 0.749 min, mass calc. for Ci5Hi4F2N602S
380.09, m/z found 380.9 [M+H1+; 1HNMR (400 MHz, CDC13) 6 9.39 (s, 1H), 8.73 (d, J = 2.3 Hz, 1H), 7.76 (dd, J= 2.3, 8.8 Hz, 1H), 7.22 (d, J= 8.8 Hz, 2H), 7.16 - 7.07 (m, 1H), 7.06 - 6.96 (m, 1H), 4.48 (s, 3H), 4.27 (d, J= 5.5 Hz, 1H), 2.71 (d, J = 5.5 Hz, 3H).
[00399] Compound 106: LCMS (ESI): RT = 0.677 min, mass calc. for Ci5Hi4F2N602S
380.09, m/z found 380.9 [M+H1+; 1HNMR (400 MHz, CDC13) 6 9.03 (s, 1H), 8.02 (d, J = 2.0 Hz, 1H), 7.81 (d, J= 8.8 Hz, 1H), 7.20 (d, J= 8.8 Hz, 1H), 7.15 - 7.10 (m, 2H), 7.09 - 7.00 (m, 1H), 4.33 (s, 4H), 2.69 (d, J= 5.5 Hz, 3H).
Example 101: 4-(cyclohexylamino)-N-methyl-3-(5-methyl-1,3,4-oxadiazol-2-yl)benzenesulfonamide (Compound 105) -S
HN
Preparation of Compound 105:
NH2NH2H20 (2.0 mL) NH2 2LCI
105-2 41 0 105-4 (1.5 eq=
l.
czN Et3N (3 eq) 0,µ N Et0H, reflux, 16 h N
= DCM, rt, 16 h -S -S
HN HN
Burgess Reagent (2.0 eq) 40:1 N DCM, MW, 9000, 1 h 0 HN' = 0 I
105-5 Compound 105 Step 1: 4-(cyclohexylamino)-3-(hydrazinecarbony1)-N-methyl-benzenesulfonamide [00400] To a solution of compound 105-1 (0.2 g, 0.61 mmol, 1.0 eq) in Et0H
(5.0 mL) was added compound 105-2 (36.8 mg, 0.74 mmol, 35.7 uL, 1.2 eq). The resulted mixture was stirred at 80 C for 16 hr. LCMS showed desired compound was found. TLC showed new spots appeared and the starting material was consumed completely. The reaction mixture was concentrated under reduced pressure to give a crude product. The crude product was purified by column chromatography over silica gel to give compound 105-3 (0.1 g, 0.306 mmol, 50.0%
yield). LCMS (ESI): RT = 0.665 min, mass calc. for C14H22N403S 326.14 m/z found 326.9 [M+H]+.
Step 2: 3-(acetamidocarbamoy1)-4-(cyclohexylamino)-N-methyl-benzenesulfonamide [00401] To a solution of compound 105-4 (36.1 mg, 0.46 mmol, 32.8 uL, 1.5 eq) and TEA
(62.0 mg, 0.61 mmol, 85.3 uL, 2.0 eq) in DCM (3.0 mL) was added compound 105-3 (0.1 g, 0.31 mmol, 1.0 eq). The resulting mixture was stirred at 20 C for 16 hr. LCMS
showed desired compound was found. TLC showed a new spot appeared. The reaction mixture was concentrated under reduced pressure to give a crude product. The crude product was purified by column chromatography over silica gel to give compound 105-5 (70.0 mg, 0.19 mmol, 62.0% yield).
The residue was directly used without further purification. LCMS (ESI): RT =
0.723 min, mass calc. for C16H24N404S 368.15 m/z found 369.0 [M+I-11+.
Step 3: 4-(cyclohexylamino)-N-methy1-3-(5-methy1-1,3,4-oxadiazol-2-yl)benzenesulfonamide [00402]
Compound 105-5 (20.0 mg, 54.2 umol, 1.0 eq), and Burgess Reagent (51.7 mg, 0.22 mmol, 4.0 eq) were taken up into a microwave tube in DCM (2.0 mL). The sealed tube was heated at 90 C for 1 hr under microwave. LCMS showed desired compound was found. The reaction was filtered to give a crude product. The crude product was purified by prep-HPLC to give Compound 105 (1.70 mg, 4.85 umol, 8.94% yield) was obtained. LCMS (ESI):
RT = 0.479 min, mass calc. for C16H22N403S 350.14, m/z found 350.9 [M+1-11+; 1HNMR (400 MHz, CDC13) 6 8.27 (d, J= 2.3 Hz, 1H), 8.19 (d, J= 6.5 Hz, 1H), 7.73 (dd, J = 2.1, 8.9 Hz, 1H), 6.84 (d, J =
9.3 Hz, 1H), 4.23 (d, J = 5.5 Hz, 1H), 3.55 (s, 1H), 2.67 (d, J= 5.5 Hz, 3H), 2.63 (s, 3H), 2.06 (d, J= 8.5 Hz, 2H), 1.83 (s, 2H), 1.65 (s, 1H), 1.51 - 1.34 (m, 5H).
Example 102: 4-((3,5-difluorophenyl)amino)-N-methyl-3-(1-methyl-1H-tetrazol-5-yl)benzenesulfonamide (Compound 107) and 4-((3,5-difluorophenyl)amino)-N-methyl-3-(2-methyl-2H-tetrazol-5-yl)benzenesulfonamide (Compound 108) N=N N-N/
NN
0 = N F 0 N= F
HN-Sµµ
-S
I o HN1 0 Compound 107 Compound 108 Preparation of Compound 107 and Compound 108:
pH
B F
1\1=N / HO
.B
NJ N-N
--N
107-1a (1 0 eq) N F
abh NH2 + NH2 ______________ DIPEA (3.0 eq), N F
HN
HNSµµ
Sµb HNSµµ Cu(OAc)2 (1 5 eq), HN
u\-Sµµ
0 02(15 PsO,DCM,25 C,36 h I F0 107-1 Compound 107 Compound 108 [00403] To a solution of a mixture of compounds 107-1 (80 mg, 0.20 mmol, 1 eq), compound 107-la (32.0 mg, 0.20 mmol, 1 eq) and DIEA (78.6 mg, 0.6 mmol, 0.11 mL, 3 eq) in DCM (2 mL) was added Cu(OAc)2 (55.2 mg, 0.3 mmol, 1.5 eq). The reaction was degassed with 02 for three times and stirred at 25 C for 36hr. LCMS showed that 9% and 20%
of desired MS
signal was detected. The reaction was filtered and concentrated. The crude product was purified by prep HPLC to give Compound 108 (12.37 mg, 32.52 umol, 16.04% yield) and Compound 107 (6.57 mg, 17.27 umol, 8.52% yield). HNMR and LCMS confirmed that desired products were obtained.
[00404] Compound 107: LCMS (ESI): RT = 0.684 min, mass calcd. For Ci5Hi4F2N602S, 380.09 m/z found 380.90[M+H1t IFINMR (400MHz, CDC13) 6 9.17 (s, 1H), 8.02 (d, J = 1.60 Hz, 1H), 7.85 (d, J= 8.80 Hz, 1H), 7.56 (d, J= 9.20 Hz, 1H), 6.85 - 6.70 (m, 2H), 6.68 - 6.55 (m, 1H), 4.45 - 4.35 (m, 1H), 4.31 (s, 3H), 2.70 (d, J= 5.60 Hz, 3H).
[00405] Compound 108: LCMS (ESI): RT = 0.745 min, mass calcd. For Ci5Hi4F2N602S, 380.09 m/z found 380.80[M+H1t IFINMR (400MHz, CDC13) 6 9.54 (s, 1H), 8.70 (d, J = 2.00 Hz, 1H), 7.79 (dd, J= 8.80, 2.40 Hz, 1H), 7.49 (d, J = 8.80 Hz, 1H), 6.84 (dd, J = 8.00, 2.00 Hz, 2H), 6.61 - 6.50 (m, 1H), 4.48 (s, 3H), 4.49 - 4.38 (m, 1H), 2.72 (d, J = 5.60 Hz, 3H).
Example 103: 4-((2,5-difluorophenyl)amino)-N-methyl-3-(1-methyl-1H-tetrazol-5-yl)benzenesulfonamide (Compound 109) and 4-((2,5-difluorophenyl)amino)-N-methyl-3-(2-methyl-2H-tetrazol-5-yl)benzenesulfonamide (Compound 110) N-N/
N=N
N
µµ N
(21µµ N
HN-Sµµ HN-Sµµ
Compound 109 Compound 110 Preparation of Compound 109 and Compound 110:
/ OH F
N=N N-N N=N;
--N N HO --N N
NH2 NH2 F 109-la (1 0 eq) N N
Rµ 40 + 40 DIPEA (3.0 eq), czµ
-S
HN,sµµ HN,Sµµ Cu(OAc)2 (1.5 eq), HN HN
I 0 I 0 02 (15 Psi),DCM,25 C,36 h I
109-1 Compound 109 Compound 110 [00406] To a solution of a mixture of compounds 109-1 (80 mg, 0.20 mmol, 1 eq), compound 109-la (32.0 mg, 0.20 mmol, 1 eq) and DIEA (78.6 mg, 0.6 mmol, 0.11 mL, 3 eq) in DCM (2 mL) was added Cu(OAc)2 (55.2 mg, 0.30 mmol, 1.5 eq). The reaction was degassed with 02 for three times and stirred at 25 C for 36hr. LCMS showed that 7% and 4% of desired MS signal was detected. The reaction was filtered and concentrated. The crude product was purified by prep-HPLC to give Compound 110 (2.22 mg, 5.84 umol, 2.9% yield) and Compound 109 (4.31 mg, 11.33 umol, 5.6% yield). HNMR and LCMS confirmed that desired product was obtained.
[00407] Compound 109: LCMS (ESI): RT = 0.671 min, mass calcd. For Ci51-114F2N602S, 380.09 m/z found 380.80[M+H1t IFINMR (400MHz, CDC13) 6 9.01 (s, 1H), 8.02 (d, J = 2.00 Hz, 1H), 7.83 (dd, J= 8.80, 2.00 Hz, 1H), 7.30 (d, J= 8.80 Hz, 1H), 7.20 -7.05 (m, 2H), 6.90 -6.75 (m, 1H), 4.41 - 4.33 (m, 1H), 4.31 (s, 3H), 2.70 (d, J= 5.60 Hz, 3H).
[00408] Compound 110: LCMS (ESI): RT = 0.733 min, mass calcd. For Ci51-114F2N602S, 380.09 m/z found 443.90 [M+Na+MeCN1+.11-INMR (400MHz, CDC13) 6 9.42 (s, 1H), 8.73 (d, J
= 2.00 Hz, 1H), 7.79 (dd, J= 9.20, 2.40 Hz, 1H), 7.31 (d, J= 9.20 Hz, 1H), 7.25 - 7.15 (m, 2H), 6.90 - 6.75 (m, 1H), 4.48 (s, 3H), 4.41 - 4.25 (m, 1H), 2.72 (d, J = 5.60 Hz, 3H).
Example 104: 4-(cyclohexylamino)-3-(1-cyclopropy1-1H-imidazol-4-y1)-N-methylbenzenesulfonamide (Compound 111) r-N
N/
0, 40 N
HN
Preparation of Compound 111:
N/
00 111-1a(1.2 eq) No Br 0, 0µ NIO Pd3(PPh)4(0.1eq) =
Cs2003(2.0eq), HN
HN,Sµ` dioxane/H20,100 C,16h 111-1 Compound 111 OH
HO-B
NH
IT 111-1b (2.0 eq) Ne 1,10-PHENANTHROLINE(1.0eq) N
Br K2CO3 (2.0 eq),Cu(OAc)2(1.0eq) DCE, 70 C,8 hr Br 111-1c 111-1a Step 1: 4-bromo-1-cyclopropyl-imidazole [00409] A mixture of 111-1c (500.0 mg, 3.4 mmol, 1.0 eq), 111-lb (584.4 mg, 6.8 mmol, 2.0 eq), 1,10-PHENANTHROLINE (613.0 mg, 3.4 mmol, 1.0 eq), K2CO3 (940.3 mg, 6.8 mmol, 2.0 eq) and Cu(OAc)2 (617.9 mg, 3.4 mmol, 1.0 eq) in DCE (25.0 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 70 C for 8 h under N2 atmosphere. TLC
indicated 50% of 111-1c was remained, and one major new spot with lower polarity was detected. The reaction mixture was concentrated under reduced pressure to remove DCE. The residue was diluted with Et0Ac (50.0 mL) and extracted with Et0Ac ( 20 mL *3) The combined organic layers were washed with brine (20 mL * 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography to give 111-la (70.0 mg, 0.374 mmol, 11% yield). IFINMR
(400MHz, CDC13) 6 7.42 (d, J = 1.0 Hz, 1H), 6.95 (d, J = 1.3 Hz, 1H), 3.37-3.27 (m, 1H), 1.03-0.94 (m, 4H).
Step 2: 4-(cyclohexylamino)-3-(1-cyclopropy1-1H-imidazol-4-y1)-N-methylbenzenesulfonamide [00410] A mixture of!!!-! (139.1 mg, 0.4 mmol, 1.1 eq), 111-la (60 mg, 0.3 mmol, 1 eq), Pd(PPh3)4 (37.0 mg, 32.0 umol, 0.1 eq) and Cs2CO3 (209.0 mg, 0.6 mmol, 2.0 eq) in dioxane (2.0 mL) and H20 (0.3 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 100 C for 16 h under N2 atmosphere. LCMS showed 111-1 was consumed completely. Several new peaks were shown on LCMS and 27% of desired compound was detected. The residue was purified by prep-HPLC to give Compound 111 (7.82 mg, 20.46 umol, 6% yield). LCMS (ESI): RT = 0.716min, mass calc. for Ci9H26N4025 374.18, m/z found 375.0 [M+H1+; IFINMR (400MHz, CDC13) 6 8.55 (d, J= 5.5 Hz, 1H), 7.85 (s, 1H), 7.55 (s, 2H), 7.32 (s, 1H), 6.66 (d, J= 8.5 Hz, 1H), 4.78 (d, J= 3.0 Hz, 1H), 3.58-3.25 (m, 2H), 2.58 (d, J= 3.0 Hz, 3H), 2.03 (s, 2H), 1.76 (s, 2H), 1.62 (s, 1H), 1.39 (d, J= 7.5 Hz, 5H), 0.98 (s, 4H).
Example 105: 4-(cyclohexylamino)-3-(1-ethy1-1H-imidazol-4-y1)-N-methylbenzenesulfonamide (Compound 112) /FN
N z HN,Sµ`
I
Preparation of Compound 112:
Br orNH2 Br MeNH2, 2M solution Br ? it 410 F in THF (2.0 eq) 0 112-2a (2.5 eq),..., HN-S
0 ___________________ ).
HN-1 4. F
\\ / 6 S DMSO, Cr" µ\ DCM, 20 C, 4 hr / 6 o 140 C,2 112-1 112-2 hr 112-3 0 p /¨
/FN /¨
13-i ''--I-1---- N) IF N
0 0t / µ Br N , 0õ0 112-3a (1.5 eq) B H 112-6 (1.0 eq) H
\µ
Pd(dppf)Cl2 (0.05 eq) 0 Pd(PPI-13).4 (0.05 eq) 0\ 0 AcOK (2.0 eq) Cs2003 (2.0 eq) ,µSµ`
,S
Dioxane,95 C, 16 hr HN\` HN
Dioxane/H20 I
I 100 C, 16 hr 112-4 Compound 112 I
/¨
7 112-5a (1.2 eq) F-N
N Z _______________ )1'. N,e NaH (1.2 eq, 60%) Br DMF, 0-20 00,16 hr Br Step 1: 3-Bromo-4-fluoro-N-methylbenzenesulfonamide [00411] To a solution of compound 112-1 (1.6 g, 5.9 mmol, 1.0 eq) in DCM
(16 mL) was added MeNH2 (2 M, 5.9 mL, 2.0 eq). The reaction mixture was stirred at 20 C
for 4 hours. The mixture was diluted with water (15 mL) and the resultant mixture was extracted with DCM (30 mL * 2). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure to obtain compound 112-2 (1.5 g, 96% yield).
Step 2: 3-Bromo-4-(cyclohexylamino)-N-methylbenzenesulfonamide [00412] A solution of compound 112-2 (1.5 g, 5.6 mmol, 1.0 eq) and compound 112-2a (1.4 g, 14 mmol, 2.5 eq) in DMSO (8 mL) was stirred at 140 C for 2 hours. The mixture was diluted with water (30 mL) and the resultant mixture was extracted with EA (50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound 112-3 (1.8 g, 93% yield). LCMS (ESI): RT = 0.794 min, mass calcd. for C13F119BrN202S 346.04, miz found 348.9 [M+1-11+.
Step 3: 4-(Cyclohexylamino)-N-methy1-3-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-yl)benzenesulfonamide [00413] A solution of compound 112-3 (2.0 g, 5.8 mmol, 1.0 eq), compound 112-3a (2.2 g, 8.6 mmol, 1.5 eq), Pd(dppf)C12 (211 mg, 0.288 mmol, 0.05 eq) and AcOK (1.1 g, 12 mmol, 2.0 eq) in Dioxane (25 mL) was heated to 95 C and stirred at 95 C for 16 hours under N2. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (20 mL) and extracted with EA (50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound 112-4 (1.6 g, 70% yield).
LCMS (ESI): RT = 0.876 min, mass calcd. for Ci9H3113N204S 394.21, m/z found 395.1 [M+I-11+.
Step 4: 4-Bromo-1-ethyl-1H-imidazole [00414] To a solution of compound 112-5 (500 mg, 3.40 mmol, 1.0 eq) in DMF
(6 mL) was added NaH (163 mg, 4.08 mmol, 60% purity, 1.2 eq) at 0 C. The reaction mixture was allowed to warm up to 20 C and then stirred at 20 C for 0.5 hour. The mixture was cooling to 0 C and followed by compound 112-5a (637 mg, 4.08 mmol, 1.2 eq). The reaction mixture was stirred at 20 C for 2.5 hours. The reaction mixture was concentrated under reduced pressure.
The mixture was diluted with water (30 mL) and the resultant mixture was extracted with DCM
(50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford a residue. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely. The title compound 112-6 (150 mg, 25% yield) was obtained. 1I-1 NMR (400MHz, CDC13) 6 7.36 (d, J = 1.0 Hz, 1H), 6.90 (d, J
= 1.5 Hz, 1H), 3.96 (q, J = 7.3 Hz, 2H), 1.45 (t, J = 7.4 Hz, 3H).
Step 5: 4-(Cyclohexylamino)-3-(1-ethy1-1H-imidazol-4-y1)-N-methylbenzenesulfonamide [00415] To a solution of compound 112-4 (100 mg, 0.254 mmol, 1.0 eq), compound 112-6 (44 mg, 0.25 mmol, 1.0 eq), Cs2CO3 (165 mg, 0.507 mmol, 2.0 eq) in Dioxane (2 mL) and H20 (0.2 mL) was added Pd(PPh3)4 (15 mg, 13 umol, 0.05 eq) under N2. The reaction mixture was stirred at 100 C for 16 hours. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely.
Compound 112 (33.80 mg, 36% yield) was obtained. LCMS (ESI): RT = 0.641 min, mass calcd.
for C181-126N402S 362.18, m/z found 363.0 [M+H1+, IFINMR (400MHz, CDC13) 6 7.83 (d, J=
2.3 Hz, 1H), 7.57 - 7.49 (m, 2H), 7.30 (d, J= 1.3 Hz, 1H), 6.69 (d, J= 9.0 Hz, 1H), 4.26 (q, J=
5.3 Hz, 1H), 4.04 (q, J= 7.4 Hz, 2H), 3.50 - 3.38 (m, 1H), 2.62 (d, J= 5.5 Hz, 3H), 2.13 - 1.99 (m, 2H), 1.85 - 1.73 (m, 2H), 1.69 - 1.58 (m, 2H), 1.51 (t, J= 7.4 Hz, 3H), 1.45 - 1.34 (m, 4H).
Example 106: 4-(cyclohexylamino)-3-(1-isopropy1-1H-imidazol-4-y1)-N-methylbenzenesulfonamide (Compound 113) fiN
N/
NQ
0µ *
HN ,\Sµ
Preparation of Compound 113:
Br 113-1b ( 1 . 1 71.9 ) NaH (1.2 eq) Br DMF, 0-20 C, 16.5 hr Br 113-1c 113-la Br fr-N
N /
0,13'0 113-la (1.0 eq) czµ = N
Pn(PPh3)4 (0.1 eq) NQ
Cs2CO3 (2.0 eq) 0, *
-Sµ Dioxane/H20, 100 C, 16 hr ;Sµ
HN HN µo I 113-1 (1.2 eq) Compound 113 Step 1: 4-bromo-1-isopropy1-1H-imidazole [00416] To the solution of compound 113-1c (500 mg, 3.4 mmol, 1 eq) in DMF
(2.5 mL) was added NaH (163 mg, 4.1 mmol, 60% purity, 1.2 eq) at 0 C. The mixture was stirred at 0 C for 30 min. Then compound 113-lb (460 mg, 3.7 mmol, 351 uL, 1.1 eq) was added to the mixture. The solution was warmed up to 20 C and stirred for 16 hr. The reaction was monitored by LCMS. LCMS showed that the starting material remained and the desired MS
was observed.
H20 (20 mL) was added to the solution. The mixture was extracted with Et0Ac (20 mL*3). The combined organic layer was dried with Na2SO4 and concentrated under reduced pressure. The residue was purified by to give compound 113-la (100 mg, 528.95 umol, 15.55%
yield). It was confirmed by HNMR and HMBC. 1H NMR (400MHz, CDC13) 6 7.41 (d, J= 1.3 Hz, 1H), 6.93 (d, J = 1.5 Hz, 1H), 4.37 - 4.27 (m, 1H), 1.48 (d, J= 6.8 Hz, 6H).
Step 2: 4-(cyclohexylamino)-3-(1-isopropy1-1H-imidazol-4-y1)-N-methylbenzenesulfonamide [00417] To the solution of compound 113-la (50 mg, 0.26 mmol, 1 eq) in dioxane (2 mL) was added compound 113-1 (125 mg, 0.32 mmol, 1.2 eq), Pd(PPh3)4 (31 mg, 26.5 umol, 0.1 eq), Cs2CO3 (172 mg, 0.53mo1, 2 eq) and H20 (0.4 mL). The mixture was stirred at 100 C for 16 hr. The reaction was monitored by LCMS. LCMS showed that the starting material was consumed and the desired MS was observed. The reaction solution was filtered.
The residue was purified by HPLC to give Compound 113 (9.07 mg, 23.61 umol, 8.9% yield). LCMS
(ESI): RT
= 0.649 min, mass calcd. for Ci9H23N90 376.19, m/z found 377.0 [M+1-11-1,11-1NMR (400MHz, CDC13) 6 8.71 (br, , 1H), 7.89 (d, J = 2.5 Hz, 1H), 7.57 - 7.51 (m, 2H), 7.36 (d, J= 1.0 Hz, 1H), 6.68 (d, J= 8.8 Hz, 1H), 4.52 (q, J= 5.4 Hz, 1H), 4.41 - 4.30 (m, 1H), 3.44 (br, , 1H), 2.61 (d, J=5.5 Hz, 3H), 2.10 - 2.02 (m, 2H), 1.84- 1.75 (m, 2H), 1.69 - 1.60 (m, 1H), 1.51 (d, J= 6.8 Hz, 6H), 1.46 - 1.27 (m, 5H).
Example 107: 4-(cyclohexylamino)-3-(1-ethy1-1H-imidazol-5-y1)-N-methylbenzenesulfonamide (Compound 114) /=N
rN
czµ N
HN,Sµ`
I
Preparation of Compound 114:
IF-NH 114-la (1.2 eq) NeNaH (1.2 eq, 60%) Br DMF, 0-20 C,16 hr Br F--N
N-N?
0, 0 114-2 (1.1 eq) No0 el 0 Pd(PPh3).4 (0.05 eq) HN
HN-Sµ` Cs2CO3 (2.0 eq) -S, Dioxane/H20 100 C, 16 hr 114-3 Compound 114 Step 1: 5-Bromo-1-ethyl-1H-imidazole [00418] To a solution of compound 114-1 (500 mg, 3.40 mmol, 1.0 eq) in DMF
(6 mL) was added NaH (163 mg, 4.08 mmol, 60% purity, 1.2 eq) at 0 C. The reaction mixture was allowed to warm up to 20 C and then stirred at 20 C for 0.5 hour. The mixture was cooling to 0 C and followed by compound 114-la (637 mg, 4.08 mmol, 1.2 eq). The reaction mixture was stirred at 20 C for 2.5 hours. The reaction mixture was concentrated under reduced pressure.
The mixture was diluted with water (30 mL) and the resultant mixture was extracted with DCM
(50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely. The title compound (60 mg, 25% yield) was obtained. IFINMR (400MHz, CDC13) 6 7.58 (s, 1H), 7.02 (s, 1H), 3.99 (q, J =
7.3 Hz, 2H), 1.43 (t, J = 7.3 Hz, 3H).
Step 2: 4-(Cyclohexylamino)-3-(1-ethy1-1H-imidazol-5-y1)-N-methylbenzenesulfonamide [00419] To a solution of compound 114-3 (120 mg, 0.304 mmol, 1.0 eq), compound 114-2 (60 mg, 0.33 mmol, 1.1 eq), Cs2CO3 (198 mg, 0.609 mmol, 2.0 eq) in Dioxane (2 mL) and H20 (0.2 mL) was added Pd(PPh3)4 (18 mg, 15 umol, 0.05 eq) under N2. The reaction mixture was stirred at 100 C for 16 hours. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely.
Compound 114 (37.86 mg, 34% yield) was obtained. LCMS (EST): RT = 0.630 min, mass calcd.
for Ci8H26N402S 362.18, m/z found 362.9 [M+H1+, 1HNMR (400MHz, CDC13) 6 7.79 -7.68 (m, 2H), 7.53 (d, J= 2.3 Hz, 1H), 7.18 - 7.05 (m, 1H), 6.73 (d, J= 9.0 Hz, 1H), 4.48 - 4.38 (m, 1H), 4.26 (d, J = 7.8 Hz, 1H), 3.82 (q, J = 7.3 Hz, 2H), 3.41 - 3.29 (m, 1H), 2.68 (d, J= 5.3 Hz, 3H), 2.02 - 1.92 (m, 2H), 1.76 - 1.61 (m, 3H), 1.45 - 1.32 (m, 2H), 1.28 (t, J= 7.3 Hz, 3H), 1.26 - 1.58 (m, 1H), 1.17 - 1.06 (m, 2H).
Example 108: 3-(2-(2-(benzyloxy)ethyl)-2H-tetrazol-5-y1)-N-methyl-4-44-(trifluoromethyl)phenyl)amino)benzenesulfonamide (Compound 115) =
N-N
;1\1 00, F
HN
Preparation of Compound 115:
N OH
Bn0 115-1a (1.2 eq) 0, el N
F PPh3 (3.0 eq))1' N
N-N
z F DIAD (3.0 eq) HN F THF, 0 - 25 C, 16 hr N
0, el ,µS
HN , 115-1 Compound 115 [00420] To a stirring solution of compound 115-1 (20 mg, 50 umol, 1.0 eq), compound 115-la (9.1 mg, 60 umol, 1.2 eq) and PPh3 (40 mg, 0.15 mmol, 3.0 eq) in THF (1 mL) was added DIAD (30 mg, 0.15 mmol, 3.0 eq) slowly at 0 C under N2. The reaction mixture was stirred at 25 C for 16 hours. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (5 mL) and the resultant mixture was extracted with EA (20 mL
* 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford Compound 115 (6.76 mg, 25% yield). LCMS (ESI): RT = 0.857 min, mass calcd. for C24H23F3N603S 532.15, m/z found 533.0 [M+H1+, IFINMR (400MHz, CDC13) 6 9.70 (s, 1H), 8.73 (d, J= 2.3 Hz, 1H), 7.79 (dd, J= 2.1, 8.9 Hz, 1H), 7.66 (d, J = 8.5 Hz, 2H), 7.51 (d, J = 8.8 Hz, 1H), 7.41 (d, J= 8.3 Hz, 2H), 7.34 - 7.29 (m, 3H), 7.27 - 7.23 (m, 2H), 4.93 (t, J = 5.4 Hz, 2H), 4.57 (s, 2H), 4.32 (q, J= 5.5 Hz, 1H), 4.11 (t, J= 5.4 Hz, 2H), 2.74 (d, J= 5.3 Hz, 3H).
Example 109: 3-(2-(2-hydroxyethyl)-2H-tetrazol-5-y1)-N-methyl-4-44-(trifluoromethyl)phenyl) amino)benzenesulfonamide (Compound 116) OH
N-N
;1\1 S
HN \
Preparation of Compound 116:
OH
.b 9 NC
H
HO .B
Nacys-- - N
F NC 0 R` 10 40 F
NC F H
40 NH2 116-1a (1.2 eq) I N
00 00 F _______________________________________________ F 116-2a (3.0eq) Of \\C) F
F
I DIPEA (2.0 eq) F DMSO, 110 C, 1 hr DCM,02, 25 C,72 hr 116-2 N-NH
NC
H
1.Na0Me(3.0eq),THF Me0H, 20 C, 1h N
NaN3 (3.0 eq) H
NH4CI (3.0 eq) N
9` 0 40 _______________________________________________ I.- µ
F
________________________ A. DMF, 100 C, 2 hr R . 0 F
,., ..S
N ,Ss 2.methanamine (3.0eq), TEA(5.0eq), NCS(2.0eq) H a F F F
HN s,-, F
THF, 20 C, 3h 1 µ-' OH
OBn N-N
1\l Bn0'-'OH N-N ','N
H
116-5a (1.2 eq) N' ,i\I Pd(OH)2 (20%) N
PPh3 (3.0 eq) H2 CIµµ el 0 F
DIAD (3.0 eq) N 0 Me0H, 25 C, 16 hr ,Ss HN ,,-, F F
THF, 0-25 C, 16 hr (I:\ el F
,\ 1 µ-HNS,.., µ FF
1 µ-' 116-6 Compound 116 Step 1: 5-Iodo-2-04-(trifluoromethyl)phenyl)amino)benzonitrile [00421] To a solution of compound 116-1 (450 mg, 1.84 mmol, 1.0 eq), compound 116-la (420 mg, 2.21 mmol, 1.2 eq) and Cu(0Ac)2 (402 mg, 2.21 mmol, 1.2 eq) in DCM (5 mL) was added DIPEA (477 mg, 3.69 mmol, 2.0 eq) under 02. The reaction mixture was stirred at 25 C
for 72 hours. The reaction mixture was concentrated under reduced pressure.
The residue was purified by column chromatography over silica gel to afford the title compound 116-2 (180 mg, 25% yield). IFINMR (400MHz, CDC13) 6 7.84 (d, J = 2.0 Hz, 1H), 7.70 (dd, J =
2.0, 8.8 Hz, 1H), 7.61 (d, J= 8.5 Hz, 2H), 7.23 (d, J= 8.5 Hz, 2H), 7.11 (d, J= 9.0 Hz, 1H), 6.46(s, 1H).
Step 2: Methyl 3-03-cyano-4-04-(trifluoromethyl)phenyl)amino)phenyl)sulfonyl)propanoate [00422] Compound 116-2 (130 mg, 0.335 mmol, 1.0 eq), compound 116-2a (175 mg, 1.00 mmol, 3.0 eq) and Cul (319 mg, 1.67 mmol, 5.0 eq) were taken up into a microwave tube in DMSO (3 mL). The sealed tube was heated at 110 C for 1 hour under microwave. The mixture was diluted with water (10 mL) and EA (30 mL). The suspension was filtered and the filtrate was separation, the water layer was extracted with EA (20 mL * 2).
The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound 116-3 (110 mg, 80% yield).
Step 3: 3-Cyano-N-methy1-4-04-(trifluoromethyl)phenyl)amino)benzenesulfonamide [00423] To a solution of compound 116-3 (110 mg, 0.267 mmol, 1.0 eq) in Me0H (1.5 mL) and THF (3 mL) was added Na0Me (43 mg, 0.80 mmol, 3.0 eq). The reaction mixture was stirred at 20 C for 1 hour, and then removed solvent to give a residue. The residue was dissolved with THF (2 mL). After MeNH2 (2 M, 0.40 mL, 3.0 eq), TEA (135 mg, 1.33 mmol, 5.0 eq) and NCS (71 mg, 0.53 mmol, 2.0 eq) were added, the reaction mixture was stirred at 20 C
for 3 hours. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound 116-4 (80 mg, 84%
yield). IFINMR
(400MHz, CDC13) 6 8.06 (d, J= 2.3 Hz, 1H), 7.85 (dd, J= 2.1, 8.9 Hz, 1H), 7.69 (d, J= 8.5 Hz, 2H), 7.35 (d, J= 8.5 Hz, 2H), 7.31 (d, J= 9.0 Hz, 1H), 6.84 (s, 1H), 4.37 (q, J= 5.3 Hz, 1H), 2.71 (d, J = 5.5 Hz, 3H).
Step 4: N-methy1-3-(2H-tetrazol-5-y1)-4-04-(trifluoromethyl)phenyl)amino)benzenesulfonamide [00424] To a solution of compound 116-4 (80 mg, 0.23 mmol, 1.0 eq) in DMF
(2 mL) were added NaN3 (60 mg, 0.92 mmol, 4.1 eq) and NH4C1 (36 mg, 0.68 mmol, 3.0 eq). The reaction mixture was stirred at 100 C for 2 hours. The mixture was diluted with water (30 mL) and the resultant mixture was extracted with EA (50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure to obtain the title compound 116-5 (85 mg, 95% yield). LCMS (ESI): RT = 0.746 min, mass calcd. for Ci5H13F3N602S 398.08, m/z found 399.1 [M+H1+.
Step 5: 3-(2-(2-(Benzyloxy)ethyl)-2H-tetrazol-5-y1)-N-methyl-4-04-(trifluoromethyl)phenyl) amino)benzenesulfonamide [00425] To a stirring solution of compound 116-5 (65 mg, 0.16 mmol, 1.0 eq), compound 116-5a (30 mg, 0.20 mmol, 1.2 eq) and PPh3 (128 mg, 0.490 mmol, 3.0 eq) in THF
(2 mL) was added DIAD (99 mg, 0.49 mmol, 3.0 eq) slowly at 0 C under N2. The reaction mixture was stirred at 25 C for 16 hours. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL
* 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford compound 116-6 (70 mg, 78% yield). LCMS (ESI): RT = 0.865 min, mass calcd. for C24H23F3N603S 532.15, m/z found 533.1 [M+H1+, IFINMR (400MHz, CDC13) 6 9.67 (s, 1H), 8.70 (d, J= 2.3 Hz, 1H), 7.77 (dd, J= 2.4, 8.9 Hz, 1H), 7.64 (d, J = 8.5 Hz, 2H), 7.49 (d, J = 9.0 Hz, 1H), 7.39 (d, J= 8.5 Hz, 2H), 7.32 - 7.26 (m, 3H), 7.25 - 7.21 (m, 2H), 4.91 (t, J= 5.4 Hz, 2H), 4.55 (s, 2H), 4.30 (q, J= 5.4 Hz, 1H), 4.09 (t, J= 5.3 Hz, 2H), 2.71 (d, J= 5.5 Hz, 3H).
Step 6: 3-(2-(2-Hydroxyethyl)-2H-tetrazol-5-y1)-N-methyl-4-44-(trifluoromethyl)phenyl) amino)benzenesulfonamide [00426] To a solution of compound 116-6 (40 mg, 75 umol, 1 eq) in Me0H (3 mL) was added Pd(OH)2 (10 mg, 20% purity) under N2. The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred under H2 (15 psi) at 25 C for 16 hours.
The reaction mixture was filtered and the filtrate was concentrated. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely.
Compound 116 (6.67 mg, 20% yield) was obtained. LCMS (ESI): RT = 0.748 min, mass calcd.
for C17I-117P3N603S 442.10, m/z found 442.9 [M+H1+, 1HNMR (400MHz, CDC13) 6 9.67 (s, 1H), 8.69 (d, J= 2.3 Hz, 1H), 7.77 (dd, J= 2.1, 8.9 Hz, 1H), 7.65 (d, J = 8.5 Hz, 2H), 7.49 (d, J = 9.0 Hz, 1H), 7.40 (d, J= 8.5 Hz, 2H), 4.92 - 4.86 (m, 2H), 4.37 (q, J= 5.5 Hz, 1H), 4.33 - 4.27 (m, 2H), 2.71 (d, J= 5.5 Hz, 3H), 2.22 (t, J= 6.0 Hz, 1H).
Example 110: 4-((3-fluorophenyl)amino)-N-methyl-3-(2-methyl-2H-tetrazol-5-yl)benzenesulfonamide (Compound 117) N-N
= F
um N-S
Preparation of Compound 117:
Ho-13 * F
NH2 117-1a (2 eq) HN-S \\ DIPEA (3 eq), ri S
\\ 401 N F
I CU(OAC)2 (1.5 eq), j 0 02 (15 Psi),DCM,rt,16 h 117-1 Compound 117 [00427] To a solution of compound 117-1 (40 mg, 0.15 mmol, 1 eq), (3-fluorophenyl)boronic acid (117-1a) (41.7 mg, 0.30 mmol, 2 eq) and DIEA (57.8 mg, 0.45 mmol, 77.90 uL, 3 eq) in DCM (2 mL) was added Cu(OAc)2 (40.6 mg, 0.22 mmol, 1.5 eq).
The reaction was stirred at 25 C under 02 (15 Psi) for 16hr. LCMS showed that 50% of desired MS signal was detected. The reaction was filtered and concentrated. The crude product was purified by prep HPLC to give Compound 117 (8.74 mg, 24.12 umol, 16.18% yield). HNMR and LCMS
confirmed that desired product was obtained. LCMS (ESI): RT = 0.746 min, mass calcd. For Ci5Hi5FN6025, 362.10 m/z found 362.9[M+H1t NMR (400MHz, CDC13) 6 9.47 (s, 1H), 8.69 (d, J= 2.4 Hz, 1H), 7.74 (d, J= 9.2 Hz, 1H), 7.45- 7.30(m, 2H), 7.15- 7.00(m, 2H), 7.00 - 6.95 (m, 1H), 4.47 (s, 3H), 4.28 (d, J= 5.6 Hz, 1H), 2.70 (d, J = 5.6 Hz, 3H).
Example 111: 4-((4-fluorophenyl)amino)-N-methyl-3-(2-methyl-2H-tetrazol-5-yl)benzenesulfonamide (Compound 118) and 4-((4-fluorophenyl)amino)-N-methyl-3-(1-methyl-1H-tetrazol-5-yl)benzenesulfonamide (Compound 119) N-NNN
-N /%\i N N
(Rµ
,õ,,s ,s rum \\ HN
Compound 118 Compound 119 Preparation of Compound 118:
N-N/ OHNN
HOB* N-N
-N
N.N N
HN =
NH2 + HNS 40 NH2 118-la (1.5 eq) uõ, N
+ IR\
o N
(Rµ
,\S -S
-S
µµ DIPEA (2 eq), HN
1 0 I 0 Cu(OAc)2 (1.5 eq), 0 1 0 02(15 Psi),DCM,rt,16 h 118-1 Compound 118 Compound 119 [00428] To a solution of a mixture of compounds 118-1 (50 mg, 0.18 mmol, 1 eq) in DCM
(3 mL) was added compound 118-la (39.1 mg, 0.28 mmol, 1.5 eq), Cu(0Ac)2 (50.8 mg, 0.28 mmol, 1.5 eq) followed by DIEA (48.2 mg, 0.37 mmol, 64.92 uL, 2 eq) under N2.
The suspension was degassed under vacuum and purged with 02 several times. The mixture was stirred under 02 (15psi) at 25 C for 16 hours. LCMS showed that 5.6% and 50%
of desired product were detected. The reaction was filtered and concentrated. The residue was added Me0H (4 mL) and filtered to give Compound 118 (18.83 mg, 50.30 umol, 27%
yield). The filtrate was concentrated. The crude product was purified by Prep HPLC to give Compound 119 (2.85 mg, 7.86 umol, 4.2% yield).
[00429] Compound 118: LCMS (ESI): RT = 0.733 min, mass calcd. For Ci5Hi5FN602S, 362.10 m/z found 362.9[M+Hr IFINMR (400MHz, CDC13) 6 9.32 (s, 1H), 8.68 (d, J
= 2.4 Hz, 1H), 7.68 (dd, J= 8.8, 2.4 Hz, 1H), 7.46 - 7.37 (m, 3H), 7.25 - 7.15 (m, 3H), 4.47 (s, 3H), 4.24 (d, J = 5.6 Hz, 1H), 2.69 (d, J= 5.6 Hz, 3H).
[00430] Compound 119: LCMS (ESI): RT = 0.679 min, mass calcd. For Ci5Hi5FN602S, 362.10 m/z found 362.9[M+Hr IFINMR (400MHz, CHLOROFORM-d) 6 8.97 (s, 1H), 7.99 (d, J= 2.0 Hz, 1H), 7.80 - 7.60 (m, 1H), 7.25 - 7.15 (m, 3H), 7.15 - 7.05 (m, 3H), 4.40 - 4.25 (m, 4H), 2.67 (d, J = 4.4 Hz, 3H).
Example 112: 4-((2-fluorophenyl)amino)-N-methyl-3-(2-methyl-2H-tetrazol-5-yl)benzenesulfonamide (Compound 120) N-N
H F
N
n \\
Preparation of Compound 120:
N-N/ pH F
1\11 HO itNN
H F
I. NH2 120-1a (1.5 eq) Rµ
N
HN-% DIPEA (2 eq), INJ n õk,,S
I CU(OAC)2 (1.5 eq), 1 0 02 (15 Psi),00M,rt,80 h 120-1 Compound 120 1004311 To a solution of compound 120-1 (50 mg, 0.19 mmol, 1 eq) in DCM (3 mL) was added (2-fluorophenyl)boronic acid 120-la (39.1 mg, 0.28 mmol, 1.50 eq) , Cu(0Ac)2 (50.8 mg, 0.28 mmol, 1.5 eq) followed by DIEA (48.2 mg, 0.37 mmol, 64.92 uL, 2 eq) under N2. The suspension was degassed under vacuum and purged with 02 several times. The mixture was stirred under 02 (15psi) at 25 C for 16 hours. LCMS showed that starting material was remained and 2% of desired product was detected. The reaction was continued to stir at 25 C for 16hr.
LCMS showed that 5% of desired MS signal was detected. The reaction was continued to stir at 25 C for 48hr. LCMS showed that 3% and 8% desired product was detected. The reaction was filtered and concentrated. The crude product was purified by Prep HPLC to give Compound 120 (2.04 mg, 5.63 umol, 3.0% yield). HNMR and LCMS confirmed that desired product was detected. LCMS (ESI): RT = 0.735 min, mass calcd. For Ci5tli5FN602S, 362.10 m/z found 362.9[M+H1t IFI NMR (400MHz, CDC13) 6 9.30 (s, 1H), 8.71 (d, J = 2.0 Hz, 1H), 7.72 (dd, J=
9.2, 2.4 Hz, 1H), 7.50 - 7.40 (m, 1H), 7.25 - 7.00 (m, 4H), 4.47 (s, 3H), 4.28 (d, J= 5.6 Hz, 1H), 2.70 (d, J = 5.2 Hz, 3H).
Example 113: N-methyl-3-(1-methyl-1H-imidazol-4-y1)-4-44-(trifluoromethyl)phenyl)amino)benzenesulfonamide (Compound 121) N/
in H
N
0\ 0 0 F
,\Sµ F
HN F
I
Preparation of Compound 121:
0 O---.
Br Br H2N 4 Br H go t013-130 F MeNH2, 2M solution F N
0\ IS inTHF (2.0 eq) ).-- 0 I* 121-2a (2.0 eq) 3"-- 0, 0 121-3a (1.5 eq) _________________________________________________________________________ v.-,\S, \S, DMSO, 140 C, 1 hr DCM, 25 C, 2 hr S\
Pd(dppf)Cl2 (0.05 eq) Cl- `0 HN b I HN `0 1 AcOK (2.0 eq) Dioxane,95 C, 16 hr /
ii-N
/
N? N
ir 0õ0 N y B
NH 00 Br 121-4a (1.1 eq),.... NH SI
Pd/C (10%), HCI (5.0 eq...
CZ\ 40 Pd(PPh3)4 (0.05 eq) CZ\ ei H2, Me0H,25 C, 16 hr Cs2CO3 (2.0 eq) -S, HN µ(-1 Dioxane/H20,90 C, 16 hr HNI µ-' \µ., I '' Hy / /
IFN
F IFN
F H
NH 2 121-6a (1.5 eq) õ... ,µ 0 N 0 CZµ 0 (:) Cu(OAc)2 (1.2 eq) F
DIPEA (4.0 eq) ,S\ ,S, F
HN `0 DCM, 25 C, 02,16 hr HN b F
1 i 121-6 Compound 121 Step 1: 3-Bromo-4-fluoro-N-methylbenzenesulfonamide [00432] To a solution of compound 121-1 (1.0 g, 3.7 mmol, 1.0 eq) in DCM
(10 mL) was added MeNH2 (2 M, 3.7 mL, 2.0 eq). The reaction mixture was stirred at 25 C
for 2 hours. The mixture was diluted with water (15 mL) and the resultant mixture was extracted with DCM (30 mL * 2). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure to obtain the title compound 121-2 (950 mg, 97%
yield).
Step 2: 4-(Benzylamino)-3-bromo-N-methylbenzenesulfonamide [00433] A solution of compound 121-2 (850 mg, 3.17 mmol, 1.0 eq) and compound 121-2a (679 mg, 6.34 mmol, 2.0 eq) in DMSO (4 mL) was stirred at 140 C for 1 hour. The mixture was diluted with water (30 mL) and the resultant mixture was extracted with EA
(50 mL * 3).
The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound 121-3 (1.0 g, 89% yield). LCMS (ESI): RT = 0.798 min, mass calcd. for Ci4H1513rN202S 354.00, m/z found 356.7 [M+Hl+.
Step 3: 4-(Benzylamino)-N-methy1-3-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)benzenesulfonamide [00434] A solution of compound 121-3 (850 mg, 2.39 mmol, 1.0 eq), compound 121-3a (911 mg, 3.59 mmol, 1.5 eq), Pd(dppf)C12 (88 mg, 0.12 mmol, 0.05 eq) and AcOK
(470 mg, 4.79 mmol, 2.0 eq) in Dioxane (10 mL) was heated to 90 C and stirred at 90 C for 16 hours under N2. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (30 mL) and the resultant mixture was extracted with EA (50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound 121-4 (800 mg, 68% yield). LCMS (ESI): RT = 0.827 min, mass calcd. for C20I-127BN204S 402.18, m/z found 402.9 [M+H]+.
Step 4: 4-(Benzylamino)-N-methy1-3-(1-methy1-1H-imidazol-4-yl)benzenesulfonamide [00435] To a solution of compound 121-4 (700 mg, 1.74 mmol, 1.0 eq), compound 121-4a (308 mg, 1.91 mmol, 1.1 eq), Cs2CO3 (1.13 g, 3.48 mmol, 2.0 eq) in Dioxane (8 mL) and H20 (2 mL) was added Pd(PPh3)4 (101 mg, 87.0 umol, 0.05 eq) under N2. The reaction mixture was stirred at 90 C for 16 hours. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (20 mL) and the resultant mixture was extracted with EA (50 mL
* 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The resulting mixture was lyophilized to dryness to remove the solvent residue completely. The title compound 121-5 (180 mg, 28% yield) was obtained. LCMS
(ESI): RT =
0.592 min, mass calcd. for Cl8H20-N-402S 356.13, m/z found 356.9 [M+Hl+, IFINMR (400MHz, CDC13) 6 9.09 (s, 1H), 7.86 (d, J = 2.3 Hz, 1H), 7.49 (dd, J = 2.3, 8.8 Hz, 1H), 7.46 (s, 1H), 7.41 - 7.30 (m, 4H), 7.29 - 7.26 (m, 2H), 6.62 (d, J= 8.8 Hz, 1H), 4.53 (s, 2H), 4.21 (q, J= 5.4 Hz, 1H), 3.75 (s, 3H), 2.61 (d, J= 5.5 Hz, 3H).
Step 5: 4-Amino-N-methyl-3-(1-methyl-1H-imidazol-4-yl)benzenesulfonamide [00436] To a solution of compound 121-5 (170 mg, 0.477 mmol, 1.0 eq) in Me0H (5 mL) were added Pd/C (50 mg, 10% purity) and HC1 (242 mg, 2.38 mmol, 236.79 uL, 36%
purity, 5.0 eq) under N2. The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred under H2 (45 psi) at 25 C for 16 hours. The reaction mixture was filtered and the filtration was concentrated to obtain the title compound 121-6 (140 mg, crude).
Step 6: N-Methyl-3-(1-methyl-1H-imidazol-4-y1)-4-44-(trifluoromethyl)phenyl)amino) benzenesulfonamide [00437] To a solution of compound 121-6 (140 mg, 0.526 mmol, 1.0 eq), compound 121-6a (150 mg, 0.789 mmol, 1.5 eq) and Cu(OAc)2 (115 mg, 0.631 mmol, 1.2 eq) in DCM (5 mL) was added DIPEA (272 mg, 2.10 mmol, 4.0 eq). The reaction mixture was stirred at 25 C for 16 hours. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (30 mL) and the resultant mixture was extracted with EA (50 mL *
3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely. Compound 121 (16.20 mg, 39.47 umol, 7.5% yield) was obtained.
LCMS (ESI): RT = 0.653 min, mass calcd. for Ci8Hi7P3N402S 410.10, m/z found 410.9 [M+H1+, IFINMR (400MHz, CDC13) 6 10.88 (s, 1H), 7.97 (s, 1H), 7.61 - 7.51 (m, 4H), 7.48 (d, J = 8.8 Hz, 1H), 7.33 (d, J= 8.3 Hz, 3H), 4.38 - 4.30 (m, 1H), 3.79 (s, 3H), 2.67 (d, J = 5.5 Hz, 3H).
Example 114: 4-((3,4-difluorophenyl)amino)-N-methyl-3-(2-methyl-2H-tetrazol-5-yl)benzenesulfonamide (Compound 122) N-N
N
F
-S
HN
Preparation of Compound 122:
N-N/ OH
N-N"
1\11 * F
N N
NH2 122-la (1.5 eq) µµ = N = F
)1... 0 ,õ
HN µµ ,,S
,\S DIPEA (2 eq), n I sl I 0 CU(OAC)2 (1.5 eq), I 0 02 (15 Psi),DCM,rt,80 h 122-1 Compound 122 [00438] To a solution of compound 122-1 (50 mg, 0.19 mmol, 1 eq) in DCM (3 mL) was added 3,4-difluorophenyl)boronic acid (122-1a, 44.1 mg, 0.28 mmol, 1.5 eq), Cu(0Ac)2 (50.8 mg, 0.28 mmol, 1.5 eq) followed by DIEA (72.3 mg, 0.56 mmol, 97.38 uL, 3 eq) under N2. The suspension was degassed under vacuum and purged with 02 several times. The mixture was stirred under 02 (15psi) at 25 C for 16 hours. LCMS showed that 7.6% and 55%
of desired product were detected. The reaction was filtered and concentrated. The crude product was purified by Prep HPLC to give Compound 122 (21.1 mg, 54.92 umol, 29.47%
yield). 1HNMR
and LCMS confirmed that desired product was obtained. LCMS (ESI): RT = 0.748 min, mass calcd. For Ci5Hi4F2N602S, 380.10 m/z found 380.9[M+Ht 1HNMR (400MHz, CDC13) 6 9.38 (s, 1H), 8.69 (d, J= 2.0 Hz, 1H), 7.72 (dd, J = 9.2, 2.0 Hz, 1H), 7.25 - 7.10 (m, 3H), 7.10 - 7.00 (m, 1H), 4.47 (s, 3H), 4.38 (d, J= 5.6 Hz, 1H), 2.69 (d, J = 5.2 Hz, 3H).
Example 115: 3-(1-ethyl-1H-imidazol-4-y1)-N-methyl-4-44-(trifluoromethyl)phenyl)amino) benzenesulfonamide (Compound 123) N-\\
N N
I
Preparation of Compound 123:
0 ).
) ). MeNH2 in 0 0 Br Ac20 HOSO2C1 (5.0 eq) 0 Br 0 Br ___________________________________________ THF(2.0 eq) Br )1. )1..
0-80 C, 1hr 0-80 C, 4 hr DCM, 0-25 0=S=0 0=S-CI C, 0.5 hr ii NI H
8 , HO
i B
F 40 Br \LOB_50-L-0 Br N i 0 0" \
F F
HCI (6 M) 123-6a (1.5 eq) 123-5a (1.0 eq) 0 0 F _____________ ).-_,...
100 C, 1 hr Cu(OAc)2 (1.2 eq) N µ`õ, F
Pd(dppf)C12 (0.05 eq) 0=S=0 H '-' F AcOK
(2.0 eq) NH DIPEA (2.0 eq) Dioxane, 90 C, 16 hr DCM, 25 C, 02, 40 hr 123-6 rN
f------\
0õ0 N N-\\
B N N
H Br N H
123-7a (1.2 eq) N
0µ,, 010 010 F _______________ N -S Pd(PPh3)4 (0.05 eq) '''µµ lel N µ`õ, F ,S
H '-' F Cs2CO3 (2.0 eq) HN b F
Dioxane/H20, 90 C, 16 hr I F
Compound 123 Step 1: N-(2-Bromophenyl)acetamide [00439] To a stirring solution of Ac20 (54.5 g, 534 mmol, 2.3 eq) was added bromoaniline (40.0 g, 233 mmol, 1.0 eq) at 0 C, and then the reaction mixture was stirred at 80 C for 1 hour. TLC showed the starting material was consumed. The reaction mixture was concentrated under reduced pressure. Petroleum ether (80 mL) was added the residue, and then the suspension was stirred for 0.5 hour at 25 C. The suspension was filtered to obtain the title compound 123-2 (48 g, 96% yield). 1HNMR (400MHz, CDC13) 6 8.34 (d, J= 8.0 Hz, 1H), 7.61 (brs, 1H), 7.53 (dd, J= 1.0, 8.0 Hz, 1H), 7.36 - 7.28 (m, 1H), 6.98 (t, J= 7.4 Hz, 1H), 2.24 (s, 3H) Step 2: 4-Acetamido-3-bromobenzene-1-sulfonyl chloride [00440] To a stirring of HS03C1 (24.1 g, 207 mmol, 4.4 eq) was added compound 123-2 (10.0 g, 46.7 mmol, 1.0 eq) at 0 C. After addition complete, the reaction mixture was stirred at 80 C for 4 hours. TLC showed the starting material was consumed. The reaction mixture was added to ice (300 g) and then warm up to 25 C. The suspension was extracted with EA (3 *80 mL) to obtain the title compound 123-3 (12 g, crude).
Step 3: N-(2-Bromo-4-(N-methylsulfamoyl)phenyl)acetamide [00441] To a solution of compound 123-3 (12.0 g, 38.4 mmol, 1.0 eq) in DCM
(120 mL) was added MeNH2 (2 M, 38.4 mL, 2.0 eq) at 0 C. The reaction mixture was stirred at 25 C for 0.5 hour. TLC showed the starting material was consumed. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (50 mL) and the resultant mixture was extracted with EA (100 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. EA
(25 mL) was added to the crude product, and then the suspension was filtered to obtain the title compound 123-4 (4.7 g, 40% yield). IFINMR (400MHz, DMSO-d6) 6 9.66 (s, 1H), 7.99 - 7.93 (m, 2H), 7.75 (dd, J = 2.0, 8.5 Hz, 1H), 7.55 (q, J = 4.9 Hz, 1H), 2.44 (d, J= 5.0 Hz, 3H), 2.15 (s, 3H).
Step 4: 4-Amino-3-bromo-N-methylbenzenesulfonamide [00442] A solution of compound 123-4 (4.7 g, 15 mmol, 1.0 eq) in HCl (50 mL) was stirred at 100 C for 1 hour. TLC (Petroleum ether: Ethyl acetate = 2:1) showed the starting material was consumed. The reaction mixture was basified with aq. NaOH (6M) until pH = 9 and the resulting suspension was extracted with EA (150 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure to obtain the title compound 123-5 (3.9 g, 95% yield). IFINMR (400MHz, DMSO-d6) 6 7.68 (d, J= 1.8 Hz, 1H), 7.43 (dd, J = 1.8, 8.5 Hz, 1H), 7.12 (q, J = 4.9 Hz, 1H), 6.86 (d, J= 8.5 Hz, 1H), 6.15 (s, 2H), 2.36 (d, J = 5.0 Hz, 3H).
Step 5: 3-Bromo-N-methy1-4-44-(trifluoromethyl)phenyl)amino)benzenesulfonamide [00443] To a solution of compound 123-5 (3.9 g, 15 mmol, 1.0 eq), compound 123-5a (4.2 g, 22 mmol, 1.5 eq) and Cu(OAc)2 (3.2 g, 18 mmol, 1.2 eq) in DCM (40 mL) was added DIPEA
(5.7 g, 44 mmol, 3.0 eq). The reaction mixture was stirred at 25 C for 40 hours under 02.
LCMS showed -50% of Reactant 123-5 was remained and one peak with desired MS
was detected. The reaction mixture was concentrated under reduced pressure. EA
(120 mL) was added, and then the suspension was filtered. The organic layer was washed with water (30 mL *
2), dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound as a mixture.
The residue was purified by column chromatography over silica gel to afford the title compound 123-6 (620 mg, 10% yield). 1HNMR (400MHz, DMSO-d6) 6 8.51 (s, 1H), 7.96 (d, J
= 2.0 Hz, 1H), 7.68 - 7.61 (m, 3H), 7.49 (d, J = 8.5 Hz, 1H), 7.45 (q, J = 5.1 Hz, 1H), 7.31 (d, J =
8.5 Hz, 2H), 2.43 (d, J = 5.0 Hz, 3H).
Step 6: N-methyl-3-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-4-44-(trifluoromethyl) phenyl)amino)benzenesulfonamide [00444] A solution of compound 123-6 (150 mg, 0.37 mmol, 1.0 eq), compound 123-6a (140 mg, 0.55 mmol, 1.5 eq), Pd(dppf)C12 (13 mg, 18 umol, 0.05 eq) and AcOK
(72 mg, 0.73 mmol, 2.0 eq) in Dioxane (3 mL) was heated to 90 C and stirred at 90 C for 16 hours under N2.
LCMS showed Reactant 123-6 was consumed completely and one main peak with desired MS
was detected. TLC showed the starting material was consumed. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by Prep-TLC to obtain the title compound 123-7 (80 mg, 48% yield).
(400MHz, CDC13) 6 8.29 (s, 1H), 8.23 (d, J= 2.3 Hz, 1H), 7.76 (dd, J = 2.4, 8.9 Hz, 1H), 7.60 (d, J = 8.5 Hz, 2H), 7.30 (t, J = 8.9 Hz, 3H), 4.24 (q, J= 5.4 Hz, 1H), 2.67 (d, J= 5.3 Hz, 3H), 1.38 (s, 12H).
Step 7: 3-(1-Ethyl-1H-imidazol-4-y1)-N-methyl-4-44-(trifluoromethyl)phenyl)amino)benzenesulfonamide [00445] To a solution of compound 123-7 (80 mg, 0.18 mmol, 1.0 eq), compound 123-7a (37 mg, 0.21 mmol, 1.2 eq) and Cs2CO3 (114 mg, 0.35 mmol, 2.0 eq) in Dioxane (3 mL) and H20 (0.6 mL) was added Pd(PPh3)4 (10 mg, 8.8 umol, 0.05 eq). The suspension was degassed under vacuum and purged with N2 several times. The reaction mixture was stirred at 90 C for 16 hours. LCMS showed Reactant 7 was consumed completely and one main peak with desired MS
was detected. The reaction mixture was concentrated under reduced pressure.
The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by Prep-TLC to obtain the Compound 123 as a crude product. The residue was purified by prep-HPLC to obtain Compound 123 (4.68 mg, 6.2%
yield). LCMS (ESI): RT = 0.668 min, mass calcd. for Ci9H19F3N4025 424.12, m/z found 425.0 [M+H1+, 1HNMR (400MHz, CDC13) 6 10.94(s, 1H), 7.98 (d, J= 2.3 Hz, 1H), 7.60-7.54(m, 4H), 7.51 - 7.46 (m, 1H), 7.38 (s, 1H), 7.33 (d, J= 8.3 Hz, 2H), 4.27 (q, J=
5.2 Hz, 1H), 4.08 (q, J = 7.4 Hz, 2H), 2.68 (d, J = 5.5 Hz, 3H), 1.56 - 1.52 (m, 3H).
Example 116: N-methyl-3-(1-methyl-1H-imidazol-4-y1)-4-43-(trifluoromethyl)phenyl) amino)benzenesulfonamide (Compound 124) \N-\\
NN
CZ`
HN,Sµ`
I F F
Preparation of Compound 124:
/r1\1/
N-\\
NN
0õ0 Br 124-1a (1.0 eq) µ` 10 Pd(PPh3)4 (0.05 eq)). ,Sµ
-S Cs2CO3 (2.0 eq) HN \(.1 H Dioxane/H20, 90 C, 16 hr F F
F F
124-1 Compound 124 [00446] To a solution of compound 124-1 (120 mg, 0.26 mmol, 1.0 eq), compound 124-la (42 mg, 0.26 mmol, 1.0 eq) and Cs2CO3 (325 mg, 0.17 mmol, 2.0 eq) in Dioxane (3 mL) and H20 (0.6 mL) was added Pd(PPh3)4 (15 mg, 13 umol, 0.05 eq). The suspension was degassed under vacuum and purged with N2 several times. The reaction mixture was stirred at 90 C for 16 hours. LCMS showed Reactant 124-1 was consumed completely and one main peak with desired MS was detected. The reaction mixture was concentrated under reduced pressure.
The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA
(30 mL * 3).
The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by prep-HPLC to obtain Compound 124 (12.40 mg, 11% yield). LCMS (ESI): RT = 0.650 min, mass calcd. for C18H17F3N4025 410.10, m/z found 410.9 [M+H1+, 1HNMR (400MHz, CDC13) 6 10.83 (s, 1H), 7.97 (d, J= 2.0 Hz, 1H), 7.56 (dd, J
= 2.3, 8.8 Hz, 1H), 7.51 (d, J= 5.8 Hz, 2H), 7.48 - 7.41 (m, 2H), 7.38 - 7.33 (m, 2H), 7.29 (d, J =
6.3 Hz, 1H), 4.33 (q, J= 5.3 Hz, 1H), 3.78 (s, 3H), 2.67 (d, J = 5.5 Hz, 3H).
Example 117: 3-(1-ethyl-1H-imidazol-4-y1)-N-methyl-4-43-(trifluoromethyl)phenyl)amino) benzenesulfonamide (Compound 125) N¨\\
NN
CZµ 401 -S
HN
I F F
Preparation of Compound 125:
/¨
rN
)..( N¨\\
Br 0 0 Br NN
125-la (1.5 eq) 'B H
125-2a (1.0 eq) -S Pd(dppf)Cl2 (0.05 eq) õ
Pd(PPh3)4 (0.05 eq) ,S\ AcOK (2.0 eq) Cs2CO3 (2.0 eq) F F Dioxane, 90 C, 16 hr N-Sµµ HN µõ
H Dioxane/H20, 90 C, 16 hr I u F F
F F
Compound 125 Step 1: N-Methy1-3-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-4-03-(trifluoromethyl) phenyl)amino)benzenesulfonamide [00447] A solution of compound 125-1 (380 mg, 0.93 mmol, 1.0 eq), compound 125-la (354 mg, 1.39 mmol, 1.5 eq), Pd(dppf)C12 (34 mg, 46 umol, 0.05 eq) and AcOK
(182 mg, 1.86 mmol, 2.0 eq) in Dioxane (5 mL) was heated to 90 C and stirred at 90 C for 16 hours under N2.
TLC showed the starting material was consumed. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (30 mL) and the resultant mixture was extracted with EA (50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by Prep-TLC to obtain the title compound 125-2 (310 mg, 73% yield).
Step 2: 3-(1-Ethy1-1H-imidazol-4-y1)-N-methy1-4-03-(trifluoromethyl)phenyl)amino) benzenesulfonamide [00448] To a solution of compound 125-2 (100 mg, 0.22 mmol, 1.0 eq), compound 125-2a (38 mg, 0.22 mmol, 1.0 eq) and Cs2CO3 (143 mg, 0.44 mmol, 2 eq) in Dioxane (3 mL) and H20 (0.6 mL) was added Pd(PPh3)4 (13 mg, 11 umol, 0.05 eq). The suspension was degassed under vacuum and purged with N2 several times. The reaction mixture was stirred at 90 C for 16 hours. LCMS showed Reactant 125-2 was consumed completely and one main peak with desired MS was detected. The reaction mixture was concentrated under reduced pressure.
The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA
(30 mL * 3).
The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by prep-HPLC to obtain Compound 125 (15.56 mg, 16.7% yield). LCMS (ESI): RT = 0.664 min, mass calcd. for C19H19F3N402S
424.12, m/z found 424.9 [M+H1+, 1HNMR (400MHz, CDC13) 6 10.87 (s, 1H), 7.98 (d, J= 2.3 Hz, 1H), 7.58- 7.54 (m, 2H), 7.51 (s, 1H), 7.48 - 7.41 (m, 2H), 7.40 - 7.35 (m, 2H), 7.29 (d, J =
6.8 Hz, 1H), 4.30 (d, J= 5.0 Hz, 1H), 4.08 (q, J= 7.4 Hz, 2H), 2.67 (d, J = 5.5 Hz, 3H), 1.54 (t, J
= 7.4 Hz, 3H).
Example 118: 3-(1-cyclopropy1-1H-imidazol-4-y1)-N-methy1-4-44-(trifluoromethyl)phenyl) amino)benzenesulfonamide (Compound 126) <N-\\
N N
CZ` 40:1 HN,Sµ`
I
FF
Preparation of Compound 126:
OH
12-8.0H
NH 126-la (1.7 eq) F-N
2,2'-bipyridine (1.0 eq) Br Cu(OAc)2 (1.0 eq) Br K2CO3 (2.0 eq) 1,2-dichloroethane, 7000,16 hr FN
Br N-\\
0õ0 126-2 (1.0 eq) N N
F Pd(PPh3)4 (0.05 eq) Cs2CO3 (2.0 eq) CZ`
HN,Sµ` F Dioxane/H20, 90 C, 16 hr ,S
F
1 FNH µ`
I F
126-3 Compound 126 Step 1: 4-Bromo-1-cyclopropy1-1H-imidazole [00449] A solution of compound 126-1 (5.0 g, 34 mmol, 1.0 eq), compound 126-la (5.0 g, 58 mmol, 1.7 eq), Cu(OAc)2 (6.2 g, 34 mmol, 1.0 eq), 2,21-bipyridine (5.3 g, 34 mmol, 1.0 eq) and potassium carbonate (9.4 g, 68 mmol, 2.0 eq) in 1,2-dichloroethane (150 mL) was stirred at 70 C for 16 hrs. TLC showed one new spot was formed. EA (220 mL) was added, and then the suspension was filtered. The organic layer was concentrated under reduced pressure. The mixture was diluted with water (80 mL) and the resultant mixture was extracted with EA (150 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound 126-2 as a crude product. The residue was purified by Prep-TLC
to obtain the title compound 126-2 (1.2 g, 18% yield). IFINMR (400MHz, CDC13) 6 7.42 (s, 1H), 6.95 (d, J= 1.3 Hz, 1H), 3.36 -3.28 (m, 1H), 1.06 - 0.90 (m, 4H).
Step 2: 3-(1-Cyclopropy1-1H-imidazol-4-y1)-N-methyl-4-44-(trifluoromethyl)phenyl) amino)benzenesulfonamide [00450] To a solution of compound 126-3 (70 mg, 0.15 mmol, 1.0 eq), compound 126-3a (34 mg, 0.18 mmol, 1.2 eq) and Cs2CO3 (100 mg, 0.31 mmol, 2.0 eq) in Dioxane (3 mL) and H20 (0.6 mL) was added Pd(PPh3)4 (8.9 mg, 7.7 umol, 0.05 eq). The suspension was degassed under vacuum and purged with N2 several times. The reaction mixture was stirred at 90 C for 16 hours. LCMS showed Reactant 126-3 was consumed completely and one main peak with desired MS was detected. The reaction mixture was concentrated under reduced pressure.
The mixture was diluted with water (20 mL) and the resultant mixture was extracted with EA
(50 mL * 3).
The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by Prep-TLC (to obtain Compound 126 as a crude product. The crude product was purified by prep-HPLC to obtain the title Compound 126 (5.39 mg, 7.4% yield, HC1). LCMS (ESI): RT = 0.677 min, mass calcd. for C20Hi9F3N4025 436.12, miz found 436.9 [M+H1+, IFINMR (400MHz, DMSO-d6) 6 9.58- 9.10(m, 1H), 8.95 (s, 1H), 8.00 (s, 1H), 7.91 (s, 1H), 7.72 - 7.67 (m, 1H), 7.59 (dd, J= 8.7, 15.7 Hz, 3H), 7.40 (d, J = 4.5 Hz, 1H), 7.24 (d, J= 8.5 Hz, 2H), 3.79 - 3.71 (m, 1H), 2.45 (d, J= 4.5 Hz, 3H), 1.15 - 1.05 (m, 4H).
Example 119: 3-(1-cyclopropy1-1H-imidazol-4-y1)-N-methyl-4-43-(trifluoromethyl)phenyl) amino)benzenesulfonamide (Compound 127) N-\\
N N
czµ N
NH,Sµ`
I F F
Preparation of Compound 127:
Nrj Br N-\\
0õ0 NN
127-1a (1.0 eq) 0, Pd(PPh3).4 (0.05 eq) CZµ
NH
S\ Cs2CO3 (2.0 eq) 'Sµ`
Dioxane/H20 I
F F
90 C, 16 hr 127-1 Compound 127 [00451] To a solution of compound 127-1 (100 mg, 0.22 mmol, 1.0 eq), compound 127-la (41 mg, 0.22 mmol, 1.2 eq) and Cs2CO3 (143 mg, 0.438 mmol, 2.0 eq) in Dioxane (3 mL) and H20 (0.6 mL) was added Pd(PPh3)4 (13 mg, 11 umol, 0.05 eq). The suspension was degassed under vacuum and purged with N2 several times. The reaction mixture was stirred at 90 C for 16 hours. LCMS showed Reactant 127-1 was consumed completely and one main peak with desired MS was detected. The reaction mixture was concentrated under reduced pressure.
The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA
(30 mL * 3).
The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by Prep-TLC to obtain Compound 127 as a crude product. The crude product was purified by prep-HPLC to obtain the title Compound 127 (19.18 mg, 18% yield, HC1). LCMS (ESI): RT = 0.675 min, mass calcd. for C20Hi9F3N4025 436.12, m/z found 436.9 [M+H1+, IFINMR (400MHz, DMSO-d6) 6 9.19 - 8.85 (m, 2H), 8.04 (s, 1H), 7.85 (d, J= 2.0 Hz, 1H), 7.70 (dd, J= 2.0, 8.5 Hz, 1H), 7.56 - 7.50 (m, 1H), 7.48 -7.35 (m, 4H), 7.31 (d, J = 7.8 Hz, 1H), 3.81 - 3.75 (m, 1H), 2.44 (d, J= 4.3 Hz, 3H), 1.17 - 1.06 (m, 4H).
Example 120: N-methyl-3-(2-methyltetrazol-5-y1)-4-(4-phenylanilino) benzenesulfonamide (Compound 128) and N,N-dimethy1-3-(2-methyltetrazol-5-y1)-4-(4-phenylanilino)benzenesulfonamide (Compound 129) N-N N-N
NIR NN
NH NH
=
N
Compound 128 Compound 129 Preparation of Compound 128 and Compound 129:
OH
N-N
OH
N-N N-N
N
110 (1.5 eq) NH2 NH2 128-1b abr. NH abh NH
NH.b\\
DIEA (2 0 eq) µ VI CI\
I Cu N
(OAc)2 (1 5 eq) S -Sµ
I 02, DCM, it, 16h IH µ` N
I Li 128-1 128-la Compound 128 Compound 129 [00452] To a mixture of compound 128-1 and compound 128-la (70 mg, 0.26 mol, 1 eq), compound 128-lb and Cu(OAc)2 (71.1 mg, 0.39 mol, 1.5 eq) in DCM (30 mL) was added DIEA
(67.4 mg, 0.52 mol, 91 uL, 2 eq). Then the suspension was degassed under vacuum and purged with 02 several times. The mixture was stirred under 02 (15 psi) at 25 C for 16 hours. LCMS
showed 41% of desired compound was detected. The reaction mixture was filtered and concentrated in vacuum to give the residue. The crude product was purified by prep-HPLC.
LCMS and NMR confirmed that Compound 128 (23.07 mg, 21.0% yield) was obtained.
LCMS and NMR confirmed that Compound 129 (2.02 mg, 1.8% yield) was obtained.
Compound 128: LCMS (ESI): RT = 0.809 min, mass calcd. for C2,H201\1602S, 420.14 m/z found 420.9[M+H] NMR
(400 MHz, CDC13) 6 9.48 (s, 1H), 8.70 (d, J = 2.0 Hz, 1H), 7.72 (dd, J
= 2.4, 8.9 Hz, 1H), 7.63 (dd, J= 8.2, 13.2 Hz, 4H), 7.47 (t, J= 7.7 Hz, 2H), 7.42 - 7.34 (m, 4H), 4.48 (s, 3H), 4.25 (d, J = 5.0 Hz, 1H), 2.71 (d, J = 5.5 Hz, 3H). Compound 129: LCMS (ESI):
RT = 0.856 min, mass calcd. for C22H22N602S, 434.15 m/z found 435.0[M+1-11+.
IFINMR (400 MHz, CDC13) 6 9.50 (s, 1H), 8.63 (d, J= 2.3 Hz, 1H), 7.68 - 7.61 (m, 5H), 7.47 (t, J = 7.7 Hz, 2H), 7.44 - 7.37 (m, 4H), 4.49 (s, 3H), 2.76 (s, 6H).
Example 121: N-methyl-3-(2-methyltetrazol-5-y1)-4-(4-phenoxyanilino) benzenesulfonamide (Compound 130) N-N
\ Ai NH, 0, NI-1.S\v 0 I
Preparation of Compound 130:
\
\ N
0 li N-N
N , N
1101 01 Nj, 1,1 HOB
NH
OH (1.2 eq) 0 40 o NH2 130-la 0 1.- µ`
.S\
DIEA (2.0 eq) NH
cu b pA02 (1.5 eq) I
IS
NH
I a 02, DCM, rt, 16h Compound 130 [00453] A mixture of compound 130-1 (70 mg, 0.26mo1, leq), compound 130-la (55.8 mg, 0.26 mol, 1 eq) and Cu(0Ac)2 (71.1 mg, 0.39 mol, 1.5 eq) in DCM (30 mL) was added DIEA (67.4 mg, 0.52 mol, 91 uL, 2 eq). The suspension was degassed under vacuum and purged with 02 several times. The mixture was stirred under 02 (15psi) at 25 C for 16 hours. LCMS
showed 37 % of desired product was detected. The reaction mixture was filtered and concentrated in vacuum to give the residue. The residue was purified by prep-HPLC. LCMS and H NMR confirmed that Compound 130 (22.02 mg, 19.3% yield) was obtained. LCMS
(ESI):
RT = 0.804 min, mass calcd. for C2,t1201\1603S, 436.49m/z found 459.0[M+Na1 -F. IFINMR (400 MHz, CDC13) 6 9.34 (s, 1H), 8.71 (d, J= 2.0 Hz, 1H), 7.74 - 7.68 (m, 1H), 7.39 (t, J = 7.9 Hz, 2H), 7.31 (s, 2H), 7.24 - 7.13 (m, 2H), 7.09 (dd, J= 6.0, 8.0 Hz, 4H), 4.49 (s, 3H), 4.27 (br d, J =
5.5 Hz, 1H), 2.71 (d, J = 5.5 Hz, 3H).
Example 122: N-methyl-3-(2-methyltetrazol-5-y1)-4-(3-phenylanilino) benzenesulfonamide (Compound 131) and N, N-dimethy1-3-(2-methyltetrazol-5-y1)-4-(3-phenylanilino) benzenesulfonamide (Compound 132) \ \
N-N N-N
NI 1\1 NL IV
H(i H
N N
c\iµ . 0õ w NH.s\\ -S
I U
Compound 131 Compound 132 Preparation of (Compound 131) and (Compound 132):
HO.6.0H
\ \
N-N N-N 0 up NI, "N NI, 'NI
NI, µNI NI, µNI (1.2 eq) H H
131-1b Rµ 40 N WINH2 + op NH2 Cu(OAc(1 5 eq) NA ).- + N
C'µ` 40 0 0µ 0 NHSµ` 'µ
N-Sµ` DIEA (2 0 eq) )2 -, -5 02, DCM, rt, 16h 1 0 I a I a I u 131-1 131-la Compound 131 Compound 132 [00454] To a mixture of compound 131-1 (70 mg, 0.26 mol, 1 eq), compound 131-la (1.00 eq), compound 131-lb (51.7 mg, 0.26 mol, 1 eq) and Cu(0Ac)2 (71.1 mg, 0.39 mol, 1.5 eq) in DCM (25 mL) was added DIEA (67.4 mg, 0.52 mol, 91 uL, 2 eq). The suspension was degassed under vacuum and purged with 02 several times. The mixture was stirred under 02 (15 psi) at 25 C for 16 hours. LCMS showed 22% of desired compound was detected.
The reaction mixture was filtered and concentrated in vacuum to give the residue. The crude product was purified by prep-HPLC. LCMS and H NMR confirmed that Compound 131 (9.86 mg, 8.9%
yield) was obtained. LCMS (ESI): RT = 0.807 min, mass calcd. for C2,t120N602S, 420.49 m/z found 421.1[M+H] -F. IFI NMR (400 MHz, CDC13) 6 9.48 (s, 1H), 8.71 (d, J= 2.3 Hz, 1H), 7.71 (dd, J =1.9, 9.2 Hz, 1H), 7.61 (d, J = 7.3 Hz, 2H), 7.54 (s, 1H), 7.52 - 7.42 (m, 4H), 7.41 - 7.35 (m, 2H), 7.31 (br d, J= 7.3 Hz, 1H), 4.47 (s, 3H), 4.25 (br d, J= 5.5 Hz, 1H), 2.70 (d, J = 5.3 Hz, 2H), 2.72 - 2.68 (m, 1H). LCMS and H NMR confirmed that Compound 132 (4.18 mg, 3.7%
yield) was obtained. LCMS (ESI): RT = 0.853 min, mass calcd. for C22H22N602S, 434.51 m/z found 435[M+H] -F. IFI NMR (400 MHz, CDC13) 6 8.62 (d, J= 2.0 Hz, 1H), 7.66 -7.59 (m, 3H), 7.54 (s, 1H), 7.50 - 7.42 (m, 5H), 7.39 (d, J = 8.8 Hz, 2H), 7.31 (br d, J=
6.8 Hz, 1H), 4.48 (s, 3H), 2.75 (s, 6H).
Example 123: 3-(5-amino-1,3,4-oxadiazol-2-y1)-N-methyl-4-[4-(trifluoromethypanilino]benzenesulfonamide (Compound 133) )=N
0 ,N
H
N
HN-SNN F
I F
Preparation of Compound 133 H
KOAc (3.0 eq) Br Xantphos (0.1 eq) H H Me0H (1:1), H
0% 0 F Pd2dba3 (0.1 eq) CO(45 psi) DMS 140 O/Me0H (5:1) N
0 F 80 C, 5 h ,µ N
HN,sµ` F HN,s,' F
I 0 F I F F F 80 C, 16 h HT N`
SNH )=11 i TMSNCS (1.0 eq) HN 0 EDCI (1.5 eq) H
N
THF, 50 C, 17 h 1401 N
R` 01 F DMSO, 100 C, 2 h Rµ 0 40 ,s F
HN N` F
HN,s F µ' F 1 F
I
133-4 Compound 133 Step 1: methyl 5-(methylsulfamoy1)-2-[4-(trifluoromethypanilino]benzoate [00455] To a solution of compound 133-1 (100 mg, 0.24 mmol, 1 eq), KOAc (71.9 mg, 0.73 mmol, 3 eq) and Xantphos (14.1 mg, 24.4 umol, 0.1 eq) in DMSO (10 mL) and Me0H (2 mL) was added Pd2(dba)3 (22.4 mg, 24.4 umol, 0.1 eq). The suspension was degassed under vacuum and purged with CO several times. The mixture was stirred under CO (45 psi) at 80 C
for 16 hours. LCMS showed that desired product was detected. The Me0H was removed. The residue was diluted with EA (40 mL) and washed with brine (2*20 mL). The organic layer was dried over Na2SO4 and concentrated. The residue was purified by flash silica gel chromatography to give compound 133-2 (80 mg, crude).
Step 2: 3-(hydrazinecarbony1)-N-methyl-4-14-(trifluoromethyDanilino]benzenesulfonamide [00456] To a solution of compound 133-2 (80 mg, 0.2 mmol, 1 eq) in Me0H (1 mL) was added hydrazine hydrate (1.03 g, 17.5 mmol, 1.00 mL, 85% solution, 84.90 eq).
The reaction was heated at 80 C for 5 hr. LCMS showed that 40% of desired product was detected. The reaction was concentrated. The residue was diluted with EA (30 mL) and washed with water (2*10 mL). The organic layer was dried over Na2SO4 and concentrated. The crude product was purified by column chromatography on silica gel (EA: PE = 1:10-1:1) to give compound 133-3 (15 mg, 18.0% yield).
Step 3: 115-(methylsulfamoy1)-2-14-(trifluoromethyDanilino]benzoyl]amino]thiourea [00457] To a solution of compound 133-3 (15 mg, 38.6 umol, 1 eq) in THF (3 mL) was added isothiocyanatotrimethylsilane (5.07 mg, 38.6 umol, 1 eq). The reaction was stirred at 50 C
for 16 hr. LCMS showed that starting material was remained and desired product was detected.
Additional of isothiocyanatotrimethylsilane (10 mg) was added. The reaction was stirred at 50 C
for 1 hr. LCMS showed that 95% of desired product was detected. The reaction was concentrated. The compound 133-4 (15 mg, 82.4% yield) was used for next step directly.
Step 4: 3-(5-amino-1,3,4-oxadiazol-2-y1)-N-methy1-4-14-(trifluoromethyDanilino]benzenesulfonamide [00458] To a solution of compound 133-4 (15 mg, 33.5 umol, 1 eq) in DMSO (1 mL) was added EDCI (9.6 mg, 50.3 umol, 1.5 eq). The reaction was heated at 100 C for 2 hr. LCMS
showed that 74% of desired product was detected. The reaction was diluted with EA (20 mL) and washed with brine (3*5 mL). The organic layer was dried over Na2SO4 and concentrated.
The residue was purified by prep-HPLC to give Compound 133 (2.38 mg, 17.2%
yield). HNMR
and LCMS showed that desired product was obtained. LCMS (ESI): RT = 0.709 min, mass calc.
for Ci6H14F3N503S 413.08, m/z found 413.9 [M+H1+; IFINMR (400 MHz, CDC13) 69.79 (s, 1H), 8.07 (d, J= 2.8 Hz, 1H), 7.80 - 7.70 (m, 3H), 7.60 - 7.50 (m, 5H), 7.50 - 7.30 (m, 1H), 2.41 (s, 3H).
Example 124: N-methy1-3-(2-methyltetrazol-5-y1)-4-(3-phenoxyanilino)benzenesulfonamide (Compound 134) and N,N-dimethy1-3-(2-methyltetrazol-5-y1)-4-(3-phenoxyanilino)benzenesulfonamide (Compound 135) N¨N N¨N
NN NN
Ai NH 0 0õ An NH 0 40 0, .Sµ` .S
N
I I
Compound 134 Compound 135 Preparation of Compound 134 and Compound 135:
Ph3SnCI (0.5 eq) Et3N (10 eq), HO op Br Cu(OAc)2 (0.4 eq) 0 Br rt, 24h N¨N N¨N
N¨N N¨N
oN
"N 1µ1 N N
K2CO3 (2.0 eq), XPhos (0.15 eq) am NH2 NH2 Pd2dha3 (0.05 eq), 134-2 (1.5 12) NH 0 NH 40 0 so 40 40 t-BuOH, 80 C, 16h CZ\ VI
NH.S .S\` -S
-S NH N
N I I u I u I u Compound 134 Compound 135 134-3 134-3a Step 1: 1-bromo-3-phenoxy-benzene [00459] To a Ph3SnC1 (1.11 g, 2.89 mmol, 0.5 eq) and compound 134-1(1 g, 5.78 mmol, 1 eq) in Et3N (5.85 g, 57.80 mmol, 8.1 mL, 10 eq) was added Cu(OAc)2 (419.9 mg, 2.31 mmol, 0.4 eq). The reaction was stirred at 25 C for 24 hr. TLC (EA:PE = 1:3, UV) showed that starting material was detected and a new spot was detected. The reaction was filtered and adjusted pH to 7 with 1N.aq.HC1. The aqueous layer was extracted with EA (3 *20 mL). The organic layer was dried over Na2SO4 and concentrated. The residue was purified by column chromatography on silica gel (EA:PE = 1:15) to give compound 134-2 (0.2 g, crude).
Step 2: N-methy1-3-(2-methyltetrazol-5-y1)-4-(3-phenoxyanilino)benzenesulfonamide and N,N-dimethy1-3-(2-methyltetrazol-5-y1)-4-(3-phenoxyanilino)benzenesulfonamide [00460] To a mixture of compound 134-3 and compound 134-3a (50 mg, 0.19 mmol, 1 eq), K2CO3 (51.51 mg, 0.37 mmol, 2 eq), 1-bromo-3-phenoxy-benzene (69.6 mg, 0.28 mmol, 1.5 eq) and XPhos (13.3 mg, 27.9 umol, 0.15 eq) in t-BuOH (3 mL) was added Pd2(dba)3 (8.5 mg, 9.3 umol, 0.05 eq). The mixture was degassed under vacuum and purged with N2 3 times. The mixture was stirred under N2 at 80 C for 16 hours. LCMS showed that 35% of P1 and 30% of P2 were detected. The reaction was diluted with EA (30 mL) and washed with water (2*10 mL).
The organic layer was dried over Na2SO4 and concentrated. The residue was purified by prep-HPLC to give Compound 134 (5.76 mg, 7.1% yield) and Compound 135 (2.12 mg, 2.5%
yield). Compound 134: LCMS (ESI): RT = 0.798 min, mass calcd. for C21H201\1603S, 436.13 miz found 436.9[M+H] NMR (400 MHz, CDC13) 6 9.40 (s, 1H), 8.67 (s, 1H), 7.68 - 7.81 (m, 1H), 7.36 (dd, J = 8.41, 4.89 Hz, 4H), 7.13 (br t, J= 7.28 Hz, 1H), 7.00 -7.10 (m, 3H), 6.96 (s, 1H), 6.82 (d, J= 8.03 Hz, 1H), 4.45 (s, 3H), 4.38 (br d, J= 5.27 Hz, 1H), 2.68 (d, J= 5.27 Hz, 3H). Compound 135: LCMS (ESI): RT = 0.842 min, mass calcd. for C22H22N603S, 450.15 miz found 451.0[M+H] NMR (400 MHz, CDC13) 6 9.42 (s, 1H), 8.58 (d, J= 2.01 Hz, 1H), 7.62 (dd, J = 8.91, 2.13 Hz, 1H), 7.32 - 7.41 (m, 4H), 7.10 - 7.17 (m, 1H), 7.03 - 7.09 (m, 3H), 6.97 (s, 1H), 6.82 (br d, J= 8.28 Hz, 1H), 4.46 (s, 3H), 2.73 (s, 6H).
Example 125: 3-12-1(2-Fluorophenyl)methyl]tetrazol-5-y1]-N-methyl-4-13-(trifluoromethypanilino]benzenesulfonamide (Compound 136) fi NI!
1\R N
FFF
CZ` W
,S
H
Preparation of Compound 136:
OH F
E F
HOB *
136-1a 1.2eq = N-N%
Cu(OAc)2 (1.2eq) czµ NH2 DIPEA (2.0 eq) N
CZ\ DCM,02, 25 C, 16 hr -S ,S
N N
H H
F F
Compound 136 [00461] To a solution of compound 136-1(100 mg, 0.28 mmol, 1.0 eq), compound 136-la (62.9 mg, 0.33 mmol, 1.2 eq) and Cu(OAc)2 (60.2 mg, 0.33 mmol, 1.2 eq) in DCM
(2 mL) was added DIPEA (71.3 mg, 0.55 mmol, 2.0 eq). The reaction mixture was stirred at 25 C for 16 hours under 02. LCMS showed reactant 1 was consumed completely and one main peak with desired MS was detected. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by prep-HPLC to give Compound 136 (52.54 mg, 37.2% yield). LCMS (ESI): RT = 1.045 min, mass calcd. for C22F118F4N6025 506.11, m/z found 507.3 [M+I-11+,1H NMR (400 MHz, CDC13) 6 ppm 9.56 (s, 1 H), 8.70 (d, J=2.26 Hz, 1 H), 7.74 (dd, J= 8.78, 2.26 Hz, 1 H), 7.54 (s, 1 H), 7.50 (m, 3 H) ,7.44 (d, J= 1.76 Hz, 1 H) ,7.41 (m, 3 H), 7.36 (s, 1 H), 7.34 (s, 1 H), 7.18 (m, 2 H), 5.94 (s, 2 H), 4.31 (q, J= 5.27 Hz, 1 H) ,2.70 (d, J= 5.27 Hz, 3 H).
Example 126: 3-[2-[(2-Fluorophenyl)methyl]tetrazol-5-y1]-N-methy1-4-14-(trifluoromethypanilino]benzenesulfonamide (Compound 137) F
. N-N
N N
H
N
0.µ 010 0 F
,S
F
H F
Preparation of Compound 137:
I` I` A' Br Ac20 ( 2.3 eq) HNit HN HN N
, HOSO2C1( 5.0 eq) Br MeNH2 in THF(2.0 eq) IP 0-80 C, 1hr 0 Br 0-80 C, 4 hr ' 40 DCM, 0-25 C, 0.5 hr Br CuCN ( 3.0 eq) -.,.. CN NaN3 (3.0 eq) ' 0 e DMF, 120 C, 16 hr NH4CI
(3.0 eq) DMF, 120 C, 16 hr 0=8=0 0=8=0 0=S=0 CI ,NH .NiFi F F F
NrIH1 C5---sF Br it . I,'I-N, N , N HOrliS F
. .-N
N-N
137-6a (1.0 eq) 14, I\I HCI (6M) N., '14 F F137-8a (1.2..9) Nr, )INI
NH 0 _____________ 0, 40 r K2CO3 (1.5 eq) H
N 0 100 C, 16 hr D..
0 NH2 CDup EAAc)2(10.2e7) H
N
.1,1H00 DMF, 80 C, 1 hr, MW C's` 0 40 os 40 T 0, DCM,02, 25 C, 16 hr F
F F
137-6 137-7 137-8 Compound 137 Step 1: N-(2-Bromophenyl)acetamide [00462] To a stirring solution of Ac20(41.0 g, 401 mmol, 2.3 eq) was added compound 137-1 (30.0 g, 174 mmol, 1.0eq) at 0 C, and then the reaction mixture was stirred at 80 C for 1 hour. TLC (Petroleum ether: Ethyl acetate = 5:1) indicated reactant 1 was completely, and one major new spot with larger polarity was detected. The reaction mixture was concentrated under reduce pressure to give a residue. The residue was washed with PE (100 mL *2) and dried under reduced pressure to obtain compound 137-2 (34.5 g, 92.4% yield).
Step 2: 4-Acetamido-3-bromo-benzenesulfonyl chloride [00463] To a stirring of HS03C1 (93.6 g, 803 mmol, 5 .0eq) was added compound 137-2 (34.0 g, 159 mmol, 1.0 eq) at 0 C. After addition, the reaction mixture was stirred at 80 C for 6 hours. TLC (Petroleum ether:Ethyl acetate = 2:1) showed the starting material was consumed and two new spots were formed. The reaction mixture was added to ice (400 g) and then warm up to 25 C. The suspension was extracted with EA (3 *400 mL) to obtain compound 137-3 (35 g, crude). NMR (400 MHz, DMSO-d6) 6 ppm 9.49 (br s, 1 H),7.76 (d, J= 1.51 Hz, 1 H), 7.54 (m, 1 H), 7.32 (dd, J= 8.16, 1.88 Hz, 1 H), 2.08 (s, 3 H).
Step 3: N- 12-Bromo-4-(methylsulfamoyl)phenyl]acetamide [00464] To a solution of compound 137-3 (33.0 g, 106 mmol, 1.0eq) in DCM (300 mL) was added MeNH2 (2 M, 106 mL, 2.0 eq) at 0 C. The reaction mixture was stirred at 25 C for 0.5 hour. TLC (Petroleum ether:Ethyl acetate = 2:1) showed the starting material was consumed.
The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (100 mL) and the resultant mixture was extracted with EA (300 mL * 3).
The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. EA (30 mL) was added to the crude product, and then the suspension was filtered to obtain compound 137-4 (12.0 g, 37.1% yield).
Step 4: N-12-Cyano-4-(methylsulfamoyl)phenyl]acetamide [00465] To a solution of compound 137-4 (2.0 g, 6.5 mmol, 1.0 eq) in DMF (20mL) was added CuCN (1.75 g, 19.5 mmol, 3.0 eq). And then the mixture was stirred at 120 C for 16 hr.
TLC (Petroleum ether:Ethyl acetate = 1:1) showed the starting material was consumed. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with EA(50mL) and the resultant mixture was extracted with water (50 mL * 3). The combined organic layers were dried over Na2SO4, and concentrated to dryness under reduced pressure. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate = 1:0 to 1:1) to obtain compound 137-5 (900 mg, 54.6% yield).
Step 5: N-14-(Methylsulfamoy1)-2-(2H-tetrazol-5-yl)phenyl]acetamide [00466] To a solution of compound 137-5 (900 mg, 3.55 mmol, 1.0 eq) and NH4C1 (570 mg, 10.7 mmol, 3.0 eq) in DMF (10 mL) was added NaN3 (690 mg, 10.6 mmol, 3.0 eq). The reaction mixture was stirred at 120 C for 16 hours. LCMS showed reactant 137-5 was consumed completely and one main peak with desired MS was detected. The reaction mixture was dropwise to HCl (15 mL, 1M), and then the suspension was filtered to obtain the title compound 137-6 (750 mg, 71.2% yield).
Step 6: N- [2-[2-[(2-Fluorophenyl)methyl]tetrazol-5-y1]-4-(methylsulfamoyl)phenyl]acetamide [00467] Compound 137-6 (500 mg, 1.69 mmol, 1.0 eq) , compound 137-6a (319 mg, 1.69 mmol, 1.0 eq) and K2CO3 (350 mg, 2.53 mmol, 1.5 eq) were taken up into a microwave tube in DMF (5 mL) .The sealed tube was heated at 80 C for 1 hr under microwave. LCMS
showed reactant 137-6 was consumed completely and one main peak with desired MS was detected. TLC
(Petroleum ether: Ethyl acetate = 2:1) indicated reactant 137-6 was remained, and one major new spot with lower polarity was detected. The reaction mixture was diluted with H20 (15 mL) and extracted with EA (40 mL). The organic layer was washed with H20 (20 mL * 3).
The organic layer was dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography (5i02, Petroleum ether/Ethyl acetate = 1:0 to 2:1) to give compound 137-7 (540 mg, 79.1% yield).
Step 7: 4-Amino-3-[2-[(2-fluorophenyl)methyl]tetrazol-5-y1]-N-methyl-benzenesulfonamide [00468] To a solution of compound 137-7 (440 mg, 1.09 mmol, 1. Oeq) was added HC1 (6 M, 8.8 mL, 48.5 eq) . The mixture was stirred at 100 C for 16 hr. LCMS showed reactant 137-7 was consumed completely and one main peak with desired MS was detected. The mixture was adjusted with NaOH (6M) to pH = 8, and then the suspension was extracted with EA (3 * 50 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure to obtain the title compound 137-8 (340 mg, 86.2%
yield) was obtained.
Step 8: 3-[2-[(2-Fluorophenyl)methyl]tetrazol-5-y1]-N-methy1-4-14-(trifluoromethypanilino]benzenesulfonamide [00469] To a solution of compound 137-8 (100 mg, 0.27 mmol, 1.0 eq) compound 137-8a (62.9 mg, 0.33 mmol, 1.2 eq) and Cu(OAc)2 (60.2 mg, 0.33 mmol, 1.2 eq) in DCM
(2 mL) was added DIPEA (71.3 mg, 0.55 mmo1,2.0 eq). The reaction mixture was stirred at 25 C for 16 hours under 02.LCMS showed reactant 137-8 was consumed completely and one main peak with desired MS was detected. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by prep-HPLC to give Compound 137 (23.0 mg, 16.3% yield). LCMS (ESI): RT = 1.042 min, mass calcd. for C22H18F4N602S506.11, m/z found 507.3 [M+H1+;11-1NMR (400 MHz,CDC13) 6 9.63 (s, 1 H), 8.69 (d, J= 2.26 Hz, 1 H) ,7.77 (d, J = 2.26 Hz, 1 H), 7.75 (d, J =
2.26 Hz, 1 H), 7.63 (d, J = 8.78 Hz, 2 H), 7.48 (d, J = 8.78 Hz, 1 H), 7.41 (m, 2 H), 7.36 (d, J=
8.28 Hz, 2 H) ,7.26 (s, 7 H) ,7.19 (m, 2 H) ,5.94 (s, 2 H) ,4.30 (q, J= 5.35 Hz, 1 H) ,2.70 (d, J=
5.27 Hz, 3 H) ,1.25 (s, 1 H).
Example 127: N-(tert-butyl)-3-(2-methyl-2H-tetrazol-5-y1)-4-44-(trifluoromethyl)phenyl)amino)benzenesulfonamide (Compound 138) N¨N
NIR
N
R` IW
HNb FF
Preparation of Compound 138 OH
N¨N a B. ON. H N¨N
"N F 138-1a (1.2 eq) F Cu(0Ac)2 (1.2 eq) NH DIEA (2 0 eq) DCM, 02, 25 C,12 hr R\ 40 HNb HNb Compound 138 [00470] To a solution of compound 138-1 (0.09 g, 0.28 mmol, 1 eq) and compound 138-la (66.0 mg, 0.34 mmol, 1.2 eq) in DCM (7 mL) was added Cu(0Ac)2 (63.2 mg, 0.34 mmol, 1.2 eq) and DIPEA (112.4 mg, 0.86 mmol, 0.2 mL, 3 eq). The mixture was stirred at 25 C for 16 hr under 02. LCMS showed the starting material was consumed and the desired mass was detected.
The reaction mixture was filtered. The filter cake was washed with ethyl acetate (10 ml*3) and the combined organic layers was washed by NaCl (8 mL*3) then concentrated in vacuum to give crude product. The residue was purified by prep-HPLC. Compound 138 (7.88 mg, 5.5% yield, HC1) was obtained. LCMS (ESI): RT = 0.833 min, mass calc. for Ci9H2IF3N602S
454.14, m/z found 455.0 [M+H]+; IFINMR (400 MHz, DMSO-d6) 6 8.95 (s, 1 H), 8.20-8.18 (d, J= 8.0 Hz, 1H), 7.89-7.89 (d, J= 1.6 Hz, 1H), 7.71 (s, 1H), 7.66-7.64 (d, J = 8.8 Hz, 2H), 7.56-7.53 (dd, Ji = 1.6 Hz, J2 = 8.0 Hz, 1H), 7.30-7.28 (d, J= 8.0 Hz, 2H), 4.46 (s, 3H), 1.38 (s, 9H).
Example 128: 4-(4-chloroanilino)-N-methyl-3-(1-methylimidazol-4-yl)benzenesulfonamide (Compound 139) \N¨\\
N N
R` el el HN-S\\ CI
I
Preparation of Compound 139:
\N¨\\ OH \¨
\\
B
N N HO a N
139-1a"' CI
=
CZ\ CZµ
Cu(OAc)2 (2 eq) N
HN,Sµ` CI
HN,sµ` DIPEA(4 eq) I
139-1 02, DCM, 25 C, 16hr Compound 139 [00471] A mixture of compound 139-1 (50 mg, 0.18 mmol, 1 eq), compound 139-la (58.7 mg, 0.37 mmol, 2 eq), Cu(0Ac)2 (68.2 mg, 0.37 mmol, 2 eq) and DIEA (97.0 mg, 0.75 mmol, 0.1 mL, 4eq) in DCM (3 mL) was degassed and purged with 02 for 3 times, and then the mixture was stirred at 25 C for 16 hr under 02 atmosphere. LCMS showed the desired compound was detected. The reaction mixture was diluted with H20 (10 mL) and the mixture extracted with EA
(15 mL * 3). The combined organic phase was washed with brine (10 mL*3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC. Compound 139 (5 mg, 6.9% yield) was obtained and confirmed by LCMS and H
NMR.
LCMS (ESI): RT = 0.657 min, mass calc. for Ci7Hi7C1N402S 376.08, m/z found 398.9 [M+Na1+;
IFINMR (400 MHz, DMSO-d6) 6 ppm 2.41 (d, J= 5.02 Hz, 3 H) 3.83 (s, 3 H) 7.18 (d, J = 8.78 Hz, 2 H) 7.29 (br d, J= 5.02 Hz, 1 H) 7.31 - 7.39 (m, 3 H) 7.60 (dd, J = 8.78, 2.26 Hz, 1 H) 7.80 (d, J = 2.01 Hz, 1 H) 7.88 (s, 1 H) 8.68 (br s, 1 H).
Example 129: 4-(3,4-dichloroanilino)-N-methyl-3-(1-methylimidazol-4-yl)benzenesulfonamide (Compound 140) N¨\\
x N
N CI
.µ
HN
I
Preparation of Compound 140:
\N-\\ \N-\\
(H0)2B CI
N N NN
140-la CI
________________________________________ )11.
CZ\ '''µµ
,Sµ` Cu(OAc)2 (1.5 eq) =
HN
DIPEA(2 eq) HN
140-1 air, DCM, 25 C, 10 mm I
Compound 140 1004721 A mixture of compound 140-1 (30 mg, 0.11 mmol, 1 eq), compound 140-la (42.9 mg, 0.22 mmol, 2 eq), DIEA (58.2 mg, 0.45 mmol, 78 uL, 4 eq) and Cu(0Ac)2 (40.9 mg, 0.22 mmol, 2 eq) in DCM (3 mL) was degassed and purged with 02 for 3 times, and then the mixture was stirred at 25 C for 10 min under 02 atmosphere. LCMS showed the desired compound was detected. The reaction mixture was diluted with H20 (10 mL) and the mixture was extracted with EA (10 mL * 3). The combined organic phase was washed with brine (10 mL*2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC. Compound 140 (5.8 mg, 12.5% yield) was obtained and confirmed by LCMS
and NMR. LCMS (ESI): RT = 0.657 min, mass calc. for Ci7H16C12N402S 410.04, m/z found 410.9 [M+H1+; IFINMR (400 MHz, DMSO-d6) 6 ppm 2.44 (d, J= 4.77 Hz, 3 H) 3.87 (s, 3 H) 7.10 -7.16 (m, 1 H) 7.34 (d, J = 2.51 Hz, 1 H) 7.41 (br d, J= 5.02 Hz, 1 H) 7.50 (dd, J= 19.83, 8.78 Hz, 2 H) 7.69 (dd, J= 8.78, 2.01 Hz, 1 H) 7.86 (d, J= 2.01 Hz, 1 H) 7.98 (s, 1 H) 8.89 - 9.04 (m, 1 H) 8.98 (br s, 1 H).
Example 130: N-methyl-3-(1-methylimidazol-4-y1)-4-13-(trifluoromethylsulfanypanilino]benzenesulfonamide (Compound 141) N-\\
x N
SF
I
Preparation of Compound 141:
\N-\\ \
Br SF N-\\
N N )<F
NN
NH= 141-1a 1.2 eq 2 _____________________________________ SF
Pd2(dba)3 (0.1eq) CZ\ 10 HN,µSµ` XPhos (0.2 eq) I K2CO3 (3.0 eq) HN µ`
141-1 Dioxane, 100 C, 10 h I
Compound 141 [00473] To a mixture of compound 141-1 (0.03 g, 0.11 mmol, 1 eq) and compound 141-la (34.7 mg, 0.13 mmol, 1.2 eq) in dioxane (2 mL) was added Pd2(dba)3 (10.3 mg, 0.01 mmol, 0.1 eq), XPhos (10.7 mg, 0.02 mmol, 0.2 eq) and K2CO3 (46.7 mg, 0.33 mmol, 3 eq) under N2. The mixture was stirred for 10 h at 100 C. LCMS showed the reaction was complete.
The mixture was quenched by EA (30 mL), and the mixture was filtered and the filtered cake was washed with EA (20 mL*3). The combined organic phase was washed with brine (20 mL*3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by pre-HPLC
was obtained. LCMS (ESI): RT = 0.662 min, mass calc. for: Ci8tli7F3N402S2 442.07, m/z found 442.9 [M+H1+; IFINMR (400 MHz, CD30D) 6 9.01 (s, 1H), 7.92 - 7.79 (m, 3H), 7.55 - 7.42 (m, 3H), 7.38 - 7.33 (m, 2H), 3.99 (s, 3H), 2.60 - 2.57 (m, 3H).
Example 131: 4-(3,5-dichloroanilino)-N-methyl-3-(1-methylimidazol-4-yl)benzenesulfonamide (Compound 142) \N-\\
x N
CI
µµ el HN,Sµ`
I CI
Preparation of Compound 142:
\N-A \N-A
(H0)2B # CI
x N x N
142-1a 2 eq Cu(OAc)2 (2 eq) s DIPEA(5 eq) HN HN,sµ`
µ0 142-1 02, DCM, 25 C, 10 min 0 CI
Compound 142 [00474] To a mixture of compound 142-1 (0.05 g, 0.18 mmol, 1 eq) and compound 142-la (71.6 mg, 0.37 mmol, 2 eq) in DCM (5 mL) was added Cu(0Ac)2 (68.2 mg, 0.37 mmol, 2 eq) and DIPEA (121.3 mg, 0.93 mmol, 0.2 mL, 5 eq) in one portion at 25 C under 02.
The mixture was stirred for 10 min under 15 PSI. LCMS showed the reaction was complete.
The mixture was quenched by EA (30 mL), and the mixture was filtered and the filtered cake was washed with EA
(20 mL*3). The combined organic phase was washed with brine (20 mL*3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by pre-HPLC.
Compound 142 (12.8 mg, 15.2% yield, HC1) was obtained. LCMS (EST): RT = 0.647 min, mass calc. for: Ci7Hi6C12N4025 410.04, m/z found 410.9 [M+1-11+; IFINMR (400 MHz, CD30D) 6 8.97 (s, 1H), 7.94 (d, J= 2.0 Hz, 1H), 7.90 - 7.83 (m, 2H), 7.53 (d, J= 8.5 Hz, 1H), 7.07 - 7.03 (m, 3H), 3.99 (s, 3H), 2.59 (s, 3H).
Example 132: 4-(3-Chloroanilino)-N-methyl-3-(1-methylimidazol-4-yl)benzenesulfonamide (Compound 143) \N-\\
x N
czµ N CI
HN-Sµ`
I
Preparation of Compound 143:
\N-\\ (H0)2B * CI \N__\\
N N 143-la N N
2 eq NH2 ____________________________________ o Cu(OAc)2 (2 eq) N CI
DIPEA(5 eq) CZµ
HNI,sµ`
02, DCM, 25 C, 10 min HN-s µ`
Compound 143 [00475] To a mixture of compound 143-1 (0.05 g, 0.18 mmol, 1 eq) and compound 143-la (58.7 mg, 0.37 mmol, 2 eq) in DCM (20 mL) was added Cu(0Ac)2 (68.2 mg, 0.37 mmol, 2 eq) and DIPEA (121.3 mg, 0.93 mmol, 0.2 mL, 5 eq) in one portion at 25 C under 02.
The mixture was stirred for 10 min under 15 psi. LCMS showed the reaction was complete.
The mixture was quenched by EA (30 mL), and the mixture was filtered and the filtered cake was washed with EA
(20 mL*3). The combined organic phase was washed with brine (20 mL*3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by pre-HPLC.
Compound 143 (22.02 mg, 28.4% yield, HC1) was obtained. LCMS (ESI): RT = 0.616 min, mass calc. for: Ci7H17C1N402S 376.08, m/z found 376.9 [M+Na1+; IFINMR (400 MHz, DMSO-d6) 6 9.20 (br s, 1H), 8.59 (br s, 1H), 8.02 (s, 1H), 7.83 (d, J = 2.3 Hz, 1H), 7.71 (dd, J = 2.1, 8.7 Hz, 1H), 7.48 - 7.39 (m, 2H), 7.32 (t, J = 8.0 Hz, 1H), 7.18 - 7.09 (m, 2H), 7.03 (dd, J = 1.3, 7.8 Hz, 1H), 3.90 - 3.87 (m, 3H), 2.46 - 2.43 (m, 3H).
Example 133: N-methy1-3-(1-methylimidazol-4-y1)-4-14-(trifluoromethylsulfanyl)anilino]benzenesulfonamide (Compound 144) \N-\\
x N
R` I.
HN,Sµ` SF
I
Preparation of Compound 144:
N 1.1 )<F
Br NN
144-1a1.2 eq CZ\ Pd2(dba)3 (0.1eq) XPhos (0.2 eq) Hµ` la SF
HN
144-1 K2CO3 (3.0 eq) I
Dioxane, 100 C, 10 h Compound 144 [00476] To a mixture of compound 144-1 (0.03 g, 0.11 mmol, 1 eq) and compound 144-la (34.7 mg, 0.13 mmol, 20 uL, 1.2 eq) in dioxane (2 mL) were added Pd2(dba)3 (10.3 mg, 0.01 mmol, 0.1 eq), XPhos (10.7 mg, 0.02 mmol, 0.2 eq) and K2CO3 (46.7 mg, 0.33 mmol, 3 eq) under N2. The mixture was stirred for 10 h at 100 C. LCMS showed the reaction was complete.
The mixture was quenched by EA (30 mL), and the mixture was filtered and the filtered cake was washed with EA (20 mL*3). The combined organic phase was washed with brine (20 mL*3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by pre-HPLC. Compound 144 (3.03 mg, 5.6% yield, HC1 salt) was obtained. LCMS
(ESI): RT = 0.672 min, mass calc. for: Ci8Hi7F3N402S2 442.07, m/z found 442.9 [M+H1+; 11-1 NMR (400 MHz, CDOD3) 6 8.99 (s, 1H), 7.93 (d, J= 2.0 Hz, 1H), 7.85 (s, 1H), 7.86 (d, J = 9.8 Hz, 2H), 7.60 (dd, J= 3.0, 8.5 Hz, 3H), 7.19 (d, J= 8.8 Hz, 2H), 3.97 (s, 3H), 2.60 (s, 3H).
Example 134: N-methy1-3-(1-methylimidazol-4-y1)-4-(3,4,5-trichloroanilino)benzenesulfonamide (Compound 145) \N¨\\
x N CI
HNµ` CI
CI
Preparation of Compound 145:
(H0)2B CI
N¨\\ N¨
NN
145-la CICI x 2 NH 2 eq N CI
CU(OAC)2 (2 eq) CZ`
HNSµ` DIPEA(4 eq) CI
HN,sµ`
0 145-1 air, DCM, 25 C, 3 min 0 CI
Compound 145 [00477] The mixture of compound 145-1 (30 mg, 0.11 mmol, 1 eq), compound 144-la (50.7 mg, 0.22 mmol, 2 eq), DIEA (58.2 mg, 0.45 mmol, 78.48 uL, 4 eq) and Cu(OAc)2 (40.9 mg, 0.22 mmol, 2 eq) in DCM (5 mL) was stirred at 25 C for 3 min. LCMS showed the desired compound was detected. The mixture was combined with E7868-127. The reaction mixture was diluted with H20 (10 mL) and the mixture was extracted with EA (10 mL * 3).
The combined organic phase was washed with brine (10 mL*2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC. Compound 145 (5.5 mg, 10.9% yield) was obtained. LCMS (ESI): RT = 0.678 min, mass calc. for Ci7Hi5C13N402S
444.00 found 446.9 [M+H1+; 1HNMR (400 MHz, DMSO-d6) 6 ppm 2.45 (br d, J= 4.52 Hz, 2 H) 2.46 - 2.47 (m, 1 H) 3.86 (s, 3 H) 7.32 (s, 2 H) 7.46 (br d, J= 5.02 Hz, 1 H) 7.57 (d, J= 8.53 Hz, 1 H) 7.72 (br d, J= 8.28 Hz, 1 H) 7.90 - 8.00 (m, 2 H) 8.91 (br s, 1 H) 9.23 (br s, 1 H).
Example 135: 4-[3,5-Bis(trifluoromethypanilino]-N-methy1-3-(1-methylimidazol-4-yl)benzenesulfonamide (Compound 146) \N¨\\
N N
HFF
czµ N
F
HN,sµ`
F F
Preparation of Compound 146:
OH F
HO F N¨
N¨ NN
NN 146-la 2 eq F F
F
NH2 _____________________________________ (31µµ
µµ Cu(OAc)2 (2 eq) ,S
HN,Sµ` DIPEA(4 eq) HN µ`
air, DCM, 25 C, 3 min I
F F
Compound 146 [00478] The mixture of compound 146-1 (50 mg, 0.18 mmol, 1 eq), compound 146-la (96.8 mg, 0.37 mmol, 2 eq), DIEA (97.0 mg, 0.75 mmol, 0.1 mL, 4 eq) and Cu(OAc)2 (68.2 mg, 0.37 mmol, 2 eq) in DCM (5 mL) was stirred at 25 C for 3 min. LCMS showed the desired compound was detected. The reaction mixture was diluted with H20 (10 mL) and the mixture was extracted with EA (10 mL * 3). The combined organic phase was washed with brine (10 mL*2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC. Compound 146 (17 mg, 18.1% yield) was obtained. LCMS
(ESI): RT =
0.728 min, mass calc. for Ci9H16P6N402S 478.09, m/z found 479.0 [M+1-11+;
IFINMR (400 MHz, DMSO-d6) 6 ppm 2.46 (d, J= 5.02 Hz, 3 H) 3.84 (s, 3 H) 7.45 (br d, J= 5.02 Hz, 1 H) 7.55 (s, 1 H) 7.60 (d, J= 8.53 Hz, 1 H) 7.58 - 7.61 (m, 1 H) 7.63 (s, 2 H) 7.74 (br d, J=
7.28 Hz, 1 H) 7.97 (br d, J= 17.82 Hz, 2 H) 8.82 (br s, 1 H) 9.25 - 9.57 (m, 1 H) .
Example 136: 4-[4-Chloro-3-(trifluoromethypanilinol-N-methyl-3-(1-methylimidazol-4-yl)benzenesulfonamide (Compound 147) N¨\\
x N
HN µ, µSµ` = CI
F F
Preparation of Compound 147:
\N¨\\ (H0)2B
\N¨\\
NN 147-la CI
N N
F F 2 eq NH2 ______________________________________ C
el HN-Sµ` DIPEA(5 eq) HN,Sµ` CI
02, DCM, 25 C, 10 min I
Compound 147 [00479] To a mixture of compound 147-1 (0.05 g, 0.18 mmol, 1 eq) and compound 147-la (84.2 mg, 0.37 mmol, 2 eq) in DCM (20 mL) was added Cu(0Ac)2 (68.2 mg, 0.37 mmol, 2 eq) and DIPEA (121.3 mg, 0.93 mmol, 0.2 mL, 5 eq) in one portion at 25 C under 02.
The mixture was stirred for 10 min under 15 Psi. LCMS showed the reaction was complete.
The mixture was quenched by EA (30 mL), and the mixture was filtered and the filtered cake was washed with EA
(20 mL*3). The combined organic phase was washed with brine (20 mL*3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by pre-HPLC.
Compound 147 (6.98 mg, 7.7% yield, HC1) was obtained. LCMS (ESI): RT = 0.662 min, mass calc. for: C181-116C1F3N402S 444.06, m/z found 444.9 [M+1-11+; IFINMR (400 MHz, CD30D) 6 8.98 (s, 1H), 7.93 - 7.82 (m, 3H), 7.55 - 7.46 (m, 3H), 7.38 (br d, J= 8.8 Hz, 1H), 4.00 (s, 3H), 2.59 (s, 3H).
Example 137: 4-[3-Chloro-4-(trifluoromethypanilino]-N-methyl-3-(1-methylimidazol-4-yl)benzenesulfonamide (Compound 148) N¨\\
x N
(:)µµ N CI
HN,sµ`
Preparation of Compound 148:
\N¨\\
(H0)2B CI N¨\\
NN 148-1a IW F NN
2 eq NH2 _______________________________________________ N CI
(:)µµ Cu(OAc)2 (2 eq) CZ\ 01 HN,Sµ` DIPEA(5 eq) ,S
I = HN
02, DCM, 25 C, 10 min 0 F F
Compound 148 [00480] To a mixture of compound 148-1 (0.05 g, 0.18 mmol, 1 eq) and compound 148-la (84.2 mg, 0.37 mmol, 2 eq) in DCM (20 mL) was added Cu(0Ac)2 (68.2 mg, 0.37 mmol, 2 eq) and DIPEA (121.3 mg, 0.93 mmol, 0.2 mL, 5 eq) in one portion at 25 C under 02.
The mixture was stirred for 10 min under 15 Psi. LCMS showed the reaction was complete.
The mixture was quenched by EA (30 mL), and the mixture was filtered and the filtered cake was washed with EA
(20 mL*3). The combined organic phase was washed with brine (20 mL*3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by pre-HPLC.
Compound 148 (6.02 mg, 6.7% yield, HC1) was obtained. LCMS (ESI): RT = 0.668 min, mass calc. for: C181-116C1F3N402S 444.06, m/z found 444.9 [M+1-11+; IFINMR (400MHz, CD30D) 6 8.97 (s, 1H), 7.99 (d, J= 2.3 Hz, 1H), 7.90 (d, J= 9.0 Hz, 1H), 7.88 - 7.86 (m, 1H), 7.64 (dd, J =
4.6, 8.7 Hz, 2H), 7.22 (d, J = 1.8 Hz, 1H), 7.11 (dd, J= 1.9, 8.7 Hz, 1H), 3.99 (s, 3H), 2.61 (s, 3H).
Example 138: 4-((2,6-Difluorophenyl)amino)-N-methyl-3-(1-methyl-1H-imidazol-4-yl)benzenesulfonamide (Compound 149) N¨\\
x N
oµµ N
HN,Sµ`
I
Preparation of Compound 149:
\N-\\ pH F \N-\\
HOB 149-la (1.5 eq) N N F DIPEA (4 eq) x N
Cu(OAc)2 (1.5 eq) NH2 __________________________________________________ N
02, DCM, 25 C, 30 min Ot S
HN Sµ` HN,µ`
I I
149-1 Compound 149 [00481] The mixture of compound 149-1 (50 mg, 0.18 mmol, 1 eq), compound 149-la (44.4 mg, 0.28 mmol, 1.5 eq), Cu(0Ac)2 (51.1 mg, 0.28 mmol, 1.5 eq) and DIEA
(97.0 mg, 0.75 mmol, 0.1mL, 4 eq) in DCM (3 mL) was degassed and purged with 02 for 3 times.
Then the mixture was stirred at 25 C for 30 min under 02 atmosphere. LCMS showed the desired compound was detected. The reaction mixture was diluted with H20 (5 mL) and the mixture was extracted with EA (15 mL * 3). The combined organic phase was washed with brine (10 mL*3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC. Compound 149 (6 mg, 8.4% yield) was obtained. LCMS (ESI): RT =
0.625 min, mass calc. for C171-116P2N402S 378.10, m/z found 400.9 [M+Na1+; 1HNMR (400 MHz, DMSO-d6) 6 = 8.75 (br s, 1H), 8.89 - 8.57 (m, 1H), 7.91 (s, 1H), 7.79 (s, 1H), 7.58 (br d, J= 8.5 Hz, 1H), 7.41 - 7.31 (m, 1H), 7.31 - 7.17 (m, 3H), 6.64 (br d, J = 8.8 Hz, 1H), 3.85 (s, 3H), 2.41 (d, J
= 4.0 Hz, 3H).
Example 139: N-methyl-3-(1-methyl-1H-imidazol-4-y1)-4-4(1s,4s)-4-(trifluoromethyl)cyclohexyl)amino)benzenesulfonamide (Compound 150) and N-methyl-3-(1-methyl-1H-imidazol-4-y1)-4-4(1r,40-4-(trifluoromethyl)cyclohexyl)amino)benzenesulfonamide (Compound 151) N-\\ N-\\
x N NN
H H H H
czµ nF czµ 1\kn < HN-Sµ` H F HN-Sµ ` F
I I
Compound 150 Compound 151 Preparation of Compound 150 and Compound 151:
F
N--\\
N N 0 NN N-\\
150-1a (3.0 eq) j N
NH2 1:1 H H
NaBH3CN (2 0 eq), HOAc 0 lit:I) 0, F
0=DCM 0-25 C 5 hr -S =
Nn HN N H F uµ,S
u Compound 150 Compound 151 [00482] To a solution of compound 150-1 (250 mg, 0.93 mmol, 1 eq) and compound 150-la (467.8 mg, 2.82 mmol, 3 eq) in DCE (5 mL) was added HOAc (169.1 mg, 2.82 mmol, 0.2 mL, 3 eq) at 25 C under N2. After addition, the mixture was stirred at 25 C
for 3 hr, and then NaBH4 (106.5 mg, 2.82 mmol, 3 eq) was added at 0 C. The resulting mixture was stirred at 25 C
for 2 hr. TLC (PE/EA = 1/1, UV 254) indicated reactant was consumed completely and two new spot formed. LCMS showed reactant was consumed completely and -83% of desired compound was detected (m/z = 439.0; RT: 0.67 min). The residue was poured into H20 (30 mL) and stirred for 5 min. The aqueous phase was extracted with EA (10 mL*3).The combined organic phase was washed with brine (20 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography to give Compound 150 (36.7 mg, 9.2% yield). LCMS (ESI): RT = 0.814 min, mass calcd for Ci8H23F3N402S 416.46, m/z found 417.4 [M+H1+, IFINMR (400 MHz, DMSO-d6) 6 9.28 (d, J= 8.0 Hz, 1H), 7.82 - 7.75 (m, 2H), 7.66 (d, J= 1.0 Hz, 1H), 7.40 (dd, J= 2.1, 8.7 Hz, 1H), 6.98 (q, J =
5.0 Hz, 1H), 6.78 (d, J = 8.8 Hz, 1H), 3.90 (br d, J = 3.8 Hz, 1H), 3.73 (s, 3H), 2.37 (d, J=
5.0 Hz, 2H), 2.42 - 2.31 (m, 1H), 2.42 - 2.31 (m, 1H), 1.99 (s, 1H), 1.87 (br d, J= 12.3 Hz, 2H), 1.77 -1.68 (m, 1H), 1.66 (br s, 1H), 1.63 (br s, 1H), 1.60 (br d, J= 3.3 Hz, 1H), 1.77 - 1.54 (m, 1H), 1.56 (br s, 1H).
Compound 151 (78.5 mg, 19.8% yield) was obtained. LCMS (ESI): RT = 0.815 min, mass calcd for Ci8H23F3N402S 416.46, m/z found 417.4 [M+H1+, 1HNMR (400 MHz, DMSO-d6) 6 8.72 (d, J = 7.5 Hz, 1H), 7.82 - 7.71 (m, 2H), 7.62 (s, 1H), 7.39 (dd, J= 2.0, 8.8 Hz, 1H), 6.97 (q, J= 5.0 Hz, 1H), 6.83 (d, J= 9.0 Hz, 1H), 6.87 - 6.79 (m, 1H), 3.72 (s, 3H), 3.49 -3.40 (m, 1H), 2.36 (d, J = 5.3 Hz, 2H), 2.33 (br s, 1H), 2.13 (br d, J=11.0 Hz, 2H), 1.92 (br d, J=
11.8 Hz, 2H), 1.55 -1.40 (m, 2H), 1.34 - 1.24 (m, 2H).
Example 140: 3-(2-Aminopyridin-4-y1)-N-methy1-4-43-(trifluoromethyl)phenyl)amino)benzenesulfonamide (Compound 152) I
/
F
H F
N
(21µµ
-S
HN µ`
I
Preparation of Compound 152:
Br Br Br H
NH2 DMAP (0.05 eq), Ac20 (1.2 eq) NI( CISO3H (11.1 eq) 1401 11 1,... 0 1\1 0 0 \
DCM, r.t, 16 hr 0 0-80 C, 4h CI\S \\0 0 FEE
Br 9 H Br 0H (152-5a 1.2 eq) (:)µµ 0 methylamine (3.0 eq) N.(-HCI (6 M) NH2 Cu(OAc)2 (1.2 eq) 0 ______________________________________________________________ DIPEA (2.0 eq) _________________ v"--Sµ`
THE, 0 to 25 C, 3 hr HN 1 100 C, 4 hr HN,sµ`
02(15 psi) 1 0 DCM, 25 C, 16h o. p Fi2N,,,Br i N NH2 Br t:i13-Bb.....c N
H 0õ0 I
czµ 0 N 0 (152-6a 1.5 eq) B
H (152-7a 2.0 eq) /
F
HNS\
Pd(dppf)C12 (0.05 eq) N 0 Pd(dppf)C12 (0.05 eq) H F
N
-` AcOK(2.0 eq) 1 Cs2CO3(2.0 eq) 0µ
F F dioxane, 90 C, 16h HN-s\µ
dioxane/H20, 90 C, 16h F 1 HN,s\\
152-6 152-7 F Compound 152 Step 1: N-(2-bromophenyl)acetamide [00483] To a solution of compound 152-1 (20 g, 116.26 mrnol, 1.0 eq) in DCM (10 mL) were added Ac20 (14.24 g, 139.5 mrnol, 13.0 mL, 1.2 eq) and DMAP (710.1 mg, 5.81 mrnol, 0.05 eq). The mixture was stirred at 25 C for 16 hr. LCMS showed the reactant was consumed completely and -95% desired MS was detected. The reaction mixture was poured into water (50 mL), and extracted with EA (50 mL * 3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue.
The crude product was used into the next step without further purification.
Compound 152-2 (23 g, crude) was obtained. LCMS (ESI): RT = 0.713 min, mass calcd. for C8H8BrNO
212.98, m/z found 214.2 [M+H1+.
Step 2: 4-acetamido-3-bromobenzene-1-sulfonyl chloride [00484] A mixture of compound 152-2 (23 g, 107.4 mrnol, 1.0 eq) in H503C1 (139.8 g, 1.2 mol, 79.9 mL, 11.1 eq) at 0 C was stirred at 80 C for 4 hr. LCMS showed the reactant was remained and -30% of desired product was detected. The reaction mixture was poured into ice water (50mL) and extracted with EA (50 mL * 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The crude product was used into the next step without further purification. Compound 152-3 (16 g, crude) was obtained. LCMS (ESI): RT = 0.703 min, mass calcd. for C8H8BrNO
212.98, m/z found 213.3 [M+I-11+.
Step 3: N-(2-bromo-4-(N-methylsulfamoyl)phenyl)acetamide [00485] To a solution of compound 152-3 (16 g, 51.1 mmol, 1.0 eq) in THF (5 mL) was added methylamine (2 M, 127.9 mL, 5.0 eq) at 0 C. The mixture was stirred at 25 C for 3 hr.
TLC showed the reactant was consumed completely, and three new spots were detected. -60%
of desired product was detected on LCMS. The reaction mixture was concentrated under reduced pressure to remove THF. The residue was purified by flash silica gel chromatography.
Compound 152-4 (5 g, 25.4% yield) was obtained. LCMS (ESI): RT = 0.568 min, mass calcd.
for C9Hi iBrN203S 305.97, m/z found 306.8 [M+I-11+.
Step 4: 4-amino-3-bromo-N-methylbenzenesulfonamide [00486] A mixture of compound 152-4 (5 g, 16.3 mmol, 1.0 eq) in HC1 (20 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 100 C for 3 hr under N2 atmosphere. LCMS showed the reactant was consumed completely, and -97% of desired product was detected. The pH of the reaction mixture was adjusted to 9-10 by adding NaHCO3 solid and then the mixture was filtered and the filter cake was dried in vacuum. The crude product was used into the next step without further purification.
Compound 152-5 (4 g, crude) was obtained. LCMS (ESI): RT = 0.568 min, mass calcd. for C7H9BrN202S
263.96, m/z found 264.8 [M+H]+; IFINMR (400MHz, CDC13) 6 7.93 (d, J= 2.0 Hz, 1H), 7.63 -7.52 (m, 1H), 6.80 (d, J = 8.5 Hz, 1H), 2.65 (d, J = 5.4 Hz, 3H).
Step 5: 3-bromo-N-methy1-4-43-(trifluoromethyl)phenyl)amino)benzenesulfonamide [00487] To a solution of compound 152-5 (1 g, 3.7 mmol, 1.0 eq) in DCM (15 mL) were added Cu(OAc)2 (822.1 mg, 4.5 mmol, 1.2 eq), DIPEA (974.9 mg, 7.5 mmol, 1.3 mL, 2.0 eq) and 5a (859.2 mg, 4.5 mmol, 1.2 eq). The mixture was stirred at 25 C for 16 hr at 02 atmosphere. LCMS showed the reactant was remained and -20% of desired product was detected. TLC showed the reactant was remained and three new spots were detected. The reaction mixture was filtered and the filtrate was concentrated in vacuum. The residue was purified by flash silica gel chromatography. Compound 152-6 (200 mg, 6.5%
yield) was obtained. LCMS (ESI): RT = 2.210 min, mass calcd. for Ci4H12BrF3N202S 407.98, m/z found 408.9 [M+H]+.
Step 6: N-methy1-3-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-4-43-(trifluoromethyl)phenyl)amino)benzenesulfonamide [00488] To a solution of compound 152-6 (200 mg, 0.5 mmol, 1.0 eq) in dioxane (10 mL) were added AcOK (95.9 mg, 0.98 mmol, 2.0 eq), Pd(dppf)C12 (17.9 mg, 24.4 umol, 0.05 eq) and compound 152-6a (186.1 mg, 0.73 mmol, 1.5 eq). The mixture was stirred at 90 C for 16 hr.
LCMS showed the reactant was consumed completely and -40% of desired product was detected. The reaction mixture was filtered and the filtrate was concentrated in vacuum. The crude product was used into the next step without further purification.
Compound 152-7 (400 mg, crude) was obtained. LCMS (ESI): RT = 0.919 min, mass calcd. for C20I-456.15, m/z found 456.7 [M+H1+.
Step 7: 3-(2-aminopyridin-4-y1)-N-methy1-4-43-(trifluoromethyl)phenyl)amino)benzenesulfonamide [00489] To a solution of compound 152-7 (200 mg, 0.45 mmol, 1.0 eq) in dioxane (15 mL) and H20 (2 mL) were added Pd(dppf)C12 (16.0 mg, 21.9 umol, 0.05 eq), Cs2CO3 (285.6 mg, 0.88 mmol, 2.0 eq) and compound 152-7a (151.6 mg, 0.88 mmol, 2.0 eq). The mixture was stirred at 90 C for 16 hr. LCMS showed the reactant was consumed completely and 40% of desired product was detected. The reaction mixture was concentrated in vacuum.
The residue was purified by prep-HPLC. Compound 152 (1.34 mg, 7.24e-1% yield) was obtained. LCMS
(ESI): RT = 0.669 min, mass calcd. for Ci9H17F3N402S 422.10, m/z found 423 [M+1-11+.11-1NMR
(400 MHz, CDC13) 6 8.18 (d, J= 5.0 Hz, 1H), 7.77 (d, J= 1.8 Hz, 1H), 7.49 (dd, J = 1.8, 8.0 Hz, 1H), 7.46 - 7.41 (m, 1H), 7.38 (d, J= 7.9 Hz, 1H), 7.29 (br s, 1H), 7.26 (br s, 1H), 6.72 (dd, J=
1.4, 5.3 Hz, 1H), 6.55 (s, 1H), 5.87 (s, 1H), 4.62 (br s, 2H), 4.34 (br d, J=
5.3 Hz, 1H), 2.75 (d, J
= 5.4 Hz, 3H).
Example 141: 3-(2-Aminopyridin-4-y1)-N-methy1-4-44-(trifluoromethyl)phenyl)amino)benzenesulfonamide (Compound 153) I
CZ%J F
Preparation of Compound 153:
Br Br H
Br Br H
H N
0 NH2 DMAP (0.05 eq), Ac20 (1.2 eq) 0 NI( ciso3H (11.1 eq,) NI,,... 0, 40 11 0 methylamine (3.0 eq) S
DCM, r.t, 16 hr 0 0-80 C, 4h ....S THF, 0 to 25 C, 3 hr HN- ,`
CI ,b I
F
F
F
Br HO B = __.)..0 0OB-Blt 0= H (153-5a 1.2 eq) .-"-4-1.---cu(OA.)2 (1.2 eq) Br H
cO
0 DIPEA (2.0 eq) N (153-6a 1.5 eq) L B
HCI (6 M) , .'s "IF 0, (15 psi) .I I. F Pd(dppf)Cl2 (0.05 eq) H
100 'C, 4 hr Hril µµ(:) DCM, 25 C, 16h N
HN-S,' F 16h F F di AcOK(2.0 eq) -- 0,, 0 -- 40 oxane, 90 C, F
153-6 HN ,)-, I ,-, H2Nõ,r...,Br N.,.....-J
(153-7a 2.0 eq) Pd(dppf)Cl2 (0.05 eq) H
____________________________ I.- N
Cs2CO3(2.0 eq) R` 40 40 dioxane/H20, 90 C, 16h F
S
HN- F
,` F
I
Compound 153 Step 1: N-(2-bromophenyl)acetamide [00490] To a solution of compound 153-1 (20 g, 116.2 mmol, 1.0 eq) in DCM
(10 mL) were added Ac20 (14.2 g, 139.5 mmol, 13.0 mL, 1.2 eq) and DMAP (710 mg, 5.81 mmol, 0.05 eq). The mixture was stirred at 25 C for 16 hr. LCMS showed the reactant was consumed completely and -95% desired MS was detected. The reaction mixture was poured into water (50 mL), and extracted with EA (50 mL * 3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue.
The crude product was used into the next step without further purification.
Compound 153-2 (23 g, crude) was obtained. LCMS (ESI): RT = 0.713 min, mass calcd. for C8H8BrNO
212.98, m/z found 214.2 [M+H1+.
Step 2: 4-acetamido-3-bromobenzene-1-sulfonyl chloride [00491] To a solution of compound 153-2 (23 g, 107.4 mmol, 1.0 eq) was added compound 153-2a (139.8 g, 1.2 mol, 79.9 mL, 11.1 eq) at 0 C. The mixture was stirred at 80 C
for 4 hr. LCMS showed the reactant was remained and -30% desired product was detected. The reaction mixture was poured into ice water (50 mL) and extracted with EA (50 mL * 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The crude product was used into the next step without further purification. Compound 153-3 (16 g, crude) was obtained.
LCMS (ESI): RT
= 0.703 min, mass calcd. for C8H8BrNO 212.98, m/z found 213.3 [M+H1+.
Step 3: N-(2-bromo-4-(N-methylsulfamoyl)phenyl)acetamide [00492] To a solution of compound 153-3 (16 g, 51.1 mmol, 1.0 eq) in THF (5 mL) was added methylamine (2 M, 127.9 mL, 5.0 eq) at 0 C. The mixture was stirred at 25 C for 3 hr.
TLC showed the reactant 153-3 was consumed completely, and three new spots were detected.
-60% desired product was detected on LCMS. The reaction mixture was concentrated under reduced pressure to remove THF. The residue was purified by flash silica gel chromatography.
Compound 153-4 (5 g, 25.4% yield) was obtained. LCMS (ESI): RT = 0.568 min, mass calcd.
for C9Hi iBrN203S 305.97, m/z found 306.8 [M+I-11+.
Step 4: 4-amino-3-bromo-N-methylbenzenesulfonamide [00493] A mixture of compound 153-4 (5 g, 16.3 mmol, 1.0 eq) in HC1 (20 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 100 C for 3 hr under N2 atmosphere. LCMS showed the reactant was consumed completely, and -97% desired product was detected. The pH of the reaction mixture was adjusted to 9-10 by adding NaHCO3 solid and then the mixture was filtered and the filter cake was dried in vacuum. The crude product was used into the next step without further purification. Compound 153-5 (4 g, crude) was obtained. LCMS (ESI): RT = 0.568 min, mass calcd. for C7H9BrN202S 263.96, m/z found 264.8 [M+H]+; 1HNMR (400 MHz, CDC13) 6 7.93 (d, J= 2.0 Hz, 1H), 7.63 - 7.52 (m, 1H), 6.80 (d, J = 8.5 Hz, 1H), 2.65 (d, J = 5.4 Hz, 3H).
Step 5: 3-bromo-N-methy1-4-04-(trifluoromethyl)phenyl)amino)benzenesulfonamide [00494] To a solution of compound 153-5 (1 g, 3.7 mmol, 1.0 eq) in DCM (15 mL) were added Cu(OAc)2 (822.1 mg, 4.5 mmol, 1.2 eq), DIPEA (974.9 mg, 7.5 mmol, 1.3 mL, 2.0 eq) and compound 153-5a (859.6 mg, 4.5 mmol, 1.2 eq). The mixture was stirred at 25 C for 16 hr at 02 atmosphere. TLC showed the reactant was remained and three new spots were detected.
The reaction mixture was filtered and the filtrate was concentrated in vacuum.
The residue was purified by flash silica gel chromatography. Compound 153-6 (150 mg, 5.8%
yield) was obtained. LCMS (ESI): RT = 2.190 min, mass calcd. for Ci4H12BrF3N202S 407.98, m/z found 408.9 [M+H]+.
Step 6: N-methy1-3-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-4-04-(trifluoromethyl)phenyl)amino)benzenesulfonamide [00495] To a solution of compound 153-6 (150 mg, 0.37 mmol, 1.0 eq) in dioxane (10 mL) were added Pd(dppf)C12 (13.4 mg, 18.3 umol, 0.05 eq), AcOK (71.9 mg, 0.73 mmol, 2.0 eq) and compound 153-6a (139.6 mg, 0.55 mmol, 1.5 eq). The mixture was stirred at 90 C for 6 hr.
LCMS showed 40% desired product was detected. The reaction mixture was filtered and the filtrate was concentrated in vacuum. The residue was purified by flash silica gel chromatography. Compound 153-7 (50 mg, 29.9% yield) was obtained. LCMS (ESI):
RT =
0.907 min, mass calcd. for C20I-124BF3N204S 456.15, m/z found 457.1 [M+I-11+.
Step 7: 3-(2-aminopyridin-4-y1)-N-methyl-4-04-(trifluoromethyl)phenyl)amino)benzenesulfonamide [00496] To a solution of compound 153-7 (50 mg, 0.10 mmol, 1.0 eq) in dioxane (15 mL) and H20 (2 mL) were added Pd(dppf)C12 (4.0 mg, 5.5 umol, 0.05 eq), Cs2CO3 (71.4 mg, 0.22 mmol, 2.0 eq) and compound 153-7a (37.9 mg, 0.22 mmol, 2.0 eq). The mixture was stirred at 90 C for 16 hr. LCMS and HPLC showed the reactant was consumed completely and 40%
desired product was detected. The reaction mixture was concentrated in vacuum.
The residue was purified by prep-HPLC. Compound 153 (5.59 mg, 11.1% yield, HC1) was obtained. LCMS
(ESI): RT = 0.698 min, mass calcd. for Ci9I-117F3N402S 422.10, m/z found 423 [M+1-11+;IFINMR
(400 MHz, DMSO-d6) 6 13.86 - 13.43 (m, 1H), 8.07 - 7.92 (m, 3H), 7.73 (d, J=
8.5 Hz, 2H), 7.41 (d, J = 8.5 Hz, 2H), 7.21 (dd, J = 2.3, 8.8 Hz, 1H), 7.06 - 7.04 (m, 1H), 6.95 (s, 1H), 6.80 (d, J= 8.8 Hz, 1H), 6.70 (dd, J= 1.4, 6.7 Hz, 1H), 6.29 (br s, 2H), 3.13 (s, 3H), 2.53 -2.52 (m, 3H).
II. Biological Evaluation Example Al: YAP Reporter Assay [00497] HEK293T cells stably transfected with 8XTBD luciferase reporter and pRLTK in 384-well plates were treated with the test compounds, starting from 311M
(final concentration in assay plate), 1:3 dilution, and 10 points in quadruplicates. Post 24-hr incubation with compounds at 37 C and 5% CO2, cells were lysed and 8XTBD-driven firefly luciferase and control TK-driven renilla luciferase activities were measured using Promega Dual-Luciferase Reporter Assay System.
[00498] Reagents: The reagents used for this study are: DMEM: Invitrogen#
11960077, Dual-Glo Luciferase Assay System: Promega-E2980, Puromycin Dihydrochloride:
Invitrogen-A1113803, 384-well plate: PerkinElmer-6007480, L-GLUTAMINE: Invitrogen-25030164, Hygromycin B: Invitrogen-10687010 , and Penicillin-Streptomycin: Merk-TMS-AB2-C
[00499] Media: The media used for this assay were: Culture Medium: DMEM+
lug/mL
puromycin + 200 ug/mL hygromycin (with 10% FBS + 1mM L-glutamine); and Assay Medium:
DMEM (with 10% FBS + 1mM L-glutamine + lx P/S).
[00500] Cell Plating: The appropriate media was warmed at 37 C by water bath: Culture Medium, Assay Medium, 1* D-PBS, 0.05% trypsin-EDTA. The cells were trypsinized after removing all media, then washed with 1* sterile D-PBS and then with 2 ml 0.05%
trypsin-EDTA. The cells were then incubated at RT for one minute. Then 10 m1/75cm2 flask Assay Medium was added to each flask. Using a 10 ml pipette, the cells were then gently resuspended in the media, until the clumps completely disappeared. The cells were then transferred into 50 ml centrifuge tubes and were centrifuged at 800 rpm for 5 mins. The medium was removed and the cells were resuspended with Assay Medium. An aliquot of cells was used to count the cell density (cells/m1). The cell suspension was then diluted with Assay Medium to a concentration of 6x104 cells/ml. 50u1 cells suspension was then plated to 384-well plate (PerkinElmer-6007480), 3x103 cells/well and the cells were incubated in an incubator at 37 C, 5% CO2.
[00501] Compound Treatment: In the afternoon (incubation of the plate with 3-4 hrs), the test compounds were added by Echo, starting from 3uM (final concentration in the assay plate), 1:3 dilution, 10 points, quadruplicates. The plate was placed at 37 C, 5% CO2 incubator for 24hrs.
[00502] Detection: The Dual-Glo Luciferase Reagent was prepared by transferring the contents of one bottle of Dual-Glo Luciferase Buffer to one bottle of Dual-Glo Luciferase Substrate to create the Dual-Glo Luciferase Reagent. Mixing was performed by inversion until the substrate was thoroughly dissolved. After mixing, the reagent was aliquoted into 15 ml tubes.
In the afternoon (24hrs post compound treatment), the DMEM+ medium in the 384 well plates were aspirated by Microplate Washer.
[00503] Measuring firefly luciferase activity: 20u1 Dual-Glo Luciferase Reagent was added to the 384-well plates. The plates were protected from light to prevent interference with the assay. The plates were shaken for lmin followed centrifuging plates at 1000rpm for 30 seconds. After waiting at least 10 minutes, the firefly luminescence was measured by Envision.
[00504] Measuring renilla luciferase activity: 20u1 Stop-Glo Reagent was added to the 384-well plates. The plates were shaken for lmin and then centrifuged at 1000rpm for 30 seconds. After waiting at least 10 minutes, the renilla luminescence was measured by Envision.
[00505] Compound IC50 and maximum inhibition on the firefly luciferase and renilla luciferase activities were reported separately. IC50 for firefly luciferase activity are shown in the table below.
Firefly Compound Name Luciferase No. IC50 (PM) N-(tert-buty1)-4-(cyclohexylamino)-3-(2H-tetrazol-5-yl)benzenesulfonamide Firefly Compound Name Luciferase No.
ICso (11,1") N-(tert-butyl)-4-(cy clohexylamino)-3 -(242-D
hydroxyethyl)-2H-tetrazol-5-yObenzenesulfonamide N-cy clohexy1-2-(5 -methy1-1,2,4-oxadiazol-3-y1)-4-(methylsulfonyl)aniline N-cy clohexy1-4-(methylsulfony1)-2-(2H-tetrazol-5 -yl)aniline N-cy clohexy1-2-(2-methy1-2H-tetrazol-5-y1)-4-B
(methylsulfonyl)aniline N-cy clohexy1-2-(1 -methy1-1H-1,2,3-triazol-4-y1)-4-B
(methylsulfonyl)aniline N-cy clohexy1-2-(1-methy1-1H-py razol-4-y1)-4-(methylsulfonyl)aniline N-cy clohexy1-2-(1-methy1-1H-py razol-3-y1)-4-B
(methylsulfonyl)aniline N-cy clohexy1-4-(methylsulfony1)-2-(1H-1,2,3-triazol-1-yl)aniline N-cy clohexy1-4-(methylsulfony1)-2-(1H-py razol-1 -C
yl)aniline N-cy clohexy1-2-(1H-imidazol-1-y1)-4-(methylsulfonyl)aniline N-cy clohexy1-4-(methylsulfony1)-2-(1H-1,2,4-triazol-1-D
yl)aniline N-cy clohexy1-4-(methylsulfony1)-2-(2H-1,2,3-triazol-2-B
yl)aniline 4-(cy clohexylamino)-3-(2-ethy1-2H-tetrazol-5-y1)-N-A
methylbenzenesulfonamide 4-(cy clohexylamino)-N-methy1-3 -(2-propy1-2H-A
tetrazol-5-yObenzenesulfonamide 4-(cy clohexylamino)-3-(2-(4-fluoropheny1)-2H-tetrazol-5 -y1)-N-methylbenzenesulfonamide Firefly Compound Name Luciferase No.
ICso (11,1") 3-(2-cy cl obuty1-2H-tetrazol-5 -y 0-4-(cy cl ohexylamino)-A
N-methylbenzenesulfonamide 4-(cy clohexylamino)-3-(2-cy cl openty1-2H-tetrazol-5-B
yO-N-methylbenzenesulfonamide 4-(cyclohexylamino)-3-(2-(2-fluorobenzy1)-2H-tetrazol-A
5-y1)-N-methylbenzenesulfonamide 3-(2-benzy1-2H-tetrazol-5 -y 0-4-(cy clohexylamino)-N-A
methylbenzenesulfonamide 3 21 -(2-buty ltetrazol-5 -y 0-4-(cy cl ohexylamino)-N-methyl-A
benzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-methy1-2H-A
tetrazol-5-yObenzenesulfonamide 4-(cyclohexylamino)-3-(2-(2-fluoropheny1)-2H-B
tetrazol-5-y1)-N-methylbenzenesulfonamide tert-butyl3 -(5 -(2-(cy cl ohexylamino)-5 -(N-24 methylsulfamoyl)pheny1)-2H-tetrazol-2-yOpyrrolidine- D
1-carboxylate tert-butyl3 -(5 -(2-(cy cl ohexylamino)-5 -(N-methylsulfamoyl)pheny1)-2H-tetrazol-2-y0azetidine-1- D
carboxylate 4-(cy cl ohexy lamino)-3-(24 s opropy1-2H-tetrazol-5 -y1)-A
N-methylbenzenesulfonamide 4-(cy cl ohexylamino)-3 -(2-is obuty1-2H-tetrazol-5 -y1)-N-B
methylbenzenesulfonamide tert-butyl 4-(5-(2-(cy cl ohexylamino)-5 -(N-28 methylsulfamoyl)pheny1)-2H-tetrazol-2-yOpiperidine-1- D
carboxylate 4-(cy cl ohexylamino)-N-methy1-3 -(2-(py ri din-3 -A
ylmethyl)-2H-tetrazol-5-yObenzenesulfonamide 4-(cy clohexylamino)-N-methy1-3-(2-(piperidin-4-y1)- D
Firefly Compound Name Luciferase No.
ICso (11,1") 2H-tetrazol-5-yl)benzenesulfonamide 3-(2-(1-acetylpiperidin-4-y1)-2H-tetrazol-5-y1)-4-B
(cyclohexylamino)-N-methylbenzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(1-32 (methylsulfonyl)piperidin-4-y1)-2H-tetrazol-5- -- D
yl)benzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(1-(pyridin-3-yOpiperidin-4-y1)-2H-tetrazol-5-yObenzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-pheny1-2H-tetrazol-5-yObenzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(pyrrolidin-3-y1)-2H-tetrazol-5-yObenzenesulfonamide 4-(cyclohexylamino)-3-(2-(1-isopropylpyrrolidin-3-y1)-C
2H-tetrazol-5-y1)-N-methylbenzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(1-37 phenylpyrrolidin-3-y1)-2H-tetrazol-5- D
yl)benzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(1-38 phenylpiperidin-4-y1)-2H-tetrazol-5- D
yl)benzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(2,2,2-trifluoroethyl)-2H-tetrazol-5-yObenzenesulfonamide 4-(cyclohexylamino)-3-(2-(2-fluoroethyl)-2H-tetrazol-A
5-y1)-N-methylbenzenesulfonamide 4-(cyclohexylamino)-3-(2-(4-fluorobenzy1)-2H-tetrazol-B
5-y1)-N-methylbenzenesulfonamide 3-(2-(1-acetylpyrrolidin-3-y1)-2H-tetrazol-5-y1)-4-B
(cyclohexylamino)-N-methylbenzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(1-(methylsulfonyOpyrrolidin-3-y1)-2H-tetrazol-5-Firefly Compound Name Luciferase No.
ICso (11,1") yl)benzenesulfonamide 4-(cyclohexylamino)-3-(2-(2-hydroxyethyl)-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(pyridin-3-y1)-2H-tetrazol-5-yObenzenesulfonamide 4-(cyclohexylamino)-3-(2-(1-isopropylpiperidin-4-y1)-D
2H-tetrazol-5-y1)-N-methylbenzenesulfonamide isopropyl 4-(5-(2-(cyclohexylamino)-5-(N-47 methylsulfamoyl)pheny1)-2H-tetrazol-2-yOpiperidine-1- .. D
carboxylate 4-(cy cl ohexylamino)-N-methy1-3 -(5 -methyl-1,2,4-A
oxadiazol-3-yl)benzenesulfonamide 3-(2-(1-acetylazetidin-3-y1)-2H-tetrazol-5-y1)-4-(cyclohexylamino)-N-methylbenzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(1-50 (methylsulfonyl)azetidin-3-y1)-2H-tetrazol-5- D
yl)benzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(1-phenylazetidin-D
3-y1)-2H-tetrazol-5-yObenzenesulfonamide 4-(cyclohexylamino)-3-(2-(1-isopropylazetidin-3-y1)-B
2H-tetrazol-5-y1)-N-methylbenzenesulfonamide 3-(2-(1-acetylpiperidin-3-y1)-2H-tetrazol-5-y1)-4-(cyclohexylamino)-N-methylbenzenesulfonamide 3-(2-(azetidin-3-y1)-2H-tetrazol-5-y1)-4-(cyclohexylamino)-N-methylbenzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(pyrimidin-5-yl)benzenesulfonamide 4-(cyclohexylamino)-N-methyl-3-(pyrimidin-2-A
yl)benzenesulfonamide 57 4-(cyclohexylamino)-N-methy1-3-(1-methy1-1H- A
Firefly Compound Name Luciferase No.
ICso (11,1") pyrazol-3-yObenzenesulfonamide 4-(cy cl ohexylamino)-N-methy1-3-(1 -methy 1-1H-1,2,3 -A
triazol-4-yl)benzenesulfonamide tert-butyl 3 -(5 -(2 -(cy cl ohexylamino)-5 -(N-59 methylsulfamoyl)pheny1)-2H-tetrazol-2-yOpiperidine-1- B
carboxylate tert-butyl 3 -(5 -(2 -(cy cl ohexylamino)-5 -(N-60 methylsulfamoyl)pheny1)-1H-tetrazol-1 -yl)pip eri dine-1 - D
carboxylate 4-(cy clohexylamino)-3 -(2-(1 -isopropylpiperidin-3-y1)-D
2H-tetrazol-5-y1)-N-methylbenzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(1-62 (methylsulfonyl)piperidin-3-y1)-2H-tetrazol-5- D
yl)benzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(1-63 phenylpiperidin-3-y1)-2H-tetrazol-5- D
yl)benzenesulfonamide 4-(cyclohexylamino)-N-methyl-3-(pyridin-2-A
yl)benzenesulfonamide 4-(cyclohexylamino)-N-methyl-3-(pyridin-4-D
yl)benzenesulfonamide 4-(cy cl ohexylamino)-N-methy1-3-(5 -methyl-1H-1,2,4 -B
triazol-3-yl)benzenesulfonamide 4-(cyclohexylamino)-3-(1,5-dimethy1-1H-1,2,4-triazol-A
3-y1)-N-methylbenzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(1-(pyridin-3-68 yOpyrrolidin-3-y1)-2H-tetrazol-5- B
yl)benzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(pyrimidin-4-yl)benzenesulfonamide Firefly Compound Name Luciferase No.
ICso (11,1") 4-(cyclohexylamino)-N-methyl-3-(2-(1-(pyridin-3-B
yl)azetidin-3-y1)-2H-tetrazol-5-yObenzenesulfonamide 4-(cyclohexylamino)-3-(2-cyclopropy1-2H-tetrazol-5-D
yO-N-methylbenzenesulfonamide 4-((4,4-difluorocyclohexyl)amino)-N-methyl-3-(2-A
methyl-2H-tetrazol-5-yObenzenesulfonamide 4-((3,3-difluorocyclohexyl)amino)-N-methy1-3-(2-methy1-2H-tetrazol-5-yObenzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(piperidin-3-y1)-2H-tetrazol-5-yObenzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(1-(piperidin-3-y1)-C
1H-tetrazol-5-yObenzenesulfonamide 3-(6-aminopyridin-2-y1)-4-(cyclohexylamino)-N-B
methylbenzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(pyridin-3-yl)benzenesulfonamide 4-(cyclohexylamino)-N-methyl-3-(3-methylpyridin-2-D
yl)benzenesulfonamide 4-(cyclohexylamino)-3-(3-fluoropyridin-2-y1)-N-methylbenzenesulfonamide 4-(cyclohexylamino)-3-(3-methoxypyridin-2-y1)-N-C
methylbenzenesulfonamide 4-(cyclohexylamino)-N-methyl-3-(2H-1,2,3-triazol-2-A
yl)benzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(1-methy1-1H-A
imidazol-4-yObenzenesulfonamide 4-(cyclohexylamino)-3-(6-(dimethylamino)pyridin-2-D
yO-N-methylbenzenesulfonamide 3-(4-aminopyridin-2-y1)-4-(cyclohexylamino)-N-methylbenzenesulfonamide Firefly Compound Name Luciferase No.
ICso (11,1") 4-(cyclohexylamino)-N-methyl-3-(6-C
(methylamino)pyridin-2-yl)benzenesulfonamide 4-(cyclohexylamino)-N-methyl-3-(2-(1-(pyridin-3-B
yOpiperidin-3-y1)-2H-tetrazol-5-yObenzenesulfonamide 4-(cyclohexylamino)-3-(4-(dimethylamino)pyridin-2-A
yO-N-methylbenzenesulfonamide 4-(cyclohexylamino)-N-methyl-3-(4-A
(methylamino)pyridin-2-yl)benzenesulfonamide 4-(cyclohexylamino)-N-methyl-3-(1H-1,2,3-triazol-1-D
yl)benzenesulfonamide N-methyl-3-(2-methy1-2H-tetrazol-5-y1)-4-A
(phenylamino)benzenesulfonamide 4-(cyclohexylamino)-N-methyl-3-(3-methy1-1,2,4-B
oxadiazol-5-yObenzenesulfonamide N-methyl-3-(2-methyl-2H-tetrazol-5-y1)-4-((3-A
(trifluoromethyl)phenyl)amino)benzenesulfonamide N-methy1-3-(2-methy1-2H-tetrazol-5-y1)-4-((2-(trifluoromethyl)phenyl)amino)benzenesulfonamide N-methy1-3-(2-methy1-2H-tetrazol-5-y1)-4-((3-(trifluoromethoxy)phenyl)amino)benzenesulfonamide N-methy1-3-(2-methy1-2H-tetrazol-5-y1)-4-((4-A
(trifluoromethyl)phenyl)amino)benzenesulfonamide N-methyl-3-(1-methy1-1H-tetrazol-5-y1)-4-44-D
(trifluoromethyl)phenyl)amino)benzenesulfonamide N-methy1-3-(1-methy1-1H-tetrazol-5-y1)-4-43-(trifluoromethyl)phenyl)amino)benzenesulfonamide N-methyl-3-(1-methy1-1H-tetrazol-5-y1)-4-42-D
(trifluoromethyl)phenyl)amino)benzenesulfonamide N-methy1-3-(1-methy1-1H-tetrazol-5-y1)-4-44-(trifluoromethoxy)phenyl)amino)benzenesulfonamide Firefly Compound Name Luciferase No.
ICso (11,1") N-methyl-3-(1-methyl-1H-tetrazol-5-y1)-4-43-D
(trifluoromethoxy)pheny Damino)benzenes ulfonami de N-methyl-3-(1-methy 1-1H-tetrazol-5-y1)-4-42-D
(trifluoromethoxy)pheny Damino)benzenes ulfonami de N-methy1-3-(2-methy1-2H-tetrazol-5-y1)-4-42-(trifluoromethoxy)pheny Damino)benzenes ulfonami de N-methyl-3-(2-methyl-2H-tetrazol-5-y1)-4-44-A
(trifluoromethoxy)pheny Damino)benzenes ulfonami de 4-((2,3 -difluorophenyl)amino)-N-methyl-3-(2-methyl-B
2H-tetrazol-5-y Obenzenes ulfonami de 4-(cy cl ohexylamino)-N-methy1-3 -(5 -methyl-1,3,4-oxadi azol-2-y Obenzenesulfonami de
l.
czN Et3N (3 eq) 0,µ N Et0H, reflux, 16 h N
= DCM, rt, 16 h -S -S
HN HN
Burgess Reagent (2.0 eq) 40:1 N DCM, MW, 9000, 1 h 0 HN' = 0 I
105-5 Compound 105 Step 1: 4-(cyclohexylamino)-3-(hydrazinecarbony1)-N-methyl-benzenesulfonamide [00400] To a solution of compound 105-1 (0.2 g, 0.61 mmol, 1.0 eq) in Et0H
(5.0 mL) was added compound 105-2 (36.8 mg, 0.74 mmol, 35.7 uL, 1.2 eq). The resulted mixture was stirred at 80 C for 16 hr. LCMS showed desired compound was found. TLC showed new spots appeared and the starting material was consumed completely. The reaction mixture was concentrated under reduced pressure to give a crude product. The crude product was purified by column chromatography over silica gel to give compound 105-3 (0.1 g, 0.306 mmol, 50.0%
yield). LCMS (ESI): RT = 0.665 min, mass calc. for C14H22N403S 326.14 m/z found 326.9 [M+H]+.
Step 2: 3-(acetamidocarbamoy1)-4-(cyclohexylamino)-N-methyl-benzenesulfonamide [00401] To a solution of compound 105-4 (36.1 mg, 0.46 mmol, 32.8 uL, 1.5 eq) and TEA
(62.0 mg, 0.61 mmol, 85.3 uL, 2.0 eq) in DCM (3.0 mL) was added compound 105-3 (0.1 g, 0.31 mmol, 1.0 eq). The resulting mixture was stirred at 20 C for 16 hr. LCMS
showed desired compound was found. TLC showed a new spot appeared. The reaction mixture was concentrated under reduced pressure to give a crude product. The crude product was purified by column chromatography over silica gel to give compound 105-5 (70.0 mg, 0.19 mmol, 62.0% yield).
The residue was directly used without further purification. LCMS (ESI): RT =
0.723 min, mass calc. for C16H24N404S 368.15 m/z found 369.0 [M+I-11+.
Step 3: 4-(cyclohexylamino)-N-methy1-3-(5-methy1-1,3,4-oxadiazol-2-yl)benzenesulfonamide [00402]
Compound 105-5 (20.0 mg, 54.2 umol, 1.0 eq), and Burgess Reagent (51.7 mg, 0.22 mmol, 4.0 eq) were taken up into a microwave tube in DCM (2.0 mL). The sealed tube was heated at 90 C for 1 hr under microwave. LCMS showed desired compound was found. The reaction was filtered to give a crude product. The crude product was purified by prep-HPLC to give Compound 105 (1.70 mg, 4.85 umol, 8.94% yield) was obtained. LCMS (ESI):
RT = 0.479 min, mass calc. for C16H22N403S 350.14, m/z found 350.9 [M+1-11+; 1HNMR (400 MHz, CDC13) 6 8.27 (d, J= 2.3 Hz, 1H), 8.19 (d, J= 6.5 Hz, 1H), 7.73 (dd, J = 2.1, 8.9 Hz, 1H), 6.84 (d, J =
9.3 Hz, 1H), 4.23 (d, J = 5.5 Hz, 1H), 3.55 (s, 1H), 2.67 (d, J= 5.5 Hz, 3H), 2.63 (s, 3H), 2.06 (d, J= 8.5 Hz, 2H), 1.83 (s, 2H), 1.65 (s, 1H), 1.51 - 1.34 (m, 5H).
Example 102: 4-((3,5-difluorophenyl)amino)-N-methyl-3-(1-methyl-1H-tetrazol-5-yl)benzenesulfonamide (Compound 107) and 4-((3,5-difluorophenyl)amino)-N-methyl-3-(2-methyl-2H-tetrazol-5-yl)benzenesulfonamide (Compound 108) N=N N-N/
NN
0 = N F 0 N= F
HN-Sµµ
-S
I o HN1 0 Compound 107 Compound 108 Preparation of Compound 107 and Compound 108:
pH
B F
1\1=N / HO
.B
NJ N-N
--N
107-1a (1 0 eq) N F
abh NH2 + NH2 ______________ DIPEA (3.0 eq), N F
HN
HNSµµ
Sµb HNSµµ Cu(OAc)2 (1 5 eq), HN
u\-Sµµ
0 02(15 PsO,DCM,25 C,36 h I F0 107-1 Compound 107 Compound 108 [00403] To a solution of a mixture of compounds 107-1 (80 mg, 0.20 mmol, 1 eq), compound 107-la (32.0 mg, 0.20 mmol, 1 eq) and DIEA (78.6 mg, 0.6 mmol, 0.11 mL, 3 eq) in DCM (2 mL) was added Cu(OAc)2 (55.2 mg, 0.3 mmol, 1.5 eq). The reaction was degassed with 02 for three times and stirred at 25 C for 36hr. LCMS showed that 9% and 20%
of desired MS
signal was detected. The reaction was filtered and concentrated. The crude product was purified by prep HPLC to give Compound 108 (12.37 mg, 32.52 umol, 16.04% yield) and Compound 107 (6.57 mg, 17.27 umol, 8.52% yield). HNMR and LCMS confirmed that desired products were obtained.
[00404] Compound 107: LCMS (ESI): RT = 0.684 min, mass calcd. For Ci5Hi4F2N602S, 380.09 m/z found 380.90[M+H1t IFINMR (400MHz, CDC13) 6 9.17 (s, 1H), 8.02 (d, J = 1.60 Hz, 1H), 7.85 (d, J= 8.80 Hz, 1H), 7.56 (d, J= 9.20 Hz, 1H), 6.85 - 6.70 (m, 2H), 6.68 - 6.55 (m, 1H), 4.45 - 4.35 (m, 1H), 4.31 (s, 3H), 2.70 (d, J= 5.60 Hz, 3H).
[00405] Compound 108: LCMS (ESI): RT = 0.745 min, mass calcd. For Ci5Hi4F2N602S, 380.09 m/z found 380.80[M+H1t IFINMR (400MHz, CDC13) 6 9.54 (s, 1H), 8.70 (d, J = 2.00 Hz, 1H), 7.79 (dd, J= 8.80, 2.40 Hz, 1H), 7.49 (d, J = 8.80 Hz, 1H), 6.84 (dd, J = 8.00, 2.00 Hz, 2H), 6.61 - 6.50 (m, 1H), 4.48 (s, 3H), 4.49 - 4.38 (m, 1H), 2.72 (d, J = 5.60 Hz, 3H).
Example 103: 4-((2,5-difluorophenyl)amino)-N-methyl-3-(1-methyl-1H-tetrazol-5-yl)benzenesulfonamide (Compound 109) and 4-((2,5-difluorophenyl)amino)-N-methyl-3-(2-methyl-2H-tetrazol-5-yl)benzenesulfonamide (Compound 110) N-N/
N=N
N
µµ N
(21µµ N
HN-Sµµ HN-Sµµ
Compound 109 Compound 110 Preparation of Compound 109 and Compound 110:
/ OH F
N=N N-N N=N;
--N N HO --N N
NH2 NH2 F 109-la (1 0 eq) N N
Rµ 40 + 40 DIPEA (3.0 eq), czµ
-S
HN,sµµ HN,Sµµ Cu(OAc)2 (1.5 eq), HN HN
I 0 I 0 02 (15 Psi),DCM,25 C,36 h I
109-1 Compound 109 Compound 110 [00406] To a solution of a mixture of compounds 109-1 (80 mg, 0.20 mmol, 1 eq), compound 109-la (32.0 mg, 0.20 mmol, 1 eq) and DIEA (78.6 mg, 0.6 mmol, 0.11 mL, 3 eq) in DCM (2 mL) was added Cu(OAc)2 (55.2 mg, 0.30 mmol, 1.5 eq). The reaction was degassed with 02 for three times and stirred at 25 C for 36hr. LCMS showed that 7% and 4% of desired MS signal was detected. The reaction was filtered and concentrated. The crude product was purified by prep-HPLC to give Compound 110 (2.22 mg, 5.84 umol, 2.9% yield) and Compound 109 (4.31 mg, 11.33 umol, 5.6% yield). HNMR and LCMS confirmed that desired product was obtained.
[00407] Compound 109: LCMS (ESI): RT = 0.671 min, mass calcd. For Ci51-114F2N602S, 380.09 m/z found 380.80[M+H1t IFINMR (400MHz, CDC13) 6 9.01 (s, 1H), 8.02 (d, J = 2.00 Hz, 1H), 7.83 (dd, J= 8.80, 2.00 Hz, 1H), 7.30 (d, J= 8.80 Hz, 1H), 7.20 -7.05 (m, 2H), 6.90 -6.75 (m, 1H), 4.41 - 4.33 (m, 1H), 4.31 (s, 3H), 2.70 (d, J= 5.60 Hz, 3H).
[00408] Compound 110: LCMS (ESI): RT = 0.733 min, mass calcd. For Ci51-114F2N602S, 380.09 m/z found 443.90 [M+Na+MeCN1+.11-INMR (400MHz, CDC13) 6 9.42 (s, 1H), 8.73 (d, J
= 2.00 Hz, 1H), 7.79 (dd, J= 9.20, 2.40 Hz, 1H), 7.31 (d, J= 9.20 Hz, 1H), 7.25 - 7.15 (m, 2H), 6.90 - 6.75 (m, 1H), 4.48 (s, 3H), 4.41 - 4.25 (m, 1H), 2.72 (d, J = 5.60 Hz, 3H).
Example 104: 4-(cyclohexylamino)-3-(1-cyclopropy1-1H-imidazol-4-y1)-N-methylbenzenesulfonamide (Compound 111) r-N
N/
0, 40 N
HN
Preparation of Compound 111:
N/
00 111-1a(1.2 eq) No Br 0, 0µ NIO Pd3(PPh)4(0.1eq) =
Cs2003(2.0eq), HN
HN,Sµ` dioxane/H20,100 C,16h 111-1 Compound 111 OH
HO-B
NH
IT 111-1b (2.0 eq) Ne 1,10-PHENANTHROLINE(1.0eq) N
Br K2CO3 (2.0 eq),Cu(OAc)2(1.0eq) DCE, 70 C,8 hr Br 111-1c 111-1a Step 1: 4-bromo-1-cyclopropyl-imidazole [00409] A mixture of 111-1c (500.0 mg, 3.4 mmol, 1.0 eq), 111-lb (584.4 mg, 6.8 mmol, 2.0 eq), 1,10-PHENANTHROLINE (613.0 mg, 3.4 mmol, 1.0 eq), K2CO3 (940.3 mg, 6.8 mmol, 2.0 eq) and Cu(OAc)2 (617.9 mg, 3.4 mmol, 1.0 eq) in DCE (25.0 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 70 C for 8 h under N2 atmosphere. TLC
indicated 50% of 111-1c was remained, and one major new spot with lower polarity was detected. The reaction mixture was concentrated under reduced pressure to remove DCE. The residue was diluted with Et0Ac (50.0 mL) and extracted with Et0Ac ( 20 mL *3) The combined organic layers were washed with brine (20 mL * 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography to give 111-la (70.0 mg, 0.374 mmol, 11% yield). IFINMR
(400MHz, CDC13) 6 7.42 (d, J = 1.0 Hz, 1H), 6.95 (d, J = 1.3 Hz, 1H), 3.37-3.27 (m, 1H), 1.03-0.94 (m, 4H).
Step 2: 4-(cyclohexylamino)-3-(1-cyclopropy1-1H-imidazol-4-y1)-N-methylbenzenesulfonamide [00410] A mixture of!!!-! (139.1 mg, 0.4 mmol, 1.1 eq), 111-la (60 mg, 0.3 mmol, 1 eq), Pd(PPh3)4 (37.0 mg, 32.0 umol, 0.1 eq) and Cs2CO3 (209.0 mg, 0.6 mmol, 2.0 eq) in dioxane (2.0 mL) and H20 (0.3 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 100 C for 16 h under N2 atmosphere. LCMS showed 111-1 was consumed completely. Several new peaks were shown on LCMS and 27% of desired compound was detected. The residue was purified by prep-HPLC to give Compound 111 (7.82 mg, 20.46 umol, 6% yield). LCMS (ESI): RT = 0.716min, mass calc. for Ci9H26N4025 374.18, m/z found 375.0 [M+H1+; IFINMR (400MHz, CDC13) 6 8.55 (d, J= 5.5 Hz, 1H), 7.85 (s, 1H), 7.55 (s, 2H), 7.32 (s, 1H), 6.66 (d, J= 8.5 Hz, 1H), 4.78 (d, J= 3.0 Hz, 1H), 3.58-3.25 (m, 2H), 2.58 (d, J= 3.0 Hz, 3H), 2.03 (s, 2H), 1.76 (s, 2H), 1.62 (s, 1H), 1.39 (d, J= 7.5 Hz, 5H), 0.98 (s, 4H).
Example 105: 4-(cyclohexylamino)-3-(1-ethy1-1H-imidazol-4-y1)-N-methylbenzenesulfonamide (Compound 112) /FN
N z HN,Sµ`
I
Preparation of Compound 112:
Br orNH2 Br MeNH2, 2M solution Br ? it 410 F in THF (2.0 eq) 0 112-2a (2.5 eq),..., HN-S
0 ___________________ ).
HN-1 4. F
\\ / 6 S DMSO, Cr" µ\ DCM, 20 C, 4 hr / 6 o 140 C,2 112-1 112-2 hr 112-3 0 p /¨
/FN /¨
13-i ''--I-1---- N) IF N
0 0t / µ Br N , 0õ0 112-3a (1.5 eq) B H 112-6 (1.0 eq) H
\µ
Pd(dppf)Cl2 (0.05 eq) 0 Pd(PPI-13).4 (0.05 eq) 0\ 0 AcOK (2.0 eq) Cs2003 (2.0 eq) ,µSµ`
,S
Dioxane,95 C, 16 hr HN\` HN
Dioxane/H20 I
I 100 C, 16 hr 112-4 Compound 112 I
/¨
7 112-5a (1.2 eq) F-N
N Z _______________ )1'. N,e NaH (1.2 eq, 60%) Br DMF, 0-20 00,16 hr Br Step 1: 3-Bromo-4-fluoro-N-methylbenzenesulfonamide [00411] To a solution of compound 112-1 (1.6 g, 5.9 mmol, 1.0 eq) in DCM
(16 mL) was added MeNH2 (2 M, 5.9 mL, 2.0 eq). The reaction mixture was stirred at 20 C
for 4 hours. The mixture was diluted with water (15 mL) and the resultant mixture was extracted with DCM (30 mL * 2). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure to obtain compound 112-2 (1.5 g, 96% yield).
Step 2: 3-Bromo-4-(cyclohexylamino)-N-methylbenzenesulfonamide [00412] A solution of compound 112-2 (1.5 g, 5.6 mmol, 1.0 eq) and compound 112-2a (1.4 g, 14 mmol, 2.5 eq) in DMSO (8 mL) was stirred at 140 C for 2 hours. The mixture was diluted with water (30 mL) and the resultant mixture was extracted with EA (50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound 112-3 (1.8 g, 93% yield). LCMS (ESI): RT = 0.794 min, mass calcd. for C13F119BrN202S 346.04, miz found 348.9 [M+1-11+.
Step 3: 4-(Cyclohexylamino)-N-methy1-3-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-yl)benzenesulfonamide [00413] A solution of compound 112-3 (2.0 g, 5.8 mmol, 1.0 eq), compound 112-3a (2.2 g, 8.6 mmol, 1.5 eq), Pd(dppf)C12 (211 mg, 0.288 mmol, 0.05 eq) and AcOK (1.1 g, 12 mmol, 2.0 eq) in Dioxane (25 mL) was heated to 95 C and stirred at 95 C for 16 hours under N2. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (20 mL) and extracted with EA (50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound 112-4 (1.6 g, 70% yield).
LCMS (ESI): RT = 0.876 min, mass calcd. for Ci9H3113N204S 394.21, m/z found 395.1 [M+I-11+.
Step 4: 4-Bromo-1-ethyl-1H-imidazole [00414] To a solution of compound 112-5 (500 mg, 3.40 mmol, 1.0 eq) in DMF
(6 mL) was added NaH (163 mg, 4.08 mmol, 60% purity, 1.2 eq) at 0 C. The reaction mixture was allowed to warm up to 20 C and then stirred at 20 C for 0.5 hour. The mixture was cooling to 0 C and followed by compound 112-5a (637 mg, 4.08 mmol, 1.2 eq). The reaction mixture was stirred at 20 C for 2.5 hours. The reaction mixture was concentrated under reduced pressure.
The mixture was diluted with water (30 mL) and the resultant mixture was extracted with DCM
(50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford a residue. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely. The title compound 112-6 (150 mg, 25% yield) was obtained. 1I-1 NMR (400MHz, CDC13) 6 7.36 (d, J = 1.0 Hz, 1H), 6.90 (d, J
= 1.5 Hz, 1H), 3.96 (q, J = 7.3 Hz, 2H), 1.45 (t, J = 7.4 Hz, 3H).
Step 5: 4-(Cyclohexylamino)-3-(1-ethy1-1H-imidazol-4-y1)-N-methylbenzenesulfonamide [00415] To a solution of compound 112-4 (100 mg, 0.254 mmol, 1.0 eq), compound 112-6 (44 mg, 0.25 mmol, 1.0 eq), Cs2CO3 (165 mg, 0.507 mmol, 2.0 eq) in Dioxane (2 mL) and H20 (0.2 mL) was added Pd(PPh3)4 (15 mg, 13 umol, 0.05 eq) under N2. The reaction mixture was stirred at 100 C for 16 hours. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely.
Compound 112 (33.80 mg, 36% yield) was obtained. LCMS (ESI): RT = 0.641 min, mass calcd.
for C181-126N402S 362.18, m/z found 363.0 [M+H1+, IFINMR (400MHz, CDC13) 6 7.83 (d, J=
2.3 Hz, 1H), 7.57 - 7.49 (m, 2H), 7.30 (d, J= 1.3 Hz, 1H), 6.69 (d, J= 9.0 Hz, 1H), 4.26 (q, J=
5.3 Hz, 1H), 4.04 (q, J= 7.4 Hz, 2H), 3.50 - 3.38 (m, 1H), 2.62 (d, J= 5.5 Hz, 3H), 2.13 - 1.99 (m, 2H), 1.85 - 1.73 (m, 2H), 1.69 - 1.58 (m, 2H), 1.51 (t, J= 7.4 Hz, 3H), 1.45 - 1.34 (m, 4H).
Example 106: 4-(cyclohexylamino)-3-(1-isopropy1-1H-imidazol-4-y1)-N-methylbenzenesulfonamide (Compound 113) fiN
N/
NQ
0µ *
HN ,\Sµ
Preparation of Compound 113:
Br 113-1b ( 1 . 1 71.9 ) NaH (1.2 eq) Br DMF, 0-20 C, 16.5 hr Br 113-1c 113-la Br fr-N
N /
0,13'0 113-la (1.0 eq) czµ = N
Pn(PPh3)4 (0.1 eq) NQ
Cs2CO3 (2.0 eq) 0, *
-Sµ Dioxane/H20, 100 C, 16 hr ;Sµ
HN HN µo I 113-1 (1.2 eq) Compound 113 Step 1: 4-bromo-1-isopropy1-1H-imidazole [00416] To the solution of compound 113-1c (500 mg, 3.4 mmol, 1 eq) in DMF
(2.5 mL) was added NaH (163 mg, 4.1 mmol, 60% purity, 1.2 eq) at 0 C. The mixture was stirred at 0 C for 30 min. Then compound 113-lb (460 mg, 3.7 mmol, 351 uL, 1.1 eq) was added to the mixture. The solution was warmed up to 20 C and stirred for 16 hr. The reaction was monitored by LCMS. LCMS showed that the starting material remained and the desired MS
was observed.
H20 (20 mL) was added to the solution. The mixture was extracted with Et0Ac (20 mL*3). The combined organic layer was dried with Na2SO4 and concentrated under reduced pressure. The residue was purified by to give compound 113-la (100 mg, 528.95 umol, 15.55%
yield). It was confirmed by HNMR and HMBC. 1H NMR (400MHz, CDC13) 6 7.41 (d, J= 1.3 Hz, 1H), 6.93 (d, J = 1.5 Hz, 1H), 4.37 - 4.27 (m, 1H), 1.48 (d, J= 6.8 Hz, 6H).
Step 2: 4-(cyclohexylamino)-3-(1-isopropy1-1H-imidazol-4-y1)-N-methylbenzenesulfonamide [00417] To the solution of compound 113-la (50 mg, 0.26 mmol, 1 eq) in dioxane (2 mL) was added compound 113-1 (125 mg, 0.32 mmol, 1.2 eq), Pd(PPh3)4 (31 mg, 26.5 umol, 0.1 eq), Cs2CO3 (172 mg, 0.53mo1, 2 eq) and H20 (0.4 mL). The mixture was stirred at 100 C for 16 hr. The reaction was monitored by LCMS. LCMS showed that the starting material was consumed and the desired MS was observed. The reaction solution was filtered.
The residue was purified by HPLC to give Compound 113 (9.07 mg, 23.61 umol, 8.9% yield). LCMS
(ESI): RT
= 0.649 min, mass calcd. for Ci9H23N90 376.19, m/z found 377.0 [M+1-11-1,11-1NMR (400MHz, CDC13) 6 8.71 (br, , 1H), 7.89 (d, J = 2.5 Hz, 1H), 7.57 - 7.51 (m, 2H), 7.36 (d, J= 1.0 Hz, 1H), 6.68 (d, J= 8.8 Hz, 1H), 4.52 (q, J= 5.4 Hz, 1H), 4.41 - 4.30 (m, 1H), 3.44 (br, , 1H), 2.61 (d, J=5.5 Hz, 3H), 2.10 - 2.02 (m, 2H), 1.84- 1.75 (m, 2H), 1.69 - 1.60 (m, 1H), 1.51 (d, J= 6.8 Hz, 6H), 1.46 - 1.27 (m, 5H).
Example 107: 4-(cyclohexylamino)-3-(1-ethy1-1H-imidazol-5-y1)-N-methylbenzenesulfonamide (Compound 114) /=N
rN
czµ N
HN,Sµ`
I
Preparation of Compound 114:
IF-NH 114-la (1.2 eq) NeNaH (1.2 eq, 60%) Br DMF, 0-20 C,16 hr Br F--N
N-N?
0, 0 114-2 (1.1 eq) No0 el 0 Pd(PPh3).4 (0.05 eq) HN
HN-Sµ` Cs2CO3 (2.0 eq) -S, Dioxane/H20 100 C, 16 hr 114-3 Compound 114 Step 1: 5-Bromo-1-ethyl-1H-imidazole [00418] To a solution of compound 114-1 (500 mg, 3.40 mmol, 1.0 eq) in DMF
(6 mL) was added NaH (163 mg, 4.08 mmol, 60% purity, 1.2 eq) at 0 C. The reaction mixture was allowed to warm up to 20 C and then stirred at 20 C for 0.5 hour. The mixture was cooling to 0 C and followed by compound 114-la (637 mg, 4.08 mmol, 1.2 eq). The reaction mixture was stirred at 20 C for 2.5 hours. The reaction mixture was concentrated under reduced pressure.
The mixture was diluted with water (30 mL) and the resultant mixture was extracted with DCM
(50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely. The title compound (60 mg, 25% yield) was obtained. IFINMR (400MHz, CDC13) 6 7.58 (s, 1H), 7.02 (s, 1H), 3.99 (q, J =
7.3 Hz, 2H), 1.43 (t, J = 7.3 Hz, 3H).
Step 2: 4-(Cyclohexylamino)-3-(1-ethy1-1H-imidazol-5-y1)-N-methylbenzenesulfonamide [00419] To a solution of compound 114-3 (120 mg, 0.304 mmol, 1.0 eq), compound 114-2 (60 mg, 0.33 mmol, 1.1 eq), Cs2CO3 (198 mg, 0.609 mmol, 2.0 eq) in Dioxane (2 mL) and H20 (0.2 mL) was added Pd(PPh3)4 (18 mg, 15 umol, 0.05 eq) under N2. The reaction mixture was stirred at 100 C for 16 hours. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely.
Compound 114 (37.86 mg, 34% yield) was obtained. LCMS (EST): RT = 0.630 min, mass calcd.
for Ci8H26N402S 362.18, m/z found 362.9 [M+H1+, 1HNMR (400MHz, CDC13) 6 7.79 -7.68 (m, 2H), 7.53 (d, J= 2.3 Hz, 1H), 7.18 - 7.05 (m, 1H), 6.73 (d, J= 9.0 Hz, 1H), 4.48 - 4.38 (m, 1H), 4.26 (d, J = 7.8 Hz, 1H), 3.82 (q, J = 7.3 Hz, 2H), 3.41 - 3.29 (m, 1H), 2.68 (d, J= 5.3 Hz, 3H), 2.02 - 1.92 (m, 2H), 1.76 - 1.61 (m, 3H), 1.45 - 1.32 (m, 2H), 1.28 (t, J= 7.3 Hz, 3H), 1.26 - 1.58 (m, 1H), 1.17 - 1.06 (m, 2H).
Example 108: 3-(2-(2-(benzyloxy)ethyl)-2H-tetrazol-5-y1)-N-methyl-4-44-(trifluoromethyl)phenyl)amino)benzenesulfonamide (Compound 115) =
N-N
;1\1 00, F
HN
Preparation of Compound 115:
N OH
Bn0 115-1a (1.2 eq) 0, el N
F PPh3 (3.0 eq))1' N
N-N
z F DIAD (3.0 eq) HN F THF, 0 - 25 C, 16 hr N
0, el ,µS
HN , 115-1 Compound 115 [00420] To a stirring solution of compound 115-1 (20 mg, 50 umol, 1.0 eq), compound 115-la (9.1 mg, 60 umol, 1.2 eq) and PPh3 (40 mg, 0.15 mmol, 3.0 eq) in THF (1 mL) was added DIAD (30 mg, 0.15 mmol, 3.0 eq) slowly at 0 C under N2. The reaction mixture was stirred at 25 C for 16 hours. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (5 mL) and the resultant mixture was extracted with EA (20 mL
* 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford Compound 115 (6.76 mg, 25% yield). LCMS (ESI): RT = 0.857 min, mass calcd. for C24H23F3N603S 532.15, m/z found 533.0 [M+H1+, IFINMR (400MHz, CDC13) 6 9.70 (s, 1H), 8.73 (d, J= 2.3 Hz, 1H), 7.79 (dd, J= 2.1, 8.9 Hz, 1H), 7.66 (d, J = 8.5 Hz, 2H), 7.51 (d, J = 8.8 Hz, 1H), 7.41 (d, J= 8.3 Hz, 2H), 7.34 - 7.29 (m, 3H), 7.27 - 7.23 (m, 2H), 4.93 (t, J = 5.4 Hz, 2H), 4.57 (s, 2H), 4.32 (q, J= 5.5 Hz, 1H), 4.11 (t, J= 5.4 Hz, 2H), 2.74 (d, J= 5.3 Hz, 3H).
Example 109: 3-(2-(2-hydroxyethyl)-2H-tetrazol-5-y1)-N-methyl-4-44-(trifluoromethyl)phenyl) amino)benzenesulfonamide (Compound 116) OH
N-N
;1\1 S
HN \
Preparation of Compound 116:
OH
.b 9 NC
H
HO .B
Nacys-- - N
F NC 0 R` 10 40 F
NC F H
40 NH2 116-1a (1.2 eq) I N
00 00 F _______________________________________________ F 116-2a (3.0eq) Of \\C) F
F
I DIPEA (2.0 eq) F DMSO, 110 C, 1 hr DCM,02, 25 C,72 hr 116-2 N-NH
NC
H
1.Na0Me(3.0eq),THF Me0H, 20 C, 1h N
NaN3 (3.0 eq) H
NH4CI (3.0 eq) N
9` 0 40 _______________________________________________ I.- µ
F
________________________ A. DMF, 100 C, 2 hr R . 0 F
,., ..S
N ,Ss 2.methanamine (3.0eq), TEA(5.0eq), NCS(2.0eq) H a F F F
HN s,-, F
THF, 20 C, 3h 1 µ-' OH
OBn N-N
1\l Bn0'-'OH N-N ','N
H
116-5a (1.2 eq) N' ,i\I Pd(OH)2 (20%) N
PPh3 (3.0 eq) H2 CIµµ el 0 F
DIAD (3.0 eq) N 0 Me0H, 25 C, 16 hr ,Ss HN ,,-, F F
THF, 0-25 C, 16 hr (I:\ el F
,\ 1 µ-HNS,.., µ FF
1 µ-' 116-6 Compound 116 Step 1: 5-Iodo-2-04-(trifluoromethyl)phenyl)amino)benzonitrile [00421] To a solution of compound 116-1 (450 mg, 1.84 mmol, 1.0 eq), compound 116-la (420 mg, 2.21 mmol, 1.2 eq) and Cu(0Ac)2 (402 mg, 2.21 mmol, 1.2 eq) in DCM (5 mL) was added DIPEA (477 mg, 3.69 mmol, 2.0 eq) under 02. The reaction mixture was stirred at 25 C
for 72 hours. The reaction mixture was concentrated under reduced pressure.
The residue was purified by column chromatography over silica gel to afford the title compound 116-2 (180 mg, 25% yield). IFINMR (400MHz, CDC13) 6 7.84 (d, J = 2.0 Hz, 1H), 7.70 (dd, J =
2.0, 8.8 Hz, 1H), 7.61 (d, J= 8.5 Hz, 2H), 7.23 (d, J= 8.5 Hz, 2H), 7.11 (d, J= 9.0 Hz, 1H), 6.46(s, 1H).
Step 2: Methyl 3-03-cyano-4-04-(trifluoromethyl)phenyl)amino)phenyl)sulfonyl)propanoate [00422] Compound 116-2 (130 mg, 0.335 mmol, 1.0 eq), compound 116-2a (175 mg, 1.00 mmol, 3.0 eq) and Cul (319 mg, 1.67 mmol, 5.0 eq) were taken up into a microwave tube in DMSO (3 mL). The sealed tube was heated at 110 C for 1 hour under microwave. The mixture was diluted with water (10 mL) and EA (30 mL). The suspension was filtered and the filtrate was separation, the water layer was extracted with EA (20 mL * 2).
The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound 116-3 (110 mg, 80% yield).
Step 3: 3-Cyano-N-methy1-4-04-(trifluoromethyl)phenyl)amino)benzenesulfonamide [00423] To a solution of compound 116-3 (110 mg, 0.267 mmol, 1.0 eq) in Me0H (1.5 mL) and THF (3 mL) was added Na0Me (43 mg, 0.80 mmol, 3.0 eq). The reaction mixture was stirred at 20 C for 1 hour, and then removed solvent to give a residue. The residue was dissolved with THF (2 mL). After MeNH2 (2 M, 0.40 mL, 3.0 eq), TEA (135 mg, 1.33 mmol, 5.0 eq) and NCS (71 mg, 0.53 mmol, 2.0 eq) were added, the reaction mixture was stirred at 20 C
for 3 hours. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound 116-4 (80 mg, 84%
yield). IFINMR
(400MHz, CDC13) 6 8.06 (d, J= 2.3 Hz, 1H), 7.85 (dd, J= 2.1, 8.9 Hz, 1H), 7.69 (d, J= 8.5 Hz, 2H), 7.35 (d, J= 8.5 Hz, 2H), 7.31 (d, J= 9.0 Hz, 1H), 6.84 (s, 1H), 4.37 (q, J= 5.3 Hz, 1H), 2.71 (d, J = 5.5 Hz, 3H).
Step 4: N-methy1-3-(2H-tetrazol-5-y1)-4-04-(trifluoromethyl)phenyl)amino)benzenesulfonamide [00424] To a solution of compound 116-4 (80 mg, 0.23 mmol, 1.0 eq) in DMF
(2 mL) were added NaN3 (60 mg, 0.92 mmol, 4.1 eq) and NH4C1 (36 mg, 0.68 mmol, 3.0 eq). The reaction mixture was stirred at 100 C for 2 hours. The mixture was diluted with water (30 mL) and the resultant mixture was extracted with EA (50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure to obtain the title compound 116-5 (85 mg, 95% yield). LCMS (ESI): RT = 0.746 min, mass calcd. for Ci5H13F3N602S 398.08, m/z found 399.1 [M+H1+.
Step 5: 3-(2-(2-(Benzyloxy)ethyl)-2H-tetrazol-5-y1)-N-methyl-4-04-(trifluoromethyl)phenyl) amino)benzenesulfonamide [00425] To a stirring solution of compound 116-5 (65 mg, 0.16 mmol, 1.0 eq), compound 116-5a (30 mg, 0.20 mmol, 1.2 eq) and PPh3 (128 mg, 0.490 mmol, 3.0 eq) in THF
(2 mL) was added DIAD (99 mg, 0.49 mmol, 3.0 eq) slowly at 0 C under N2. The reaction mixture was stirred at 25 C for 16 hours. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL
* 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford compound 116-6 (70 mg, 78% yield). LCMS (ESI): RT = 0.865 min, mass calcd. for C24H23F3N603S 532.15, m/z found 533.1 [M+H1+, IFINMR (400MHz, CDC13) 6 9.67 (s, 1H), 8.70 (d, J= 2.3 Hz, 1H), 7.77 (dd, J= 2.4, 8.9 Hz, 1H), 7.64 (d, J = 8.5 Hz, 2H), 7.49 (d, J = 9.0 Hz, 1H), 7.39 (d, J= 8.5 Hz, 2H), 7.32 - 7.26 (m, 3H), 7.25 - 7.21 (m, 2H), 4.91 (t, J= 5.4 Hz, 2H), 4.55 (s, 2H), 4.30 (q, J= 5.4 Hz, 1H), 4.09 (t, J= 5.3 Hz, 2H), 2.71 (d, J= 5.5 Hz, 3H).
Step 6: 3-(2-(2-Hydroxyethyl)-2H-tetrazol-5-y1)-N-methyl-4-44-(trifluoromethyl)phenyl) amino)benzenesulfonamide [00426] To a solution of compound 116-6 (40 mg, 75 umol, 1 eq) in Me0H (3 mL) was added Pd(OH)2 (10 mg, 20% purity) under N2. The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred under H2 (15 psi) at 25 C for 16 hours.
The reaction mixture was filtered and the filtrate was concentrated. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely.
Compound 116 (6.67 mg, 20% yield) was obtained. LCMS (ESI): RT = 0.748 min, mass calcd.
for C17I-117P3N603S 442.10, m/z found 442.9 [M+H1+, 1HNMR (400MHz, CDC13) 6 9.67 (s, 1H), 8.69 (d, J= 2.3 Hz, 1H), 7.77 (dd, J= 2.1, 8.9 Hz, 1H), 7.65 (d, J = 8.5 Hz, 2H), 7.49 (d, J = 9.0 Hz, 1H), 7.40 (d, J= 8.5 Hz, 2H), 4.92 - 4.86 (m, 2H), 4.37 (q, J= 5.5 Hz, 1H), 4.33 - 4.27 (m, 2H), 2.71 (d, J= 5.5 Hz, 3H), 2.22 (t, J= 6.0 Hz, 1H).
Example 110: 4-((3-fluorophenyl)amino)-N-methyl-3-(2-methyl-2H-tetrazol-5-yl)benzenesulfonamide (Compound 117) N-N
= F
um N-S
Preparation of Compound 117:
Ho-13 * F
NH2 117-1a (2 eq) HN-S \\ DIPEA (3 eq), ri S
\\ 401 N F
I CU(OAC)2 (1.5 eq), j 0 02 (15 Psi),DCM,rt,16 h 117-1 Compound 117 [00427] To a solution of compound 117-1 (40 mg, 0.15 mmol, 1 eq), (3-fluorophenyl)boronic acid (117-1a) (41.7 mg, 0.30 mmol, 2 eq) and DIEA (57.8 mg, 0.45 mmol, 77.90 uL, 3 eq) in DCM (2 mL) was added Cu(OAc)2 (40.6 mg, 0.22 mmol, 1.5 eq).
The reaction was stirred at 25 C under 02 (15 Psi) for 16hr. LCMS showed that 50% of desired MS signal was detected. The reaction was filtered and concentrated. The crude product was purified by prep HPLC to give Compound 117 (8.74 mg, 24.12 umol, 16.18% yield). HNMR and LCMS
confirmed that desired product was obtained. LCMS (ESI): RT = 0.746 min, mass calcd. For Ci5Hi5FN6025, 362.10 m/z found 362.9[M+H1t NMR (400MHz, CDC13) 6 9.47 (s, 1H), 8.69 (d, J= 2.4 Hz, 1H), 7.74 (d, J= 9.2 Hz, 1H), 7.45- 7.30(m, 2H), 7.15- 7.00(m, 2H), 7.00 - 6.95 (m, 1H), 4.47 (s, 3H), 4.28 (d, J= 5.6 Hz, 1H), 2.70 (d, J = 5.6 Hz, 3H).
Example 111: 4-((4-fluorophenyl)amino)-N-methyl-3-(2-methyl-2H-tetrazol-5-yl)benzenesulfonamide (Compound 118) and 4-((4-fluorophenyl)amino)-N-methyl-3-(1-methyl-1H-tetrazol-5-yl)benzenesulfonamide (Compound 119) N-NNN
-N /%\i N N
(Rµ
,õ,,s ,s rum \\ HN
Compound 118 Compound 119 Preparation of Compound 118:
N-N/ OHNN
HOB* N-N
-N
N.N N
HN =
NH2 + HNS 40 NH2 118-la (1.5 eq) uõ, N
+ IR\
o N
(Rµ
,\S -S
-S
µµ DIPEA (2 eq), HN
1 0 I 0 Cu(OAc)2 (1.5 eq), 0 1 0 02(15 Psi),DCM,rt,16 h 118-1 Compound 118 Compound 119 [00428] To a solution of a mixture of compounds 118-1 (50 mg, 0.18 mmol, 1 eq) in DCM
(3 mL) was added compound 118-la (39.1 mg, 0.28 mmol, 1.5 eq), Cu(0Ac)2 (50.8 mg, 0.28 mmol, 1.5 eq) followed by DIEA (48.2 mg, 0.37 mmol, 64.92 uL, 2 eq) under N2.
The suspension was degassed under vacuum and purged with 02 several times. The mixture was stirred under 02 (15psi) at 25 C for 16 hours. LCMS showed that 5.6% and 50%
of desired product were detected. The reaction was filtered and concentrated. The residue was added Me0H (4 mL) and filtered to give Compound 118 (18.83 mg, 50.30 umol, 27%
yield). The filtrate was concentrated. The crude product was purified by Prep HPLC to give Compound 119 (2.85 mg, 7.86 umol, 4.2% yield).
[00429] Compound 118: LCMS (ESI): RT = 0.733 min, mass calcd. For Ci5Hi5FN602S, 362.10 m/z found 362.9[M+Hr IFINMR (400MHz, CDC13) 6 9.32 (s, 1H), 8.68 (d, J
= 2.4 Hz, 1H), 7.68 (dd, J= 8.8, 2.4 Hz, 1H), 7.46 - 7.37 (m, 3H), 7.25 - 7.15 (m, 3H), 4.47 (s, 3H), 4.24 (d, J = 5.6 Hz, 1H), 2.69 (d, J= 5.6 Hz, 3H).
[00430] Compound 119: LCMS (ESI): RT = 0.679 min, mass calcd. For Ci5Hi5FN602S, 362.10 m/z found 362.9[M+Hr IFINMR (400MHz, CHLOROFORM-d) 6 8.97 (s, 1H), 7.99 (d, J= 2.0 Hz, 1H), 7.80 - 7.60 (m, 1H), 7.25 - 7.15 (m, 3H), 7.15 - 7.05 (m, 3H), 4.40 - 4.25 (m, 4H), 2.67 (d, J = 4.4 Hz, 3H).
Example 112: 4-((2-fluorophenyl)amino)-N-methyl-3-(2-methyl-2H-tetrazol-5-yl)benzenesulfonamide (Compound 120) N-N
H F
N
n \\
Preparation of Compound 120:
N-N/ pH F
1\11 HO itNN
H F
I. NH2 120-1a (1.5 eq) Rµ
N
HN-% DIPEA (2 eq), INJ n õk,,S
I CU(OAC)2 (1.5 eq), 1 0 02 (15 Psi),00M,rt,80 h 120-1 Compound 120 1004311 To a solution of compound 120-1 (50 mg, 0.19 mmol, 1 eq) in DCM (3 mL) was added (2-fluorophenyl)boronic acid 120-la (39.1 mg, 0.28 mmol, 1.50 eq) , Cu(0Ac)2 (50.8 mg, 0.28 mmol, 1.5 eq) followed by DIEA (48.2 mg, 0.37 mmol, 64.92 uL, 2 eq) under N2. The suspension was degassed under vacuum and purged with 02 several times. The mixture was stirred under 02 (15psi) at 25 C for 16 hours. LCMS showed that starting material was remained and 2% of desired product was detected. The reaction was continued to stir at 25 C for 16hr.
LCMS showed that 5% of desired MS signal was detected. The reaction was continued to stir at 25 C for 48hr. LCMS showed that 3% and 8% desired product was detected. The reaction was filtered and concentrated. The crude product was purified by Prep HPLC to give Compound 120 (2.04 mg, 5.63 umol, 3.0% yield). HNMR and LCMS confirmed that desired product was detected. LCMS (ESI): RT = 0.735 min, mass calcd. For Ci5tli5FN602S, 362.10 m/z found 362.9[M+H1t IFI NMR (400MHz, CDC13) 6 9.30 (s, 1H), 8.71 (d, J = 2.0 Hz, 1H), 7.72 (dd, J=
9.2, 2.4 Hz, 1H), 7.50 - 7.40 (m, 1H), 7.25 - 7.00 (m, 4H), 4.47 (s, 3H), 4.28 (d, J= 5.6 Hz, 1H), 2.70 (d, J = 5.2 Hz, 3H).
Example 113: N-methyl-3-(1-methyl-1H-imidazol-4-y1)-4-44-(trifluoromethyl)phenyl)amino)benzenesulfonamide (Compound 121) N/
in H
N
0\ 0 0 F
,\Sµ F
HN F
I
Preparation of Compound 121:
0 O---.
Br Br H2N 4 Br H go t013-130 F MeNH2, 2M solution F N
0\ IS inTHF (2.0 eq) ).-- 0 I* 121-2a (2.0 eq) 3"-- 0, 0 121-3a (1.5 eq) _________________________________________________________________________ v.-,\S, \S, DMSO, 140 C, 1 hr DCM, 25 C, 2 hr S\
Pd(dppf)Cl2 (0.05 eq) Cl- `0 HN b I HN `0 1 AcOK (2.0 eq) Dioxane,95 C, 16 hr /
ii-N
/
N? N
ir 0õ0 N y B
NH 00 Br 121-4a (1.1 eq),.... NH SI
Pd/C (10%), HCI (5.0 eq...
CZ\ 40 Pd(PPh3)4 (0.05 eq) CZ\ ei H2, Me0H,25 C, 16 hr Cs2CO3 (2.0 eq) -S, HN µ(-1 Dioxane/H20,90 C, 16 hr HNI µ-' \µ., I '' Hy / /
IFN
F IFN
F H
NH 2 121-6a (1.5 eq) õ... ,µ 0 N 0 CZµ 0 (:) Cu(OAc)2 (1.2 eq) F
DIPEA (4.0 eq) ,S\ ,S, F
HN `0 DCM, 25 C, 02,16 hr HN b F
1 i 121-6 Compound 121 Step 1: 3-Bromo-4-fluoro-N-methylbenzenesulfonamide [00432] To a solution of compound 121-1 (1.0 g, 3.7 mmol, 1.0 eq) in DCM
(10 mL) was added MeNH2 (2 M, 3.7 mL, 2.0 eq). The reaction mixture was stirred at 25 C
for 2 hours. The mixture was diluted with water (15 mL) and the resultant mixture was extracted with DCM (30 mL * 2). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure to obtain the title compound 121-2 (950 mg, 97%
yield).
Step 2: 4-(Benzylamino)-3-bromo-N-methylbenzenesulfonamide [00433] A solution of compound 121-2 (850 mg, 3.17 mmol, 1.0 eq) and compound 121-2a (679 mg, 6.34 mmol, 2.0 eq) in DMSO (4 mL) was stirred at 140 C for 1 hour. The mixture was diluted with water (30 mL) and the resultant mixture was extracted with EA
(50 mL * 3).
The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound 121-3 (1.0 g, 89% yield). LCMS (ESI): RT = 0.798 min, mass calcd. for Ci4H1513rN202S 354.00, m/z found 356.7 [M+Hl+.
Step 3: 4-(Benzylamino)-N-methy1-3-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)benzenesulfonamide [00434] A solution of compound 121-3 (850 mg, 2.39 mmol, 1.0 eq), compound 121-3a (911 mg, 3.59 mmol, 1.5 eq), Pd(dppf)C12 (88 mg, 0.12 mmol, 0.05 eq) and AcOK
(470 mg, 4.79 mmol, 2.0 eq) in Dioxane (10 mL) was heated to 90 C and stirred at 90 C for 16 hours under N2. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (30 mL) and the resultant mixture was extracted with EA (50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound 121-4 (800 mg, 68% yield). LCMS (ESI): RT = 0.827 min, mass calcd. for C20I-127BN204S 402.18, m/z found 402.9 [M+H]+.
Step 4: 4-(Benzylamino)-N-methy1-3-(1-methy1-1H-imidazol-4-yl)benzenesulfonamide [00435] To a solution of compound 121-4 (700 mg, 1.74 mmol, 1.0 eq), compound 121-4a (308 mg, 1.91 mmol, 1.1 eq), Cs2CO3 (1.13 g, 3.48 mmol, 2.0 eq) in Dioxane (8 mL) and H20 (2 mL) was added Pd(PPh3)4 (101 mg, 87.0 umol, 0.05 eq) under N2. The reaction mixture was stirred at 90 C for 16 hours. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (20 mL) and the resultant mixture was extracted with EA (50 mL
* 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The resulting mixture was lyophilized to dryness to remove the solvent residue completely. The title compound 121-5 (180 mg, 28% yield) was obtained. LCMS
(ESI): RT =
0.592 min, mass calcd. for Cl8H20-N-402S 356.13, m/z found 356.9 [M+Hl+, IFINMR (400MHz, CDC13) 6 9.09 (s, 1H), 7.86 (d, J = 2.3 Hz, 1H), 7.49 (dd, J = 2.3, 8.8 Hz, 1H), 7.46 (s, 1H), 7.41 - 7.30 (m, 4H), 7.29 - 7.26 (m, 2H), 6.62 (d, J= 8.8 Hz, 1H), 4.53 (s, 2H), 4.21 (q, J= 5.4 Hz, 1H), 3.75 (s, 3H), 2.61 (d, J= 5.5 Hz, 3H).
Step 5: 4-Amino-N-methyl-3-(1-methyl-1H-imidazol-4-yl)benzenesulfonamide [00436] To a solution of compound 121-5 (170 mg, 0.477 mmol, 1.0 eq) in Me0H (5 mL) were added Pd/C (50 mg, 10% purity) and HC1 (242 mg, 2.38 mmol, 236.79 uL, 36%
purity, 5.0 eq) under N2. The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred under H2 (45 psi) at 25 C for 16 hours. The reaction mixture was filtered and the filtration was concentrated to obtain the title compound 121-6 (140 mg, crude).
Step 6: N-Methyl-3-(1-methyl-1H-imidazol-4-y1)-4-44-(trifluoromethyl)phenyl)amino) benzenesulfonamide [00437] To a solution of compound 121-6 (140 mg, 0.526 mmol, 1.0 eq), compound 121-6a (150 mg, 0.789 mmol, 1.5 eq) and Cu(OAc)2 (115 mg, 0.631 mmol, 1.2 eq) in DCM (5 mL) was added DIPEA (272 mg, 2.10 mmol, 4.0 eq). The reaction mixture was stirred at 25 C for 16 hours. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (30 mL) and the resultant mixture was extracted with EA (50 mL *
3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by preparative high performance liquid chromatography. The pure fractions were collected and the volatiles were removed under vacuum. The residue was re-suspended in water (10 mL) and the resulting mixture was lyophilized to dryness to remove the solvent residue completely. Compound 121 (16.20 mg, 39.47 umol, 7.5% yield) was obtained.
LCMS (ESI): RT = 0.653 min, mass calcd. for Ci8Hi7P3N402S 410.10, m/z found 410.9 [M+H1+, IFINMR (400MHz, CDC13) 6 10.88 (s, 1H), 7.97 (s, 1H), 7.61 - 7.51 (m, 4H), 7.48 (d, J = 8.8 Hz, 1H), 7.33 (d, J= 8.3 Hz, 3H), 4.38 - 4.30 (m, 1H), 3.79 (s, 3H), 2.67 (d, J = 5.5 Hz, 3H).
Example 114: 4-((3,4-difluorophenyl)amino)-N-methyl-3-(2-methyl-2H-tetrazol-5-yl)benzenesulfonamide (Compound 122) N-N
N
F
-S
HN
Preparation of Compound 122:
N-N/ OH
N-N"
1\11 * F
N N
NH2 122-la (1.5 eq) µµ = N = F
)1... 0 ,õ
HN µµ ,,S
,\S DIPEA (2 eq), n I sl I 0 CU(OAC)2 (1.5 eq), I 0 02 (15 Psi),DCM,rt,80 h 122-1 Compound 122 [00438] To a solution of compound 122-1 (50 mg, 0.19 mmol, 1 eq) in DCM (3 mL) was added 3,4-difluorophenyl)boronic acid (122-1a, 44.1 mg, 0.28 mmol, 1.5 eq), Cu(0Ac)2 (50.8 mg, 0.28 mmol, 1.5 eq) followed by DIEA (72.3 mg, 0.56 mmol, 97.38 uL, 3 eq) under N2. The suspension was degassed under vacuum and purged with 02 several times. The mixture was stirred under 02 (15psi) at 25 C for 16 hours. LCMS showed that 7.6% and 55%
of desired product were detected. The reaction was filtered and concentrated. The crude product was purified by Prep HPLC to give Compound 122 (21.1 mg, 54.92 umol, 29.47%
yield). 1HNMR
and LCMS confirmed that desired product was obtained. LCMS (ESI): RT = 0.748 min, mass calcd. For Ci5Hi4F2N602S, 380.10 m/z found 380.9[M+Ht 1HNMR (400MHz, CDC13) 6 9.38 (s, 1H), 8.69 (d, J= 2.0 Hz, 1H), 7.72 (dd, J = 9.2, 2.0 Hz, 1H), 7.25 - 7.10 (m, 3H), 7.10 - 7.00 (m, 1H), 4.47 (s, 3H), 4.38 (d, J= 5.6 Hz, 1H), 2.69 (d, J = 5.2 Hz, 3H).
Example 115: 3-(1-ethyl-1H-imidazol-4-y1)-N-methyl-4-44-(trifluoromethyl)phenyl)amino) benzenesulfonamide (Compound 123) N-\\
N N
I
Preparation of Compound 123:
0 ).
) ). MeNH2 in 0 0 Br Ac20 HOSO2C1 (5.0 eq) 0 Br 0 Br ___________________________________________ THF(2.0 eq) Br )1. )1..
0-80 C, 1hr 0-80 C, 4 hr DCM, 0-25 0=S=0 0=S-CI C, 0.5 hr ii NI H
8 , HO
i B
F 40 Br \LOB_50-L-0 Br N i 0 0" \
F F
HCI (6 M) 123-6a (1.5 eq) 123-5a (1.0 eq) 0 0 F _____________ ).-_,...
100 C, 1 hr Cu(OAc)2 (1.2 eq) N µ`õ, F
Pd(dppf)C12 (0.05 eq) 0=S=0 H '-' F AcOK
(2.0 eq) NH DIPEA (2.0 eq) Dioxane, 90 C, 16 hr DCM, 25 C, 02, 40 hr 123-6 rN
f------\
0õ0 N N-\\
B N N
H Br N H
123-7a (1.2 eq) N
0µ,, 010 010 F _______________ N -S Pd(PPh3)4 (0.05 eq) '''µµ lel N µ`õ, F ,S
H '-' F Cs2CO3 (2.0 eq) HN b F
Dioxane/H20, 90 C, 16 hr I F
Compound 123 Step 1: N-(2-Bromophenyl)acetamide [00439] To a stirring solution of Ac20 (54.5 g, 534 mmol, 2.3 eq) was added bromoaniline (40.0 g, 233 mmol, 1.0 eq) at 0 C, and then the reaction mixture was stirred at 80 C for 1 hour. TLC showed the starting material was consumed. The reaction mixture was concentrated under reduced pressure. Petroleum ether (80 mL) was added the residue, and then the suspension was stirred for 0.5 hour at 25 C. The suspension was filtered to obtain the title compound 123-2 (48 g, 96% yield). 1HNMR (400MHz, CDC13) 6 8.34 (d, J= 8.0 Hz, 1H), 7.61 (brs, 1H), 7.53 (dd, J= 1.0, 8.0 Hz, 1H), 7.36 - 7.28 (m, 1H), 6.98 (t, J= 7.4 Hz, 1H), 2.24 (s, 3H) Step 2: 4-Acetamido-3-bromobenzene-1-sulfonyl chloride [00440] To a stirring of HS03C1 (24.1 g, 207 mmol, 4.4 eq) was added compound 123-2 (10.0 g, 46.7 mmol, 1.0 eq) at 0 C. After addition complete, the reaction mixture was stirred at 80 C for 4 hours. TLC showed the starting material was consumed. The reaction mixture was added to ice (300 g) and then warm up to 25 C. The suspension was extracted with EA (3 *80 mL) to obtain the title compound 123-3 (12 g, crude).
Step 3: N-(2-Bromo-4-(N-methylsulfamoyl)phenyl)acetamide [00441] To a solution of compound 123-3 (12.0 g, 38.4 mmol, 1.0 eq) in DCM
(120 mL) was added MeNH2 (2 M, 38.4 mL, 2.0 eq) at 0 C. The reaction mixture was stirred at 25 C for 0.5 hour. TLC showed the starting material was consumed. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (50 mL) and the resultant mixture was extracted with EA (100 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. EA
(25 mL) was added to the crude product, and then the suspension was filtered to obtain the title compound 123-4 (4.7 g, 40% yield). IFINMR (400MHz, DMSO-d6) 6 9.66 (s, 1H), 7.99 - 7.93 (m, 2H), 7.75 (dd, J = 2.0, 8.5 Hz, 1H), 7.55 (q, J = 4.9 Hz, 1H), 2.44 (d, J= 5.0 Hz, 3H), 2.15 (s, 3H).
Step 4: 4-Amino-3-bromo-N-methylbenzenesulfonamide [00442] A solution of compound 123-4 (4.7 g, 15 mmol, 1.0 eq) in HCl (50 mL) was stirred at 100 C for 1 hour. TLC (Petroleum ether: Ethyl acetate = 2:1) showed the starting material was consumed. The reaction mixture was basified with aq. NaOH (6M) until pH = 9 and the resulting suspension was extracted with EA (150 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure to obtain the title compound 123-5 (3.9 g, 95% yield). IFINMR (400MHz, DMSO-d6) 6 7.68 (d, J= 1.8 Hz, 1H), 7.43 (dd, J = 1.8, 8.5 Hz, 1H), 7.12 (q, J = 4.9 Hz, 1H), 6.86 (d, J= 8.5 Hz, 1H), 6.15 (s, 2H), 2.36 (d, J = 5.0 Hz, 3H).
Step 5: 3-Bromo-N-methy1-4-44-(trifluoromethyl)phenyl)amino)benzenesulfonamide [00443] To a solution of compound 123-5 (3.9 g, 15 mmol, 1.0 eq), compound 123-5a (4.2 g, 22 mmol, 1.5 eq) and Cu(OAc)2 (3.2 g, 18 mmol, 1.2 eq) in DCM (40 mL) was added DIPEA
(5.7 g, 44 mmol, 3.0 eq). The reaction mixture was stirred at 25 C for 40 hours under 02.
LCMS showed -50% of Reactant 123-5 was remained and one peak with desired MS
was detected. The reaction mixture was concentrated under reduced pressure. EA
(120 mL) was added, and then the suspension was filtered. The organic layer was washed with water (30 mL *
2), dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound as a mixture.
The residue was purified by column chromatography over silica gel to afford the title compound 123-6 (620 mg, 10% yield). 1HNMR (400MHz, DMSO-d6) 6 8.51 (s, 1H), 7.96 (d, J
= 2.0 Hz, 1H), 7.68 - 7.61 (m, 3H), 7.49 (d, J = 8.5 Hz, 1H), 7.45 (q, J = 5.1 Hz, 1H), 7.31 (d, J =
8.5 Hz, 2H), 2.43 (d, J = 5.0 Hz, 3H).
Step 6: N-methyl-3-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-4-44-(trifluoromethyl) phenyl)amino)benzenesulfonamide [00444] A solution of compound 123-6 (150 mg, 0.37 mmol, 1.0 eq), compound 123-6a (140 mg, 0.55 mmol, 1.5 eq), Pd(dppf)C12 (13 mg, 18 umol, 0.05 eq) and AcOK
(72 mg, 0.73 mmol, 2.0 eq) in Dioxane (3 mL) was heated to 90 C and stirred at 90 C for 16 hours under N2.
LCMS showed Reactant 123-6 was consumed completely and one main peak with desired MS
was detected. TLC showed the starting material was consumed. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by Prep-TLC to obtain the title compound 123-7 (80 mg, 48% yield).
(400MHz, CDC13) 6 8.29 (s, 1H), 8.23 (d, J= 2.3 Hz, 1H), 7.76 (dd, J = 2.4, 8.9 Hz, 1H), 7.60 (d, J = 8.5 Hz, 2H), 7.30 (t, J = 8.9 Hz, 3H), 4.24 (q, J= 5.4 Hz, 1H), 2.67 (d, J= 5.3 Hz, 3H), 1.38 (s, 12H).
Step 7: 3-(1-Ethyl-1H-imidazol-4-y1)-N-methyl-4-44-(trifluoromethyl)phenyl)amino)benzenesulfonamide [00445] To a solution of compound 123-7 (80 mg, 0.18 mmol, 1.0 eq), compound 123-7a (37 mg, 0.21 mmol, 1.2 eq) and Cs2CO3 (114 mg, 0.35 mmol, 2.0 eq) in Dioxane (3 mL) and H20 (0.6 mL) was added Pd(PPh3)4 (10 mg, 8.8 umol, 0.05 eq). The suspension was degassed under vacuum and purged with N2 several times. The reaction mixture was stirred at 90 C for 16 hours. LCMS showed Reactant 7 was consumed completely and one main peak with desired MS
was detected. The reaction mixture was concentrated under reduced pressure.
The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by Prep-TLC to obtain the Compound 123 as a crude product. The residue was purified by prep-HPLC to obtain Compound 123 (4.68 mg, 6.2%
yield). LCMS (ESI): RT = 0.668 min, mass calcd. for Ci9H19F3N4025 424.12, m/z found 425.0 [M+H1+, 1HNMR (400MHz, CDC13) 6 10.94(s, 1H), 7.98 (d, J= 2.3 Hz, 1H), 7.60-7.54(m, 4H), 7.51 - 7.46 (m, 1H), 7.38 (s, 1H), 7.33 (d, J= 8.3 Hz, 2H), 4.27 (q, J=
5.2 Hz, 1H), 4.08 (q, J = 7.4 Hz, 2H), 2.68 (d, J = 5.5 Hz, 3H), 1.56 - 1.52 (m, 3H).
Example 116: N-methyl-3-(1-methyl-1H-imidazol-4-y1)-4-43-(trifluoromethyl)phenyl) amino)benzenesulfonamide (Compound 124) \N-\\
NN
CZ`
HN,Sµ`
I F F
Preparation of Compound 124:
/r1\1/
N-\\
NN
0õ0 Br 124-1a (1.0 eq) µ` 10 Pd(PPh3)4 (0.05 eq)). ,Sµ
-S Cs2CO3 (2.0 eq) HN \(.1 H Dioxane/H20, 90 C, 16 hr F F
F F
124-1 Compound 124 [00446] To a solution of compound 124-1 (120 mg, 0.26 mmol, 1.0 eq), compound 124-la (42 mg, 0.26 mmol, 1.0 eq) and Cs2CO3 (325 mg, 0.17 mmol, 2.0 eq) in Dioxane (3 mL) and H20 (0.6 mL) was added Pd(PPh3)4 (15 mg, 13 umol, 0.05 eq). The suspension was degassed under vacuum and purged with N2 several times. The reaction mixture was stirred at 90 C for 16 hours. LCMS showed Reactant 124-1 was consumed completely and one main peak with desired MS was detected. The reaction mixture was concentrated under reduced pressure.
The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA
(30 mL * 3).
The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by prep-HPLC to obtain Compound 124 (12.40 mg, 11% yield). LCMS (ESI): RT = 0.650 min, mass calcd. for C18H17F3N4025 410.10, m/z found 410.9 [M+H1+, 1HNMR (400MHz, CDC13) 6 10.83 (s, 1H), 7.97 (d, J= 2.0 Hz, 1H), 7.56 (dd, J
= 2.3, 8.8 Hz, 1H), 7.51 (d, J= 5.8 Hz, 2H), 7.48 - 7.41 (m, 2H), 7.38 - 7.33 (m, 2H), 7.29 (d, J =
6.3 Hz, 1H), 4.33 (q, J= 5.3 Hz, 1H), 3.78 (s, 3H), 2.67 (d, J = 5.5 Hz, 3H).
Example 117: 3-(1-ethyl-1H-imidazol-4-y1)-N-methyl-4-43-(trifluoromethyl)phenyl)amino) benzenesulfonamide (Compound 125) N¨\\
NN
CZµ 401 -S
HN
I F F
Preparation of Compound 125:
/¨
rN
)..( N¨\\
Br 0 0 Br NN
125-la (1.5 eq) 'B H
125-2a (1.0 eq) -S Pd(dppf)Cl2 (0.05 eq) õ
Pd(PPh3)4 (0.05 eq) ,S\ AcOK (2.0 eq) Cs2CO3 (2.0 eq) F F Dioxane, 90 C, 16 hr N-Sµµ HN µõ
H Dioxane/H20, 90 C, 16 hr I u F F
F F
Compound 125 Step 1: N-Methy1-3-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-4-03-(trifluoromethyl) phenyl)amino)benzenesulfonamide [00447] A solution of compound 125-1 (380 mg, 0.93 mmol, 1.0 eq), compound 125-la (354 mg, 1.39 mmol, 1.5 eq), Pd(dppf)C12 (34 mg, 46 umol, 0.05 eq) and AcOK
(182 mg, 1.86 mmol, 2.0 eq) in Dioxane (5 mL) was heated to 90 C and stirred at 90 C for 16 hours under N2.
TLC showed the starting material was consumed. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (30 mL) and the resultant mixture was extracted with EA (50 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by Prep-TLC to obtain the title compound 125-2 (310 mg, 73% yield).
Step 2: 3-(1-Ethy1-1H-imidazol-4-y1)-N-methy1-4-03-(trifluoromethyl)phenyl)amino) benzenesulfonamide [00448] To a solution of compound 125-2 (100 mg, 0.22 mmol, 1.0 eq), compound 125-2a (38 mg, 0.22 mmol, 1.0 eq) and Cs2CO3 (143 mg, 0.44 mmol, 2 eq) in Dioxane (3 mL) and H20 (0.6 mL) was added Pd(PPh3)4 (13 mg, 11 umol, 0.05 eq). The suspension was degassed under vacuum and purged with N2 several times. The reaction mixture was stirred at 90 C for 16 hours. LCMS showed Reactant 125-2 was consumed completely and one main peak with desired MS was detected. The reaction mixture was concentrated under reduced pressure.
The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA
(30 mL * 3).
The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by prep-HPLC to obtain Compound 125 (15.56 mg, 16.7% yield). LCMS (ESI): RT = 0.664 min, mass calcd. for C19H19F3N402S
424.12, m/z found 424.9 [M+H1+, 1HNMR (400MHz, CDC13) 6 10.87 (s, 1H), 7.98 (d, J= 2.3 Hz, 1H), 7.58- 7.54 (m, 2H), 7.51 (s, 1H), 7.48 - 7.41 (m, 2H), 7.40 - 7.35 (m, 2H), 7.29 (d, J =
6.8 Hz, 1H), 4.30 (d, J= 5.0 Hz, 1H), 4.08 (q, J= 7.4 Hz, 2H), 2.67 (d, J = 5.5 Hz, 3H), 1.54 (t, J
= 7.4 Hz, 3H).
Example 118: 3-(1-cyclopropy1-1H-imidazol-4-y1)-N-methy1-4-44-(trifluoromethyl)phenyl) amino)benzenesulfonamide (Compound 126) <N-\\
N N
CZ` 40:1 HN,Sµ`
I
FF
Preparation of Compound 126:
OH
12-8.0H
NH 126-la (1.7 eq) F-N
2,2'-bipyridine (1.0 eq) Br Cu(OAc)2 (1.0 eq) Br K2CO3 (2.0 eq) 1,2-dichloroethane, 7000,16 hr FN
Br N-\\
0õ0 126-2 (1.0 eq) N N
F Pd(PPh3)4 (0.05 eq) Cs2CO3 (2.0 eq) CZ`
HN,Sµ` F Dioxane/H20, 90 C, 16 hr ,S
F
1 FNH µ`
I F
126-3 Compound 126 Step 1: 4-Bromo-1-cyclopropy1-1H-imidazole [00449] A solution of compound 126-1 (5.0 g, 34 mmol, 1.0 eq), compound 126-la (5.0 g, 58 mmol, 1.7 eq), Cu(OAc)2 (6.2 g, 34 mmol, 1.0 eq), 2,21-bipyridine (5.3 g, 34 mmol, 1.0 eq) and potassium carbonate (9.4 g, 68 mmol, 2.0 eq) in 1,2-dichloroethane (150 mL) was stirred at 70 C for 16 hrs. TLC showed one new spot was formed. EA (220 mL) was added, and then the suspension was filtered. The organic layer was concentrated under reduced pressure. The mixture was diluted with water (80 mL) and the resultant mixture was extracted with EA (150 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography over silica gel to afford the title compound 126-2 as a crude product. The residue was purified by Prep-TLC
to obtain the title compound 126-2 (1.2 g, 18% yield). IFINMR (400MHz, CDC13) 6 7.42 (s, 1H), 6.95 (d, J= 1.3 Hz, 1H), 3.36 -3.28 (m, 1H), 1.06 - 0.90 (m, 4H).
Step 2: 3-(1-Cyclopropy1-1H-imidazol-4-y1)-N-methyl-4-44-(trifluoromethyl)phenyl) amino)benzenesulfonamide [00450] To a solution of compound 126-3 (70 mg, 0.15 mmol, 1.0 eq), compound 126-3a (34 mg, 0.18 mmol, 1.2 eq) and Cs2CO3 (100 mg, 0.31 mmol, 2.0 eq) in Dioxane (3 mL) and H20 (0.6 mL) was added Pd(PPh3)4 (8.9 mg, 7.7 umol, 0.05 eq). The suspension was degassed under vacuum and purged with N2 several times. The reaction mixture was stirred at 90 C for 16 hours. LCMS showed Reactant 126-3 was consumed completely and one main peak with desired MS was detected. The reaction mixture was concentrated under reduced pressure.
The mixture was diluted with water (20 mL) and the resultant mixture was extracted with EA
(50 mL * 3).
The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by Prep-TLC (to obtain Compound 126 as a crude product. The crude product was purified by prep-HPLC to obtain the title Compound 126 (5.39 mg, 7.4% yield, HC1). LCMS (ESI): RT = 0.677 min, mass calcd. for C20Hi9F3N4025 436.12, miz found 436.9 [M+H1+, IFINMR (400MHz, DMSO-d6) 6 9.58- 9.10(m, 1H), 8.95 (s, 1H), 8.00 (s, 1H), 7.91 (s, 1H), 7.72 - 7.67 (m, 1H), 7.59 (dd, J= 8.7, 15.7 Hz, 3H), 7.40 (d, J = 4.5 Hz, 1H), 7.24 (d, J= 8.5 Hz, 2H), 3.79 - 3.71 (m, 1H), 2.45 (d, J= 4.5 Hz, 3H), 1.15 - 1.05 (m, 4H).
Example 119: 3-(1-cyclopropy1-1H-imidazol-4-y1)-N-methyl-4-43-(trifluoromethyl)phenyl) amino)benzenesulfonamide (Compound 127) N-\\
N N
czµ N
NH,Sµ`
I F F
Preparation of Compound 127:
Nrj Br N-\\
0õ0 NN
127-1a (1.0 eq) 0, Pd(PPh3).4 (0.05 eq) CZµ
NH
S\ Cs2CO3 (2.0 eq) 'Sµ`
Dioxane/H20 I
F F
90 C, 16 hr 127-1 Compound 127 [00451] To a solution of compound 127-1 (100 mg, 0.22 mmol, 1.0 eq), compound 127-la (41 mg, 0.22 mmol, 1.2 eq) and Cs2CO3 (143 mg, 0.438 mmol, 2.0 eq) in Dioxane (3 mL) and H20 (0.6 mL) was added Pd(PPh3)4 (13 mg, 11 umol, 0.05 eq). The suspension was degassed under vacuum and purged with N2 several times. The reaction mixture was stirred at 90 C for 16 hours. LCMS showed Reactant 127-1 was consumed completely and one main peak with desired MS was detected. The reaction mixture was concentrated under reduced pressure.
The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA
(30 mL * 3).
The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by Prep-TLC to obtain Compound 127 as a crude product. The crude product was purified by prep-HPLC to obtain the title Compound 127 (19.18 mg, 18% yield, HC1). LCMS (ESI): RT = 0.675 min, mass calcd. for C20Hi9F3N4025 436.12, m/z found 436.9 [M+H1+, IFINMR (400MHz, DMSO-d6) 6 9.19 - 8.85 (m, 2H), 8.04 (s, 1H), 7.85 (d, J= 2.0 Hz, 1H), 7.70 (dd, J= 2.0, 8.5 Hz, 1H), 7.56 - 7.50 (m, 1H), 7.48 -7.35 (m, 4H), 7.31 (d, J = 7.8 Hz, 1H), 3.81 - 3.75 (m, 1H), 2.44 (d, J= 4.3 Hz, 3H), 1.17 - 1.06 (m, 4H).
Example 120: N-methyl-3-(2-methyltetrazol-5-y1)-4-(4-phenylanilino) benzenesulfonamide (Compound 128) and N,N-dimethy1-3-(2-methyltetrazol-5-y1)-4-(4-phenylanilino)benzenesulfonamide (Compound 129) N-N N-N
NIR NN
NH NH
=
N
Compound 128 Compound 129 Preparation of Compound 128 and Compound 129:
OH
N-N
OH
N-N N-N
N
110 (1.5 eq) NH2 NH2 128-1b abr. NH abh NH
NH.b\\
DIEA (2 0 eq) µ VI CI\
I Cu N
(OAc)2 (1 5 eq) S -Sµ
I 02, DCM, it, 16h IH µ` N
I Li 128-1 128-la Compound 128 Compound 129 [00452] To a mixture of compound 128-1 and compound 128-la (70 mg, 0.26 mol, 1 eq), compound 128-lb and Cu(OAc)2 (71.1 mg, 0.39 mol, 1.5 eq) in DCM (30 mL) was added DIEA
(67.4 mg, 0.52 mol, 91 uL, 2 eq). Then the suspension was degassed under vacuum and purged with 02 several times. The mixture was stirred under 02 (15 psi) at 25 C for 16 hours. LCMS
showed 41% of desired compound was detected. The reaction mixture was filtered and concentrated in vacuum to give the residue. The crude product was purified by prep-HPLC.
LCMS and NMR confirmed that Compound 128 (23.07 mg, 21.0% yield) was obtained.
LCMS and NMR confirmed that Compound 129 (2.02 mg, 1.8% yield) was obtained.
Compound 128: LCMS (ESI): RT = 0.809 min, mass calcd. for C2,H201\1602S, 420.14 m/z found 420.9[M+H] NMR
(400 MHz, CDC13) 6 9.48 (s, 1H), 8.70 (d, J = 2.0 Hz, 1H), 7.72 (dd, J
= 2.4, 8.9 Hz, 1H), 7.63 (dd, J= 8.2, 13.2 Hz, 4H), 7.47 (t, J= 7.7 Hz, 2H), 7.42 - 7.34 (m, 4H), 4.48 (s, 3H), 4.25 (d, J = 5.0 Hz, 1H), 2.71 (d, J = 5.5 Hz, 3H). Compound 129: LCMS (ESI):
RT = 0.856 min, mass calcd. for C22H22N602S, 434.15 m/z found 435.0[M+1-11+.
IFINMR (400 MHz, CDC13) 6 9.50 (s, 1H), 8.63 (d, J= 2.3 Hz, 1H), 7.68 - 7.61 (m, 5H), 7.47 (t, J = 7.7 Hz, 2H), 7.44 - 7.37 (m, 4H), 4.49 (s, 3H), 2.76 (s, 6H).
Example 121: N-methyl-3-(2-methyltetrazol-5-y1)-4-(4-phenoxyanilino) benzenesulfonamide (Compound 130) N-N
\ Ai NH, 0, NI-1.S\v 0 I
Preparation of Compound 130:
\
\ N
0 li N-N
N , N
1101 01 Nj, 1,1 HOB
NH
OH (1.2 eq) 0 40 o NH2 130-la 0 1.- µ`
.S\
DIEA (2.0 eq) NH
cu b pA02 (1.5 eq) I
IS
NH
I a 02, DCM, rt, 16h Compound 130 [00453] A mixture of compound 130-1 (70 mg, 0.26mo1, leq), compound 130-la (55.8 mg, 0.26 mol, 1 eq) and Cu(0Ac)2 (71.1 mg, 0.39 mol, 1.5 eq) in DCM (30 mL) was added DIEA (67.4 mg, 0.52 mol, 91 uL, 2 eq). The suspension was degassed under vacuum and purged with 02 several times. The mixture was stirred under 02 (15psi) at 25 C for 16 hours. LCMS
showed 37 % of desired product was detected. The reaction mixture was filtered and concentrated in vacuum to give the residue. The residue was purified by prep-HPLC. LCMS and H NMR confirmed that Compound 130 (22.02 mg, 19.3% yield) was obtained. LCMS
(ESI):
RT = 0.804 min, mass calcd. for C2,t1201\1603S, 436.49m/z found 459.0[M+Na1 -F. IFINMR (400 MHz, CDC13) 6 9.34 (s, 1H), 8.71 (d, J= 2.0 Hz, 1H), 7.74 - 7.68 (m, 1H), 7.39 (t, J = 7.9 Hz, 2H), 7.31 (s, 2H), 7.24 - 7.13 (m, 2H), 7.09 (dd, J= 6.0, 8.0 Hz, 4H), 4.49 (s, 3H), 4.27 (br d, J =
5.5 Hz, 1H), 2.71 (d, J = 5.5 Hz, 3H).
Example 122: N-methyl-3-(2-methyltetrazol-5-y1)-4-(3-phenylanilino) benzenesulfonamide (Compound 131) and N, N-dimethy1-3-(2-methyltetrazol-5-y1)-4-(3-phenylanilino) benzenesulfonamide (Compound 132) \ \
N-N N-N
NI 1\1 NL IV
H(i H
N N
c\iµ . 0õ w NH.s\\ -S
I U
Compound 131 Compound 132 Preparation of (Compound 131) and (Compound 132):
HO.6.0H
\ \
N-N N-N 0 up NI, "N NI, 'NI
NI, µNI NI, µNI (1.2 eq) H H
131-1b Rµ 40 N WINH2 + op NH2 Cu(OAc(1 5 eq) NA ).- + N
C'µ` 40 0 0µ 0 NHSµ` 'µ
N-Sµ` DIEA (2 0 eq) )2 -, -5 02, DCM, rt, 16h 1 0 I a I a I u 131-1 131-la Compound 131 Compound 132 [00454] To a mixture of compound 131-1 (70 mg, 0.26 mol, 1 eq), compound 131-la (1.00 eq), compound 131-lb (51.7 mg, 0.26 mol, 1 eq) and Cu(0Ac)2 (71.1 mg, 0.39 mol, 1.5 eq) in DCM (25 mL) was added DIEA (67.4 mg, 0.52 mol, 91 uL, 2 eq). The suspension was degassed under vacuum and purged with 02 several times. The mixture was stirred under 02 (15 psi) at 25 C for 16 hours. LCMS showed 22% of desired compound was detected.
The reaction mixture was filtered and concentrated in vacuum to give the residue. The crude product was purified by prep-HPLC. LCMS and H NMR confirmed that Compound 131 (9.86 mg, 8.9%
yield) was obtained. LCMS (ESI): RT = 0.807 min, mass calcd. for C2,t120N602S, 420.49 m/z found 421.1[M+H] -F. IFI NMR (400 MHz, CDC13) 6 9.48 (s, 1H), 8.71 (d, J= 2.3 Hz, 1H), 7.71 (dd, J =1.9, 9.2 Hz, 1H), 7.61 (d, J = 7.3 Hz, 2H), 7.54 (s, 1H), 7.52 - 7.42 (m, 4H), 7.41 - 7.35 (m, 2H), 7.31 (br d, J= 7.3 Hz, 1H), 4.47 (s, 3H), 4.25 (br d, J= 5.5 Hz, 1H), 2.70 (d, J = 5.3 Hz, 2H), 2.72 - 2.68 (m, 1H). LCMS and H NMR confirmed that Compound 132 (4.18 mg, 3.7%
yield) was obtained. LCMS (ESI): RT = 0.853 min, mass calcd. for C22H22N602S, 434.51 m/z found 435[M+H] -F. IFI NMR (400 MHz, CDC13) 6 8.62 (d, J= 2.0 Hz, 1H), 7.66 -7.59 (m, 3H), 7.54 (s, 1H), 7.50 - 7.42 (m, 5H), 7.39 (d, J = 8.8 Hz, 2H), 7.31 (br d, J=
6.8 Hz, 1H), 4.48 (s, 3H), 2.75 (s, 6H).
Example 123: 3-(5-amino-1,3,4-oxadiazol-2-y1)-N-methyl-4-[4-(trifluoromethypanilino]benzenesulfonamide (Compound 133) )=N
0 ,N
H
N
HN-SNN F
I F
Preparation of Compound 133 H
KOAc (3.0 eq) Br Xantphos (0.1 eq) H H Me0H (1:1), H
0% 0 F Pd2dba3 (0.1 eq) CO(45 psi) DMS 140 O/Me0H (5:1) N
0 F 80 C, 5 h ,µ N
HN,sµ` F HN,s,' F
I 0 F I F F F 80 C, 16 h HT N`
SNH )=11 i TMSNCS (1.0 eq) HN 0 EDCI (1.5 eq) H
N
THF, 50 C, 17 h 1401 N
R` 01 F DMSO, 100 C, 2 h Rµ 0 40 ,s F
HN N` F
HN,s F µ' F 1 F
I
133-4 Compound 133 Step 1: methyl 5-(methylsulfamoy1)-2-[4-(trifluoromethypanilino]benzoate [00455] To a solution of compound 133-1 (100 mg, 0.24 mmol, 1 eq), KOAc (71.9 mg, 0.73 mmol, 3 eq) and Xantphos (14.1 mg, 24.4 umol, 0.1 eq) in DMSO (10 mL) and Me0H (2 mL) was added Pd2(dba)3 (22.4 mg, 24.4 umol, 0.1 eq). The suspension was degassed under vacuum and purged with CO several times. The mixture was stirred under CO (45 psi) at 80 C
for 16 hours. LCMS showed that desired product was detected. The Me0H was removed. The residue was diluted with EA (40 mL) and washed with brine (2*20 mL). The organic layer was dried over Na2SO4 and concentrated. The residue was purified by flash silica gel chromatography to give compound 133-2 (80 mg, crude).
Step 2: 3-(hydrazinecarbony1)-N-methyl-4-14-(trifluoromethyDanilino]benzenesulfonamide [00456] To a solution of compound 133-2 (80 mg, 0.2 mmol, 1 eq) in Me0H (1 mL) was added hydrazine hydrate (1.03 g, 17.5 mmol, 1.00 mL, 85% solution, 84.90 eq).
The reaction was heated at 80 C for 5 hr. LCMS showed that 40% of desired product was detected. The reaction was concentrated. The residue was diluted with EA (30 mL) and washed with water (2*10 mL). The organic layer was dried over Na2SO4 and concentrated. The crude product was purified by column chromatography on silica gel (EA: PE = 1:10-1:1) to give compound 133-3 (15 mg, 18.0% yield).
Step 3: 115-(methylsulfamoy1)-2-14-(trifluoromethyDanilino]benzoyl]amino]thiourea [00457] To a solution of compound 133-3 (15 mg, 38.6 umol, 1 eq) in THF (3 mL) was added isothiocyanatotrimethylsilane (5.07 mg, 38.6 umol, 1 eq). The reaction was stirred at 50 C
for 16 hr. LCMS showed that starting material was remained and desired product was detected.
Additional of isothiocyanatotrimethylsilane (10 mg) was added. The reaction was stirred at 50 C
for 1 hr. LCMS showed that 95% of desired product was detected. The reaction was concentrated. The compound 133-4 (15 mg, 82.4% yield) was used for next step directly.
Step 4: 3-(5-amino-1,3,4-oxadiazol-2-y1)-N-methy1-4-14-(trifluoromethyDanilino]benzenesulfonamide [00458] To a solution of compound 133-4 (15 mg, 33.5 umol, 1 eq) in DMSO (1 mL) was added EDCI (9.6 mg, 50.3 umol, 1.5 eq). The reaction was heated at 100 C for 2 hr. LCMS
showed that 74% of desired product was detected. The reaction was diluted with EA (20 mL) and washed with brine (3*5 mL). The organic layer was dried over Na2SO4 and concentrated.
The residue was purified by prep-HPLC to give Compound 133 (2.38 mg, 17.2%
yield). HNMR
and LCMS showed that desired product was obtained. LCMS (ESI): RT = 0.709 min, mass calc.
for Ci6H14F3N503S 413.08, m/z found 413.9 [M+H1+; IFINMR (400 MHz, CDC13) 69.79 (s, 1H), 8.07 (d, J= 2.8 Hz, 1H), 7.80 - 7.70 (m, 3H), 7.60 - 7.50 (m, 5H), 7.50 - 7.30 (m, 1H), 2.41 (s, 3H).
Example 124: N-methy1-3-(2-methyltetrazol-5-y1)-4-(3-phenoxyanilino)benzenesulfonamide (Compound 134) and N,N-dimethy1-3-(2-methyltetrazol-5-y1)-4-(3-phenoxyanilino)benzenesulfonamide (Compound 135) N¨N N¨N
NN NN
Ai NH 0 0õ An NH 0 40 0, .Sµ` .S
N
I I
Compound 134 Compound 135 Preparation of Compound 134 and Compound 135:
Ph3SnCI (0.5 eq) Et3N (10 eq), HO op Br Cu(OAc)2 (0.4 eq) 0 Br rt, 24h N¨N N¨N
N¨N N¨N
oN
"N 1µ1 N N
K2CO3 (2.0 eq), XPhos (0.15 eq) am NH2 NH2 Pd2dha3 (0.05 eq), 134-2 (1.5 12) NH 0 NH 40 0 so 40 40 t-BuOH, 80 C, 16h CZ\ VI
NH.S .S\` -S
-S NH N
N I I u I u I u Compound 134 Compound 135 134-3 134-3a Step 1: 1-bromo-3-phenoxy-benzene [00459] To a Ph3SnC1 (1.11 g, 2.89 mmol, 0.5 eq) and compound 134-1(1 g, 5.78 mmol, 1 eq) in Et3N (5.85 g, 57.80 mmol, 8.1 mL, 10 eq) was added Cu(OAc)2 (419.9 mg, 2.31 mmol, 0.4 eq). The reaction was stirred at 25 C for 24 hr. TLC (EA:PE = 1:3, UV) showed that starting material was detected and a new spot was detected. The reaction was filtered and adjusted pH to 7 with 1N.aq.HC1. The aqueous layer was extracted with EA (3 *20 mL). The organic layer was dried over Na2SO4 and concentrated. The residue was purified by column chromatography on silica gel (EA:PE = 1:15) to give compound 134-2 (0.2 g, crude).
Step 2: N-methy1-3-(2-methyltetrazol-5-y1)-4-(3-phenoxyanilino)benzenesulfonamide and N,N-dimethy1-3-(2-methyltetrazol-5-y1)-4-(3-phenoxyanilino)benzenesulfonamide [00460] To a mixture of compound 134-3 and compound 134-3a (50 mg, 0.19 mmol, 1 eq), K2CO3 (51.51 mg, 0.37 mmol, 2 eq), 1-bromo-3-phenoxy-benzene (69.6 mg, 0.28 mmol, 1.5 eq) and XPhos (13.3 mg, 27.9 umol, 0.15 eq) in t-BuOH (3 mL) was added Pd2(dba)3 (8.5 mg, 9.3 umol, 0.05 eq). The mixture was degassed under vacuum and purged with N2 3 times. The mixture was stirred under N2 at 80 C for 16 hours. LCMS showed that 35% of P1 and 30% of P2 were detected. The reaction was diluted with EA (30 mL) and washed with water (2*10 mL).
The organic layer was dried over Na2SO4 and concentrated. The residue was purified by prep-HPLC to give Compound 134 (5.76 mg, 7.1% yield) and Compound 135 (2.12 mg, 2.5%
yield). Compound 134: LCMS (ESI): RT = 0.798 min, mass calcd. for C21H201\1603S, 436.13 miz found 436.9[M+H] NMR (400 MHz, CDC13) 6 9.40 (s, 1H), 8.67 (s, 1H), 7.68 - 7.81 (m, 1H), 7.36 (dd, J = 8.41, 4.89 Hz, 4H), 7.13 (br t, J= 7.28 Hz, 1H), 7.00 -7.10 (m, 3H), 6.96 (s, 1H), 6.82 (d, J= 8.03 Hz, 1H), 4.45 (s, 3H), 4.38 (br d, J= 5.27 Hz, 1H), 2.68 (d, J= 5.27 Hz, 3H). Compound 135: LCMS (ESI): RT = 0.842 min, mass calcd. for C22H22N603S, 450.15 miz found 451.0[M+H] NMR (400 MHz, CDC13) 6 9.42 (s, 1H), 8.58 (d, J= 2.01 Hz, 1H), 7.62 (dd, J = 8.91, 2.13 Hz, 1H), 7.32 - 7.41 (m, 4H), 7.10 - 7.17 (m, 1H), 7.03 - 7.09 (m, 3H), 6.97 (s, 1H), 6.82 (br d, J= 8.28 Hz, 1H), 4.46 (s, 3H), 2.73 (s, 6H).
Example 125: 3-12-1(2-Fluorophenyl)methyl]tetrazol-5-y1]-N-methyl-4-13-(trifluoromethypanilino]benzenesulfonamide (Compound 136) fi NI!
1\R N
FFF
CZ` W
,S
H
Preparation of Compound 136:
OH F
E F
HOB *
136-1a 1.2eq = N-N%
Cu(OAc)2 (1.2eq) czµ NH2 DIPEA (2.0 eq) N
CZ\ DCM,02, 25 C, 16 hr -S ,S
N N
H H
F F
Compound 136 [00461] To a solution of compound 136-1(100 mg, 0.28 mmol, 1.0 eq), compound 136-la (62.9 mg, 0.33 mmol, 1.2 eq) and Cu(OAc)2 (60.2 mg, 0.33 mmol, 1.2 eq) in DCM
(2 mL) was added DIPEA (71.3 mg, 0.55 mmol, 2.0 eq). The reaction mixture was stirred at 25 C for 16 hours under 02. LCMS showed reactant 1 was consumed completely and one main peak with desired MS was detected. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by prep-HPLC to give Compound 136 (52.54 mg, 37.2% yield). LCMS (ESI): RT = 1.045 min, mass calcd. for C22F118F4N6025 506.11, m/z found 507.3 [M+I-11+,1H NMR (400 MHz, CDC13) 6 ppm 9.56 (s, 1 H), 8.70 (d, J=2.26 Hz, 1 H), 7.74 (dd, J= 8.78, 2.26 Hz, 1 H), 7.54 (s, 1 H), 7.50 (m, 3 H) ,7.44 (d, J= 1.76 Hz, 1 H) ,7.41 (m, 3 H), 7.36 (s, 1 H), 7.34 (s, 1 H), 7.18 (m, 2 H), 5.94 (s, 2 H), 4.31 (q, J= 5.27 Hz, 1 H) ,2.70 (d, J= 5.27 Hz, 3 H).
Example 126: 3-[2-[(2-Fluorophenyl)methyl]tetrazol-5-y1]-N-methy1-4-14-(trifluoromethypanilino]benzenesulfonamide (Compound 137) F
. N-N
N N
H
N
0.µ 010 0 F
,S
F
H F
Preparation of Compound 137:
I` I` A' Br Ac20 ( 2.3 eq) HNit HN HN N
, HOSO2C1( 5.0 eq) Br MeNH2 in THF(2.0 eq) IP 0-80 C, 1hr 0 Br 0-80 C, 4 hr ' 40 DCM, 0-25 C, 0.5 hr Br CuCN ( 3.0 eq) -.,.. CN NaN3 (3.0 eq) ' 0 e DMF, 120 C, 16 hr NH4CI
(3.0 eq) DMF, 120 C, 16 hr 0=8=0 0=8=0 0=S=0 CI ,NH .NiFi F F F
NrIH1 C5---sF Br it . I,'I-N, N , N HOrliS F
. .-N
N-N
137-6a (1.0 eq) 14, I\I HCI (6M) N., '14 F F137-8a (1.2..9) Nr, )INI
NH 0 _____________ 0, 40 r K2CO3 (1.5 eq) H
N 0 100 C, 16 hr D..
0 NH2 CDup EAAc)2(10.2e7) H
N
.1,1H00 DMF, 80 C, 1 hr, MW C's` 0 40 os 40 T 0, DCM,02, 25 C, 16 hr F
F F
137-6 137-7 137-8 Compound 137 Step 1: N-(2-Bromophenyl)acetamide [00462] To a stirring solution of Ac20(41.0 g, 401 mmol, 2.3 eq) was added compound 137-1 (30.0 g, 174 mmol, 1.0eq) at 0 C, and then the reaction mixture was stirred at 80 C for 1 hour. TLC (Petroleum ether: Ethyl acetate = 5:1) indicated reactant 1 was completely, and one major new spot with larger polarity was detected. The reaction mixture was concentrated under reduce pressure to give a residue. The residue was washed with PE (100 mL *2) and dried under reduced pressure to obtain compound 137-2 (34.5 g, 92.4% yield).
Step 2: 4-Acetamido-3-bromo-benzenesulfonyl chloride [00463] To a stirring of HS03C1 (93.6 g, 803 mmol, 5 .0eq) was added compound 137-2 (34.0 g, 159 mmol, 1.0 eq) at 0 C. After addition, the reaction mixture was stirred at 80 C for 6 hours. TLC (Petroleum ether:Ethyl acetate = 2:1) showed the starting material was consumed and two new spots were formed. The reaction mixture was added to ice (400 g) and then warm up to 25 C. The suspension was extracted with EA (3 *400 mL) to obtain compound 137-3 (35 g, crude). NMR (400 MHz, DMSO-d6) 6 ppm 9.49 (br s, 1 H),7.76 (d, J= 1.51 Hz, 1 H), 7.54 (m, 1 H), 7.32 (dd, J= 8.16, 1.88 Hz, 1 H), 2.08 (s, 3 H).
Step 3: N- 12-Bromo-4-(methylsulfamoyl)phenyl]acetamide [00464] To a solution of compound 137-3 (33.0 g, 106 mmol, 1.0eq) in DCM (300 mL) was added MeNH2 (2 M, 106 mL, 2.0 eq) at 0 C. The reaction mixture was stirred at 25 C for 0.5 hour. TLC (Petroleum ether:Ethyl acetate = 2:1) showed the starting material was consumed.
The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (100 mL) and the resultant mixture was extracted with EA (300 mL * 3).
The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. EA (30 mL) was added to the crude product, and then the suspension was filtered to obtain compound 137-4 (12.0 g, 37.1% yield).
Step 4: N-12-Cyano-4-(methylsulfamoyl)phenyl]acetamide [00465] To a solution of compound 137-4 (2.0 g, 6.5 mmol, 1.0 eq) in DMF (20mL) was added CuCN (1.75 g, 19.5 mmol, 3.0 eq). And then the mixture was stirred at 120 C for 16 hr.
TLC (Petroleum ether:Ethyl acetate = 1:1) showed the starting material was consumed. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with EA(50mL) and the resultant mixture was extracted with water (50 mL * 3). The combined organic layers were dried over Na2SO4, and concentrated to dryness under reduced pressure. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate = 1:0 to 1:1) to obtain compound 137-5 (900 mg, 54.6% yield).
Step 5: N-14-(Methylsulfamoy1)-2-(2H-tetrazol-5-yl)phenyl]acetamide [00466] To a solution of compound 137-5 (900 mg, 3.55 mmol, 1.0 eq) and NH4C1 (570 mg, 10.7 mmol, 3.0 eq) in DMF (10 mL) was added NaN3 (690 mg, 10.6 mmol, 3.0 eq). The reaction mixture was stirred at 120 C for 16 hours. LCMS showed reactant 137-5 was consumed completely and one main peak with desired MS was detected. The reaction mixture was dropwise to HCl (15 mL, 1M), and then the suspension was filtered to obtain the title compound 137-6 (750 mg, 71.2% yield).
Step 6: N- [2-[2-[(2-Fluorophenyl)methyl]tetrazol-5-y1]-4-(methylsulfamoyl)phenyl]acetamide [00467] Compound 137-6 (500 mg, 1.69 mmol, 1.0 eq) , compound 137-6a (319 mg, 1.69 mmol, 1.0 eq) and K2CO3 (350 mg, 2.53 mmol, 1.5 eq) were taken up into a microwave tube in DMF (5 mL) .The sealed tube was heated at 80 C for 1 hr under microwave. LCMS
showed reactant 137-6 was consumed completely and one main peak with desired MS was detected. TLC
(Petroleum ether: Ethyl acetate = 2:1) indicated reactant 137-6 was remained, and one major new spot with lower polarity was detected. The reaction mixture was diluted with H20 (15 mL) and extracted with EA (40 mL). The organic layer was washed with H20 (20 mL * 3).
The organic layer was dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by column chromatography (5i02, Petroleum ether/Ethyl acetate = 1:0 to 2:1) to give compound 137-7 (540 mg, 79.1% yield).
Step 7: 4-Amino-3-[2-[(2-fluorophenyl)methyl]tetrazol-5-y1]-N-methyl-benzenesulfonamide [00468] To a solution of compound 137-7 (440 mg, 1.09 mmol, 1. Oeq) was added HC1 (6 M, 8.8 mL, 48.5 eq) . The mixture was stirred at 100 C for 16 hr. LCMS showed reactant 137-7 was consumed completely and one main peak with desired MS was detected. The mixture was adjusted with NaOH (6M) to pH = 8, and then the suspension was extracted with EA (3 * 50 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure to obtain the title compound 137-8 (340 mg, 86.2%
yield) was obtained.
Step 8: 3-[2-[(2-Fluorophenyl)methyl]tetrazol-5-y1]-N-methy1-4-14-(trifluoromethypanilino]benzenesulfonamide [00469] To a solution of compound 137-8 (100 mg, 0.27 mmol, 1.0 eq) compound 137-8a (62.9 mg, 0.33 mmol, 1.2 eq) and Cu(OAc)2 (60.2 mg, 0.33 mmol, 1.2 eq) in DCM
(2 mL) was added DIPEA (71.3 mg, 0.55 mmo1,2.0 eq). The reaction mixture was stirred at 25 C for 16 hours under 02.LCMS showed reactant 137-8 was consumed completely and one main peak with desired MS was detected. The mixture was diluted with water (10 mL) and the resultant mixture was extracted with EA (30 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by prep-HPLC to give Compound 137 (23.0 mg, 16.3% yield). LCMS (ESI): RT = 1.042 min, mass calcd. for C22H18F4N602S506.11, m/z found 507.3 [M+H1+;11-1NMR (400 MHz,CDC13) 6 9.63 (s, 1 H), 8.69 (d, J= 2.26 Hz, 1 H) ,7.77 (d, J = 2.26 Hz, 1 H), 7.75 (d, J =
2.26 Hz, 1 H), 7.63 (d, J = 8.78 Hz, 2 H), 7.48 (d, J = 8.78 Hz, 1 H), 7.41 (m, 2 H), 7.36 (d, J=
8.28 Hz, 2 H) ,7.26 (s, 7 H) ,7.19 (m, 2 H) ,5.94 (s, 2 H) ,4.30 (q, J= 5.35 Hz, 1 H) ,2.70 (d, J=
5.27 Hz, 3 H) ,1.25 (s, 1 H).
Example 127: N-(tert-butyl)-3-(2-methyl-2H-tetrazol-5-y1)-4-44-(trifluoromethyl)phenyl)amino)benzenesulfonamide (Compound 138) N¨N
NIR
N
R` IW
HNb FF
Preparation of Compound 138 OH
N¨N a B. ON. H N¨N
"N F 138-1a (1.2 eq) F Cu(0Ac)2 (1.2 eq) NH DIEA (2 0 eq) DCM, 02, 25 C,12 hr R\ 40 HNb HNb Compound 138 [00470] To a solution of compound 138-1 (0.09 g, 0.28 mmol, 1 eq) and compound 138-la (66.0 mg, 0.34 mmol, 1.2 eq) in DCM (7 mL) was added Cu(0Ac)2 (63.2 mg, 0.34 mmol, 1.2 eq) and DIPEA (112.4 mg, 0.86 mmol, 0.2 mL, 3 eq). The mixture was stirred at 25 C for 16 hr under 02. LCMS showed the starting material was consumed and the desired mass was detected.
The reaction mixture was filtered. The filter cake was washed with ethyl acetate (10 ml*3) and the combined organic layers was washed by NaCl (8 mL*3) then concentrated in vacuum to give crude product. The residue was purified by prep-HPLC. Compound 138 (7.88 mg, 5.5% yield, HC1) was obtained. LCMS (ESI): RT = 0.833 min, mass calc. for Ci9H2IF3N602S
454.14, m/z found 455.0 [M+H]+; IFINMR (400 MHz, DMSO-d6) 6 8.95 (s, 1 H), 8.20-8.18 (d, J= 8.0 Hz, 1H), 7.89-7.89 (d, J= 1.6 Hz, 1H), 7.71 (s, 1H), 7.66-7.64 (d, J = 8.8 Hz, 2H), 7.56-7.53 (dd, Ji = 1.6 Hz, J2 = 8.0 Hz, 1H), 7.30-7.28 (d, J= 8.0 Hz, 2H), 4.46 (s, 3H), 1.38 (s, 9H).
Example 128: 4-(4-chloroanilino)-N-methyl-3-(1-methylimidazol-4-yl)benzenesulfonamide (Compound 139) \N¨\\
N N
R` el el HN-S\\ CI
I
Preparation of Compound 139:
\N¨\\ OH \¨
\\
B
N N HO a N
139-1a"' CI
=
CZ\ CZµ
Cu(OAc)2 (2 eq) N
HN,Sµ` CI
HN,sµ` DIPEA(4 eq) I
139-1 02, DCM, 25 C, 16hr Compound 139 [00471] A mixture of compound 139-1 (50 mg, 0.18 mmol, 1 eq), compound 139-la (58.7 mg, 0.37 mmol, 2 eq), Cu(0Ac)2 (68.2 mg, 0.37 mmol, 2 eq) and DIEA (97.0 mg, 0.75 mmol, 0.1 mL, 4eq) in DCM (3 mL) was degassed and purged with 02 for 3 times, and then the mixture was stirred at 25 C for 16 hr under 02 atmosphere. LCMS showed the desired compound was detected. The reaction mixture was diluted with H20 (10 mL) and the mixture extracted with EA
(15 mL * 3). The combined organic phase was washed with brine (10 mL*3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC. Compound 139 (5 mg, 6.9% yield) was obtained and confirmed by LCMS and H
NMR.
LCMS (ESI): RT = 0.657 min, mass calc. for Ci7Hi7C1N402S 376.08, m/z found 398.9 [M+Na1+;
IFINMR (400 MHz, DMSO-d6) 6 ppm 2.41 (d, J= 5.02 Hz, 3 H) 3.83 (s, 3 H) 7.18 (d, J = 8.78 Hz, 2 H) 7.29 (br d, J= 5.02 Hz, 1 H) 7.31 - 7.39 (m, 3 H) 7.60 (dd, J = 8.78, 2.26 Hz, 1 H) 7.80 (d, J = 2.01 Hz, 1 H) 7.88 (s, 1 H) 8.68 (br s, 1 H).
Example 129: 4-(3,4-dichloroanilino)-N-methyl-3-(1-methylimidazol-4-yl)benzenesulfonamide (Compound 140) N¨\\
x N
N CI
.µ
HN
I
Preparation of Compound 140:
\N-\\ \N-\\
(H0)2B CI
N N NN
140-la CI
________________________________________ )11.
CZ\ '''µµ
,Sµ` Cu(OAc)2 (1.5 eq) =
HN
DIPEA(2 eq) HN
140-1 air, DCM, 25 C, 10 mm I
Compound 140 1004721 A mixture of compound 140-1 (30 mg, 0.11 mmol, 1 eq), compound 140-la (42.9 mg, 0.22 mmol, 2 eq), DIEA (58.2 mg, 0.45 mmol, 78 uL, 4 eq) and Cu(0Ac)2 (40.9 mg, 0.22 mmol, 2 eq) in DCM (3 mL) was degassed and purged with 02 for 3 times, and then the mixture was stirred at 25 C for 10 min under 02 atmosphere. LCMS showed the desired compound was detected. The reaction mixture was diluted with H20 (10 mL) and the mixture was extracted with EA (10 mL * 3). The combined organic phase was washed with brine (10 mL*2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC. Compound 140 (5.8 mg, 12.5% yield) was obtained and confirmed by LCMS
and NMR. LCMS (ESI): RT = 0.657 min, mass calc. for Ci7H16C12N402S 410.04, m/z found 410.9 [M+H1+; IFINMR (400 MHz, DMSO-d6) 6 ppm 2.44 (d, J= 4.77 Hz, 3 H) 3.87 (s, 3 H) 7.10 -7.16 (m, 1 H) 7.34 (d, J = 2.51 Hz, 1 H) 7.41 (br d, J= 5.02 Hz, 1 H) 7.50 (dd, J= 19.83, 8.78 Hz, 2 H) 7.69 (dd, J= 8.78, 2.01 Hz, 1 H) 7.86 (d, J= 2.01 Hz, 1 H) 7.98 (s, 1 H) 8.89 - 9.04 (m, 1 H) 8.98 (br s, 1 H).
Example 130: N-methyl-3-(1-methylimidazol-4-y1)-4-13-(trifluoromethylsulfanypanilino]benzenesulfonamide (Compound 141) N-\\
x N
SF
I
Preparation of Compound 141:
\N-\\ \
Br SF N-\\
N N )<F
NN
NH= 141-1a 1.2 eq 2 _____________________________________ SF
Pd2(dba)3 (0.1eq) CZ\ 10 HN,µSµ` XPhos (0.2 eq) I K2CO3 (3.0 eq) HN µ`
141-1 Dioxane, 100 C, 10 h I
Compound 141 [00473] To a mixture of compound 141-1 (0.03 g, 0.11 mmol, 1 eq) and compound 141-la (34.7 mg, 0.13 mmol, 1.2 eq) in dioxane (2 mL) was added Pd2(dba)3 (10.3 mg, 0.01 mmol, 0.1 eq), XPhos (10.7 mg, 0.02 mmol, 0.2 eq) and K2CO3 (46.7 mg, 0.33 mmol, 3 eq) under N2. The mixture was stirred for 10 h at 100 C. LCMS showed the reaction was complete.
The mixture was quenched by EA (30 mL), and the mixture was filtered and the filtered cake was washed with EA (20 mL*3). The combined organic phase was washed with brine (20 mL*3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by pre-HPLC
was obtained. LCMS (ESI): RT = 0.662 min, mass calc. for: Ci8tli7F3N402S2 442.07, m/z found 442.9 [M+H1+; IFINMR (400 MHz, CD30D) 6 9.01 (s, 1H), 7.92 - 7.79 (m, 3H), 7.55 - 7.42 (m, 3H), 7.38 - 7.33 (m, 2H), 3.99 (s, 3H), 2.60 - 2.57 (m, 3H).
Example 131: 4-(3,5-dichloroanilino)-N-methyl-3-(1-methylimidazol-4-yl)benzenesulfonamide (Compound 142) \N-\\
x N
CI
µµ el HN,Sµ`
I CI
Preparation of Compound 142:
\N-A \N-A
(H0)2B # CI
x N x N
142-1a 2 eq Cu(OAc)2 (2 eq) s DIPEA(5 eq) HN HN,sµ`
µ0 142-1 02, DCM, 25 C, 10 min 0 CI
Compound 142 [00474] To a mixture of compound 142-1 (0.05 g, 0.18 mmol, 1 eq) and compound 142-la (71.6 mg, 0.37 mmol, 2 eq) in DCM (5 mL) was added Cu(0Ac)2 (68.2 mg, 0.37 mmol, 2 eq) and DIPEA (121.3 mg, 0.93 mmol, 0.2 mL, 5 eq) in one portion at 25 C under 02.
The mixture was stirred for 10 min under 15 PSI. LCMS showed the reaction was complete.
The mixture was quenched by EA (30 mL), and the mixture was filtered and the filtered cake was washed with EA
(20 mL*3). The combined organic phase was washed with brine (20 mL*3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by pre-HPLC.
Compound 142 (12.8 mg, 15.2% yield, HC1) was obtained. LCMS (EST): RT = 0.647 min, mass calc. for: Ci7Hi6C12N4025 410.04, m/z found 410.9 [M+1-11+; IFINMR (400 MHz, CD30D) 6 8.97 (s, 1H), 7.94 (d, J= 2.0 Hz, 1H), 7.90 - 7.83 (m, 2H), 7.53 (d, J= 8.5 Hz, 1H), 7.07 - 7.03 (m, 3H), 3.99 (s, 3H), 2.59 (s, 3H).
Example 132: 4-(3-Chloroanilino)-N-methyl-3-(1-methylimidazol-4-yl)benzenesulfonamide (Compound 143) \N-\\
x N
czµ N CI
HN-Sµ`
I
Preparation of Compound 143:
\N-\\ (H0)2B * CI \N__\\
N N 143-la N N
2 eq NH2 ____________________________________ o Cu(OAc)2 (2 eq) N CI
DIPEA(5 eq) CZµ
HNI,sµ`
02, DCM, 25 C, 10 min HN-s µ`
Compound 143 [00475] To a mixture of compound 143-1 (0.05 g, 0.18 mmol, 1 eq) and compound 143-la (58.7 mg, 0.37 mmol, 2 eq) in DCM (20 mL) was added Cu(0Ac)2 (68.2 mg, 0.37 mmol, 2 eq) and DIPEA (121.3 mg, 0.93 mmol, 0.2 mL, 5 eq) in one portion at 25 C under 02.
The mixture was stirred for 10 min under 15 psi. LCMS showed the reaction was complete.
The mixture was quenched by EA (30 mL), and the mixture was filtered and the filtered cake was washed with EA
(20 mL*3). The combined organic phase was washed with brine (20 mL*3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by pre-HPLC.
Compound 143 (22.02 mg, 28.4% yield, HC1) was obtained. LCMS (ESI): RT = 0.616 min, mass calc. for: Ci7H17C1N402S 376.08, m/z found 376.9 [M+Na1+; IFINMR (400 MHz, DMSO-d6) 6 9.20 (br s, 1H), 8.59 (br s, 1H), 8.02 (s, 1H), 7.83 (d, J = 2.3 Hz, 1H), 7.71 (dd, J = 2.1, 8.7 Hz, 1H), 7.48 - 7.39 (m, 2H), 7.32 (t, J = 8.0 Hz, 1H), 7.18 - 7.09 (m, 2H), 7.03 (dd, J = 1.3, 7.8 Hz, 1H), 3.90 - 3.87 (m, 3H), 2.46 - 2.43 (m, 3H).
Example 133: N-methy1-3-(1-methylimidazol-4-y1)-4-14-(trifluoromethylsulfanyl)anilino]benzenesulfonamide (Compound 144) \N-\\
x N
R` I.
HN,Sµ` SF
I
Preparation of Compound 144:
N 1.1 )<F
Br NN
144-1a1.2 eq CZ\ Pd2(dba)3 (0.1eq) XPhos (0.2 eq) Hµ` la SF
HN
144-1 K2CO3 (3.0 eq) I
Dioxane, 100 C, 10 h Compound 144 [00476] To a mixture of compound 144-1 (0.03 g, 0.11 mmol, 1 eq) and compound 144-la (34.7 mg, 0.13 mmol, 20 uL, 1.2 eq) in dioxane (2 mL) were added Pd2(dba)3 (10.3 mg, 0.01 mmol, 0.1 eq), XPhos (10.7 mg, 0.02 mmol, 0.2 eq) and K2CO3 (46.7 mg, 0.33 mmol, 3 eq) under N2. The mixture was stirred for 10 h at 100 C. LCMS showed the reaction was complete.
The mixture was quenched by EA (30 mL), and the mixture was filtered and the filtered cake was washed with EA (20 mL*3). The combined organic phase was washed with brine (20 mL*3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by pre-HPLC. Compound 144 (3.03 mg, 5.6% yield, HC1 salt) was obtained. LCMS
(ESI): RT = 0.672 min, mass calc. for: Ci8Hi7F3N402S2 442.07, m/z found 442.9 [M+H1+; 11-1 NMR (400 MHz, CDOD3) 6 8.99 (s, 1H), 7.93 (d, J= 2.0 Hz, 1H), 7.85 (s, 1H), 7.86 (d, J = 9.8 Hz, 2H), 7.60 (dd, J= 3.0, 8.5 Hz, 3H), 7.19 (d, J= 8.8 Hz, 2H), 3.97 (s, 3H), 2.60 (s, 3H).
Example 134: N-methy1-3-(1-methylimidazol-4-y1)-4-(3,4,5-trichloroanilino)benzenesulfonamide (Compound 145) \N¨\\
x N CI
HNµ` CI
CI
Preparation of Compound 145:
(H0)2B CI
N¨\\ N¨
NN
145-la CICI x 2 NH 2 eq N CI
CU(OAC)2 (2 eq) CZ`
HNSµ` DIPEA(4 eq) CI
HN,sµ`
0 145-1 air, DCM, 25 C, 3 min 0 CI
Compound 145 [00477] The mixture of compound 145-1 (30 mg, 0.11 mmol, 1 eq), compound 144-la (50.7 mg, 0.22 mmol, 2 eq), DIEA (58.2 mg, 0.45 mmol, 78.48 uL, 4 eq) and Cu(OAc)2 (40.9 mg, 0.22 mmol, 2 eq) in DCM (5 mL) was stirred at 25 C for 3 min. LCMS showed the desired compound was detected. The mixture was combined with E7868-127. The reaction mixture was diluted with H20 (10 mL) and the mixture was extracted with EA (10 mL * 3).
The combined organic phase was washed with brine (10 mL*2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC. Compound 145 (5.5 mg, 10.9% yield) was obtained. LCMS (ESI): RT = 0.678 min, mass calc. for Ci7Hi5C13N402S
444.00 found 446.9 [M+H1+; 1HNMR (400 MHz, DMSO-d6) 6 ppm 2.45 (br d, J= 4.52 Hz, 2 H) 2.46 - 2.47 (m, 1 H) 3.86 (s, 3 H) 7.32 (s, 2 H) 7.46 (br d, J= 5.02 Hz, 1 H) 7.57 (d, J= 8.53 Hz, 1 H) 7.72 (br d, J= 8.28 Hz, 1 H) 7.90 - 8.00 (m, 2 H) 8.91 (br s, 1 H) 9.23 (br s, 1 H).
Example 135: 4-[3,5-Bis(trifluoromethypanilino]-N-methy1-3-(1-methylimidazol-4-yl)benzenesulfonamide (Compound 146) \N¨\\
N N
HFF
czµ N
F
HN,sµ`
F F
Preparation of Compound 146:
OH F
HO F N¨
N¨ NN
NN 146-la 2 eq F F
F
NH2 _____________________________________ (31µµ
µµ Cu(OAc)2 (2 eq) ,S
HN,Sµ` DIPEA(4 eq) HN µ`
air, DCM, 25 C, 3 min I
F F
Compound 146 [00478] The mixture of compound 146-1 (50 mg, 0.18 mmol, 1 eq), compound 146-la (96.8 mg, 0.37 mmol, 2 eq), DIEA (97.0 mg, 0.75 mmol, 0.1 mL, 4 eq) and Cu(OAc)2 (68.2 mg, 0.37 mmol, 2 eq) in DCM (5 mL) was stirred at 25 C for 3 min. LCMS showed the desired compound was detected. The reaction mixture was diluted with H20 (10 mL) and the mixture was extracted with EA (10 mL * 3). The combined organic phase was washed with brine (10 mL*2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC. Compound 146 (17 mg, 18.1% yield) was obtained. LCMS
(ESI): RT =
0.728 min, mass calc. for Ci9H16P6N402S 478.09, m/z found 479.0 [M+1-11+;
IFINMR (400 MHz, DMSO-d6) 6 ppm 2.46 (d, J= 5.02 Hz, 3 H) 3.84 (s, 3 H) 7.45 (br d, J= 5.02 Hz, 1 H) 7.55 (s, 1 H) 7.60 (d, J= 8.53 Hz, 1 H) 7.58 - 7.61 (m, 1 H) 7.63 (s, 2 H) 7.74 (br d, J=
7.28 Hz, 1 H) 7.97 (br d, J= 17.82 Hz, 2 H) 8.82 (br s, 1 H) 9.25 - 9.57 (m, 1 H) .
Example 136: 4-[4-Chloro-3-(trifluoromethypanilinol-N-methyl-3-(1-methylimidazol-4-yl)benzenesulfonamide (Compound 147) N¨\\
x N
HN µ, µSµ` = CI
F F
Preparation of Compound 147:
\N¨\\ (H0)2B
\N¨\\
NN 147-la CI
N N
F F 2 eq NH2 ______________________________________ C
el HN-Sµ` DIPEA(5 eq) HN,Sµ` CI
02, DCM, 25 C, 10 min I
Compound 147 [00479] To a mixture of compound 147-1 (0.05 g, 0.18 mmol, 1 eq) and compound 147-la (84.2 mg, 0.37 mmol, 2 eq) in DCM (20 mL) was added Cu(0Ac)2 (68.2 mg, 0.37 mmol, 2 eq) and DIPEA (121.3 mg, 0.93 mmol, 0.2 mL, 5 eq) in one portion at 25 C under 02.
The mixture was stirred for 10 min under 15 Psi. LCMS showed the reaction was complete.
The mixture was quenched by EA (30 mL), and the mixture was filtered and the filtered cake was washed with EA
(20 mL*3). The combined organic phase was washed with brine (20 mL*3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by pre-HPLC.
Compound 147 (6.98 mg, 7.7% yield, HC1) was obtained. LCMS (ESI): RT = 0.662 min, mass calc. for: C181-116C1F3N402S 444.06, m/z found 444.9 [M+1-11+; IFINMR (400 MHz, CD30D) 6 8.98 (s, 1H), 7.93 - 7.82 (m, 3H), 7.55 - 7.46 (m, 3H), 7.38 (br d, J= 8.8 Hz, 1H), 4.00 (s, 3H), 2.59 (s, 3H).
Example 137: 4-[3-Chloro-4-(trifluoromethypanilino]-N-methyl-3-(1-methylimidazol-4-yl)benzenesulfonamide (Compound 148) N¨\\
x N
(:)µµ N CI
HN,sµ`
Preparation of Compound 148:
\N¨\\
(H0)2B CI N¨\\
NN 148-1a IW F NN
2 eq NH2 _______________________________________________ N CI
(:)µµ Cu(OAc)2 (2 eq) CZ\ 01 HN,Sµ` DIPEA(5 eq) ,S
I = HN
02, DCM, 25 C, 10 min 0 F F
Compound 148 [00480] To a mixture of compound 148-1 (0.05 g, 0.18 mmol, 1 eq) and compound 148-la (84.2 mg, 0.37 mmol, 2 eq) in DCM (20 mL) was added Cu(0Ac)2 (68.2 mg, 0.37 mmol, 2 eq) and DIPEA (121.3 mg, 0.93 mmol, 0.2 mL, 5 eq) in one portion at 25 C under 02.
The mixture was stirred for 10 min under 15 Psi. LCMS showed the reaction was complete.
The mixture was quenched by EA (30 mL), and the mixture was filtered and the filtered cake was washed with EA
(20 mL*3). The combined organic phase was washed with brine (20 mL*3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by pre-HPLC.
Compound 148 (6.02 mg, 6.7% yield, HC1) was obtained. LCMS (ESI): RT = 0.668 min, mass calc. for: C181-116C1F3N402S 444.06, m/z found 444.9 [M+1-11+; IFINMR (400MHz, CD30D) 6 8.97 (s, 1H), 7.99 (d, J= 2.3 Hz, 1H), 7.90 (d, J= 9.0 Hz, 1H), 7.88 - 7.86 (m, 1H), 7.64 (dd, J =
4.6, 8.7 Hz, 2H), 7.22 (d, J = 1.8 Hz, 1H), 7.11 (dd, J= 1.9, 8.7 Hz, 1H), 3.99 (s, 3H), 2.61 (s, 3H).
Example 138: 4-((2,6-Difluorophenyl)amino)-N-methyl-3-(1-methyl-1H-imidazol-4-yl)benzenesulfonamide (Compound 149) N¨\\
x N
oµµ N
HN,Sµ`
I
Preparation of Compound 149:
\N-\\ pH F \N-\\
HOB 149-la (1.5 eq) N N F DIPEA (4 eq) x N
Cu(OAc)2 (1.5 eq) NH2 __________________________________________________ N
02, DCM, 25 C, 30 min Ot S
HN Sµ` HN,µ`
I I
149-1 Compound 149 [00481] The mixture of compound 149-1 (50 mg, 0.18 mmol, 1 eq), compound 149-la (44.4 mg, 0.28 mmol, 1.5 eq), Cu(0Ac)2 (51.1 mg, 0.28 mmol, 1.5 eq) and DIEA
(97.0 mg, 0.75 mmol, 0.1mL, 4 eq) in DCM (3 mL) was degassed and purged with 02 for 3 times.
Then the mixture was stirred at 25 C for 30 min under 02 atmosphere. LCMS showed the desired compound was detected. The reaction mixture was diluted with H20 (5 mL) and the mixture was extracted with EA (15 mL * 3). The combined organic phase was washed with brine (10 mL*3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC. Compound 149 (6 mg, 8.4% yield) was obtained. LCMS (ESI): RT =
0.625 min, mass calc. for C171-116P2N402S 378.10, m/z found 400.9 [M+Na1+; 1HNMR (400 MHz, DMSO-d6) 6 = 8.75 (br s, 1H), 8.89 - 8.57 (m, 1H), 7.91 (s, 1H), 7.79 (s, 1H), 7.58 (br d, J= 8.5 Hz, 1H), 7.41 - 7.31 (m, 1H), 7.31 - 7.17 (m, 3H), 6.64 (br d, J = 8.8 Hz, 1H), 3.85 (s, 3H), 2.41 (d, J
= 4.0 Hz, 3H).
Example 139: N-methyl-3-(1-methyl-1H-imidazol-4-y1)-4-4(1s,4s)-4-(trifluoromethyl)cyclohexyl)amino)benzenesulfonamide (Compound 150) and N-methyl-3-(1-methyl-1H-imidazol-4-y1)-4-4(1r,40-4-(trifluoromethyl)cyclohexyl)amino)benzenesulfonamide (Compound 151) N-\\ N-\\
x N NN
H H H H
czµ nF czµ 1\kn < HN-Sµ` H F HN-Sµ ` F
I I
Compound 150 Compound 151 Preparation of Compound 150 and Compound 151:
F
N--\\
N N 0 NN N-\\
150-1a (3.0 eq) j N
NH2 1:1 H H
NaBH3CN (2 0 eq), HOAc 0 lit:I) 0, F
0=DCM 0-25 C 5 hr -S =
Nn HN N H F uµ,S
u Compound 150 Compound 151 [00482] To a solution of compound 150-1 (250 mg, 0.93 mmol, 1 eq) and compound 150-la (467.8 mg, 2.82 mmol, 3 eq) in DCE (5 mL) was added HOAc (169.1 mg, 2.82 mmol, 0.2 mL, 3 eq) at 25 C under N2. After addition, the mixture was stirred at 25 C
for 3 hr, and then NaBH4 (106.5 mg, 2.82 mmol, 3 eq) was added at 0 C. The resulting mixture was stirred at 25 C
for 2 hr. TLC (PE/EA = 1/1, UV 254) indicated reactant was consumed completely and two new spot formed. LCMS showed reactant was consumed completely and -83% of desired compound was detected (m/z = 439.0; RT: 0.67 min). The residue was poured into H20 (30 mL) and stirred for 5 min. The aqueous phase was extracted with EA (10 mL*3).The combined organic phase was washed with brine (20 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography to give Compound 150 (36.7 mg, 9.2% yield). LCMS (ESI): RT = 0.814 min, mass calcd for Ci8H23F3N402S 416.46, m/z found 417.4 [M+H1+, IFINMR (400 MHz, DMSO-d6) 6 9.28 (d, J= 8.0 Hz, 1H), 7.82 - 7.75 (m, 2H), 7.66 (d, J= 1.0 Hz, 1H), 7.40 (dd, J= 2.1, 8.7 Hz, 1H), 6.98 (q, J =
5.0 Hz, 1H), 6.78 (d, J = 8.8 Hz, 1H), 3.90 (br d, J = 3.8 Hz, 1H), 3.73 (s, 3H), 2.37 (d, J=
5.0 Hz, 2H), 2.42 - 2.31 (m, 1H), 2.42 - 2.31 (m, 1H), 1.99 (s, 1H), 1.87 (br d, J= 12.3 Hz, 2H), 1.77 -1.68 (m, 1H), 1.66 (br s, 1H), 1.63 (br s, 1H), 1.60 (br d, J= 3.3 Hz, 1H), 1.77 - 1.54 (m, 1H), 1.56 (br s, 1H).
Compound 151 (78.5 mg, 19.8% yield) was obtained. LCMS (ESI): RT = 0.815 min, mass calcd for Ci8H23F3N402S 416.46, m/z found 417.4 [M+H1+, 1HNMR (400 MHz, DMSO-d6) 6 8.72 (d, J = 7.5 Hz, 1H), 7.82 - 7.71 (m, 2H), 7.62 (s, 1H), 7.39 (dd, J= 2.0, 8.8 Hz, 1H), 6.97 (q, J= 5.0 Hz, 1H), 6.83 (d, J= 9.0 Hz, 1H), 6.87 - 6.79 (m, 1H), 3.72 (s, 3H), 3.49 -3.40 (m, 1H), 2.36 (d, J = 5.3 Hz, 2H), 2.33 (br s, 1H), 2.13 (br d, J=11.0 Hz, 2H), 1.92 (br d, J=
11.8 Hz, 2H), 1.55 -1.40 (m, 2H), 1.34 - 1.24 (m, 2H).
Example 140: 3-(2-Aminopyridin-4-y1)-N-methy1-4-43-(trifluoromethyl)phenyl)amino)benzenesulfonamide (Compound 152) I
/
F
H F
N
(21µµ
-S
HN µ`
I
Preparation of Compound 152:
Br Br Br H
NH2 DMAP (0.05 eq), Ac20 (1.2 eq) NI( CISO3H (11.1 eq) 1401 11 1,... 0 1\1 0 0 \
DCM, r.t, 16 hr 0 0-80 C, 4h CI\S \\0 0 FEE
Br 9 H Br 0H (152-5a 1.2 eq) (:)µµ 0 methylamine (3.0 eq) N.(-HCI (6 M) NH2 Cu(OAc)2 (1.2 eq) 0 ______________________________________________________________ DIPEA (2.0 eq) _________________ v"--Sµ`
THE, 0 to 25 C, 3 hr HN 1 100 C, 4 hr HN,sµ`
02(15 psi) 1 0 DCM, 25 C, 16h o. p Fi2N,,,Br i N NH2 Br t:i13-Bb.....c N
H 0õ0 I
czµ 0 N 0 (152-6a 1.5 eq) B
H (152-7a 2.0 eq) /
F
HNS\
Pd(dppf)C12 (0.05 eq) N 0 Pd(dppf)C12 (0.05 eq) H F
N
-` AcOK(2.0 eq) 1 Cs2CO3(2.0 eq) 0µ
F F dioxane, 90 C, 16h HN-s\µ
dioxane/H20, 90 C, 16h F 1 HN,s\\
152-6 152-7 F Compound 152 Step 1: N-(2-bromophenyl)acetamide [00483] To a solution of compound 152-1 (20 g, 116.26 mrnol, 1.0 eq) in DCM (10 mL) were added Ac20 (14.24 g, 139.5 mrnol, 13.0 mL, 1.2 eq) and DMAP (710.1 mg, 5.81 mrnol, 0.05 eq). The mixture was stirred at 25 C for 16 hr. LCMS showed the reactant was consumed completely and -95% desired MS was detected. The reaction mixture was poured into water (50 mL), and extracted with EA (50 mL * 3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue.
The crude product was used into the next step without further purification.
Compound 152-2 (23 g, crude) was obtained. LCMS (ESI): RT = 0.713 min, mass calcd. for C8H8BrNO
212.98, m/z found 214.2 [M+H1+.
Step 2: 4-acetamido-3-bromobenzene-1-sulfonyl chloride [00484] A mixture of compound 152-2 (23 g, 107.4 mrnol, 1.0 eq) in H503C1 (139.8 g, 1.2 mol, 79.9 mL, 11.1 eq) at 0 C was stirred at 80 C for 4 hr. LCMS showed the reactant was remained and -30% of desired product was detected. The reaction mixture was poured into ice water (50mL) and extracted with EA (50 mL * 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The crude product was used into the next step without further purification. Compound 152-3 (16 g, crude) was obtained. LCMS (ESI): RT = 0.703 min, mass calcd. for C8H8BrNO
212.98, m/z found 213.3 [M+I-11+.
Step 3: N-(2-bromo-4-(N-methylsulfamoyl)phenyl)acetamide [00485] To a solution of compound 152-3 (16 g, 51.1 mmol, 1.0 eq) in THF (5 mL) was added methylamine (2 M, 127.9 mL, 5.0 eq) at 0 C. The mixture was stirred at 25 C for 3 hr.
TLC showed the reactant was consumed completely, and three new spots were detected. -60%
of desired product was detected on LCMS. The reaction mixture was concentrated under reduced pressure to remove THF. The residue was purified by flash silica gel chromatography.
Compound 152-4 (5 g, 25.4% yield) was obtained. LCMS (ESI): RT = 0.568 min, mass calcd.
for C9Hi iBrN203S 305.97, m/z found 306.8 [M+I-11+.
Step 4: 4-amino-3-bromo-N-methylbenzenesulfonamide [00486] A mixture of compound 152-4 (5 g, 16.3 mmol, 1.0 eq) in HC1 (20 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 100 C for 3 hr under N2 atmosphere. LCMS showed the reactant was consumed completely, and -97% of desired product was detected. The pH of the reaction mixture was adjusted to 9-10 by adding NaHCO3 solid and then the mixture was filtered and the filter cake was dried in vacuum. The crude product was used into the next step without further purification.
Compound 152-5 (4 g, crude) was obtained. LCMS (ESI): RT = 0.568 min, mass calcd. for C7H9BrN202S
263.96, m/z found 264.8 [M+H]+; IFINMR (400MHz, CDC13) 6 7.93 (d, J= 2.0 Hz, 1H), 7.63 -7.52 (m, 1H), 6.80 (d, J = 8.5 Hz, 1H), 2.65 (d, J = 5.4 Hz, 3H).
Step 5: 3-bromo-N-methy1-4-43-(trifluoromethyl)phenyl)amino)benzenesulfonamide [00487] To a solution of compound 152-5 (1 g, 3.7 mmol, 1.0 eq) in DCM (15 mL) were added Cu(OAc)2 (822.1 mg, 4.5 mmol, 1.2 eq), DIPEA (974.9 mg, 7.5 mmol, 1.3 mL, 2.0 eq) and 5a (859.2 mg, 4.5 mmol, 1.2 eq). The mixture was stirred at 25 C for 16 hr at 02 atmosphere. LCMS showed the reactant was remained and -20% of desired product was detected. TLC showed the reactant was remained and three new spots were detected. The reaction mixture was filtered and the filtrate was concentrated in vacuum. The residue was purified by flash silica gel chromatography. Compound 152-6 (200 mg, 6.5%
yield) was obtained. LCMS (ESI): RT = 2.210 min, mass calcd. for Ci4H12BrF3N202S 407.98, m/z found 408.9 [M+H]+.
Step 6: N-methy1-3-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-4-43-(trifluoromethyl)phenyl)amino)benzenesulfonamide [00488] To a solution of compound 152-6 (200 mg, 0.5 mmol, 1.0 eq) in dioxane (10 mL) were added AcOK (95.9 mg, 0.98 mmol, 2.0 eq), Pd(dppf)C12 (17.9 mg, 24.4 umol, 0.05 eq) and compound 152-6a (186.1 mg, 0.73 mmol, 1.5 eq). The mixture was stirred at 90 C for 16 hr.
LCMS showed the reactant was consumed completely and -40% of desired product was detected. The reaction mixture was filtered and the filtrate was concentrated in vacuum. The crude product was used into the next step without further purification.
Compound 152-7 (400 mg, crude) was obtained. LCMS (ESI): RT = 0.919 min, mass calcd. for C20I-456.15, m/z found 456.7 [M+H1+.
Step 7: 3-(2-aminopyridin-4-y1)-N-methy1-4-43-(trifluoromethyl)phenyl)amino)benzenesulfonamide [00489] To a solution of compound 152-7 (200 mg, 0.45 mmol, 1.0 eq) in dioxane (15 mL) and H20 (2 mL) were added Pd(dppf)C12 (16.0 mg, 21.9 umol, 0.05 eq), Cs2CO3 (285.6 mg, 0.88 mmol, 2.0 eq) and compound 152-7a (151.6 mg, 0.88 mmol, 2.0 eq). The mixture was stirred at 90 C for 16 hr. LCMS showed the reactant was consumed completely and 40% of desired product was detected. The reaction mixture was concentrated in vacuum.
The residue was purified by prep-HPLC. Compound 152 (1.34 mg, 7.24e-1% yield) was obtained. LCMS
(ESI): RT = 0.669 min, mass calcd. for Ci9H17F3N402S 422.10, m/z found 423 [M+1-11+.11-1NMR
(400 MHz, CDC13) 6 8.18 (d, J= 5.0 Hz, 1H), 7.77 (d, J= 1.8 Hz, 1H), 7.49 (dd, J = 1.8, 8.0 Hz, 1H), 7.46 - 7.41 (m, 1H), 7.38 (d, J= 7.9 Hz, 1H), 7.29 (br s, 1H), 7.26 (br s, 1H), 6.72 (dd, J=
1.4, 5.3 Hz, 1H), 6.55 (s, 1H), 5.87 (s, 1H), 4.62 (br s, 2H), 4.34 (br d, J=
5.3 Hz, 1H), 2.75 (d, J
= 5.4 Hz, 3H).
Example 141: 3-(2-Aminopyridin-4-y1)-N-methy1-4-44-(trifluoromethyl)phenyl)amino)benzenesulfonamide (Compound 153) I
CZ%J F
Preparation of Compound 153:
Br Br H
Br Br H
H N
0 NH2 DMAP (0.05 eq), Ac20 (1.2 eq) 0 NI( ciso3H (11.1 eq,) NI,,... 0, 40 11 0 methylamine (3.0 eq) S
DCM, r.t, 16 hr 0 0-80 C, 4h ....S THF, 0 to 25 C, 3 hr HN- ,`
CI ,b I
F
F
F
Br HO B = __.)..0 0OB-Blt 0= H (153-5a 1.2 eq) .-"-4-1.---cu(OA.)2 (1.2 eq) Br H
cO
0 DIPEA (2.0 eq) N (153-6a 1.5 eq) L B
HCI (6 M) , .'s "IF 0, (15 psi) .I I. F Pd(dppf)Cl2 (0.05 eq) H
100 'C, 4 hr Hril µµ(:) DCM, 25 C, 16h N
HN-S,' F 16h F F di AcOK(2.0 eq) -- 0,, 0 -- 40 oxane, 90 C, F
153-6 HN ,)-, I ,-, H2Nõ,r...,Br N.,.....-J
(153-7a 2.0 eq) Pd(dppf)Cl2 (0.05 eq) H
____________________________ I.- N
Cs2CO3(2.0 eq) R` 40 40 dioxane/H20, 90 C, 16h F
S
HN- F
,` F
I
Compound 153 Step 1: N-(2-bromophenyl)acetamide [00490] To a solution of compound 153-1 (20 g, 116.2 mmol, 1.0 eq) in DCM
(10 mL) were added Ac20 (14.2 g, 139.5 mmol, 13.0 mL, 1.2 eq) and DMAP (710 mg, 5.81 mmol, 0.05 eq). The mixture was stirred at 25 C for 16 hr. LCMS showed the reactant was consumed completely and -95% desired MS was detected. The reaction mixture was poured into water (50 mL), and extracted with EA (50 mL * 3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue.
The crude product was used into the next step without further purification.
Compound 153-2 (23 g, crude) was obtained. LCMS (ESI): RT = 0.713 min, mass calcd. for C8H8BrNO
212.98, m/z found 214.2 [M+H1+.
Step 2: 4-acetamido-3-bromobenzene-1-sulfonyl chloride [00491] To a solution of compound 153-2 (23 g, 107.4 mmol, 1.0 eq) was added compound 153-2a (139.8 g, 1.2 mol, 79.9 mL, 11.1 eq) at 0 C. The mixture was stirred at 80 C
for 4 hr. LCMS showed the reactant was remained and -30% desired product was detected. The reaction mixture was poured into ice water (50 mL) and extracted with EA (50 mL * 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The crude product was used into the next step without further purification. Compound 153-3 (16 g, crude) was obtained.
LCMS (ESI): RT
= 0.703 min, mass calcd. for C8H8BrNO 212.98, m/z found 213.3 [M+H1+.
Step 3: N-(2-bromo-4-(N-methylsulfamoyl)phenyl)acetamide [00492] To a solution of compound 153-3 (16 g, 51.1 mmol, 1.0 eq) in THF (5 mL) was added methylamine (2 M, 127.9 mL, 5.0 eq) at 0 C. The mixture was stirred at 25 C for 3 hr.
TLC showed the reactant 153-3 was consumed completely, and three new spots were detected.
-60% desired product was detected on LCMS. The reaction mixture was concentrated under reduced pressure to remove THF. The residue was purified by flash silica gel chromatography.
Compound 153-4 (5 g, 25.4% yield) was obtained. LCMS (ESI): RT = 0.568 min, mass calcd.
for C9Hi iBrN203S 305.97, m/z found 306.8 [M+I-11+.
Step 4: 4-amino-3-bromo-N-methylbenzenesulfonamide [00493] A mixture of compound 153-4 (5 g, 16.3 mmol, 1.0 eq) in HC1 (20 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 100 C for 3 hr under N2 atmosphere. LCMS showed the reactant was consumed completely, and -97% desired product was detected. The pH of the reaction mixture was adjusted to 9-10 by adding NaHCO3 solid and then the mixture was filtered and the filter cake was dried in vacuum. The crude product was used into the next step without further purification. Compound 153-5 (4 g, crude) was obtained. LCMS (ESI): RT = 0.568 min, mass calcd. for C7H9BrN202S 263.96, m/z found 264.8 [M+H]+; 1HNMR (400 MHz, CDC13) 6 7.93 (d, J= 2.0 Hz, 1H), 7.63 - 7.52 (m, 1H), 6.80 (d, J = 8.5 Hz, 1H), 2.65 (d, J = 5.4 Hz, 3H).
Step 5: 3-bromo-N-methy1-4-04-(trifluoromethyl)phenyl)amino)benzenesulfonamide [00494] To a solution of compound 153-5 (1 g, 3.7 mmol, 1.0 eq) in DCM (15 mL) were added Cu(OAc)2 (822.1 mg, 4.5 mmol, 1.2 eq), DIPEA (974.9 mg, 7.5 mmol, 1.3 mL, 2.0 eq) and compound 153-5a (859.6 mg, 4.5 mmol, 1.2 eq). The mixture was stirred at 25 C for 16 hr at 02 atmosphere. TLC showed the reactant was remained and three new spots were detected.
The reaction mixture was filtered and the filtrate was concentrated in vacuum.
The residue was purified by flash silica gel chromatography. Compound 153-6 (150 mg, 5.8%
yield) was obtained. LCMS (ESI): RT = 2.190 min, mass calcd. for Ci4H12BrF3N202S 407.98, m/z found 408.9 [M+H]+.
Step 6: N-methy1-3-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-4-04-(trifluoromethyl)phenyl)amino)benzenesulfonamide [00495] To a solution of compound 153-6 (150 mg, 0.37 mmol, 1.0 eq) in dioxane (10 mL) were added Pd(dppf)C12 (13.4 mg, 18.3 umol, 0.05 eq), AcOK (71.9 mg, 0.73 mmol, 2.0 eq) and compound 153-6a (139.6 mg, 0.55 mmol, 1.5 eq). The mixture was stirred at 90 C for 6 hr.
LCMS showed 40% desired product was detected. The reaction mixture was filtered and the filtrate was concentrated in vacuum. The residue was purified by flash silica gel chromatography. Compound 153-7 (50 mg, 29.9% yield) was obtained. LCMS (ESI):
RT =
0.907 min, mass calcd. for C20I-124BF3N204S 456.15, m/z found 457.1 [M+I-11+.
Step 7: 3-(2-aminopyridin-4-y1)-N-methyl-4-04-(trifluoromethyl)phenyl)amino)benzenesulfonamide [00496] To a solution of compound 153-7 (50 mg, 0.10 mmol, 1.0 eq) in dioxane (15 mL) and H20 (2 mL) were added Pd(dppf)C12 (4.0 mg, 5.5 umol, 0.05 eq), Cs2CO3 (71.4 mg, 0.22 mmol, 2.0 eq) and compound 153-7a (37.9 mg, 0.22 mmol, 2.0 eq). The mixture was stirred at 90 C for 16 hr. LCMS and HPLC showed the reactant was consumed completely and 40%
desired product was detected. The reaction mixture was concentrated in vacuum.
The residue was purified by prep-HPLC. Compound 153 (5.59 mg, 11.1% yield, HC1) was obtained. LCMS
(ESI): RT = 0.698 min, mass calcd. for Ci9I-117F3N402S 422.10, m/z found 423 [M+1-11+;IFINMR
(400 MHz, DMSO-d6) 6 13.86 - 13.43 (m, 1H), 8.07 - 7.92 (m, 3H), 7.73 (d, J=
8.5 Hz, 2H), 7.41 (d, J = 8.5 Hz, 2H), 7.21 (dd, J = 2.3, 8.8 Hz, 1H), 7.06 - 7.04 (m, 1H), 6.95 (s, 1H), 6.80 (d, J= 8.8 Hz, 1H), 6.70 (dd, J= 1.4, 6.7 Hz, 1H), 6.29 (br s, 2H), 3.13 (s, 3H), 2.53 -2.52 (m, 3H).
II. Biological Evaluation Example Al: YAP Reporter Assay [00497] HEK293T cells stably transfected with 8XTBD luciferase reporter and pRLTK in 384-well plates were treated with the test compounds, starting from 311M
(final concentration in assay plate), 1:3 dilution, and 10 points in quadruplicates. Post 24-hr incubation with compounds at 37 C and 5% CO2, cells were lysed and 8XTBD-driven firefly luciferase and control TK-driven renilla luciferase activities were measured using Promega Dual-Luciferase Reporter Assay System.
[00498] Reagents: The reagents used for this study are: DMEM: Invitrogen#
11960077, Dual-Glo Luciferase Assay System: Promega-E2980, Puromycin Dihydrochloride:
Invitrogen-A1113803, 384-well plate: PerkinElmer-6007480, L-GLUTAMINE: Invitrogen-25030164, Hygromycin B: Invitrogen-10687010 , and Penicillin-Streptomycin: Merk-TMS-AB2-C
[00499] Media: The media used for this assay were: Culture Medium: DMEM+
lug/mL
puromycin + 200 ug/mL hygromycin (with 10% FBS + 1mM L-glutamine); and Assay Medium:
DMEM (with 10% FBS + 1mM L-glutamine + lx P/S).
[00500] Cell Plating: The appropriate media was warmed at 37 C by water bath: Culture Medium, Assay Medium, 1* D-PBS, 0.05% trypsin-EDTA. The cells were trypsinized after removing all media, then washed with 1* sterile D-PBS and then with 2 ml 0.05%
trypsin-EDTA. The cells were then incubated at RT for one minute. Then 10 m1/75cm2 flask Assay Medium was added to each flask. Using a 10 ml pipette, the cells were then gently resuspended in the media, until the clumps completely disappeared. The cells were then transferred into 50 ml centrifuge tubes and were centrifuged at 800 rpm for 5 mins. The medium was removed and the cells were resuspended with Assay Medium. An aliquot of cells was used to count the cell density (cells/m1). The cell suspension was then diluted with Assay Medium to a concentration of 6x104 cells/ml. 50u1 cells suspension was then plated to 384-well plate (PerkinElmer-6007480), 3x103 cells/well and the cells were incubated in an incubator at 37 C, 5% CO2.
[00501] Compound Treatment: In the afternoon (incubation of the plate with 3-4 hrs), the test compounds were added by Echo, starting from 3uM (final concentration in the assay plate), 1:3 dilution, 10 points, quadruplicates. The plate was placed at 37 C, 5% CO2 incubator for 24hrs.
[00502] Detection: The Dual-Glo Luciferase Reagent was prepared by transferring the contents of one bottle of Dual-Glo Luciferase Buffer to one bottle of Dual-Glo Luciferase Substrate to create the Dual-Glo Luciferase Reagent. Mixing was performed by inversion until the substrate was thoroughly dissolved. After mixing, the reagent was aliquoted into 15 ml tubes.
In the afternoon (24hrs post compound treatment), the DMEM+ medium in the 384 well plates were aspirated by Microplate Washer.
[00503] Measuring firefly luciferase activity: 20u1 Dual-Glo Luciferase Reagent was added to the 384-well plates. The plates were protected from light to prevent interference with the assay. The plates were shaken for lmin followed centrifuging plates at 1000rpm for 30 seconds. After waiting at least 10 minutes, the firefly luminescence was measured by Envision.
[00504] Measuring renilla luciferase activity: 20u1 Stop-Glo Reagent was added to the 384-well plates. The plates were shaken for lmin and then centrifuged at 1000rpm for 30 seconds. After waiting at least 10 minutes, the renilla luminescence was measured by Envision.
[00505] Compound IC50 and maximum inhibition on the firefly luciferase and renilla luciferase activities were reported separately. IC50 for firefly luciferase activity are shown in the table below.
Firefly Compound Name Luciferase No. IC50 (PM) N-(tert-buty1)-4-(cyclohexylamino)-3-(2H-tetrazol-5-yl)benzenesulfonamide Firefly Compound Name Luciferase No.
ICso (11,1") N-(tert-butyl)-4-(cy clohexylamino)-3 -(242-D
hydroxyethyl)-2H-tetrazol-5-yObenzenesulfonamide N-cy clohexy1-2-(5 -methy1-1,2,4-oxadiazol-3-y1)-4-(methylsulfonyl)aniline N-cy clohexy1-4-(methylsulfony1)-2-(2H-tetrazol-5 -yl)aniline N-cy clohexy1-2-(2-methy1-2H-tetrazol-5-y1)-4-B
(methylsulfonyl)aniline N-cy clohexy1-2-(1 -methy1-1H-1,2,3-triazol-4-y1)-4-B
(methylsulfonyl)aniline N-cy clohexy1-2-(1-methy1-1H-py razol-4-y1)-4-(methylsulfonyl)aniline N-cy clohexy1-2-(1-methy1-1H-py razol-3-y1)-4-B
(methylsulfonyl)aniline N-cy clohexy1-4-(methylsulfony1)-2-(1H-1,2,3-triazol-1-yl)aniline N-cy clohexy1-4-(methylsulfony1)-2-(1H-py razol-1 -C
yl)aniline N-cy clohexy1-2-(1H-imidazol-1-y1)-4-(methylsulfonyl)aniline N-cy clohexy1-4-(methylsulfony1)-2-(1H-1,2,4-triazol-1-D
yl)aniline N-cy clohexy1-4-(methylsulfony1)-2-(2H-1,2,3-triazol-2-B
yl)aniline 4-(cy clohexylamino)-3-(2-ethy1-2H-tetrazol-5-y1)-N-A
methylbenzenesulfonamide 4-(cy clohexylamino)-N-methy1-3 -(2-propy1-2H-A
tetrazol-5-yObenzenesulfonamide 4-(cy clohexylamino)-3-(2-(4-fluoropheny1)-2H-tetrazol-5 -y1)-N-methylbenzenesulfonamide Firefly Compound Name Luciferase No.
ICso (11,1") 3-(2-cy cl obuty1-2H-tetrazol-5 -y 0-4-(cy cl ohexylamino)-A
N-methylbenzenesulfonamide 4-(cy clohexylamino)-3-(2-cy cl openty1-2H-tetrazol-5-B
yO-N-methylbenzenesulfonamide 4-(cyclohexylamino)-3-(2-(2-fluorobenzy1)-2H-tetrazol-A
5-y1)-N-methylbenzenesulfonamide 3-(2-benzy1-2H-tetrazol-5 -y 0-4-(cy clohexylamino)-N-A
methylbenzenesulfonamide 3 21 -(2-buty ltetrazol-5 -y 0-4-(cy cl ohexylamino)-N-methyl-A
benzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-methy1-2H-A
tetrazol-5-yObenzenesulfonamide 4-(cyclohexylamino)-3-(2-(2-fluoropheny1)-2H-B
tetrazol-5-y1)-N-methylbenzenesulfonamide tert-butyl3 -(5 -(2-(cy cl ohexylamino)-5 -(N-24 methylsulfamoyl)pheny1)-2H-tetrazol-2-yOpyrrolidine- D
1-carboxylate tert-butyl3 -(5 -(2-(cy cl ohexylamino)-5 -(N-methylsulfamoyl)pheny1)-2H-tetrazol-2-y0azetidine-1- D
carboxylate 4-(cy cl ohexy lamino)-3-(24 s opropy1-2H-tetrazol-5 -y1)-A
N-methylbenzenesulfonamide 4-(cy cl ohexylamino)-3 -(2-is obuty1-2H-tetrazol-5 -y1)-N-B
methylbenzenesulfonamide tert-butyl 4-(5-(2-(cy cl ohexylamino)-5 -(N-28 methylsulfamoyl)pheny1)-2H-tetrazol-2-yOpiperidine-1- D
carboxylate 4-(cy cl ohexylamino)-N-methy1-3 -(2-(py ri din-3 -A
ylmethyl)-2H-tetrazol-5-yObenzenesulfonamide 4-(cy clohexylamino)-N-methy1-3-(2-(piperidin-4-y1)- D
Firefly Compound Name Luciferase No.
ICso (11,1") 2H-tetrazol-5-yl)benzenesulfonamide 3-(2-(1-acetylpiperidin-4-y1)-2H-tetrazol-5-y1)-4-B
(cyclohexylamino)-N-methylbenzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(1-32 (methylsulfonyl)piperidin-4-y1)-2H-tetrazol-5- -- D
yl)benzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(1-(pyridin-3-yOpiperidin-4-y1)-2H-tetrazol-5-yObenzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-pheny1-2H-tetrazol-5-yObenzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(pyrrolidin-3-y1)-2H-tetrazol-5-yObenzenesulfonamide 4-(cyclohexylamino)-3-(2-(1-isopropylpyrrolidin-3-y1)-C
2H-tetrazol-5-y1)-N-methylbenzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(1-37 phenylpyrrolidin-3-y1)-2H-tetrazol-5- D
yl)benzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(1-38 phenylpiperidin-4-y1)-2H-tetrazol-5- D
yl)benzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(2,2,2-trifluoroethyl)-2H-tetrazol-5-yObenzenesulfonamide 4-(cyclohexylamino)-3-(2-(2-fluoroethyl)-2H-tetrazol-A
5-y1)-N-methylbenzenesulfonamide 4-(cyclohexylamino)-3-(2-(4-fluorobenzy1)-2H-tetrazol-B
5-y1)-N-methylbenzenesulfonamide 3-(2-(1-acetylpyrrolidin-3-y1)-2H-tetrazol-5-y1)-4-B
(cyclohexylamino)-N-methylbenzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(1-(methylsulfonyOpyrrolidin-3-y1)-2H-tetrazol-5-Firefly Compound Name Luciferase No.
ICso (11,1") yl)benzenesulfonamide 4-(cyclohexylamino)-3-(2-(2-hydroxyethyl)-2H-tetrazol-5-y1)-N-methylbenzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(pyridin-3-y1)-2H-tetrazol-5-yObenzenesulfonamide 4-(cyclohexylamino)-3-(2-(1-isopropylpiperidin-4-y1)-D
2H-tetrazol-5-y1)-N-methylbenzenesulfonamide isopropyl 4-(5-(2-(cyclohexylamino)-5-(N-47 methylsulfamoyl)pheny1)-2H-tetrazol-2-yOpiperidine-1- .. D
carboxylate 4-(cy cl ohexylamino)-N-methy1-3 -(5 -methyl-1,2,4-A
oxadiazol-3-yl)benzenesulfonamide 3-(2-(1-acetylazetidin-3-y1)-2H-tetrazol-5-y1)-4-(cyclohexylamino)-N-methylbenzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(1-50 (methylsulfonyl)azetidin-3-y1)-2H-tetrazol-5- D
yl)benzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(1-phenylazetidin-D
3-y1)-2H-tetrazol-5-yObenzenesulfonamide 4-(cyclohexylamino)-3-(2-(1-isopropylazetidin-3-y1)-B
2H-tetrazol-5-y1)-N-methylbenzenesulfonamide 3-(2-(1-acetylpiperidin-3-y1)-2H-tetrazol-5-y1)-4-(cyclohexylamino)-N-methylbenzenesulfonamide 3-(2-(azetidin-3-y1)-2H-tetrazol-5-y1)-4-(cyclohexylamino)-N-methylbenzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(pyrimidin-5-yl)benzenesulfonamide 4-(cyclohexylamino)-N-methyl-3-(pyrimidin-2-A
yl)benzenesulfonamide 57 4-(cyclohexylamino)-N-methy1-3-(1-methy1-1H- A
Firefly Compound Name Luciferase No.
ICso (11,1") pyrazol-3-yObenzenesulfonamide 4-(cy cl ohexylamino)-N-methy1-3-(1 -methy 1-1H-1,2,3 -A
triazol-4-yl)benzenesulfonamide tert-butyl 3 -(5 -(2 -(cy cl ohexylamino)-5 -(N-59 methylsulfamoyl)pheny1)-2H-tetrazol-2-yOpiperidine-1- B
carboxylate tert-butyl 3 -(5 -(2 -(cy cl ohexylamino)-5 -(N-60 methylsulfamoyl)pheny1)-1H-tetrazol-1 -yl)pip eri dine-1 - D
carboxylate 4-(cy clohexylamino)-3 -(2-(1 -isopropylpiperidin-3-y1)-D
2H-tetrazol-5-y1)-N-methylbenzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(1-62 (methylsulfonyl)piperidin-3-y1)-2H-tetrazol-5- D
yl)benzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(1-63 phenylpiperidin-3-y1)-2H-tetrazol-5- D
yl)benzenesulfonamide 4-(cyclohexylamino)-N-methyl-3-(pyridin-2-A
yl)benzenesulfonamide 4-(cyclohexylamino)-N-methyl-3-(pyridin-4-D
yl)benzenesulfonamide 4-(cy cl ohexylamino)-N-methy1-3-(5 -methyl-1H-1,2,4 -B
triazol-3-yl)benzenesulfonamide 4-(cyclohexylamino)-3-(1,5-dimethy1-1H-1,2,4-triazol-A
3-y1)-N-methylbenzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(1-(pyridin-3-68 yOpyrrolidin-3-y1)-2H-tetrazol-5- B
yl)benzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(pyrimidin-4-yl)benzenesulfonamide Firefly Compound Name Luciferase No.
ICso (11,1") 4-(cyclohexylamino)-N-methyl-3-(2-(1-(pyridin-3-B
yl)azetidin-3-y1)-2H-tetrazol-5-yObenzenesulfonamide 4-(cyclohexylamino)-3-(2-cyclopropy1-2H-tetrazol-5-D
yO-N-methylbenzenesulfonamide 4-((4,4-difluorocyclohexyl)amino)-N-methyl-3-(2-A
methyl-2H-tetrazol-5-yObenzenesulfonamide 4-((3,3-difluorocyclohexyl)amino)-N-methy1-3-(2-methy1-2H-tetrazol-5-yObenzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(2-(piperidin-3-y1)-2H-tetrazol-5-yObenzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(1-(piperidin-3-y1)-C
1H-tetrazol-5-yObenzenesulfonamide 3-(6-aminopyridin-2-y1)-4-(cyclohexylamino)-N-B
methylbenzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(pyridin-3-yl)benzenesulfonamide 4-(cyclohexylamino)-N-methyl-3-(3-methylpyridin-2-D
yl)benzenesulfonamide 4-(cyclohexylamino)-3-(3-fluoropyridin-2-y1)-N-methylbenzenesulfonamide 4-(cyclohexylamino)-3-(3-methoxypyridin-2-y1)-N-C
methylbenzenesulfonamide 4-(cyclohexylamino)-N-methyl-3-(2H-1,2,3-triazol-2-A
yl)benzenesulfonamide 4-(cyclohexylamino)-N-methy1-3-(1-methy1-1H-A
imidazol-4-yObenzenesulfonamide 4-(cyclohexylamino)-3-(6-(dimethylamino)pyridin-2-D
yO-N-methylbenzenesulfonamide 3-(4-aminopyridin-2-y1)-4-(cyclohexylamino)-N-methylbenzenesulfonamide Firefly Compound Name Luciferase No.
ICso (11,1") 4-(cyclohexylamino)-N-methyl-3-(6-C
(methylamino)pyridin-2-yl)benzenesulfonamide 4-(cyclohexylamino)-N-methyl-3-(2-(1-(pyridin-3-B
yOpiperidin-3-y1)-2H-tetrazol-5-yObenzenesulfonamide 4-(cyclohexylamino)-3-(4-(dimethylamino)pyridin-2-A
yO-N-methylbenzenesulfonamide 4-(cyclohexylamino)-N-methyl-3-(4-A
(methylamino)pyridin-2-yl)benzenesulfonamide 4-(cyclohexylamino)-N-methyl-3-(1H-1,2,3-triazol-1-D
yl)benzenesulfonamide N-methyl-3-(2-methy1-2H-tetrazol-5-y1)-4-A
(phenylamino)benzenesulfonamide 4-(cyclohexylamino)-N-methyl-3-(3-methy1-1,2,4-B
oxadiazol-5-yObenzenesulfonamide N-methyl-3-(2-methyl-2H-tetrazol-5-y1)-4-((3-A
(trifluoromethyl)phenyl)amino)benzenesulfonamide N-methy1-3-(2-methy1-2H-tetrazol-5-y1)-4-((2-(trifluoromethyl)phenyl)amino)benzenesulfonamide N-methy1-3-(2-methy1-2H-tetrazol-5-y1)-4-((3-(trifluoromethoxy)phenyl)amino)benzenesulfonamide N-methy1-3-(2-methy1-2H-tetrazol-5-y1)-4-((4-A
(trifluoromethyl)phenyl)amino)benzenesulfonamide N-methyl-3-(1-methy1-1H-tetrazol-5-y1)-4-44-D
(trifluoromethyl)phenyl)amino)benzenesulfonamide N-methy1-3-(1-methy1-1H-tetrazol-5-y1)-4-43-(trifluoromethyl)phenyl)amino)benzenesulfonamide N-methyl-3-(1-methy1-1H-tetrazol-5-y1)-4-42-D
(trifluoromethyl)phenyl)amino)benzenesulfonamide N-methy1-3-(1-methy1-1H-tetrazol-5-y1)-4-44-(trifluoromethoxy)phenyl)amino)benzenesulfonamide Firefly Compound Name Luciferase No.
ICso (11,1") N-methyl-3-(1-methyl-1H-tetrazol-5-y1)-4-43-D
(trifluoromethoxy)pheny Damino)benzenes ulfonami de N-methyl-3-(1-methy 1-1H-tetrazol-5-y1)-4-42-D
(trifluoromethoxy)pheny Damino)benzenes ulfonami de N-methy1-3-(2-methy1-2H-tetrazol-5-y1)-4-42-(trifluoromethoxy)pheny Damino)benzenes ulfonami de N-methyl-3-(2-methyl-2H-tetrazol-5-y1)-4-44-A
(trifluoromethoxy)pheny Damino)benzenes ulfonami de 4-((2,3 -difluorophenyl)amino)-N-methyl-3-(2-methyl-B
2H-tetrazol-5-y Obenzenes ulfonami de 4-(cy cl ohexylamino)-N-methy1-3 -(5 -methyl-1,3,4-oxadi azol-2-y Obenzenesulfonami de
106 4-((2,3 -difluorophenyl)amino)-N-methy1-3-(1-methyl-D
1H-tetrazol-5-yObenzenesulfonamide
1H-tetrazol-5-yObenzenesulfonamide
107 4-((3,5 -difluorophenyl)amino)-N-methy1-3-(1-methyl-D
1H-tetrazol-5-yObenzenesulfonamide
1H-tetrazol-5-yObenzenesulfonamide
108 4-((3,5 -difluorophenyl)amino)-N-methyl-3-(2-methyl-B
2H-tetrazol-5-y Obenzenes ulfonami de
2H-tetrazol-5-y Obenzenes ulfonami de
109 4-((2,5 -difluorophenyl)amino)-N-methy1-3-(1-methyl-D
1H-tetrazol-5-yObenzenesulfonamide
1H-tetrazol-5-yObenzenesulfonamide
110 4-((2,5 -difluorophenyl)amino)-N-methyl-3-(2-methyl-A
2H-tetrazol-5-y Obenzenes ulfonami de
2H-tetrazol-5-y Obenzenes ulfonami de
111 4-(cy clohexylamino)-3 -(1-cy clopropy1-1H-imi dazol-4-A
yO-N-methylbenzenesulfonamide
yO-N-methylbenzenesulfonamide
112 4-(cy clohexylamino)-3 -(1 -ethy1-1H-imidazol-4-y1)-N-A
methy lb enzenesulfonami de
methy lb enzenesulfonami de
113 4-(cyclohexylamino)-3-(1-isopropyl-1H-imidazol-4-y1)-A
N-methylbenzenesulfonamide 4-(cy clohexylamino)-3 -(1 -ethy1-1H-imidazol-5 -y1)-N-
N-methylbenzenesulfonamide 4-(cy clohexylamino)-3 -(1 -ethy1-1H-imidazol-5 -y1)-N-
114 D
methy lb enzenesulfonami de Firefly Compound Name Luciferase No.
ICso (11,1") 3-(2-(2-(benzyloxy)ethyl)-2H-tetrazol-5-y1)-N-methyl-
methy lb enzenesulfonami de Firefly Compound Name Luciferase No.
ICso (11,1") 3-(2-(2-(benzyloxy)ethyl)-2H-tetrazol-5-y1)-N-methyl-
115 4-((4- B
(trifluoromethyl)phenyl)amino)benzenesulfonamide
(trifluoromethyl)phenyl)amino)benzenesulfonamide
116 3-(2-(2-hydroxyethyl)-2H-tetrazol-5-y1)-N-methyl-4-A
((4-(trifluoromethyl)phenyl)amino)benzenesulfonamide
((4-(trifluoromethyl)phenyl)amino)benzenesulfonamide
117 4-((3-fluorophenyl)amino)-N-methy1-3-(2-methy1-2H-B
tetrazol-5-yObenzenesulfonamide N-methyl-3-(2-methyltetrazol-5-y1)-4-(4-phenylanilino) C
benzenesulfonamide N-methyl-3-(2-methyltetrazol-5-y1)-4-(4-C
phenoxyanilino) benzenesulfonamide N-methyl-3-(2-methyltetrazol-5-y1)-4-(3-phenylanilino) A
benzenesulfonamide 3-(5-amino-1,3,4-oxadiazol-2-y1)-N-methy1-4-[4-(trifluoromethyDanilinolbenzenesulfonamide N-methy1-3-(2-methyltetrazol-5-y1)-4-(3-phenoxyanilino)benzenesulfonamide 3-[2-[(2-FluorophenyOmethylltetrazol-5-y11-N-methyl-A
443-(trifluoromethyDanilinolbenzenesulfonamide 3-[2-[(2-FluorophenyOmethylltetrazol-5-y11-N-methyl-A
444-(trifluoromethyDanilinolbenzenesulfonamide 4-(4-chloroanilino)-N-methyl-3-(1-methylimidazol-4-A
yl)benzenesulfonamide 4-(3,4-dichloroanilino)-N-methy1-3-(1-methylimidazol-A
4-yl)benzenesulfonamide N-methyl-3-(1-methylimidazol-4-y1)-4-[3-A
(trifluoromethylsulfanypanilinolbenzenesulfonamide 4-(3,5-dichloroanilino)-N-methy1-3-(1-methylimidazol-4-yl)benzenesulfonamide 143 4-(3-Chloroanilino)-N-methyl-3-(1-methylimidazol-4- A
Firefly Compound Name Luciferase No.
ICso (11,1") yl)benzenesulfonamide N-methyl-3-(1-methylimidazol-4-y1)-4-[4-A
(trifluoromethylsulfanypanilinolbenzenesulfonamide N-methyl-3-(1-methylimidazol-4-y1)-4-(3,4,5-A
trichloroanilino)benzenesulfonamide 4- [3 methylimidazol-4-yObenzenesulfonamide 4-[4-Chloro-3-(trifluoromethyDanilinol-N-methy1-3-(1-A
methylimidazol-4-yObenzenesulfonamide 4-[3-Chloro-4-(trifluoromethyDanilinol-N-methy1-3-(1-A
methylimidazol-4-yObenzenesulfonamide 4-((2,6-Difluorophenyl)amino)-N-methy1-3-(1-methyl-A
1H-imidazol-4-yObenzenesulfonamide N-methyl-3-(1-methyl-1H-imidazol-4-y1)-4-4(1s,4s)-4-A
(trifluoromethyl)cyclohexyl)amino)benzenesulfonamide N-methyl-3-(1-methyl-1H-imidazol-4-y1)-4-4(1r,40-4-A
(trifluoromethyl)cyclohexyl)amino)benzenesulfonamide 152 3-(2-Aminopyridin-4-y1)-N-methy1-4-((3-(trifluoromethyl)phenyl)amino)benzenesulfonamide Note: Biochemical assay IC50 data are designated within the following ranges:
A: < 0.100 M
B: > 0.100 p.M to < 1.000 p.M
C: > 1.000 p.M to <3.000 p.M
D: > 3.000 p.M
Example A2: Tumor Suppression Assay [00506] The procedures described herein for the tumor suppression assay is as described in PCT/US2013/043752 (WO 2013/188138). Mouse procedures are performed according to the guidelines of approved animal protocol and based on the methods. After the cells are grown to 90%> confluence, these cells are harvested by trypsinization, washed in phosphate-buffered saline (PBS), and resuspended in PBS supplemented with 50% Matrigel (BD
Biosciences). An appropriate amount of cells is prepared for administration, such as 200 pt per injection site.
Immuno-compromised mice are injected on the dorsolateral sites subcutaneously.
Any one of the compounds described herein is formulated accordingly and is then administered at a suitable dose. Control mice received vehicle alone. The average tumor diameter (two perpendicular axes of the tumor are measured) are recorded. The data are expressed in tumor volume estimated by ([width]2 x length/2). Paired, two-tailed Student's t-test is performed to access the statistical significance.
Example A3: Cell Proliferation Assay [00507] Cancer cell lines are plated in 384-well plates 24h before drug treatment. Post incubation for various time periods with the test compounds, starting from 31.1.M (final concentration in assay plate), 1:3 dilution, and 10 points in duplicates, the number of viable cells and proliferative cells are determined using CellTiter-Glo0 Luminescent Cell Viability Assay Kit (Promega) and Click-iT EdU HCS Assay Kit (Invitrogen) according to the manufacturers' protocols. The ICso values and maximum % inhibition of the test compounds are calculated using the dose response curves.
[00508] The examples and embodiments described herein are for illustrative purposes only and various modifications or changes suggested to persons skilled in the art are to be included within the spirit and purview of this application and scope of the appended claims.
tetrazol-5-yObenzenesulfonamide N-methyl-3-(2-methyltetrazol-5-y1)-4-(4-phenylanilino) C
benzenesulfonamide N-methyl-3-(2-methyltetrazol-5-y1)-4-(4-C
phenoxyanilino) benzenesulfonamide N-methyl-3-(2-methyltetrazol-5-y1)-4-(3-phenylanilino) A
benzenesulfonamide 3-(5-amino-1,3,4-oxadiazol-2-y1)-N-methy1-4-[4-(trifluoromethyDanilinolbenzenesulfonamide N-methy1-3-(2-methyltetrazol-5-y1)-4-(3-phenoxyanilino)benzenesulfonamide 3-[2-[(2-FluorophenyOmethylltetrazol-5-y11-N-methyl-A
443-(trifluoromethyDanilinolbenzenesulfonamide 3-[2-[(2-FluorophenyOmethylltetrazol-5-y11-N-methyl-A
444-(trifluoromethyDanilinolbenzenesulfonamide 4-(4-chloroanilino)-N-methyl-3-(1-methylimidazol-4-A
yl)benzenesulfonamide 4-(3,4-dichloroanilino)-N-methy1-3-(1-methylimidazol-A
4-yl)benzenesulfonamide N-methyl-3-(1-methylimidazol-4-y1)-4-[3-A
(trifluoromethylsulfanypanilinolbenzenesulfonamide 4-(3,5-dichloroanilino)-N-methy1-3-(1-methylimidazol-4-yl)benzenesulfonamide 143 4-(3-Chloroanilino)-N-methyl-3-(1-methylimidazol-4- A
Firefly Compound Name Luciferase No.
ICso (11,1") yl)benzenesulfonamide N-methyl-3-(1-methylimidazol-4-y1)-4-[4-A
(trifluoromethylsulfanypanilinolbenzenesulfonamide N-methyl-3-(1-methylimidazol-4-y1)-4-(3,4,5-A
trichloroanilino)benzenesulfonamide 4- [3 methylimidazol-4-yObenzenesulfonamide 4-[4-Chloro-3-(trifluoromethyDanilinol-N-methy1-3-(1-A
methylimidazol-4-yObenzenesulfonamide 4-[3-Chloro-4-(trifluoromethyDanilinol-N-methy1-3-(1-A
methylimidazol-4-yObenzenesulfonamide 4-((2,6-Difluorophenyl)amino)-N-methy1-3-(1-methyl-A
1H-imidazol-4-yObenzenesulfonamide N-methyl-3-(1-methyl-1H-imidazol-4-y1)-4-4(1s,4s)-4-A
(trifluoromethyl)cyclohexyl)amino)benzenesulfonamide N-methyl-3-(1-methyl-1H-imidazol-4-y1)-4-4(1r,40-4-A
(trifluoromethyl)cyclohexyl)amino)benzenesulfonamide 152 3-(2-Aminopyridin-4-y1)-N-methy1-4-((3-(trifluoromethyl)phenyl)amino)benzenesulfonamide Note: Biochemical assay IC50 data are designated within the following ranges:
A: < 0.100 M
B: > 0.100 p.M to < 1.000 p.M
C: > 1.000 p.M to <3.000 p.M
D: > 3.000 p.M
Example A2: Tumor Suppression Assay [00506] The procedures described herein for the tumor suppression assay is as described in PCT/US2013/043752 (WO 2013/188138). Mouse procedures are performed according to the guidelines of approved animal protocol and based on the methods. After the cells are grown to 90%> confluence, these cells are harvested by trypsinization, washed in phosphate-buffered saline (PBS), and resuspended in PBS supplemented with 50% Matrigel (BD
Biosciences). An appropriate amount of cells is prepared for administration, such as 200 pt per injection site.
Immuno-compromised mice are injected on the dorsolateral sites subcutaneously.
Any one of the compounds described herein is formulated accordingly and is then administered at a suitable dose. Control mice received vehicle alone. The average tumor diameter (two perpendicular axes of the tumor are measured) are recorded. The data are expressed in tumor volume estimated by ([width]2 x length/2). Paired, two-tailed Student's t-test is performed to access the statistical significance.
Example A3: Cell Proliferation Assay [00507] Cancer cell lines are plated in 384-well plates 24h before drug treatment. Post incubation for various time periods with the test compounds, starting from 31.1.M (final concentration in assay plate), 1:3 dilution, and 10 points in duplicates, the number of viable cells and proliferative cells are determined using CellTiter-Glo0 Luminescent Cell Viability Assay Kit (Promega) and Click-iT EdU HCS Assay Kit (Invitrogen) according to the manufacturers' protocols. The ICso values and maximum % inhibition of the test compounds are calculated using the dose response curves.
[00508] The examples and embodiments described herein are for illustrative purposes only and various modifications or changes suggested to persons skilled in the art are to be included within the spirit and purview of this application and scope of the appended claims.
Claims (57)
1. A compound of Formula (I) or a pharmaceutically acceptable salt thereof:
wherein, is a substituted or unsubstituted monocyclic 5-membered heterocyclic ring containing at least one N atom or a substituted or unsubstituted monocyclic 6-membered heteroaryl ring containing at least one N atom;
each R z is independently H, halogen, -CN, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6haloalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -L1-yl, or -L2-L3-Y2;
m is 0, 1, 2, 3, 4, or 5;
L1 is substituted or unsubstituted C1-C6alkylene, substituted or unsubstituted C2-C10cyclolkylene, or substituted or unsubstituted C2- C10heterocycloalkylene;
yl is substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10 heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
L2 is absent, substituted or unsubstituted C1-C6alkylene, substituted or unsubstituted C2-C10cyclolkylene, or substituted or unsubstituted C2-C10heterocycloalkylene;
L3 is -O-, -S-, -(S=O)-, -(SO2)-, -NR3-, -(C=O)-, -(C=O)O-, -O(C=O)-, -(C=O)NR3-, -(C=O)NR3-O-, -O-NR3(C=O)-, -NR3(C=O)-, -NR3(C=O)NR3-, -O(C=O)NR3-, -NR3(C=O)O-, -NR3(SO2)NR3-, -NR3(SO2)-,-(SO2)NR3-, -(SO2)NR3-(C=O)-, -(C=O)-NR3(SO2)-, -(SO2)NR3-(C=O)O-, -O(C=O)-NR3(SO2)-, -NR3(SO2)NR3-(C=O)-, -(C=O)-NR3(SO2)NR3-, -O(C=O)-NR3(SO2)-NR3-, or -NR3(SO2)NR3-(C=O)O-;
each R3 is independently H or substituted or unsubstituted C1-C6alkyl;
Y2 is H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C6haloalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
or R3 and Y2 on the same N atom are taken together with the N atom to which they are attached to form a substituted or unsubstituted N-containing heterocycle;
R is NHR1 or R1;
R1 is substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6haloalky1, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
is substituted or unsubstituted phenyl or substituted or unsubstituted cyclohexyl;
each R2 is independently H, halogen, -N3, -CN, -OR4, -SR4, -(SO2)R4, -N(R4) 2, -CO2R4, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6haloalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or n is 0, 1, 2, 3, 4, or 5; and each R4 is independently H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6haloalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
wherein, is a substituted or unsubstituted monocyclic 5-membered heterocyclic ring containing at least one N atom or a substituted or unsubstituted monocyclic 6-membered heteroaryl ring containing at least one N atom;
each R z is independently H, halogen, -CN, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6haloalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -L1-yl, or -L2-L3-Y2;
m is 0, 1, 2, 3, 4, or 5;
L1 is substituted or unsubstituted C1-C6alkylene, substituted or unsubstituted C2-C10cyclolkylene, or substituted or unsubstituted C2- C10heterocycloalkylene;
yl is substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10 heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
L2 is absent, substituted or unsubstituted C1-C6alkylene, substituted or unsubstituted C2-C10cyclolkylene, or substituted or unsubstituted C2-C10heterocycloalkylene;
L3 is -O-, -S-, -(S=O)-, -(SO2)-, -NR3-, -(C=O)-, -(C=O)O-, -O(C=O)-, -(C=O)NR3-, -(C=O)NR3-O-, -O-NR3(C=O)-, -NR3(C=O)-, -NR3(C=O)NR3-, -O(C=O)NR3-, -NR3(C=O)O-, -NR3(SO2)NR3-, -NR3(SO2)-,-(SO2)NR3-, -(SO2)NR3-(C=O)-, -(C=O)-NR3(SO2)-, -(SO2)NR3-(C=O)O-, -O(C=O)-NR3(SO2)-, -NR3(SO2)NR3-(C=O)-, -(C=O)-NR3(SO2)NR3-, -O(C=O)-NR3(SO2)-NR3-, or -NR3(SO2)NR3-(C=O)O-;
each R3 is independently H or substituted or unsubstituted C1-C6alkyl;
Y2 is H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C6haloalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
or R3 and Y2 on the same N atom are taken together with the N atom to which they are attached to form a substituted or unsubstituted N-containing heterocycle;
R is NHR1 or R1;
R1 is substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6haloalky1, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
is substituted or unsubstituted phenyl or substituted or unsubstituted cyclohexyl;
each R2 is independently H, halogen, -N3, -CN, -OR4, -SR4, -(SO2)R4, -N(R4) 2, -CO2R4, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6haloalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or n is 0, 1, 2, 3, 4, or 5; and each R4 is independently H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6haloalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
2. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein:
is a substituted or unsubstituted monocyclic 5-membered heterocyclic ring containing at least one N atom.
is a substituted or unsubstituted monocyclic 5-membered heterocyclic ring containing at least one N atom.
3. The compound or pharmaceutically acceptable salt thereof of claim 1 or 2, wherein:
is a substituted or unsubstituted monocyclic 5-membered heterocyclic ring containing 1-4 N atoms, 0-2 O atoms, and 0-2 S atoms.
is a substituted or unsubstituted monocyclic 5-membered heterocyclic ring containing 1-4 N atoms, 0-2 O atoms, and 0-2 S atoms.
4. The compound or pharmaceutically acceptable salt thereof of claim 1 or 2, wherein:
Z1 is ¨N-, ¨CH-, or -C-;
each Z2 is independently -CR z, -CHR z-, -C(R z)2-, -NR z-, -N-, -O-, or ¨S-;
each - - is independently a single or double bond; and with the provision that the 5-membered heterocyclic ring contains at least one N atom.
Z1 is ¨N-, ¨CH-, or -C-;
each Z2 is independently -CR z, -CHR z-, -C(R z)2-, -NR z-, -N-, -O-, or ¨S-;
each - - is independently a single or double bond; and with the provision that the 5-membered heterocyclic ring contains at least one N atom.
5. The compound or pharmaceutically acceptable salt thereof of claim 1 or 2, wherein:
is substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted imidazolidinyl, substituted or unsubstituted pyrazolidinyl, substituted or unsubstituted oxazolidinyl, substituted or unsubstituted isoxazolidinyl, substituted or unsubstituted thiazolidinyl, or substituted or unsubstituted isothiazolidinyl.
is substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted imidazolidinyl, substituted or unsubstituted pyrazolidinyl, substituted or unsubstituted oxazolidinyl, substituted or unsubstituted isoxazolidinyl, substituted or unsubstituted thiazolidinyl, or substituted or unsubstituted isothiazolidinyl.
6. The compound or pharmaceutically acceptable salt thereof of claim 5, wherein:
7. The compound or pharmaceutically acceptable salt thereof of claim 1 or 2, wherein:
is substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted pyrazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted isothiazolyl, substituted or unsubstituted triazoyl, substituted or unsubstituted tetrazoyl, substituted or unsubstituted oxadiazolyl, substituted or unsubstituted thiadiazolyl, or substituted or unsubstituted dithiazolyl.
is substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted pyrazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted isothiazolyl, substituted or unsubstituted triazoyl, substituted or unsubstituted tetrazoyl, substituted or unsubstituted oxadiazolyl, substituted or unsubstituted thiadiazolyl, or substituted or unsubstituted dithiazolyl.
8. The compound or pharmaceutically acceptable salt thereof of claim 7, wherein:
9. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein:
is a substituted or unsubstituted monocyclic 6-membered heteroaryl ring containing at least one N atom.
is a substituted or unsubstituted monocyclic 6-membered heteroaryl ring containing at least one N atom.
10. The compound or pharmaceutically acceptable salt thereof of claim 1 or 9, wherein:
is a substituted or unsubstituted monocyclic 6-membered heteroaryl ring containing 1 or 2 N atoms.
is a substituted or unsubstituted monocyclic 6-membered heteroaryl ring containing 1 or 2 N atoms.
11. The compound or pharmaceutically acceptable salt thereof of claim 1 or 9, wherein:
each Z2 is independently CR Z or N; and at least one Z2 is N.
each Z2 is independently CR Z or N; and at least one Z2 is N.
12. The compound or pharmaceutically acceptable salt thereof of claim 1 or 9, wherein:
is substituted or unsubstituted pyridinyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted pyridazinyl.
is substituted or unsubstituted pyridinyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted pyridazinyl.
13. The compound or pharmaceutically acceptable salt thereof of claim 12, wherein:
14. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound has the structure of Formula (Ia), or a pharmaceutically acceptable salt thereof:
wherein:
Z1 is ¨N-, ¨CH-, or -C-.
wherein:
Z1 is ¨N-, ¨CH-, or -C-.
15. The compound or pharmaceutically acceptable salt thereof of claim 14, wherein:
is a substituted or unsubstituted monocyclic 5-membered heterocyclic ring containing at least one N atom, and the at least one N atom is adjacent to Z1.
is a substituted or unsubstituted monocyclic 5-membered heterocyclic ring containing at least one N atom, and the at least one N atom is adjacent to Z1.
16. The compound or pharmaceutically acceptable salt thereof of claim 14 or 15, wherein:
Z1 is ¨N-, ¨CH-, or -C-;
each Z2 is independently CR Z, NR Z, N, O, or S;
each - - is independently a single or double bond; and with the provision that the 5-membered heterocyclic ring contains at least one N atom.
Z1 is ¨N-, ¨CH-, or -C-;
each Z2 is independently CR Z, NR Z, N, O, or S;
each - - is independently a single or double bond; and with the provision that the 5-membered heterocyclic ring contains at least one N atom.
17. The compound or pharmaceutically acceptable salt thereof of claim 14 or 15, wherein:
is substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted imidazolidinyl, substituted or unsubstituted pyrazolidinyl, substituted or unsubstituted oxazolidinyl, substituted or unsubstituted isoxazolidinyl, substituted or unsubstituted thiazolidinyl, or substituted or unsubstituted isothiazolidinyl.
is substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted imidazolidinyl, substituted or unsubstituted pyrazolidinyl, substituted or unsubstituted oxazolidinyl, substituted or unsubstituted isoxazolidinyl, substituted or unsubstituted thiazolidinyl, or substituted or unsubstituted isothiazolidinyl.
18. The compound or pharmaceutically acceptable salt thereof of claim 17, wherein:
19. The compound or pharmaceutically acceptable salt thereof of claim 14 or 15, wherein:
is substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted pyrazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted isothiazolyl, substituted or unsubstituted triazoyl, substituted or unsubstituted tetrazoyl, substituted or unsubstituted oxadiazolyl, substituted or unsubstituted thiadiazolyl, or substituted or unsubstituted dithiazolyl.
is substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted pyrazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted isothiazolyl, substituted or unsubstituted triazoyl, substituted or unsubstituted tetrazoyl, substituted or unsubstituted oxadiazolyl, substituted or unsubstituted thiadiazolyl, or substituted or unsubstituted dithiazolyl.
20. The compound or pharmaceutically acceptable salt thereof of claim 19, wherein:
21. The compound or pharmaceutically acceptable salt thereof of claim 14, wherein:
is a substituted or unsubstituted monocyclic 6-membered heteroaryl ring containing at least one N atom, and wherein the at least one N atom is adjacent to Z1.
is a substituted or unsubstituted monocyclic 6-membered heteroaryl ring containing at least one N atom, and wherein the at least one N atom is adjacent to Z1.
22. The compound or pharmaceutically acceptable salt thereof of claim 14 or 21, wherein:
; and each Z2 is independently CR Z or N.
; and each Z2 is independently CR Z or N.
23. The compound or pharmaceutically acceptable salt thereof of claim 14 or 21, wherein:
is substituted or unsubstituted pyridinyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted pyridazinyl.
is substituted or unsubstituted pyridinyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted pyridazinyl.
24. The compound or pharmaceutically acceptable salt thereof of claim 23, wherein:
25. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-24, wherein:
each R Z is independently H, halogen, -CN, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6haloalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
each R Z is independently H, halogen, -CN, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6haloalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
26. The compound or pharmaceutically acceptable salt thereof of claim 25, wherein:
each R Z is independently H, halogen, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6haloalkyl, substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
each R Z is independently H, halogen, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6haloalkyl, substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
27. The compound or pharmaceutically acceptable salt thereof of claim 25 or 26, wherein:
each R Z is independently H, -F, -Cl, -Br, -I, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or phenyl.
each R Z is independently H, -F, -Cl, -Br, -I, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or phenyl.
28. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-24, wherein:
each R Z is -L1-Y1.
each R Z is -L1-Y1.
29. The compound or pharmaceutically acceptable salt thereof of claim 28, wherein:
L1 is substituted or unsubstituted C1-C4alkylene; and Y1 is substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10 heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
L1 is substituted or unsubstituted C1-C4alkylene; and Y1 is substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10 heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
30. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-24, wherein:
each R Z is -L2-L3-Y2.
each R Z is -L2-L3-Y2.
31. The compound or pharmaceutically acceptable salt thereof of claim 30, wherein:
L2 is substituted or unsubstituted C1-C6alkylene;
L3 is -O-, -S-, -(S=O)-, -(SO2)-, -NR3-, -(C=O)-, -(C=O)O-, -O(C=O)-, -(C=O)NR3-, -(C=O)NR3-O-, -NR3(C=O)-, -NR3(C=O)NR3-, -O(C=O)NR3-, -NR3(C=O)-, -NR3(SO2)NR3-, -NR3(SO2)-, -(SO2)NR3-, -(SO2)NR3-(C=O)-, -(SO2)NR3-(C=O)O-, -NR3(SO2)NR3-(C=O)-, or -NR3(SO2)NR3-(C=O)O-;
each R3 is independently H or substituted or unsubstituted C1-C6alkyl; and Y2 is H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C6haloalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
L2 is substituted or unsubstituted C1-C6alkylene;
L3 is -O-, -S-, -(S=O)-, -(SO2)-, -NR3-, -(C=O)-, -(C=O)O-, -O(C=O)-, -(C=O)NR3-, -(C=O)NR3-O-, -NR3(C=O)-, -NR3(C=O)NR3-, -O(C=O)NR3-, -NR3(C=O)-, -NR3(SO2)NR3-, -NR3(SO2)-, -(SO2)NR3-, -(SO2)NR3-(C=O)-, -(SO2)NR3-(C=O)O-, -NR3(SO2)NR3-(C=O)-, or -NR3(SO2)NR3-(C=O)O-;
each R3 is independently H or substituted or unsubstituted C1-C6alkyl; and Y2 is H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C6haloalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
32. The compound or pharmaceutically acceptable salt thereof of claim 30, wherein:
L2 is absent;
L3 is -O-, -S-, -(S=O)-, -(SO2)-, -NR3-, -(C=O)-, -(C=O)O-, -O(C=O)-, -(C=O)NR3-, -(C=O)NR3-O-, -NR3(C=O)-, -NR3(C=O)NR3-, -O(C=O)NR3-, -NR3(C=O)O-, -NR3(SO2)NR3-, -NR3(SO2)-, -(SO2)NR3-, -(SO2)NR3-(C=O)-, -(SO2)NR3-(C=O)O-, -NR3(SO2)NR3-(C=O)-, or -NR3(SO2)NR3-(C=O)O-;
each R3 is independently H or substituted or unsubstituted C1-C6alkyl; and Y2 is H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C6haloalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
L2 is absent;
L3 is -O-, -S-, -(S=O)-, -(SO2)-, -NR3-, -(C=O)-, -(C=O)O-, -O(C=O)-, -(C=O)NR3-, -(C=O)NR3-O-, -NR3(C=O)-, -NR3(C=O)NR3-, -O(C=O)NR3-, -NR3(C=O)O-, -NR3(SO2)NR3-, -NR3(SO2)-, -(SO2)NR3-, -(SO2)NR3-(C=O)-, -(SO2)NR3-(C=O)O-, -NR3(SO2)NR3-(C=O)-, or -NR3(SO2)NR3-(C=O)O-;
each R3 is independently H or substituted or unsubstituted C1-C6alkyl; and Y2 is H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C6haloalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
33. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-32, wherein:
34. The compound or pharmaceutically acceptable salt thereof of claim 33, wherein:
35. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-34, wherein:
R is NHR1; and R1 is substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6haloalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
R is NHR1; and R1 is substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6haloalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
36. The compound or pharmaceutically acceptable salt thereof of claim 35, wherein:
R1 is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or phenyl.
R1 is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or phenyl.
37. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-34, wherein:
R is R1; and R1 is substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6haloalky1, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
R is R1; and R1 is substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6haloalky1, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
38. The compound or pharmaceutically acceptable salt thereof of claim 37, wherein:
R1 is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or phenyl.
R1 is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or phenyl.
39. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-38, wherein:
40. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound has the structure of Formula (Ib), or a pharmaceutically acceptable salt thereof:
41. The compound or pharmaceutically acceptable salt thereof of claim 39 or 40, wherein:
42. The compound or pharmaceutically acceptable salt thereof of claim 39 or 40, wherein:
43. The compound or pharmaceutically acceptable salt thereof of claim 39 or 40, wherein:
44. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-38, wherein:
45. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound has the structure of Formula (Ic), or a pharmaceutically acceptable salt thereof:
46. The compound or pharmaceutically acceptable salt thereof of claim 44 or 45, wherein:
47. The compound or pharmaceutically acceptable salt thereof of claim 44 or 45, wherein:
48. The compound or pharmaceutically acceptable salt thereof of claim 44 or 45, wherein:
49. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-48, wherein:
each R2 is independently H, halogen, -N3, -CN, -OR4, -SR4, -(SO2)R4, -N(R4) 2, -CO2R4, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6haloalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
each R2 is independently H, halogen, -N3, -CN, -OR4, -SR4, -(SO2)R4, -N(R4) 2, -CO2R4, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6haloalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
50. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound has the structure of Formula (Id), or a pharmaceutically acceptable salt thereof:
51. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound has the structure of Formula (Ie), or a pharmaceutically acceptable salt thereof:
52. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound has the structure of Formula (If), or a pharmaceutically acceptable salt thereof:
53. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the compound has the structure of Formula (Ig), or a pharmaceutically acceptable salt thereof:
54. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-53, wherein the compound exhibits an IC50 of no more than about 3.000 µM.
55. A compound or pharmaceutically acceptable salt thereof, wherein the compound is a compound from Table 1, or a pharmaceutically acceptable salt thereof
56. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of any one of claims 1-55 or a pharmaceutically acceptable salt thereof
57. A method for treating a cancer in a subject in need thereof comprising administering a therapeutically effective amount of a compound of any one of claims 1-55 or a pharmaceutically acceptable salt thereof
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762548037P | 2017-08-21 | 2017-08-21 | |
US62/548,037 | 2017-08-21 | ||
PCT/US2018/047112 WO2019040380A1 (en) | 2017-08-21 | 2018-08-20 | Benzosulfonyl compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3073543A1 true CA3073543A1 (en) | 2019-02-28 |
Family
ID=65439937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3073543A Abandoned CA3073543A1 (en) | 2017-08-21 | 2018-08-20 | Benzosulfonyl compounds |
Country Status (7)
Country | Link |
---|---|
US (1) | US11192865B2 (en) |
EP (1) | EP3691623B1 (en) |
JP (1) | JP7245229B2 (en) |
CN (1) | CN111542315B (en) |
AU (1) | AU2018321291A1 (en) |
CA (1) | CA3073543A1 (en) |
WO (1) | WO2019040380A1 (en) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020518669A (en) | 2017-05-03 | 2020-06-25 | ビバーチェ セラピューティクス,インク. | Non-fused tricyclic compound |
CN111542315B (en) | 2017-08-21 | 2023-05-12 | 维瓦斯治疗公司 | Benzosulfonyl compounds |
WO2019113236A1 (en) | 2017-12-06 | 2019-06-13 | Vivace Therapeutics, Inc. | Benzocarbonyl compounds |
CA3100503A1 (en) * | 2018-05-16 | 2019-11-21 | Vivace Therapeutics, Inc. | Oxadiazole compounds |
CN109912584B (en) * | 2019-03-22 | 2021-08-13 | 中国药科大学 | BRD4 protein inhibitor with anti-tumor activity and preparation method and application thereof |
CN114502540A (en) * | 2019-05-31 | 2022-05-13 | 医肯纳肿瘤学公司 | TEAD inhibitors and uses thereof |
CN114466839A (en) * | 2019-05-31 | 2022-05-10 | 医肯纳肿瘤学公司 | TEAD inhibitors and uses thereof |
MX2022001125A (en) | 2019-07-29 | 2022-04-18 | Basilea Pharm Int Ag | 1,2,4-oxadiazol-5-one derivatives for the treatment of cancer. |
CN115279368B (en) * | 2019-11-20 | 2024-05-24 | 维瓦斯治疗公司 | Heteroaryl compounds |
EP4081202A4 (en) * | 2019-12-24 | 2024-02-21 | Dana-Farber Cancer Institute, Inc. | Transcriptional enhanced associate domain (tead) transcription factor inhibitors and uses thereof |
WO2021247634A1 (en) * | 2020-06-03 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcriptional enhanced associate domain (tead) and uses thereof |
US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
JP2023544719A (en) | 2020-09-30 | 2023-10-25 | カトリーケ・ユニフェルシテイト・ルーヴァン | 1,2,3,4-tetrahydroquinoline derivatives as inhibitors of YAP/TAZ-TEAD activity for cancer therapy |
WO2022120353A1 (en) * | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
WO2022120355A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead degraders and uses thereof |
KR20230149885A (en) | 2021-01-25 | 2023-10-27 | 이케나 온콜로지, 인코포레이티드 | Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide TEAD inhibitor with an EGFR inhibitor and/or MEK inhibitor for use in the treatment of lung cancer |
US20240083903A1 (en) * | 2021-02-18 | 2024-03-14 | Merck Sharp & Dohme Llc | Aryl ether compounds as tead modulators |
WO2022221866A1 (en) | 2021-04-16 | 2022-10-20 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
CN117337193A (en) * | 2021-05-19 | 2024-01-02 | 基因泰克公司 | combination therapy |
CN115466243A (en) * | 2021-06-11 | 2022-12-13 | 武汉人福创新药物研发中心有限公司 | Heterocyclic compounds for TEAD inhibitors |
WO2023280254A1 (en) * | 2021-07-07 | 2023-01-12 | 武汉人福创新药物研发中心有限公司 | Tead inhibitor |
EP4395769A1 (en) | 2021-09-01 | 2024-07-10 | Novartis AG | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
EP4405346A2 (en) * | 2021-09-24 | 2024-07-31 | The General Hospital Corporation | Small molecule inhibitors of tead-yap |
WO2023057371A1 (en) | 2021-10-04 | 2023-04-13 | Basilea Pharmaceutica International Ag, Allschwil | 1,2,4-oxadiazol-5-one derivatives for the treatment of cancer |
WO2023060227A1 (en) | 2021-10-07 | 2023-04-13 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
TW202339734A (en) | 2021-12-23 | 2023-10-16 | 比利時魯汶大學 | 2-pyrazole anilines and related analogs for inhibiting yap/taz-tead |
WO2023116877A1 (en) * | 2021-12-24 | 2023-06-29 | 武汉人福创新药物研发中心有限公司 | Heterocyclic compound as tead inhibitor |
WO2023143354A1 (en) * | 2022-01-30 | 2023-08-03 | 希格生科(深圳)有限公司 | Tricyclic compound and application thereof |
WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
WO2023204822A1 (en) * | 2022-04-22 | 2023-10-26 | Vivace Therapeutics, Inc. | Phenyl phosphine oxide compounds and methods of use thereof |
TW202404581A (en) | 2022-05-25 | 2024-02-01 | 美商醫肯納腫瘤學公司 | Mek inhibitors and uses thereof |
WO2024061366A1 (en) * | 2022-09-23 | 2024-03-28 | 杭州天玑济世生物科技有限公司 | Small molecule compound having phosphorylated aryl structure, and use thereof |
TW202417429A (en) * | 2022-10-13 | 2024-05-01 | 南韓商韓美藥品股份有限公司 | Novel heterobicyclic compound for inhibiting yap-tead interaction and pharmaceutical composition comprising same |
KR20240051859A (en) | 2022-10-13 | 2024-04-22 | 한미약품 주식회사 | Novel heterobicyclic compound for inhibiting YAP-TEAD interaction and pharmaceutical composition comprising same |
WO2024092116A1 (en) | 2022-10-26 | 2024-05-02 | Ikena Oncology, Inc. | Combination of tead inhibitors and egfr inhibitors and uses thereof |
WO2024088398A1 (en) * | 2022-10-27 | 2024-05-02 | 勤浩医药(苏州)有限公司 | Phosphorus-containing compound, pharmaceutical composition and use thereof |
CN118005606A (en) * | 2022-11-10 | 2024-05-10 | 武汉人福创新药物研发中心有限公司 | TEAD inhibitors |
TW202421158A (en) | 2022-11-18 | 2024-06-01 | 瑞士商諾華公司 | Pharmaceutical combinations and uses thereof |
WO2024173761A1 (en) | 2023-02-17 | 2024-08-22 | Ikena Oncology, Inc. | Combinations comprising mek inhibitors for use in the treatment of cancer |
WO2024176130A1 (en) | 2023-02-23 | 2024-08-29 | Novartis Ag | Tead- and her2-inhibitor combinations for treating cancer |
WO2024176131A1 (en) | 2023-02-23 | 2024-08-29 | Novartis Ag | Tead- and kras g12d-inhibitor combinations for treating cancer |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3903106A (en) | 1974-04-12 | 1975-09-02 | Lilly Co Eli | Pyrazole-3-carboxylic acids |
US3895027A (en) | 1974-04-12 | 1975-07-15 | Lilly Co Eli | Process for preparing pyrazole-3-carboxylic acids |
DE2419970C3 (en) | 1974-04-25 | 1980-06-12 | Hoechst Ag, 6000 Frankfurt | 3- <1-Pyrrolidinyl) -4-phenoxy-5sulfamoylbenzoic acid and process for its preparation |
DE2917997A1 (en) * | 1979-05-04 | 1980-11-20 | Hoechst Ag | SUBSTITUTED PYRROLIDINYL-BENZOESAEUR DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF |
JP2630432B2 (en) | 1987-08-24 | 1997-07-16 | コニカ株式会社 | Silver halide color photographic light-sensitive materials containing a novel cyan coupler |
US5066668A (en) | 1989-06-09 | 1991-11-19 | Warner-Lambert Co. | Triazole derivatives of fenamates as antiinflammatory agents |
US4962119A (en) | 1989-06-09 | 1990-10-09 | Warner-Lambert Company | Triazole derivatives of fenamates as antiinflammatory agents |
FI902771A0 (en) | 1989-06-09 | 1990-06-04 | Warner Lambert Co | FOERFARANDE FOER FRAMSTAELLNING AV ANTIINFLAMMATORISKA 1,3,4-TIADIAZOLER OCH 1,3,4-OXADIAZOLER. |
US5114958A (en) | 1991-05-09 | 1992-05-19 | Warner-Lambert Company | 1,2,4-oxadiazole and 1,2,4-thiadiazole derivatives of fenamates as antiinflammatory agents |
US5670526A (en) | 1995-12-21 | 1997-09-23 | Otsuka Pharmaceutical Co., Ltd. | 1,3,4-oxadiazoles |
US6310060B1 (en) | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
US6211209B1 (en) | 1997-08-08 | 2001-04-03 | Warner-Lambert Company | Method of inhibiting connective tissue degradation |
WO2000042029A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | 1-heterocycle substituted diarylamines |
US6972287B1 (en) | 1999-06-10 | 2005-12-06 | Pfizer Inc. | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits |
WO2001005391A2 (en) | 1999-07-16 | 2001-01-25 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
US7030141B2 (en) | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
US20090048301A1 (en) | 2003-07-09 | 2009-02-19 | Imclone Systems Incorporated | Heterocyclic compounds and their use as anticancer agents |
US7956191B2 (en) | 2004-10-20 | 2011-06-07 | Merck Serono Sa | 3-arylamino pyridine derivatives |
US8097650B2 (en) | 2005-07-27 | 2012-01-17 | The Trustees Of Columbia University In The City Of New York | Method of treating a condition associated with phosphorylation of TASK-1 |
AU2007240860A1 (en) | 2006-04-19 | 2007-11-01 | Merck Serono Sa | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors |
US8383657B2 (en) | 2007-12-21 | 2013-02-26 | Abbott Laboratories | Thiazolylidine urea and amide derivatives and methods of use thereof |
ES2711936T3 (en) | 2009-09-04 | 2019-05-08 | Biogen Ma Inc | Bruton tyrosine kinase inhibitors |
WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
EP2858635A1 (en) | 2012-06-11 | 2015-04-15 | The Regents of The University of California | Inhibitors of hippo-yap signaling pathway |
SG11201408324QA (en) | 2012-06-12 | 2015-01-29 | Abbvie Inc | Pyridinone and pyridazinone derivatives |
WO2014043568A1 (en) | 2012-09-13 | 2014-03-20 | The Board Of Trustees Of The Leland Stanford Junior University | Stimulation of ovarian follicle development and oocyte maturation |
BR112015022551A2 (en) | 2013-03-12 | 2017-07-18 | Abbvie Inc | pyrrol starch inhibitors |
CN108558889B (en) * | 2013-10-18 | 2021-11-05 | 赛尔基因昆蒂赛尔研究公司 | Bromodomain inhibitors |
CA2953843C (en) | 2014-07-04 | 2023-03-14 | Merck Patent Gmbh | Azepanyl-derivatives and pharmaceutical compositions comprising the same with antiparasitic activity |
WO2016161279A1 (en) | 2015-04-03 | 2016-10-06 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer |
WO2017058716A1 (en) * | 2015-09-28 | 2017-04-06 | Vivace Therapeutics, Inc. | Tricyclic compounds |
EP3156404A1 (en) * | 2015-10-15 | 2017-04-19 | Inventiva | New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma |
JP2020518669A (en) | 2017-05-03 | 2020-06-25 | ビバーチェ セラピューティクス,インク. | Non-fused tricyclic compound |
CN111542315B (en) | 2017-08-21 | 2023-05-12 | 维瓦斯治疗公司 | Benzosulfonyl compounds |
WO2019113236A1 (en) | 2017-12-06 | 2019-06-13 | Vivace Therapeutics, Inc. | Benzocarbonyl compounds |
CA3100503A1 (en) | 2018-05-16 | 2019-11-21 | Vivace Therapeutics, Inc. | Oxadiazole compounds |
-
2018
- 2018-08-20 CN CN201880068676.0A patent/CN111542315B/en active Active
- 2018-08-20 US US16/640,557 patent/US11192865B2/en active Active
- 2018-08-20 CA CA3073543A patent/CA3073543A1/en not_active Abandoned
- 2018-08-20 EP EP18848395.2A patent/EP3691623B1/en active Active
- 2018-08-20 JP JP2020510091A patent/JP7245229B2/en active Active
- 2018-08-20 AU AU2018321291A patent/AU2018321291A1/en not_active Abandoned
- 2018-08-20 WO PCT/US2018/047112 patent/WO2019040380A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3691623B1 (en) | 2022-10-05 |
WO2019040380A1 (en) | 2019-02-28 |
CN111542315A (en) | 2020-08-14 |
EP3691623A4 (en) | 2021-05-26 |
AU2018321291A1 (en) | 2020-03-26 |
US11192865B2 (en) | 2021-12-07 |
EP3691623A1 (en) | 2020-08-12 |
JP7245229B2 (en) | 2023-03-23 |
JP2020533280A (en) | 2020-11-19 |
US20200354325A1 (en) | 2020-11-12 |
CN111542315B (en) | 2023-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3073543A1 (en) | Benzosulfonyl compounds | |
US11524943B1 (en) | Benzocarbonyl compounds | |
JP7482861B2 (en) | Bicyclic Compounds | |
US11661403B2 (en) | Oxadiazole compounds | |
US11420935B2 (en) | Bicyclic compounds | |
CA3062294A1 (en) | Non-fused tricyclic compounds | |
KR102438302B1 (en) | Inhibitors of lysine specific demethylase-1 | |
JP6663866B2 (en) | Lysine-specific inhibitors of demethylase-1 | |
EP4061364A1 (en) | Heteroaryl compounds | |
CA2919783C (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
WO2017058716A1 (en) | Tricyclic compounds | |
WO2022087008A1 (en) | Tertiary carboxamide compounds | |
WO2023146513A1 (en) | Compounds and methods of use thereof | |
EA047446B1 (en) | BICYCLIC COMPOUNDS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20240222 |